<SEC-DOCUMENT>0001144204-15-000474.txt : 20150105
<SEC-HEADER>0001144204-15-000474.hdr.sgml : 20150105
<ACCEPTANCE-DATETIME>20150105164252
ACCESSION NUMBER:		0001144204-15-000474
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20150105
DATE AS OF CHANGE:		20150105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AmpliPhi Biosciences Corp
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-193458
		FILM NUMBER:		15505588

	BUSINESS ADDRESS:	
		STREET 1:		4870 SADLER ROAD
		STREET 2:		SUITE 300
		CITY:			GLEN ALLEN
		STATE:			VA
		ZIP:			23060
		BUSINESS PHONE:		650-888-2422

	MAIL ADDRESS:	
		STREET 1:		4870 SADLER ROAD
		STREET 2:		SUITE 300
		CITY:			GLEN ALLEN
		STATE:			VA
		ZIP:			23060

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGETED GENETICS CORP /WA/
		DATE OF NAME CHANGE:	19940331
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>v398030_424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>

     <HEAD>

          <TITLE></TITLE>

     </HEAD>

<BODY>

<DIV style="text-align: center; min-width: 708">


<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-indent:0pt; text-align: right; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-193458</P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prospectus </H1>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;<BR>&nbsp;&nbsp;<BR>&nbsp;&nbsp;<BR>&nbsp;&nbsp;<BR>&nbsp;&nbsp;<BR><IMG SRC="logo_ampliphi-biocorp2.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> &nbsp;</P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 14pt; line-height: 16pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">73,362,164 Shares </H1>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 14pt; line-height: 16pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Common Stock </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This prospectus covers the sale of an aggregate of up to 73,362,164 shares, or the Shares, of our common stock, par value $0.01 per share, by the selling stockholders identified in this prospectus (collectively with any such holder&#146;s transferee, pledgee, donee or successor, referred to below as the Selling Stockholders). The Shares consist of 72,007,000 shares of our common stock that were issued pursuant to a Subscription Agreement, dated as of December 19, 2013 and 1,355,164 shares underlying the exercise of warrants held by certain of the Selling Stockholders. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will not receive any proceeds from the sale by the Selling Stockholders of the shares covered by this prospectus. We are paying the cost of registering the shares covered by this prospectus, as well as various related expenses. The shares included in this prospectus may be offered and sold directly by the Selling Stockholders in accordance with one or more of the methods described in the plan of distribution, which begins on page <a href="#tPOD">30</a> of this prospectus. The Selling Stockholders are responsible for all selling commissions, transfer taxes and other costs related to the offer and sale of their shares under
this prospectus. If required, the number of shares to be sold, the public offering price of those shares, the names of any broker-dealers and any applicable commission or discount will be included in a supplement to this prospectus, called a prospectus supplement. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are an &#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 and a &#147;smaller reporting company&#148; as that term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, and as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. See &#147;Prospectus Summary&nbsp;&#151;&nbsp;Implications of Being an Emerging Growth Company.&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Our business and an investment in our common stock involve significant risks. These risks are described under the caption &#147;Risk Factors&#148; beginning on page <a href="#tRF">5</a> of this prospectus.</B> </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B> </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The date of this prospectus is December 29, 2014. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="TOC"></a>TABLE OF CONTENTS </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="552"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="40"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Page</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tPS">Prospectus Summary</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tPS">1</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tRF">Risk Factors</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tRF">5</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSNR">Special Note Regarding Forward-Looking Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSNR">25</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tUOP">Use of Proceeds</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tUOP">27</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSSH">Selling Stockholders</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSSH">27</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tPOD">Plan of Distribution</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tPOD">30</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tDP">Dividend Policy</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tDP">31</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tDIL">Dilution</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tDIL">31</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tMPD">Market Price of and Dividends on Common Stock and Related Matters</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tMPD">32</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tMDA">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tMDA">34</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tBUS">Business</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tBUS">44</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tMGMT">Management</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tMGMT">67</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tEDC">Executive and Director Compensation</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tEDC">74</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tCRRT">Certain Relationships and Related Party Transactions</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tCRRT">81</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tPST">Principal Stockholders</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tPST">83</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tDCS">Description of Capital Stock</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tDCS">85</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSEF">Shares Eligible for Future Sale</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSEF">90</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tLM">Legal Matters</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tLM">90</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tEXP">Experts</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tEXP">90</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tWYC">Where You Can Find More Information About Us</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tWYC">90</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tICF">Index to Consolidated Financial Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tICF">92</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">
i
<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>You should rely only on the information contained in this prospectus. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.</I> </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tPS"></a>PROSPECTUS SUMMARY </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This summary provides an overview of selected information contained elsewhere in this prospectus and does not contain all of the information you should consider before investing in our common stock. You should carefully read this prospectus and the registration statement of which this prospectus is a part in their entirety before investing in our common stock, including the information discussed under &#147;Risk Factors&#148; beginning on page <a href="#tRF">5</a> and our financial statements and notes thereto that appear elsewhere in this prospectus. As used in this prospectus, unless the context requires otherwise, the
&#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to AmpliPhi Biosciences Corporation, a Washington corporation, or, where appropriate, Targeted Genetics Corporation or AmpliPhi Biosciences Corporation, a Delaware corporation to be formed in connection with the Company&#146;s planned reincorporation. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Company </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics. Our proprietary pipeline is based on the use of bacteriophages, a family of viruses that infect only bacteria. Phages have powerful and highly selective mechanisms of action that permit them to target and kill specific bacterial pathogens, including the so-called multi-drug-resistant (MDR) or &#147;Superbug&#148; strains. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe that we are a leading developer of phage-based therapeutics. We are combining our proprietary approach and expertise in identifying, characterizing and developing naturally occurring bacteriophages with that of our collaboration partners in bacteriophage biology, drug engineering, development and manufacturing, to develop second-generation bacteriophage products. We believe that phages represent a promising means to treat bacterial infections, especially those that have developed resistance to current medicines. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The extensive use of antibiotics, since their discovery in the 1940s, has resulted in drug resistance among many disease-causing bacteria. Resistance to antibiotics, according to the Centers for Disease Control (CDC), threatens to reverse the medical advances of the last half-century. Examples of clinically important microbes that are rapidly developing resistance to available antimicrobials include bacteria that cause skin, bone, lung and bloodstream infections (e.g., <I>S. aureus</I> and MRSA), pneumonia and lung infections in the community, hospital and cystic fibrosis (e.g., <I>A. baumanii, P. aeruginosa,</I> and <I>K.
pneumoniae</I>), meningitis (e.g., <I>S. pneumonia</I>), urinary tract and gastrointestinal infections (e.g., <I>E. coli</I> and <I>C. difficile</I>). As a phage kills bacteria in ways entirely unlike the mechanisms used by antibiotics, multi-drug resistant bacteria are not resistant to a phage in the same manner. Furthermore, as new resistant bacteria emerge, it should be possible to identify new phages that will still have efficacy.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our lead program is AmpliPhage-002, for the treatment of <I>S. aureus</I> infections (including methicillin-resistant MRSA). We also have two other product candidates in development: AmpliPhage-001 for the treatment of <I>P. aeruginosa</I> lung infections in CF patients, and AmpliPhage-004 for the treatment of <I>C. difficile</I> infections. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are developing these phage product candidates using our proprietary discovery and development platform, which is designed for rapid identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several carefully chosen phages which target a specific disease-causing bacterial pathogen such as MRSA, <I>P. aeruginosa</I> and <I>C. difficile</I>. We believe that our understanding of unique regulatory and development requirements of bacteriophage biology combined with the scientific expertise of our collaboration partners will enable the rapid advancement of phage treatments
through the clinic and eventually to the market.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2013, we entered into an Exclusive Channel Collaboration (ECC) with Intrexon Corporation, which we refer to as Intrexon, directed towards the research, development and commercialization of new bacteriophage-based therapies to target specific antibiotic-resistant infections, including for use in the treatment of bacterial infections associated with acute and chronic wounds, the treatment of acute and chronic <I>P. aeruginosa</I> lung infections, and the treatment of infections of <I>C. difficile</I>. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2013, we entered into a collaboration agreement, which we refer to as the April Collaboration Agreement, and on September 5, 2013, we entered into a license agreement, which we refer to as the Leicester License Agreement, with the University of Leicester to develop a phage therapy that targets and kills all toxin types of <I>C. difficile</I>. Pursuant to the Leicester License Agreement, we may be obligated to pay the University of Leicester a percentage royalty in the single digits and an aggregate of up to &#8364;575,000 in milestone payments. We also entered into a collaboration agreement on August 1, 2013, which we
refer to as the August Collaboration Agreement, with the University of Leicester and the University of Glasgow, whereby the University of Glasgow will carry out certain animal model development work. Pursuant to the August Collaboration Agreement, we may be obligated to pay up to a total of approximately &#8364;205,000 in milestone payments. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2013, we entered a cooperative research and development agreement (CRADA) with the United States Army Reserve Medical Corps (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR) focusing on developing bacteriophage therapeutics to treat <I>S. aureus</I>, <I>E. coli</I> and <I>P. aeruginosa</I> infections. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We plan to initiate a clinical trial in 2015 in collaboration with the U.S. Army that will support the development of a treatment for <I>S. Aureus</I> infections for wound and skin infections. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Risks </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An investment in our common stock involves a high degree of risk. You should carefully consider the risks summarized below. These risks are discussed more fully in the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus summary. These risks include, but are not limited to, the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we are seeking to develop antibacterial agents using bacteriophage technology, which has not resulted in any approved product on the market to date; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and our future profitability is uncertain; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we must hire additional members of our senior management team, including a Chief Executive Officer, and we must retain and motivate our personnel; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we must develop commercial-scale manufacturing capabilities;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we are dependent on patents and proprietary technology. If we fail to adequately protect our intellectual property or if we otherwise do not have exclusivity for the marketing of our products, our ability to commercialize products could suffer; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">if our competitors are able to develop and market products that are more effective, safer or more affordable than ours, or obtain marketing approval before we do, our commercial opportunities may be limited; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the price of our common stock has been and may continue to be volatile; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our auditors have expressed substantial doubt about our ability to continue as a going concern and we must raise additional capital to continue operations. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Implications of Being an Emerging Growth Company </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until the earliest of (1) the last day of the first fiscal year (a) following the fifth anniversary of the completion of an initial public offering, (b) in which we have total annual gross revenue of at least $1.0 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeded $700.0 million as of the prior June 30<sup>th</sup>; or (2) the date on which we have issued more than $1.0
billion in non-convertible debt </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">during the prior three-year period. We refer to the Jumpstart Our Business Startups Act of 2012 herein as the &#147;JOBS Act&#148; and references herein to &#147;emerging growth company&#148; shall have the meaning associated with it in the JOBS Act. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As an emerging growth company, we intend to take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">only two years of audited consolidated financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Conditions and Results of Operations&#148; disclosure; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reduced disclosure about our executive compensation arrangements; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">no requirement that we hold non-binding advisory votes on executive compensation or golden parachute arrangements; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards, and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We also qualify as a &#147;smaller reporting company,&#148; as defined by Regulation S-K under the Securities Act of 1933, as amended, which we refer to as the Securities Act. As such, we also are exempt from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and also are subject to less extensive disclosure requirements regarding executive compensation in our periodic reports and proxy statements, and to exemptions from the requirements to hold a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will continue to
be deemed a smaller reporting company until our public float exceeds $75 million on the last day of our second fiscal quarter in any fiscal year. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Corporate Information </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We were incorporated under the laws of the State of Washington in March 1989 as a wholly owned subsidiary of Immunex Corporation and began operations as an independent company in 1992 as Targeted Genetics Corporation. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In January 2011, we completed the acquisition of Biocontrol Ltd, which we refer to as Biocontrol, an antimicrobial biotechnology company based in the United Kingdom, with the goal of developing their phage therapy programs using funding from the sale of our legacy gene therapy assets. On February 22, 2011, we changed our name to &#147;AmpliPhi Biosciences Corporation.&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2012, we completed the acquisition of Special Phage Holdings Pty Ltd, a company based in Australia, which we refer to as SPH, pursuant to our offer to acquire all outstanding shares of SPH from its shareholders under the terms of a Shareholder Sale Agreement and a Managers Warranty Deed. SPH was formed in 2004 to address the rapidly escalating problem of antibiotic resistance through the development of a series of bacteriophage-based treatments. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to reincorporate as AmpliPhi Biosciences Corporation in the State of Delaware. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our principal executive offices are located at 4870 Sadler Road, Suite 300, Glen Allen, VA 23060. The telephone number at our principal executive office is (804) 205-5069. Our website address is <I>http://www.ampliphibio.com</I>. Our website and the information contained on, or that can be accessed through, our website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus. You should not rely on our website or any such information in making your decision whether to purchase our common stock. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">3</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">THE OFFERING </H1>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Common stock covered by this prospectus </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">73,362,164 shares </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt"><a name="tSTKOUT"></a>Common stock outstanding as of October 20, 2014 </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">273,869,493 shares </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Use of proceeds </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">The Selling Stockholders will receive all of the proceeds from the sale of the shares offered for sale by them under this prospectus. We will not receive proceeds from the sale of the shares by the Selling Stockholders. See &#147;Use of Proceeds.&#148; </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">We may receive proceeds upon the cash exercise of warrants held by the Selling stockholders, the underlying shares of which are offered under this prospectus. Any proceeds of such warrant exercises will be used for general corporate purposes. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Risk factors </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">See the section entitled &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in shares of our common stock. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Dividend policy </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">We currently intend to retain any future earnings to fund the development activities and operation of our business. Therefore, we do not currently anticipate paying cash dividends on our common stock. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Trading symbol </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">Our common stock is quoted on the OTCQB market under the symbol &#147;APHB.&#148; </TD>

</TR>

</TABLE><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The number of shares of our common stock outstanding as of October 20, 2014 is 273,869,493, which consists of 187,159,093 shares of common stock outstanding as of October 20, 2014, and 86,710,400 shares of common stock issuable upon conversion of all outstanding shares of Series B Convertible Preferred Stock as of October 20, 2014 (assuming a conversion ratio equal to ten (10) common shares for each share of Series B Convertible Preferred Stock), and does not include the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">25,555,000 shares of our common stock issuable upon the exercise of stock options outstanding under our 2012 Stock Incentive Plan, or the 2012 Plan, at a weighted-average exercise price of $0.19 per share; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">9,322,964 shares of our common stock reserved for future issuance under the 2012 Plan; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">164,000 shares of our common stock issuable upon the exercise of stock options outstanding under our Targeted Genetics Corporation Stock Incentive Plan, or the 2009 Plan, at a weighted-average exercise price of $0.75 per share; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">1,306,760 shares of our common stock reserved for future issuance under the 2009 Plan; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">750,000 shares of Common Stock issuable upon the exercise of stock options outstanding under our 2013 Stock Incentive Plan, or the 2013 Plan, at a weighted-average exercise price of $10.28 per share;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">39,250,000 shares of common stock reserved for future issuance under the 2013 Plan; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">38,890,451 shares of our common stock issuable upon the exercise of outstanding warrants, at a weighted-average exercise price of $0.15 per share. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">4</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tRF"></a>RISK FACTORS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>An investment in our common stock involves a high degree of risk. We operate in an industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This could cause the trading price of our common stock to decline, and you may lose all or part of your investment.</I> </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to Our Business </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are seeking to develop antibacterial agents using bacteriophage technology, which has not resulted in any approved product on the market to date. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are developing our product candidates with bacteriophage technology. We have not, nor to our knowledge has any other company, received regulatory approval from the U.S. Food and Drug Administration, or FDA or equivalent foreign agencies for a pharmaceutical drug based on this approach. While <I>in vitro </I>studies have characterized the behavior of bacteriophages in cell cultures and there exists a body of literature regarding the use of phage therapy in humans, the safety and efficacy of phage therapy in humans has not been extensively studied in well-controlled modern clinical trials. Most of the prior research on
phage-based therapy was conducted in the former Soviet Union prior to and immediately after World War II and lacked appropriate control group design or lacked control groups at all. Furthermore, the standard of care has changed substantially during the ensuing decades since those studies were performed, making claims of improved cure rates open for debate. We cannot be certain that our approach will lead to the development of approvable or marketable drugs. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Developing phage-based therapies on a commercial scale will also require developing new manufacturing processes and techniques. We and our third-party collaborators may experience delays in developing manufacturing capabilities for our product candidates, and may not be able to do so at the scale required to conduct efficiently the clinical trials required to obtain regulatory approval of our products, or to manufacture commercial quantities of our products, if approved. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, the FDA or other regulatory agencies may lack experience in evaluating the safety and efficacy of drugs based on these targeting approaches, which could lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Delays in our clinical trials could result in us not achieving anticipated developmental milestones when expected, increased costs and delay our ability to obtain regulatory approval and commercialize our product candidates. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Delays in our ability to commence or enroll patients for our clinical trials could result in us not meeting anticipated clinical milestones and could materially impact our product development costs and delay regulatory approval of our product candidates. We do not know whether planned clinical trials will be commenced or completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in the development of manufacturing capabilities for our product candidates to enable their consistent production at clinical trial scale; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in the commencement of clinical trials as a result of clinical trial holds or the need to obtain additional information to complete an Investigational New Drug Application (IND);</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in obtaining regulatory approval to commence new trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">adverse safety events experienced during our clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in obtaining clinical materials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">slower than expected patient recruitment for participation in clinical trials; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in reaching agreement on acceptable clinical trial agreement terms with prospective sites or obtaining institutional review board approval.</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">5</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we do not successfully commence or complete our clinical trials on schedule, the price of our common stock may decline. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not completed formulation development of any of our product candidates. </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The development of our bacteria phage product candidates requires that we isolate, select and combine a number of bacteria phages that target the desired bacteria for that product candidate. The selection of bacteria phages for any of our product candidates is based on a variety of factors, including without limitation the ability of the selected phages, in combination, to successfully kill the targeted bacteria, the degree of cross-reactivity of the individual phages with the same part of the bacterial targets, the ability of the combined phages to satisfy regulatory requirements, our ability to manufacture sufficient
quantities of the phages, intellectual property rights of third parties, and other factors. While we have selected an initial formulation of AmpliPhage-002 for the treatment of methicillin-resistant S. aureus (MRSA) infections, there can be no assurance that this will be the final formulation of AmpliPhage-002 for commercialization. In addition, we are still finalizing initial formulations of AmpliPhage-001 and AmpliPhage-004. If we are unable to complete formulation development of our product candidates in the time frame that we have anticipated, then our product development timelines, and the regulatory approval of our product candidates, could be delayed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We must hire a new chief executive officer and additional members of our senior management team.</H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">By mutual agreement of the Board of Directors of the Company and Philip J. Young, Mr. Young stepped down from his role as President and Chief Executive Officer of the Company in September 2014. We are looking to replace Mr. Young with a new Chief Executive Officer, and in the interim, Jeremy Curnock Cook, the Chairman of our Board of Directors, is acting as interim Chief Executive Officer, and Wendy Johnson, a member of our Board of Directors, is acting as interim Chief Operating Officer. If we are unable to find a suitable Chief Executive Officer, we may have difficulty executing our business plans, which could cause delays in
the commencement of clinical trials or other business activities. The change in Chief Executive Officer may also make it difficult to retain other personnel, and the loss of additional personnel could also have an adverse impact on our business and operations. We are also looking to add additional members to the Company&#146;s management team, including the possible additions of senior staff to manage key functions in research, clinical and non-clinical development. . If we do not hire additional senior management personnel, we may not be able to effectively manage our business and operations.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our auditors have expressed substantial doubt about our ability to continue as a going concern and we must raise additional capital to continue operations. </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our consolidated financial statements were prepared under the assumption that we would continue our operations as a going concern. However, as discussed in Note 2 to our consolidated financial statements, we have had recurring losses from operations, negative operating cash flow and an accumulated deficit that raise substantial doubt about our ability to continue as a going concern. Uncertainty concerning our ability to continue as a going concern may hinder our ability to obtain future financing. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In December 2013, we completed a private placement of shares of our common stock, which raised approximately $18 million, prior to commissions. We do not generate any cash from operations and must raise additional funds in order to continue operating our business. We expect to continue to fund our operations primarily through equity and debt financings in the future. If additional capital is not available, we may not be able to continue to operate our business pursuant to our business plan or we may have to discontinue our operations entirely. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Developing drugs and conducting clinical trials is expensive. Our future funding requirements will depend on many factors, including: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs and timing of our research and development activities;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the progress and cost of our clinical trials and other research and development activities;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the cost and timing of securing manufacturing capabilities for our clinical product candidates and commercial products, if any;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">6</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the terms and timing of any collaborative, licensing, acquisition or other arrangements that we may establish;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs and timing of obtaining regulatory approvals;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs of filing, prosecuting, defending and enforcing any patent applications, claims, patents and other intellectual property rights; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs of lawsuits involving us or our product candidates.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">We will seek additional capital to support our product development activities. We may seek funds through arrangements with collaborators or others that may require us to relinquish rights to the products candidates that we might otherwise seek to develop or commercialize independently. We cannot be certain that we will be able to enter into any such arrangements on reasonable terms, if at all. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">We may seek to raise capital through a variety of sources, including:</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the public equity market;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">private equity financing;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborative arrangements;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">licensing arrangements; and/or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">public or private debt.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our ability to raise additional funds will depend, in part, on the status of our product development activities and other business operations, as well as factors related to financial, economic, and market conditions, collaboration or license agreement with others and factors related to financial, economic and market conditions, many of which are beyond our control. We cannot be certain that sufficient funds will be available to us when required or on satisfactory terms, if at all. Raising additional capital through the sale of securities could cause significant dilution to our stockholders. If adequate funds are not available,
we may be required to significantly reduce or refocus our operations or to obtain funds through additional arrangements that may require us to relinquish rights to certain of our products, technologies or potential markets, any of which could delay or require that we curtail or eliminate some or all of our development programs or otherwise have a material adverse effect on our business, financial condition and results of operations. In addition, we may have to delay, reduce the scope of or eliminate some of our research and development, which could delay the time to market for any of our product candidates, if adequate funds are not available. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are unable to secure additional financing on a timely basis or on terms favorable to us, we may be required to cease or reduce certain research and development projects, to sell some or all of our technology or assets or to merge all or a portion of our business with another entity. Insufficient funds may require us to delay, scale back, or eliminate some or all of our activities, and if we are unable to obtain additional funding, there is uncertainty regarding our continued existence. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Preclinical studies and Phase 1 or 2 clinical trials of our product candidates may not predict the results of subsequent human clinical trials. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Preclinical studies, including studies of our product candidates in animal models of disease, may not accurately predict the result of human clinical trials of those product candidates. In particular, promising animal studies suggesting the efficacy of prototype phage products in the treatment of bacterial infections, such as <I>P. aeruginosa</I> may not predict the ability of these products to treat similar infections in humans. Our phage technology may be found not to be efficacious in treating bacterial infections alone or in combination with other agents, when studied in human clinical trials. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To satisfy FDA or foreign regulatory approval standards for the commercial sale of our product candidates, we must demonstrate in adequate and controlled clinical trials that our product candidates are safe and effective. Success in early clinical trials, including Phase 2 trials, does not ensure that later clinical trials will be successful. Our initial results from Phase 1/2 clinical trials also may not be confirmed by later analysis </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">7</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">or subsequent larger clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our product candidates must undergo rigorous clinical testing, the results of which are uncertain and could substantially delay or prevent us from bringing them to market. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Before we can obtain regulatory approval for a product candidate, we must undertake extensive clinical testing in humans to demonstrate safety and efficacy to the satisfaction of the FDA or other regulatory agencies. Clinical trials of new drug candidates sufficient to obtain regulatory marketing approval are expensive and take years to complete. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We cannot be certain of successfully completing clinical testing within the time frame we have planned, or at all. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent us from receiving regulatory approval or commercializing our product candidates, including the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and/or preclinical testing or to abandon programs; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the results obtained in earlier stage clinical testing may not be indicative of results in future clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">clinical trial results may not meet the level of statistical significance required by the FDA or other regulatory agencies;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">enrollment in our clinical trials for our product candidates may be slower than we anticipate, resulting in significant delays and additional expense;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we, or regulators, may suspend or terminate our clinical trials if the participating patients are being exposed to unacceptable health risks; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the effects of our product candidates on patients may not be the desired effects or may include undesirable side effects or other characteristics that may delay or preclude regulatory approval or limit their commercial use, if approved.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Completion of clinical trials depends, among other things, on our ability to enroll a sufficient number of patients, which is a function of many factors, including: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the therapeutic endpoints chosen for evaluation; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the eligibility criteria defined in the protocol;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the perceived benefit of the investigational drug under study;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the size of the patient population required for analysis of the clinical trial&#146;s therapeutic endpoints;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to recruit clinical trial investigators and sites with the appropriate competencies and experience;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to obtain and maintain patient consents; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">competition for patients by clinical trial programs for other treatments.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may experience difficulties in enrolling patients in our clinical trials, which could increase the costs or affect the timing or outcome of these clinical trials. This is particularly true with respect to diseases with relatively small patient populations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We must develop manufacturing processes for our lead product candidates and any delay in or our inability to do so would result in delays in our clinical trials and materially and negatively affect our business and results.</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are developing novel manufacturing processes for the production of AmpliPhage-002 for treatment of <I>S. aureus</I> (MRSA) infections, AmpliPhage-001 for the treatment of <I>P. aeruginosa</I> infections and AmpliPhage-004 for the treatment of <I>C. difficile</I> infections at facilities in Ljubljana, Slovenia. The manufacturing processes </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">8</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">for our product candidates, and the scale up of such process for clinical trials, is novel, and there can be no assurance that we will be able to complete this work in a timely manner, if at all. Any delay in the development or scale up of these manufacturing processes could delay the start of clinical trials and harm our business. Our facilities in Slovenia must also undergo inspections by JAZMP, the Slovenian agency that rgulates and supervises pharmaceutical products in Slovenia, for compliance with their and the FDA&#146;s current good manufacturing practice regulations, or cGMP regulations, before the respective product
candidates can be approved for use in clinical trials or commercialization. As a result of an initial inspection, we are taking certain non-critical corrective actions regarding the manufacture of AmpliPhage-002, which we believe will lead to certification by JAZMP to manufacture AmpliPhage-002; however, there can be no assurance that we will receive such certification. We will also be subject to additional inspections for GMP compliance for our other product candidates, and may be subject to additional inspections for AmpliPhage-002. In the event these facilities do not receive a satisfactory cGMP inspection for the manufacture of our product candidates, we may need to fund additional modifications to our manufacturing process, conduct additional validation studies, or find alternative manufacturing facilities, any of which would result in significant cost to us as well as a delay of up to several years in obtaining approval for such product candidate.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our manufacturing facilities will be subject to ongoing periodic inspection by the European regulatory authorities, including JAZMP, and the FDA for compliance with European and FDA cGMP regulations. Compliance with these regulations and standards is complex and costly, and there can be no assurance that we will be able to comply. Any failure to comply with applicable regulations could result in sanctions being imposed (including fines, injunctions and civil penalties), failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of product candidates or products, operating restrictions and criminal prosecution. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have conducted and may in the future conduct clinical trials for our products or product candidates outside the United States and the FDA may not accept data from such trials. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have conducted and may in the future choose to conduct one or more of our clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject to certain conditions. For example, the study must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The study population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful.
Generally, the patient population for any clinical studies conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition, such studies would be subject to the applicable local laws and FDA acceptance of the data would be dependent upon its determination that the studies also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept any such data, it would likely result in the need for additional trials, which would be costly and time consuming and delay aspects of our business plan. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may need to license additional intellectual property rights. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The development and commercialization of phage-based antibacterial agents may require us to obtain rights to intellectual property from third parties. For example, pursuant to our Collaborative Research and Development Agreement, or CRADA, with the United States Army Medical Research and Materiel Command, or USAMRMC and the Walter Reed Army Institute of Research, or WRAIR, we are focusing on developing bacteriophage therapeutics to treat <I>S. aureus, E. coli</I> and <I>P.</I> <I>aeruginosa</I> infections. To the extent the intellectual property is generated from the USAMRMC or WRAIR that is used in a commercial product, we
may be obligated to make payments such as royalties, licensing fees and milestone payments. We may also determine that it is necessary or advisable to license other intellectual property from third parties. There can be no assurance that such intellectual property rights would be available on commercially reasonable terms, if at all. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are subject to significant regulatory approval requirements, which could delay, prevent or limit our ability to market our product candidates. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our research and development activities, preclinical studies, clinical trials and the anticipated manufacturing and marketing of our product candidates are subject to extensive regulation by the FDA and </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">9</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">other regulatory agencies in the United States and by comparable authorities in Europe and elsewhere. There can be no assurance that our planned manufacturing facilities will satisfy the requirements of the FDA or comparable foreign authorities. We require the approval of the relevant regulatory authorities before we may commence commercial sales of our product candidates in a given market. The regulatory approval process is expensive and time-consuming, and the timing of receipt of regulatory approval is difficult to predict. Our product candidates could require a significantly longer time to gain regulatory approval than
expected, or may never gain approval. We cannot be certain that, even after expending substantial time and financial resources, we will obtain regulatory approval for any of our product candidates. A delay or denial of regulatory approval could delay or prevent our ability to generate product revenues and to achieve profitability. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Changes in regulatory approval policies during the development period of any of our product candidates, changes in, or the enactment of, additional regulations or statutes, or changes in regulatory review practices for a submitted product application may cause a delay in obtaining approval or result in the rejection of an application for regulatory approval. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Regulatory approval, if obtained, may be made subject to limitations on the indicated uses for which we may market a product. These limitations could adversely affect our potential product revenues. Regulatory approval may also require costly post-marketing follow-up studies. In addition, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping related to the product will be subject to extensive ongoing regulatory requirements. Furthermore, for any marketed product, its manufacturer and its manufacturing facilities will be subject to continual review and periodic inspections by the
FDA or other regulatory authorities. Failure to comply with applicable regulatory requirements may, among other things, result in fines, suspensions of regulatory approvals, product recalls, product seizures, operating restrictions and criminal prosecution. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA and foreign regulatory authorities may impose significant restrictions on the indicated uses and marketing of pharmaceutical products. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">FDA rules for pharmaceutical promotion require that a company not promote an unapproved drug or an approved drug for an unapproved use. In addition to FDA requirements, regulatory and law enforcement agencies, such as the United States Department of Health and Human Services&#146; Office of Inspector General and the United States Department of Justice, monitor and investigate pharmaceutical sales, marketing and other practices. For example, sales, marketing and scientific/educational grant programs must comply with the Medicare-Medicaid Anti-Fraud and Abuse Act, as amended, the False Claims Act, as amended, and similar state
laws. In recent years, actions by companies&#146; sales forces and marketing departments have been scrutinized intensely to ensure, among other things, that actions by such groups do not qualify as &#147;kickbacks&#148; to healthcare professionals. A &#147;kickback&#148; refers to the provision of any item of value to a healthcare professional or other person in exchange for purchasing, recommending, or referring an individual for an item or service reimbursable by a federal healthcare program. These kickbacks increase the expenses of the federal healthcare program and may result in civil penalties, criminal prosecutions, and exclusion from participation in government programs, any of which would adversely affect our financial condition and business operations. In addition, even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which would also
harm our financial condition. Comparable laws also exist at the state level. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. As a biotechnology company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other
third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#146; rights are and will be applicable to our business. Federal healthcare Anti-Kickback Statute will </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">10</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">constrain our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities, by prohibiting, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. Federal civil and criminal false claims laws and civil monetary penalty laws
impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, also imposes obligations,
including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The federal physician sunshine requirements under the Affordable Care Act requires manufacturers of drugs, devices, biologics and medical supplies to report annually to HHS information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations. Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims
involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not
comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are, and in the future may be, subject to new federal and state requirements to submit information on our open and completed clinical trials to public registries and databases. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In 1997, a public registry of open clinical trials involving drugs intended to treat serious or life-threatening diseases or conditions was established under the Food and Drug Administration Modernization Act, or FDMA, in order to promote public awareness of and access to these clinical trials. Under FDMA, pharmaceutical manufacturers and other clinical trial sponsors are required to post the general purpose of these clinical trials, as well as the eligibility criteria, location and contact information of the clinical trials. Since the establishment of this registry, there has been significant public debate focused on
broadening the types of clinical trials included in this or other registries, as well as providing for public access to clinical trial results. A voluntary coalition of medical journal editors has adopted a resolution to publish results only from those clinical trials that have been registered with a no-cost, publicly accessible database, such as <I>www.clinicaltrials.gov</I>. The Pharmaceuticals and Research Manufacturers of America has also issued voluntary principles for its members to make results from certain clinical trials publicly available and has established a </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">11</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">website for this purpose. Other groups have adopted or are considering similar proposals for clinical trial registration and the posting of clinical trial results. The state of Maine has enacted legislation, with penalty provisions, requiring the disclosure of results from clinical trials involving drugs marketed in the state, and similar legislation has been introduced in other states. Federal legislation was introduced in the fall of 2004 to expand <I>www.clinicaltrials.gov</I> and to require the inclusion of clinical trial results in this registry. In some states, such as New York, prosecutors have alleged that a lack of
disclosure of clinical trial information constitutes fraud, and these allegations have resulted in settlements with pharmaceutical companies that include agreements to post clinical trial results. Our failure to comply with any clinical trial posting requirements could expose us to negative publicity, fines, and other penalties, all of which could materially harm our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We do not have a sales force and do not currently have plans to develop one. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The commercial success of any of our product candidates will depend upon the strength of sales and marketing efforts for them. We do not have a sales force and have no experience in sales, marketing or distribution. To successfully commercialize our product candidates, we will need to develop such a capability ourselves or seek assistance from a third party with a large distribution system and a large direct sales force. We may be unable to put such a plan in place. In addition, if we arrange for others to market and sell our products, our revenues will depend upon the efforts of those parties. Such arrangements may not
succeed. Even if one or more of our product candidates is approved for marketing, if we fail to establish adequate sales, marketing and distribution capabilities, independently or with others, our business will be materially harmed. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to Our Financial Performance and Operations </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and our future profitability is uncertain. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have incurred losses in each year since our inception in 1992. Prior to the merger of Targeted Genetics Corporation with Biocontrol in January 2011, our accumulated deficit was $315.5 million, and Biocontrol had an accumulated deficit of $6.9 million. Since January 2011 and through September 30, 2014, we have incurred an accumulated deficit of $37.9 million, and we expect to incur losses for the foreseeable future. We have devoted, and will continue to devote for the foreseeable future, substantially all of our resources to research and development of our product candidates. For the year ended December 31, 2012, we had an
operating loss of $4.3 million and a net loss of $1.1 million. For the year ended December 31, 2013, we had an operating loss and a net loss of $57.7 million. Clinical trials and activities associated with discovery research are costly. We do not expect to generate any revenue from the commercial sales of our product candidates in the near term, and we expect to continue to have significant losses for the foreseeable future. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To attain ongoing profitability, we will need to develop products successfully and market and sell them effectively, or rely on other parties to do so. We cannot predict when we will achieve ongoing profitability, if at all. We have never generated revenue from the commercial sales of our product candidates, and there is no guarantee that we will be able to do so in the future. If we fail to become profitable, or if we are unable to fund our continuing losses, we would be unable to continue our research and development programs. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our success depends in part on retaining and motivating our personnel. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our success depends on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel and on our ability to develop and maintain important relationships with leading academic institutions, clinicians and scientists. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of October 20, 2014, we had 22 employees. Our success will depend on our ability to retain and motivate remaining personnel and hire additional qualified personnel when required. Competition for qualified personnel in the biotechnology field is intense. We face competition for personnel from other biotechnology and pharmaceutical companies, universities, public and private research institutions and other organizations. We may not be able to attract and retain qualified personnel on acceptable terms given the competition for such personnel. If we are unsuccessful in our retention, motivation and recruitment efforts, we may
be unable to execute our business strategy. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">12</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have determined that a material weakness existed in our system of internal control over financial reporting, which could have had a material impact on our business.</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are required to maintain internal control over financial reporting adequate to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our consolidated financial statements in accordance with generally accepted accounting principles. In connection with the restatement of our consolidated financial statements for the years ended December 31, 2012 and the quarter ended September 30, 2013, we determined that we had a material weakness as of December 31, 2013, namely that our controls over the evaluation and review of complex and non-routine transactions were not effective. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Due to this material weakness, we have concluded that as of December 31, 2013, our internal control over financial reporting were not effective. Subsequent to December 31, 2013, we have restated our consolidated financial statements as of December 31, 2013 to correct for errors caused by this weakness.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We do not expect that our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Over time, controls may become
inadequate because changes in conditions or deterioration in the degree of compliance with policies or procedures may occur. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. As a result, we cannot assure you that significant deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future. A material weakness means a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the registrant&#146;s annual or interim financial statements will not be prevented or detected on a timely basis. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to Our Dependence on Third Parties </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We rely on third parties for aspects of product development. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We rely on third parties such as the University of Leicester and the U.S. Army for certain aspects of product development. We are working with the University of Leicester for research and development of product candidates to treat <I>C. difficile</I> infections. We are working with the U.S. Army for research and development of product candidates to treat <I>S. aureus</I> infections, and we are working with Intrexon to develop new strains of manufacturing hosts for our phage therapies. Because we rely on third parties to conduct these activities, we have less control over the success of these programs than we would if we were
conducting them on our own. Factors beyond our control that could impact the success of these programs include the amount of resources devoted to the programs by the applicable third party, the staffing of those projects by third-party personnel, and the amount of time such personnel devote to our programs compared to other programs. Failure of our third-party collaborators to successfully complete the projects that we are working on with them could result in delays in product development and the need to expend additional resources, increasing our expenses beyond current expectations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will rely on third parties to conduct some of our clinical trials, and their failure to perform their obligations in a timely or competent manner may delay development and commercialization of our product candidates. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect to use third parties such as clinical research organizations or the U.S. Army to assist in conduct of our clinical trials. There are numerous alternative sources to provide these services. However, we may face delays outside of our control if these parties do not perform their obligations in a timely or competent fashion or if we are forced to change service providers. This risk is heightened for clinical trials conducted outside of the United States, where it may be more difficult to ensure that clinical trials are conducted in compliance with FDA requirements. Any third-party that we hire to conduct clinical trials
may also provide services to our competitors, which could compromise the performance of their obligations to us. If we experience significant delays in the progress of our clinical trials and in our plans to file New Drug </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">13</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Applications (NDAs), the commercial prospects for product candidates could be harmed and our ability to generate product revenue would be delayed or prevented. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will rely on the U.S. Army to conduct our Phase 1 clinical trial, and their failure to perform in a timely manner may significantly delay the AmpliPhage-002 clinical program.</H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to our Collaborative Research and Development Agreement, or CRADA, with the United States Army Medical Research and Materiel Command, or USAMRMC and the Walter Reed Army Institute of Research, or WRAIR, we expect to utilize US Army human resources and facilities to conduct our planned Phase 1 clinical trial of AmpliPhage-002. Due to recent outbreaks of the Ebola virus, the Army has diverted significant resources to studying this potential epidemic. As a result, the U.S. Army has advised the Company there may be a delay in initiating the planned Phase 1AmpliPhage-002 study, which may significantly impact our ability to
conduct this clinical trial prior to the first half of 2015. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We must manage a geographically dispersed organization. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">While we are a small company, we currently have operations in the United States, Australia, United Kingdom and Slovenia. In the future, we may also locate facilities in other locations based on proximity to personnel with the expertise needed to research, develop and manufacture phage-based therapeutics, costs of operations or other factors. Managing our organization across multiple locations and multiple time zones may reduce our efficiency, increase our expenses and increase the risk of operational difficulties in the execution of our plans. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to Our Intellectual Property </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are dependent on patents and proprietary technology. If we fail to adequately protect this intellectual property or if we otherwise do not have exclusivity for the marketing of our products, our ability to commercialize products could suffer. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our commercial success will depend in part on our ability to obtain and maintain patent protection sufficient to prevent others from marketing our product candidates, as well as to defend and enforce these patents against infringement and to operate without infringing the proprietary rights of others. Protection of our product candidates from unauthorized use by third parties will depend on having valid and enforceable patents cover our product candidates or their manufacture or use, or having effective trade secret protection. If our patent applications do not result in issued patents, or if our patents are found to be
invalid, we will lose the ability to exclude others from making, using or selling the inventions claimed therein. We have a limited number of patents and pending patent applications. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The patent positions of biotechnology companies can be uncertain and involve complex legal and factual questions. This is due to inconsistent application of policy and changes in policy relating to examination and enforcement of biotechnology patents to date on a global scale. The laws of some countries may not protect intellectual property rights to the same extent as the laws of countries having well-established patent systems, and those countries may lack adequate rules and procedures for defending our intellectual property rights. Also, changes in either patent laws or in interpretations of patent laws may diminish the
value of our intellectual property. We are not able to guarantee that all of our patent applications will result in the issuance of patents and we cannot predict the breadth of claims that may be allowed in our patent applications or in the patent applications we may license from others. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we might not have been the first to make the inventions covered by each of our pending patent applications and issued patents, and we may have to participate in expensive and protracted interference proceedings to determine priority of invention; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we might not have been the first to file patent applications for these inventions;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">others may independently develop similar or alternative product candidates to any of our product candidates that fall outside the scope of our patents;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">14</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our pending patent applications may not result in issued patents;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our issued patents may not provide a basis for commercially viable products or may not provide us with any competitive advantages or may be challenged by third parties;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">others may design around our patent claims to produce competitive products that fall outside the scope of our patents;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may not develop additional patentable proprietary technologies related to our product candidates; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we are dependent upon the diligence of our appointed agents in national jurisdictions, acting for and on our behalf, which control the prosecution of pending domestic and foreign patent applications and maintain granted domestic and foreign patents.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An issued patent does not guarantee us the right to practice the patented technology or commercialize the patented product. Third parties may have blocking patents that could be used to prevent us from commercializing our patented products and practicing our patented technology. Our issued patents and those that may be issued in the future may be challenged, invalidated or circumvented, which could limit our ability to prevent competitors from marketing the same or related product candidates or could limit the length of the term of patent protection of our product candidates. Moreover, because of the extensive time required
for development, testing and regulatory review of a potential product, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent. Patent term extensions may not be available for these patents. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We rely on trade secrets and other forms of non-patent intellectual property protection. If we are unable to protect our trade secrets, other companies may be able to compete more effectively against us. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We rely on trade secrets to protect certain aspects of our technology, including our proprietary processes for manufacturing and purifying bacteriophages. Trade secrets are difficult to protect, especially in the pharmaceutical industry, where much of the information about a product must be made public during the regulatory approval process. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained
and is using our trade secret information is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to or may not protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are sued for infringing intellectual property rights of third parties or if we are forced to engage in an interference proceeding, it will be costly and time-consuming, and an unfavorable outcome in that litigation or interference would have a material adverse effect on our business. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our ability to commercialize our product candidates depends on our ability to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties. Numerous United States and foreign patents and patent applications, which are owned by third parties, exist in the general field of anti-infective products or in fields that otherwise may relate to our product candidates. If we are shown to infringe, we could be enjoined from use or sale of the claimed invention if we are unable to prove that the patent is invalid. In addition, because patent applications can take many years to
issue, there may be currently pending patent applications, unknown to us, which may later result in issued patents that our product candidates may infringe, or which may trigger an interference proceeding regarding one of our owned or licensed patents or applications. There could also be existing patents of which we are not aware that our product candidates may inadvertently infringe or which may become involved in an interference proceeding. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The biotechnology and pharmaceutical industries are characterized by the existence of a large number of patents and frequent litigation based on allegations of patent infringement. For so long as our product candidates are in clinical trials, we believe our clinical activities fall within the scope of the exemptions provided by 35 U.S.C. Section 271(e) in the United States, which exempts from patent infringement liability activities reasonably related to the development and submission of information to the FDA. As our clinical </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">15</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">investigational drug product candidates progress toward commercialization, the possibility of a patent infringement claim against us increases. While we attempt to ensure that our active clinical investigational drugs and the methods we employ to manufacture them, as well as the methods for their use we intend to promote, do not infringe other parties&#146; patents and other proprietary rights, we cannot be certain they do not, and competitors or other parties may assert that we infringe their proprietary rights in any event. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may be exposed to future litigation based on claims that our product candidates, or the methods we employ to manufacture them, or the uses for which we intend to promote them, infringe the intellectual property rights of others. Our ability to manufacture and commercialize our product candidates may depend on our ability to demonstrate that the manufacturing processes we employ and the use of our product candidates do not infringe third-party patents. If third-party patents were found to cover our product candidates or their use or manufacture, we could be required to pay damages or be enjoined and therefore unable to
commercialize our product candidates, unless we obtained a license. A license may not be available to us on acceptable terms, if at all. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to Our Industry </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If our competitors are able to develop and market products that are more effective, safer or more affordable than ours, or obtain marketing approval before we do, our commercial opportunities may be limited. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Competition in the biotechnology and pharmaceutical industries is intense and continues to increase. Some companies that are larger and have significantly more resources than we do are aggressively pursuing antibacterial development programs, including traditional therapies and therapies with novel mechanisms of action. In addition, other companies are developing phage-based products for non-therapeutic uses, and may elect to use their expertise in phage development and manufacturing to try to develop products that would compete with ours. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We also face potential competition from academic institutions, government agencies and private and public research institutions engaged in the discovery and development of drugs and therapies. Many of our competitors have significantly greater financial resources and expertise in research and development, preclinical testing, conducting clinical trials, obtaining regulatory approvals, manufacturing, sales and marketing than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established pharmaceutical companies. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our competitors may succeed in developing products that are more effective, have fewer side effects and are safer or more affordable than our product candidates, which would render our product candidates less competitive or noncompetitive. These competitors also compete with us to recruit and retain qualified scientific and management personnel, establish clinical trial sites and patient registration for clinical trials, as well as to acquire technologies and technology licenses complementary to our programs or advantageous to our business. Moreover, competitors that are able to achieve patent protection, obtain regulatory
approvals and commence commercial sales of their products before we do, and competitors that have already done so, may enjoy a significant competitive advantage. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In July 2012, the Food and Drug Administration Safety and Innovation Act was passed, which included the Generating Antibiotics Incentives Now Act, or the GAIN Act. The GAIN Act is intended to provide incentives for the development of new, qualified infectious disease products. These incentives may result in more competition in the market for new antibiotics, and may cause pharmaceutical and biotechnology companies with more resources than we have to shift their efforts towards the development of products that could be competitive with our product candidates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There is a substantial risk of product liability claims in our business. If we do not obtain sufficient liability insurance, a product liability claim could result in substantial liabilities. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our business exposes us to significant potential product liability risks that are inherent in the development, manufacturing and marketing of human therapeutic products. Regardless of merit or eventual outcome, product liability claims may result in: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delay or failure to complete our clinical trials; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">withdrawal of clinical trial participants;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">16</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">decreased demand for our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">injury to our reputation;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">litigation costs;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">substantial monetary awards against us; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">diversion of management or other resources from key aspects of our operations.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we succeed in marketing products, product liability claims could result in an FDA investigation of the safety or efficacy of our products, our manufacturing processes and facilities or our marketing programs. An FDA investigation could also potentially lead to a recall of our products or more serious enforcement actions, or limitations on the indications, for which they may be used, or suspension or withdrawal of approval. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have product liability insurance that covers our clinical trials up to a $10 million annual aggregate limit. We intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for our product candidates or any other compound that we may develop. However, insurance coverage is expensive and we may not be able to maintain insurance coverage at a reasonable cost or at all, and the insurance coverage that we obtain may not be adequate to cover potential claims or losses. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which would negatively affect our ability to achieve profitability. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our product candidates may not gain market acceptance among physicians, patients, healthcare payors and the medical community. The degree of market acceptance of any approved products will depend on a number of factors, including: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the effectiveness of the product; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the prevalence and severity of any side effects; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">potential advantages or disadvantages over alternative treatments; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">relative convenience and ease of administration; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the strength of marketing and distribution support; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the price of the product, both in absolute terms and relative to alternative treatments; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">sufficient third-party coverage or reimbursement. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If our product candidates receive regulatory approval but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate product revenues sufficient to attain profitability. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If third-party payors do not adequately reimburse patients for any of our product candidates, if approved for marketing, we may not be successful in selling them. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our ability to commercialize any products successfully will depend in part on the extent to which reimbursement will be available from governmental and other third-party payors, both in the United States and in foreign markets. Even if we succeed in bringing one or more products to the market, the amount reimbursed for our products may be insufficient to allow us to compete effectively and could adversely affect our profitability. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Reimbursement by a governmental and other third-party payor may depend upon a number of factors, including a governmental or other third-party payor&#146;s determination that use of a product is: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a covered benefit under its health plan; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">safe, effective and medically necessary; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">appropriate for the specific patient; </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">17</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">cost-effective; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">neither experimental nor investigational. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Obtaining reimbursement approval for a product from each third-party and governmental payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to each payor. We may not be able to provide data sufficient to obtain reimbursement. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Eligibility for coverage does not imply that any drug product will be reimbursed in all cases or at a rate that allows us to make a profit. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not become permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on payments allowed for lower-cost drugs that are already reimbursed, may be incorporated into existing payments for other products or services and may reflect budgetary constraints and/or Medicare or Medicaid data used to calculate these rates.
Net prices for products also may be reduced by mandatory discounts or rebates required by government healthcare programs or by any future relaxation of laws that restrict imports of certain medical products from countries where they may be sold at lower prices than in the United States. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The healthcare industry is experiencing a trend toward containing or reducing costs through various means, including lowering reimbursement rates, limiting therapeutic class coverage and negotiating reduced payment schedules with service providers for drug products. The Medicare Prescription Drug, Improvement and Modernization Act of 2003, or MMA, became law in November 2003 and created a broader prescription drug benefit for Medicare beneficiaries. The MMA also contains provisions intended to reduce or eliminate delays in the introduction of generic drug competition at the end of patent or non-patent market exclusivity. The
impact of the MMA on drug prices and new drug utilization over the next several years is unknown. The MMA also made adjustments to the physician fee schedule and the measure by which prescription drugs are presently paid, changing from Average Wholesale Price to Average Sales Price. The effects of these changes are unknown but may include decreased utilization of new medicines in physician prescribing patterns, and further pressure on drug company sponsors to provide discount programs and reimbursement support programs. There have been, and we expect that there will continue to be, federal and state proposals to constrain expenditures for medical products and services, which may affect reimbursement levels for our future products. In addition, the Centers for Medicare &amp; Medicaid Services frequently change product descriptors, coverage policies, product and service codes, payment methodologies and reimbursement values. Third-party payors often follow Medicare coverage policy and
payment limitations in setting their own reimbursement rates and may have sufficient market power to demand significant price reductions. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Foreign governments tend to impose strict price controls, which may adversely affect our future profitability. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In some foreign countries, particularly in the European Union, prescription drug pricing is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our profitability will be
negatively affected. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may incur significant costs complying with environmental laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our research and development activities use biological and hazardous materials that are dangerous to human health and safety or the environment. We are subject to a variety of federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these materials and wastes resulting from these materials. We are also subject to regulation by the Occupational Safety and Health Administration, or OSHA, state and federal environmental protection agencies and to regulation under the Toxic Substances Control Act. OSHA, state governments or federal Environmental Protection Agency,
or EPA, may adopt regulations that may affect our research and development programs. We are unable to predict </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">18</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">whether any agency will adopt any regulations that could have a material adverse effect on our operations. We have incurred, and will continue to incur, capital and operating expenditures and other costs in the ordinary course of our business in complying with these laws and regulations. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although we believe our safety procedures for handling and disposing of these materials comply with federal, state and local laws and regulations, we cannot entirely eliminate the risk of accidental injury or contamination from the use, storage, handling or disposal of hazardous materials. In the event of contamination or injury, we could be held liable for any resulting damages, and any liability could significantly exceed our insurance coverage. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to Our Common Stock </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The price of our common stock has been and may continue to be volatile. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The stock markets in general, the markets for biotechnology stocks and, in particular, the stock price of our common stock, have experienced extreme volatility. Although we intend to apply to be listed on the NYSE MKT, our stock is currently quoted on the OTCQB market. The market for our common shares is characterized by significant price volatility when compared to the shares of larger, more established companies that trade on a national securities exchange and have large public floats, and we expect that our share price will continue to be more volatile than the shares of such larger, more established companies for the
indefinite future, even if we are listed on the NYSE MKT. The volatility in our share price is attributable to a number of factors. First, our common shares are, compared to the shares of such larger, more established companies, sporadically and thinly traded. As a consequence of this limited liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influence the price of those shares in either direction. The price for our shares could, for example, decline precipitously in the event that a large number of our common shares are sold on the market without commensurate demand. Secondly, we are a speculative or &#147;risky&#148; investment due to the early stage of our drug development programs and our lack of profits to date, and uncertainty of future market acceptance for our potential products. As a consequence of this enhanced risk, more risk-adverse investors may, under the fear of losing all or most of their investment in the event of
negative news or lack of progress, be more inclined to sell their shares on the market more quickly and at greater discounts than would be the case with the stock of a larger, more established company that trades on a national securities exchange and has a large public float. Many of these factors are beyond our control and may decrease the market price of our common shares, regardless of our operating performance. We cannot make any predictions or projections as to what the prevailing market price for our common shares will be at any time, including as to whether our common shares will sustain their current market prices, or as to what effect that the sale of shares or the availability of common shares for sale at any time will have on the prevailing market price. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Price declines in our common stock could result from general market and economic conditions and a variety of other factors, including: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">adverse results or delays in our clinical trials; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">adverse actions taken by regulatory agencies with respect to our product candidates, clinical trials or the manufacturing processes of our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">announcements of technological innovations, patents or new products by our competitors;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">regulatory developments in the United States and foreign countries;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any lawsuit involving us or our product candidates;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">announcements concerning our competitors, or the biotechnology or pharmaceutical industries in general;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">developments concerning any strategic alliances or acquisitions we may enter into;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">actual or anticipated variations in our operating results;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">changes in recommendations by securities analysts or lack of analyst coverage;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">deviations in our operating results from the estimates of analysts;</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">19</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">sales of our common stock by our executive officers, directors and five percent stockholders or sales of substantial amounts of common stock; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">loss of any of our key scientific or management personnel.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the past, following periods of volatility in the market price of a particular company&#146;s securities, litigation has often been brought against that company. Any such lawsuit could consume resources and management time and attention, which could adversely affect our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You may incur substantial dilution as a result of future offerings of our securities.</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You may incur substantial dilution as a result of future offerings by us of debt or equity securities. Since inception, we have funded our operations primarily through issuances of equity and debt. On June 26, 2013, we completed a private placement of convertible preferred stock and warrants to purchase common stock with gross proceeds of approximately $7.0 million through the sale of shares of our newly-created Series B Convertible Preferred Stock. As part of the same transaction, approximately $5.5 million in outstanding convertible notes were converted into shares of Series B Convertible Preferred Stock and warrants to
purchase common stock. On July 15, 2013, we completed a second closing in which we converted approximately $0.8 million of outstanding convertible notes into Series B Convertible Preferred Stock and warrants to purchase common stock. The financing was led by life-sciences investors RA Capital Management and Third Security, LLC, with participation from BioScience Managers Pty Ltd.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the terms of the financing, we issued an aggregate amount of approximately 10.0 million shares of Series B Convertible Preferred Stock for an aggregate purchase price of approximately $13.3 million (including the conversion of approximately $6.3 million of outstanding convertible notes). Each share of Series B Convertible Preferred Stock is convertible into 10 shares of common stock and accrues dividends at the rate of 10% per year. Additionally, we issued warrants to purchase an aggregate of up to approximately 25.0 million shares of common stock at an exercise price of $0.14 per share.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, in December 2013, we completed a private placement in which we issued 72,007,000 shares of the Company's common stock at a price per share of $0.25, and, in connection with the private placement, issued warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share to the placement agents.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A significant number of shares of our common stock are subject to issuance upon exercise of outstanding warrants and options, which upon such exercise would result in dilution to our security holders. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of October 20, 2014, we have outstanding warrants to purchase 38,890,451 shares of our common stock at an average exercise price of $0.15 per share, and outstanding options to purchase 25,719,000 shares of our common stock at an average exercise price of $0.19 per share. The exercise price and/or the number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances, including certain issuances of securities at a price equal to or less than the then current exercise price, subdivisions and stock splits, stock dividends, combinations, reorganizations, reclassifications,
consolidations, mergers or sales of properties and assets and upon the issuance of certain assets or securities to holders of our common stock, as applicable. Although we cannot determine at this time which of these warrants will ultimately be exercised, it is reasonable to assume that such warrants will be exercised only if the exercise price is below the market price of our common stock. To the extent the warrants are exercised, additional shares of our common stock will be issued that will be eligible for resale in the public market, which will result in dilution to our security holders. The issuance of additional securities could also have an adverse effect on the market price of our common stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If our officers, directors and largest stockholders choose to act together, they may be able to control our management and operations, acting in their best interests and not necessarily those of other stockholders. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of October 20, 2014, our officers and directors beneficially owned approximately 17.18% of our outstanding common stock. As a result, these stockholders, acting together, may be able to significantly influence all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of this group of stockholders </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">20</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">may not always coincide with the interests of other stockholders, and they may act in a manner that advances their best interests and not necessarily those of other stockholders. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our (i) current articles of incorporation and bylaws, (ii) our intended certificate of incorporation and bylaws upon reincorporation in Delaware, (iii) Washington law and, (iv) upon reincorporation, Delaware law contains provisions that could discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Provisions of (i) Washington law, where we are incorporated, (ii) Delaware law, where we intend to reincorporate, (iii) our current articles of incorporation and bylaws and (iv) our intended certificate of incorporation and bylaws upon our reincorporation in Delaware may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to
replace or remove our board of directors. These provisions include: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">authorizing the issuance of &#147;blank check&#148; preferred stock without any need for action by stockholders; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">providing for a classified board of directors with staggered terms; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">requiring supermajority stockholder voting to effect certain amendments to (i) our current articles of incorporation and bylaws and (ii) our intended certificate of incorporation and bylaws upon reincorporation in Delaware; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">eliminating the ability of stockholders to call special meetings of stockholders; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">prohibiting stockholder action by written consent; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">establishing advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, because we are incorporated in Washington, we are governed by the provisions of Chapter 23B.19 of the Washington Business Corporation Act, or the WBCA, which, among other things, restricts the ability of shareholders owning ten percent (10%) or more of our outstanding voting stock from merging or combining with us. Because we are reincorporating in Delaware, we will then be governed by the provisions of Section 203 of the Delaware General Corporation Law, or the DGCL. These provisions may prohibit large stockholders, in particular those owning fifteen percent (15%) or more of our outstanding voting stock, from
merging or combining with us. These provisions could discourage potential acquisition attempts and could reduce the price that investors might be willing to pay for shares of our common stock in the future and result in the market price being lower than it would without these provisions. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although we believe these provisions collectively provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with our board of directors, they would apply even if an offer may be considered beneficial by some shareholders. In addition, these provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making it difficult for shareholders to replace members of our board of directors, which is responsible for appointing the members of our management. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have never paid dividends on our common stock, and we do not anticipate paying any cash dividends in the foreseeable future. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be our stockholders&#146; sole source of gain for the foreseeable future. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">21</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Maintaining and improving our financial controls and the requirements of being a public company may strain our resources, divert management&#146;s attention and affect our ability to attract and retain qualified board members. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and, if our common stock is listed on an exchange (such as the NYSE MKT), the rules of such exchange. The requirements of these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and may also place undue strain on our personnel, systems and resources. The Exchange Act will require, among other things, that we file annual, quarterly and current reports with respect to our business and financial condition. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Sarbanes-Oxley Act will require, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Ensuring that we have adequate internal financial and accounting controls and procedures in place is a costly and time-consuming effort that needs to be re-evaluated frequently. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently do not have an internal audit group, and we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. Implementing any appropriate changes to our internal controls may require specific compliance training for our directors, officers and employees, entail substantial costs to modify our existing accounting systems, and take a significant period of time to complete. Such changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to
produce accurate financial statements on a timely basis, could increase our operating costs and could materially impair our ability to operate our business. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent fraud. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, our independent registered public accounting firm did not perform an evaluation of our internal control over financial reporting as of December 31, 2013, December 31, 2012 or December 31, 2011 in accordance with the provisions of the Sarbanes-Oxley Act because no such evaluation was required. Although not required, our management did review our internal controls for the year ended December 31, 2013 and identified material weakness in the area of complex and non-routine transactions as further described in Item 9A of our Form 10-K/A filed on September 12, 2014. If we are unable to successfully remediate any
significant deficiency or material weakness in our internal control over financial reporting, identify any additional significant deficiencies or material weaknesses that may exist, or satisfy the requirements of the Sarbanes-Oxley Act, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, and our stock price may decline materially as a result. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In accordance with NYSE MKT rules, we will be required to maintain a majority independent board of directors. We also expect that the various rules and regulations applicable to public companies will make it more difficult and more expensive for us to maintain directors&#146; and officers&#146; liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to maintain coverage. If we are unable to maintain adequate directors&#146; and officers&#146; insurance, our ability to recruit and retain qualified directors, especially those directors who may be deemed independent for purposes
of NYSE MKT rules, and officers will be significantly curtailed. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Compliance with these reporting rules, Sarbanes-Oxley Act and NYSE MKT requirements may require us to build out our accounting and finance staff. We may need to expand our accounting and financing staff, and our failure to adequately do so would harm our ability to comply with the requirements listed above. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We currently have one security analyst and may never obtain additional research coverage by other securities and industry analysts. If no additional securities or industry analysts commence coverage of our company, the trading price for our stock could be negatively </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">22</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">impacted. If we obtain additional securities or industry analyst coverage and if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Future sales of our common stock or securities convertible into our common stock may depress our stock price. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sales of a substantial number of shares of our common stock or securities convertible into our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Moreover, we also intend to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to the lock-up agreements contained in the relevant agreements. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If a large number of shares of our common stock or securities convertible into our common stock are sold in the public market after they become eligible for sale, the sales could reduce the trading price of our common stock and impede our ability to raise future capital. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Trading of our stock is restricted by the SEC&#146;s &#147;penny stock&#148; regulations and certain FINRA rules, which may limit a stockholder&#146;s ability to buy and sell our common stock. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our securities are covered by certain &#147;penny stock&#148; rules, which impose additional sales practice requirements on broker-dealers who sell low-priced securities to persons other than established customers and accredited investors. For transactions covered by these rules, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser&#146;s written consent to the transaction prior to sale, among other things. In addition, the penny stock rules require a broker-dealer, before effecting a transaction in a penny stock not otherwise exempt from the rules, to deliver a
standardized risk disclosure document prepared by the SEC that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer&#146;s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing before effecting the transaction, and must be given to the customer in writing before or with the customer&#146;s confirmation. These rules may affect the ability of broker-dealers and holders to sell our common stock and may negatively impact the level of trading activity for our common stock. To the extent our common stock remains subject to the penny stock regulations, such regulations
may discourage investor interest in and adversely affect the market liquidity of our common stock. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Financial Industry Regulatory Authority, or FINRA, has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#146;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low priced securities
will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are an &#147;emerging growth company&#148; and we cannot be certain if the reduced disclosure requirements applicable to &#147;emerging growth companies&#148; will make our common stock less attractive to investors. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are an &#147;emerging growth company,&#148; as defined under the JOBS Act. For so long as we are an &#147;emerging growth company,&#148; we intend to take advantage of certain exemptions from reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies&#148; including, but not limited to, compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">23</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We could be an &#147;emerging growth company&#148; for up to five years, although we may lose such status earlier, depending on the occurrence of certain events. We will remain an &#147;emerging growth company&#148; until the earliest to occur of (i) the last day of the fiscal year (a) following the fifth anniversary of our initial public offering, (b) in which we have total annual gross revenue of at least $1.0 billion or (c) in which we are deemed to be a &#147;large accelerated filer&#148; under the Securities Exchange Act of 1934, which we refer to as the Exchange Act, which means that the market value of our common stock
that is held by non-affiliates exceeds $700 million as of the prior June 30, and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We cannot predict if investors will find our common stock less attractive or our company less comparable to certain other public companies because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the JOBS Act, &#147;emerging growth companies&#148; can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards, and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not &#147;emerging growth companies.&#148; </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">24</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSNR"></a>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This prospectus contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business.&#148; These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or
implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to manufacture, or otherwise secure the manufacture of, sufficient amounts of our product candidates for our preclinical studies and clinical trials; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our clinical development plans, including planned clinical trials;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our research and development plans, including our plans to initiate at least one new clinical study in 2015; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to select combinations of phages to formulate our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the safety and efficacy of our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the anticipated regulatory pathways for our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected timeframes or at all; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the content and timing of submissions to and decisions made by the FDA and other regulatory agencies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to leverage the experience of our management team; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to attract and keep management and other key personnel; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the capacities and performance of our suppliers, manufacturers, contract research organizations, or CROs, and other third parties over whom we have limited control; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the actions of our competitors and success of competing drugs that are or may become available; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our expectations with respect to future growth and investments in our infrastructure, and our ability to effectively manage any such growth; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the size and potential growth of the markets for any of our product candidates, and our ability to capture share in or impact the size of those markets; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the benefits of our products and product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">market and industry trends; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the effects of government regulation and regulatory developments, and our ability and the ability of the third parties with whom we engage to comply with applicable regulatory requirements; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our financial performance, including our net revenue, return rates and related estimates, cost of revenue, gross profit and gross margin, operating expenses, utilization of net operating losses, or NOLs, stock-based compensation expense, cash flows, expected uses of anticipated cash flow, funding requirements and market risk; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our expectations regarding future planned expenditures; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our expectations with respect to product pricing; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to effectively remediate any significant deficiencies or material weaknesses in our internal control over financial reporting; </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">25</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to achieve and maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of any of our products and product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to operate our business without infringing the intellectual property rights of others; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our plans to potentially transact business outside the United States. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In some cases, you can identify these statements by terms such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; or the negative of those terms, and similar expressions. These forward-looking statements reflect our management&#146;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this prospectus and are subject to risks and
uncertainties. We discuss many of these risks in greater detail in the section entitled &#147;Risk Factors.&#148; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this prospectus are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You should read this prospectus and the documents that we reference in this prospectus, and have filed as exhibits to the registration statement of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">26</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tUOP"></a>USE OF PROCEEDS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Selling Stockholders will receive all of the proceeds from the sale of the Shares offered for sale under this prospectus. We will not receive any proceeds from the sale of the Shares by the Selling Stockholders. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSSH"></a>SELLING STOCKHOLDERS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This prospectus covers the sale of an aggregate of up to 73,362,164 shares (including 1,355,164 shares underlying the exercise of warrants by certain of the Selling Stockholders) of our Common Stock, $0.01 par value per share, by the Selling Stockholders. See &#147;Description of Capital Stock&#148; beginning on page <a href="#tDCS">85</a> for a description of the Common Stock. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Each Selling Stockholder represented to us that it was an accredited investor and that it was acquiring the Common Stock for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof in a manner that would violate the Securities Act or any applicable state securities laws. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or share voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options or warrants or pursuant to the conversion of our Series B Convertible Preferred Stock that are either immediately exercisable or convertible or exercisable or convertible within 60 days of October 20, 2014. Shares underlying such options, warrants and Series B Convertible
Preferred Stock, however, are only considered outstanding for the purpose of computing the percentage ownership of that person and are not considered outstanding when computing the percentage ownership of any other person. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth certain information regarding the Selling Stockholders, the Shares that may be offered by this prospectus and other shares of Common Stock beneficially owned by them as of October 20, 2014. Selling Stockholders may offer Shares under this prospectus from time to time and may elect to sell none, some or all of the Shares set forth below. As a result, we cannot estimate the number of shares of Common Stock that a Selling Stockholder will beneficially own after termination of sales under this prospectus. However, for the purposes of the table below, we have assumed that, after completion of the
offering, none of the Shares covered by this prospectus will be held by the Selling Stockholders. In addition, a Selling Stockholder may have sold, transferred or otherwise disposed of all or a portion of that holder&#146;s Shares since the date on which they provided information for this table. We are relying on the Selling Stockholders to notify us of any changes in their beneficial ownership after the date they originally provided this information. See &#147;Plan of Distribution&#148; beginning on page <a href="#tPOD">30</a>. Unless otherwise disclosed in the footnotes to the table below, except for the ownership of the Common Stock, the Selling Stockholders have not had any material relationship with us within the past three years. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="274"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Selling Stockholder<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Shares<BR> Beneficially<BR> Owned Before<BR> Offering</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Shares<BR>Covered by<BR> This<BR>Prospectus</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Shares<BR> Beneficially<BR> Owned After Offering<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Percentage of<BR> Shares<BR>Beneficially<BR> Owned after Offering<sup>&#040;3&#041;</sup></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Edward Cappabianca<sup>&#040;4&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>338,791</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>338,791</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>OTA, LLC<sup>&#040;5&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,016,373</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,016,373</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>NRM VII Holdings I, LLC<sup>&#040;6&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>46,785,712</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;7&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>26,785,712</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;7&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9.78</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Broadfin Healthcare Master Fund, Ltd</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>14,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>14,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>MSD Credit Opportunity Master Fund, L.P.<sup>&#040;8&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,827,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,827,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Mintz &amp; Co.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Smokeshire Partners, LLC</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>BioMatrix Partners, Ltd.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,100,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>100,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Perceptive Life Sciences Master Fund Ltd.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,740,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,740,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Titan Perc Ltd.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>260,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>260,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Sphera Global Healthcare Master Fund LP</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,787,200</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,787,200</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>HFR HE Sphera Global Healthcare Master Trust</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>212,800</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>212,800</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Empery Asset Master, Ltd<sup>&#040;9&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,200,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,200,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151; </TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">27</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="274"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Selling Stockholder<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Shares<BR> Beneficially<BR> Owned Before<BR> Offering</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Shares<BR>Covered by<BR> This<BR>Prospectus</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of<BR> Shares<BR> Beneficially<BR> Owned After Offering<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Percentage of<BR> Shares<BR>Beneficially<BR> Owned after Offering<sup>&#040;3&#041;</sup></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Allen Adler</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,200,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,200,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gerald Pogue &amp; Mai Pogue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>315,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>200,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>115,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Michael Bego</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>381,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>300,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>81,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Marcus Pelham-Webb</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>450,890</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>90,890</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Vinh C. Nguyen &amp; JanMari Williams-Nguyen</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>100,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>100,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Susan K. Rho</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>362,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>200,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>162,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Hudson Bay Master Fund, Ltd.<sup>&#040;10&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Brio Capital Master Fund Ltd.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gemini Master Fund, Ltd.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Kingsbrook Opportunities Master Fund LP<sup>&#040;11&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>600,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>600,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Baxter F. Phillips III<sup>&#040;12&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>503,125</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>300,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>203,125</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Marc Levy</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>200,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>200,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>BTG Investments LLC<sup>&#040;13&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>72,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>72,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Griffin Securities, Inc.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,944,571</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;14&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>48,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,896,571</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;14&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Phillip Asset Management Ltd<sup>&#040;15&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>14,928,562</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;16&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,928,562</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;16&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3.26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">If required, information about other selling stockholders, except for any future transferees, pledgees, donees or successors of Selling Stockholders named in this table, will be set forth in a prospectus supplement or amendment to the registration statement of which this prospectus is a part. Additionally, post-effective amendments to the registration statement will, to the extent necessary, be filed to disclose any material changes to the plan of distribution from the description contained in the final prospectus. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">This number assumes the sale of all shares offered by this prospectus. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">These percentages are based upon 273,869,493 shares of Common Stock outstanding on October 20, 2014. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">Consists of shares of common stock underlying a warrant to purchase 338,791 shares of common stock. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(5)</TD>

          <TD STYLE="text-align: left">Consists of shares of common stock underlying a warrant to purchase 1,016,373 shares of common stock. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(6)</TD>

          <TD STYLE="text-align: left">Julian P. Kirk, a member of the Company&#146;s Board of Directors, is the son of Randal J. Kirk, who controls NRM VII Holdings I, LLC. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(7)</TD>

          <TD STYLE="text-align: left">Includes 21,428,570 shares of common stock issuable upon conversion of Series B Convertible Preferred Stock (assuming a conversion ratio equal to ten (10) common shares for each share of Series B Convertible Preferred Stock) and shares of common stock underlying a warrant to purchase 5,357,142 shares of common stock. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(8)</TD>

          <TD STYLE="text-align: left">MSDC Management, L.P. is the investment manager of, and may be deemed to have or share voting and dispositive power over, and/or beneficially own securities owned by, MSD Credit Opportunity Master Fund, L.P. MSDC Management (GP), LLC is the general partner of and may be deemed to have or share voting and dispositive power over, and/or beneficially own securities owned by, MSDC Management, L.P. Each of Glenn R. Fuhrman, John C. Phelan and Marc R. Lisker is manager of MSDC Management (GP), LLC and may be deemed to have or share voting and/or dispositive power over, and beneficially own, the common stock beneficially owned by MSD Management (GP), LLC. Each of Mr. Fuhrman, Mr. Phelan and Mr. Lisker disclaim beneficial ownership of such common stock, except to the extent of the pecuniary interest of such person in such shares. The mailing address for MSD Credit Opportunity Master Fund, L.P. is c/o MSDC Management, L.P., 645 Fifth Avenue, 21<sup>
st</sup> Floor, New York, NY 10022. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(9)</TD>

          <TD STYLE="text-align: left">Empery Asset Management LP, the authorized agent of Empery Asset Master Ltd. (&#147;EAM&#148;), has discretionary authority to vote and dispose of the shares held by EAM and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have investment discretion and voting power over the shares held by EAM. EAM, Mr. Hoe and Mr. Lane each disclaim any beneficial ownership of these shares. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">28</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(10)</TD>

          <TD STYLE="text-align: left">Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Sander Gerber disclaims beneficial ownership over these securities. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(11)</TD>

          <TD STYLE="text-align: left">Kingsbrook Partners LP, referred to as Kingsbrook Partners, is the investment manager of Kingsbrook Opportunities Master Fund LP, referred to as Kingsbrook Opportunities, and consequently has voting control and investment discretion over securities held by Kingsbrook Opportunities. Kingsbrook Opportunities GP LLC, referred to as Opportunities GP, is the general partner of Kingsbrook Opportunities and may be considered the beneficial owner of any securities deemed to be beneficially owned by Kingsbrook Opportunities. KB GP LLC, referred to as GP LLC, is the general partner of Kingsbrook Partners and may be considered the beneficial owner of any securities deemed to be beneficially owned by Kingsbrook Partners. Ari J. Storch, Adam J. Chill and Scott M. Wallace are the sole managing members of Opportunities GP and GP LLC and as a result may be considered beneficial owners of any securities deemed beneficially owned by Opportunities GP and GP LLC.
Each of Kingsbrook Partners, Opportunities GP, GP LLC and Messrs. Storch, Chill and Wallace disclaim beneficial ownership of these securities. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(12)</TD>

          <TD STYLE="text-align: left">Consists of options to purchase 203,125 shares of common stock and 300,000 shares of common stock purchased by Mr. Phillips in the December 2013 private placement.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(13)</TD>

          <TD STYLE="text-align: left">Byron Roth and Gordon Roth, as members of the selling stockholder have shared voting and investment power over the shares. The address of the selling stockholder is 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660. The selling stockholder is a registered broker-dealer and acted as the placement agent for the private placement of shares of the Company&#146;s common stock that occurred in December 2013. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(14)</TD>

          <TD STYLE="text-align: left">Consists of shares of common stock underlying warrants to purchase 693,168 shares of common stock. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(15)</TD>

          <TD STYLE="text-align: left">Phillip Asset Management Ltd holds all shares in its capacity as trustee for Bioscience Managers Pty Ltd. Jeremy Curnock Cook, the Chairman of the Company&#146;s Board of Directors, is a Managing Director and holds an ownership interest in Bioscience Managers Pty Ltd. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(16)</TD>

          <TD STYLE="text-align: left">Includes 7,142,850 shares of common stock issuable upon conversion of Series B Convertible Preferred Stock (assuming a conversion ratio equal to ten (10) common shares for each share of Series B Convertible Preferred Stock) and shares of common stock underlying a warrant to purchase 1,785,712 shares of common stock.<B></B> </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">29</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tPOD"></a>PLAN OF DISTRIBUTION </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The shares of common stock being offered for resale by the Selling Stockholders consist of an aggregate of up to 73,362,164 shares, of which 72,007,000 shares were issued pursuant to a Subscription Agreement, dated as of December 19, 2013, and 1,355,164 shares are underlying the exercise of warrants held by certain of the Selling Stockholders. We will pay any fees and expenses incurred by us incident to the registration of the securities. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Each Selling Stockholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the OTCQB market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an exchange distribution in accordance with the rules of the applicable exchange; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">privately negotiated transactions; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a combination of any such methods of sale; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any other method permitted pursuant to applicable law. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Selling Stockholders may also sell securities under Rule 144 under the Securities Act, if available, rather than under this prospectus. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or
create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">30</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of securities of the common stock by the Selling Stockholders or any other person. We
will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act). </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tDP"></a>DIVIDEND POLICY </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have never declared or paid any cash dividends on our common stock and currently do not plan to declare cash dividends on shares of our common stock in the foreseeable future. We expect that we will retain all of our available funds and future earnings, if any, for use in the operation and expansion of our business. Subject to the foregoing, the payment of cash dividends in the future, if any, will be at the discretion of our board of directors and will depend upon such factors as earnings levels, capital requirements, restrictions imposed by applicable law, our overall financial condition and any other factors deemed
relevant by our board of directors. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tDIL"></a>DILUTION </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are not offering any shares of our common stock by this prospectus. All shares of the common stock that are being registered are beneficially owned by the Selling Shareholders and either are issued and outstanding or, in the case of the warrants, will be issued and outstanding prior to the effectiveness of this registration statement. Accordingly, the sale of the registered shares will not have a dilutive effect to potential shareholders since the common stock to be sold will already be issued and outstanding. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our historical net tangible book value as of December 31, 2013 was approximately $18,532,000, or $0.10 per share, based on 182,535,562 shares of common stock outstanding as of December 31, 2013. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">31</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tMPD"></a>MARKET PRICE OF AND DIVIDENDS ON COMMON STOCK AND RELATED MATTERS </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Market Information </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our shares of common stock are quoted on the OTCQB market under the symbol &#147;APHB.&#148; Our shares were previously quoted under the symbol &#147;TGEN.&#148; On February 22, 2011, in connection with our name change to AmpliPhi Biosciences Corporation, our quotation symbol was changed to &#147;APHB.&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth the range of reported high and low closing bid quotations for our common stock for the fiscal quarters indicated. These quotations reflect inter-dealer prices, without retail markup, markdown or commission, and may not represent actual transactions. Consequently, the information provided below may not be indicative of our common stock price under different conditions. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="480"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>High</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Low</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Fiscal Year 2014<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Period from October 1, 2014 to December 26, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.23</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.14</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Third Quarter ended September 30, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.45</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.22</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Second Quarter ended June 30, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.58</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.38</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>First Quarter ended March 31, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.74</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.45</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Fiscal Year 2013<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fourth Quarter ended December 31, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.59</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.31</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Third Quarter ended September 30, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.71</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.15</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Second Quarter ended June 30, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.10</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>First Quarter ended March 31, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.18</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.11</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Fiscal Year 2012<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fourth Quarter ended December 31, 2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.22</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.14</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Third Quarter ended September 30, 2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.09</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Second Quarter ended June 30, 2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.23</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.13</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>First Quarter ended March 31, 2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.24</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.11</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Fiscal Year 2011<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fourth Quarter ended December 31, 2011</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.27</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.14</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Third Quarter ended September 30, 2011</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.29</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Second Quarter ended June 30, 2011</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.39</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.25</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>First Quarter ended March 31, 2011</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.17</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.06</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Holders of Common Stock </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of October 20, 2014, there were 296 holders of record of our common stock. As of such date, the number of shares of our common stock outstanding was 273,869,493, which consists of 187,159,093 shares of common stock outstanding as of October 20, 2014, and 86,710,400 shares of common stock issuable upon conversion of all outstanding shares of Series B Convertible Preferred Stock as of October 20, 2014 (assuming a conversion ratio equal to ten (10) common shares for each share of Series B Convertible Preferred Stock). </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Dividends </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have never declared or paid any cash dividends or distributions on our capital stock. See &#147;Dividend Policy&#148; on page <a href="#tDP">31</a> for a description of our dividend policy. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Securities Authorized for Issuance under Equity Compensation Plans </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2012, our board of directors approved and adopted the 2012 Plan. Under the 2012 Plan, we are authorized to issue up to 35,000,000 shares of our common stock in stock incentive awards to employees, directors and consultants. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2009, our board of directors and shareholders adopted the 2009 Plan. Under the 2009 Plan, we are authorized to issue up to 4,200,000 shares of our common stock in stock incentive awards to employees, directors and consultants. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">32</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In December 2013, our board of directors adopted the 2013 Plan. Under the 2013 Plan, we are authorized to issue up to 39,250,000 shares of our common stock in stock incentive awards to employees, directors and consultants. Our shareholders approved the 2013 Plan on February 11, 2014. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table provides information as of December 31, 2013 with respect to our equity compensation plans: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="204"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="100"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="100"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="114"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Plan Category</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of securities<BR> to be issued upon<BR> exercise of<BR> outstanding options,<BR> warrants and rights</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted-average<BR> exercise price of<BR> outstanding options,<BR> warrants and rights</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of securities<BR> remaining available for<BR> future issuance under<BR> equity compensation<BR> plans (excluding<BR> securities reflected<BR>in column (a))</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>(a)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>(b)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>(c)</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Equity compensation plans approved by security holders<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>166,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.90</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,304,760</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Equity compensation plans not approved by security holders<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>25,555,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>0.19</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>9,322,964</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,721,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.19</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,627,724</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">The 2009 Plan. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">The 2012 Plan. Excludes shares of our common stock subject to the 2013 Plan, which was adopted by our board of directors in December 2013 and approved by our shareholders in February 2014. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">33</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tMDA"></a>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF<BR> FINANCIAL CONDITION AND RESULTS OF OPERATIONS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following discussion and analysis of our financial condition and results of operations should read in conjunction with &#147;Selected Consolidated Financial Data&#148; and the Unaudited Condensed Consolidated Financial Statements and related Notes included in this prospectus. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This discussion contains forward-looking statements that involve risks and uncertainties. Such statements, which include statements concerning product development plans, the use of bacteriophages to kill bacterial pathogens, future revenue sources, selling and marketing expenses, general and administrative expenses, clinical trial and other research and development expenses, capital resources, capital expenditures, tax credits and carry-forwards, the Company&#146;s ability to raise capital through additional financings or borrowings, are subject to risks and uncertainties, including, but not limited to, those discussed below
and elsewhere in this prospectus, &#147;Risk Factors,&#148; that could cause actual results to differ materially from those projected. The forward-looking statements set forth in this prospectus are as of the close of business on November 14, 2014, and we do not intend to update this forward-looking information. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Overview</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences is a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics. Our proprietary pipeline is based on the use of bacteriophages, a family of viruses that infect only bacteria. Phages have powerful and highly selective mechanisms of action that permit them to target and kill specific bacterial pathogens, including the so-called multi-drug-resistant (MDR) or &#147;Superbug&#148; strains.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are combining our proprietary approach and expertise in identifying, characterizing and developing naturally occurring bacteriophages with that of our collaboration partners in bacteriophage biology, drug engineering, development and manufacturing, to develop second-generation bacteriophage products. We believe that phages represent a promising means to treat bacterial infections, especially those that have developed resistance to current medicines.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our lead program is AmpliPhage-002, for the treatment of methicillin-resistant <I>S. aureus</I> (MRSA) infections. We have two other product candidates in development: AmpliPhage-001 for the treatment of <I>P. Aeruginosa</I> lung infections in CF patients and AmpliPhage-004 for the treatment of <I>C. difficile</I> infections.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have incurred net losses since our inception. Our operations to date have been limited to research and development and raising capital. Since November 2010, we have raised approximately $5.6 million through the sale and issuance of convertible notes and warrants to purchase common stock. In June and July of 2013, we completed a private placement of shares of our Series B Convertible Preferred Stock and warrants to purchase common stock, with proceeds to the Company of approximately $7.0 million. At the same time we converted approximately $6.3 million in outstanding convertible notes to Series B Convertible Preferred Stock.
In December 2013, we completed a private placement of shares of common stock, with gross proceeds of approximately $18 million, prior to commissions. To date, we have not generated any meaningful revenue and have primarily financed our operations through the sale and issuance of convertible notes and the private placement of our equity securities. As of September 30, 2014, we had an accumulated deficit of $355.3 million. We recorded annual net losses of $57.7 million in 2013 and $1.1 million in 2012. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the development and obtaining regulatory approval of our product candidates. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect our research and development expenses to expand as we increase our development activities and commence clinical trials to pursue regulatory approval for our product candidates. We also expect to incur additional expenses associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses at least for the next several years. We do not expect to generate product revenue unless and until we successfully complete development and obtain marketing approval for at least one of our product candidates.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently expect to use our existing cash and cash equivalents for the continued research and development of our product candidates and for working capital and other general corporate purposes.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">34</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may also use a portion of our cash and cash equivalents for the potential acquisition of, or investment in, product candidates, technologies, formulations or companies that complement our business, although we have no current understandings, commitments or agreements to do so. We expect that our current cash and cash equivalents will not be sufficient to enable us to complete all necessary development of any potential product candidates. Accordingly, we will be required to obtain further funding through other public offerings, debt financing, collaboration and licensing arrangements or other sources. Adequate additional
funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Financial Operations Overview</H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Comparison of the Nine Months Ended September 30, 2014 and 2013</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Revenue</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We recognized no revenues for the quarter ended September 30, 2014. For the nine month period ending September 30, 2014, we recognized revenues of $310,000 in revenue from sublicensing arrangements, a decrease from $333,000 for the same period in 2013, as a result of reduced grant revenue.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and Development</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development expenses were $1.8 million for the quarter ended September 30, 2014, up $0.7 million from the $1.1 million recorded for the quarter ended September 30, 2013. Research and development expenses were $4.7 million for the nine month period ended September 30, 2014, compared to $5.4 million for the nine month period ended September 30, 2013. Research and development costs for the nine month period in 2013 included a $3.0 million non-cash one-time technology access fee which was incurred in April 2013. Adjusted for this one-time item, research and development expense for the nine months of 2014 represented
an increase of $2.3 million. The increase in research and development expense for both the three month and nine month periods ended September 30, 2014 were due to an increase in discovery, laboratory, nonclinical testing, research and development collaborations, consulting, and clinical development planning expenses for all of our product candidates.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Adjusted for the one-time non-cash technology access fee incurred in 2013, research and development expenses are expected to increase in 2014 compared to 2013 as we plan to continue investing substantial resources to research and development as we prepare to initiate clinical trials and continue our discovery efforts.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and Administrative</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and administrative expenses were $1.6 million for the quarter ended September 30, 2014 compared to $1.2 million for the quarter ended September 30, 2013. The $0.4 million increase in general and administrative expense was due primarily to a $0.3 million accrual for payments to certain shareholders as required by the terms of our Series B Preferred Stock Purchase Agreement. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and administrative expenses were $5.4 million for the nine month period ended September 30, 2014 compared to $4.8 million for the nine month period ended September 30, 2013. This increase of $0.6 million was attributable to the accrual of payments to certain shareholders outlined above and higher legal, accounting, and staffing expenses incurred to satisfy our obligations as a public company. Partially offsetting these cost increases were reduced investment fees resulting from the fees incurred in 2013 for our Series B private placement.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently expect our general and administrative expenses to increase in 2014 compared to 2013 due to additional costs associated with being a public company.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Severance Charge</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company recorded a severance charge in the quarter ended September 30, 2014 of $1.5 million related to severance-period compensation and benefits and stock-based compensation expense related to the acceleration of vested stock options related to the termination of the Company&#146;s Chief Executive Officer during the quarter.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">35</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Derivative Liabilities</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the quarter ended September 30, 2014, we recognized a gain on derivative liabilities of $24.3 million related to reductions in the fair value of derivative liabilities for warrants issued in June, July, and December 2013 and the conversion feature of the shares of Series B Preferred Stock issued in June and July 2013. The reduction in fair value was attributable to a decline in the market value of our common stock at September 30, 2014. During the quarter ended September 30, 2013, we recognized a loss on derivative liabilities of $41.5 million for warrants issued in June 2013 and the conversion feature of the shares of
Series B Preferred Stock issued in June 2013.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the nine month period ended September 30, 2014, we recognized a gain on derivative liabilities of $34.0 million compared to $45.6 million loss for the nine month period ended September 30, 2013.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Derivative liabilities are adjusted to fair value each reporting period and are influenced by several factors including the price of the Company&#146;s common stock as of the balance sheet date. On September 30, 2014, the price per share of the Company&#146;s common stock was $0.22 per share compared to $0.50 per share at December 31, 2013.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Income Taxes</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We incurred net operating losses for the years ended December 31, 2013 and 2012 and, accordingly, we did not pay any U. S. federal or state income taxes. As of December 31, 2013, we had accumulated approximately $175.4 million in U.S. and UK operating loss carry-forwards and research tax credit carry-forwards of approximately $3.7 million. The carry-forwards began to expire in 2012. Our net operating loss carry-forwards are subject to certain limitations on annual utilization as a result of changes in ownership of the Company, as defined by federal and state tax laws.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net Operating Losses</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not recorded a benefit from our net operating loss or research credit carry-forwards because we believe that it is uncertain that we will have sufficient income from future operations to realize the carry-forwards prior to their expiration. Accordingly, we have established a 100% valuation allowance against the deferred tax asset arising from the carry-forwards.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Liquidity and Capital Resources </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have incurred net losses since inception through September 30, 2014 of $355.3 million, of which $315.5 million was incurred in the Company&#146;s prior focus on gene therapy in 2010 and years earlier. We have not generated any product revenues and do not expect to generate revenue from the sale of product candidates in the near term. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We had cash and cash equivalents of $9.8 million and $20.4 million at September 30, 2014 and December 31, 2013, respectively. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash used in operating activities for the nine month period ended September 30, 2014 was $9.4 million. We recorded net income for the nine-month period of $22.8 million, including a non-cash gain on derivative liabilities of $34.0 million. Other items in uses of funds from operations included non-cash charges related to stock-based compensation expense, depreciation expenses, and patent amortization, which collectively totaled $1.7 million. Increases in accounts payable and accrued liabilities increased net cash from operating activities by $0.3 million, partially offset by an increase in receivables and prepaid expenses
of $0.1 million. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash used in operating activities for the nine month period ended September 30, 2013 was $4.9 million. We recorded a net loss of $58.3 for the period, including a non-cash charge on derivative liabilities of $45.6 million. The net impact of these two factors was a use of funds of $12.7 million. Other items in uses of funds from operations included non-cash charges for a technology access, amortization of loan discount, stock-based compensation expense, depreciation expenses, warrant-based investment fees, and a loss on disposal of equipment, which collectively totaled $6.4 million. Net changes in accrued liabilities,
receivables and other asset also generated $0.1 million in cash.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">36</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash used in investing activities for the nine month period ended September 30, 2014 and September 30, 2013 were $1.1 million and $0.9 million, respectively, due to purchases of equipment.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash provided by financing activities for the nine month period ended September 30, 2013 was $9.0 million due to proceeds from our issuance of shares of Series B Preferred Stock and convertible loan notes. We expect 2014 cash requirements to be in the range of $15.0 million to $17.0 million. We believe that our cash as of September 30, 2014, will be sufficient to fund our projected operating requirements through the first quarter of 2015.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our total use of cash in the nine month period ended September 30, 2014 was $10.6 million.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect to need to raise additional capital or incur indebtedness to continue to fund our future operations. We may seek to raise capital through a variety of sources, including: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the public equity market;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">private equity financing;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborative arrangements;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">licensing arrangements; and/or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">public or private debt. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our ability to raise additional funds will depend on our clinical and regulatory developments, our product development activities, our ability to identify promising in-licensing opportunities and factors related to financial, economic and market conditions, many of which are beyond our control. We cannot be certain that sufficient funds will be available to us when required or on satisfactory terms. If adequate funds are not available, we may be required to significantly reduce or refocus our operations or to obtain funds through arrangements that may require us to relinquish rights to certain of our products, technologies or
potential markets, any of which could delay or require that we curtail our development programs or otherwise have a material adverse effect on our business, financial condition and results of operations. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities would result in ownership dilution to our existing stockholders.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are unable to secure additional financing on a timely basis or on terms favorable to us, we may be required to cease or reduce certain research and development projects, to sell some or all of our technology or assets or to merge all or a portion of our business with another entity. Insufficient funds may require us to delay, scale back or eliminate some or all of our activities, and if we are unable to obtain additional funding, there is uncertainty regarding our continued existence.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Off-Balance Sheet Arrangements</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of September 30, 2014, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. Therefore, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Critical Accounting Policies and Use of Estimates</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our management&#146;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based
compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">37</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Goodwill</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized. As of December 31, 2013, we have recorded goodwill of $4.3 million due to the 2012 acquisition of SPH&#146;s knowhow and phage libraries and the 2011 acquisition of Biocontrol&#146;s patents and phage library. In management&#146;s opinion, no goodwill has been impaired as of December 31, 2013.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In Process Research and Development Costs</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In Process Research &amp; Development (IPR&amp;D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with
the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&amp;D assets, for impairment at least quarterly. As of December 31, 2013, we have recorded IPR&amp;D of $12.5 million due to the 2012 acquisition of SPH&#146;s know-how and phage libraries and the 2011 acquisition of Biocontrol&#146;s patents and phage library. In management&#146;s opinion, no IPR&amp;D has been impaired as of December 31, 2013.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-Based Compensation Expenses</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We account for stock options and restricted stock units related to our Stock Incentive Plans under the provisions of ASC 718, which requires the recognition of the fair value of stock-based compensation. The fair value of stock options and restricted stock units was estimated using a Black-Scholes option valuation model.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This model requires the input of subjective assumptions in implementing ASC 718, including expected dividend, expected life, expected volatility and forfeiture rate of each award, as well as the prevailing risk-free interest rate and the fair value of the underlying common stock on the date of grant. The fair value of equity based awards is amortized over the vesting period of the award, and we have elected to use the straight-line method of amortization. Actual results could differ from our assumptions, which may cause us to record adjustments to increase or decrease compensation expense, in future periods. The assumptions
used in the Black-Scholes option valuation model for the years ended December 31, 2013 and 2012 are set forth below.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following are the assumptions for the periods in which we granted stock options:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Expected Dividend</I>:&nbsp;&nbsp;We do not anticipate any dividends.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Expected Life</I>:&nbsp;&nbsp;The expected life represents the period that we expect our stock-based awards to be outstanding. We determine life based on historical experience and vesting schedules of similar awards.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Expected Volatility</I>:&nbsp;&nbsp;Our expected volatility represents the weighted average historical volatility of the shares of our common stock for the most recent four-year and five-year periods.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Risk-Free Interest Rate</I>:&nbsp;&nbsp;We base the risk-free interest rate used on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Where the expected term of our stock-based awards does not correspond with the terms for which interest rates are quoted, we perform a straight-line interpolation to determine the rate from the available term maturities.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Forfeiture Rate</I>:&nbsp;&nbsp;We apply an estimated forfeiture rate that is derived from historical forfeited shares. If the actual number of forfeitures differs from our estimates, we may record additional adjustments to compensation expense in future periods.</TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">38</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fairvalue of the stock option grants were as follows:</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="370"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Risk-free interest rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.13</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.6</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected volatility</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>160.9</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>172.1</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected term (in years)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected dividend yield</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Warrant and Preferred Shares Conversion Feature Liability</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We account for warrants and the preferred shares conversion feature with anti-dilution (&#147;down-round&#148;) provisions under the guidance of ASC 815, Derivatives and Hedging and Emerging Issue Task Force Statement 07-5: Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity&#146;s Own Stock, which require the warrants and the preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period. We estimate the fair values of these securities using a Monte Carlo valuation model.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accounting for Income Taxes</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our income tax policy records the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets, as well as operating loss and tax credit carry-forwards. We have recorded a full valuation allowance to reduce our deferred tax assets, as based on available objective evidence; it is more likely than not that the deferred tax assets will not be realized. In the event that we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the deferred tax assets would increase net income in the
period such determination was made. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Recent Accounting Pronouncements </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">None.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">JOBS Act</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an &#147;emerging growth company.&#148; As an &#147;emerging growth company,&#148; we are electing not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section 107 of the JOBS Act provides that our decision not to
take advantage of the extended transition period is irrevocable. In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if as an &#147;emerging growth company&#148; we choose to rely on such exemptions, we may not be required to, among other things, (i) provide an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv)
disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer&#146;s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our initial public offering or until we no longer meet the requirements of being an &#147;emerging growth company,&#148; whichever is earlier.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">39</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Results of Operations</H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Comparison of the Years Ended December 31, 2013 and 2012</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Revenue</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the years ended December 31, 2013 and 2012, we recognized $0.3 million and $0.7 million in revenue, respectively. For the years ended December 31, 2013 and 2012, we earned $0.3 million and $0.6 million of revenue through sublicensing agreements involving our former gene therapy program, respectively. For the year ended December 31, 2012, we also earned $0.1 million in grant revenue.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and Development</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development expenses were $6.5 million for the year ended December 31, 2013, compared to $1.5 million for the year ended December 31, 2012. The $5.0 million increase in expenses is due to an increase in discovery, laboratory, nonclinical testing, research and development collaborations, consulting and clinical development planning expenses for all of our product candidates.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development expenses are expected to increase in 2014 compared to 2013 as we plan to continue devoting substantial resources to research and development in future periods as we start clinical trials and continue our discovery efforts.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and Administrative</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and administrative expenses were $6.3 million for 2013, compared to $3.2 million for 2012. The $3.1 million increase is due to $1.0 million in placement agent fees associated with the June 2013 Series B Preferred Shares placement, $0.7 million in higher legal expenses due to preparation to become a public company, and $1.4 million in higher staffing and outside consulting expenses (including non-cash compensation expense related to options granted to Company executives).</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently expect our general and administrative expenses to increase in 2014 compared to 2013 due to the costs associated with being a public company.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Discontinued Operations</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2012, we sold certain assets used in our gene therapy business including process development, quality control, quality assurance, manufacturing and bioanalytical functions for $3.1 million. In addition to this cash consideration, we may receive a long-term royalty of 1.75% on all product sales. This royalty may be completely canceled at any time by a one-time payment of $1.8 million.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Interest Income (Expense)</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During 2013 and 2012, we issued $2.0 million and $1.0 million in convertible notes, respectively. Interest expense in 2013 was $0.2 million, compared to $0.3 million for 2012. The decrease was due to conversion of the convertible notes into Series B preferred Shares in June and July 2013 and thus eliminating future interest expense. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Income Taxes</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We incurred net operating losses for the years ended December 31, 2013 and 2012 and, accordingly, we did not pay any federal or state income taxes. As of December 31, 2013, we had approximately $175.4 million in U.S. and UK operating loss carry-forwards and research tax credit carry-forwards of approximately $3.7 million. The carry-forwards began to expire in 2012. Our net operating loss carry-forwards are subject to certain limitations on annual utilization as a result of changes in ownership of the Company, as defined by federal and state tax laws. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net Operating Losses</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not recorded a benefit from our net operating loss or research credit carry-forwards because we believe that it is uncertain that we will have sufficient income from future operations to realize the carry-forwards prior to their expiration. Accordingly, we have established a 100% valuation allowance against the deferred tax asset arising from the carry-forwards.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">40</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Liquidity and Capital Resources</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have incurred net losses since inception through December 31, 2013 of $378.1 million, of which $315.5 million was incurred by Targeted Genetics prior to its merger with Biocontrol, and $6.9 million of which was incurred by Biocontrol. We have not generated any product revenues and do not expect to generate revenue from the sale of product candidates in the near term.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We had cash of $20.4 million and $0.9 million at December 31, 2013 and 2012, respectively.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash used in operating activities for the years ended December 31, 2013 and 2012 was $6.3 million and $4.3 million, respectively. For the year ended December 31, 2013, cash used in operations was attributable to the net loss for the year after adding back non-cash charges for loss on derivative liabilities, shares issued for technology access fee, amortization of loan discount, fair market value of warrants issued as June and July investment fees, stock-based compensation expense, and depreciation expenses. For the year ended December 31, 2012, cash used in operations was attributable to the net loss for the year after
adding back non-cash charges for stock-based compensation expense, depreciation expenses and a loss on disposal of equipment, which were partially offset by a decrease in accrued liabilities and an increase in receivables. Net cash used in investing activities for the year ended December 31, 2013 was $0.1 million due to purchases of equipment. Net cash provided by investing activities for the year ended December 31, 2012 was $3.1 million due to the sale of assets from discontinued operations slightly offset by purchases of property and equipment. Net cash provided by financing activities was $25.9 million for the year ended December 31, 2013, due to the December 2013 private placement, the Series B financing and convertible loan notes. Net cash provided by financing activities was $1.0 million for the year ended December 31, 2012, due to proceeds from convertible notes. We expect 2014 cash requirements to be in the range of $15.0 million to $17.0 million. We believe that our cash as of
December 31, 2013, will be sufficient to fund our projected operating requirements into the first quarter of 2015.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect to need to raise additional capital or incur indebtedness to continue to fund our future operations. We may seek to raise capital through a variety of sources, including:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the public equity market;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">private equity financing;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">collaborative arrangements;</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">licensing arrangements; and/or</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">public or private debt.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our ability to raise additional funds will depend on our clinical and regulatory events, our ability to identify promising in-licensing opportunities and factors related to financial, economic and market conditions, many of which are beyond our control. We cannot be certain that sufficient funds will be available to us when required or on satisfactory terms. If adequate funds are not available, we may be required to significantly reduce or refocus our operations or to obtain funds through arrangements that may require us to relinquish rights to certain of our products, technologies or potential markets, any of which could
delay or require that we curtail our development programs or otherwise have a material adverse effect on our business, financial condition and results of operations. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities would result in ownership dilution to our existing stockholders. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are unable to secure additional financing on a timely basis or on terms favorable to us, we may be required to cease or reduce certain research and development projects, to sell some or all of our technology or assets or to merge all or a portion of our business with another entity. Insufficient funds may require us to delay, scale back or eliminate some or all of our activities, and if we are unable to obtain additional funding, there is uncertainty regarding our continued existence.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Contractual Obligations and Commitments</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In February 2011, the Company entered into an agreement with Virginia Biotechnology Research Partnership Authority for Richmond, Virginia laboratory space. This agreement has a contractual expiration </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">41</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">date of February 29, 2012 at which time it converted to a rolling three-month lease. At September 30, 2014, the Company&#146;s minimum payment commitment for the Richmond, Virginia laboratory space was $4,900. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In December 2011, the Company entered into an agreement with Nevis Limited and Charter Limited for laboratory space in Bedfordshire, United Kingdom. This agreement has a minimum period of 3 years and a contractual expiration date of December 8, 2016. At September 30, 2014 the Company&#146;s minimum payment commitment for the Bedfordshire laboratory space was $67,600. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In February 2013, we entered into an agreement with Office Suites Plus (now Regus Management Group, LLC) for office space in Glen Allen, Virginia. The agreement has a minimum period of one year ending February 28, 2014. In October 2014, the Company entered an agreement to extend this lease for six months to April 2015, with a monthly cost of $3,340. At September 30, 2014, our minimum payment commitment for the Glen Allen space was $23,380.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In September 2013, we entered into an agreement with PBC Carlsbad, LLC for office space in Carlsbad, California. The agreement has a minimum period of six months ending February 28, 2014, at which time it was extended through August 2014, with a monthly cost of $1,033. The agreement was extended through February 28, 2015, with a monthly cost of $1,033. At September 30, 2014, our minimum payment commitment for the Carlsbad office space was $5,165.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Off-Balance Sheet Arrangements</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2013, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. Therefore, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Recent Financings</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On December 16, 2013, we entered into subscription agreements to issue an aggregate amount of 72,007,000 shares of common stock for an aggregate purchase price of approximately $18 million as part of a private placement. The purchasers of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of such purchasers was an &#147;accredited investor&#148; under Rule 506 of Regulation D or not a &#147;U.S. person&#148; under Regulation S.
</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 26, 2013, we completed a private placement of convertible preferred stock and warrants to purchase common stock with gross proceeds of $7.0 million through the sale of shares of our newly-created Series B Convertible Preferred Stock. As part of the same transaction, approximately $5.5 million in outstanding convertible notes were converted into shares of Series B Convertible Preferred Stock and warrants to purchase common stock. On July 15, 2013, we completed a second closing in which we converted approximately $0.8 million of outstanding convertible notes into Series B Convertible Preferred Stock and warrants to
purchase common stock. The financing was led by life-sciences investors RA Capital Management and Third Security, LLC, with participation from BioScience Managers Pty Ltd.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the terms of the financing, we issued an aggregate amount of approximately 10.0 million shares of the Series B Convertible Preferred Stock for an aggregate purchase price of approximately $13.3 million (including the conversion of approximately $6.3 million of outstanding convertible notes). Each share of Series B Convertible Preferred Stock is convertible into 10 shares of common stock. Additionally, we issued warrants to purchase an aggregate of up to approximately 25.0 million shares of common stock at an exercise price of $0.14 per share. As a result of the completion of this private placement, as of July 15, 2013,
all previously issued convertible notes have been converted and there are no convertible notes outstanding. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">42</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Comparison of the Years Ended December 31, 2012 and 2011 </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Revenue </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the years ended December 31, 2012 and 2011, we recognized $0.7 million and $0.1 million in revenue, respectively. For the years ended December 31, 2012 and 2011, we earned $0.6 million and $0.1 million of revenue through sublicensing agreements involving our former gene therapy program. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the years ended December 31, 2012 and 2011, we also earned $0.1 million and $20,000 in grant revenue, respectively. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and Development </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development expenses were $1.5 million for the year ended December 31, 2012, compared to $0.7 million for the year ended December 31, 2011. The $0.8 million increase in expenses is due to an increase in consulting and development expenses. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development expenses are expected to increase in 2013 compared to 2012 as we plan to continue devoting substantial resources to research and development in future periods as we start clinical trials and continue our discovery efforts. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and Administrative </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and administrative expenses were $3.2 million for 2012, compared to $3.3 million for 2011. The $0.1 million decrease is due to lower administrative staffing and facilities expenses, partially offset by higher legal expenses related to the acquisition of SPH. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently expect our general and administrative expenses to increase in 2013 compared to 2012 due to the costs associated with preparing this registration statement and being a public company. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Discontinued Operations</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2012, we sold certain assets used in our gene therapy business including process development, quality control, quality assurance, manufacturing and bioanalytical functions for $3.1 million. In addition to this cash consideration, we may receive a long-term royalty of 1.75% on all product sales. This royalty may be completely canceled at any time by a one-time payment of $1.8 million.</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Tax Refund </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2012, we had a United Kingdom research and development tax refund of $0.1 million (&#163;0.1 million) for the losses in the subsidiary based in the United Kingdom, compared to $0.3 million for 2011. The decrease in the refund was due to reduced staffing in 2012 compared to 2011. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Interest Income (Expense) </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Interest expense in 2012 was $0.3 million, compared to $0.1 million for 2011. The increase was due to interest accrued for convertible notes. During 2012 and 2011, we issued $1.0 million and $2.7 million in convertible notes, respectively. Interest on the unpaid principal balance of these notes accrues at the rate of ten percent (10%) per annum. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Income Taxes</I></B> </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We incurred net operating losses for the years ended December 31, 2012 and 2011 and, accordingly, we did not pay any federal or state income taxes. As of December 31, 2012, we had accumulated approximately $170.4 million in U.S. and UK operating loss carry-forwards and research tax credit carry-forwards of approximately $4.3 million. The carry-forwards began to expire in 2012. Our net operating loss carry-forwards are subject to certain limitations on annual utilization as a result of changes in ownership of us, as defined by federal and state tax laws. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net Operating Losses </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not recorded a benefit from our net operating loss or research credit carry-forwards because we believe that it is uncertain that we will have sufficient income from future operations to realize the carry-forwards prior to their expiration. Accordingly, we have established a 100% valuation allowance against the deferred tax asset arising from the carry-forwards. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">43</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tBUS"></a>BUSINESS </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Company History </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We were incorporated under the laws of the State of Washington in March 1989 as a wholly owned subsidiary of Immunex Corporation and began operations as an independent company in 1992 as Targeted Genetics Corporation.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In January 2011, we completed the acquisition of Biocontrol Ltd, which we refer to as Biocontrol, an antimicrobial biotechnology company based in the United Kingdom, with the goal of developing their phage therapy programs using funding from the sale of our legacy gene therapy assets. On February 22, 2011, we changed our name to &#147;AmpliPhi Biosciences Corporation.&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2012, we completed the acquisition of Special Phage Holdings Pty Ltd, a company based in Australia, which we refer to as SPH, pursuant to our offer to acquire all outstanding shares of SPH from its shareholders under the terms of a Shareholder Sale Agreement and a Managers Warranty Deed. SPH was formed in 2004 to address the rapidly escalating problem of antibiotic resistance through the development of a series of bacteriophage-based treatments.We intend to reincorporate as AmpliPhi Biosciences Corporation in the State of Delaware.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Company Overview </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics. Our proprietary pipeline is based on the use of bacteriophages, a family of viruses that infect only bacteria. Phages have powerful and highly selective mechanisms of action that permit them to target and kill specific bacterial pathogens, including the so-called multi-drug-resistant (MDR) or &#147;Superbug&#148; strains. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe that we are a leading developer of phage-based therapeutics. We are combining our proprietary approach and expertise in identifying, characterizing and developing naturally occurring bacteriophages with that of our collaboration partners in bacteriophage biology, drug engineering, development and manufacturing, to develop second-generation bacteriophage products. We believe that phages represent a promising means to treat bacterial infections, especially those that have developed resistance to current medicines. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The extensive use of antibiotics, since their discovery in the 1940s, has resulted in drug resistance among many disease-causing bacteria. Resistance to antibiotics, according to the Centers for Disease Control (CDC), threatens to reverse the medical advances of the last half-century. Examples of clinically important microbes that are rapidly developing resistance to available antimicrobials include bacteria that cause skin, bone, lung and bloodstream infections (e.g., <I>S.</I> <I>aureus</I> and MRSA), pneumonia and lung infections in the community, hospital and cystic fibrosis (e.g., <I>A.</I> <I>baumanii</I>, <I>P.</I> <I>
aeruginosa</I>, and <I>K.</I> <I>pneumoniae</I>), meningitis (e.g., <I>S.</I> <I>pneumonia</I>), urinary tract and gastrointestinal infections (e.g., <I>E.</I> <I>coli</I> and <I>C.</I> <I>difficile</I>). As a phage kills bacteria in ways entirely unlike the mechanisms used by antibiotics, MDR bacteria are not resistant to a phage in the same manner. Furthermore, as new resistant bacteria emerge, it should be possible to identify new phages that will still have efficacy. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our lead program is AmpliPhage-002, for the treatment of <I>S. aureus</I> infections (including methicillin-resistant MRSA). We also have two other product candidates in development: AmpliPhage-001 for the treatment of <I>P. aeruginosa</I> lung infections in CF patients, and AmpliPhage-004 for the treatment of <I>C. difficile</I> infections. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are developing these phage product candidates using our proprietary discovery and development platform, which is designed for rapid identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several carefully chosen phages which target a specific disease-causing bacterial pathogen such as MRSA, <I>P. aeruginosa</I> and <I>C. difficile</I>. We believe that our understanding of unique regulatory and development requirements of bacteriophage biology combined with the scientific expertise of our collaboration partners will enable the rapid advancement of phage treatments
through the clinic and eventually to the market. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">44</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2013, we entered into an Exclusive Channel Collaboration (ECC) with Intrexon Corporation, which we refer to as Intrexon, directed towards the research, development and commercialization of new bacteriophage-based therapies to target specific antibiotic-resistant infections, including for use in the treatment of bacterial infections associated with acute and chronic wounds, the treatment of acute and chronic <I>P. aeruginosa</I> lung infections, and the treatment of infections of <I>C. difficile.</I> </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In April 2013, we entered into a collaboration agreement, which we refer to as the April Collaboration Agreement, and on September 5, 2013, we entered into a license agreement, which we refer to as the Leicester License Agreement, with the University of Leicester to develop a phage therapy that targets and kills all toxin types of <I>C. difficile</I>. Pursuant to the Leicester License Agreement, we may be obligated to pay the University of Leicester a royalty in the single digits and an aggregate of up to &#163;575,000 in milestone payments. We also entered into a collaboration agreement on August 1, 2013, which we refer to as
the August Collaboration Agreement, with the University of Leicester and the University of Glasgow, whereby the University of Glasgow will carry out certain animal model development work. Pursuant to the August Collaboration Agreement, we may be obligated to pay up to a total of approximately &#163;205,000 in milestone payments. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2013, we entered a cooperative research and development agreement (CRADA) with the United States Army Reserve Medical Corps (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR) focusing on developing bacteriophage therapeutics to treat <I>S. aureus</I>, <I>E. coli</I> and <I>P. aeruginosa</I> infections. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2014, we entered into a collaboration agreement, effect as of November 9, 2014, with the University of Leicester to develop phage therapies targeting <I>C. difficile</I>. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We plan to initiate a clinical trial in 2015 in collaboration with the U.S. Army that will support the development of a treatment for <I>S. Aureus</I> infections for wound and skin infections. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Need for New Anti-Infective Therapies </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The rapid and continuous emergence of antibiotic-resistant bacteria has become a global crisis. While the numbers of novel anti-infective therapies in development are at historically low levels, antibiotic-resistant infections have dramatically increased. The CDC estimates that more than two million people in the United States acquire an antibiotic-resistant infection each year and more than 23,000 of these prove fatal. It is estimated that 50 &#150; 70% of hospital-acquired infections are resistant to first-line anti-infective therapies. The cumulative annual cost for treating resistant bacterial infections in the United
States alone is estimated to be $20 billion, while the global antibiotics market opportunity is estimated to be $40.3 billion by 2015. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The CDC&#146;s latest report on the matter, <I>Antibiotic Resistance Threats in the United States, 2013</I>, notes that there are &#147;potentially catastrophic consequences of inaction&#148; and ranks <I>C. difficile</I> as belonging to the highest tier of threat, &#147;Urgent Threats.&#148; Despite the potential market opportunity, only two new antibacterial drug applications were approved between 2010 and 2012 compared to eighteen in the period between 1980 and 1984. One of the primary CDC recommendations is the development of new antibiotics to diversify treatment options. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Product Candidates </H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhage-002: Wound and Skin Infections Caused by <B><I>S. aureus</I></B> </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In conjunction with our CRADA with the USAMRMC, we are developing a phage product that is intended to effectively treat acute and chronic wound and skin infections caused by <I>S. aureus</I>, including infections caused by methicillin-resistant (MRSA) strains of the same bacterium. MRSA infections are one of the most common causes of hospital-acquired (nosocomial) infections and Global Data estimates the MRSA market for infections alone was more than $2.7 billion in 2007. This market is forecast to grow to more than $3.5 billion by 2019.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">By screening our proprietary library of phage samples against a panel of <I>S. aureus</I> bacterium, we have selected a phage product mix that has demonstrated in in vitro studies greater than 85% efficacy with high overlap against a global diversity panel that includes some of the most virulent isolates of <I>S. aureus</I>, including MRSA identified by the U.S. Army.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We plan to initiate a clinical trial in 2015 in collaboration with the U.S. Army that will support the development of a treatment for <I>S. Aureus</I> infections for wound and skin infections. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">45</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After extensive financial and capability evaluation and a global search we have elected to proceed with cGMP manufacturing at a wholly owned facility that has been constructed in Ljubljana, Slovenia. We have been able to access and hire highly skilled process development and phage manufacturing expertise and believe that we now have control of our proprietary platform from phage identification through final product fill and finish. Our facility inclusive of laboratory and office space is approximately 4,000 sq. ft. and is expected to produce cGMP product for our currently planned and future studies. We believe that this
facility should be sufficient to meet our product needs through Phase 3 and initial commercialization. Our current formulation for AmpliPhage -002 is intended for nasal and/or topical delivery via a small spray device. We plan to further formulate our product for delivery to patients with wound and skin infections. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhage-001: Lung Infections in Cystic Fibrosis (CF) Patients Caused by <B><I>P. aeruginosa</I></B> </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">According to Global Data in April 2013, the market for CF therapeutics was $1.2 billion in 2012 and forecasted to grow to $4.6 billion in 2017, with 65% of this market in the United States. One of our lead programs targets <I>P. aeruginosa</I>, the most prevalent bacterial infection that leads to the highest mortality in patients with CF with approximately 440 deaths per year in the United States. To develop our products, we have created a global &#147;diversity&#148; panel of relevant <I>P. aeruginosa</I> clinical isolates from CF clinics around the globe. Clinical isolates are bacteria isolated from patients. This diversity
panel has been screened against our phage library that was isolated and characterized according to our proprietary discovery and development platform. We have demonstrated <I>in vitro</I> that we are able to effectively kill the targeted bacteria with a mixture of a few phages propagated in carefully selected bacterial hosts. Furthermore, our phage mix was selected to exhibit a high degree of overlap, defined as the number of bacteria targeted by more than one phage in the product. We believe that high overlap is an important factor in preventing bacteria from developing resistance to our phage products. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In collaboration with Institut Pasteur (Paris, France) and Brompton Clinic, Imperial College (London, United Kingdom), we have demonstrated in the preclinical studies described below that phages can effectively treat infections in animal models of acute <I>P. aeruginosa</I> lung infections. The graphic below shows the three groups from a study conducted at the Institute Pasteur. Each group consisted of eight mice. Group 1 was treated with Placebo, or PBS, Group 2 was treated with an antibiotic (note the model was optimized for this antibiotic) and Group 3 was treated with an AmpliPhi phage mix. The colored regions, measured by
light, intensity, or luminescence, demonstrate where the <I>P. aeruginosa</I> infection is active and the bacteria are actively replicating. By the 24th hour, the surviving untreated animals (Group 1) are sacrificed as the infection has spread and in some cases has already proved lethal whereas the two treatment groups (Group 2, antibiotic and Group 3, phage) demonstrate effective reduction of the active infection. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">46</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v367027_img-mice.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> &nbsp; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Average luminescence for each group is shown below: </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v367027_chrt-line.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> &nbsp; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Bacterial counts and the number of bacteriophage infection units detected by assay, or phage titers, were measured in these animals after 24 hours, and the results demonstrated that our phage mix effectively lowered the bacterial counts, or CFU, in the mouse lung to levels comparable to antibiotic treatment (PBS vs. antibiotic, p=0.0003; PBS vs. bacteriophage, p=0.0003). Furthermore, it was evident that phage replicated to high levels in the infected lung. These results are shown in the graphics below. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">47</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v365643_chrt-scatter1.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> &nbsp; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In a separate <I>in vivo</I> study of acute <I>P. aeruginosa</I> infection of the mouse lung conducted at the Brompton Clinic, results demonstrated that our phage mix reduced CFU levels upon simultaneous intranasal administration (six mice in each of the treatment and control groups) and also when administered 24 hours post-bacterial infection (seven mice in the treatment group and eight mice in the control group) using Pa01, a standard strain of<I> P. aeruginosa</I>. These results are depicted in the graphics below. </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v365643_chrt-scatter2.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> &nbsp; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Importantly, a preclinical study conducted at the Institut Pasteur in mice (12 mice in each of the treatment and control groups) demonstrated the ability of our phage mix to reach the lung within two hours of being delivered by oral administration. The phage levels increased between two and six hours post-treatment, and the results were statistically significant (p-value &lt;0.001). A p-value is a statistical measure of the probability that the difference in two values could have occurred by chance. The smaller the p-value, the greater the confidence that the results are significant. These results demonstrate that when orally
administered in mice, phages not only reached the lungs but were also able to infect and multiply in target bacteria. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We were granted an advisory meeting with United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) in the first quarter of 2014 to discuss our plans and intent to move the CF program into additional preclinical testing in preparation for a Phase 1/2 study in CF patients. We also sought advice and comment that our planned Chemistry Manufacturing and Controls (CMC) plans were acceptable to the MHRA. The MHRA concurred with our approach and plans as presented, including a first in man dose </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">48</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ranging clinical study in CF patients. Subject to the availability of adequate financing, we expect to continue product selection and formulation work. Upon final product selection, we plan to manufacture the AmpliPhage-001 product in our facility in Ljubljana, Slovenia. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe that successful proof of concept in this lung indication could lead to other acute and chronic lung infection markets, such as Ventilator Associated Bacterial Pneumonia (VABP) and Chronic Obstructive Pulmonary Disease (COPD). The bacteria we are currently targeting are predominant pathogens in both of these indications. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhage-004: Gastrointestinal (GI) Infection Caused by <B><I>C. difficile Infection (CDI)</I></B> </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">From 2000 through 2007, deaths in the United States from <I>C. difficile</I> infection increased over 400%. Over 90% of such deaths occur in hospitalized or confined patients over the age of 65. Global Data estimates that the major European Union and United States markets for CDI therapies grew to more than $314 million in 2011 and they are expected to grow to more than $500 million by 2019. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">According to the CDC, almost 250,000 people each year require hospitalization for <I>C. difficile</I> infections, and at least 14,000 people die each year in the United States from <I>C. difficile</I> infections. From 2000 through 2007, deaths in the United States from <I>C. difficile</I> infections increased over 400%. We are actively working with researchers at the University of Leicester and the University of Glasgow to develop a phage therapy that targets and kills all toxin types of <I>C. difficile</I>. We believe that orally delivered phages are well suited to treat CDI. Within this collaboration, researchers at the
University of Leicester have discovered phages that have been shown to be effective against clinically-relevant strains of <I>C. difficile</I> isolated from around the world<I>.</I> Since current therapies against <I>C. difficile</I> are considered less than optimal, we believe that there is a significant market opportunity for our product in treating this disease. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior Clinical Development </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In 2010, the Company&#146;s wholly owned subsidiary, Biocontrol, reported a double-blind placebo-controlled, randomized Phase 1/2 clinical trial targeting chronic ear infections (otitis) caused by antibiotic-resistant <I>P. aeruginosa</I>. This was the first, and to date, we believe the only, regulated efficacy trial of bacteriophage therapy in humans that has been reported. Positive results were reported demonstrating decreasing levels of <I>P. aeruginosa</I> in the ear and improvement of clinical condition with a single input dose of 2.4 nanograms of bacteriophage preparation. While this was a small trial (n=24), changes
from baseline at the end of the trial in the test group (n=12) were statistically significant for both clinical condition (p=0.001) and bacterial load (p=0.016). No significant changes were seen in the control group (n=12) compared to baseline at the end of the trial. Difference between test and control groups was statistically significant by analysis by covariance (ANCOVA) on day 21 for bacterial count (p=0.0365). These results will need to be validated in larger well-controlled trials. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Anti-Infective Therapeutics Market </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The market opportunity for antibiotics is extremely large, with the market estimated to reach $40.3 billion in annual sales globally in 2015. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Almost one in every five deaths worldwide occurs as a result of infection and, according to the World Health Organization, or WHO, many bacterial infections will become difficult or impossible to cure as the efficacy of current antibiotic drugs wanes. Despite the advances in antimicrobial and vaccine development, infectious diseases still remain as the third-leading cause of death in the United States and the second-leading cause of death worldwide. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">49</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The number of new antibiotics approved by the FDA and other global regulatory authorities has declined consistently over the last two decades. According to the Infectious Diseases Society of America, as of early 2013, only two new antibiotics have been approved by the FDA since 2009 and only seven new antibiotics targeting multi-drug-resistant Gram-negative bacilli were in either Phase 2 or Phase 3 trials. This dramatic decrease in productivity is evidenced by only two classes of antibiotics oxazolidinones and cyclic lipopeptides having been developed and launched in the last 30 years. At the same time, the evolution of
antibiotic-resistant bacteria has led to an increasing number of infections for which there are no current treatments available. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Hospital-acquired (nosocomial) infections are a major healthcare problem throughout the world, affecting developed countries as well as resource-poor countries. The WHO reports that hospital-acquired infections are among the major causes of death and increased morbidity among hospitalized patients and estimates that more than 1.4 million people per year worldwide suffer from infectious complications from a hospital stay. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A recent CDC report also cites that in the United States, between 5 and 10% of all patients admitted to a hospital will be affected by a hospital-acquired infection during their stay, typically requiring extended stays and additional care. There is also a significant risk of death from such infections. In the United States, the CDC estimates that approximately 99,000 people die from hospital-acquired infections each year. The Cystic Fibrosis Foundation estimates that <I>P. aeruginosa</I> accounts for 10% of all hospital-acquired infections. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Infections also occur in connection with Cystic Fibrosis (CF), which is a genetic disease affecting primarily Caucasians of northern European descent. According to the Cystic Fibrosis Foundation, there are approximately 50,000 cases of CF in North America and Europe. <I>P. aeruginosa</I> opportunistically infects the mucous membranes, primarily the lungs, of CF patients and quickly grows out of control, resulting in pneumonia. <I>P. aeruginosa</I> infections are notoriously resistant to known antibiotics, and treatment may be further complicated by the formation of biofilms. Biofilms are organized structures of microorganisms
growing on solid surfaces (such as lung tissue) and often limit access of antibiotics to the covered tissues. Since phages attack bacteria in a manner independent of chemical antibiotic resistance mechanisms and can infect bacteria growing in biofilms, we believe that <I>P. aeruginosa</I> infection among CF patients represents a compelling indication to pursue. The availability of <I>Pseudomonas</I>-specific phages along with validated animal models of <I>P. aeruginosa</I> lung infections has contributed to the development of our bacteriophage program in CF. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Compounding the above situations is the alarming and continuing rise in the prevalence of antibiotic-resistant bacterial infections. This, coupled with the lack of new antibiotics in current discovery and development pipelines, has generated a significant clinical management problem worldwide, leading to increases in morbidity and mortality due to these antibiotic-resistant bacteria as well as increases in healthcare costs. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The first of these antibiotic-resistant infections to reach epidemic proportions was caused by the Gram-positive bacterium <I>S. aureus</I>. <I>S. aureus</I> resistance to a broad range of antibiotics has necessitated the use of expensive and potentially toxic &#147;drugs of last resort&#148;, most notably vancomycin. Antibiotic-resistant forms of <I>S. aureus</I>, usually termed MRSA (methicillin-resistant <I>S. aureus</I>), VISA (vancomycin-intermediate <I>S. aureus</I>), or VRSA (vancomycin-resistant <I>S. aureus</I>), can be extremely challenging to treat. Although several antibiotics targeting <I>S. aureus</I> have been
developed, rapidly developing bacterial resistance has been noted for all of these including linezolid, daptomycin and tigecycline. On the basis of historical evidence, resistance to these existing products is likely to increase over time, and this picture is further complicated by the reduced efficacy of conventional antibiotics against <I>Staphylococcus</I> biofilms. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Typically <I>S. aureus</I> infection causes a variety of suppurative (pus-forming) infections and toxinoses in humans. It causes superficial skin lesions such as boils, styes and furuncles; more serious infections such as pneumonia, mastitis, phlebitis, meningitis and urinary tract infections; and deep-seated infections, such as osteomyelitis and endocarditis. <I>S. aureus</I> is the leading cause of wound infections, in particular, hospital-acquired (nosocomial) infection of surgical wounds and infections associated with indwelling medical devices. <I>S. aureus</I> is the leading pathogen in healthcare-associated infections
in the United States as a whole, accounting for 30.4% of surgical site infections (SSI), and 15.6% of such infections overall. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">50</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Anti-Infective Treatments with Bacteriophages </H3>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Background </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The dramatic rise in antibiotic resistance, the appearance of an increasing number of new &#147;superbugs&#148; and the lack of new antibiotics in the pipeline has prompted calls to action from many of the world&#146;s major health bodies such as the CDC and the WHO, who warn of an &#147;antibiotic cliff&#148; and a &#147;post-antibiotic era.&#148; In 2009, the European Antimicrobial Resistance Surveillance System, or EARSS, concluded that &#147;the loss of effective antimicrobial therapy increasingly threaten[s] the delivery of crucial health services in hospitals and in the community.&#148; This conclusion was reinforced by
The Antimicrobial Availability Task Force, or AATF, of the Infectious Diseases Society of America, or IDSA, and the European Centre for Disease Prevention and Control, or ECDC, in conjunction with the European Medicine Agency, or EMA. Clearly, there is a pressing need to find alternative antibacterial therapies. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Bacteriophage therapy has the potential to be an alternative method of treating bacterial infection. Phages are ubiquitous environmental viruses that grow only within bacteria. The name &#147;bacteriophage&#148; translates as &#147;eaters of bacteria&#148; and reflects the fact that as they grow, phages kill the bacterial host by multiplying inside and then bursting through the cell membrane in order to release the next generation of phages. Phages can differ substantially in morphology and each phage is active against a specific range of a given bacterial species. Phages were first discovered in 1915 at the Institut Pasteur
and were shown to kill bacteria taken from patients suffering from dysentery. Furthermore, it was noted that phage numbers rose as patients recovered from infection, suggesting a direct association. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Life Cycle of a Bacteriophage </H2>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v365643_img-lifecycle.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> &nbsp; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Until the discovery of effective antibiotics, phages were used as an effective means of combating bacterial infection. When broad-spectrum antibiotics came into common use in the early 1940s, phages were considered unnecessary, with antibiotics being seen for many years as the answer to bacterial disease. This attitude persisted until the development of the wide-ranging, and in some cases total, resistance to antibiotics seen within the last 10 years. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">It is now clear that bacteria can adapt to resist chemical antibiotics. In addition, there is now strong pressure to limit the use of antibiotics for human and veterinary use. There is a real need for different approaches to the control of antibiotic-resistant bacterial infections. In the light of current knowledge, it is apparent that early work with phages was hindered by poor understanding of the biology of phages, leading to exaggerated claims that damaged the reputation of phage therapy. Several companies in the 1920s and 1930s began to produce and market bacteriophage preparations. Unfortunately, these were often
marketed with promises of efficacy against diseases that are now known to have nothing to do with bacteria, and many preparations themselves failed to actually contain bacteriophages. These conditions made bacteriophage subject to understandable skepticism. Now, with the far greater understanding of phages and their function that is now available, it is possible to identify the bacteria that are causing disease and then target them with highly specific phages that will kill only those bacteria. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Phages have the potential to provide both an alternative to, and a synergistic approach with, antibiotic therapy. Since they use entirely different mechanisms of action, phages are unaffected by resistance to conventional antibiotics. Phage containing certain enzymes also have the ability to disrupt bacterial biofilms, thus potentiating the effect of chemical antibiotics when used in combination with them. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In fact, the ability to isolate and develop phages for any of a broad range of bacterial targets, combined with their ability to disrupt bacterial biofilms, suggests strong potential for this approach in the control of </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">51</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">bacterial infections. Published literature indicates that phages have the potential to be used as topical agents for the control of bacterial infection, and that such use is compatible with the approaches that have been shown to be effective in the treatment of wound injuries. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Bacteriophage therapy for the treatment of bacterial infections has been in constant use since 1917. Most of the research on phage-based therapy was conducted in the former Soviet Union prior to and immediately after World War II. While the West primarily focused resources into the development of chemical antibiotics, physicians and researchers in the Soviet Union were mass-producing phages and demonstrating their efficacy against a wide range of bacterial infections affecting the GI tract (dysentery), wounds (surgical and combat), skin (boils) and bone (osteomyelitis). While these studies are compelling, most lacked
appropriate control group design or lacked control groups completely. Furthermore, the standard of care has changed substantially during the ensuing decades since those studies were performed, making claims of improved cure rates open for debate. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Despite numerous encouraging case studies, bacteriophage treatment was never adopted by Western medicine due to a lack of robust scientific evidence generated through systematically planned, controlled and regulated clinical trials. Recently, however, an increasing number of papers, reviews and books appearing on bacteriophage therapy indicate an increasing appetite among the scientific community and healthcare industry for developing bacteriophage therapy as part of mainstream medicine. Current biomedical technology is vastly superior to that available during the early days of bacteriophage therapy and our understanding of
phage biology and the mechanisms of phage-bacterial host interaction have improved, along with advances in knowledge concerning bacterial infection. Although our knowledge of the biology, genetics and bactericidal efficacy of bacteriophages <I>in vitro</I> is impressive, less is known about their pharmacokinetic behavior <I>in vivo</I>, in particular in human subjects. To date very few human clinical trials have been conducted to modern standards in either the United States or Europe. In 2009, a U.S. Phase 1 clinical trial carried out at the Southwestern Regional Wound Care Center in venous ulcers using a mixture or &#147;cocktail&#148; of phages which individually attack different species of bacteria (<I>S. aureus</I>, <I>P. aeruginosa</I> and <I>E. coli</I>) was reported. The results of this trial showed this multi-bacteriophage preparation to be safe in trial subjects. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These trials, alongside published reports of less well-conducted studies, suggest that phage therapy shows promise for treating infectious diseases caused by antibiotic-resistant bacteria. One, conducted by the Polish Academy of Sciences, started in 2005 and is treating a broad range of infections and clinical conditions associated with antibiotic-refractory infections. This work derives from a phage therapy clinic that has operated at this location. A second is the European Union-sponsored &#147;Phagoburn&#148; Phase 1/2 clinical trial, which is being conducted at multiple centers in France, Belgium and Switzerland. The
project has been under way since June 2013, using a large phage mix for treatment of burn wounds infected with <I>E. coli</I> and <I>P. aeruginosa</I>. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Strategy </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our strategy is to use techniques of modern biotechnology and current state-of-the-art practices for drug development in concert with existing regulatory guidance to develop a pipeline of bacteriophage products that will destroy bacterial pathogens such as MRSA, which are resistant to chemical antibiotics. Our business strategy will apply state-of-the-art techniques in molecular biology and in clinical trial design to build upon the long successful history of using phages therapeutically to treat and cure infections. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In collaboration with the U.S. Army, we plan to initiate a clinical trial that will support the development of a treatment for <I>S. Aureus</I> infections for wound and skin infections. Additionally, subject to the availability of adequate financing, we expect to continue product selection and formulation work for AmpliPhage-001, and following final product selection, in conjunction with leading Centers of Excellence in the UK, we would expect to conduct a Phase 1/2 study using AmpliPhage-001 to treat CF patients with <I>P. aeruginosa</I> lung infections. Through our collaboration agreement with the University of Leicester, we
are also continuing to develop AmpiPhage-004 to treat patients suffering from serious gastrointestinal infections caused by <I>C. difficile</I>. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Recent Acquisitions </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In January 2011, we completed the acquisition of Biocontrol, with the goal of developing their phage therapy programs using funding from the sale of our legacy gene therapy assets. Under the terms of our </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">52</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">acquisition of Biocontrol, we issued 22,817,198 shares of our common stock to the shareholders of Biocontrol with a total fair value of approximately $8.6 million as of January 6, 2011, resulting in Biocontrol&#146;s former shareholders owning approximately 50% of our outstanding equity securities at the time. As a condition to closing the acquisition, Biocontrol raised approximately &#163;200,000 (US$310,000) in working capital for use by us. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2012, we acquired SPH, pursuant to our offer to acquire all outstanding shares of SPH from its shareholders under the terms of a Shareholder Sale Agreement and a Managers Warranty Deed, collectively referred to as the SPH Agreements, in exchange for up to 40,000,000 shares of our common stock. 20,000,000 of those shares were issued directly to the selling stockholders of SPH upon the closing of the acquisition, and the remaining 20,000,000 shares were issued and held in escrow. Of the escrow shares, 8,000,000 shares, referred to as Claims Shares, were subject to claims by us for breaches of representations by the
selling stockholders of certain individual representations and certain additional representations made with respect to SPH itself and its operations by Dr. Anthony Smithyman and Mrs. Margaret Smithyman, the two largest shareholders of SPH, referred to as the Managers. The Claims Shares were released from escrow in November 2013, 12 months following the closing of the acquisition. The remaining 12,000,000 shares were released from escrow in November 2013, 12 months following the closing of the acquisition. The remaining 12,000,000 shares were released from escrow in November 2014 following the Board&#146;s determination, based on the review of an independent committee of the Board of Directors, that the release of such shares was appropriate under the terms of the applicable agreement. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with our acquisition of SPH, we entered into certain other arrangements, including the repayment under a Loan Repayment Deed (as amended) of a $770,000 loan originally made by Cellabs Pty Ltd, or Cellabs, an Australian company affiliated with Dr. Smithyman, to SPH, a consulting agreement with Dr. Smithyman and the payment of $3,017 per month to Cellabs for our laboratory space in Australia. Under the terms of the Loan Repayment Deed, the loan from Cellabs to SPH was to be repaid and fully satisfied partly in cash and partly by issuing 2,000,000 shares of our common stock to Cellabs. As of December 31, 2013,
$350,000 has been paid by us to Cellabs and all 2,000,000 shares have been issued. The SPH acquisition also included several phage therapy projects which had reached the pre-clinical or animal study stage, including the Brompton Hospital CF study, the Adelaide University MRSA chronic rhinosinusitis study and the University of Leicester <I>C. difficile</I> project. We believe that acquisition of SPH brings substantial phage scientific expertise and know-how to the Company sufficient to develop, manufacture and commercialize phage-based therapeutics. Under the terms of the consulting agreement with Dr. Smithyman, we were obligated to pay a fee of $10,000 per month to Dr. Smithyman, who provided management consulting services as an independent contractor for an initial term of 12 months ending October 2013. Between the acquisitions of Biocontrol and SPH, we believe that we are the leading therapeutically focused phage company in the world. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Strategic Alliances and Research Agreements </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As discussed below, we have established collaborations with Intrexon, the U.S. Army and the University of Leicester, which provide us with access to the considerable scientific, developmental, and regulatory capabilities of our collaborators. We believe that our collaborations contribute to our ability to rapidly advance our product candidates, build our product platform and concurrently progress a wide range of discovery and development programs. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Exclusive Channel Collaboration with Intrexon </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On March 29, 2013, we entered into the ECC with Intrexon that governs a collaboration arrangement in which AmpliPhi uses Intrexon&#146;s technologies directed towards the research, development and commercialization of new bacteriophage-based therapies to target specific antibiotic-resistant infections. We believe that combining the broadest and most advanced synthetic biology platform with our world-leading phage capabilities will lead to the development of innovative second-generation phage products. The ECC establishes committees comprised of representatives of the Company and Intrexon that govern activities related to the
bacteriophage programs in the areas of project establishment and prioritization, as well as budgets and their approval, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">53</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Intrexon is a publicly held biotechnology company focused on the industrial engineering of synthetic biology. According to Intrexon, their advanced bioindustrial engineering platform enables Better DNA<sup>TM</sup> technology by combining DNA control systems with corresponding advancements in modular transgene design, assembly and optimization to enable unprecedented control over the function and output of living cells. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the terms of the ECC, the Company will receive an exclusive, worldwide license to utilize Intrexon&#146;s proprietary technology and expertise for the standardized design and production of genetically modified bacteriophages, which we refer to collectively as the Bacteriophage Program. The ECC seeks to develop bacteriophage-containing human therapeutics for use in the treatment of bacterial infections associated with acute and chronic wounds, the treatment of acute and chronic <I>P. aeruginosa</I> lung infections and the treatment of infections of <I>C. difficile</I>, which we collectively refer to as AmpliPhi Products.
The ECC grants the Company a worldwide license to use patents and other intellectual property of Intrexon in connection with the research, development, use, importing, manufacture, sale and offer for sale of AmpliPhi Products. Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of AmpliPhi Products, and otherwise is non-exclusive. Subject to limited exceptions, we may not sublicense the rights to Intrexon&#146;s technology without Intrexon&#146;s written consent. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the ECC, and subject to certain exceptions, we are responsible for, among other things, the performance of the Bacteriophage Program, including development, commercialization and certain aspects of manufacturing AmpliPhi Products. Intrexon is responsible for the costs of establishing manufacturing capabilities and facilities, subject to certain exceptions, for the bulk manufacture of products developed under the Bacteriophage Program, certain other aspects of manufacturing and costs of basic-stage research with respect to Intrexon Channel Technology and Intrexon materials, i.e., platform improvements and costs of filing,
prosecution and maintenance of Intrexon&#146;s patents. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Subject to certain expense allocations and other offsets provided in the ECC, AmpliPhi has agreed to pay Intrexon on a quarterly basis tiered royalties on net sales derived in that quarter from the sale of AmpliPhi Products, which are based on or incorporate Intrexon&#146;s technology, calculated on a product-by-product basis. If AmpliPhi sublicenses a product developed under the collaboration with Intrexon, AmpliPhi has likewise agreed to pay Intrexon on a quarterly basis a certain percentage of revenues received from the sublicensee. Pursuant to the ECC, Intrexon received 24,000,000 shares of our common stock as an upfront
technology access fee. We may also pay Intrexon up to $7.5 million in aggregate milestone payments for each product, payable either in cash or equity upon the achievement of certain events. Intrexon is also entitled to tiered royalties as a percentage in the upper-single digits of the net product sales of a product developed under the ECC. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Global R&amp;D Agreement with U.S. Army </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2013, we entered a CRADA with the USAMRMC and the WRAIR. The CRADA will focus on developing bacteriophage therapeutics to treat at least three types of infections: <I>S. aureus</I>, <I>E. coli</I> and <I>P. aeruginosa</I>. The increasing prevalence of antibiotic-resistant bacteria poses a serious threat to public health and military personnel and is a major problem in hospitals and clinics around the world. The initial indication will be wounds and skin infections from <I>S. aureus</I>, which is the leading pathogen in healthcare-associated infections in the United States as a whole, accounting for 30.4% of surgical
site infections. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with our CRADA with the U.S. Army, we submitted a Pre-IND briefing package to the FDA to obtain their feedback on our Chemistry, Manufacturing and Controls (CMC) program and plans for our first human study with our lead product, AmpliPhage-002 (<I>S. aureus</I>). The FDA endorsed our plan for progressing bacteriophage therapy to the clinic, specifically agreeing to our platform&#146;s manufacturing process, product specifications and the absence of any need of non-clinical toxicology to initiate our first Phase 1 study. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We plan to conduct our Phase 1 study at the WRAIR and to conduct further clinical trials at various sites throughout the world. We plan to initiate a clinical trial in 2015 in collaboration with the U.S. Army that will support the development of a treatment for <I>S. Aureus</I> infections for wound and skin infections. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">54</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will retain global regulatory ownership and commercial rights to all products developed by us under the agreement. USAMRMC will gain access rights to any products developed. We also have the rights to exclusively license any intellectual property developed by USAMRMC under the collaboration on terms to be agreed upon. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The CRADA expires in June 2018 and can be terminated by either USAMRMC or AmpliPhi upon 60 days&#146; written notice to the other party at any time. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">University of Leicester Development Agreements </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 24, 2013, we entered into the April Collaboration Agreement and on September 5, 2013, we entered into the &#147;Leicester License Agreement&#148; with the University of Leicester to develop a phage therapy that targets and kills all toxin types of <I>C. difficile</I>. We also entered into the August Collaboration Agreement with the University of Leicester and the University of Glasgow, whereby the University of Glasgow will carry out certain animal model development work. These agreements were extended in November 2014. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under these agreements, which we refer to collectively as the Leicester Development Agreements, we are funding the University of Leicester to carry out <I>in vitro</I> and the University of Glasgow to carry out animal model development work on the University of Leicester&#146;s development of a bacteriophage therapeutic to resolve <I>C. difficile</I> infections and we are licensing related patents, materials and know-how from the University of Leicester. Under the Leicester Development Agreements, the University of Leicester will provide the bacteriophage and act as overall project coordinator for the development work. All
rights, title and interest to any intellectual property developed under the Leicester Development Agreements belong to us. Under the Leicester License Agreement, we have exclusive rights to certain background intellectual property of the University of Leicester, for which we will pay the University of Leicester royalties based on product sales and make certain milestone payments based on product development. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The April Collaboration Agreement expires on November 12, 2015 and is terminable by either party upon (a) material breach by the other party, subject to a 90-day cure period, (b) the inability of the principal investigator to continue the collaboration or (c) our bankruptcy or winding up of our operations. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The August Collaboration Agreement expires on January 22, 2015 and is terminable under the same conditions as the April Collaboration Agreement. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The license agreement expires on the later of the expiration of the licensed patents or September 5, 2028, and is terminable by us at any time upon 60 days&#146; notice, by the University of Leicester (a) if we legally challenge the validity or ownership of any of the licensed patents, (b) if we fail to pay the fees, milestones or royalties due under the license agreement or (c) if we fail to make substantial commercial process and agree with Leicester that we will be unable to do so. The license agreement is also terminable by either party upon the material breach by the other party (subject to a 30-day cure period) or upon
the other party&#146;s bankruptcy or insolvency. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sale of Assets to Celladon Corporation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 27, 2012, we entered into an asset purchase agreement and amended and restated license agreement, or license agreement, with Celladon Corporation, or Celladon, where we sold and transferred all of our rights and interest in our gene therapy business, subject to certain limitations relating to rights contained in our license agreements with the University of Pennsylvania and Genzyme Corporation. Pursuant to our license agreement with the University of Pennsylvania, or UPenn, we may be obligated to make certain royalty and license payments to UPenn as a result of Celladon&#146;s (or its affiliate&#146;s or
licensee&#146;s) use of certain technology licensed under our license agreement with Celladon. Pursuant to the license agreement with Celladon, Celladon has agreed to comply with certain terms of the UPenn license agreement and to reimburse us for any payments that come due under the UPenn license agreement. Pursuant to the license agreement, we may receive a long-term royalty of 1.75% on certain product sales. This royalty may be completely canceled at any time by making a one-time payment to us in the amount of $1.75 million. In May 2013, we received a royalty payment from Celladon in the amount of $0.3 million. Celladon&#146;s obligation to pay us these royalties continues until the earlier of Celladon&#146;s termination of the agreement (which it may elect to do at any time upon thirty days&#146; notice to us) or expiration of the patents related to the licensed technology. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">55</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the terms of the Celladon asset sale and license agreement, we retained certain liabilities, including obligations to indemnify against charges of infringement of certain intellectual property pursuant to our asset purchase agreement with Genzyme Corporation, our license agreement with Amsterdam Molecular Therapeutics B.V. and our collaboration and license agreement dated January 1, 2005 with the International AIDS Vaccine Initiative, the Children&#146;s Research Institute and the Children&#146;s Hospital of Philadelphia. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Intellectual Property </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our goal is to obtain, maintain and enforce patent protection for our product candidates, formulations, processes, methods and any other proprietary technologies, preserve our trade secrets and operate without infringing on the proprietary rights of other parties, both in the United States and in other countries. Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our current product candidates and any future product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the United
States and abroad. However, patent protection may not afford us with complete protection against competitors who seek to circumvent our patents. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We also depend upon the skills, knowledge, experience and know-how of our management and research and development personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary know-how, which is not patentable, and for inventions for which patents may be difficult to enforce, we currently and will in the future rely on trade secret protection and confidentiality agreements to protect our interests. To this end, we require all of our employees, consultants, advisors and other contractors to enter into confidentiality agreements that prohibit the disclosure of confidential
information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We hold or have exclusive license rights to five U.S. patents (and corresponding foreign patents), expiring on various dates between 2024 and 2029. These patents relate to the therapeutic uses of bacteriophages, bacteriophage compositions, the sequential use of bacteriophages in combination with conventional antibiotics, genetic sequence variations, biofilm disrupting agents, methods to reduce antibiotic resistance, and methods to design therapeutic combination panels of bacteriophage. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">US 7758856 and national patents within the EU deriving from PCT WO2004062677; Bacteriophage for the treatment of bacterial biofilms </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under an existing license from the United Kingdom Secretary of State for the Department of Health (DoH), we have exclusive rights to develop and exploit technologies relating to the use of bacteriophages combined with biofilm-disrupting agents in treating biofilm infections. The patent specifies agents able to facilitate the penetration of biofilms, and their combination with therapeutic bacteriophage preparations. The priority date for these patents is January 10, 2003 and the date of U.S. grant is July 20, 2010. The date of expiry is December 5, 2026 in the United States (noting Patent Term Adjustment, PTA, by the United
States Patent and Trademark Office, or USPTO). The patent is also granted in the European Union (France, Germany, Netherlands, Switzerland/Liechtenstein and the United Kingdom). The date of expiration is January 12, 2024 in the European Union. Pursuant to this license agreement, we may be required to pay the United Kingdom DoH aggregate milestone payments of up to &#163;10,000 per product and single-digit royalties. The agreement, which may be terminated by the DoH upon our default, continues until the earlier of such termination or the expiry of the DoH&#146;s rights in the licensed intellectual property. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">US 7807149, US 8105579, US 8388946, continuation application and national filings deriving from PCT WO2005009451; Bacteriophage containing therapeutic agents </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Through our wholly owned subsidiary, Biocontrol Ltd, we have three granted U.S. patents and a pending continuation application filed. The granted patents relate to therapeutic, sequential use of bacteriophages in combination with conventional antibiotics, to bacteriophage compositions, and to the uses of bacteriophages. The filed continuation application relates to genetic sequence variation around the protected agents. The priority dates for these patents is July 23, 2003. Dates of U.S. grant are October 5, 2010, January 31, 2012 </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">56</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">and March 5, 2013. The dates of expiry for the granted patents are March 18, 2027 (noting PTA by the USPTO), July 23, 2024 and July 23, 2024 in the United States. The national application in Australia was granted as AU 2004258731 on June 10, 2010, with July 23, 2024 as the date of expiry. Examination in other jurisdictions is proceeding: for example, in the EU, claims for bacteriophage compositions are approaching allowance; and a divisional application has been submitted for therapy claims although there is no assurance that claims or applications will ultimately be granted. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">US 8475787, continuation application and national filings deriving from PCT WO2008110840; Beneficial effects of bacteriophage treatment </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Through our wholly owned subsidiary, Biocontrol Ltd, we have one granted U.S. patent, and a pending continuation application filed. The granted patent relates to bacteriophage-induced induction of antibiotic sensitivity for <I>P. aeruginosa</I>. The priority date for these patents is March 9, 2007. The date of U.S. grant is July 2, 2013 and the date of expiry for the granted patent is March 21, 2029 (noting PTA by the USPTO). The continuation application has been filed relating to other bacterial species. The national application in Australia was granted as AU 2008224651 on December 19, 2013, with March 7, 2028 as the date of
expiry. National applications are under examination in other jurisdictions. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">PCT WO2013/16464 (United Kingdom priority filing 1207910.9); Therapeutic bacteriophage compositions </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Through our wholly owned subsidiary, Biocontrol Ltd, we have a PCT application relating to the design of effective combinations of bacteriophages. The priority date for this application is May 4, 2012. The PCT application published on November 7, 2013. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our success in preserving market exclusivity for our product candidates relies on patent protection, including extensions to this where appropriate, and on data exclusivity relating to an approved biologic. This may be extended by orphan drug and/or pediatric use protection where appropriate. Once any regulatory period of data exclusivity expires, depending on the status of our patent coverage, we may not be able to prevent others from marketing and selling biosimilar versions of our product candidates. We are also dependent upon the diligence of our appointed agents in national jurisdictions, acting for and on behalf of the
Company, which manage the prosecution of pending domestic and foreign patent applications and maintain granted domestic and foreign patents. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Competition </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We operate in highly competitive segments of the biotechnology and biopharmaceutical markets. We face competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions all seeking to develop novel treatment modalities for bacterial disease. Many of our competitors have significantly greater financial, product development, manufacturing and marketing resources than we do. Large pharmaceutical companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. In
addition, many universities and private and public research institutes are active in antibacterial research, some in direct competition with us. We also may compete with these organizations to recruit scientists and clinical development personnel. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Manufacturing and Supply </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The manufacturing process for our bacteriophage product is currently under development. We have developed our own manufacturing capabilities at a wholly owned facility in Ljubljana, Slovenia. Our facility must comply with applicable cGMP regulations, which require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation. Pharmaceutical product manufacturers and other entities involved in the manufacture and distribution of approved pharmaceutical products are required to register their establishments with the FDA, and certain state agencies, including the
applicable government agency where the facility is located, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Our facility in Ljubljana Slovenia is subject to inspection and regulation by JAZMP, the Slovenian agency that regulates and supervises pharmaceutical products in Slovenia. As a result of an initial inspection, we are taking certain </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">57</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">corrective actions regarding the manufacture of AmpliPhage-002, which we believe will lead to certification by JAZMP to manufacture AmpliPhage-002; however, there can be no assurance that we will receive such certification. Accordingly, we must continue to expend time, money and effort in the areas of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA/Biologics License Application, or BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing
process generally require prior regulatory approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further regulatory review and approval, including approval by the FDA. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Commercialization and Marketing </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have full worldwide commercial rights to all of our phage-based products to treat drug-resistant bacterial infections, including our lead programs: AmpliPhage-001 for the treatment of CF patients with <I>P. aeruginosa</I> lung infections; AmpliPhage-002, for the treatment of antibiotic-resistant <I>S. aureus</I> (MRSA) infections; and AmpliPhage-004 for the treatment of <I>C. difficile</I> infections. We believe we can maximize the value of our company by retaining substantial global commercialization rights to these product candidates and, where appropriate, entering into partnerships to develop and commercialize our other
product candidates. We plan to build a successful commercial enterprise using a sales team in the United States and possibly other major markets and with partners in other territories. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not yet established a sales, marketing or product distribution infrastructure because our lead candidates are still in early clinical development. We generally expect to retain commercialization and co-commercialization rights in the United States for all of our product candidates for which we receive marketing approvals. Subject to receiving marketing approvals, we intend to explore building the necessary marketing and sales infrastructure to market and sell our current product candidates. We also intend to explore the use of a variety of distribution agreements and commercial partnerships in those territories where
we do not establish a sales force for any of our product candidates that obtain marketing approval. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Government Regulation and Product Approval </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">United States Product Development Process </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States, the FDA regulates biological products under the Federal Food, Drug and Cosmetic Act, or FDCA, and the Public Health Service Act, or the PHS Act, and related regulations. Biological products are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process or
approval process, or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be marketed in the United States generally includes the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">completion of preclinical laboratory tests, animal studies and formulation studies according to good laboratory practice requirements, or GLP, or other applicable regulations; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">submission to the FDA of an IND, which must become effective before human clinical trials may begin in the United States; </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">58</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">performance of adequate and well-controlled human clinical trials according to the FDA&#146;s regulations commonly referred to as good clinical practices, or GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use or uses; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">submission to the FDA of a Biologics License Application (BLA) for a new biological product; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with the FDA&#146;s cGMP regulations, to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s identity, strength, quality and purity; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">potential FDA audit of the nonclinical study sites and clinical trial sites that generated the data in support of the BLA; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">FDA review and approval, or licensure, of the BLA which must occur before a biological product can be marketed or sold. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources even when approvals are inherently uncertain. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The strategies, nature, and technologies of bacteriophage products are different from the conventional antibiotic therapy products. From the regulatory requirements established to ensure the safety, efficacy and quality of bacteriophage preparations, there are several major points to consider during the development, manufacturing, characterization, preclinical study and clinical study of bacteriophage. The major issues include: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">bacteriophage preparation design (single agent versus phage mixes and wild-type phage versus genetically engineered phage); </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">proof of concept in development of bacteriophage products; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">selectivity of bacteriophage replication and targeting to specific species of bacteria; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">relevant animal models in preclinical studies; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">clinical safety. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Before testing any compounds with potential therapeutic value in humans, the biological product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product biology, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the biological product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLP. The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed
clinical protocol, to the FDA as part of the IND application. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the IND on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be certain that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trial. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Clinical trials involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by the sponsor. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject inclusion and exclusion criteria and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA if conducted under an IND. Clinical trials must be conducted in accordance with GCP requirements. Further, each clinical trial must be reviewed
and approved by an independent institutional review board, or IRB, or ethics committee if conducted outside of the U.S., at </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">59</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">or servicing each institution at which the clinical trial will be conducted. An IRB or ethics committee is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB or ethics committee also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. We intend to use third-party CROs to administer and conduct our planned clinical
trials and will rely upon such CROs, as well as medical institutions, clinical investigators and consultants, to conduct our trials in accordance with our clinical protocols and to play a significant role in the subsequent collection and analysis of data from these trials. The failure by any of such third parties to meet expected timelines, adhere to our protocols or meet regulatory standards could adversely impact the subject product development program and we remain legally responsible for compliance with applicable laws and regulations governing the conduct of these clinical trials. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Phase 1:&nbsp;&nbsp;The biological product is initially introduced into healthy human subjects and tested primarily for safety and dosage tolerance. Absorption, metabolism, distribution and excretion may also be tested. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Phase 2:&nbsp;&nbsp;The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Phase 3:&nbsp;&nbsp;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA and other regulatory authorities for approval of a marketing application. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Post-approval studies, or Phase 4 clinical trials, may be requested by the FDA as a condition of approval and are conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests that there may be a significant risk for human subjects. The FDA or the sponsor or, if used, its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB or ethics committee can
suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s or ethics committee&#146;s requirements or if the pharmaceutical product has been associated with unexpected serious harm to patients. Suspension of a clinical study due to safety risks attributed to the investigational product will result in termination of the study and possibly others that are underway. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents or other impurities with the use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing
quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency, and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">United States Review and Approval Processes </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In order to obtain approval to market a biological product in the United States, a BLA must be submitted to the FDA that provides data establishing to the FDA&#146;s satisfaction the safety and effectiveness of the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">60</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">investigational biological product for the proposed indication. The application includes all data available from nonclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s manufacture and composition, and proposed labeling, among other things. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. According to the FDA&#146;s fee schedule, effective through September 30, 2014, the user fee for an application requiring clinical data, such that the biological product candidate does not undergo unacceptable deterioration over its shelf life as a BLA, is $2,169,100. PDUFA also imposes an annual product fee for biologics ($104,060), and an annual establishment fee ($554,600) on facilities used to manufacture prescription biologics. Fee waivers or reductions are
available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#146;s threshold determination that the application is sufficiently complete to permit substantive review. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. After the BLA submission is accepted for filing, the FDA reviews the BLA to
determine, among other things, whether the proposed product is safe and effective for its intended use, has an acceptable purity profile, and whether the product is being manufactured in accordance with GMP regulations to assure and preserve the product&#146;s identity, safety, strength, quality, potency, and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA may ultimately decide that the NDA/BLA does not satisfy the criteria for approval. If a product receives regulatory approval, the approval may be significantly limited to
specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Special FDA Expedited Review and Approval Programs </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA has various programs, including fast track designation, accelerated approval and priority review, that are intended to expedite the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs and biological products to patients earlier than under standard FDA review procedures. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life threatening disease or condition and demonstrates the potential to address an unmet medical need, or if the drug or biological product qualifies as a qualified infectious disease product under the recently enacted Generating Antibiotic Incentives Now, or GAIN Act. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or
safety factors. We intend to request fast track designation for our product candidates if applicable. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biological may request the FDA to designate the drug or biologic as a Fast Track product at any time during the clinical development of the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">61</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">product. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated
for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a condition of approval, the FDA may require a sponsor of a drug or biological product receiving accelerated approval perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biological product may be subject to accelerated withdrawal procedures. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track designation, priority review and accelerated approval do not change the
standards for approval but may expedite the development or approval process. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Moreover, under the provisions of the new Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted in 2012, a sponsor can request designation of a product candidate as a &#147;breakthrough therapy.&#148; A breakthrough therapy is defined as a drug or biological product that is intended, alone or in combination with one or more other drugs or biological products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the biological product or drug may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biological products designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. We intend to request &#147;breakthrough therapy&#148; designation for our product candidates if applicable. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Drug Price Competition and Patent Term Restoration Act of 1984 </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Amendments, a portion of a product&#146;s patent term that was lost during clinical development and application review by the FDA may be restored. The Hatch-Waxman Amendments also provide for a statutory protection, known as non-patent market exclusivity, against the FDA&#146;s acceptance or approval of certain competitor applications. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patent term restoration can compensate for time lost during product development and the regulatory review process by returning up to five years of patent life for a patent that covers a new product or its use. This period is generally one-half the time between the effective date of an IND (falling after issuance of the patent) and the submission date of an NDA, plus the time between the submission date of a BLA and the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">62</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">approval of that application. Patent term restorations, however, cannot extend the remaining term of a patent beyond a total of 14 years. The application for patent term extension is subject to approval by the United States Patent and Trademark Office in conjunction with the FDA. It takes at least six months to obtain approval of the application for patent term extension. Up to five years of interim one-year extensions are available if a product is still undergoing development or FDA review at the time of the expiration. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A patent term extension is only available when the FDA approves a biological product for the first time. However, we cannot be certain that the PTO and the FDA will agree with our analysis or will grant a patent term extension. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A biological product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#147;Written Request&#148; for such a study. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009, which was part of the Patient Protection and Affordable Care Act, or PPACA, signed into law on March 23, 2010. This amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal
studies, and a clinical study or studies. Interchangeability requires that a biological product is biosimilar to the reference biological product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the product and the reference product may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product. However, complexities associated with the larger, and often more complex, structure of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A reference biological product is granted twelve years of exclusivity from the time of first licensure of the reference product. On April 10, 2013, President Obama released his proposed budget for fiscal year 2014 and proposed to cut this twelve year period of exclusivity down to seven years. He also proposed to prohibit additional periods of exclusivity for brand biological products due to minor changes in product formulation, a practice often referred to as &#147;evergreening.&#148; The first biological product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference
product has exclusivity against other biologics submitting under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant&#146;s favor of a lawsuit challenging the biologic&#146;s patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">FDA Post-Approval Requirements </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Maintaining substantial compliance with applicable federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to GMP. We will rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the GMP regulations, including quality control and quality assurance and maintenance
of records and documentation. We cannot be certain that we or our present or future suppliers will be able to comply with the GMP and other FDA regulatory requirements. Other post-approval requirements applicable to biological products include reporting of GMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">63</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological
products. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements, by us or our suppliers, may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or
communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register their facilities with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMPs and other laws. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.
</P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Labeling, Marketing and Promotion </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA closely regulates the labeling, marketing and promotion of biological products, including direct-to-consumer advertising, promotional activities involving the internet, and industry-sponsored scientific and educational activities. While doctors are free to prescribe any product approved by the FDA for any use, a company can only make claims relating to safety and efficacy of a biological product that are consistent with FDA approval, and the company is allowed to actively market a biological product only for the particular use and treatment approved by the FDA. In addition, any claims we make for our products in
advertising or promotion must be appropriately balanced with important safety information and otherwise be adequately substantiated. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising, injunctions and potential civil and criminal penalties. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Other Healthcare Laws and Compliance Requirements </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services (formerly the Health Care Financing Administration), other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector General), the United States Department of Justice and individual United States Attorney offices within the Department of Justice and state and local governments. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">International Regulation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our future products. Our manufacturing facility in Ljubljana Slovenia is subject to inspection and regulation by JAZMP, the Slovenian agency that regulates and supervises pharmaceutical products in Slovenia. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval
process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under European Union regulatory systems, marketing authorizations may be submitted either under a centralized or a mutual recognition procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The mutual recognition procedure </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">64</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">provides for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member states. Within 90 days of receiving the applications and assessment report, each member state must decide whether to recognize approval. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pricing and Reimbursement </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although none of our product candidates has been commercialized for any indication, if they are approved for marketing, commercial success of our product candidates will depend, in part, upon the availability of coverage and reimbursement from third-party payors at the federal, state and private levels. Government payor programs, including Medicare and Medicaid, private healthcare insurance companies and managed-care plans have attempted to control costs by limiting coverage and the amount of reimbursement for particular drug treatments. The U.S. Congress and state legislatures from time to time propose and adopt initiatives
aimed at cost-containment. Ongoing federal and state government initiatives directed at lowering the total cost of healthcare will likely continue to focus on healthcare reform, the cost of prescription drugs and biological products and on the reform of the Medicare and Medicaid payment systems. Examples of how limits on drug coverage and reimbursement in the United States may cause reduced payments for drugs in the future include: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">changing Medicare reimbursement methodologies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">fluctuating decisions on which drugs to include in formularies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">revising drug rebate calculations under the Medicaid program; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reforming drug importation laws. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Indeed, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Healthcare Reform Act, which was signed into law in March of 2010, substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts drugs and biological products manufacturers. The Healthcare Reform Act includes, among other things, the following measures: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">annual, non-deductible fees on any entity that manufactures or imports certain prescription drugs; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">increases in Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program for both branded and generic drugs; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">new requirements for manufacturers to discount drug prices to eligible patients by 50 percent at the pharmacy level and for mail order services in order for their outpatient drugs to be covered under Medicare Part D; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an increase in the number of entities eligible for discounts under the Public Health Service pharmaceutical pricing program. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Additionally, some third-party payors also require pre-approval of coverage for new or innovative drug therapies before they will reimburse healthcare providers who use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, the announcement or adoption of these proposals could have a material adverse effect on our ability to obtain adequate prices for our product candidates and operate profitably. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers and other organizations. Third-party payors are increasingly examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy, and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">65</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Adequate third-party reimbursement may not be available for our products to enable us realize an appropriate return on our investment in research and product development. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Employees </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of October 20, 2014, we had 22 full-time employees. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Facilities </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our principal offices occupy approximately 471 square feet of leased office space pursuant to a lease agreement that expires in April 2015 and is located at 4870 Sadler Road, Suite 300, Glen Allen, VA 23060. We also lease approximately 708 square feet of lab space in Richmond (Virginia), approximately 153 square feet of office space in Carlsbad (California), approximately 5,000 square feet of lab space in Brookvale (Australia), approximately 2,672 square feet of lab space in Bedford (United Kingdom) and approximately 4,000 square feet of lab and office space in Slovenia. We believe our facilities are adequate for our current
and near-term needs. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Legal Proceedings </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">From time to time we are involved in legal proceedings or subject to claims arising in the ordinary course of our business. Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">History </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi was incorporated under the laws of the State of Washington in March 1989 as a wholly owned subsidiary of Immunex Corporation and began operations as an independent company in 1992 as Targeted Genetics Corporation (TGEN). This predecessor company was effectively closed and any remaining technology was licensed or otherwise sold. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In January 2011, the board of directors of TGEN completed the acquisition of Biocontrol, with the goal of developing their phage therapy programs using funding from the sale of our legacy gene therapy assets. On February 22, 2011, the corporate name was changed to &#147;AmpliPhi Biosciences Corporation.&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2012, AmpliPhi completed the acquisition of SPH, pursuant to an offer to acquire all outstanding shares of SPH from its shareholders under the terms of a Shareholder Sale Agreement and a Managers Warranty Deed. SPH was formed in 2004 to address the rapidly escalating problem of antibiotic resistance through the development of a series of bacteriophage-based treatments. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As used in this prospectus, unless the context requires otherwise, the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to AmpliPhi Biosciences Corporation, a Washington corporation, or, where appropriate, Targeted Genetics Corporation or AmpliPhi Biosciences Corporation, a Delaware corporation to be formed in connection with the Company&#146;s planned reincorporation. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">66</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tMGMT"></a>MANAGEMENT </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth certain information about our executive officers, key employees and directors as of the date of this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="168"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="32"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="376"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Age</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Position</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Jeremy Curnock Cook<sup>&#040;1&#041;</sup><sup>&#040;2&#041;</sup><sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">65</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Interim Chief Executive Officer, Chairman of the Board</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Wendy Johnson</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">62</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Interim Chief Operating Officer, Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>David E. Bosher</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">61</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Interim Chief Financial Officer</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Baxter F. Phillips III</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">39</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Business Officer</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>David Harper, Ph.D.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">54</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Scientific Officer</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Louis Drapeau<sup>&#040;1&#041;</sup><sup>&#040;2&#041;</sup><sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">70</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Michael S. Perry, Ph.D.<sup>&#040;1&#041;</sup><sup>&#040;2&#041;</sup><sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">55</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Anthony Smithyman, Ph.D.</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">66</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Julian P. Kirk</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">40</TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Member of the audit committee. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Member of the compensation committee. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Member of the nominating and corporate governance committee. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">No events listed in Item 401(f) of Regulation S-K have occurred during the past 10 years that are material to the evaluation of the ability or integrity of any of our directors or executive officers. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following is a brief biography of the business experience during the past five years (and, in some instances, for prior years) of each director and executive officer of the Company, with each director biography including information regarding the experiences, qualifications, attributes or skills that caused our board of directors to determine that such member of our board of directors should serve as a director as of the date of this registration statement. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Executive Officers and Significant Employees </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Jeremy Curnock Cook</I></B> was appointed Interim Chief Executive Officer in September 2014 and has served as a member of our board of directors since July 1995 and as chairman of the board of directors since February 1998. Mr. Curnock Cook has served as Chairman of International Bioscience Managers Limited, a corporate and investment advisory firm since 2000, and also currently serves as Managing Director of Bioscience Managers Pty Ltd, a medical sciences fund manager. From 1987 to 2000, Mr. Curnock Cook was a director of Rothschild Asset Management Limited, a corporate and investment advisory company, and was
responsible for the Rothschild Bioscience Unit. Mr. Curnock Cook founded the International Biochemicals Group in 1975, which was sold in 1985 to Royal Dutch Shell, where he served as managing director until 1987. Mr. Curnock Cook holds an M.A. in natural sciences from Trinity College, Dublin. He also serves as a member of the board of Avita Medical Ltd, Nexus6 Ltd and SeaDragon Ltd. Mr. Curnock Cook brings to the board significant experience as an investor in and board member of multiple biotechnology companies.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Wendy Johnson</I></B> was appointed Interim Chief Operating Officer in September 2014 and joined our Board of Directors in May 2014. Between 2005 and January 2014 Ms. Johnson served as a venture partner at ProQuest Investments, a venture capital firm. From November 2006 until January 2014, Ms. Johnson served as the President and Chief Executive Officer of Aires Pharmaceuticals, a ProQuest portfolio company. Prior to joining ProQuest, she served as Senior Vice President, Corporate Development, at Salmedix Inc., and she held senior business and corporate development positions at WomenFirst Healthcare, Prizm Pharmaceuticals
(Selective Genetics Inc.), Cytel Corp., Synbiotics Corp., and Murex Corp. (Cambridge U.K.). Additionally, Ms. Johnson served as Assistant Director with the Center for Devices and Radiological Health at the U.S. Food and Drug Administration. Ms. Johnson holds an M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School and a B.S. in microbiology from the University of Maryland. Ms. Johnson brings to our board significant experience in pharmaceutical drug development and business development, as well as a strong background in microbiology.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">67</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>David E. Bosher</I></B> has served as our Interim Chief Financial Officer since July 2014. Since October 1, 2013, Mr. Bosher is serving as Managing Director for Fahrenheit Advisors, a consulting and financial services company based in Richmond, Virginia. Prior to joining Fahrenheit, Mr. Bosher served from 2006 to 2013 as Senior Vice President and Chief Financial Officer of Snagajob.com, Inc., a leading human capital services and hourly employment network for job seekers and employers, headquartered in Richmond, Virginia. Prior to Snagajob, he served from 2001 to 2006 as Senior Vice President and Chief Financial Officer
of Payerpath, Inc., a U.S.-based healthcare revenue-cycle-management software company based in Richmond, Virginia. From 1988 to 2001, Mr. Bosher served in various senior finance roles with Cadmus Communications Corporation (NMS:CDMS) and was Cadmus' Senior Vice President and Chief Financial Officer from 1999 to 2001. His work experience also includes having served as Director of Corporate Accounting at a major publicly traded pharmaceutical firm and as senior audit professional with a large regional public accounting firm. Mr. Bosher received a B.S. in Business, with a major in Accounting, and a Masters in Business Administration, from the University of Richmond.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Baxter F. Phillips III</I></B> has served as our Chief Business Officer as of October 2014 and as our Vice President, Corporate Strategy and Business Development since October 2013. Prior to joining AmpliPhi, Mr. Phillips served as Director, Business Development at Depomed, Inc., a commercially engaged specialty pharmaceutical company developing and commercializing products to treat pain and other central nervous system conditions, from 2011 to 2013. Prior to Depomed, Mr. Phillips served as Senior Director, Corporate Development at Osteologix, Inc., a global biopharmaceutical company, from 2007 to 2011. Prior to
Osteologix, Mr. Phillips served in a number of senior research, corporate, sales and marketing positions at Insmed Inc., a publically traded biotechnology company, from 1998 to 2007. Mr. Phillips has a B.S. in Biology from Hampden-Sydney College and an MBA from The Mason School of Business at the College of William and Mary. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>David Harper, Ph.D.</I></B> has served as our Chief Scientific Officer since the January 2011 acquisition of Biocontrol Ltd. by Targeted Genetics Corporation. Prior to joining AmpliPhi, Dr. Harper served as Chief Scientific Officer of Biocontrol, which he founded in 1997, from 2002 to 2011. He previously served as leader of the herpes virus research group in the Department of Virology at St. Bartholomew&#146;s Medical School, joining the faculty in 1991 as a Lecturer in Molecular Virology. Dr. Harper received his B.Sc. in microbiology and virology at the University of Warwick and his Ph.D. at the University of
Newcastle-upon-Tyne, studying viral genetics. He carried out post-doctoral work at St. Bartholomew&#146;s Medical School in London and at the University of Iowa. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Non-Employee Directors </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Louis Drapeau </I></B>has served as a member of our board of directors since March 2011. Mr. Drapeau currently serves as Vice President and Chief Financial officer of InSite Vision, an ophthalmology drug development company, a position he has held since October 2007. From November 2008 until December 2010, he was also CEO of InSite Vision. Prior to InSite Vision, he served as Chief Financial Officer, Senior Vice President, Finance, at Nektar Therapeutics, a biopharmaceutical company, from January 2006 to August 2007. Prior to Nektar, he served as Acting Chief Executive Officer from August 2004 to May 2005 and as Senior
Vice President and Chief Financial Officer from August 2002 to August 2005 for BioMarin Pharmaceutical Inc. Previously, Mr. Drapeau spent 30 years at Arthur Andersen, including 19 years as an Audit Partner in Arthur Andersen&#146;s Northern California Audit and Business Consulting practice, which included 12 years as Managing Partner. Mr. Drapeau received both his undergraduate degree in mechanical engineering and an M.B.A. from Stanford University. He also serves as a member of the board of Bio-Rad Laboratories and InterMune, Inc. Mr. Drapeau is able to provide valuable input with respect to accounting and financial matters as a result of his experience.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Michael S. Perry, D.V.M., Ph.D. </I></B>has served as a member of our board of directors since November 2005. Dr. Perry is currently Global Head of Stem Cell Therapy and Vice President of the Integrated Hospital Care Franchise for Novartis Pharmaceuticals Corporation. Prior to joining Novartis in 2012, he was a Venture Partner with Bay City Capital, a venture capital firm, from 2005 to 2012. While serving in this capacity, he concurrently served as President and Chief Medical Officer at Poniard Pharmaceuticals, Inc., a publicly held drug development company, from 2009 to 2011 and also previously served as Chief
Development Officer of VIA Pharmaceuticals, Inc., another publicly held biotechnology </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">68</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">company, from 2005 to 2009. Dr. Perry served as chairman and Chief Executive Officer of Extropy Pharmaceuticals, Inc., a privately held pediatric specialty pharmaceutical company, from 2003 to 2005. From 2002 to 2003, Dr. Perry served as President and Chief Executive Officer of Pharsight Corporation, a publicly held software and consulting services firm. From 2000 to 2002, Dr. Perry served as Global Head of Research and Development for Baxter Healthcare. From 1997 to 2000, Dr. Perry was President and Chief Executive Officer of both SyStemix Inc. and Genetic Therapy Inc., two wholly owned subsidiaries of Novartis Pharma; he was
Vice President of Regulatory Affairs for Novartis from 1994 to 1997. Prior to 1994, Dr. Perry held various management positions with Syntex Corporation, Schering-Plough Corporation and BioResearch Laboratories, Inc. Dr. Perry holds a Doctor of Veterinary Medicine, a Ph.D. in Biomedical Science-CardioPulmonary Pharmacology and a B.S. in Physics from the University of Guelph. He also serves as a member of the board of Arrowhead Research Corporation and of Avita Medical Ltd. Dr. Perry brings to the board substantial scientific and medical knowledge, as well as operational and investing experience. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Anthony Smithyman, Ph.D. </I></B>joined our board of directors in November 2012 following the merger with Special Phage Services Pty Ltd of Sydney, Australia. Born in Malawi, Central Africa, Dr. Smithyman was educated in Scotland and obtained a B.Sc. from the University of St. Andrews, followed by a Ph.D. in Bacteriology and Immunology from Glasgow University. After completing a two-year post-doctoral Fellowship at the Sloan-Kettering Cancer Center in New York in 1978, he joined ICI Pharmaceuticals Ltd in Alderley Edge, Cheshire, England as Laboratory Head in the Immunology Department before moving to Australia in 1982.
Dr. Smithyman has been involved with the Australian biotechnology industry for over 30 years, including as the current Managing Director of Cellabs Pty Ltd., a longstanding Australian biotechnology company. In 2004, Dr. Smithyman established Special Phage Services Pty Ltd to develop novel phage therapeutics for the human health, veterinary and aquaculture industries. Dr. Smithyman&#146;s experience in the biotechnology industry, and with phage therapeutics specifically, bring a valuable perspective to our board. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Julian P. Kirk</I></B> has served as a member of our board of directors since June 2013. Mr. Kirk is a Managing Director of Third Security, LLC, where he has worked since the firm&#146;s inception with several portfolio companies of its managed investment funds. He is also involved with oversight of Third Security, LLC&#146;s internal operations. Since October 2012, he has served on the board of directors of Fibrocell Science, Inc. Since August 2010, he has served on the board of the New River Valley Economic Development Alliance. From October 2006 until December 2011, he served as member of the board of directors of
IntelliMat, Inc. and as co-chairman of the board between September 2008 and December 2011. From September 2005 until December 2011, Mr. Kirk served as President of Harvest Pharmaceuticals Inc. Mr. Kirk also served as chairman of the board of managers of ECDS, LLC from June 2008 until March 2010. Mr. Kirk graduated as an Echols Scholar from the University of Virginia. Mr. Kirk brings to our board significant financial and operations expertise within our industry.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Board Composition and Election of Directors </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our board of directors currently consists of six members. Our directors serve under a classified board structure, with each director serving for a three-year term of office. Directors are divided into three classes with one class standing for election every year at our annual meeting of stockholders. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors are divided among the three classes as follows: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The Class I directors are Jeremy Curnock Cook and Louis Drapeau and their terms will expire at our annual meeting of stockholders to be held in 2016; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The Class II directors are Julian P. Kirk, Wendy Johnson and Michael S. Perry and their terms will expire at our annual meeting of stockholders to be held in 2017; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The Class III director is Anthony Smithyman and his term will expire at our annual meeting of stockholders to be held in 2015. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">69</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The classification of the board of directors may have the effect of delaying or preventing changes in control of our company. We expect that additional directorships resulting from an increase in the number of directors, if any, will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Director Independence </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the listing requirements and rules of the NYSE MKT for smaller reporting companies, independent directors must compose at least 50% of a listed company&#146;s board of directors within a one-year period following such company&#146;s initial listing with the NYSE MKT. In addition, applicable NYSE MKT rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating committees must be independent within the meaning of applicable NYSE rules. Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In September 2014, our board of directors undertook a review of the independence of each director and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. In making this determination, our board of directors considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee
director. As a result of this review, our board of directors determined that Messrs. Louis Drapeau and Michael Perry qualify as &#147;independent&#148; directors within the meaning of the NYSE MKT rules. Our board of directors also concluded that Mr. Curnock Cook and Ms. Johnson were not at such time &#147;independent&#148; directors within the meaning of the NYSE MKT rules given their roles as Interim Chief Executive Officer and Interim Chief Operating Officer, respectively. We anticipate that Mr. Curnock Cook and Ms. Johnson will qualify as &#147;independent&#148; directors within the meaning of the NYSE MKT rules once each ceases to operate in the interim executive roles in which each now serves. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As required under applicable NYSE MKT rules, we anticipate that our independent directors will meet in regularly scheduled executive sessions at which only independent directors are present. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Board Committees </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our board of directors has established three committees of the board of directors: (1) an audit committee; (2) a compensation committee; and (3) a nominating and corporate governance committee. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Audit Committee.</I></B>&nbsp;&nbsp;The audit committee, established in September 2008, is comprised of three members, each of whom is a non-employee member of the board of directors. The committee&#146;s members meet the financial literacy requirements under the Exchange Act, and related SEC rules, and NYSE MKT listing requirements. In addition, at least one member of the committee is qualified as an &#147;audit committee financial expert&#148; as defined in SEC rules. The audit committee consists of Jeremy Curnock Cook, Louis Drapeau and Michael S. Perry. Louis Drapeau serves as the chair of the audit committee. The
audit committee operates under a charter approved by our board. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The functions of the audit committee include, among other things: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">choosing the independent certified public accountants to serve as the independent auditors of the Company; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">evaluating the performance, independence and qualifications of our independent auditors; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing and discussing with management and the independent auditors the results of the independent auditors&#146; annual audit examination; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing and discussing with management and the independent auditors the annual audited financial statements of the Company; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing with our independent auditors and management significant issues that arise regarding accounting principles and financial statement presentation, and matters concerning the scope, adequacy and effectiveness of our financial controls; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters and other matters; </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">70</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing and providing oversight with respect to any related-party transactions and monitoring compliance with the Company&#146;s code of business conduct ethics; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">adopting the guidelines governing hiring of employees or former employees of the independent auditors in accordance with SEC rules; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing and discussing with management and the independent auditors the Company&#146;s off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company&#146;s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">resolving any disagreements between management and the independent auditors regarding the Company&#146;s financial reporting; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">recommending to the board of directors whether, based on the review and discussions described above, the Company&#146;s annual audited financial statements should be included in the Company&#146;s Annual Report on Form 10-K; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">preparing an audit committee report for inclusion in the Company&#146;s proxy statement for its annual meeting of stockholders. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Compensation Committee.</I></B>&nbsp;&nbsp;The compensation committee, established in January 2004, is comprised of three members, each of whom is a non-employee member of the board of directors. The compensation committee consists of Jeremy Curnock Cook, Louis Drapeau and Michael S. Perry. Michael S. Perry serves as the chair of the compensation committee. The compensation committee operates under a charter approved by our board. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The functions of the compensation committee include, among other things: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">taking any and all actions that may be taken by the board of directors with respect to executive compensation, including developing executive compensation programs and policies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing and approving corporate and individual goals and objectives relevant to the compensation of the Company&#146;s executives; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">evaluating the performance of the Company&#146;s CEO and other executive officers in light of such goals and objectives and, based on this evaluation, determining the compensation of the CEO and executive officers (including salary, bonus, stock option grants, expense accounts, perquisites and other direct or indirect benefits); </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing and making recommendations regarding the compensation of non-officer employees, directors and consultants of the Company; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">supervising the administration of the Company&#146;s stock option plans, employee stock purchase plan and other stock- or cash-based compensation and incentive programs; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">approving and making grants and awards of stock options and other equity securities to the Company&#146;s executive officers and non-employee directors under the Company&#146;s stock option plans and other incentive programs; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">making recommendations to the board of directors with respect to incentive compensation plans and equity-based plans; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing and approving, for the Company&#146;s executive officers, employment, severance, retirement and change of control agreements, arrangements or provisions and any special or supplemental benefits; </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">71</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing and discussing with management the Company&#146;s proposed disclosure under the &#147;Compensation Discussion and Analysis&#148; required by Regulation S-K under the Exchange Act and recommend to the Board whether such Compensation Discussion and Analysis should be included in the Company&#146;s proxy statement and Annual Report on Form 10-K; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">preparing a compensation committee report in accordance with the rules and regulations of the SEC for inclusion in the Company&#146;s proxy statement. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Nominating and Corporate Governance Committee.</I></B>&nbsp;&nbsp;The nominating and corporate governance committee, established in March, 2004, is comprised of three members, each of whom is a non-employee member of the board of directors. The nominating and corporate governance committee consists of Jeremy Curnock Cook, Louis Drapeau and Michael S. Perry. Jeremy Curnock Cook serves as the chair of the nominating and corporate governance committee. The nominating and corporate governance committee operates under a charter approved by our board. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The functions of the nominating and corporate governance committee include, among other things: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">developing and recommending to the board of directors criteria for board membership to assist the board in identifying and attracting candidates to become directors; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">monitoring the independence under NYSE MKT listing requirements of directors; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">annually presenting to the board of directors a list of individuals recommended for nomination for election as directors at the annual meeting of stockholders; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">conducting the appropriate and necessary inquiries into the backgrounds, qualifications and skills of potential candidates and selecting and approving potential candidates for nomination as directors; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">before recommending an incumbent director for re-nomination, reviewing his or her qualifications, including capability, availability to serve, conflicts of interest, past performance and other relevant factors; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing any potential conflicts between the directors and director candidates and the interests of the Company; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing and evaluating stockholder submissions for director nominees; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">monitoring regulatory developments concerning stockholder access to director nominations, and recommending amendments or modifications to the Company&#146;s policies and procedures concerning stockholder access to director nominations; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing the qualifications, requirements, membership, structure (including authority to delegate) and performance of board committees, including the nominating and corporate governance committee, and making recommendations to the board of directors regarding committee memberships; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing and assessing the Company&#146;s corporate governance principles, including information reporting procedures to the board of directors, director engagement and the code of conduct applicable to the Company&#146;s directors, officers and employees; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">overseeing evaluation of the performance of each director; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing with the board of directors the Company&#146;s succession plans relating to positions held by executive officers, and making recommendations with respect to the selection of individuals to occupy these positions; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reviewing the outside activities of senior executives. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Compensation Committee Interlocks and Insider Participation </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">None of our officers currently serves, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more officers serving as a member of our board of directors. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">72</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Code of Business Conduct and Ethics </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We adopted a code of business conduct and ethics that applies to all of our employees, officers and directors including those officers responsible for financial reporting. Following our initial public offering, the code of business conduct and ethics will be available on our website at <I>http://www.ampliphibio.com.</I> We intend to disclose future amendments to the code or any waivers of its requirements on our website to the extent permitted by the applicable rules and exchange requirements. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Board Leadership Structure </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our board of directors has a chairman, Jeremy Curnock Cook, who has authority, among other things, to call and preside over board meetings, to set meeting agendas and to determine materials to be distributed to the board of directors. Accordingly, the chairman has substantial ability to shape the work of the board of directors. We believe that having a separate board chairman creates an environment that is more conducive to objective evaluation and oversight of management&#146;s performance, increasing management accountability and improving the ability of the board of directors to monitor whether management&#146;s actions are
in the best interests of us and our stockholders. As a result, we believe that having a separate board chairman can enhance the effectiveness of the board of directors as a whole. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Role of the Board in Risk Oversight </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our audit committee is primarily responsible for overseeing our financial risk management processes on behalf of the full board of directors. Going forward, we expect that the audit committee will receive reports from management at least quarterly regarding our assessment of risks. In addition, the audit committee reports regularly to the full board of directors, which also considers our risk profile. The audit committee and the full board of directors focus on the most significant risks we face and our general risk management strategies. While the board oversees our risk management, management is responsible for day-to-day
risk management processes. Our board of directors expects management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and processes for day-to-day activities and to effectively implement risk management strategies adopted by the audit committee and the board of directors. We believe this division of responsibilities is the most effective approach for addressing the risks we face and that our board leadership structure, which also emphasizes the independence of the board in its oversight of its business and affairs, supports this approach. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Family Relationships </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">No family relationships exist between any of the directors or executive officers of our company. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">73</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tEDC"></a>EXECUTIVE AND DIRECTOR COMPENSATION </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Summary Compensation Table </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table provides information regarding the compensation paid during the last two fiscal years to our principal executive officer, and our two most highly compensated executive officers other than our principal executive officer who were serving as executive officers at the end of the last completed fiscal year, who are collectively referred to as &#147;named executive officers&#148; elsewhere in this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="184"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="42"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name and Principal Position</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Year</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Salary</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Bonus</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Option Awards<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>All Other Compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt; vertical-align: text-top" ROWSPAN=2 COLSPAN=1>Philip J. Young <BR> &nbsp;&nbsp;President, Chief Executive<BR> &nbsp;&nbsp;Officer and Director<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,856,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>105,396</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,361,396</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2012</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>325,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,680,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,005,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt; vertical-align: text-top" ROWSPAN=2 COLSPAN=1>David Harper, Ph.D. <BR> &nbsp;&nbsp;Chief Scientific Officer</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>225,541</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>225,541</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2012</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>228,672</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>240,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>468,672</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt; vertical-align: text-top" ROWSPAN=2 COLSPAN=1>Kelley A. Wendt, <BR> &nbsp;&nbsp;Chief Financial Officer<sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>155,938</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>18,575</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>174,513</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2012</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>100,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>120,247</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>220,247</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Represents the aggregate grant date fair value computed in accordance with FASB ASC Topic 718. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Mr. Young&#146;s employment as President and Chief Executive Officer ended on September 15, 2014. His service as a director terminated on December 19, 2014.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Ms. Wendt became Chief Financial Officer on January 1, 2013. Prior to this date, Ms. Wendt was engaged as an accounting consultant and all compensation paid during the year ended December 31, 2012 was for her services in that capacity. On May 15, 2014, Ms. Wendt informed the Company of her intent to resign from the position of Chief Financial Officer, effective May 23, 2014. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Grants of Plan-Based Awards </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth certain information regarding grants of plan-based awards to our named executive officers for 2013. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="216"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Grant Date</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>All other option awards: number of securities underlying options (#)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Exercise or base price of option awards<BR> ($/share)<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Grant date fair value of option awards ($)<sup>&#040;2&#041;</sup></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Philip J. Young</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6/25/2013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11,600,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.16</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,856,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>David Harper, Ph.D.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Kelley A. Wendt</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Represents the per share fair market value of our common stock, as determined in good faith by our board of directors on the grant date. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Amounts listed represent the aggregate fair value amount computed as of the grant date of each option and award during 2013 in accordance with FASB ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note 6, Stock Options and Warrants, of the Notes to the Financial Statements. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. Our named executive officers will only realize compensation to the extent the trading price of our common stock is greater than the exercise price of such stock options. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">74</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Outstanding Equity Awards at Fiscal Year-End </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth certain information regarding all outstanding equity awards held by our named executive officers as of December 31, 2013. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="216"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of Securities Underlying Unexercised Options<BR> (# Exercisable)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of Securities Underlying Unexercised Options<BR> (# Unexercisable)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Option<BR> Exercise<BR> Price<BR> ($)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Option<BR> Expiration<BR> Date</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Philip J. Young</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,100,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;1&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,300,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10/23/2022</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,152,334</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;2&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,447,666</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.16</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6/25/2023</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>David Harper, Ph.D.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>300,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;3&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>800,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10/23/2022</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Kelley A. Wendt</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>125,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;4&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>375,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10/23/2022</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">6.25% of the total shares underlying this option vested and became exercisable on January 23, 2013. 6.25% of the total shares underlying this option vests and becomes exercisable on the first business day of each three (3) month period thereafter, subject to continued service through each vesting date. This option may be subject to accelerated vesting as described above. As of December 31, 2013, 2,100,000 of the total shares underlying this option are vested and exercisable. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">3,862,800 of the total shares underlying this option vested and became exercisable on the grant date, which was June 26, 2013. 1/36 of the remaining unvested shares underlying this option vests and becomes exercisable on each one month anniversary of the grant date thereafter, subject to continued service through each vesting date. This option may be subject to accelerated vesting as described above. As of December 31, 2013, 5,152,334 of the total shares underlying this option are vested and exercisable. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">6.25% of the total shares underlying this option vested and became exercisable on January 23, 2013. 6.25% of the total shares underlying this option vests and becomes exercisable on the first business day of each three (3) month period thereafter, subject to continued service through each vesting date. This option may be subject to accelerated vesting as described below. As of December 31, 2013, 300,000 of the total shares underlying this option are vested and exercisable. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">6.25% of the total shares underlying this option vested and became exercisable on January 23, 2013. 6.25% of the total shares underlying this option vests and becomes exercisable on the first business day of each three (3) month period thereafter, subject to continued service through each vesting date. This option may be subject to accelerated vesting as described below. As of December 31, 2013, 125,000 of the total shares underlying this option are vested and exercisable. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Option Exercises and Stock Vested </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our named executive officers did not exercise any stock option awards during the year ended December 31, 2013. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pension Benefits </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">None of our named executive officers participate in or have account balances in qualified or non-qualified defined benefit plans sponsored by us. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Non-Qualified Deferred Compensation </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">None of our named executive officers participate in or have account balances in qualified or non-qualified defined contribution plans or other non-qualified compensation plans sponsored by us. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Equity Incentive Plans </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The purpose of all of our equity incentive plans is to promote the long-term success of the Company and the creation of shareholder value by offering key service providers an opportunity to share in such long-term success by acquiring a proprietary interest in the Company and to attract and retain the best available personnel for positions of substantial responsibility, and to provide additional incentive to employees, consultants and directors. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">75</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our equity incentive plans seek to achieve these purposes by providing for discretionary long-term incentive awards in the form of options (which may constitute incentive stock options or nonstatutory stock options), stock appreciation rights, stock grants and stock units. Our equity incentive plans are administered by the board or a committee appointed by the board, which we refer to as the plan administrator and have a term of 10 years from the date they were adopted by the board of directors. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2009 Targeted Genetics Stock Incentive Plan and 2012 Stock Incentive Plan </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our board of directors and shareholders adopted our 2009 Plan in March 2009. Our board of directors adopted our 2012 Plan in October 2012. As of October 20, 2014, there are 1,306,760 shares of common stock and 9,068,948 shares of common stock remaining for future awards under the 2009 Plan and the 2012 Plan, respectively. We refer to the 2009 Plan and the 2012 Plan together as the Existing Plans. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The number of shares authorized under each of the Existing Plans is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. The shares we issue under the Existing Plans may be authorized but unissued shares or shares we reacquire. The shares of common stock underlying any equity awards that are forfeited, canceled, repurchased, expired or are otherwise terminated (other than by exercise) under the Existing Plans are currently added back to the shares of common stock available for issuance under the Existing Plans. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Existing Plans permit us to make grants of incentive stock options to employees and grants of non-qualified stock options and restricted stock to employees, officers, directors and consultants. The Existing Plans are administered by our board of directors. Our board of directors has the authority to select the individuals to whom awards will be granted, to make any combination of awards to participants, to accelerate the exercisability or vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the Existing Plans. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Existing Plans permit the grant of (1) options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended, or the Code, and (2) options that do not so qualify. The option exercise price of each option will be determined by our board of directors but may not be less than 100% of the fair market value of the common stock on the date of grant. The term of each option will be fixed by our board of directors and may not exceed 10 years from the date of grant. All stock option awards that are granted pursuant to the Existing Plans are covered by an
option agreement. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Existing Plans also permit the award of stock grants, stock appreciation rights and stock units to participants, subject to such terms, conditions and restrictions as our board of directors may determine. All stock grants, stock appreciation rights and stock units that are granted pursuant to the Existing Plans are covered by a written agreement. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Existing Plans provide that upon the effectiveness of a &#147;corporate transaction,&#148; as defined in each of the Existing Plans, in the event that all awards are not assumed or continued or substituted by the successor entity, all awards granted under the Existing Plans shall terminate. In addition, in connection with a corporate transaction, the plan administrator may provide the full automatic vesting and exercisability of one or more outstanding unvested awards under the Existing Plans in connection with a corporate transaction, on such terms and conditions as the plan administrator may specify. Furthermore, in
connection with a &#147;change in control,&#148; as defined in each of the Existing Plans, the Existing Plans provide for the full automatic vesting and exercisability of any outstanding unvested awards held by certain &#147;key service providers,&#148; which under the terms of the Existing Plans, is defined as any employee, director or consultant who has been designated as a key service provider by the plan administrator, in the event that any such awards are not assumed or continued or substituted by the successor entity, or otherwise fully automatically vested by the plan administrator in connection with such change in control. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our board of directors may amend, alter, suspend or terminate the Existing Plans at any time, subject to stockholder approval where such approval is required by applicable law. Our board of directors may also amend, modify or terminate any outstanding award, provided that no amendment to an award may materially </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">76</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">impair any of the rights of a participant under any awards previously granted without his or her written consent. No awards may be granted under the 2009 Plan and 2012 Plan after March 3, 2019 and October 19, 2022, respectively. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2013 Stock Incentive Plan </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our 2013 Plan was approved by our board of directors in December 2013 and was approved by our shareholders in February 2014. The 2013 Plan replaces the 2009 Plan and the 2012 Plan. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 2013 Plan allows the plan administrator, to make equity-based incentive awards to our officers, employees, directors and other key persons (including consultants). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of October 20, 2014, there were outstanding options to purchase 750,000 shares of common stock and 39,250,000 shares of common stock reserved for the issuance of awards under the 2013 Plan. This number is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The shares issuable pursuant to awards granted under the 2013 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock underlying any awards from the 2013 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of common stock, expire or are otherwise terminated (other than by exercise) under the 2013 Plan will be added back to the shares of common stock available for issuance under the 2013 Plan. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 2013 Plan will be administered by the plan administrator. The plan administrator has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the 2013 Plan. Persons eligible to participate in the 2013 Plan will be those full or part-time officers, employees, non-employee directors and other key persons (including consultants) as selected from time to time by our plan administrator in its discretion. The plan
administrator may re-price options or stock appreciation rights without stockholder approval. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 2013 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code and options that do not so qualify. The exercise price of each stock option will be determined by our plan administrator but may not be less than 100% of the fair market value of our common stock on the date of grant or, in the case of an incentive stock option granted to a 10% owner, less than 110% of the fair market value of our common stock on the date of grant. The term of each stock option will be fixed by the plan administrator and may not exceed 10 years from the date
of grant. The plan administrator will determine at what time or times each option may be exercised. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The plan administrator may also award stock appreciation rights subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price may not be less than 100% of the fair market value of the common stock on the date of grant. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The plan administrator may also award restricted stock or restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals or continued employment with us through a specified vesting period. The plan administrator may also grant shares of common stock that are free from any restrictions under the 2013 Plan. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The plan administrator may grant cash bonuses under the 2013 Plan to participants, subject to the achievement of certain performance goals. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The plan administrator may grant performance-based awards to participants in the form of restricted stock, restricted stock units or cash-based awards upon the achievement of certain performance goals and such other conditions as the plan administrator shall determine. The plan administrator may grant such performance-based awards under the 2013 Plan that are intended to qualify as &#147;performance-based compensation&#148; under Section 162(m) of the Code. Those awards would only vest or become payable upon the attainment of performance goals that are established by our plan administrator and related to one or more
performance criteria. The performance criteria that could be used with respect to any such awards include: net </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">77</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">earnings or net income (before or after taxes); earnings per share; revenues or sales (including net sales or revenue growth); net operating profit; return measures (including return on assets, net assets, capital, invested capital, equity, sales, or revenue); cash flow (including operating cash flow, free cash flow, cash flow return on equity, and cash flow return on investment); earnings before or after taxes, interest, depreciation, and/or amortization; gross or operating margins; productivity ratios; share price (including growth measures and total stockholder return); expense targets; margins; operating efficiency; market
share; working capital targets and change in working capital; economic value added or net operating income, any of which may be measured either in absolute terms or as compared to any incremental increase or as compared to results of a peer group. From and after the time that we become subject to Section 162(m) of the Code, the maximum award that is intended to qualify as &#147;performance-based compensation&#148; under Section 162(m) of the Code that may be made to any one employee during any one calendar year period with respect to options and stock appreciation rights is 18,000,000 shares for existing employees and 5,000,000 shares in the case of new hires. The 12-month limit with respect to restricted stock and restricted stock units is 10,000,000 shares in the case of either existing or new employees. From and after the time that we become subject to Section 162(m) of the Code, the maximum cash-based award that is intended to qualify as &#147;performance-based compensation&#148;
is limited to $10,000,000 in any 12-month period, which is pro-rated in the case of a partial performance period. The share limits are subject to adjustments in the event of a stock split, stock dividend or other change in our capitalization. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 2013 Plan provides that upon the effectiveness of a &#147;corporate transaction,&#148; as defined in the 2013 Plan, in the event that all awards are not assumed or continued or substituted by the successor entity, all awards granted under the 2013 Plan shall terminate. In addition, in connection with a corporate transaction, the plan administrator may provide the full or partial automatic vesting and exercisability of one or more outstanding unvested awards under the 2013 Plan and the release from restrictions on transfer or forfeiture rights of such awards in connection with a corporate transaction, on such terms and
conditions as the plan administrator may specify. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our board of directors may amend or discontinue the 2013 Plan and our plan administrator may amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder&#146;s consent. Certain amendments to the 2013 Plan require the approval of our stockholders. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">No awards may be granted under the 2013 Plan after the date that is 10 years from the earlier of the date of adoption by our board of directors or the date of stockholder approval of the 2013 Plan. No awards under the 2013 Plan have been made prior to the date of this prospectus. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Non-Executive Director Compensation </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table and related footnotes show the compensation paid during the year ended December 31, 2013 to our non-executive directors. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="258"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Fees Earned or Paid in Cash</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Option Awards</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>All Other Compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Jeremy Curnock Cook<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>70,875</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>70,875</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Louis Drapeau<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>41,250</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>41,250</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Anthony Peter Gellert<sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11,666</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11,666</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Michael S. Perry, Ph.D.<sup>&#040;4&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>39,750</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>39,750</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Anthony Smithyman, Ph.D.<sup>&#040;5&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13,333</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13,333</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Caroline A. Williams<sup>&#040;6&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,750</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,750</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Julian P. Kirk<sup>&#040;7&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">As of December 31, 2013, Mr. Cook holds stock options for an aggregate of 440,000 shares, of which 110,000 shares are vested and exercisable. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">As of December 31, 2013, Mr. Drapeau holds stock options for an aggregate of 120,000 shares, of which 30,000 shares are vested and exercisable. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">78</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">On June 26, 2013, Mr. Gellert resigned from our board of directors. As of June 26, 2013, Mr. Gellert held stock options for an aggregate of 50,000, of which 6,250 shares were vested and exercisable. Pursuant to the terms of his resignation, vesting will continue until December 31, 2015 as if that was his resignation date, at which time all unvested shares will have vested and will be exercisable pursuant to the standard post-termination exercise terms of the applicable stock option agreements, which will allow the stock options to be exercised for a period of ninety (90) days following December 31, 2015. As of December 31, 2013, Mr. Gellert holds stock options for an aggregate of 50,000 shares, of which 12,500 shares are vested and exercisable. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">As of December 31, 2013, Mr. Perry holds stock options for an aggregate of 170,000 shares, of which 42,500 shares are vested and exercisable. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(5)</TD>

          <TD STYLE="text-align: left">As of December 31, 2013, Mr. Smithyman holds stock options for an aggregate of 50,000 shares, of which 12,500 shares are vested and exercisable. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(6)</TD>

          <TD STYLE="text-align: left">On June 26, 2013, Ms. Williams resigned from our board of directors. As of June 26, 2013, Ms. Williams held stock options for an aggregate of 150,000, of which 6,250 shares were vested and exercisable. Pursuant to the terms of her resignation, vesting will continue until December 31, 2015 as if that was her resignation date, at which time all unvested shares will have vested and will be exercisable pursuant to the standard post-termination exercise terms of the applicable stock option agreements, which will allow the stock options to be exercised for a period of ninety (90) days following December 31, 2015. As of December 31, 2013, Ms. Williams holds stock options for an aggregate of 150,000 shares, of which 37,500 shares are vested and exercisable. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(7)</TD>

          <TD STYLE="text-align: left">Mr. Kirk has served as a member of our board of directors since June 2013. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Liability and Indemnification of Directors and Officers </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sections 23B.08.510 and 23B.08.570 of the WBCA authorize Washington corporations to indemnify directors and officers under certain circumstances against expenses and liabilities incurred in legal proceedings in which they are involved by reason of being a director or officer, as applicable. Section 23B.08.560 of the WBCA authorizes a corporation by provision in a bylaw approved by its shareholders to indemnify or agree to indemnify a director made a party to a proceeding, or obligate itself to advance or reimburse expenses incurred in a proceeding, without regard to the limitations imposed by Sections 23B.08.510 through
23B.08.550; provided that no such indemnity shall indemnify any director from or on account of (a) acts or omissions of the director finally adjudged to be intentional misconduct or a knowing violation of law, (b) conduct of the director finally adjudged to be in violation of Section 23B.08.310 of the WBCA (which section relates to unlawful distributions) or (c) any transaction with respect to which it was finally adjudged that such director personally received a benefit in money, property or services to which the director was not legally entitled. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Article 11 of the Company&#146;s current articles of incorporation, provides that, to the fullest extent that the WBCA permits the limitation or elimination of the liability of a director, a director shall not be liable to the Registrant or its shareholders for monetary damages for conduct as a director. Section 10 of the Company&#146;s amended and restated bylaws requires the Company to indemnify every present or former director or officer against expenses, liabilities and losses incurred in connection with serving as a director or officer, as applicable, and to advance expenses of such director or officer incurred in
defending any proceeding covered by the indemnity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Upon reincorporation in Delaware, we intend to adopt provisions in our certificate of incorporation that limit the liability of our directors for monetary damages for breach of their fiduciary duty as directors, except for liability that cannot be eliminated under Delaware law. Under Delaware law, our directors have a fiduciary duty to us which will not be eliminated by this provision in our certificate of incorporation. In addition, each of our directors will continue to be subject to liability under Delaware law for breach of the director&#146;s duty of loyalty to us for acts or omissions which are found by a court of
competent jurisdiction to be not in good faith or which involve intentional misconduct or knowing violations of law for actions leading to improper personal benefit to the director and for payment of dividends or approval of stock repurchases or redemptions that are prohibited by Delaware law. This provision does not affect the directors&#146; responsibilities under any other laws, such as the Federal securities laws. Delaware law further provides that directors of a company will not be personally liable for monetary damages for breach of their fiduciary duty as directors, except for liability for the following: (i) any breach of the director&#146;s duty of loyalty to us or our stockholders; (ii) acts or </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">79</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) unlawful payment of dividends or unlawful stock repurchases or redemptions; or (iv) any transaction from which the director derived an improper personal benefit. Additionally, Delaware law provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under our bylaws, any agreement, a vote of stockholders or otherwise. Our certificate of incorporation and bylaws, upon reincorporation, will eliminate the personal liability of
directors to the maximum extent permitted by Delaware law. In addition, such certificate of incorporation and bylaws will provide that we may fully indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was one of our directors, officers, employees or other agents, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company maintains a policy of directors&#146; and officers&#146; liability insurance that insures the directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. The Company has also entered into indemnification agreements with its executive officers and directors that provide for the indemnification of directors and executive officers to the fullest extent permitted by the WBCA against expenses reasonably incurred by such persons in any threatened, pending or completed action, suit, investigation or proceeding in connection with their service as (i) a director or
officer or (ii) as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, at the registrant&#146;s request. In addition, the indemnification agreements provide the Company with the obligation to advance expenses under certain circumstances and provide for procedural protections, including a determination by a reviewing party whether the indemnitee is permitted to be indemnified under applicable law. In addition, the Company acknowledges that it will be the indemnitor of first resort should the indemnitee have rights to indemnification provided by other persons. Upon reincorporation in Delaware, the Company intends to enter into substantially similar indemnification agreements with the same persons to indemnify such persons to the fullest extent permitted under the DGCL. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">80</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tCRRT"></a>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Transactions with Related Persons </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following is a summary of transactions since January 1, 2013 to which we have been a participant in which the amount involved exceeded or will exceed $120,000, and in which any of our then directors, executive officers or holders of more than 5% of any class of our capital stock at the time of such transaction, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation arrangements which are described under the section of this prospectus titled &#147;Executive and Director Compensation.&#148; </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sale of Convertible Notes </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Since January 1, 2013, we have sold convertible notes to Pendinas Limited in varying principal amounts for an aggregate total of $2,000,000. Additionally, we issued warrants to purchase an aggregate of up to approximately 7.0 million shares of common stock at an exercise price of $0.14 per share. All such convertible notes have been converted as a result of the completion of our private placement of convertible preferred stock, as of July 15, 2013. The following table summarizes sales of such convertible notes to Pendinas Limited, which was a holder of more than 5% of our common stock as of the dates of each such transaction:
</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="290"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="112"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="120"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Related Party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Date</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Principal Amount</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Pendinas Limited</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>February 4, 2013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>March 12, 2013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>April 12, 2013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>May 13, 2013</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>500,000.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sale of Series B Convertible Preferred Stock </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2013, we sold an aggregate of 9,357,935 shares of our Series B Convertible Preferred Stock and warrants to purchase an aggregate of 23,394,835 shares of our common stock. Pendinas Limited, a holder of more than 5% of our common stock as of the date of such transaction, converted all of its outstanding convertible notes into 3,225,061 shares of Series B Convertible Preferred Stock and a warrant to purchase 8,062,652 shares of our common stock in the transaction. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with our June 2013 private placement of convertible preferred stock, we paid a placement fee to Griffin Securities, Inc. in the amount of $270,000 in cash and warrants to purchase 4,285,714 shares of common stock at an exercise price of $0.14 per share, and to Phillip Capital Ltd in the amount of $60,000 in cash and warrants to purchase 714,285 shares of common stock at an exercise price of $0.14 per share. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, in connection with the June 2013 private placement, NRM VII Holdings I, LLC purchased 2,142,857 shares of our Series B Convertible Preferred Stock and warrants to purchase an additional 5,357,142 shares of our common stock. NRM VII Holdings I, LLC is controlled by Randal J. Kirk, the father of Julian P. Kirk, a member of our board of directors. Randal J. Kirk is also deemed a holder of more than five percent of the shares of our common stock, as described in the section entitled &#147;Principal Stockholders.&#148; Phillip Asset Management Ltd also purchased 714,285 shares of our Series B Convertible Preferred
Stock and warrants to purchase an additional 1,785,712 shares of our common stock. Phillip Asset Management Ltd holds its shares in its capacity as trustee for Bioscience Managers Pty Ltd. Jeremy Curnock Cook, the chairman of our board of directors, is a Managing Director and holds an ownership interest in Bioscience Managers Pty Ltd.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The shares of common stock post-conversion pursuant to the June private placement of our Series B Convertible Preferred Stock will be entitled to piggyback rights and S-1 and S-3 registration rights. See the section of this prospectus titled &#147;Description of Capital Stock&nbsp;&#151;&nbsp;Registration Rights&#148; for additional information. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sale of Common Stock </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In December 2013, in connection with a private placement of our common stock, we sold an aggregate of 300,000 shares of our common stock to Baxter F. Phillips III, our Chief Business Officer, for $0.25 per share, which was the same price paid by the other investors participating in the private placement.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">81</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, in connection with the December 2013 private placement, NRM VII Holdings I, LLC and Phillip Asset Management Ltd purchased 20,000,000 shares and 6,000,000 shares, respectively, of our common stock at a price per share of $0.25, which was the same price paid by the other investors participating in the offering. NRM VII Holdings I, LLC is controlled by Randal J. Kirk, the father of Julian P. Kirk, a member of our board of directors. Randal J. Kirk is also deemed a holder of more than five percent of the shares of our common stock, as described in the section entitled &#147;Principal Stockholders.&#148; Phillip Asset
Management Ltd holds its shares in its capacity as trustee for Bioscience Managers Pty Ltd. Jeremy Curnock Cook, the chairman of our board of directors, is a Managing Director and holds an ownership interest in Bioscience Managers Pty Ltd.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The shares of common stock purchased in the December 2013 private placement are entitled to certain registration rights, including the registration of shares for resale pursuant to this prospectus. See the section of this prospectus titled &#147;Description of Capital Stock &#151; Registration Rights&#148; for additional information. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">82</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tPST"></a>PRINCIPAL STOCKHOLDERS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of October 20, 2014, for: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">each person known by us to beneficially own more than 5% of our outstanding shares of common stock, </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">each of our directors, </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">each of our named executive officers, and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">all such directors, nominees for director and executive officers as a group. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The percentage of ownership depicted below is based on 273,869,493 shares of common stock outstanding on October 20, 2014, which consists of 187,159,093 shares of common stock outstanding as of October 20, 2014, and 86,710,400 shares of common stock issuable upon conversion of all outstanding shares of Series B Convertible Preferred Stock as of October 20, 2014 (assuming a conversion ratio equal to ten (10) common shares for each share of Series B Convertible Preferred Stock). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or share voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options or warrants or pursuant to the conversion of our Series B Convertible Preferred Stock that are either immediately exercisable or convertible or exercisable or convertible within 60 days of October 20, 2014. Shares underlying such options, warrants and Series B Convertible
Preferred Stock, however, are only considered outstanding for the purpose of computing the percentage ownership of that person and are not considered outstanding when computing the percentage ownership of any other person. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="429"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="69"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name of Beneficial Owner<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares Beneficially Owned</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Percentage Total Voting Power</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>5% Stockholders<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Anthony M. Smithyman</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>26,688,680</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;2&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9.75</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Randal J. Kirk</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>70,785,712</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;3&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25.85</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Philip J. Young</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>17,565,741</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;7&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6.41</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>RA Capital Management, LLC</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>21,428,570</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;4&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7.82</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Pendinas Limited</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>47,343,649</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;5&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>17.29</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Broadfin Healthcare Master Fund, Ltd</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>14,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.11</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Phillip Asset Management Ltd</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>14,928,562</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;6&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5.45</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Named Executive Officers and Directors<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Philip J. Young</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>17,565,741</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;7&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6.41</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Kelley A. Wendt</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>218,750</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;8&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>David Harper, Ph.D.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,429,352</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;9&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Jeremy Curnock Cook</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>381,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;10&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Louis Drapeau</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>60,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;11&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Michael S. Perry, Ph.D.</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>198,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;12&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Anthony M. Smithyman</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>26,688,680</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;2&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9.75</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Julian P. Kirk</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Baxter F. Phillips III</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>503,125</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><sup>&#040;13&#041;</sup><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Wendy Johnson</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>All officers and directors as a group (9 persons)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>47,044,648</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>17.18</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">*</TD>

          <TD STYLE="text-align: left">Less than 1%. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Unless otherwise indicated, the address of such stockholder is c/o AmpliPhi Biosciences Corporation, 4870 Sadler Road, Suite 300, Glen Allen, VA 23060. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">83</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Includes options to purchase 25,000 shares of common stock. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Consists of 46,785,712 shares held by NRM VII Holdings I, LLC, which we refer to as NRM VII Holdings (20,000,000 shares of common stock, 21,428,570 shares of common stock issuable upon conversion of Series B Convertible Preferred Stock (assuming a conversion ratio equal to ten (10) common shares for each share of Series B Convertible Preferred Stock) and 5,357,142 shares of common stock issuable upon exercise of warrants) and 24,000,000 shares held by Intrexon Corporation. Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Exchange Act) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon Corporation. Mr.
Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon Corporation. Shares held by Intrexon Corporation may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Exchange Act) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(4)</TD>

          <TD STYLE="text-align: left">Consists of an aggregate of 21,428,570 of common stock issuable upon conversion of Series B Convertible Preferred Stock (assuming a conversion ratio equal to ten (10) common shares for each share of Series B Convertible Preferred Stock) and an aggregate of 5,357,142 shares of common stock issuable upon the exercise of warrants, held by two of its funds, RA Capital Healthcare Fund, LP and Blackwell Partners, LLC. The address of such stockholder is 20 Park Plaza, Suite 1200, Boston, MA 02116. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(5)</TD>

          <TD STYLE="text-align: left">Consists of 32,250,610 shares of common stock issuable upon conversion of Series B Convertible Preferred Stock and 15,093,039 shares of common stock issuable upon exercise of warrants. The address of such stockholder is Ballacarrick, Pooilvaaish Road, Isle of Man, IM9 4PJ. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(6)</TD>

          <TD STYLE="text-align: left">Phillip Asset Management Ltd holds all shares in its capacity as trustee for Bioscience Managers Pty Ltd. Jeremy Curnock Cook, the Chairman of the Company&#146;s Board of Directors, is a Managing Director and holds an ownership interest in Bioscience Managers Pty Ltd.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(7)</TD>

          <TD STYLE="text-align: left">Consists of options to purchase 17,565,741 shares of common stock.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(8)</TD>

          <TD STYLE="text-align: left">Consists of options to purchase 218,750 shares of common stock.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(9)</TD>

          <TD STYLE="text-align: left">Includes options to purchase 600,000 shares of common stock.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(10)</TD>

          <TD STYLE="text-align: left">Includes options to purchase 316,000 shares of common stock.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(11)</TD>

          <TD STYLE="text-align: left">Consists of options to purchase 60,000 shares of common stock.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(12)</TD>

          <TD STYLE="text-align: left">Includes options to purchase 153,000 shares of common stock. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(13)</TD>

          <TD STYLE="text-align: left">Consists of options to purchase 203,125 shares of common stock and 300,000 shares of common stock purchased by Mr. Phillips in the December 2013 private placement. </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">84</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tDCS"></a>DESCRIPTION OF CAPITAL STOCK </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following description of our capital stock, certain provisions of our articles of incorporation and bylaws as currently in effect and our intended certificate of incorporation and bylaws upon our reincorporation in Delaware, and certain provisions of Washington and Delaware law are summaries. You should also refer to the current articles of incorporation and the bylaws, which are filed as exhibits to this registration statement. We refer in this section to our certificate of incorporation and bylaws that we intend to adopt upon Delaware reincorporation as our certificate of incorporation and bylaws, respectively. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to our reincorporation in Delaware, our articles of incorporation authorize us to issue up to 445,000,000 shares of common stock, $0.01 par value per share, and 10,000,000 shares of preferred stock, $0.01 par value per share, of which 180,000 shares of preferred stock are designated &#147;Series A Participating Cumulative Preferred Stock,&#148; 9,357,935 shares of preferred stock are designated &#147;Series B Convertible Preferred Stock&#148; and 462,065 shares of preferred stock are undesignated. After our reincorporation in Delaware, and without giving effect to the reverse stock split we intend to effect in connection
with such reincorporation, which has been approved by our stockholders our certificate of incorporation will authorize us to issue up to 445,000,000 shares of common stock, $0.01 par value per share, and 10,000,000 shares of preferred stock, $0.01 par value per share, of which 9,357,935 shares of preferred stock will be designated &#147;Series B Convertible Preferred Stock&#148; and 642,065 shares of preferred stock will be undesignated. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our board of directors may establish the rights and preferences of the preferred stock from time to time, both before and after our reincorporation in Delaware. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Common Stock </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Voting Rights </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of October 20, 2014, there were 187,159,093 shares of common stock issued and outstanding, which excludes 86,710,400 shares of common stock issuable as of such date upon conversion of shares of Series B Convertible Preferred Stock and other shares issuable or reserved for issuance pursuant to outstanding options or option plans as set forth on page <a href="#tSTKOUT">4</a> of this prospectus. Each holder of common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of the stockholders, including the election of directors. Our amended and restated articles of incorporation and
amended and restated bylaws do not provide for cumulative voting rights. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Dividends </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of our outstanding shares of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Liquidation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Rights and Preferences </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that are outstanding or that we may designate and issue in the future. All of our outstanding shares of common stock are fully paid and non-assessable. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Common Stock Held in Escrow </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2012, the Company announced the acquisition of SPH and its wholly owned subsidiary Special Phage Services Pty Ltd, and the consideration for such acquisition was paid in shares of our common </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">85</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">stock. As a condition of the acquisition, 20,000,000 shares of such common stock were held in escrow, with 8,000,000 to satisfy potential warranty claims on behalf of the Company under the acquisition documents and the remaining 12,000,000 shares to be held pending completion of certain milestones. In November 2013, twelve months following the closing, 8,000,000 of the shares then held in escrow were released, with 12,000,000 shares remaining in escrow. Some or all of such 12,000,000 shares of common stock may, in the future, depending on certain circumstances, be returned to the Company as treasury stock. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Preferred Stock </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of October 20, 2014, there were 8,671,040 shares of Series B Convertible Preferred Stock outstanding, which are convertible into 86,710,400 shares of common stock as of such date. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to our reincorporation in Delaware, our board of directors will have the authority, without further action by our stockholders, to issue up to 462,065 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. After our reincorporation in Delaware, our board of
directors will possess identical authority, except the number of shares of preferred stock authorized for issuance will equal up to 642,065 (without giving effect to the reverse stock split we intend to effect in connection with the reincorporation, which has been approved by our stockholders). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of us
and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders of common stock until the board of directors determines the specific rights attached to that preferred stock. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There currently are no other provisions under our amended and restated articles of incorporation (nor will there be under our Delaware certificate of incorporation after reincorporation) or under any other contractual obligations whereby we are authorized or required to issue or sell shares of preferred stock and we have no present plans to issue any shares of preferred stock. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Series A Participating Cumulative Preferred Stock </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s current amended and restated articles of incorporation grant the board of directors authority to issue shares of Series A Participating Cumulative Preferred Stock upon the exercise of certain rights by certain stockholders pursuant to a Rights Agreement, dated October 17, 1996, between the Company and ChaseMellon Shareholder Services, as Rights Agent, as amended, which we refer to as the Rights Agreement. The Rights Agreement and all rights thereunder expired in October, 2006 and the Company currently has no plans to reauthorize or extend the effective term of any rights under the Rights Agreement or enter
into a new rights agreement providing the same or similar rights to stockholders. Upon our reincorporation in Delaware, no shares of Series A Participating Cumulative Preferred Stock will be authorized. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Series B Convertible Preferred Stock </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Shares of our Series B Convertible Preferred Stock are subject to automatic conversion into common stock upon the completion of an underwritten public offering with aggregate offering proceeds to the Company of at least $7 million dollars (after reduction for underwriting discounts and commissions) and a price per share to the public of at least the purchase price of the shares of Series B Convertible Preferred Stock (subject to adjustment in the event of any stock dividend, stock split, stock distribution or combination with respect to such shares) upon the closing of which the shares of common stock of the company shall be
</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">86</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">listed for trading on the national securities exchanges operated by the New York Stock Exchange or NASDAQ Stock Market, or (ii) at the election of the holders of two-thirds of the then outstanding shares of Series B Convertible Preferred Stock. The shares of Series B Convertible Preferred Stock are also subject to voluntary conversion by the holders thereof at any time. The number of shares of our common stock to be issued upon the conversion of all outstanding shares of our Series B Convertible Preferred Stock depends on the closing date of our initial public offering that triggers conversion, or the date of election by
individual holders or holders of at least two-thirds of the then outstanding shares of Series B Convertible Preferred Stock. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The terms of our Series B Convertible Preferred Stock provide that the shares of Series B Convertible Preferred Stock accrue dividends at the rate of 10% per year, which results in additional shares of our common stock being issuable upon conversion of our Series B Convertible Preferred Stock as such dividends accrue. Subsequent to June 30, 2013, 1,345,040, shares of Series B Convertible Preferred Stock were converted into shares of common stock. As of October 20, 2014, the outstanding shares of our Series B Convertible Preferred Stock would convert into an aggregate of 86,710,400 shares of our common stock (assuming a
conversion ratio of 10 shares of common stock for each share of Series B Convertible Preferred Stock). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to the mandatory conversion of the Series B Convertible Preferred Stock, if the Company issues any shares of common stock for consideration per share of less than the conversion price then in effect for the Series B Convertible Preferred Stock, the conversion rate for the Series B Convertible Preferred Stock shall be adjusted to a new rate that equals the product of: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the conversion rate in effect immediately before such issuance, multiplied by </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a fraction, the numerator of which is the &#147;Series B Stated Value&#148; (as defined in the &#147;Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock&#148;), and the denominator of which is the consideration per share received in such issue multiplied by the conversion rate in effect immediately before such issuance.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Except for matters requiring the separate approval of the holders of the Series B Convertible Preferred Stock, the holders of the Series B Convertible Preferred Stock are entitled to that number of votes equal to the number of shares of the common stock into which the Series B Convertible Preferred Stock may be converted as of the date such vote is held. Approval of the holders of at least two-thirds of the then outstanding shares of Series B Convertible Preferred Stock is required to:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">authorize, create or issue (by reclassification or otherwise) any other class or series of capital stock having rights, preferences or privileges senior to or in parity with the Series B Convertible Preferred Stock; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">alter or change the rights, preferences or privileges of the Series B Convertible Preferred Stock, or increase or decrease the authorized or issued and outstanding number of shares of Series B Convertible Preferred Stock.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The holders of the Series B Convertible Preferred Stock are also entitled to preferential payments upon a liquidation event that occurs prior to the mandatory conversion of the Series B Convertible Preferred Stock. In the case of any &#147;Liquidation Event&#148; (as defined in the &#147;Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock&#148;), the holders of the Series B Convertible Preferred Stock then outstanding shall be entitled to receive and to be paid out of the assets or surplus funds available for distribution to our shareholders, prior to and in preference to any payments to
be made to the holders of the shares of common stock, an amount per share equal to the greater of:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(i)</TD>

          <TD STYLE="text-align: left">the sum of (A) the Series B Stated Value then in effect plus (B) all accrued but unpaid dividends through the Liquidation Event plus (C) after the distribution contemplated by (A) and (B) above and assuming a distribution to the holders of shares of common stock in proportion to the shares of common stock held or that the holder has the right to acquire upon conversion of the Series B Convertible Preferred Stock, such additional aggregate amount that would be distributable with </TD>

</TR>

</TABLE>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">87</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px; text-align: left"></TD>

          <TD STYLE="width: 20px; text-align: left"></TD>

          <TD STYLE="text-align: left">respect to the aggregate number of shares of common stock issuable upon conversion of such shares of Series B Convertible Preferred Stock, assuming conversion of all shares of Series B Convertible Preferred Stock; and</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">(ii)</TD>

          <TD STYLE="text-align: left">assuming a distribution to the holders of shares of common stock in proportion to the shares of common stock held or that the holder has the right to acquire upon conversion of the Series B Convertible Preferred Stock, the aggregate amount that would be distributable with respect to the aggregate number of shares of common stock issuable upon conversion of such shares of Series B Convertible Preferred Stock, assuming conversion of all shares of Series B Convertible Preferred Stock.</TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For purposes of clause (i) above only, the holders of Series B Convertible Preferred Stock shall be entitled to receive remaining assets and funds of the Company of an aggregate value below or equal to, but not to exceed, the aggregate of two times the Series B Stated Value at the time of such Liquidation Event.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Warrants </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of October 20, 2014, there were outstanding warrants to purchase the following shares of our capital stock: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="354"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Description</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3># of shares subject to such Warrants</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted-average exercise price of such Warrants</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Common Stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>38,890,451</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.15</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In December 2011, as compensation for certain services provided in connection with our acquisition of Biocontrol, we issued warrants to purchase an aggregate of 1,355,164 shares of our common stock with an initial exercise price of $0.46 per share. These warrants were issued to Rodman &amp; Renshaw LLC and its affiliate, Edward Cappabianca. Rodman &amp; Renshaw LLC subsequently assigned its ownership interest in its warrants (exercisable for 1,016,373 shares of our common stock) to OTA, LLC. All of the warrants held by Edward Cappabianca and OTA, LLC expire in December 2016. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In February through May 2013, we issued warrants to purchase 7,030,387 shares of common stock at an exercise price of $0.14 per share in connection with the issuance of convertible notes. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2013, we issued warrants to purchase an aggregate of up to approximately 12.5 million shares of common stock at an exercise price of $0.14 per share in connection with the private placement of our Series B Convertible Preferred Stock. In connection with the financing, we issued warrants to purchase approximately 12.5 million shares of common stock at an exercise price of $0.14 per share to holders of our convertible notes that were converted in the financing. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with our June 2013 private placement of convertible preferred stock, we paid a placement fee to Griffin Securities, Inc. in the amount of $270,000 in cash and warrants to purchase 4,285,714 shares of common stock at an exercise price of $0.14 per share and to Phillip Capital Ltd in the amount of $60,000 in cash and warrants to purchase 714,285 shares of common stock at an exercise price of $0.14 per share. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with our December 2013 private placement of common stock, we paid a placement fee to Roth Capital Partners and Griffin Securities, Inc., consisting in the aggregate of $1,080,045 in cash and warrants to purchase 4,320,180 shares of common stock. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Options </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of October 20, 2014, there were 25,719,000 shares of common stock subject to outstanding options. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Anti-Takeover Provisions </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Provisions in our current articles of incorporation and bylaws and under Washington law and our intended certificate of incorporation and bylaws (upon reincorporation in Delaware) under Delaware law may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on shareholder actions by less than unanimous written consent, and a requirement for the vote of shareholders holding at least two-thirds of all shares of our issued and outstanding </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">88</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">capital stock to approve certain changes to our articles of incorporation or any business combination, such as a merger or a share exchange with another company. In addition, because we are incorporated in Washington, we are governed by the provisions of Chapter 23B.19 of the WBCA, which, among other things, restricts the ability of shareholders owning ten percent (10%) or more of our outstanding voting stock from merging or combining with us. In addition, these provisions may frustrate or prevent any attempts by our shareholders to replace or remove our current management by making it difficult for shareholders to replace
members of our board of directors, which is responsible for appointing the members of our management. Also, because we are reincorporating in Delaware, we will then be governed by the provisions of Section 203 of the DGCL. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Registration Rights </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Holders of warrants to purchase an aggregate of 1,355,164 shares of our common stock at an exercise price of $0.46 per share are entitled to certain registration rights with respect to such shares and have elected to exercise such rights in connection with this registration statement. In addition, the shares of common stock issued in connection with the ECC with Intrexon, the shares of common stock issuable in connection with the June private placement of our Series B Convertible Preferred Stock (upon conversion of Series B Convertible Preferred Stock and/or exercise of warrants) and the shares of common stock to be issued in
connection with the December 2013 private placement of our common stock are entitled to certain rights with respect to registration of such shares under the Securities Act. These shares are collectively referred to herein as registrable securities. The holders of these registrable securities possess registration rights pursuant to their respective executed agreements and as described in additional detail below. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Piggyback Registration Rights </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we propose to register any of our securities under the Securities Act either for our own account or, in the case of the warrants described above, for the account of other stockholders, the holders of our registrable securities then outstanding will each be entitled to notice of the registration and will be entitled to include their shares of common stock in any such registration statement. These piggyback registration rights are subject to specified conditions and limitations, including, in the case of an underwritten offering, the right of the underwriters to limit the number of shares included in any such registration
under specified circumstances. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Demand Registration Rights </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">From the date that is 180 days after the effective date of the registration statement relating to our initial public offering, holders of at least 50% of our registrable shares from the June private placement of our Series B Convertible Preferred Stock are entitled to request to have such shares registered by us on a Form S-1 registration statement. As of October 20, 2014, approximately 119,925,267 shares of common stock held by those holders post-conversion (assuming a conversion ratio equal to ten (10) common shares for each share of Series B Convertible Preferred Stock and the exercise of all warrants issued in connection
with the June private placement) will be entitled to these Form S-1 registration rights. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At any time we are eligible to use a Form S-3 registration statement, holders of at least 30% of our registrable securities from the June private placement of our Series B Convertible Preferred Stock are entitled to request to have such shares registered by us on a Form S-3 registration statement. As of October 20, 2014, approximately 119,925,267 shares of common stock held by those holders post-conversion (assuming a conversion ratio equal to ten (10) common shares for each share of Series B Convertible Preferred Stock and the exercise of all warrants issued in connection with the June private placement) will be entitled to
these Form S-3 registration rights. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Resale Registration Statement </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the Registration Rights Agreement, dated December 16, 2013, by and between the Company and the purchasers of shares in the December 2013 private placement, the Company agreed to file, within 30 days of the closing of the private placement, a registration statement on Form S-1 covering the resale of the shares purchased in the private placement. The Company would be liable for certain liquidated damages in the event the registration statement is not filed by, or declared or kept effective during, the time periods specified in the Registration Rights Agreement. The Company is filing this registration statement in
satisfaction of this obligation. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">89</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Expenses of Registration </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will pay all expenses relating to any piggyback or Form S-1 or S-3 registration, other than underwriting discounts and commissions, subject to specified conditions and limitations. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Transfer Agent </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our shares of common stock are issued in certificated form. The transfer agent and registrar for our common stock is Computershare. The transfer agent&#146;s address is 250 Royall Street, Canton, MA 02021. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSEF"></a>SHARES ELIGIBLE FOR FUTURE SALE </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Upon the effectiveness of the registration statement, there will be 73,362,164 outstanding common shares registered for resale by the Selling Stockholders in accordance with the Securities Act of 1933. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to this registration statement, no public trading market has existed for shares of our common stock other than it being quoted on the OTCQB Market. The sale or availability for sale, of substantial amounts of common stock in the public trading market could adversely affect the market prices for our common stock. See &#147;Risk Factors&nbsp;&#151;&nbsp;Risks Related to This Offering and to Our Common Stock.&#148; </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tLM"></a>LEGAL MATTERS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The validity of the common stock being offered hereby will be passed upon for us by Morrison &amp; Foerster LLP, Washington, DC. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tEXP"></a>EXPERTS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">PBMares, LLP, an independent registered public accounting firm, has audited our consolidated financial statements for the fiscal years ended December 31, 2011, December 31, 2012 and December 31, 2013, as stated in their report appearing herein, and such audited consolidated financial statements have been so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tWYC"></a>WHERE YOU CAN FIND MORE INFORMATION ABOUT US </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have filed with the Securities and Exchange Commission, or SEC, a registration statement on Form S-1, including exhibits, under the Securities Act that registers the shares of our common stock to be sold in this offering. This prospectus does not contain all the information contained in the registration statement and the exhibits filed as part of the registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and the exhibits filed as part of the registration statement. Statements contained in this prospectus as to the contents of any contract or other
document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, we refer you to the copies of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">When this registration statement becomes effective, we will begin to file annual, quarterly and current reports, proxy statements, information statements and other information with the SEC. You may read and copy this information, for a copying fee, at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information on its Public Reference Room. Our SEC filings will also be available to the public from commercial document retrieval services, and at the website maintained by the SEC at <I>http://www.sec.gov.</I> </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Internet website address is <I>http://www.ampliphibio.com.</I> Information contained on the website does not constitute part of this registration statement. When this registration statement is effective, we will make available, through a link to the SEC&#146;s website, electronic copies of the materials it files with the SEC (including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, the Section 16 reports filed by executive officers, directors and 10% shareholders and amendments to those reports). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The representations, warranties and covenants made by us in any agreement that is filed as an exhibit to the registration statement of which this prospectus is a part were made solely for the benefit of the parties to </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">90</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were made as of an earlier date. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This prospectus includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that they have gathered their information from sources they believe to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">91</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tICF"></a>AMPLIPHI BIOSCIENCES CORPORATION<BR> &nbsp;&nbsp;<BR>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="552"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="40"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>AmpliPhi Biosciences Corporation<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tACBS1">Consolidated Balance Sheets as of September 30, 2014 (Unaudited) and December 31, 2013 (Restated)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tACBS1">F-1</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tACSOCL1">Consolidated Statements of Operations and Comprehensive Income (Loss) for the Nine Months and Three Months Ended September 30, 2014 (Unaudited) and September 30, 2013 (Unaudited)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tACSOCL1">F-2</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tACSSE">Consolidated Statements of Stockholders&#146; Equity (Deficit) for the Nine Months Ended September 30, 2014 (Unaudited) and the Year Ended December 31, 2013 (Restated)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tACSSE">F-3</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tACFS">Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2014 (Unaudited) and September 30, 2013 (Unaudited)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tACFS">F-4</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tANOT14">Notes to Consolidated Financial Statements for the Nine Months Ended September 30, 2014 (Unaudited)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tANOT14">F-5</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tRIR1">Report of Independent Registered Public Accounting Firm</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tRIR1">F-14</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tCBS1">Consolidated Balance Sheets as of December 31, 2013 and 2012 (Audited) (Restated)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tCBS1">F-15</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tCSOCL1">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2013 and 2012 (Audited) (Restated)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tCSOCL1">F-16</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tCSSE1">Consolidated Statements of Stockholders&#146; Equity (Deficit) for the Years Ended December 31, 2013 and 2012 (Audited) (Restated)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tCSSE1">F-17</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tCSCS1">Consolidated Statements of Cash Flows for the Years Ended December 31, 2013 and 2012 (Audited) (Restated)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tCSCS1">F-18</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tNCFS1">Notes to Consolidated Financial Statements for the Years Ended December 31, 2013 and 2012 (Audited)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tNCFS1">F-19</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tRAR">Report of Independent Registered Public Accounting Firm</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tRAR">F-31</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tCBSD">Consolidated Balance Sheets as of December 31, 2012 and 2011 (Audited) (Restated)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tCBSD">F-32</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tCSOD">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2012 and 2011 (Audited) (Restated)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tCSOD">F-33</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tCSSD">Consolidated Statements of Stockholders&#146; Equity (Deficit) for the Years Ended December 31, 2012 and 2011 (Audited) (Restated)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tCSSD">F-34</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tCSCD">Consolidated Statements of Cash Flows for the Years Ended December 31, 2012 and 2011<BR> (Audited) (Restated)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tCSCD">F-35</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tNCFSD">Notes to Consolidated Financial Statements for the Years Ended December 31, 2012 and 2011 (Audited)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tNCFSD">F-36</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1><U>Special Phage Holdings Pty Ltd</U><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSRIR">Report of Independent Registered Public Accounting Firm</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSRIR">F-48</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSBS">Balance Sheet</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSBS">F-49</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSSOC">Statement of Operations and Comprehensive Loss</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSSOC">F-50</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSSSE">Statement of Stockholders&#146; Equity (Deficit)</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSSSE">F-51</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSSCF">Statement of Cash Flows</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSSCF">F-52</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSNFS">Notes to Financial Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSNFS">F-53</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">92</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tACBS1"></a>AMPLIPHI BIOSCIENCES CORPORATION<BR>&nbsp;&nbsp;<BR>CONSOLIDATED BALANCE SHEETS </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="384"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="92"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="100"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>September 30, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>December 31, 2013</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(Unaudited)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(Restated)</FONT></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Assets</B><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Current assets</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9,786,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20,355,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>27,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Prepaid expenses and other current assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>279,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>171,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><B>Total current assets</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>10,092,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>20,534,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Property and equipment, net of accumulated depreciation of $559,000 and $473,000 as of September 30, 2014 and December 31, 2013, respectively</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,175,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>145,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Intangible assets</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>In process research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,446,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,446,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Patents, net of accumulated amortization of $116,000 and $93,000 as of September 30, 2014 and December 31, 2013, respectively</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>377,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Goodwill</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,329,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,329,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><B>Total intangible assets</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>17,152,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>17,175,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1><B>Total assets</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>28,419,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>37,854,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Liabilities and Stockholders&#146; Equity (Deficit)</B><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Current liabilities</B><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts payable and accrued expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,840,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,147,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accrued severance</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>659,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total current liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,499,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,147,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Long term liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Derivative preferred shares conversion liability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,633,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>34,443,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Derivative warrants liability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>6,949,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>16,664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total long term liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>14,582,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>51,107,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>17,081,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>53,254,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stockholders&#146; equity (deficit)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Preferred stock, $0.01 par value, 10,000,000 shares authorized; 8,671,040 shares issued and outstanding at September 30, 2014 and 8,859,978 shares issued and outstanding at December 31, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>87,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>89,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Common stock, $0.01 par value, 445,000,000 shares authorized, 187,159,093 shares issued and outstanding at September 30, 2014 and 182,535,562 shares issued and outstanding at December 31, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,872,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,825,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Additional paid-in capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>363,032,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>358,988,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Paid-in-capital&nbsp;&#150;&nbsp;contingent shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,837,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,837,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accumulated other comprehensive loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(178,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(65,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accumulated deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(355,312,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(378,074,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><B>Total stockholders&#146; equity (deficit) </B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>11,338,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(15,400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1><B>Total liabilities and stockholders&#146; equity (deficit) </B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>28,419,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>37,854,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>See accompanying condensed notes to consolidated financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-1</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tACSOCL1"></a>AMPLIPHI BIOSCIENCES CORPORATION<BR>&nbsp;&nbsp;<BR> CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="216"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Three Months Ended September 30,</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Nine Months Ended September 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(Unaudited)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(Unaudited)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(Unaudited)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(Unaudited)</FONT></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><B>Revenue</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(3,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>310,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>333,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Operating expenses</B><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,804,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,106,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,687,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,378,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>General and administrative</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,632,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,211,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,377,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,777,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Severance charge</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,510,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,510,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><B>Total operating expenses</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,946,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,317,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>11,574,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>10,155,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><B>Loss from operations</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,946,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(2,320,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(11,264,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(9,822,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Other income (expense)</B><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gain (loss) on derivative liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>24,334,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(41,548,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>34,026,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(45,617,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization of note discount and patents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(23,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,660,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Interest expense, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(9,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(233,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><B>Other income (expense), net</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>24,334,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(41,580,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>34,026,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(48,510,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Net income (loss)</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>19,388,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(43,900,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,762,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(58,332,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Other comprehensive income (loss)</B><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net unrealized gain (loss) on foreign currency translations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(93,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(21,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(113,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(24,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1><B>Comprehensive income (loss)</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>19,295,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(43,921,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>22,649,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(58,356,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net income (loss) per share&nbsp;&#150;&nbsp;basic</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.10</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.44</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.68</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Weighted average number of shares of common stock outstanding&nbsp;&#150;&nbsp;basic</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>187,159,093</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>99,156,809</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>184,445,172</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>85,688,356</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net income (loss) per share&nbsp;&#150;&nbsp;diluted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.06</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.44</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.07</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.68</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Weighted average number of shares of common stock outstanding&nbsp;&#150;&nbsp;diluted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>315,990,084</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>99,156,809</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>323,604,642</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>85,688,356</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>See accompanying condensed notes to consolidated financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-2</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tACSSE"></a>AMPLIPHI BIOSCIENCES CORPORATION<BR>&nbsp;&nbsp;<BR> CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY (DEFICIT) </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="708" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 9pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="178"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="46"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="46"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="57"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="63"></TD>

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="178"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="46"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="46"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="57"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="63"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7><FONT STYLE="font-size: 7pt">Preferred Stock</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7><FONT STYLE="font-size: 7pt">Common Stock</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=15></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Shares</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Amount</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Shares</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Amount</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Additional<BR> Paid-in<BR> Capital</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Accumulated<BR> Deficit</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Accumulated<BR> Other<BR> Comprehensive<BR> Loss</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 7pt">Total<BR> Stockholders&#146;<BR> Equity (Deficit)</FONT></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Balances, December 31, 2012 (Restated)</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>66,908,810</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>669,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>332,806,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(320,426,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(106,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,943,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(57,648,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(57,648,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,437,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,437,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Beneficial conversion feature and warrants associated with issuance of convertible loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,635,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,635,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares issued for Intrexon</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>24,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>240,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,760,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of preferred stock from conversion of convertible loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,016,081</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of preferred stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,999,999</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Preferred stock converted to common stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,156,102</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(11,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11,561,020</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>115,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,511,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,615,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock options exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>61,018</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares released from escrow</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>80,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(80,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of common stock for December financing</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>72,007,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>720,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>14,744,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>15,464,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Escheat shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,286</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Foreign currency translations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>41,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>41,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Balances, December 31, 2013 (Restated)</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,859,978</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>89,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>182,535,562</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,825,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>360,825,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(378,074,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(65,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(15,400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net income</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,762,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,762,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrants exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,734,151</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>28,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,730,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,758,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Preferred stock converted to common stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(188,938</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,889,380</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>19,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>724,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>741,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>759,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>759,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Stock-based compensation - severance</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>831,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>831,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Foreign currency translations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(113,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(113,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1><B>Balances, September 30, 2014 (Unaudited)</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>8,671,040</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>87,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>187,159,093</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,872,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>364,869,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(355,312,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(178,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>11,338,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>See accompanying condensed notes to consolidated financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-3</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tACFS"></a>AMPLIPHI BIOSCIENCES CORPORATION<BR>&nbsp;&nbsp;<BR> CONSOLIDATED STATEMENTS OF CASH FLOWS </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="624" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="408"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Nine Months Ended September 30,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(Unaudited)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(Unaudited)</FONT></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Cash flows from operating activities</B><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net income (loss) from operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,762,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(58,332,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Adjustments required to reconcile net income (loss) to cash used in operating activities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Derivative liability (gain) loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(34,026,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>45,617,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares issued for technology access fee</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization of patents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>23,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>23,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization of note discount</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,637,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrants issued as investment fees</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>759,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>59,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>66,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>759,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,206,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation&nbsp;&#151;&nbsp;severance</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>831,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Changes in operating assets and liabilities net of acquisitions:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(19,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(125,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tax refund</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>618,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts payable and accrued expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(307,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(453,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accrued severance</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>659,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Prepaid expenses and other current assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(108,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(153,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Interest on loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>233,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><B>Net cash used in operating activities</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(9,367,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,904,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Cash flows from investing activities</B><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Purchases of property and equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,089,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(97,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><B>Net cash used in investing activities</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,089,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(97,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><B>Cash flows from financing activities</B><BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds from Preferred Series B</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds from convertible loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Payment of convertible loan note</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(26,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><B>Net cash provided by financing activities</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>8,974,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Effect of exchange rates</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(113,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>24,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net increase (decrease) in cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(10,569,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,997,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents, beginning of period</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>20,355,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>862,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents, end of period</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>9,786,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>4,589,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>See accompanying condensed notes to consolidated financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-4</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Condensed Notes to Consolidated Financial Statements<BR> September 30, 2014 (Unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Nature of Business </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tANOT14"></a>AmpliPhi Biosciences Corporation (the &#147;Company&#148;) was incorporated in the state of Washington in 1989. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Basis of Presentation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries - Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All amounts on the financial statements and disclosures have been rounded to the nearest $1,000 except share and per share data. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company&#146;s management, all adjustments (consisting of normal recurring adjustments, reclassifications, and non-recurring adjustments) necessary to present fairly our results of operations for the three months and nine months ended September 30, 2014 and 2013, our cash flows for the nine months ended September 30, 2014 and 2013 and our financial position as of September 30, 2014 have been made. The
results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Use of Estimates </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cash and Cash Equivalents </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accounts Receivable </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of September 30, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and Equipment </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-5</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Condensed Notes to Consolidated Financial Statements<BR> September 30, 2014 (Unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prepaid Expenses and Other Current Assets </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prepaid and other current assets as of September 30, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Goodwill </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In 2012, the rights to SPH Holdings Pty Ltd&#146;s know-how and phage libraries were acquired in a business combination with an aggregate value of $7,172,000. Goodwill in the amount of $2,381,000 was recorded. In management&#146;s opinion, no goodwill has been impaired as of September 30, 2014 and December 31, 2013. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In 2011, the rights to Biocontrol Limited&#146;s patents and phage libraries were acquired in a business combination with an aggregate value of $8,584,000. Goodwill in the amount of $1,948,000 was recorded. In management&#146;s opinion, no goodwill has been impaired as of September 30, 2014 and December 31, 2013. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patents </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In 2011, the rights to Biocontrol Limited&#146;s patents were acquired in a business combination. Patents in the amount of $493,000 have been recorded. These patents are being amortized over their useful life through December 2026. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-Based Compensation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, <I>Stock Compensation</I>, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Warrant and Preferred Shares Conversion Feature Liability </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company accounts for warrants and the preferred shares conversion feature of the Company&#146;s Series B preferred stock with anti-dilution (&#147;down-round&#148;) provisions under the guidance of ASC 815, <I>Derivatives</I>, <I>and Hedging</I> and Emerging Issue Task Force Statement 07-5: <I>Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity&#146;s Own Stock</I>, which require such warrants and the Series B preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Fair Value of Financial Assets and Liabilities &#151; Derivative Instruments </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-6</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Condensed Notes to Consolidated Financial Statements<BR> September 30, 2014 (Unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value: </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Level 1&nbsp;&#151;&nbsp;quoted prices in active markets for identical assets or liabilities. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Level 2&nbsp;&#151;&nbsp;quoted prices for similar assets and liabilities in active markets or inputs that are observable. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Level 3&nbsp;&#151;&nbsp; inputs that are unobservable. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company estimates fair values of these derivatives utilizing Level 2 inputs. The Company uses the Monte Carlo valuation technique as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, and risk free rates) necessary to fair value these instruments. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Estimating fair values of derivative financial instruments, including Level 2 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Revenue Recognition </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company generates revenue from technology licenses. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, Multiple Element Arrangements, which requires the Company to satisfy the following before revenue can be recognized: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The delivered items have value to the customer on a stand-alone basis; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Any undelivered items have objective and reliable evidence of fair value; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Delivery or performance is probable and within the Company&#146;s control for any delivered items that have a right of return. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company classifies advance payments received in excess of amounts earned as deferred revenue. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-7</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Condensed Notes to Consolidated Financial Statements<BR> September 30, 2014 (Unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and Development </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In Process Research &amp; Development (IPR&amp;D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with
the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&amp;D assets, for impairment at least annually. In 2012, the rights to SPH Holdings Pty Ltd&#146;s know-how and phage libraries were acquired by a business combination for $7,172,000. In 2012, IPR&amp;D in the amount of $5,161,000 was recorded. In management&#146;s opinion, this IPR&amp;D has not been impaired as of September 30, 2014 and December 31, 2013. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In 2011, the rights to Biocontrol Limited&#146;s patents and phage libraries were acquired by a business combination $8,584,000. In 2011, IPR&amp;D in the amount of $7,285,000 was recorded. In management&#146;s opinion, this IPR&amp;D has not been impaired as of September 30, 2014 and December 31, 2013. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net Income (Loss) per Common Share </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net income (loss) per common share is based on net income (loss) divided by the weighted average number of common shares outstanding during the period. For the three months ended September 30, 2014 and the nine months ended September 30, 2014, both basic and diluted net income (loss) are disclosed in the Consolidated Statements of Operations and Comprehensive Income. For the three months ended September 30, 2013 and the nine months ended September 30, 2013, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B Preferred shares were
antidilutive with respect to computing the net loss per share and therefore were excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share was 150,283,630 shares for the three month period ending September 30, 2013 and 63,155,331 shares for the nine month period ending September 30, 2013. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Recent Accounting Pronouncements </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities,
the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2. Liquidity </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has prepared the accompanying consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception, has negative operating cash flows </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-8</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Condensed Notes to Consolidated Financial Statements<BR> September 30, 2014 (Unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2. Liquidity &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">and has an accumulated deficit of $355.3 million as of September 30, 2014. These circumstances raise substantial doubt about the Company&#146;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#146;s ability to continue as a going concern. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company believes that its current resources will only be sufficient to fund operations through the first quarter of 2015. This estimate is based on the Company&#146;s ability to manage its staffing expenses and its working capital. Actual results could differ from its estimates. The Company intends to seek additional financing in order to fund operations through 2015; however, the Company cannot provide assurances that it will be successful in obtaining additional financing for these periods or as needed in the future. If the Company does not raise additional funds by the first quarter of 2015, it plans to implement cost
reduction measures, such as a reduction in workforce, reducing its intellectual property prosecution, reducing other operating activities, and/or the pursuit of alternative financing transactions that would likely be on terms disadvantageous to the Company and dilutive to its shareholders. The Company could also be required to relinquish rights to its technology or product candidates or in-licensed technology on unfavorable terms, either of which would reduce the ultimate value of the technology or product candidates, or to sell assets likely at values significantly below their potential worth. If the Company is unable to secure additional capital, it may be required to cease operations, declare bankruptcy or otherwise wind-up its business. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">3. Preferred Shares </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 13, 2013, the Company&#146;s Board of Directors approved a resolution designating 10,016,080 shares of Preferred Stock as Series B Convertible Preferred Stock with an initial stated value of $1.40 and par value of $0.01. Each Series B preferred share is convertible into 10 shares of common stock and is entitled to the number of votes equal to the number of shares of common stock. These Series B shares may be converted to common stock by the holder of the shares at any time. The Series B shares shall be automatically converted into common shares upon the closing of an underwritten initial public offering with aggregate
proceeds to the Company of at least $7 million and a price per share to the public of at least the Series B stated value upon the closing of which the shares of common stock of the Company shall be listed for trading on the New York Stock Exchange. The Series B shares are also convertible into common shares upon the election of the holders of two-thirds of the outstanding Series B shares. Until conversion, the holders of Series B Preferred shares shall be entitled to receive dividends of 10% of the Series B stated value per annum. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the private placement of Series B Convertible Preferred Stock, the Company recorded a liability for a complex embedded derivative that required bifurcation under ASC Section 815. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with a down-round ratchet provision. The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013(dates of issuance) and recorded the initial liability as part of the private
placement proceeds. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 26, 2013, the Company issued 4,999,999 shares of the Company&#146;s newly-created Series B Convertible Preferred Stock and warrants to purchase 12,499,996 shares of common stock at an exercise price of $0.14 per share for an aggregate purchase price of $7.0 million. The value of the derivative liability related to the warrants was $1,886,000 and the value of the derivative liability related to the preferred shares was $5,064,000. As part of the same transaction, the Company converted $5,491,001 in outstanding convertible loan notes (principal and interest) into 4,357,936 shares of Series B Convertible Preferred Stock
and warrants to purchase 10,894,839 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $1,644,000 and the value of the derivative liability related to </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-9</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Condensed Notes to Consolidated Financial Statements<BR> September 30, 2014 (Unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">3. Preferred Shares &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">the preferred shares was $3,804,000. As part of this issuance, the Company issued warrants to purchase 4,999,999 shares of common stock at an exercise price of $0.14 per share with an initial fair value of $759,000 and paid $350,000 to the placement agents. As a result of this financing, all outstanding convertible notes were converted into shares of Series B Convertible Preferred Stock and warrants to purchase common stock. On July 15, 2013, the remaining outstanding convertible loan notes, totaling $829,277 in principal and interest, were converted into 658,145 shares of Series B Convertible Preferred Stock and warrants to
purchase 1,645,361 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $674,000 and the value of the derivative liability related to the preferred shares was $155,000. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the private placement of Series B Convertible Preferred Stock, the Company recorded a liability for the conversion feature that contains a provision that protect holders from a decline in the issue price of the Company&#146;s common stock (&#147;down-round&#148; provision). The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On May 16, 2014, 188,938 preferred shares were converted into 1,889,380 shares of common stock. Due to this conversion, a gain on derivative liabilities of $118,000 was recognized and $741,000 was reclassified out of the derivative liability account and into equity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company re-measured the fair value of the conversion feature at September 30, 2014 and recorded $18.4 million gain on derivative liabilities during the third quarter to adjust the liability associated with the conversion feature to an estimated fair value of $7.6 million. The change in fair value and the associated gain was attributable to a decline in the market value of our common stock as of September 30, 2014. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">4. Warrants and Warrants Liability </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company follows ASC 815-40, <I>Contracts in an Entity&#146;s Own Equity</I>, as it relates to outstanding warrants. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the December 2013 private placement of 72,007,000 shares of the Company&#146;s common stock at a price per share of $0.25, the Company issued an aggregate of warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share to the placement agents. These warrants expire December 2018. The warrants contain provisions that protect holders from a decline in the issue price of the Company&#146;s common stock (&#147;down-round&#148; provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the private placement of Series B Convertible Preferred Stock, which occurred through two closings on June 26, 2013 and July 15, 2013, respectively, the Company issued an aggregate of warrants to purchase 30,040,194 shares of common stock at an exercise price of $0.14 per share. These warrants expire June 2018. The warrants contain provisions that protect holders from a decline in the issue price of the Company&#146;s common stock (&#147;down-round&#148; provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. The
Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds and expensed $1.4 million for the warrants issued to the placement agent. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-10</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Condensed Notes to Consolidated Financial Statements<BR> September 30, 2014 (Unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">4. Warrants and Warrants Liability &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="258"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>June 26, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>July 15, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>December 23, 2013</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrants issued</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>28,394,834</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>1,645,360</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>4,320,420</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Risk free interest rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>.0109</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>.0109</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0.0167</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Volatility</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>160.94&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>163.08&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>155.24&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected term</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>5 years</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>5 years</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>5 years</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercise price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0.14</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0.14</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0.25</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants to purchase up to 7,030,387 shares of its common stock. These warrants expire February through May 2018 and are exercisable at a price of $0.14 per share. These warrants are considered to be equity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In 2011, in connection with the Biocontrol business combination, the Company issued warrants to purchase up to 1,355,164 shares of its common stock. These warrants expire in December 2016 and are exercisable at a price of $0.46 per share. These warrants are considered to be equity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 26, 2014, 3,855,714 warrants, issued on June 26, 2013, were exercised. Due to this exercise, 2,734,151 shares of common stock were issued, a gain on derivative liabilities of $398,000 was recognized, and $1,729,000 was classified out of the derivative liability account and into equity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company re-measured the fair value of the liability warrants at September 30, 2014 and recorded a $5.9 million gain on derivative liabilities during the third quarter to adjust the liabilities associated with the warrants to their estimated fair values totaling $6.9 million. The change in fair value and the resulting gain was attributable to a decline in the market value of our common stock as of September 30, 2014. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">5. Stock Options </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In October 2012, our board of directors approved and adopted the 2012 Stock Incentive Plan, which we refer to as the 2012 Plan. Under the 2012 Plan, we are authorized to issue up to 35,000,000 shares of our common stock in stock incentive awards to employees, directors and consultants. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2009, our board of directors and shareholders adopted the 2009 Stock Incentive Plan, which we refer to as the 2009 Stock Incentive Plan. Under the 2009 Plan, we are authorized to issue up to 4,200,000 shares of our common stock in stock incentive awards to employees, directors and consultants. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In December 2013, our board of directors adopted the 2013 Plan. Under the 2013 Plan, we are authorized to issue up to 40,000,000 shares of our common stock in stock incentive awards to employees, directors and consultants. Our shareholders approved the 2013 Plan in February 2014. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s 2013 Stock Incentive Plan provides for the issuance of long-term incentive awards, or Awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The Awards may be granted by the Company&#146;s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the
date of grant and generally vest and become exercisable over a four-year period following the date of grant. Under the 2012 Plan, every non-employee member of the Company&#146;s Board of Directors may elect to receive a non-qualified Option or restricted stock unit grant in lieu of certain cash compensation. Upon the exercise of Options, the Company issues the resulting shares from shares reserved for issuance under the Company&#146;s Incentive Plans. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-11</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Condensed Notes to Consolidated Financial Statements<BR> September 30, 2014 (Unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">5. Stock Options &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under ASC 718<I> Stock Compensation</I>, the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company&#146;s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company&#146;s estimates for the three and nine month periods ended September 30, 2013 and 2014. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive income (loss): </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="226"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Three Months Ended</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Nine Months Ended</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>September 30,<BR> 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>September 30,<BR> 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>September 30,<BR> 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>September 30, 2013</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Income statement category:</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>38,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>40,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>116,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>153,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>General and administrative</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>195,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>208,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>643,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,053,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Severance charge</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>831,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>831,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total stock-based compensation expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,064,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>248,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,590,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,206,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table summarizes Option activity: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="226"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted<BR>Average<BR>Exercise<BR>Price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Average<BR>Remaining<BR>Contractual Term<BR>(Years)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Intrinsic<BR>Value</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding at December 31, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,721,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.19</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Forfeited</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,137,378</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.19</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Expired</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>13.10</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Outstanding at September 30, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>22,581,622</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>0.19</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2.15</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>862,982</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Exercisable at September 30, 2014</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>19,972,558</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>0.19</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1.35</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>822,989</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The aggregate intrinsic value is determined using the closing price of the Company&#146;s common stock of $0.22 on September 30, 2014. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of September 30, 2014, the Company had unrecognized compensation cost related to unvested Options of approximately $559,358 net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately two and a half years. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of September 30, 2014, the Company had reserved shares of its common stock for future issuance as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="434"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="104"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares Reserved</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock options outstanding</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,581,622</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Available for future grants under the 2013 Stock Incentive Plan</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>39,250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Warrants</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>38,890,451</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total Shares reserved</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>99,972,073</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-12</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Condensed Notes to Consolidated Financial Statements<BR> September 30, 2014 (Unaudited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">6. Severance Charge </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On September 15, 2014, by mutual agreement of the Board of Directors (the &#147;Board&#148;) of the Company and Philip J. Young, Mr. Young stepped down from his role as President and Chief Executive Officer of the Company, effective September 15, 2014. In accordance with Mr. Young&#146;s employment agreements, the Company recorded a severance charge in the quarter ended September 30, 2014 of $1,510,000 related to severance-period compensation and benefits, as well as stock-based compensation expense related to the accelerated vesting of stock options.. The composition of the severance charge is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="448" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="296"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="136"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="136"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Compensation and benefits</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>679,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Stock-based compensation expenses related to accelerated vesting</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>831,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1><B>Total severance charge</B></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,510,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-13</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tRIR1"></a>INDEPENDENT AUDITOR'S REPORT</H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To the Board of Directors and Shareholders<BR>AmpliPhi Biosciences Corporation and Subsidiaries<BR>Richmond, Virginia<BR></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have audited the accompanying consolidated balance sheets of AmpliPhi Biosciences Corporation and Subsidiaries (the Company) as of December 31, 2013 and 2012, and the related consolidated statements of operations and comprehensive loss, stockholders' equity (deficit), and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of AmpliPhi Biosciences Corporation and Subsidiaries as of December 31, 2013 and 2012, and the results of their operations and their cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has had recurring losses from operations and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As discussed in Note 14 to the financial statements, the 2013 and 2012 financial statements have been restated to correct misstatements.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">/s/ PBMares, LLP</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Richmond, Virginia<BR>April 15, 2014, except for Note 14, as to which date is September 2, 2014 </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-14</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tCBS1"></a>AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Consolidated Balance Sheets </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="408"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Current assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20,355,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>862,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>23,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tax refund</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>618,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Prepaid expenses and other current assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>171,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>148,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total current assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>20,534,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,651,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Property and equipment, net of accumulated depreciation of $473,000 and $391,000 as of December 31, 2013 and December 31, 2012, respectively</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>145,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>136,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Intangible Assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>In process research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,446,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,446,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Patents, net of accumulated amortization of $93,000 and $62,000 as of December 31, 2013 and December 31, 2012, respectively</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>431,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Goodwill</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,329,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,329,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total intangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>17,175,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>17,206,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>37,854,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,993,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Liabilities and Stockholders&#146; Equity (Deficit)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Current liabilities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts payable and accrued expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,147,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,937,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Convertible loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,648,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accrued interest</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>465,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total current liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,147,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>6,050,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Long term liabilities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Derivative preferred shares conversion liability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>34,443,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Derivative warrants liability</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>16,664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total long term liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>51,107,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>53,254,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>6,050,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Commitments and Contingencies (Note 5)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Stockholders&#146; equity (deficit)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Preferred stock, $0.01 par value, 10,000,000 shares authorized; 8,859,978 shares issued and outstanding as of December 31, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>89,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Common stock, $0.01 par value, 445,000,000 shares authorized, 182,535,562 shares issued and outstanding at December 31, 2013 and 66,908,810 shares issued and outstanding at December 31,<BR> 2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,825,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>669,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Additional paid-in capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>358,988,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>329,609,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Paid-in-capital&nbsp;&#150;&nbsp;contingent shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,837,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,837,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Paid-in-capital&nbsp;&#150;&nbsp;escrow shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accumulated other comprehensive loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(65,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(106,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accumulated deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(378,074,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(320,426,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total stockholders&#146; equity (deficit)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(15,400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>12,943,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total liabilities and stockholders&#146; equity (deficit)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>37,854,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,993,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these consolidated financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-15</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tCSOCL1"></a>AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Consolidated Statements of Operations and Comprehensive Loss </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="408"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Revenue<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Licensing revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>325,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>325,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Operating expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,502,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,480,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>General and administrative</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>6,285,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,208,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total operating expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>12,787,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,688,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Loss from operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(12,462,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,024,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Other income (expense)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Loss on derivative liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(42,317,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization of note discount</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,636,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Interest expense, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(233,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(339,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tax refund and other income</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>133,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Loss on disposal of property and equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(30,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Other income (expense), net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(45,186,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(236,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Loss from continuing operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(57,648,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(4,260,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Discontinued operations<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Gain on sale of discontinued operations assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,150,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net loss available for common stockholders</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(57,648,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(1,110,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss from continuing operations per share&nbsp;&#150;&nbsp;basic &amp; diluted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.57</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.09</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gain from discontinued operations per share&nbsp;&#150;&nbsp;basic &amp; diluted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.07</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss per share&nbsp;&#150;&nbsp;basic &amp; diluted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.57</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.02</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Weighted average number of shares of common stock outstanding&nbsp;&#150;&nbsp;basic &amp; diluted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>101,201,753</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>48,034,493</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(57,648,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,110,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Other comprehensive income (loss)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net unrealized gain (loss) on foreign currency translations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>41,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(14,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Comprehensive loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(57,607,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(1,124,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these consolidated financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-16</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tCSSE1"></a>AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Consolidated Statements of Stockholders&#146; Equity (Deficit) </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="708" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 9pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="181"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="62"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="62"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="181"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="62"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="62"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Preferred Stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=11>Common Stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Accumulated Deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Accumulated Other Comprehensive Loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Total Stockholders&#146; Equity (Deficit)</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Additional<BR> Paid-in Capital</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Balances, December 31, 2011 (Restated)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>44,908,810</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>449,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>326,080,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(319,316,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(92,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,121,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,110,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,110,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares issued for SPH<BR> Holdings</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>220,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,520,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,740,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares held in escrow for SPH Holdings</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,197,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,197,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Foreign currency translations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(14,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(14,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Balances, December 31, 2012 (Restated)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>66,908,810</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>669,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>332,806,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(320,426,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(106,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,943,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(57,648,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(57,648,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,437,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,437,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Beneficial conversion feature and warrants associated with issuance of convertible loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,635,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,635,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares issued for Intrexon</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>24,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>240,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,760,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of preferred stock from conversion of convertible loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,016,081</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of preferred stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,999,999</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>50,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Preferred shares converted to common stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,156,102</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(11,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>11,561,020</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>115,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,511,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,615,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock options exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>61,018</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares released from escrow</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>80,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(80,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of common stock for December financing</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>72,007,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>720,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>14,744,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>15,464,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Escheat shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,286</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Foreign currency translations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>41,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>41,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Balances, December 31, 2013 (Restated)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>8,859,978</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>89,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>182,535,562</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,825,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>360,825,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(378,074,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(65,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(15,400,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these consolidated financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-17</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tCSCS1"></a>AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Consolidated Statements of Cash Flows </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="408"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Cash flows from operating activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Loss from continuing operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(57,648,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(4,260,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Adjustments required to reconcile net loss from continuing operations to net cash used in operating activities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Loss on derivative liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>42,317,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares issued for technology access fee</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization of note discount and patents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,667,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>31,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrants issued as investment fees</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>759,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>82,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>60,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Loss on disposal of property &amp; equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>30,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,437,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Changes in operating assets and liabilities net of acquisitions:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>15,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>99,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tax refund</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>618,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(133,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts payable and accrued expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>210,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(458,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Prepaid expenses and other current assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(23,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accrued interest on loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>233,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>339,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash used in operating activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(6,333,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,281,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Cash flows from investing activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gain on sale of discontinued operations assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,150,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Purchases of property and equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(102,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(53,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash provided by (used in) investing activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(102,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,097,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Cash flows from financing activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds from December financing</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>16,887,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds from Preferred Series B</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Proceeds from issuance of convertible loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>950,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash provided by financing activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>25,887,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>950,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Effect of exchange rates</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>41,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net increase (decrease) in cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>19,493,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(234,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents, beginning of year</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>862,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,096,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents, end of year</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>20,355,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>862,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Supplemental schedule of non-cash financing activities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Conversion of convertible loan notes and accrued interest to Series B Convertible Preferred Stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,316,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these consolidated financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-18</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Nature of Business </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tNCFS1"></a>AmpliPhi Biosciences Corporation (the &#147;Company&#148;) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Basis of Presentation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries AmpliPhi Australia Pty Ltd, Biocontrol Limited, Genovo, Inc. (inactive), and TGCF Manufacturing Corporation (inactive). All significant intercompany accounts and transactions have been eliminated. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Use of Estimates </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cash and Cash Equivalents </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accounts Receivable </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of December 31, 2013 and December 31, 2012, management determined no allowance for doubtful accounts was required. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and Equipment </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prepaid Expenses and Other Current Assets </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prepaid and other current assets as of December 31, 2013 and December 31, 2012 consist primarily of prepaid insurance and deposits. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Goodwill </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#146;s know-how and phage libraries were acquired by the business combination described in Note 11 for $7,172,000. At December 31, 2012, goodwill in the amount of $2,381,000 has been recorded. In management&#146;s opinion, no goodwill has been impaired as of December 31, 2013 and December 31, 2012. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-19</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2011, the rights to Biocontrol Limited&#146;s patents and phage libraries were acquired by the business combination described in Note 11. At December 31, 2011, goodwill in the amount of $1,948,000 has been recorded. In management&#146;s opinion, no goodwill has been impaired as of December 31, 2013 and December 31, 2012. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patents </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2011, the rights to Biocontrol Limited&#146;s patents were acquired by the business combination described in Note 11. At December 31, 2011, patents in the amount of $493,000 have been recorded. These patents are amortized over their useful life through December 2026. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-Based Compensation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, <I>Stock Compensation</I>, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Warrants and Preferred Shares Conversion Feature Liability </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company accounts for warrants and preferred shares conversion feature with anti-dilution (&#147;down-round&#148;) provisions under the guidance of ASC 815, <I>Derivative and Hedging</I>, and Emerging Issue Task Force Statement 07-5: <I>Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock</I>, which require the warrants and the preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Fair Value of Financial Assets and Liabilities&nbsp;&#151;&nbsp;Derivative Instruments</I></B> </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value: </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Level 1&nbsp;&#151;&nbsp;quoted prices in active markets for identical assets or liabilities. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Level 2&nbsp;&#151;&nbsp;quoted prices for similar assets and liabilities in active markets or inputs that are observable. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Level 3&nbsp;&#151;&nbsp;inputs that are unobservable. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-20</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company estimates fair values of these derivatives utilizing Level 2 inputs. The Company uses the Monte Carlo valuation technique for derivatives as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, risk free rates) necessary to fair value these instruments. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Estimating fair values of derivative financial instruments, including Level 2 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Revenue Recognition </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company generates revenue from technology licenses, collaborative research arrangements and agreements to provide research and development services. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, <I>Multiple Element Arrangements</I>, which requires the Company to satisfy the following before revenue can be recognized: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The delivered items have value to the customer on a stand-alone basis; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Any undelivered items have objective and reliable evidence of fair value; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Delivery or performance is probable and within the Company&#146;s control for any delivered items that have a right of return. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company classifies advance payments received in excess of amounts earned as deferred revenue. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and Development Costs </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In Process Research &amp; Development (IPR&amp;D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with
the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&amp;D assets, for impairment at least quarterly. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#146;s IPR&amp;D were acquired by the business combination described in Note 11. At December 31, 2012, IPR&amp;D in the amount of $5,161,000 has been recorded. In management&#146;s opinion, this IPR&amp;D has not been impaired as of December 31, 2013 and December 31, 2012. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-21</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2011, the rights to Biocontrol IPR&amp;D and patents were acquired by the business combination described in Note 11. At December 31, 2011, IPR&amp;D in the amount of $7,285,000 has been recorded. In management&#146;s opinion, this IPR&amp;D has not been impaired as of December 31, 2013 and December 31, 2012. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net Loss per Common Share </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For each fiscal year reported, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B Preferred shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share were 77,490,242 shares for the year ending December 31, 2013 and
2,841,530 shares for the year ending December 31, 2012. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Recent Accounting Pronouncements </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities,
the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2. Liquidity </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has prepared the accompanying consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception, has negative operating cash flows and has an accumulated deficit of $378.1 million and $320.4 million as of December 31, 2013 and December 31, 2012, respectively. These circumstances raise substantial doubt about the Company&#146;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to
reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#146;s ability to continue as a going concern. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company believes that its current resources will only be sufficient to fund operations into the first quarter of 2015. This estimate is based on the Company&#146;s ability to manage its staffing expenses and its working capital and actual results could differ from its estimates. The Company is seeking additional financing in order to fund operations through 2015; however, the Company cannot provide assurances that it will be successful in obtaining additional financing for these periods or as needed in the future. If the Company does not raise additional funds by the first quarter of 2015, it plans to implement cost
reduction measures, such as a reduction in workforce, reducing its intellectual property prosecution, reducing other operating activities, and/or the pursuit of alternative financing transactions that would likely be on terms disadvantageous to the Company and dilutive to its shareholders. The Company could also be required to relinquish rights to its technology or product candidates or in-licensed technology on unfavorable terms, either of which would </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-22</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2. Liquidity &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">reduce the ultimate value of the technology or product candidates, or to sell assets likely at values significantly below their potential worth. If the Company is unable to secure additional capital, it may be required to cease operations, declare bankruptcy or otherwise wind up its business. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">3. Property and Equipment </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and equipment consist of the following: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Furniture and equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>618,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>527,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Less: accumulated depreciation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(473,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(391,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total furniture and equipment, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>145,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>136,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Depreciation expense totaled $82,000 and $60,000 for the years ended December 31, 2013 and 2012, respectively. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2012, the Company sold or disposed of certain property and equipment no longer used as a result of the reprioritization of its business priorities. The Company recognized a net loss of $30,000 on the disposal of property and equipment in the consolidated statements of operations for the year ended December 31, 2012. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">4. Income Taxes </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Significant components of our US and UK deferred tax assets and liabilities were as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="354"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred tax assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net operating loss carry-forwards</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>60,765,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>57,774,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and orphan drug credit carry-forwards</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,700,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,297,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation and amortization</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(4,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Restructure and other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,121,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>467,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gross deferred tax assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>65,582,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>62,540,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Valuation allowance for deferred tax assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(65,582,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(62,540,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net deferred tax asset</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The change in the valuation allowance was a $3.0 million increase in 2013 and a $5.5 million decrease in 2012. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At December 31, 2013, the Company had US and UK net operating loss carry-forwards, or &#147;NOLs&#148;, of approximately $175.4 million and research tax credit carry-forwards of approximately $3.7 million. The carry-forwards began to expire in 2012, and may be further subject to the application of Section 382 of the Internal Revenue Code of 1986 or the &#147;Code&#148;, as discussed further below. The Company has provided a valuation allowance to offset the deferred tax assets due to the uncertainty of realizing the benefits of the net deferred tax asset. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s past sales and issuances of stock have likely resulted in ownership changes as defined by Section 382 of the Code. A study has not been done at this time because the full valuation allowance eliminating potential profit and loss adjustments due to changes in the gross amount of the NOLs and credits would be offset by a change in the valuation allowance. It is possible that a future analysis may result in the conclusion that a substantial portion, or perhaps substantially all, of the NOLs and credits will expire due to </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-23</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">4. Income Taxes &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">the limitations of Sections 382 and 383 of the Code. As a result, the utilization of the NOLs and tax credits may be limited and a portion of the carry-forwards may expire unused. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company does not have any material unrecognized tax benefits as of December 31, 2013. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company is subject to income taxes in the U.S. federal jurisdiction as well as in the United Kingdom for any activity of Biocontrol Ltd and in Australia for any activity of Special Phage Holdings Pty Ltd. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company is subject to U.S. federal tax examinations by tax authorities for the years 1998 to 2012 due to the fact that NOLs exist going back to 1998 that may be utilized on a current or future year tax return. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has a policy of recognizing tax related interest and penalties as additional tax expense. During the years ended December 31, 2013, and 2012 the Company did not recognize any interest and penalties. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">5. Commitments and Contingencies </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As part of the acquisition of SPH Holdings Pty Ltd (Note 11), the Company paid $100,000 and issued an additional 2,000,000 shares of common stock to Cellabs Pty Ltd (Cellabs) as part of a repayment agreement for its outstanding loans to SPH Holdings Pty Ltd. In January 2013, the Company paid an additional $50,000 to Cellabs. The remaining loan balance of $200,000 was paid in December 2013. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In February 2011, the Company entered into an agreement with Virginia Biotechnology Research Partnership Authority for Richmond, Virginia laboratory space. This agreement had a contractual expiration date of February 29, 2012 at which time it converted to a rolling three-month lease. At December 31, 2013, the Company&#146;s minimum payment commitment for the Company&#146;s Richmond, Virginia laboratory space was $4,800. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In December 2011, the Company entered into an agreement with Nevis Limited and Charter Limited for laboratory space in Bedfordshire, United Kingdom. This agreement has a minimum period of 3 years and a contractual expiration date of December 8, 2016. At December 31, 2013, the Company&#146;s minimum payment commitment for the Company&#146;s Bedfordshire laboratory space was $127,000. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In February 2013, the Company entered into an agreement with Office Suites Plus (now Regus Management Group, LLC) for office space in Glen Allen, Virginia. The agreement has a minimum period of one year ending February 28, 2014, at which time it was extended through June 2014, with a monthly cost of $2,555. At December 31, 2013, our minimum payment commitment for the Glen Allen space was $5,110. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In September 2013, the Company entered into an agreement with PBC Carlsbad, LLC for office space in Carlsbad, California. The agreement has a minimum period of six months ending February 28, 2014, at which time it was extended through August 2014, with a monthly cost of $1,033. At December 31, 2013, our minimum payment commitment for the Carlsbad office space was $2,066. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company recognized rent expense under operating leases of $214,000 in 2013 and $146,000 in 2012. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company is subject to legal claims and actions related to the operations of its business. The Company does not expect the ultimate outcome of any such actions to have a material impact on its consolidated financial position or results of operations. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">6. Collaborative and Other Agreements </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2013, the Company entered into a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-24</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">6. Collaborative and Other Agreements &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Walter Reed Army Institute of Research (WRAIR). The CRADA will focus on developing and commercializing bacteriophage therapeutics to treat <I>S. aureus</I>, <I>E. coli</I> and <I>P. aeruginosa</I> infections. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2013, the Company entered into an Exclusive Channel Collaboration Agreement with Intrexon Corporation. This agreement allows the Company to utilize Intrexon&#146;s synthetic biology platform for the identification, development and production of bacteriophage-containing human therapeutics. The Company paid a one-time technology access fee to Intrexon of $3,000,000 in common stock. The Company shall pay Intrexon, in cash or stock, milestone fees for the initiation of a Phase 2 trial of $2,500,000 upon commencement of the first Phase 2 trial and $5,000,000 upon the first regulatory approval of any product in any major
market country. With regard to each product sold by the Company, the Company will pay, in cash, tiered royalties on a quarterly basis based on net sales of AmpliPhi Products, calculated on a product-by-product basis. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">7. Preferred Shares </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 13, 2013, the Company&#146;s Board of Directors approved a resolution designating 10,016,080 shares of Preferred Stock as Series B Convertible Preferred Stock with an initial stated value of $1.40 and par value of $0.01. Each Series B preferred share is convertible into 10 shares of common stock and is entitled to the number of votes equal to the number of shares of common stock. These Series B shares may be converted to common stock by the holder of the shares at any time. The Series B shares shall be automatically converted into common shares upon the closing of an underwritten initial public offering with aggregate
proceeds to the Company of at least $7 million and a price per share to the public of at least the Series B stated value upon the closing of which the shares of common stock of the Company shall be listed for trading on the New York Stock Exchange. Until conversion, the holders of Series B Preferred shares shall be entitled to receive dividends of 10% of the Series B stated value per annum. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the private placement of Series B Convertible Preferred Stock, the Company recorded a liability for a complex embedded derivative that required bifurcation under ASC Section 815. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with a down-round ratchet provision. The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013 (dates of issuance) and recorded the initial liability as part of the private
placement proceeds.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 26, 2013, the Company issued 4,999,999 shares of the Company&#146;s newly-created Series B Convertible Preferred Stock and warrants that would each be used to purchase 12,499,996 shares of common stock at an exercise price of $0.14 per share for an aggregate purchase price of $7.0 million. The value of the derivative liability related to the warrants was $1,886,000 and the value of the derivative liability related to the preferred shares was $5,064,000. As part of the same transaction, the Company converted $5,491,000 in outstanding convertible loan notes (principal and interest) into 4,357,936 shares of Series B
Convertible Preferred Stock and warrants to purchase 10,894,839 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $1,644,000 and the value of the derivative liability related to the preferred shares was $3,804,000. As part of this issuance, the Company issued warrants to purchase 4,999,999 shares of common stock at an exercise price of $0.14 per share with an initial fair value of $759,000 and paid $350,000 to the placement agents. As a result of this financing, all outstanding convertible notes were converted into shares of Series B Convertible Preferred Stock and warrants to purchase common stock. On July 15, 2013, the remaining outstanding convertible loan notes, totaling $829,277 in principal and interest, were converted into 658,145 shares of Series B Convertible Preferred Stock and warrants to purchase 1,645,361 shares of common stock at an exercise price of $0.14 per share. The value of the
derivative liability related to the warrants was $674,000 and the value of the derivative liability related to the preferred shares was $155,000. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-25</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">7. Preferred Shares &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On July 25, 2013, 1,132,875 preferred shares were converted into 11,328,750 shares of common stock. In connection with the conversion, a loss on derivative of $5,035,000 was recorded in relation to the conversion. $6,518,000 was reclassified from the derivative liability to equity due to conversion. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On October 17, 2013, 23,227 preferred shares were converted into 232,270 shares of common stock. In connection with the conversion, a gain on the derivative liability was recorded in the amount of $5,000. Due to this conversion, $97,000 was reclassified out of the derivative liability account and into equity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company re-measured the fair value of the conversion feature and recorded $32,035,000 in total charges to record the liabilities associated with the conversion feature at their estimated fair value totaling $34,443,000 as of December 31, 2013. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">8. Stock Options and Warrants </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company follows ASC 815-40, <I>Contracts in an Entity&#146;s Own Equity</I>, as it relates to outstanding warrants. No warrants were exercised through December 31, 2013. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the December 2013 private placement of 72,007,000 shares of the Company's common stock at a price per share of $0.25, the Company issued an aggregate of warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share to the placement agents. These warrants expire December 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company&#146;s common stock (&#147;down-round&#148; provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In connection with the private placement of Series B Convertible Preferred Stock, which occurred through two closings on June 26, 2013 and July 15, 2013, respectively, the Company issued an aggregate of warrants to purchase 30,040,194 shares of common stock at an exercise price of $0.14 per share. These warrants expire June 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company&#146;s common stock (&#147;down-round&#148; provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. The
Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds and expensed $759,000 for the warrants issued to the placement agent. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="258"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>June 26,<BR> 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>July 15,<BR> 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>December 23,<BR> 2013</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Warrants issued</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>28,394,834</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>1,645,360</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>4,320,420</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Risk free interest rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>.0109</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>.0109</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0.0167</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Volatility</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>160.94&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>163.08&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>155.24&#37;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected term</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>5 years</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>5 years</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>5 years</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercise price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0.14</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0.14</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0.25</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company re-measured the fair value of these warrants and recorded $10,282,000 in charges to record the liabilities associated with these warrants at their estimated fair values totaling $16,664,000 as of December 31, 2013. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants to purchase up to 7,030,387 shares of its common stock. These warrants expire February through May 2018 and are exercisable at a price of $0.14 per share. These warrants are considered to be equity. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-26</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">8. Stock Options and Warrants &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On December 22, 2011, in connection with the Biocontrol business combination, the Company issued warrants to purchase up to 1,355,164 shares of its common stock. These warrants expire in December 2016 and are exercisable at a price of $0.46 per share. These warrants are considered to be equity. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-Based Compensation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s Stock Incentive Plan provides for the issuance of long-term incentive awards, or awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The awards may be granted by the Company&#146;s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the date of
grant and generally vest and become exercisable over a four-year period following the date of grant. Every non-employee member of the Company&#146;s Board of Directors receives an annual non-qualified Option or restricted stock unit grant. Upon the exercise of Options, the Company issues the resulting shares from shares reserved for issuance under the Company&#146;s Incentive Plan. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under ASC 718, <I>Stock Compensation,</I> the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company&#146;s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company&#146;s estimates for the year ended December 31, 2013 and year ended December 31, 2012. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive loss: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="354"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Year Ended<BR> December 31,<BR> 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Year Ended<BR> December 31,<BR> 2012</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock options:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>191,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>General and administrative expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,246,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Restricted stock units:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>General and administrative expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total stock-based compensation expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,437,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>9,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-27</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">8. Stock Options and Warrants &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table summarizes Option activity: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="280"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted Average Exercise Price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Average Remaining Contractual Term (Years)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Intrinsic<BR> Value</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding at December 31, 2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13,749,552</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.21</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,350,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.18</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(91,677</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Forfeited</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(284,375</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Expired</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(2,500</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>5.70</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding at December 31, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,721,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.19</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9.15</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,451,441</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercisable at December 31, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,619,584</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.19</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9.15</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,776,669</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The aggregate intrinsic value is determined using the closing price of the Company&#146;s common stock of $0.50 on December 31, 2013. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2013, the Company had unrecognized compensation cost related to unvested Options of approximately $2,219,000 net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately three years. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The fair value of each Option is estimated on the date of grant using the Black-Scholes valuation method with the key inputs as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Risk-free interest rate</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.13</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.6</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected volatility</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>160.9</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>172.1</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected term (in years)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Expected dividend yield</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Reserved Shares </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of October 20, 2014, the Company had reserved shares of its common stock for future issuance as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="434"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="104"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares Reserved</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock options outstanding</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>25,721,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Available for future grants under the Stock Incentive Plan</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,658,083</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Warrants</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>42,746,165</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Total Shares reserved </TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>79,125,248</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">9. Discontinued Operations </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2012, the Company sold all of its assets used in its gene therapy business including process development, quality control, quality assurance, manufacturing and bioanalytical functions for $3.0 million. In addition to this cash consideration, the Company may receive a long term royalty of 1.75% on certain product sales. This royalty may be completely canceled at any time by a one-time payment of $1.75 million. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">10. Employee Retirement Plan </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company sponsors an employee retirement plan under Section 401(k) of the Internal Revenue Code of 1986, as amended. All of the Company&#146;s employees who meet minimum eligibility requirements are eligible to participate in the plan. Matching contributions to the 401(k) plan are made at the discretion of the Company&#146;s Board of Directors. The Company suspended matching contributions effective January 1, 2009. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-28</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">11. Business Combinations </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On November 9, 2012, the Company acquired Australia-based Special Phage Services (&#147;SPS&#148;). The acquisition of SPS primarily focused on IPR&amp;D being performed on <I>S. aureus</I> infections, which is currently being developed under AmpliPhage-002: Wound and Skin Infections Caused by <I>S. aureus. </I></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In a share exchange transaction, AmpliPhi Australia Pty Limited, a wholly owned subsidiary of US-based AmpliPhi, acquired Sydney-based SPH, the holding company of SPS. Under the terms of the acquisition, the Company offered 40 million shares of its common stock in exchange for 100% of the fully diluted share capital of SPH. 20 million shares are held in escrow, 8 million to satisfy potential warranty claims under the transaction documents and the remaining 12 million shares are held pending completion of certain milestones. At December 31, 2012, IPR&amp;D in the amount of $5,161,000 and goodwill in the amount of $2,381,000
have been recorded. In management&#146;s opinion, this IPR&amp;D and goodwill have not been impaired as of December 31, 2013 and December 31, 2012. As part of this transaction, the Company acquired $260,000 in assets to include a $221,000 receivable for an Australian research and development tax refund, $37,000 in equipment, and $2,000 in cash. The Company also assumed liabilities of $613,000. On November 9, 2013, the 8 million shares held to satisfy potential warranty claims were released. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On January 6, 2011, the Company acquired Biocontrol, a clinical development stage biotechnology company in the United Kingdom (the &#147;Acquisition&#148;). The acquisition of Biocontrol included an IPR&amp;D project related to AmpliPhage-001: Lung Infections in Cystic Fibrosis (CF) Patients Caused by <I>P. aeruginosa. </I></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company acquired 100% of the voting stock of Biocontrol and issued 22,817,198 shares of its common stock to the Biocontrol shareholders with a total fair value of approximately $8.6 million as of January 6, 2011. The Acquisition was made through an acquisition subsidiary, which has continued post-Acquisition as Biocontrol. At December 31, 2011, IPR&amp;D in the amount of $7,285,000, goodwill in the amount of $1,948,000, and patents in the amount of $493,000 have been recorded. In management&#146;s opinion, this IPR&amp;D and goodwill have not been impaired as of December 31, 2013 and December 31, 2012. The patents are
being amortized over their useful life through December 2026. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">12. Convertible Loan Notes </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On February 1, 2013, the Company&#146;s Board of Directors approved the issuance of new convertible promissory notes in an aggregate principal amount not to exceed $7,500,000, together with warrants to purchase shares of common stock of the Company. Interest on the unpaid principal balance of these notes shall accrue from the investment date at the rate of ten percent (10%) per annum. The warrants have the right to purchase the number of shares of the Company&#146;s common stock equal to twenty five percent (25%) of the principal amount of such holder&#146;s note divided by $0.14. The company issued $2,000,000 in new
convertible loan notes from February through May 2013, converted $1,900,000 of previous convertible loan notes and accrued interest into this new security, and issued warrants for 7,030,387 share of common stock. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a result of the private placement of Series B Convertible Preferred Stock that consisted of two closings, occurring on June 26, 2013 and July 15, 2013, respectively, all outstanding convertible notes were converted into shares of Series B Convertible Preferred Stock and warrants to purchase shares of common stock at an exercise price of $0.14 per share. On June 26, 2013, as part of the first closing, the Company converted $5,491,001 in outstanding convertible loan notes into 4,357,936 shares of Series B Convertible Preferred Stock and warrants to purchase 10,894,839 shares of common stock at an exercise price of $0.14 per
share. On July 15, 2013, the remaining outstanding convertible loan notes, totaling $829,277, were converted into 658,145 shares of Series B Convertible Preferred Stock and warrants to purchase 1,645,361 shares of common stock at an exercise price of $0.14 per share. $233,000 of interest expense was accrued for all convertible loan notes held through July 15, 2013. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-29</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR> &nbsp;<BR>Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2013 (Audited) </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">13. Related Parties </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the years ended December 31, 2013 and December 31, 2012, $110,000 and $30,000, respectively, were recognized in General and Administrative expenses for management and accounting consultancy fees provided by two shareholders. The Company shares resources in the new Australian operations such as facility space, electricity, insurance, and equipment with Cellabs, owned by a shareholder, and receives a quarterly invoice for these services. The total expense for these services for the year ended December 31, 2013 was $70,000 and for December 31, 2012 was $6,000. As part of the acquisition of SPH (Note 11), the Company also
entered into a loan repayment agreement with Cellabs (Note 5) which was paid in full during 2013. As of December 31, 2013 and December 31, 2012, $152,000 and $562,000, respectively, of current liabilities are due to related parties.</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">14. Correction of Errors </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s previously issued December 31, 2013 financial statements have been restated to remove deemed dividends booked on the issuance of preferred shares and to recognize the increase in derivative expense due to adding several features to the valuation model used to measure the compound derivatives and changing from a Black-Scholes valuation model to a Monte Carlo valuation model. Additional paid in capital and accumulated deficit have been reduced by $8,464,000 after removing the deemed dividends. Loss on derivative liabilities increased by $1,755,000 to $42,317,000 due to the change in the valuation model. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company also contracted a valuation team to review the purchase price allocation of Biocontrol. As a result, in process research and development (IPR&amp;D) was restated and a new intangible asset, patents, was recognized. For the Biocontrol acquisition, $493,000 of IPR&amp;D was reclassed to patents. In addition, amortization expense for patents of $31,000 was recognized in both 2012 and 2013. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a result of these corrections, the Company&#146;s net loss in 2013 increased $1,787,000 to $57,648,000. The net loss per share decreased by $0.07 per share to $(0.57) per share which also reflects the removal of the deemed dividends. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">15. Common Stock </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In December 2013, the Company issued 72,007,000 shares of the Company's common stock at a price per share of $0.25. As part of this private placement, the Company issued warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share with an initial fair value of $1,442,000 and paid $1,115,000 to the placement agents. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">16. Subsequent Events </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On February 11, 2014, the Company held a special meeting of shareholders at which the shareholders approved the planned reincorporation of the Company as a Delaware corporation, a reverse stock split in a ratio at least one-for-five and up to one-for-twenty (with the timing and specific ratio to be determined by the board of directors and to be effected prior to the reincorporation), the execution of indemnification agreements with the Company&#146;s directors and certain officers, and the adoption of the Company&#146;s 2013 Stock Incentive Plan (pursuant to which 39,250,000 shares of common stock are reserved for issuance,
before giving effect to the reverse stock split).</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-30</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tRAR"></a>INDEPENDENT AUDITOR'S REPORT</H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To the Board of Directors and Shareholders<BR>AmpliPhi Biosciences Corporation and Subsidiaries<BR>Richmond, Virginia</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have audited the accompanying consolidated balance sheets of AmpliPhi Biosciences Corporation and Subsidiaries (the Company) as of December 31, 2012 and 2011, and the related consolidated statements of operations and comprehensive loss, stockholders' equity (deficit), and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of AmpliPhi Biosciences Corporation and Subsidiaries as of December 31, 2012 and 2011, and the results of their operations and their cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has had recurring losses from operations and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As discussed in Note 12 to the consolidated financial statements, the 2012 and 2011 consolidated financial statements have been restated to correct a misstatement.</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">/s/ PBMares, LLP</P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Richmond, Virginia<BR>October 28, 2013, except for note 12 as to which date is September 2, 2014 </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-31</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tCBSD"></a>AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Consolidated Balance Sheets </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="408"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2011</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Current assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>862,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,096,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>23,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>122,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tax refund</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>618,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Prepaid expenses and other current assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>148,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>150,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total current assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,651,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,618,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Property and equipment, net of accumulated depreciation of $391,000 and $268,000 as of December 31, 2012 and December 31, 2011, respectively</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>136,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>138,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Intangible Assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>In process research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12,446,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,285,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Goodwill</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,329,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,948,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Patent, net of accumulated amortization of 62,000 and 31,000 as of December 31, 2012 and 2011, respectively</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>431,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>462,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total intangible assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>17,206,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>9,695,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,993,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>11,451,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Liabilities and stockholders&#146; equity<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Current liabilities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Convertible loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,648,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts payable and accrued expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,937,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,506,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accrued interest</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>465,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total current liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>6,050,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,506,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Long term liabilities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Convertible loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,698,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accrued interest</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>126,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total long term liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,824,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>6,050,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,330,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Commitments and Contingencies (Note 5)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Stockholders&#146; equity<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Preferred stock, $0.01 par value, 10,000,000 shares authorized; none issued and outstanding</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Common stock, $0.01 par value, 445,000,000 shares authorized, 66,908,810 shares issued and outstanding at December 31, 2012 and 44,908,810 shares issued and outstanding at December 31, 2011</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>669,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>449,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Additional paid-in capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>329,609,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>326,080,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Paid-in-capital&nbsp;&#150;&nbsp;Contingent shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,837,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Paid-in-capital&nbsp;&#150;&nbsp;Escrow shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,360,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accumulated other comprehensive loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(106,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(92,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accumulated deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(320,426,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(319,316,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total stockholders&#146; equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>12,943,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7,121,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total liabilities and stockholders&#146; equity</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>18,993,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>11,451,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these consolidated financial statements.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-32</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tCSOD"></a>AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Consolidated Statements of Operations and Comprehensive Loss </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="424"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2011</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Revenue<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Licensing revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>120,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>664,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>120,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Operating expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,480,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>707,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>General and administrative</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,208,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,357,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total operating expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,688,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>4,064,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Loss from continuing operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,024,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(3,944,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Other income (expense)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Interest expense, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(339,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(128,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tax refund and other income</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>133,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>264,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Loss on disposal of assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(30,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(10,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Other income (expense), net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(236,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>126,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net loss from continuing operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,260,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(3,818,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Discontinued Operations<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Gain on sale of discontinued operations assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,150,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net Loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(1,110,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(3,818,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss from continuing operations per share&nbsp;&#150;&nbsp;basic &amp; diluted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.09</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.09</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gain from discontinued operations per share&nbsp;&#150;&nbsp;basic &amp; diluted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.07</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss per share&nbsp;&#150;&nbsp;basic &amp; diluted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.02</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(0.09</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Weighted average number of shares of common stock outstanding&nbsp;&#150;&nbsp;basic &amp; diluted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>48,034,493</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>44,564,027</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Other comprehensive loss<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net unrealized foreign currency translations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(14,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(92,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Comprehensive loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(1,124,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(3,910,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these consolidated financial statements.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-33</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tCSSD"></a>AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Consolidated Statements of Stockholders&#146; Equity (Deficit) </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="157"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Common Stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Additional Paid-in Capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Accumulated Deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Accumulated Other Comprehensive Loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Total Stockholders&#146; Equity</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Balances, December 31,<BR> 2010</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,004,503</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>220,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>317,641,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(315,498,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,363,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(3,818,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(3,818,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>85,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>85,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares issued for Biocontrol</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,817,198</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>228,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,355,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,583,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Vested restricted stock units, net of 10,560 shares withheld for taxes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>87,109</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Foreign currency translations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(92,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(92,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Balances, December 31,<BR> 2011 (Restated)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>44,908,810</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>449,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>326,080,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(319,316,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(92,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,121,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,110,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,110,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares issued for SPH Holdings</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,000,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>220,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,520,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,740,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares held in escrow for SPH Holdings</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,197,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,197,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Foreign currency translations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(14,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(14,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Balances, December 31,<BR> 2012 (Restated)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>66,908,810</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>669,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>332,806,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(320,426,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(106,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>12,943,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these consolidated financial statements.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-34</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tCSCD"></a>AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Consolidated Statements of Cash Flows </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="424"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year Ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2011</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(RESTATED)</FONT></TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Cash flows from operating activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Loss from continuing operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(4,260,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(3,818,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Adjustments required to reconcile net loss to net cash (used in) provided by operating activities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>60,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>80,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization of Patents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>31,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>31,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Loss on disposal of property and equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>30,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>85,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Changes in operating assets and liabilities net of acquisitions:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>99,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>157,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tax refund</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(133,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(250,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts payable and accrued expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(458,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,001,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Prepaid expenses and other current assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(85,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accrued interest on loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>339,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>126,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash used in operating activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,281,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(4,665,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Cash flows from investing activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gain on sale of discontinued operations assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,150,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Purchases of property and equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(53,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(106,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash provided by (used in) investing activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,097,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(106,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Cash flows from financing activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Proceeds from issuance of convertible loan notes</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>950,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,492,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash provided by financing activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>950,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2,492,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net increase (decrease) in cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(234,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2,279,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents, beginning of year</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,096,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3,375,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents, end of year</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>862,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,096,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>The accompanying notes are an integral part of these consolidated financial statements.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-35</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Nature of Business </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tNCFSD"></a>AmpliPhi Biosciences Corporation (the &#147;Company&#148;) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Basis of Presentation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Ampliphi Australia Pty Ltd, Biocontrol Limited, Genovo, Inc. (inactive), and TGCF Manufacturing Corporation (inactive). All significant intercompany accounts and transactions have been eliminated. All numbers on the financial statements and disclosures have been rounded to the nearest 1,000. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Use of Estimates </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cash and Cash Equivalents </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Restricted Cash </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company maintains a cash account for the payment of employee wages through HR Novations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accounts Receivable </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of December 31, 2012 and 2011, management determined no allowance for doubtful accounts was required. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and Equipment </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prepaid Expenses and Other Current Assets </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prepaid and other current assets as of December 31, 2012 and 2011 consist primarily of prepaid insurance and deposits. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Goodwill </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-36</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#146;s know-how and phage libraries were acquired by the business combination described in Note 9 for $7,172,000. At December 31, 2012, goodwill in the amount of $2,381,000 has been recorded. In management&#146;s opinion, no goodwill has been impaired as of December 31, 2012. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2011, the rights to Biocontrol Limited&#146;s patents and phage libraries were acquired by the business combination described in Note 9 for $8,584,000. At December 31, 2011, goodwill in the amount of $1,948,000 has been recorded. In management&#146;s opinion, no goodwill has been impaired as of December 31, 2012 and December 31, 2011. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patents </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2011, the rights to Biocontrol Limited&#146;s patents were acquired by the business combination described in Note 9. At December 31, 2011, patents in the amount of $493,000 have been recorded. These patents are amortized over their useful life through December 2026. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and Development Costs</H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In Process Research &amp; Development (IPR&amp;D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with
the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&amp;D assets, for impairment at least quarterly.</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#146;s IPR&amp;D were acquired by the business combination described in Note 9. At December 31, 2012, IPR&amp;D in the amount of $5,161,000 has been recorded. In management&#146;s opinion, this IPR&amp;D has not been impaired as of December 31, 2012. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2011, the rights to Biocontrol IPR&amp;D and patents were acquired by the business combination described in Note 9 for $8,584,000. At December 31, 2011, IPR&amp;D in the amount of $7,285,000 has been recorded. In management&#146;s opinion, this IPR&amp;D has not been impaired as of December 31, 2012 and December 31, 2011. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-Based Compensation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718-10, <I>Stock Compensation</I>, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Revenue Recognition </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company generates revenue from technology licenses, collaborative research arrangements and agreements to provide research and development services. Revenue under technology licenses typically </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-37</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, <I>Multiple Element Arrangements</I>, which requires the Company to satisfy the following before revenue can be recognized: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The delivered items have value to the customer on a stand-alone basis; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Any undelivered items have objective and reliable evidence of fair value; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Delivery or performance is probable and within the Company&#146;s control for any delivered items that have a right of return. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company classifies advance payments received in excess of amounts earned as deferred revenue. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net Loss per Common Share </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For each fiscal year reported, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants and contingent shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share were 2,841,530 shares for the year ending December 31, 2012. For the year ending December 31,
2011, there were no dilutive shares. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Recent Accounting Pronouncements </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In September 2011, the FASB issued Accounting Standards Update (ASU) no. 2011-08, Intangibles &#151; Goodwill and Other (Topic 350): Testing Goodwill for Impairment that simplifies how public and nonpublic entities test goodwill for impairment. The amendments permit an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test described in FASB Accounting Standards Codification Topic 350. The more-likely-than-not threshold is
defined as having a likelihood of more than 50%. The guidance also includes examples of the types of events and circumstances to consider in conducting the qualitative assessment. The amendments will be effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. The Company elected to early adopt this standard and used these new guidelines in assessing goodwill impairment for the consolidated financial statements. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities,
the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-38</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities,
the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2. Liquidity </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has prepared the accompanying consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception, has negative operating cash flows and has an accumulated deficit of $320.4 million as of December 31, 2012. These circumstances raise substantial doubt about the Company&#146;s ability to continue as a going concern. The Company&#146;s cash balance as of December 31, 2012 was $862,000, the receivables balance was $641,000 and the current
liabilities were $6,050,000. $4,113,000 of the current liabilities are the convertible loan notes and accrued interest that may be converted to another security and extend the maturity date. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#146;s ability to continue as a going concern. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company believes that its current resources, in addition to the revenue received in February and March 2013 detailed in the Subsequent Events disclosure (Note 13), will only be sufficient to fund operations into the second quarter of 2013. This estimate is based on the Company&#146;s ability to manage its staffing expenses and its working capital and actual results could differ from its estimates. The Company is seeking additional financing in order to fund operations through 2013; however, the Company cannot provide assurances that it will be successful in obtaining additional financing for these periods or as needed in
the future. If the Company does not raise additional funds by the second quarter of 2013, it plans to implement cost reduction measures, such as a reduction in workforce, reducing its intellectual property prosecution, reducing other operating activities, and/or the pursuit of alternative financing transactions that would likely be on terms disadvantageous to the Company and dilutive to its shareholders. The Company could also be required to relinquish rights to its technology or product candidates or in-licensed technology on unfavorable terms, either of which would reduce the ultimate value of the technology or product candidates, or to sell assets likely at values significantly below their potential worth. If the Company is unable to secure additional capital, it may be required to cease operations, declare bankruptcy or otherwise wind up its business. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-39</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">3. Property and Equipment </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and equipment consist of the following: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="402"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2011</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Furniture and equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>527,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>406,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Less: accumulated depreciation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(391,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(268,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total furniture and equipment, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>136,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>138,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Depreciation expense totaled $60,000 and $80,000 for the years ended December 31, 2012 and 2011, respectively. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the periods ending December 31, 2012 and 2011, the Company sold or disposed of certain property and equipment no longer used as a result of the reprioritization of its business priorities. The Company recognized net losses of $30,000 and $10,000 on the disposal of property and equipment in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2012 and 2011, respectively. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">4. Income Taxes </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">At December 31, 2012, the Company had US and UK net operating loss carry-forwards, or NOLs, of approximately $170.4 million and research tax credit carry-forwards of approximately $4.3 million. The carry-forwards began to expire in 2012, and may be further subject to the application of Section 382 of the Code, as discussed further below. The Company has provided a valuation allowance to offset the deferred tax assets due to the uncertainty of realizing the benefits of the net deferred tax asset. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Significant components of our US deferred tax assets and liabilities were as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="354"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2011</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deferred tax assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net operating loss carry-forwards</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>57,774,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>62,391,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Capital loss carry-forwards</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>109,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and orphan drug credit carry-forwards</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,297,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,847,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation and amortization</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>53,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Restructure and other</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>467,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>666,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Gross deferred tax assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>62,540,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>68,066,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Valuation allowance for deferred tax assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(62,540,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(68,066,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net deferred tax asset</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The change in the valuation allowance was a $5.5 million decrease in 2012 and a $3.9 million decrease in 2011. All of the capital losses generated by the sale of CellExSys and Chromos have expired as of 2012. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The past sales and issuances of stock have likely resulted in ownership changes as defined by Section 382 of the Code. A study has not been done at this time because the full valuation allowance eliminating potential profit and loss adjustments due to changes in the gross amount of the NOLs and credits would be offset by a change in the valuation allowance. It is possible that a future analysis may result in the conclusion that a substantial portion, or perhaps substantially all, of the NOLs and credits will expire due to the limitations of Sections 382 and 383 of the Code. As a result, the utilization of our net operating
losses and tax credits may be limited and a portion of the carry-forwards may expire unused. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company adopted the provisions of ASC 740, <I>Income Taxes</I>, the successor of FASB Interpretation 48, Accounting for Uncertainty in Income Taxes, or FIN 48, on January 1, 2007. Previously, the Company had accounted for tax contingencies in accordance with ASC 450, <I>Contingencies</I>, the successor of </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-40</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">4. Income Taxes &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SFAS 5,<I> Accounting for Contingencies</I>. As required by FIN 48, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. At the adoption date, the Company applied FIN 48 to all tax positions for which the statute of limitations
remained open. The Company does not have any material unrecognized tax benefits as of December 31, 2012. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company is subject to income taxes in the U.S. federal jurisdiction as well as in the United Kingdom for any activity of Biocontrol Ltd and in Australia for any activity of Special Phage Holdings Pty Ltd. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. With few exceptions, the Company is no longer subject to U.S. federal tax examinations by tax authorities for the years before 2009. However, tax years from 1998 to 2008 may be subject to examination in the event that the Company utilizes the NOLs from those years in
our current or future year tax returns. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has a policy of recognizing interest and penalties accrued related to unrecognized tax benefits as additional tax expense for all periods presented. During the years ended December 31, 2012 and 2011 the Company did not recognize any interest and penalties. The Company has not accrued any interest and penalties at December 31, 2012 and December 31, 2011. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the year ending December 31, 2012, the Company had a UK research and development tax refund of $135,000 (&#163;85,000) for the losses in the UK subsidiary and an Australian research and development tax refund of $221,000 (USD) for the losses in the Australian subsidiary. The Company also has a 2011 UK research and development tax refund as of December 31, 2012 of $262,000 which was received in January 2013. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">5. Commitments and Contingencies </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As part of the acquisition of SPH Holdings Pty Ltd (Note 9), the Company paid $100,000 and issued an additional 2,000,000 shares of common stock to Cellabs Pty Ltd (Cellabs) as part of a repayment agreement for its outstanding loans to SPH Holdings Pty Ltd. In July 2013, the Company will pay an additional $50,000 to Cellabs. The remaining loan balance of $200,000 will be repaid either by 10% of any proceeds received by the Company until Cellabs has received $200,000, or, starting in May 2014; the Company shall pay the remaining balance in monthly installments equal to the lesser of $10,000 or the amount remaining unpaid at the
time of payment. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In February 2011, the Company entered into an agreement with Virginia Biotechnology Research Partnership Authority for Richmond, Virginia laboratory space. This agreement has a contractual expiration date of February 29, 2012 at which time it converted to a rolling three-month lease. At December 31, 2012, the Company&#146;s minimum payment commitment for the Company&#146;s Richmond, Virginia laboratory space was $4,800. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In December 2011, the Company entered into an agreement with Nevis Limited and Charter Limited for laboratory space in Bedfordshire, United Kingdom. This agreement has a minimum period of 3 years and a contractual expiration date of December 8, 2016. At December 31, 2012, the Company&#146;s minimum payment commitment for the Company&#146;s Bedfordshire laboratory space was $266,000. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company recognized rent expense under operating leases of $146,000 in 2012 and $148,000 in 2011. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company is subject to legal claims and actions related to the operations of its business. The Company does not expect the ultimate outcome of any such actions to have a material impact on its consolidated financial position or results of operations. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-41</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">6. Stock Options and Warrants </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On December 22, 2011, in connection with the Biocontrol business combination in Note 9, the Company issued warrants to purchase up to 1,355,164 shares of its common stock. These warrants expire in December 2016 and are exercisable at a price of $0.46 per share. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On June 27, 2007, in connection with a private placement, the Company issued additional warrants to purchase up to 7.6 million shares of its common stock. These warrants were to originally expire in June 2012 and were originally exercisable at a price of $3.25 per share. The Company also issued a warrant to purchase 334,989 shares of its common stock, with the same terms as those issued pursuant to this private placement, as compensation to the placement agent in this transaction. In connection with the acquisition of Biocontrol Limited (see Note 9), and in return for suspension or waiver of certain provisions within the June
27, 2007 warrant agreements, the Company modified these warrant agreements in November 2010. The exercise price of the warrants was reset to $1.50 per share and the warrants now expire in June 2013. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On January 11, 2007, in connection with a private placement, the Company issued warrants to purchase up to 763,000 shares of its common stock. These warrants expired in January 2012. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company follows ASC 815-40, <I>Contracts in an Entity&#146;s Own Equity</I>, as it relates to outstanding warrants. All of the Company&#146;s outstanding warrants are considered to be equity under this guidance. No warrants were exercised in 2012 or 2011. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-Based Compensation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s Stock Incentive Plan provides for the issuance of long-term incentive awards, or Awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The Awards may be granted by the Company&#146;s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the date of
grant and generally vest and become exercisable over a four-year period following the date of grant. Restricted stock units generally vest over a three-year period following the date of grant. Every non-employee member of the Company&#146;s Board of Directors receives an annual non-qualified Option or restricted stock unit grant. Upon the exercise of Options and the vesting of restricted stock units, the Company issues the resulting shares from shares reserved for issuance under the Company&#146;s Incentive Plan. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under ASC 718-10, <I>Share-Based Payment</I>, the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718-10 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company&#146;s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company&#146;s estimates for the years ending December 31, 2012 or 2011. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-42</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">6. Stock Options and Warrants &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="418"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Year ended December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2011</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock options:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>General and administrative expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Restricted stock units:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>General and administrative expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>85,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total stock-based compensation expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>9,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>85,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table summarizes Option activity: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="304"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted Average Exercise Price</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Average Remaining Contractual Term (Years)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Intrinsic Value</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding at December 31, 2010</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,116,096</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.64</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Forfeited</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(82,032</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.27</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Expired</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(743,196</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2.21</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding at December 31, 2011</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>340,868</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.74</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13,581,052</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercised</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Forfeited</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Expired</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(172,368</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>0.52</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding at December 31, 2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13,749,552</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.21</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6.49</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Exercisable at December 31, 2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>194,552</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.87</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6.49</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The aggregate intrinsic value is determined using the closing price of the Company&#146;s common stock of $0.18 on December 31, 2012. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2012, the Company had unrecognized compensation cost related to unvested Options of approximately $1,679,000 net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately four years. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The fair value of each Option is estimated on the date of the grant using the Black-Scholes-Merton option pricing model. There were 13,581,052 options granted in the year ended December 31, 2012 and no options granted in 2011. The following are the assumptions for the periods in which there were Options granted: </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Expected Dividend:</I>&nbsp;&nbsp;The Company does not anticipate any dividends. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Expected Life:</I>&nbsp;&nbsp;The expected life represents the period that the Company expects its stock-based Awards to be outstanding. The Company determines life based on historical experience and vesting schedules of similar awards. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Expected Volatility:</I>&nbsp;&nbsp;The Company&#146;s expected volatility represents the weighted average historical volatility of the shares of its common stock for the most recent four-year and five-year periods. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Risk-Free Interest Rate:</I>&nbsp;&nbsp;The Company based the risk-free interest rate used on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Where the </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-43</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">6. Stock Options and Warrants &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">expected term of its stock-based awards does not correspond with the terms for which interest rates are quoted, the Company performs a straight-line interpolation to determine the rate from the available term maturities. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Forfeiture Rate:</I>&nbsp;&nbsp;The Company applies an estimated forfeiture rate that is derived from historical forfeited shares. If the actual number of forfeitures differs from its estimates, the Company may record additional adjustments to compensation expense in future periods. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table summarizes activity related to the Company&#146;s restricted stock units: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="370"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="88"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted-Average Grant Date Fair Value per Share</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>December 31, 2010</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>157,669</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.44</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Vested</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(97,669</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.50</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Forfeited</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>December 31, 2011</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>60,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.34</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Vested</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(60,000</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.34</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Forfeited</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>December 31, 2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The fair value of each Award is estimated on the date of the grant using the closing market price of the Company&#146;s common stock. As of December 31, 2012, there is no unrecognized compensation cost related to unvested restricted stock units. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Reserved Shares </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2012, the Company had reserved shares of its common stock for future issuance as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares Reserved</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock options and restricted stock units outstanding</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>13,749,552</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Available for future grants under the Stock Incentive Plan</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22,741,689</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Warrants</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>8,389,946</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total Shares reserved</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>44,881,187</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">7. Discontinued Operations </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In June 2012, the Company sold all of its assets used in its gene therapy business including process development, quality control, quality assurance, manufacturing and bioanalytical functions for $3.0 million. In addition to this cash consideration, the Company may receive a long term royalty of 1.75% on certain product sales. This royalty may be completely canceled at any time by a one-time payment of $1.75 million. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">8. Employee Retirement Plan </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company sponsors an employee retirement plan under Section 401(k) of the Internal Revenue Code of 1986, as amended. All of the Company&#146;s employees who meet minimum eligibility requirements are eligible to participate in the plan. Matching contributions to the 401(k) plan are made at the discretion of the Company&#146;s Board of Directors. The Company suspended matching contributions effective January 1, 2009. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-44</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">9. Business Combinations </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On November 9, 2012, the Company acquired Australia-based Special Phage Services (&#147;SPS&#148;). The acquisition of SPS primarily focused on .IPR&amp;D being performed on S. aureus infections, which is currently being developed under AmpliPhage-002: Wound and Skin Infections Caused by S. aureus. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In a share exchange transaction, AmpliPhi Australia Pty Limited, a wholly owned subsidiary of US-based AmpliPhi, acquired Sydney-based SPH, the holding company of SPS. Under the terms of the acquisition, the Company offered 40 million shares of its common stock in exchange for 100% of the fully diluted share capital of SPH. 20 million shares are held in escrow, 8 million to satisfy potential warranty claims under the transaction documents and the remaining 12 million shares are held pending completion of certain milestones. At December 31, 2012, IPR&amp;D in the amount of $5,161,000 and goodwill in the amount of $2,381,000
have been recorded. In management&#146;s opinion, this IPR&amp;D and goodwill have not been impaired as of December 31, 2012. As part of this transaction, the Company acquired $260,000 in assets to include a $221,000 receivable for an Australian research and development tax refund, $37,000 in equipment, and $2,000 in cash. The Company also assumed liabilities of $613,000. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On January 6, 2011, the Company acquired Biocontrol, a clinical development stage biotechnology company in the United Kingdom (the &#147;Acquisition&#148;). The acquisition of Biocontrol included an IPR&amp;D project related to AmpliPhage-001: Lung Infections in Cystic Fibrosis (CF) Patients Caused by <I>P. aeruginosa.</I> </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company acquired 100% of the voting stock of Biocontrol and issued 22,817,198 shares of its common stock to the Biocontrol shareholders with a total fair value of approximately $8.6 million as of January 6, 2011. The Acquisition was made through an acquisition subsidiary, which has continued post-Acquisition as Biocontrol, At December 31, 2011, IPR&amp;D in the amount of $7,285,000, goodwill in the amount of $1,94800, and patents in the amount of $493,000 have been recorded. In management&#146;s opinion, this IPR&amp;D and goodwill have not been impaired as of December 31, 2012 and December 31, 2011. The patents are being
amortized over their life through December 2026. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">10. Convertible Loan Notes </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During 2012 and 2011, the Company issued $950,000 and $2,492,000 in convertible loan notes respectively. The Company is required to pay the holders of the notes the outstanding principal amount and all accrued interest by June 18, 2013. Interest on the unpaid principal balance of these notes accrues at the rate of ten percent (10%) per annum. As of December 31, 2012, $465,000 of interested expense was accrued. $126,000 of interest expense was accrued through December 31, 2011. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the event the Company shall raise a minimum of $3,000,000 in gross proceeds, in connection with an offering of debt or equity securities of the Company at any time following the issuance of these notes and prior to the maturity date of June 18, 2013 or the payment in full of the principal balance and all accrued interest due under these notes, the Company may, at its option, elect to convert the principal balance and unpaid accrued interest into securities of the Company. If the Company completed the subsequent funding event and determined to exercise the conversion option, the Company shall notify the note holders that it
has determined to exercise the conversion option and the holders shall elect to convert the unpaid principal balance and unpaid accrued interest into either of the following: (1) the number and type of securities issued in the subsequent funding event at a conversion rate that shall be equal to a ten percent (10%) discount on the effective price per share or per unit, as applicable, of the subsequent funding event securities; or (2) the number of shares of common stock of the Company equal to the conversion amount divided by $0.20. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-45</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">11. Related Parties </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During 2012, $30,000 was recognized in General and Administrative expenses for management and accounting consultancy fees provided by two shareholders. The Company shares resources in the new Australian operations such as facility space, electricity, insurance, equipment and staffing with Cellabs, owned by a shareholder, and receives a quarterly invoice for these services. The total expense for these services for the period November 8 through December 31, 2012 was $6,000. As part of the acquisition of SPH (Note 9), the Company also entered into a loan repayment agreement with Cellabs (Note 5). As of December 31, 2012, $562,000
of current liabilities are due to related parties. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">12. Correction of Errors </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s previously issued financial statements have been restated to reclassify the revenue from the sale of assets that was previously reported as part of revenue to a gain on sale of assets from discontinued operations. As a result of this correction, revenue for 2012 was reduced $3,150,000 and a gain on sale of assets from discontinued operations was recorded for $3,150,000. The net loss per share remained the same, but additional disclosures were added to the Consolidated Statements of Operations and Comprehensive Loss for net loss per share from continuing operations and gain from discontinued operations per
share. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company also contracted a valuation team to review the purchase price allocation of Biocontrol and Special Phage Services. As a result, overall goodwill was restated and a new intangible asset, in process research and development (IPR&amp;D), was recognized. For the Biocontrol acquisition, $7,285,000 of goodwill was reclassed to IPR&amp;D and $493,000 to patents. For the Special Phage Services, $5,161,000 of goodwill was reclassed to IPR&amp;D. The overall purchase price of Special Phage Services was reduced by $299,000 due to a decrease in the valuation of contingent shares reserved for the milestone agreement. This
further reduced goodwill by $299,000 and paid- in-capital contingent shares by $299,000. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company also contracted a valuation team to review the purchase price allocation of Biocontrol. As a result, in process research and development (IPR&amp;D) was restated and a new intangible asset, patents, was recognized. For the Biocontrol acquisition, $493,000 of IPR&amp;D was reclassed to patents. In addition, amortization expense for patents of $31,000 was recognized in both 2012 and 2011. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">13. Subsequent Events </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On February 1, 2013, the Company&#146;s Board of Directors approved the issuance of new convertible promissory notes in an aggregate principal amount not to exceed $7,500,000, together with warrants to purchase shares of common stock of the Company. Interest on the unpaid principal balance of these notes shall accrue from the investment date at the rate of ten percent (10%) per annum. The warrants have the right to purchase the number of shares of the Company&#146;s common stock equal to twenty-five percent (25%) of the principal amount of such holder&#146;s note divided by $0.14 (subject to adjustment to reflect forward or
reverse stock splits, stock dividends, recapitalizations and the like). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the event the Company shall raise a minimum of $3,000,000 in gross proceeds, in connection with an offering of debt or equity securities of the Company at any time following the issuance of these new notes and prior to the maturity date of one year from issuance or the payment in full of the principal balance and all accrued interest due under these notes, the Company may, at its option, elect to convert the principal balance and unpaid accrued interest into securities of the Company. If the Company completed the subsequent funding event and determined to exercise the conversion option, the Company shall notify the note
holders that it has determined to exercise the conversion option and the holders shall elect to convert the unpaid principal balance and unpaid accrued interest into either of the following: (1) the number and type of securities issued in the subsequent funding event at a conversion rate that shall be equal to a ten percent (10%) discount on the effective price per share or per unit, as applicable, of the subsequent funding event securities; or (2) the number of shares of common stock of the Company equal to the conversion amount divided by $0.14. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-46</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">AmpliPhi Biosciences Corporation<BR>&nbsp;<BR> Notes to Consolidated Financial Statements<BR> Year Ended December 31, 2011 and 2012 </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">13. Subsequent Events &nbsp;&#150;&nbsp;(continued)</H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Through March 29, the Company issued $1,000,000 in new convertible loan notes and converted $1,900,000 of previous convertible loan notes and accrued interest into the new security. As part of these transactions, warrants for 5,244,673 shares were also issued. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On March 29, 2013, the Company entered into an Exclusive Channel Collaboration Agreement with Intrexon Corporation. This agreement allows the Company to utilize Intrexon&#146;s synthetic biology platform for the identification, development, and production of bacteriophage-containing human therapeutics. The Company paid a one-time technology access fee to Intrexon of $3,000,000 in common stock. The Company shall pay Intrexon, in cash or stock, milestone fees for the initiation of a Phase 2 trial of $2,500,000 upon commencement of the first Phase 2 trial and $5,000,000 upon the first regulatory approval of any product in any
major market country. With regard to each product sold by the Company, the Company will pay, in cash, royalties of 6&nbsp;&#150;&nbsp;10% based on net sales to Intrexon.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-47</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSRIR"></a>To the Board of Directors and<BR> Stockholders of AmpliPhi Biosciences Corporation </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have audited the accompanying balance sheet of Special Phage Holdings Pty Ltd (Company) as of June 30, 2012, and the related statements of operations and comprehensive loss, stockholders&#146; equity (deficit), and cash flows for the year then ended. Special Phage Holdings Pty Ltd&#146;s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audit. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Special Phage Holdings Pty Ltd as of June 30, 2012, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has had recurring losses from operations and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to those matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">/s/ PBMares, LLP<BR> Richmond, VA<BR> February 3, 2014 </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-48</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSBS"></a>Special Phage Holdings Pty Ltd<BR>&nbsp;<BR> Balance Sheet </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="528"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>June 30,<BR> 2012</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Current Assets<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>38,962</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Tax refund</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>216,615</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total Current Assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>255,577</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Property and equipment, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>35,628</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Trademarks, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>2,164</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total Assets</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>293,369</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Liabilities and Stockholders&#146; Equity (Deficit)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Current Liabilities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Related parties payables</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>884,406</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts payable and other accrued expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>77,249</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accrued employee expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>44,937</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total Current Liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>1,006,592</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total Liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>1,006,592</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Commitments and Contingencies (Note 6)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Stockholders&#146; Equity (Deficit)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Common stock, no par value, 22,347,952 shares issued and outstanding</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>&#151;</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Additional paid-in capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>1,526,300</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accumulated other comprehensive loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>(47,436</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accumulated deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>(2,192,087</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total Stockholders&#146; Equity (Deficit)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>(713,223</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total Liabilities and Stockholders&#146; Equity (Deficit)</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>293,369</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>See accompanying notes to financial statements.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-49</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSSOC"></a>Special Phage Holdings Pty Ltd<BR>&nbsp;<BR> Statement of Operations and Comprehensive Loss </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="520"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Year ended<BR> June 30,<BR> 2012</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Consulting Revenue</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>19,613</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Operating Expenses<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>320,989</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>General and administrative</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>328,238</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Total Operating Expenses</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>649,227</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Loss from Operations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>(629,614</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Other Income<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Interest income</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>5</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Tax refund</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>220,112</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Other Income</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>220,117</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net Loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>(409,497</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Other comprehensive loss<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net unrealized loss on foreign currency translations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>(5,082</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Comprehensive loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>(414,579</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>See accompanying notes to financial statements.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-50</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSSSE"></a>Special Phage Holdings Pty Ltd<BR>&nbsp;<BR> Statements of Stockholders&#146; Equity (Deficit) </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="154"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="77"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Common Stock</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Additional Paid-in Capital</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Accumulated Deficit</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Accumulated Other Comprehensive Loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Total Stockholders&#146; Equity (Deficit)</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Balances, June 30, 2011</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>19,953,272</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>&#151;</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>1,190,675</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>(1,782,590</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>(42,354</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>(634,269</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(409,497</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(409,497</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shares issued</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,394,680</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>335,625</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>335,625</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Foreign Currency Translations</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(5,082</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(5,082</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Balances, June 30, 2012</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>22,347,952</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>&#151;</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>1,526,300</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>(2,192,087</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>(47,436</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>(713,223</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>See accompanying notes to financial statements.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-51</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSSCF"></a>Special Phage Holdings Pty Ltd<BR>&nbsp;<BR> Statement of Cash Flows </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="520"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Year ended<BR> June 30,<BR> 2012</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Operating Activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net loss</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>(409,497</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Adjustments to reconcile net loss to net cash used in operating activities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Adjustment of loan balances to purchase agreement limits</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>136,915</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>4,777</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amortization</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>472</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Changes in operating assets and liabilities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounts receivable</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>976</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Tax refund</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>(11,904</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 40pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Current liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>151,306</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net Cash Used in Operating Activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>(126,955</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Investing Activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Purchases of trademarks</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>(1,078</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Purchases of property and equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>(30,144</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net Cash Used in Investing Activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>(31,222</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Financing Activities<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Proceeds from shares issued</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>198,710</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net Cash Provided by Financing Activities</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>198,710</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Effect of Foreign Currency Translations on Cash</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>(5,082</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Net Increase in Cash and Cash Equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>35,451</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Cash and Cash Equivalents, beginning of year</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>3,511</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Cash and Cash Equivalents, end of year</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>38,962</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Supplemental Schedule of non-cash financing activities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; font-weight: bold; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Conversion of debt to shares</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>136,915</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>See accompanying notes to financial statements.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-52</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Special Phage Holdings Pty Ltd<BR>&nbsp;<BR> Notes to Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Nature of Business </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSNFS"></a>Special Phage Holdings Pty Ltd (&#147;the Company&#148;) was incorporated in New South Wales, Australia in 2004. The Company is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phage are naturally occurring viruses that preferentially target and kill their bacterial targets. This novel approach to antimicrobial therapy positions the Company as one of the leaders in phage therapy. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Use of Estimates </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cash and Cash Equivalents </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accounts Receivable </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of June 30, 2012, management determined no allowance for doubtful accounts was required. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and Equipment </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Revenue Recognition </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company recognizes revenue under research and development contracts as the related costs are incurred. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Concentration of Risk </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s primary source of funding to continue operations is from one related party, Cellabs. As of June 30, 2012, 91% of the balance in related parties payables is due to Cellabs. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and Development Costs </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs include salaries, costs of outside collaborators and outside services, and supplies. The Company expenses research and development costs as incurred. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-53</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Special Phage Holdings Pty Ltd<BR>&nbsp;<BR> Notes to Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1. Nature of Business and Significant Accounting Policies &nbsp;&#150;&nbsp;(continued)</H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Fair Value of Financial Instruments </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the compatibility of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value: </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Level 3 inputs are unobservable inputs based on the Company&#146;s own assumptions used to measure assets and liabilities at fair value </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A financial asset or liability&#146;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">All of the Company&#146;s cash equivalents are invested in money market accounts that are based on quoted prices in active markets for identical assets and are included within Level 1 of the fair value hierarchy. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company believes that the carrying amounts of financial instruments such as cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short-term nature of these items. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2. Liquidity </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has prepared the accompanying financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception, has negative operating cash flows and has an accumulated deficit of $2.19 million as of June 30, 2012. These circumstances raise substantial doubt about the Company&#146;s ability to continue as a going concern. The Company&#146;s cash balance as of June 30, 2012 was $38,962, the accounts receivable balance was $216,615 and the current liabilities were
$1,006,592. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#146;s ability to continue as a going concern. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company believes that its current resources, in addition to the acquisition of the Company by AmpliPhi Biosciences detailed in the Subsequent Events disclosure (Note 10), will be sufficient to fund operations into the first quarter of 2015. This estimate is based on the Company&#146;s ability to manage its staffing expenses and its working capital and actual results could differ from its estimates. The Company will be seeking additional financing in order to fund operations through 2015; however, the Company cannot provide assurances that it will be successful in obtaining additional financing for these periods or as
needed in the future. If the Company does not raise additional funds by the first quarter of 2015, it plans to implement cost reduction measures, such as a reduction in workforce, reducing its intellectual property prosecution, reducing other operating activities, and/or the pursuit of alternative financing transactions that would likely be on terms disadvantageous to the Company and dilutive to its shareholders. The Company could also be required to relinquish rights to its technology or product candidates or in-licensed technology on unfavorable terms, either of which would reduce the ultimate value of the technology or product candidates, or to sell assets likely at values significantly below their potential worth. If the Company is unable to secure additional capital, it may be required to cease operations, declare bankruptcy or otherwise wind up its business. </P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-54</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Special Phage Holdings Pty Ltd<BR>&nbsp;<BR> Notes to Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">3. Property and Equipment </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and equipment consist of the following: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="466"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>June 30,<BR>2012</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Furniture and equipment</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1><B>189,452</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Less: accumulated depreciation</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1><B>(153,824</TD>

<TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT --><b>)</b>&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total furniture and equipment, net</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ --><B>$</B></TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1><B>35,628</B></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Depreciation expense totaled $4,777 for the year ended June 30, 2012. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">4. Income Taxes </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of June 30, 2012, the Company had an Australian research and development tax refund of $216,615. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">5. Commitments and Contingencies </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has an informal month to month lease with Cellabs, a related party. The Company recognized rent expense under this informal operating lease of $37,280 in 2012. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company is subject to legal claims and actions related to the operations of its business. The Company does not expect the ultimate outcome of any such actions to have a material impact on its financial position or results of operations. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">6. Other Comprehensive Loss </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Comprehensive loss is the total of net loss and all other non-owner changes in equity. For the year ended June 30, 2012, the Company&#146;s net loss was $409,497 and other comprehensive loss was $5,082. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">7. Stock Options </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As part of the 2005 Subscription Agreement, the Company issued one option for every share purchased by the investor in 2005 totaling 3,125,000 options granted at $.20 each. Under the terms of the agreement, the investor must give the Company written notice of the exercise together with payment for the options. All options held by an investor must be exercised at the same time and one occasion. During 2012, 8 shareholders exercised 925,000 options. As of June 30, 2012, 2,200,000 options remain outstanding. These options expired on the acquisition of the Company by AmpliPhi Biosciences described in the Subsequent Events
disclosure (Note 10). </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">8. Superannuation </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company contributed, as required by the Superannuation Guarantee (Administration) Act 1992, 9% of employees&#146; salaries and wages into a superannuation fund. For the year ended June 30, 2012, the Company&#146;s contributions to superannuation totaled $17,465.<B></B> </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">9. Related Parties </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During 2012, $180,929 was recognized in operating expenses for research consulting, management consulting, accounting, and housekeeping provided by 8 shareholders. The following is a schedule of the expenses: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="184"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="282"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Related Party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total Expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Description of Service</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cellabs Pty Ltd</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>41,341</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Management Consulting</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>A.P.G. Nominees Pty Ltd</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>41,291</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Management Consulting</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>HGM Biopharma</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>28,154</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Management Consulting</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dr. Bernie Hudson</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>28,153</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Management Consulting </TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-55</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Special Phage Holdings Pty Ltd<BR>&nbsp;<BR> Notes to Financial Statements </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">9. Related Parties &nbsp;&#150;&nbsp;(continued)</H2>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="184"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="282"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Related Party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total Expense</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Description of Service</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Doug Crease</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>21,792</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Accounting</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Argylle Europe Limited</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>15,485</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Management Consulting</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Colleen Black</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,949</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Housekeeping</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Biofirm Pty Ltd</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>764</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Research Consulting</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>180,929</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company also shares resources such as facility space, electricity, insurance, equipment, and staffing with Cellabs Pty Ltd, which is owned by a shareholder, Dr. Anthony Smithyman, and receives a quarterly invoice for these services. The total expense for these services for the year ending June 30, 2012 was $134,146. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of June 30, 2012, $884,406 of current liabilities are due to related parties. The following is a schedule of the liabilities. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; *margin-top: -20pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="184"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="282"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Related Party</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Payables Balance</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Description of Service</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cellabs Pty Ltd</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>815,768</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Facility and Services</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>A.P.G. Nominees Pty Ltd</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>35,557</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Management Consulting</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>HGM Biopharma</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>15,583</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Management Consulting</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Doug Crease</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10,666</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Accounting</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dr. Bernie Hudson</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,080</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left" ROWSPAN=1 COLSPAN=1>Management Consulting</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Colleen Black</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,752</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Housekeeping</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #cceeff">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>884,406</TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">10. Subsequent Events </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has evaluated subsequent events through February 3, 2014, the date on which the financial statements were available to be issued. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2012, the Company was acquired by AmpliPhi Biosciences (AmpliPhi) in a share exchange transaction. The combination of the two companies results in the creation of a leading anti-infective company focused on developing phage-based therapies to combat the growing threat of antibiotic-resistant infection. Under the terms of the acquisition, AmpliPhi offered 40 million shares of its common stock in exchange for 100% of the fully diluted share capital of the Company. 20 million shares will be held in escrow, 8 million to satisfy potential warranty claims under the transaction documents and the remaining 12 million
shares to be held pending completion of certain milestones. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As part of the acquisition, existing loan balances for services provided by Cellabs Pty Ltd, a related party (see Note 9), were capped at $782,000. The Cellabs Pty Ltd balances for services were adjusted to this cap for these financial statements as of June 30, 2012. In addition to these services, lab equipment and supplies totaling $33,768 which were purchased by Cellabs Pty Ltd and transferred to the Company as part of the acquisition were recognized as an additional related party liability. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In November 2013, 8 million of the escrow shares were released. The remaining 12 million shares continue to be in escrow until November 2014 or completion of the milestones. As of February 3, 2014 the agreed upon milestones have not been achieved.</P>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-56</P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

<DIV STYLE="width: 708px; border-top: 1pt white solid; border-bottom: 1pt white solid; border-right: 1pt white solid; border-left: 1pt white solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><BR>&nbsp;&nbsp;<BR>&nbsp;&nbsp;<BR><IMG SRC="logo_ampliphi-biocorp2.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> &nbsp;</P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 14pt; line-height: 16pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">73,362,164 Shares </H1>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 14pt; line-height: 16pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Common Stock</H1>

</DIV>

<P STYLE="width: 708px; text-indent:0px; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; color: black; text-transform: none; text-decoration: none; padding-top: 12pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<HR align="left" STYLE="width: 708px; height: 2px; text-align: center">



</DIV>

</B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B></B>

</I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I></I>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_ampliphi-biocorp2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_ampliphi-biocorp2.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^(,6$E#
M0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`
M,0``86-S<$U31E0`````245#('-21T(``````````````````/;6``$`````
MTRU(4"`@````````````````````````````````````````````````````
M```````````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````4
M8FMP=````@0````4<EA96@```A@````49UA96@```BP````48EA96@```D``
M```49&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P``
M`]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E12
M0P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`
M````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V
M,3DV-BTR+C$`````````````````````````````````````````````````
M`````````````````%A96B````````#S40`!`````1;,6%E:(```````````
M``````````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4`
M`!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO
M+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`
M````````````````````````````````````````````````````````````
M9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````````````
M`&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````````````
M``!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@````
M``!,"58`4````%<?YVUE87,``````````0````````````````````````*/
M`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`
M*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5
M`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!
M#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A
M`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"
M9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/
M`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$
M<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U
M!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'
M/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG
M"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*
MW`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS
M#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/
M7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H
M$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4
MSA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2
M%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;
M.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^
M'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(B
MKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W
M)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K
M-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'
M+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XT
MV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY
M.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_
MHC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D55
M19I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+
MFDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F
M4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8
MRUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S
M8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG
M/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$
M;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV
M^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C
M?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(
M!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6
MD3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R:
M:)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/F
MI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN
M+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9
MN-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#
M6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XV
MSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9
M\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$
MY@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q
M__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+
M_MS_;?___^X`#D%D;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&
M!@@+#`H*"PH*#!`,#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?
M'P$'!P<-#`T8$!`8&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?_\``$0@`*P"=`P$1``(1`0,1`?_$`*4`
M``(#`0$!`0`````````````&!`4'`P((`0$``@,!`0````````````````0"
M`P4!!A```0,#`@,$!`80!P```````@$#!!$%!@`2(1,',4$B%%%A,A5Q@6)R
M=3:AP4)2LB,S8[,D=+0E%C<(D;&"<S2U.!$``00``P8$!@$%`````````0`1
M`@,Q$@0A05%Q,A-AP2(%\(&1H3,4<N&"0S1$_]H`#`,!``(1`Q$`/P#ZIT(1
MH0C0A*V3=0['9-[`EYR>/#RS2I05_.'Q0?@XKZM,TZ64]N`2=^MA7LQ*H<`R
MZ]9!E<E9KNV.$1PFHK?A;%>:VE:=Z\>U=7:FB,(!N*6T>IG9:7P;#Z+1](+5
M1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"JK]E%EL3/,N#Z"9)5
MM@/$Z?S1^VO#5M=,IX*F[40K'J*R?/.KX$[;[:KSEHCW&(LI'T7>*_K+S&QT
M@3F`E&*U&O;1>''3E-`@2^UE#LV:FG/66QV?U2FXV8(!K0@='>TZ*H8&*_=`
M8JHDGK1=/QD#@O/652@6D&*>.COUFE?L1_I6M*:[H'-/>V?D/\?,+8=92W%@
MW5SK5DV/YRMIL+@>2MK;*W$%;!S>X:H9)O5%44V&(\._3M&G$HN4[1IQ*+E;
MC;I\6XV^-<(A[XLMH'V#](."A"O^"Z3(8LDR&+*KLV;XK>KI+M5LN+<FXP=R
M2HR(8D&P]A>T(UH7!::E*N0#D*4JY`.0O5ZS/&+)<85MNEP;C3K@J##CJA$1
MJ1(">RA4J2T2NB-<B'"(UR(<+KD>4V#&H(3KY,&%$<=1@'3$R17"$B0:`A+[
M(*NN0@9%@N0@9%@HV-YWB&2FXW8[HS->93<XR*J+B#V;MAH);:KVTIKLZY1Q
M"[.N4<0I99-8QR`<>*6*7DV?,C#VEN5KCXMU-O=Z=<R%GW+F0L^Y3)\Z+`@R
M)TMQ&HD1HWY#JHJH#;8J1DJ)5>`I77`'++@#EE&L5_M%^MK=SM$D9<%U2%M\
M4(450)1+@2"O!4]&NRB8EBNRB8EBLUM63=1[FEQ?@S&WFK;XG63;915%5)4V
MT!*\&U[]:,ZJHL",5AUWWS<@]/).N'Y>-ZQ]VXS`%AR(IC+V(2C0!0]XIQ6F
MU>SCI2^C))AO3^FU/<AF.QL5<6B]6R\1%EVY[GQT)6U/:8>)$152AH*]^JIU
MF)8J^NV,P\2X7.VY#9[G*E18,CG/PRVR0V&.U:J/:0BB\17LUV=4H@$[URNZ
M,R0#M"XIEN/K=5M7FOU]'$95GEN>VJ*J)NV[>[TZ[V99<S;%']F&;*_J2;G'
M4>ZP93MLM\4X3@\%ER!\1)V5:%:C1>XEKIO3Z6)#DND=7KI1.6(;Q*S"1)D2
M7C?D.D\\XM3<<52)5]:KK1``V!9$I$ERD_JO_P`G'OHI?^PF:H'5+GY!>R]E
M_P!<<RERQ91=[,2C%<1R*:U=A/(IL&OI4:HHE\H%0O7KI">U&FKN#3#KZ#Z$
MSVKI<G[BW&>AH40PY+W$3JZ%28<\/,!%&A>%-JJB<>W2NKF3%CQ6#'0#3V[)
M.XPW[EKUUN,:V6R7<I1;8T)ER0\7H!H5,OL)K/`<LFP'++X_MN8X\_$S-_(6
M9+UWR0%6$XP#9MM.<U9'C(W`)!YHMIX17@GQ:U3`^EL`M4UGTM@%NO\`;ED_
MO;!/=KI[I5E=6.M>*\ARKC*_A`GS=):J#2?BDM5!I/Q6.Q@R&S9/D6=V55/^
M7[TX$Z/QH;$AYQ%W4^X7;M+T51>[398Q$3O";+&(B=X768Y?\CRBR9]=$5J/
M=KXQ$MD=>.UAAT?97[T5\->\MRZX&C$Q&X+@:,3$;@M2_NB^H%O^E6?W:1I;
M1]7R2VCZODJO![;+O_5Z-E=IQI[&L>A1#;?1YE(Z2'#;,$5`1!%27F#[-4H%
M56JZG8<M>4ERIV'+7E)<J\E?^DHGT(OX3FH#\/S4!^'YIXZA_4#)OHJ=^['J
MBKJ'-45=0YI7_MZ_I9;?]V3^G/5NJZRK=5UE+6)L9=(*\1L?V"#Q"$TS445!
M57$':I?ZNS6A<:QE,UY?3"TYA#Y_=/\`:,87'<*N,1QQ'9+K+[L@QKMW*TJ4
M&O&B(.D9W=RP%:=>G[5)&]BEC`+SD\.Q$U;++[PC<\R5_G"WXE0:C1?1IG4U
MP,MLF2>CMLC!HQS!^*F=+''G+[D+CS?*>,Q)QJM=I*XXJC7OHNH:SIBK/;R3
M.;_&*JQ_JFY](!^`>K/\/R5/_3_<M0NMFMEVBK&N$<7VE[-WM"OI$DXBOP:S
MH6&)<+7LJC,-(.LOR?I1<(>^39B69&3BL<J<X4]7<?\`GZM:-.M!V2V+(O\`
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MH)"39$:.!14\-`7<*?)75EEPE$`XA6679H@'$*3T\Z>3<;G90]<78\N/?IBR
M6F@0B1&U)PMKB&*)V.>O4;;1(!MRC;:)`-N73J!T_E9"YC?NUR/#8LD\)CC1
M(HHK8$*J+:`*I7AHJMRN^]%5N5WWA>NK>`3,XQN-:8DMN&XQ,"6KKHD0J(-.
MM[:#W_C=%%N0NBBW(73MJE4K+\[Z79;><U;R?'[ZW:'VX@Q$7:2N40B4N*<*
M+NTS7=$1RD.F:[HB.4ATP6_$\F+I_<\=O=W2Y76?'EQTN)(NU$D-D`53MH&[
M59F,P(&Q5F8S`@;%(Z:8A)Q'$(MBDR`E.QS=-7FT417F.*:<"X\-VN6SS2=<
MMGFDZ_,)P^3CSMQ-Z0#Z32;($!%3;L4UXU^?JW47BQMF"S]+IC42Y=TQ7"*L
MN!)BH6Q9#1M(=*TWBHUI\>J(EB"FIQS1(XJJP[&SQZTK`-])"JZ3O,0=B>)$
M2E%5?O=67VYY.J=+1VHY7=1\8Q%RRW2Z3BDH^EQ/>(("CL\9%15JM?;U*Z_/
M$!L%#3Z;MRD7ZE"3`7DRPK[YT=A21D<CEK6@BH[=V[Y7HU/]GT96W*'Z9[N=
M][IQTHGD:$*FR3$[1D$=&YH*CK:+R9#:T,*_85/4J:MJNE`[%1?IXVABLER;
MIY?+)N>$?.0$JOF6D6HI^<#BH_93UZU*=5&?@5B7Z*=>W$*RZ._6:5^Q'^E:
MU7KN@<U=[9^0_P`?,)WZFXS<,EQ-VU0$;*0;\=W:Z2""@R\+AI4@='B(_=`J
M>E-9],Q&3E>AIF(R<I&=Z598EO;;-(LP6PL22[>3[@MS`MC3X2(YF0K02)X"
M'<BHM.Q-7=Z+_7[J[O1?Z_=>[5TPRN+-Q5\VXR>ZY;[[S1/(^Q%BO2$>\NR#
MC6Y7!$40'`(:+P6HZY*Z)!\5R5T2_BNELZ8W^/%MT5R!#"=`O4*XS[ZD@B=N
M#4>0XZ1N`H;A<03[%)>/9PT&X;>6'!!N&WEAP59`Z.Y;'PZ%:&R8BW*)<6KB
M,MHVJ(Y'BR!;.H,LF5'C;]M3*E>.I&^.9_!2-\<S^"N;!T]R*#<\?F76V1+J
M,.)'84#D$"V^0W*)YR0P.PQ<J)"O"A*HTJB:A*T$%BWFH2M!!8MYJDC](,LC
M85!L[<>*=SBSAE(XKK/E:\OEJ;S7EA5Y$3LW*IHO%"X4U,WQS/N4S?',^Y:)
MU&QNXWV#;0B1V9[,*:$F;:9#I,M2VA`QY9&B$GA(D-$)-JTXZHJF(DJBJ8B2
MDV-TSR<<JA7`(<2(VU.@S0GMR3-V+"C,(VY:VPV#N;X;4*J"J<53N2TVQRM\
M<U:;HY6^.:IK3T&R1NQI9ILB,++TZ%+?>;7>@`S%D,O(+1`@$:&\*H5*EW^R
MFIRU(=PIRU(=PK4.DF2,9$VXT3+PL3VI361O2#*:L%J,C'D#;VT7<J<2K2BK
MWZCWPWEYJ/?#>7FH=KZ,YA$Q2=C8R(;;-V>MYS7T(]J-1V55]OEMHUNJ\`IN
M0D4A5:K773?$R?@ZZ;XF3\'5PG2V]RF795Q8A'>3QE^S^;0E4BG$!QVWE)0K
MXHZHA%V\534.\!AAF=0[P&&&9UUD]-<B<RZV7-/*DU&*U'Y\GG$?C-P`49,9
MIM`H025[5W)V\470+1E(YH%HRD<TMGT,RX[FRZ5P:\@RX[-;C<PN$AZ6V9MU
MV_DE;9%SY_"G?JS]B+*S]B+8+=M)))&A"-"$+V+]O0A(.*\C^?9NSW?S?*.\
MSW=SJ?EFJ<S?^+W>G9\>G;G[0QQWK-T[=X].&Y^(3]I):2-"$:$(T(1H0C0A
6&A"-"$:$(T(1H0C0A&A"-"$:$+__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>spacer.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 spacer.gif
K1TE&.#EA`0`!`(```````````"'Y!`$`````+``````!``$```("1`$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>line.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 line.gif
K1TE&.#EA`0`!`(```````/___R'Y!```````+``````!``$```("1`$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>v367027_img-mice.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v367027_img-mice.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!@0))`P$1``(1`0,1`?_$`0T```$#!`,!````````
M```````("0H$!08'`@,+`0$``@(#`0$!`0````````````$"`P0%!@<("0H0
M```%`P($`@0&"@@,#0H1#0$"`P0%$08'``@A,1()01-1(A0*87$R%188@9&Q
M0M(CESAX6:'!4A=WM[@9\-%B<C,D)K8G*-@Y@I+"0U,EEC?72%B8&N&R<S2U
M-D;61U>B8Z-4I#5%575F=H9GAZ=H*7GQL\/31+25I5:FB*@1``$#`@0#!`4'
M!@H(!00"`P$`$0(#!"$Q$@5!409A<2(3@9&A,@?PL<%"%!46T>%2DB,S8G*B
MLE.S-%07"/&"0W.C)'0U8V0E977"1#8WI";2@Y/_V@`,`P$``A$#$0`_`),W
M<?[MS+M\95LC&[_"J.1&EUXT7R,]NAYD=W9K6%2"[CV@RAR1D;CB_I&3</'A
M!4%4I4B)D"@AXZV>T[/N&]W/V7;XQE5`XD!4W%>%O#7-]+IN,_O/UBIE,<VW
M&!`"<3`;-5^%,/AP`=L?_5UTLOASU?$M&U$H\Q(?2L?[RM,')R7'_I0%C`)`
M-MQ@"^;\@?WZ[[X5"O$/JQ>C43\.NL?[I_*C^5+[RM.:[/\`I/MC?\G"`_+;
M??\`DQZ/\.NL?[I_+"/O*VX$H_Z3]8W_`"<+?_+;??\`DQZ/\.NL?[I_+"/O
M*VYE=:WO0-BH=(J[;X$.OY/3FN_#B/\`I=L6JO\`#[K`'^R?R@I?>%MS0;WH
M*Q"D*<NV^$4*8*AT9HOX>'_-@XZ/\/>L?[H?U@E]Y6G,JF#WHO'XB%=N,"F%
M0`?.S5?Z0TKX5VO"'+X=`^'W6#^*U8<S**/O*TX$NJHOO05@'`3%V[6U0/\`
MZ<KZ$?L%#;#4=7'X=]5-X:,">0F'*/O&VXDKL2]Y[L9<@G2VXV^<`&G#-M^<
M1X>G;"`?LZB/AWU?_=,/X\4OO*U;WEVA[SG9PC^;;`4_AMOJM?\`FQCIGX=]
M7\+3^6$OO*U&.HGT+Z?WG2SDR]9]M<"!`$`,;]^Z^J%KP`1_Q8^0C0/LZ7^'
M76/]T_E!1^]+7F5R+[SC9QU#I%VV0/6F`>9_AOOFA1-Q*'YLG,0XZ?\`AUUC
M_=/Y81]ZVG$KM_Z39:50`-M<`-1I_OWWSP]'_%D'1_AUU@/_`+3^4$?>EH<B
M5])[S7:1U#)!MK@.LM/_`"W7U00$/@VQ#RU$_#OK!V^RM_K13^]+7M7-/WF:
MUU1,">VB`,!#=(F_?RO4H5I7AU[9B#0`'1_AYUAD;7^4$CNMIS*[C>\OVV4!
M$=LT!0.?^'2\O\FC3_P\ZO\`[I_*"/O6T=G7/_I+=N]/5]6>WJ4K_OZ7ER^/
MZM&E_AWUA_=?Y01]ZVG,KM)[RK`G(!PVR6_QK7_#I>7V*?XM'CH_P\ZO_NG\
MH)?>UIS7(GO*4$<1`-LEO^KS_P`.MX_Y-.G_`(>=7?W7^4$?>UKP==@>\G0H
M\ML<`/\`]>EW_P"39^UI?X>=7_W7^4/R)_>MKVKF7WDF+-RVO0/P?X=[M_;V
MV:/\/.K_`.ZC]<?D4/OBT=L5V?\`21(W_DO0'Y>+L_R;='^'G6']U'ZX_(G]
M\6?,KM+[Q_'&Y;7[?_+S=G^39H_P\ZO_`+K_`"PC[WM.978'O'+,P@!=KUO"
M(B'#]_F[0^V/U;.&G_AYU?\`W7^6$?>]IS*[0]XS1&G^*W;7'_Z?[J_R:N&E
M_A[U?_=1^N%'[XM.9787WBY(P])=K=MU&O\`Y?KL_P`FK1_AYU=_=1^N$??%
MIVKM_P"D4!_R6[:'_P"OZZ_\FO1_A[U<S_91^N%$[W9QS=<@]XD4'_BLVW\8
MY^ND*?;VVAI?X?=7?W4?KA+[]LOX2[`]X@5$`IM8MO\`YP-S?;_-PT?X>]7_
M`-U_EA'WY8\SZEV_](;<#3IVK6T:OHW!7(%/AJ.W#43\/^KAG:C]<(^_;'^$
MNPOO"SPP\-JMM?']82XJ?L[<BZ7X`ZM_NH_7"#OMC_"7<'O!S\PC3:K;(AP_
MXPMP!^S]73CH_`/5O]U'ZX4?OZRX.NXOO!$B8*AM5MCX?\8:X/VMNFC\`]6G
M*U_EA+\0;>/>)"^A[P++"/J[4;9.`\A#<//%`/@];;IH_`/5O]U_EA'X@V\Y
M278'?_G#"(%VGVQ0/'ZQ,]_DZ:8Z!ZKXVP!_CA(]0[<.)7:7O\7`;_BGVO3T
M_6)GOV/\731^`>J_[L/UPC\1;=S*Y_S^=Q^&TZV/^<1/?Y.FH_@+JM_[+_*"
ME^(MMYE<R]_"Y3<MIUL?\XB>^Z.W2@:#T'U9_=?Y82_$6V@.25WE[]-U&_XI
M-K_!_C&S?&O+_BZ#STCT'U6,[9O]8)?B/:6QG)_XI7(._+=XCPVB6S2OCN-F
MR_LCMSIJ/X(ZBXTH_K!+\2[0[:Y_JE=X=]Z\A`1^J+:@>BNY.7"OV]NH<=/\
M$=1<*4?U@E^)MH_3G^J5S_GVKT-3IVBVI_SDY;C\0_5V`-'X(ZBXT8_K!'XF
MV?\`I)#_`%2NT.^K>XAZNT.U1'P`=RLD4/AXCMZII?@GJ+^AC^L$OQ1LV7F2
M_5*[`[Y]^#Q^J%:0<N'UF)$1#T_\7H.6C\$]1<*,?U@G^)MHXSD/]0KN)WR;
M].'#:%:OV-RTB/W-O6D>BNH1G2B!_&"0ZGV<_P"TE^J5S_GQ<@^&S^U1^+<K
M)?Y/6G^"M_\`Z.'ZP4OQ-L^>N7J*YAWP<AFY;/K7#X]RDD/W-O6@]%;^/]G'
M]8*!ZHVA\)S_`%2N7\]]D8>6SVU?L[F)$!^T.WD-'X)ZB.5*+?Q@E^*=H_3E
M^J5V%[W.2C_)V=VH/P_69?\`^3UJ,NBNHA_LH_K!'XIVC]*?ZI7<'>RR<80I
MLZM00'_[S,A_D]:!T9U`<Z40?XP1^*=H_2E^JNS^>NRA6@;.;5'_`/V9D`I_
M_P`\\M/\%[__`$</U@E^*=H_2EZEV!WJ,J&$`#9O:OQCN8D*?R>0TOP9O_\`
M1Q_6"9ZIV<9SE^J5S+WH\LF$0^IK:?#Q^L\Z#]@VWX!T_P`%[]PIP_6"0ZKV
M4_[20_U2NW^>?RU2OU-;4_YSSG]O;^&C\%[_`,*4?U@@]5[+_2']4H+WG,NF
MK_B:VGSI^<^M]C_R!:#T7OX_V4?U@H?B_8_Z27ZI7>7O*Y@'_B:6GRK^=`L'
MW<!:B>C=^'^RC^L$?B[9/Z27ZI07O*9B-_Q,[2IZ?K/K_P#`%H_!N_?T4?U@
ME^+]D_I)?JE=P=X_,0APV9VG7])];C]K`6C\&;__`$<?U@C\7['_`$DOU2@>
M\=F;[W9C:9C>`!N?7_X`M'X-W[^CC^O%/\7[%QJR'?$KL#O$9K,'#9;:@?UV
MZ%4OVJX"TAT;OY.-*+?QQ^5,=7;`?]L?45]_GA<W#RV6V@/Q;IC_`/`#J7X,
MWW]"'Z\?RJ1ZMV#^F/ZI7,.\%G$>6RNT?^=,?_@!T_P7OWZ$/UX_E1^+=@'^
MV/ZI7T.\#G(1_,KM'_G2J?M8`$-+\&;Z,X0_6"@>K^GP?WQ]17(>[]G/@`;*
MK2$1_P#O2J?\`&@=&;Z0XA#]8('6'3YQ\[^25V!W><ZC_P`2JT?^=*I_P`Z?
MX,W[]"'ZX_*@]8=/`_OC^J5C-[=Z+,UC6A<MYRFR>V5HRUH.3G7Z;/=$"CD[
M6+:*/%B-R*X'0(991-(0(`F`HFX"(<]4U>D=ZI>*I&,81C(G%V`&&2='J[8J
M]04J54F<I`#PG,E;L1W\;Q\P9ONW%VUW;UMPE8*PMN6U'/=UW#GK/U]8[=H'
MW4Q.0I.`MJ*;VEAF^V;_`.CXX\<)+N%5&HJ'63Z$^(@7F@)1PG[W%=*2'\.,
M5MG]\/O"_P#)@V`_\[?.'^2SH1BJ9#)_=Y=&=$;;:NWPX.R<"S>%0W>YL6,T
M=@DBN+5R">ULPH.00<)G$AJ&`BA1I0P"(C%5/[X?>%_Y,&P'_G;YP_R6="6*
M/WP^\+_R8-@/_.WSA_DLZ$8K#F.[[?CC;<]M&PCN=V[[8+8LS=9D')..8N[\
M,Y_R1D&X[:F+`P7DG-)7+NW;LPC8$<NPD4,?"S$Q7O60SCJ`H]--",4[?H34
M+SWF8/\`&(QC2H=>V-D`_#3.3JE1YA3X*:]'^&$8'?Y@Q!>D3Z0,%KMS/["(
M(!&I145JK+IH`-4TA]H7.''K-P$2B80,/4(CQ^'7T$9$:1$EF!/I#KG-,#)B
M`NUR119,]!"I1`Y*%*`E``KTA0*@--+7,\3ZT&,&<`+L15*N0JH4`IB`(A0M
M0,(<?#TZ#,G%SZRI#2PP"YU`0ZN!0`.(B!>?+T>G1JES/K*EX>05(@)EE5%1
MX))&\M`!*'RQIZXU#UBZBY=WDW>5``'@&7)H/00R`=56QC%`!,>HIF&A*^MQ
MX>.@/S.':GIAR"K!`M!ZB@8*#4!`#5#Q#UJ\PT%R&)+=ZBT>05*Z31!,4DTD
MO-5.5(@@0H!ZXA4_JT&A0YZCY<.`8]Y_*DX=F"YM&*!"JI?CB';J&#\6J8*@
M<"]!J"(@(4`VGI8YR]90T>0"K?95@#\4]5)3D4Q"K#_I?5&GPZGXA[I/K*,"
M,5R6]N(U4ZET5TZ`!B&1$IC`)@`.`<`'JIHU5A@3)N\J&F+L0NR/5=))`)6P
M.#J5%8X*D*;K)0M!*8*U*`TT&4VQ)]:#"+9!7<KT""4RK1TE3Q!#S"#P#CU<
MN&EJD,B?64A&(R"[3OFA#)KIGZC%`Z)DQ(<IQ\THB4YA$H!ZABZKF22"27[R
MD6CDK_'@0B*92&(H82E,<Q3E^48*F`0*8!J`^&JR.TGTE0+',*ZE*)^HI^`"
MF:O%2@_N0`:B%=&D=OK*6F/(+BF;SD2H@)A,(@!A`3EI0?A-6FD8X,Y]:-,>
M2O9#"4I2<RE*4.9JU#X>K3T]I]:EICR"[6PB54PC6APZAXF\`\/6T:>T^LI:
M8ODJ]N8U:ATT'E4*T#C\.C2_$^LIZ02RN*8!U<OW/P!73C!\R?6575IP&("K
M2'$3"`@6@`/A\-/3IF`YGUE5:8L[*N1XT"@?T#J)CAF?64"()975O2HC0*A2
MG[.C2PS/K*C4`B6"NJ90$0$0#Q\`\*_!K'U2YGUE8ZJR4*8!`I0'T](?TM,$
MGB?64CABJROJ@;A7@-:!X_8T1<EB3ZRC`XE5Z8B(`%1Y`/`:#]L-6`=I]900
M,F5<01"E#&^53Y0_!IMVGUE42PR"K"\0XB(TY5,;^GI:0V9]941,C'!527(O
MPTKS$.?H$1U03(%G/K5COFKND/2%``/'F`:8)/$^M1.;*L34,(#R#@/(`#T:
M"9"3.<>U1E&)S`*NK?B4M0`:@/@'@)OZ6J]4W9SZU"48C@%<"#2M``.7AI:'
M+DR?O*@0'R"N"8!ZH4#UJU_ZFEIQS/K*-,2,E7D./3X<.'+PIJL@N<9>LJ!A
M%V56F-!`.%/AX^%=0#NSR;O*!"+*Y)*=11`2)T#@'J!Z.?QZ)..);O*D\HQ8
M$JM2$0``#AQ'EP'Q\0XZ-,&?3%8YJ5/TBKF0Q@$`ZC<P^^'^GJ`,?T0IO-B=
M4L%=TA$I>`CR\1$?'X1T$A_=BJA.H0QD56)!U4`1J`UKP#PH/H^'1X/T8JLR
MG'*1]GY%6E```*!X>@-,"'Z,5/74,<9%7!$:"'`HUX<2AZ?BU75C3,6,1FJM
M4@<RJXHTY`4/]"7^EJC13_1"F"6S5<!A*(`%*#7F!?Z6K12I'ZH59E4.<I*I
M(0@@41`*CQ^WJ<80B<(A0)D3F55HE`HAT\.?+[>F1!_=BAY`YE7=L4!)Q#[X
M1UCU(0..D*F9D)#$JXI%*)R@(!3ER#^CPTO+IGZH54:E1_>*K"B(5`!$``0I
M3ASY\M3%&D0YB%,SF(OJ*K2"(A6HU$`^^-\/]5I"E2?W0H!Y!R2ZJ:`(!6H\
M`YG/Z/Z[3-&D?JA-CS*K$R%"M*A2GB/'X^.JC3IA_",.]5ZBKJ0`Z*TXB'P^
M`T].J1&!FQC%E$DKD0`"@4YCZ1_IZO\`)HL#I"`2JTAA+R``_H^/2-.E^A%&
MJ0Q!Q58D/48H&`!J%>->=!'A00U"5*BSB$4:YGWBX[56$*'36G$!$.8CP`?0
M(B&J=%,'W8I2+C(>I5-/']H/'[&IP%,EM$6[E`,PP"JP`:!Q'D'+Q^/AJ[RZ
M7Z$?EZ5%^P+F2O4'K&^W]G3\NED(Q9!8Y@>I511&O,>`AZ*\?AII^72)QA%&
MF(R`50!SA]\/]'Q:#1HM[D4F!.0]2T_N.#_%_P`T5XUQC>H#41X_[0//0(>`
MB'Q#K7[J?*VZO"F!&,K>H[=@69M\C&_HB.`%2)]H"<%VP6W<MT9>WH0UFP3F
MY[D_FXNR])Q-N,GL7'O9M6WV.XV>5BV+V;?1<.W?/6L8=-$SIR@AYIB@=0A1
M$P?.8)(<YKWYFP2@-P.*^X-ER_K=-8".9,;VG`FS7?"KAOG&&M-G)3%[6FO-
M89LYXULG(+E[*_O;W8FBPDFCM(T*)^H$3O&9C'%\4UK.)VC]QYDEG&>:Y-R1
M"7C)OX*V\9.4\X2\G$&QZ>Q<F6_>,H]M$UV-+:F,E/`:6JFSG)0$YPKU,BQ9
M)L(+N2F'%'S+:M@X"WH0TU:@Y!E]Q61;)C&6-6=U-S9V4L>_'$'$L;B+`6];
M8VIF\("6=V]<CF*E;WE)1VWGI`C->-)+70Q5,!QPAEKRR=J?<F81USSDAFO+
M3O(D2R>+8X>75F)XTLYG?=T7?8C'($K)61$7G=]O738)[?1GGEO(3:3P8QNL
M0647$+@DS12,&6D;UQ9F^T.ZSVKKIOMSG&-Q7)Y<S)`XIL/*.339)1LQLQV%
MY[6GF5U3:^8[Y>3^47MXIS3XTBHP?"$$]9M@FC`D$:U:2DVZ2:A<^\V*`CN"
MQFIS/]6)F5,/ZH<Y.@X>GGKT7X8R(ZAER\F7S+6[K_9X_P`=1E+5Q7D6Y++N
MV_+<LNY)^S[&!DM?%T14.^>P]K?.97(L/GF11+[&P]H%J82`J<@&\*TU[W7O
MK*S\J%Y4C"=9H0=W,F&6#<1S6CI49W1G&A[](&<NV`S'^A827ESK4:B-*5&E
M!&G48.(!X#35\@03$AB"H``ASQ^G)4S>J0ND1^\.55,/_2E#<"AZ>@-)&"YN
MSB)"HI\3K*>6!@^]`1IYG*E`TRV2%L"&QAD*;L>YLB0=F7#*V!8ZT:TNZ\8^
M+=.;>MM>86,WBTIN7`@,XY:36+1#K,8%!`0#D.L.K=V5&K3MI5I>=7PCX1C_
M`+K#Q'GK=.G"53S=#>'):]/^)=(J!P*XJBI3CZZ8"*9AK6E0UF#/O49%NY5^
MA)=")`65,O2A4>I%$>(ATE]8YN-:]8CPK]C0Z9`S7<012<HG.'JN2BB<W*@I
ME.=$34\:5#X:Z>`5?%E=*"`B4`X\^J@<A^,/$--VRS3[%TB'GJ)(#ZR:%'"@
MC3I.H8?Q1!#E^+\?37CI2D3FH3P#JX-^I-RLD;@"PBY*```%`3#16@!0`J<0
MX!P#PT1\3@H)5R3KU&H/30O5PX=0A6@"(4KHD&;2EF>Q=*A#.3'3$1,FDEUC
MTE`QSKB-4TR]732G2/C2H\=(0G(CPZJ3@%O?#Y:1D1S<)384R?K`X+9%PXQO
M&SF%H2UZ6--VQ'WY`(7/9TA+QB\<TN2WEEW#1*<A5%BIG>QBSMJHF50HB43$
M$*U`=8D;FWK5ZE*A(2-*>B6!!$F=I8828C+!$J<X4A6D"(=K9K&TV1.C\6JX
M0+0PU*HH8`Z.'F%*<YBCT<>`A0=7$-EDH1E%G*S0,:9%C[/CLEN;;N1ICV?D
MGD/"WN]B%`MJ4DH[H._8-),&YD#R;4AJG)4"E)S];6+"]VX7-2SJ5X1O!$$0
MD_'M`;%/RZDJ4JT,H]RM")7PF$/)07,:H)I%%1-4/6Z3=12F4\PZ=0``+P,>
MH<J:N&MC(L=.>G+T.BJ13P&9`_.MNWS@[-F,[=M>[\AXIOBR;6O+I&UKAN."
M>Q\3<*0HD<]42]7010>""%3&\L3``#P'6)1W/;+NM.%&ZHQG`@2@=1(/:64Q
M&IY49RB6.+]F2U^W62(4.HHE,`<2])AI2@"`5$>&LUP<B".8XJ(Y]JR:W828
MNJ21B+8BI"?F'0F]EBHQLN[>N13(99P9-!)(!.FU3"IAJ2@<Q'5=>K3HTIU9
MST4:47E+/YU`BI4E"F`\ZDF"ZO),DJJBL4Z*Z:JR*A%"])DU$!`%B'`>(&(I
M4!"G"FG&M&L!Y>7R^=U1*-2!TSS&'I8*X,D5%UT$$B"HJLH1)-,I3&,HHJH!
M$DR@7B85#"```<1$=6$:AI!:9P!3)$(^8<@"?8M@W=CR^L8SH6OD6TI^S+A^
M;V$H:'N:/7BY,&$NU0?QCTS)1(BAFCMFY*=$Y0Z3$&IAXAK$M;ZVOS4JVTQY
M%)X%LM8[<3GPR2K4*U*,#5/O1U`\P_T,K&G7I"E*A3C7A2OK?Z&FAFP6*LPL
MJR[PR'<3.U+&MN8NZXY`5S,82W&"\K)NRMFJ[QR5NS;E.LJ*#1N90PTH4I3"
M/`-2K5[2TM_M-W4I4:`9YSU:0Y8/IQQ+`-Q.*E&F9R%,9E6UTR>QKQU%R;9P
MRD6+M5F^8.T3MW;%RW5,BNU<I*`4Q%T%2"4Q:5*8..HT:M&O'SK:<:E(C.+Z
M?;BBK`TI"!S7<A4:^/@'VR^@!UD!1"N2)#*=!2CZYS%`I0(90XF.8"%Z$R>N
M>AO``$?@U&1R@/>/'DJ:K`.Q+<`MJWAAK+&.(:WKBO\`QS=]H0%V5&W9FX()
M_%QTV4J1%3GBEW::/M?214@B)>HI`.'5Q$-85/=;"YOIV]K4C*,&$@,XG\^*
MMJVLXV_VC28Q(P]#O]'J6!=(%H`%,6A@#C6E:`-`-6@B%>.KI!JA'!58:0>*
MN1/V_P!K3"@<U5I4IQ"OK4'XN%0^,=*6!!3XLLF@HN4G)*/AH2.>S,O)NR,X
MZ*CFRCEZ_<+")4VK5%+\:LL)ZC4I1``YZCYE"$)5*WA@./)0TRG/3'&7)BM@
M9`Q3DC$\BSB<EV-=-B2;Y#VEHPNJ)<P[IZB"@I'4:IO$D15134'B(<0"@^.L
M.POK/<!_RE:-0QS;BI5K:O;C76B="XR%B7E!P%NW7,VW,QEM71YYK<G7T<Y0
MC)WV4Q4W01;OI\EP1%10O48#"``//5GVJV-V;.$P;C3JTXN!FQ4-$_L_VL1_
M8ZM/I5B2`H@`TI4M:5\1`/V]#EG.;JK,NJDGR@^S]P=1&:%<$.0_&&B2."N;
M8H&`PCQH:@?9KZ-1)(#+'`!]:N*1>HP!XB/V?M4&M-1BG(M$K*I"!G((6I)J
M(D(PS]HF^9`^;BV!RS7#J0=-RJ"14R*I>(&$!`?#485*-4D49:I#/L4)4ZM(
M#S8Z0<CS5.01#HI0*#QK6@A4`$.H1#Y5/@U,2B,^:@8F78%LFP,59+RDL]9X
MZLBZ;W=L$B+.V]M0[J57:D5Z_*%?V=$42E4Z>'$1#AK'O;NVVYI7->C#46'F
M$B(],<7Y<,U=3HW%W(T[*D9$1?Y.5;!MR>;SJUL*Q$DA<B3WYI-!.&:Q9=*5
M(IY*C$T<!"N2/2K>KTB4P=5>%*:KC=TZUN;P2A]D_2B7CWXXJF=*5&J+:IJ^
MU?HD,>Y7*9M>XK:G7%LW'"2,-/LU4D',,^;J-Y-NLL<"I-UVBA07]J4,8``I
M"B''TZ=&<+MC:G5"3X]V?L2JPK6\3YPTR#%NPJY75:-TV1+_`#!>-O2UL3:;
M9L\4BIMBK'R)&STGFMECME3GZ45TO6(:M3`-::5G=4;J!J4IZAJ(9LF3KT:M
M"0A4BS@%^;JU$^27X@UE\51Q54ES#XQ^YH*#FKLU^1_HAU3-4S]X=RN2/]D+
MI!41S]"JBAS_`*\@?8X:L!P4IG!5X``5IZ1#[`<M`1#W54!R#X@^YIJ2JB&&
MG/GSY>G5)SEW*C@KN7Y`?%K&C^\05R+][\8?=UE\`D,E5%\=0*)*M1^43XO]
M2.HR]TJ*KD_DC_7#]W6.?I3.2J?#[`:E3]Y1&056'(/B#61Q4%S)\H/Z/#33
M&:J0^5]D-2&:?-=VF<E$9K4.X_\`-_S/_!E>W_<%YK5;Q_8*W_3U?YH678_]
MPI?QX_S@G>^V8(!O,W-"(@`!VYNSY41&@!_<1NHYCKYS'NA?0'%/E^:E_LJ?
M^G+_`$]-"[-"$:$(T(356^?\^GLU_I4[D?Y!6Y70DG5=":A:>\WF1+N%Q<9<
MW24NV1D8HB/#J#.3KB(4UZ/\+P#U"7R\F7S+6[I^XC_'3=6RYRBOVR^Y>"2J
M"E`PC00Z0JH=_=A3H`900`YCHF$U`]'P:[SXB0M3<=/^89"7WE!\Q'$TAB1P
M95].O3O;L2`\NIM]?O+&+?2L#[3^$L69XS=E&ULJV3%W_%1&W[)-U0,5)GD2
MD0N2&2C?FV10^;7[)91TR%P82@8QB<>)1X:VG7&X7UETQ7N]NN*?VT58>*G*
M)E&))?`O@0.(6'M<(SW6UI7D&M)5!`OE+##Z,DL#:5M'P+>.`-D]Y9`PY$25
MPY.WY2F+KTF)0;@;.KEQHA:_MB,`L1.2:I&BTY$IP!1!--41"OF"`4UJMSWN
MO]^SH[?=&5I3Z=K5],6;SXS`$R6?5$8<NQ66%M#[MW*=T/VU.\I1I2_1A*I3
M!`[")'/FM\SUB=N\EJY1R.78_:\<;`FZ=/!$+;J>2+V389&97#<+F)/(7J83
MKJ=$8HW4%H@S.W`B92@HH<>.N:L+WJRYN-HMOMTS+=J$I$Z8-2C!GE$MXI$%
MR^1X+87UO:VDMUI>7'_T^E3J`X^+7'4RM>XK:[AK#>)NYU;M@6_)PMM6UDS:
M8ZM2WVEW7:W@(>*R#[#-2L"M"-YQ*$N!HU4=]#<\DW=K($J*9B"(CK8=.[K?
M;GO/34;NJ:TZFY7]*<B(@RA1<0&$0PB0_A8\W5_V6WI&XJTX1A3J;6*L1RJ-
M4>0?%\!V89+;V4=L^PF9W/[D=ED#L]MZTW%L;;+@R_!YDA[PNQ:Z+>NB$L16
MY$6L+"NI%U$M8DQF):BO[0H=110`H`A3GZ6\=4?AB\ZF^WU9QLMSIT/+`@]0
M2G2BSZ7QUG(.JK2C:?>NU[?4HPF+VW$B2^<M8U8',,_HR7#%FQ3MQVAMYVZV
M5F7Z(N<B;BL#+9$E;J<1>:;IS:A)R\(HX7E<2LL;PLY981-J.E2"<CY!<Y`(
M(GX"6N5U!U!U3>;ENEOM%6I:FPJQT?NQ3AE("OYNDSC,^$F!&!(<'%5V=A:V
M8A=735:-6M.F'R.EXR$`#J$HCQ8YYY8+#]D&SS9+>FV>WH-3%F.LNYON1'(!
MG,=E^XK]PWD&\G19MS;=I*X%G9@L78$Q$)-&9')B&)(N2/!6*H4H4`,CK3J+
M?Z=Q4J4)U[.WA0H2TT32G*D33%2KY\9"4_"68Q`B8EA)U5MEM8PK51=$ST7<
MH`R'[.5.+`:2&(E)R<268X>%)'LO%>W/:?M;Q;DW+NSTNZN^\XY]R1C.1A)2
M[KB9O<<1N/)*)AV-OVH:S^EM(WW/?/2GD>>"J3MRW`")@4!`=[N6Z[GOV\T]
MIVN]%E0^Z:=S&48@3K3J@@Z?,!`$):=7Z`+D8JNA8T*5O>[I<,10OZ=$4Y/I
MA`^8221B6$27^M$8,0E6;2=H.Q6W=NTCN!W`6-$6TME/<%=F-K5L+<>WRR^G
M,>VU&*F<0EIL(W%$.G,'R8NU7`"*/VY$71")F!$#'`-:?>=^ZAG<VFT[;<&K
M.-EYE2M0T#S)1E*!)-3PX2#3`Q$G`P"=.WHRJW-[5IQA"E*G`4R?#XH4YB3/
MJ.MR1BS29:]/@;9#MOP5O&R^M@]EN2C<2[M[3LC%Y;^<7YCR14@+IL2,F'5O
M7,T71AITL1"G>NE`3,R1<'502-Y@$`P&A/>.J[RITWMAK^1=[E3N(5)0\N6H
MTQ=2C6)#@:A2C$`8`@\UFW%C:5+G<*].-/R*5G3K:`)-2)G3B8@DYDR`Q?WN
MY;!O#91M(A]P=]YOC\,JO\9VCL$Q]N_C-M#>>E_H_+73=J\DQ6M@)=N9Q<![
M:;HLT7"H$5%85>NA@#@%M3J3>=KVR^V^I7E4W"EU#.P\^>D&G3:/C$0&.G%G
M&>;X*BSV^UW6CM5_$1I4+FWG.<0[RTPIRB0YS/F>H+6FT_`^T[>#GLN5)[:]
M+;:,46-MYN#*MP6%/RU[2.(,AW#:JC4J$O9KHD:-[S-C,V)S*S";%9TZ.*I!
M2$@G*76PZ@O=]Z1V:],K^-Y?_:Z,*9GHU4*-?6\ZD8L(GP`T]3:?%J=EJX>1
M?WMK;4:)A$^>9&+M4\J5,1@Y?Q/+%F<8#FDR]S3%&TJTVV#\B;8W5L11L@0T
MZVN^W\>P&6([&;QS#R*Y65T6-)Y4B6$H_;*MS@W?`5PY(1TGZHE`2UV71MUO
MPW:XL-WE4J4"(5(:YTI3INV)-`L(G#1&6+8XOAF;C1LZNU0KTHPA*%0Q!B"/
M,#2]X$GQ1D""S8`!L'+B.+-N^`+UNS:$RRE8#F_[6)VP;[RS,6]+W=>#PA;D
MMZ;GW#65AA>SCE.WU4$&Y_9VS0B;(JHB86XF,(CH.H-UW&QH=47-I6E3KV]]
M0C3D`'CKHZI'+%^9?@K=CM:6X;=M5&M$&5SN$Z<W?Q1:.F)[B7P9)"W4X[VY
M9&[<V.-V.*,`06WR^/W_`.2Q%+PUIW%/W#$3<0VB9MTG)2#F?=+K"_.DS04$
M$RHE!43\!+0-;':JN^6?6-OMFY7D[BVKVAJZ-($8_M*D1B`^`AS6OM84-PVF
M]G2HQA5M:NG4Y?`1?C_"6Y-I&$L9Y&P)V^XN^;<<71!WONFR=;5VP<G<EU&M
MZ4A6UHR+Q!!6`0GTH)FH5XW*<R[9!!P8Y2B<Y@J`W[W>5J'4E_3MC&(I['YL
M3IB=-3S&$W()<#M;L4-OC&IL-><@]3[;1@_'3+4X[BL\DK%V@7OB3<E=UC;4
M[:Q].[0L]8O:Q4JTO2Z)-YDB`D;X7CGD/=QG[KRFK1^DB`F*T(4W2!0$U:B.
MBVW<>H81V*]N+R=:WWFG*G*#0`C,4G$BPXD&7`8K87MM9RW;<MC\L1J6U(U!
M4QP:4FB,6R`"7KE*V<';E,\7NEG6T+=B<>;7\!61>\9$W)>N3Y.P'KN[H>#Z
M5[BM&`=.GT?%V\S7%$IX=!-RM4#*"/'7,VMUN.Q65Q?6-43O+K<96N,(FI$Q
M/O@R!BYR\6#8*V+7T;7;)4]-/[+Y^&!D!G%^,>)'O)'+K:#LCN7<*MD"Q(ME
M>-@VQMHNK.<WA:UXS)MKV;=ESV@Z!!A&6<]OV%C[KD[-GH]0KA4R:BRG44W2
M?PUO:/4?5>U;/>6MUC<?:J,:=Q7-(RIBJ3&M$BF1&)HL)1)'UAFJJEA975>Q
M%,QITJWG:A$GQ"FVDL7/BQ!&&2I=C&2,(W'NEM"]K`V/O<+(W!B7)#5R+R5O
M"0QW).8&,<.5'MB2,HW(\5>/V@BT>`9PK3@*?0(<=CU%:[C;=(;E;SW.-[YE
M,5(P>(G*!&,9&#",22&.#+$H2IW&YV%/[/Y-,71IF6.9(8XG@MJX<VZ;%GN-
MH7,68K%Q;!2FX_*&0B,+8G%<Q7.O9\<PEUH]M:>+$+`:23H]PMD4A75)*E4.
M8P@($Z=::_W3?:$Z.Q;3<5Y5*6VPK&I",!.>L`F<I3\&BF/"T<6S5UO2M[H5
M]TN:+4H7)I`8Z&CAK8>)ZC9^Z^23M;V%]KVW+#%Y9A=85+NF"8W)RN([34G)
M*ZK5^@MO,7D46.>FCT6K"4)=2QY,4T"NT`*99,A3)TJ&M]0W;?MWO=NVRXKQ
MV^5:W%6<P(RE4E%\(.XT'3JEQ:18Y+&N;';J="_O*6JK2I"(%*6#:H\,C^8+
M3G>,,@KO;DO(;JL&ZN+<-&29.S`5PR;&L"#*1NY_%D$'":8]'$H5$HT`-9WP
M[AYFUW-*<]<OO"3SX28Y_F5>_3A*TLB(Z0:!8?HXNW^E.+6A@'93(7%C7"]Q
M;9(91W>&U,F7;@R2PNVYHR<9SD/`L),Z<3'G<.F39S+"H87"JA%"A41(F`<N
M<WO<M^I3W2_MKR=*UL;D",-,2)"1TB.(?,CM4]OM+,VNVPKTXU*MX91E+%PQ
M..'+T*CQ'A7;I>5W[#LUXYQ(3$*>47.<+8NBV+3O.\DB/D;*MJX`CY<;@9RD
M;.I2KH*><H@H@B8/4$HE$P#._O\`?+*TW>SO*YJU:6TTKFGJC`B%0U8#2`S$
MZ2?>!]:C2C:3%.M2I"/E;E]FEGXXZ27QX.!DDZ.+'V[8!QE9]\7CMF6W-W#G
M7+&1;==BYN>ZF\M9[6WY@[)JPM,8P5SR%TR'S@!BF>BN955(HB!^-=A&^W'<
M:]/;:%X-OA2VJE7UB,`*\YQ\0Q#`CL'%9-Y9V5M6O+R<#6IQO!",,?!$ODW#
MO6[]LNV#9W;^%4,H9JM&`C7F3\GW!;4+;.:&F4GUP6=%,WJR3*V(9AC>+]K^
MF**!JF&00*13H`0)2NL3>]YZD%Y;[;8SF!&T-252!I@S(T@$F?A;$X!B_8M?
M8TMOE]JN[B!C3C6C",)`M%P^#8E_5FFI<@6_CO$.ZU[#6DT&^L?6OD=D:-B;
MC9S<!\Y1GMR)PBI)O(-8R9:D2%3I#J1(8P%"OCKN^G+O<KS8J<KLC[7*E)Y@
MQ,G8XG22.[):KJ"G;4+^4+.8$`(RTB)##,YYJ0-G:X<,Y.RQEYAEG"$3=EM;
M?]MT)D*W8)Q>EYDC'DQ)BQ%LW0A$91*-B"-6@@B91L@)U"#U*`)@*(>06$+[
M;=KGN%M=3^UW.[>29X.`!(.<Q@[Y+LC0H;A6MMM;32-J:H'9X</2D#0$=MKL
MG"UCY\G-I=O9.<[@<GOK>;6DA<MX-[2Q-#LS-V;>+@UX]51\ZG%PZE0]K./6
M(\0UV]R.H*F^PZ7%[Y-2A:QJSK'3JJ:A(OB!%HL`6Q7-T/L<]IK;U2H1F8U1
M&-%R&9@3F^.:W]([8]KVW6V=S5U7)B&.S$WLB_,9_0Z'N2<F8]U`,[T\H5[<
ME'D0X;^8D@"U!*!!5X!4P5UI:6^=0;G+;+.A6\HW%2O2-6,0TQ"+QJXOD7`&
M&3K85+"QI3N[J=,>73MZ=31B1!R=0&+^M7F_]NVTI]*YXQ?:N"F-M2T)M\C\
M[1]Y)7-.OI*W9F6MV,ET;9@F#I0C,D&W4>F+5<5U1Z*]6L*&Y]11H"]J7M0P
MH[E&V(:#5&)<^[QP!;@%?0MMMJW=&U%"+7%I*I$XX%L#GF$A_M<Q]OO-RCIQ
M.`[5/!XUOF7AB,$FZDBG)-620%6B#."JE1ER(`H9!0I1$I^0".N^ZOKW,.G)
MU(1C&5248Q(X.SZN0P/+@N7VFE3EN]&VJ/*GK:6+`X=G:LOWMBWO+">#<LP-
MZ9BFK2F+BON!:6IFZ;:7/<\%)Q*S(7CZ.N5:-9S1V;_S@ZD#F.DAT!TZT/2%
MM7VS=ZVWFC;"MY$)ZJ<B7<$Y:B`>:VN[4YU[,W-*<A"G6E$QDS2;+@[<DJJS
M9S$S/;=L.MK*.'(?+B-[STK;3<LY.RD6QMQG)W"P;.I1NTB/(=O)/K6`2=:H
M$-T>@=85Y9WUUUO=U-NK2MJU.S\QPW"+GW@533N:=GTY2JW%,5*<KEM+8.[#
M$+&9?;E@;;ZSW39>DL7'S9%XKR>VQ]:6-9B9DV4(P93`0Z_SM-.X4"R9BQQ9
M`R:(@<"U`.JHZHM]_P!SOK':MOJ5_L]Q=1F9W)`))@"P(]WQMJP`[%G3VFR&
MXWEV1'R*-`2C0<LYY8OZR5FL1M5P1+WB^NYGCAJPB,C[2+QRS$8P?O)9Y^]_
M>$>U<+(.(=4KEO(.&A$D>IM[1UB(\P-RUC7V][O8[=?6-*XE6KVE[3$;A@#.
M$@\H9:6&63XYIV5A87=>TO*M&%.G6HR>DYQD!@<W=8?@S;UAZ=Q'M"G[GQQ&
MNI?(6X.<MF\'KL)A%Q<=KLV4P+2-.4'R!`9BHR`0.D0AQ,'RN%-;J_W>YI[K
M?4[:N9VE/9IUHLWAJ"<1J&&8!.>&.2T^W65.MMIJW-,QK?;=#EW$<,.[-9IA
M&W=I61\OY=CYG!]A6)!V&F%IVLE=#[(CJP9-Z%PIIKSEUW'%G\N"G3MP\E$%
MG"#4""-:CQUJK^XWZUV2TW"-W5G7N")&,1$D0(+:0V;L_);`4]J.\U[*K0IP
MM:0D`027EJBVK'DZ1[NTQQ!X<W),D8G'<1;%GR2%L77$VS'78E=MM2T6O(+)
MJ.H.88G.N$%)F:"!$SG.L!1^4//73]'7]UN>WSA=5)U+V$])/EZ#%\/$Y8GT
M+3=16=.RN(FA3$+>4'9W$B"^'$)S/+]KXGRYF*`/=.*HU1GB?;JWRI\T1$G,
M%=Y#3;P\:I&66ND/6*$+%")@$[8"K"!AZAKQ#C+"M?[5:[G<1KR-]._-&(DW
M@AB14RXG`<,5OJU&CN$]OMI0CY9H&9.3R`#P?NQYI"N=K'Q7>^VRS]QUCXR;
MX1E7%]R-AR-DQTG(R4%/LT$3KA+Q"DV91^#MBJ<"+&$PIB!1H`"&NEVZZW#;
MM[CMUY<QOJ5Q:^:^'[*0!P&EL2W'FM-<4+.^V6I>TJ(H5J%QH:)(U@D>]J)R
M!X<E5[0)+,\W;$]:=NWB3$&%;=FXN^<IY7CA>Q4M&LH@AC-XY.9:R31=\#TA
M3%29)$-YAZ=0"'`<SJ#[JI>3N.XQA5NJD)4X49`$2G(82+Y&//#!8&TSW&IY
MEI8O&(,29C.$0<6YOVI:V'(<^><Z96W>65CQ6[V%MW-$VM8%L)IQZ"EPRZ;9
MFQ<WY/\`MJK4A!(S`[Y0HE,H*QP#CSUQ]Q6.S;%1V6I5A3KW@E*4HO*%*(?P
MM'`<AB_%=`*5/==]E<4Z9-&U`BYPE.>!?'-\7P9(PWSVI<EK;N;C<7)%N(TM
MS345/12JID5!?QBK]),KQ$K9=99-(KIL)>D]#A3T:ZCHBZMZVT:[>;QIRE!F
M.&&9?$D@YC!@M5U;2JROQ4G$1C*$<,,3$NX;('D4XUF6W,-9:W#Y1Q5=6+63
MFXFV"AN]/*)YB4+.Q<I%6FH[8-8]@F9*'1:MBI!0%`4,-..N'V^6ZV&T7&\V
M=:<*-*\,#`,=6N<0^(+-_P#4M_=2M*V\6NW7=&-:56V!#@AM,9'@1F0/4DJV
M38N%<=63MJA[FPF3+,UN)>JIS5XNY2;:JVJBZNE>U096PC%"5D:4B6IR/3D7
M\SJZ!&G3KL;JIO&Y;K>VEM=BTA94M8#1>8%,5-4C+.)/@\.(6CI6EEM^WT+N
MK1%S*O>SI%W\($R`,#Q&3]@XJGRQMVQYCK"6:RP<4C<%RV%N?:V-%76`NG,T
MC:#JW8%Z2*=$;K>QB"3]\9$YQ1`3+=0`/$`#%L.H[S<-QV&M>3C;VUY;5#5B
M&T2G$W`!QQ&$(EG'!7WNSVEO9[I]FCYM>A*B89ZH"<Z6H8'%M1B[9+?+K#&"
M[%N'*DM-XEAIN(L7;-B*_4K:7>33%,]WS2:9)5PLX3?'=H&DWAP!QZHE*2H%
M*4=8-WNVYUK0T[>O*-66\5J,:@T_NQ-HC$,P'I.3JZUVS;I4Z%2M2AJ&VFK(
M'5XIZ'<X\^6"[-O.-MN^2;`1G7&+[&)>MZ2]YR86?>,W=5I"1J612CH"!Q-<
MDD9K`2;9HU51$QECO%/:5#=0!Q*6KJ"^W[;;L4*->I.A3HTS*5/1*0,HRD95
M0Q(&3,V&+JK8[3:=PI?:/LT15G5,1&0F($1.EHR?$DCTE^2;EF',19S'(>-9
M+'<:>YT+U<IL[MD9-ZM/6NSBG2[<\(B5F<D4^2=>5Q5,01,(5*(!PUW=H1N8
ML[NC="G2-M&1B""*IQQ+AW[L%RM[`;?4NK6I;"50'`ZM7E.<G!8^E:Q"H5#X
M:@(\_6`!H/PEUM*<M<=>3\.Y:H#03#-N/>%4!R#X@^YJ::J2<@_H\=4',]RH
MX*\A\@/B#6/']X@KZ7[WXP^[K+X!(9*J+XZ@425:C\HGQ?ZD=1E[I457I?)'
M^N'[NJ0FJH0]2OQ:</>"1P+#)5(<@^(-7\56N9/E!_1X::8S52'ROLAJ0S3Y
MKNTSDHC-:AW'_F_YG_@RO;_N"\UJMX_L%;_IZO\`-"R['_N%+^/'^<%<]QL[
M/6]B;N%.K=FI6">2&P3L,6Z\=PT@[C';B$N6\,UP4_%*.62R"XL9F&?K-7*8
M&`JJ"IR&J4PAKY6ZFN*UKTW>7-O*4*T+:<HRB6((&!!&2^U_@3M>V[W\9NF=
MHWFA2N=JN=YMJ=6E5B)TZD)5`)0G&0(E$C`@ADPS%#*1\U;[YI,W"V<M+BMY
M=!=*XIQ-1%5.:8&(<A@D:E,40X:^?.G.J^H+G?[.WK7MS.C.YIQD#4D009`$
M$/D5^Q'QG^"7P;V?X1]2[IM/3.QV^YV^R7E2E5IV=&-2G4A0F8SA(0!C*)`(
M(+@KU'`IX>&OJ$+\(%]T(1H0FJM\_P"?3V:_TJ=R/\@K<KH23JNA-0N?>:O+
M^L/B\JE.D^V-F6@A4*_OXN_`=>D_"YOQ!+_<R^9:W=/[/'^.F%]L6^#<9L^C
M[TBL#W9;ELQF0584UVQ\]8./[W93)H$7OL)ED;XM:>2:^05\8I"I5ZA,(CQX
M:]IZ@Z>L^H;:VI[C2G.WMS&<2)D-+`N!P((&(X@%:*E7G:UI500208Y91.8?
MD6Q"VG,]TK>K/Y'LG*JV3+<A;YL!&0;6](V=BG%UH-TV,J4GMS*9BK=LZ$C;
MF8K^67J;OT5TA$H#2@!K7T>C>GZ-"K;4K:O5MZX8B521;U\7<A75+^I5$=&D
M&)<%L7Y@\#P5+?O=5WP7^_Q^]G<L0CAUC7(C?*EC),L:XNC(ZW[N;1BD.E)M
MHZ(LYJP6:)MSF`6)TP9*J&%02=6J*/1.QV\I5:=&L*TJ)HRD*A!E3.)@2^,"
M<3$X$XE*-_<BC*@0/*F091Q8F)!!(Y@@$',,.2T6YW@[AI>W+PMQWD!`8G(.
M4FN9[K;!:%DD-)Y!BY!60;3*3E"%348()OE3&!DU`C00-TF+0`#6PI;)L]O6
MM:]"$Z<K*!A1@&_9@L):/T=1#R`PEQ=6UK^O<?:#4)E4N:485')Q$0P)YL,E
MFU][^-VF28[+<5>&3(:4CLW/<?R.24/H!8;%2?<XQ;HM;%406C(1F:+"-0;%
M)_:'EF<`%%.K55ETYL>V5K&YM14\RTJU)Q8$:952\Y!C@9?6(Q/%([A=&`AF
M!3\O,^YCX3V8G#M78OW`]W:V:KNW#+7]!N,KWU8<AC.Y;B+8ME-F[ZS)2%/;
MKYA\R)VX$`S.M#&$@.6[9-8HFJ4P"`"$8=(;/2VVOM%.A4^Q5+B-;]X6E*,H
MR!(R)\,>W`(C>5:=:SNA)ZMK2TQQQB`"P!S`<G`<U78U[F>]W&F'7."[0R^Y
M86`V@IFUHP3P=I2=T6S;LXDLW?15I7[*P*UZVJP*T5.B@2.>-B)D-ZHEH`A7
MN71/3^[W!K7]M4E*H?%$2)A/$'34'UX$X2B7!BX*5+<KFA5^T4FC,S,PWU)R
MSG'E/BXQ=7?"G<YWF[?,:$Q+CC*+F)LEDO+.()O,V78U[2]I&G$R!(IVA<=T
M0<G<-K-E7"JBY`9.$"D<*&5+0XB89[KTWT_N]Y]IOJ=7[8(B),7TR`P$98X@
M`,'<!0M[RM;>*GIE'5J,2&<C(]_:J/`G<AW8[:8"X[6QAE9W'05RW"XNIXPO
M*SK3OA!&YW/FF<W!#&O.)N$UNSL@<2**/(\6RZBB9%#'ZB%$'N?36Q;T:7VN
M%6G.A#1&0+'0,=!;.)9M)PQR2C=W-*I4N-7FSJES$GCD[=@79A#N7;QL&.;Z
M2L/-CMPED"Y7UYW4M>L#:V0225VR:RCA:X6"-]1$_P#,=RNCN/QKMGY"]$R4
M.'2%,:YZ/Z7NZ5M:^7.C"VCHIF($0Q+Z0W"1SCD3FI?;KF=:5>L=4I@.^/N@
M"+\](``Y`8+!I3=GG6X\:Y$Q-.Y!/<-FY7R,RRM?B,NSB).9N*^V3,K!K*N+
MB>1JUPM/+:%\OR47)4O+&@D$"A3.I=/;%&ZLY6]*=*KMP,:``:,93U$ALA$B
M51VXR/,J,]SOB+IY:I7=(0F>,FE"<=1XZ3")#Y$#D%L]MW`]V4=DFQ<OQ>4C
M,+VQOB^!P[;#QE;-I%BBXYM9)VE%VG<5OH1!H:[F#;VTX*_.R#E1<1`3U\)?
MACI^M1O;:H*LH7MR:U<D?[<YR#8_ZV;@+&A7KTH6E*B6A9P:.+-@(F,>08`,
M.`5>\[CN\N=S5:VX%YF9^WR!94$Z@X3YM@;:BK0AX-^5(CZW4<?1D&WL0L/*
M.$2KO69F`H.U2`=0IAXZPZ?2W3-O9UMKC2J3A=-YDR[S,0P,I%S(A\'RX*^I
M?7=64"&IT:,C*$1EJ.9'(X9K`MPFZ7.>ZFY8FZ,V7F%URMMPQ("!8LX""M.W
MH.-!072J$3;5K1D9;D6+UPIYJYT6I!6/035$-;#8]CVKIZM.6VB4JE0`5-6<
MF?2Y+DLY9\E1<7M:ZIPH5`1&!)B!@`3F6YE9U;V_+<Y;4G9+V)R%'M%[+P=/
M;>+6'Z(V6\,RQ?<"KIU)0!BO($$7;IY[:M1XIU/$JCTGH4M,:^Z5VV\C7I52
M#0NZHJUGQ>40(B,N$@`&8\">"OAN5S8TK<401Y%?S(:21HEAX@V1PX+!3[E,
MPRN`VVVMU=#-?"\9?:F1(VUPM^W2+)W;Y*\>ZF"W&E$%N51N9-8Z?E>=[.4`
MJ4O$=7SVC:_O*&Z$5#N%*CY<91);0"3[3(^M8U.\KTA7MZ0TT+BH9DC!W8$'
MGC'V+/\`'N\G<+B^W<86Q9%YLHJ)PQ><OD+';1:T+1EC0=SSS%>+D9)VZD8-
MT[EFKMJY.4&SDQT@.("`!0!TKS9-NN[N>X7%*9JUJ'DR,:AB#3_1[GQ;GCFE
M1KW%&D;6W,!1,A(OD91RD1S'`YJ@B]W&=HRV,MVW&78U;P^>)Z)N/)$>>U+5
M,K/3L%*KS;!TDNK$"]A/9'RQU119B1L8!H(#0`UCQZ<VBUIV=&$*\/L4B:8<
MD0<-X3P.EAAP5LMPNYW5>O5(G<W`\<G?#CZ\3WK9<!OZW7PF73YSB,EMT,A+
MVG'V5(29+7M-2+E;9B6+5@QB)BT_H^I:<TW;MVB0D,[;J*=1:CQ$1T2Z<Z=-
MM5LC&J;6M4\PCQ>&9SD&.$B>*J-U=DT33+^1$B+DX@^W+!?'.^_=7)YL8[@W
MN69,N48N.)#Q$BQCX.+A&5O)%$BEN-;/8QK.U0MM41ZEF7L@MCGYDXUT4.G>
MGK>PJ;6*,ZEM7EJF2',I,!J)+N0PQ..`"*]U7NZL*Q/D^3[L8EAVMWXK*+@[
MA>[JZ\I63FB8RL8;PQXS>,+--&VQ9\);$,VD"4E$B67%1#2TCIR)"@*_6S-Y
MQBEZJTUCV_2?3-C95K",)587$-$Y$.3`X:2>(#J=SN-W=1C&7@IB0F,3[PRD
M_`]H6:VMW.=YEI+7H>!RJP9C?%P/;IEF_P"]]CYRTCYZ59BB[?V>U=6P*%F*
MN5A$ZBD5[*)E?6YA76'7Z%V.5"E1-O4TT8F,)^801"1QBWZ)?&.1=3ANUX:Q
MN'AHEI!AP.G(GF1F"5A6&M\NYW`[6[8_'N3'#9I?DHK-W,WN"`MR\$',Z['\
M;--?I=%RY8Z;44.4XN6Y2+@<H"4P"`"&=?\`3NP[C3HT:M*5'[.`(3C[P`PT
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M6M5[\QN;Y178W`JX6?0[IU*`Z2?'3Z'8F*D90#)])RE,$[W8]OOIW5Q.-3SK
MNG3A.+90A,29\VDS8\U&-]6H^\/#YGF9GWF]YN;<>*RG%6_+=/AN-N"'L3)R
M;",N28D+A=M)2TK-N!NPF)%1PH]D[?1G(:0/:3M5=R8Y5(\[<X"!1`0$H4IW
M#IK8=U-`U85!Y,=(_BAO#_%PRR3&Z7M.K4NL)QKRU-CGS[^U56)]^NZO#+:Y
MV5DY76*UO2;=W+,J7)!VW>!3W`Z%<7<O'*W5%2Z\1*N#N3',LT424J4O'@&G
MN/3.PW\J49T:HIT@`#$9MP[NS)1ANUW3E.KC/S#DY]??VI-$E=-P3MS/KOG)
M=S+W/)2XSKZ7DS^T.WDJ9P5U[<N8Z)^L06*`@F/J"`4'AK?6EI;6MK&TMX>5
M0B&`&&![EAW%6M=U37KG54D&+XX<NY*1DMY.X2X):^IR1O5FM(9*L9ECJ[EQ
MM&STBR%I1Q4DF3!))O"`DU<(@0.EPF)53CQ,-2AK2#I/:XTO*&D4(U?,$6P,
MR_BQPU8D/V]BRH[M<T90G`R\V%/1$ZBXC^B"[Z>S)7;!.\[<7M\MQ_:^+<@%
MB+:DGOS@:'F;<M>[XIE(\"*/HIG=D5)-HJ0,0H%.NV*F8#``UJ%=&[].[3O$
MXSW(3C7A$1$XMJ,1P,LVQ9G98UG?U[&1J0#P)+QX$GB1D_:K2KNAS@\MN_K2
ME+V5F8K)URP]X7J>180DC(RUP0Z_M$<]/,/&"L@R]F5*`@@B<J!P)TTH(ZKA
ML6R4Q0C1A.C]FB8TV+``^](-D99$\<N*L.Y7\Y59&49?:!ID#Q'`-Q`<K+C[
MQMP"]QW7=0WNQ/.7OCUGC"Y'06K:"82%E1\<WBFL85G\T"R9'3:-2%!=,H+&
MI435`!T3Z;VNK9BQIG3;QK>=D"3-WQ[>78B.Y7EM*$YOKIQT1()\(/`<AS"T
M_CR^[QQG=L/>MB3SZW+HA70K1TO'+JI+MEP*(J)&(9N=-RU<D$2G*H`IF*-*
M4UN;BE2KVIM+P1-M,`,<B<@X9CDZUXF:-87`.FK$N"WT\%MC,^Y/,>XE_#/L
MKW62=4@FSQ.%81\/#VY#QH/#@=\LVA+=:,(XCMT=,.M3R@.:E1$1UI]NZ:VO
M9*\J]CI^TMC)W+<B<V[,E?=;E=7]`6\W^S1+\6)YMS[54H;BLM?1_%-OA<[+
MYJPQ)'F,>-QA(,P0C_VI*1]I7>FC3.Y8"KMP$$W)CI!0:A01U?\`=FWU-SJ[
MG,515K6WER;B"&([0W#DJJEU6^S0LHAZ$9^8`Y9QB[9`]JV3;&\G<A:60;NR
M;"7YY%S7ZNJM>";RWK:=V_,K&20(*CVT'L<[MHQTC-B*$4%`!`U#!0=:B>Q;
M'5VZGMDJ<S3@!IEQ@P;P\L,,.&"N.YWLKG[86%0AB'/B`_2Y^E<8W>!N*89<
M'-S?(T@;(IXYU#A).(F(5BTX19N=NK$)6THP4MT(--)0?*;`T!$#"%"@(`(7
MQZ=VT;9+:?+C]FJR!G)@"2",21Q<#'-0K;M>5;VG=0EXJ0:(X1P+MRP6;3N^
M_<S>#NU)&:ON.<+61="EV6P#>R+,CFL7-'9G8'61;QULHIF;B10QO9A**)3'
M$P!7CJNCTCM-EK-"E.4ZM,TY3\TEX'.)?ZN`)CE@%;/>]P$1&6DP$M;$,'X'
MO'/-8MB[<YF[$-T73=5CW66+E[V*H>Z"O(.!F863,N]*\!5U;<U&/8,S@CR@
MIF]F*9,IAZ1`!$!E=[#MM]8TMOJ@BWH@Z2`!(=@.8&/!N"Q*6ZW=.\J;A38U
MJGOYL<G[RL6R;EW(F9;Q7OS(]R#/W&JBU;)N0;-6#:.9-%%56L=&1[!JTCF#
M)LJN82)($(D41X%IK(VO;=KVJ'E6E*II)Q).#Y8\U1?W]SN$]5:9$^#/@'6\
M$MZ&Y`Z^/UCY".@ZQFV(RM>0;0%N-7I8\Z:;8\;,OB1*2L['+H`"9D7HN$S!
MS#6%+IO;:=2M6T>;2KGQCEVCY<BKZN\WWETJ-.6F5/&,G.![^#A8EE[<=E[/
MBL2&2KK"82A2C\U1#2%A[:@V2RHC[2[3A+<9L8LCU?@!U?)\TP!Q'GJS:M@V
M?9YF[M*<I5B&U2QD`7<.7(#<%7=[G?WL!3K&`B#B!@"<,>_!9SB+=UG;!EJ/
M[/QS<D+#VU(N#/9-@^L.R+A]O7`OED%TXN*`>.%R$KZG68P%#EJK<NF]MW>M
M&M?F<ZL?<`EI,3WX%3LMRN=LA*%II%0MJU,Q'I6+7)GK*5Y7J.0Y6[#)7-YC
M%=5:#CXNVH@B[$P%;G-"VXT91"G2%`&J/K<AX:MH[+9V-M*S-(QB0P)GJ[,'
M]IXK$K[C>W=<7,F9\0,/FX*TWODN],EW@[OR\IL\Q<SMTW>+2)FC=NF#ALH5
M=`Y8Y!H#))(AR<4P#RQJ(B&K;.RL]NMOL]L`)'D`&?#@BZNJUS4\VL3H',DY
M=ZVLINGS8M?\ME%6[&87M.VVK9LE*DMVW!26MY9@:*%HK'&B?FQ!0S9;H,J1
M/SA`1&M=8?W#MWV2=E$C[+4GK(U?6!!RRS`/H"N&\WL;FG=O_P`Q1CI!Q<`Y
M8YL,<%=<:[L\^XLM<MEV;>XL+?*L[<LV;^&@IU2!<2/FB[=VR]EXE:0MQ4ZZ
MQE1,R.CT*#UAQ`-%]TWL]Y5C=70D:D8")E'.H!^F<Y#!F+A.VWJ_M=4:1@:<
MI:FDX$9/G$9`]N:XXTW/YMQ<E<I;4OA4K>\7_P`[7"E-1,/=J,C+D4,524!.
MX6+PB,DL`!5PF!5O53X\`TJ_3VTWT*4)VU0QH_NR):-(+C`<`7+@9N>:A2W/
M<K6I.M3G&1JXS?%\0?2Q#XY,ZO$ONBS3=*]W/9V[D9)>_+/@[$N9T$#;Z:TI
M;5NF\Z/;*^SQI08.TSAU"NG^-5$1ZQ$=5CIK;+:A2L[8,*=8UF)U'7+$D]KJ
M=??=TN(DRE"!T&&3>`X$!N!'#)E>,8;I\Z8FM5"T;+NQ)G;Z+LS]BTF("`GQ
MA5GI3F=?,CJY8QXYATW#DH+&%H*8><'53J&NC<]AVO<[@5;B-35&(!,<I`8"
M)/$#(#%@ZQ['>=SV^,J5&5,Q)=LM)..H`9$XK`$,H7P:U[FLU:20>PUY3R5S
M7"=Y',7LS)S:!C*J/?GIS'FFFY'!U#"H1)8$Q$:TUL);;:W%6C<1!I&A#1&/
M.(X,J#?UZ4:L*C59UB\I9X]O-8>6M*<0X\`$PF$O@):B4IO5$/'CK8^%WB&"
MUT79CB54AR#X@^YH4E4DY!_1XZH.9[E1P5Y#Y`?$&L>/[Q!7TOWOQA]W67P"
M0R547QU`HDJU'Y1/B_U(ZC+W2HJO3^2/]</W=4?E3.2J/#[`:</>41D%5AR#
MX@UD<5!<R?*#^CPTTQFJD/E?9#4AFGS7=IG)1&:U#N/_`#?\S_P97M_W!>:U
M6\?V"M_T]7^:%EV/_<*7\>/\X+OW+I"MBK?JD`5%39'[OR6GQY'S`&ODOK66
MCH_<9<K*H?Y*^X?\OD_+^.'2L^6]VI_X@3*TC;@KH)HF%PV*L^BT3.6:IVKQ
M`JLDT3%9JZ3HHW<I`:I%"C4A@`0Y:^2>C[^,^JMN@^=Y2'\L+]K?CEN$:GP:
MZHIOGL-Z/_X\UZ3V*\7L\4PC^#97EDF]DW\JI+'DLGWU-7]-MCJ-6K06+*5G
M%%7+2+(5H"A6Y1\LJJBAP"IQU]OK^?%;.T(1H0FJM\_Y]/9K_2IW(_R"MRNA
M).JZ$U"R]YR*([@L9&)Q.GMD8*`'P%SFZKKTGX7?_D,O]S+YEK-V_LP_CJ+(
M0P&(0X??ID,/QB`&$/AH;7OTP'!XZ1\P6B!*^GI\L>/2`FJ/$>H.(&#X0#QU
M$1`R`1B!@NAN`F$5U.(K!T)U\$RCU5"OP\?CT"(Y!E$$L^97Q'\6X<(A\DX"
MX3#P$3"->'+B;C\>IZB#F<D\`_,Y]JJ:!PX!P-UA\!_W0?U7P\]1<C+BI*F=
M&,8H(E^4X'H*/B4@?+,`^`B0>8:&BVE@R@0/2OHD(V6;F(-"F(1KPX<2]*J)
MN%/6HF(`/H'1$"#:`W<@X%7,@C0?A$*_#3E7XJ\-2!(=CFEGFNWS012,<WR"
M%,/3]Z-0`:"7D(">E0\=!)D&ECWJ``C)XX'L5(FD"1TE5"@;VLJA5A,`"(&$
M.M/G7F``'Q:'=GR'SJ7;Q5S*Q:&(`*-45.%!*)`"H"``(B)0`1X%`..HF1<G
MGFJG.K/!=AF#,A14`AR"7B'0LL6@TZ0$*G$.'#[`:8D>WVHP9<6#`I17(+AT
MF8QBJT3H(#U@8H&.)P'J'I+0!YTT"4H\2.Y-RROB;5<A>DCM42"(#Y:B2(DJ
M%``1^2("`!JN>)U'WE&1.2^NOG$J8=2B*E353`"J$.)@`0,/44W`03,(<!Y"
M.H,#$Q&1.(YE1>3-P5S;*/RI)@5JU.02>I^,/U=(`4*>L;A\D/M!J8E.,=,2
M=')\$N#<%=D'#GU`68&*)>HW4DH4PUXC4`,(T&HZA("7O!RAARP7!LZ+YQRG
M15(DB-.@4R\`$:AR#IH`\M2$I1#1)`2``+LLA3=('$#5,)C`):F'UND0H(<Z
MB`E\/1H>38$J3@KO\\A#>HH`"J'E_$`\@X>`:!.<0P)9!$99@%75N5,.(?*&
MG4/C7QX_#XZ<9$`Q!+*%09!5@"("8`$0`0H(5$`$`X@`A6@@`CRU'3$C(*DQ
MB<2`ZNC?@(&#@8.`&#F`#4!`!YT$`TY$R/B)/>G'@."N;<I1$:E*-*4J`<.)
MC</1ZW'X]!E)B'+*-3#PCW5=T@#U>`<Q'[-!"OQTUA\7XK'524I:AP#[[P#[
M\!`W^F`>/IU9&K4U&6J6HYERY[TI$D8E5@`'2`T"OJC7QK4!K7G73A.1.)/K
M3C*6D!RP58`C0/AXC\(CQ$?C'5L:E2(82('>5'+)5R?$U!X@/2(AX"/IIZ=1
M..)Q*JJJX$$1`0$1$`$!`!X@`@`@`_&`"(?9TB`1B`52,,L%5)"/JC4:T`M:
M\>D!J!:\Z`(\M8\L9%U<)2S<NKLEZO$O`?6"H<.!@'J#AX#7CI@DYJ!`,@3F
M%6I"(%X"(4J4*#R*(!4H>@H^C49\N"#RX*Z-RE`A:%*'R@X``<*B%/BIJ3";
M"6('-*9)+')5Y/6``-ZP`-0KQH/*H5Y#0-0,8ZB6#JHDCPCW5<B``BF`@`@(
MG$0'E4WRAIRJ;Q].@2D#@3ADF"?8JTG$./'C7CQ\`#[FJM4@2Q*@<WXJL((]
M0<1_H#5?%N"![K<"K@B81J(B(B`=("(B(@40XEJ/WHTY:4@`&&3)$!O0J]'U
M:"7U1J/$.`^/HT,-('`+&!,7TX*Y)\!``X`%"A3A0*\@IR#4!*3:7.GDK#B"
M3FRO!`#I#@'`:APY#0Q:_'01#XM(>`G3AW*F.1'!5Z(CZH5X``T#P#@'+[>I
MB<V9RW>JY`9MBJP!$"``#PKR\.'$.'P#JLTZ<I`RB">X*1Q&.*KD!&I!J-0X
M@->("(A4:^D=*I&)#D!W47(P&2K@Y!\'`/@#G0/0%=5,%+,!U7FYD'Q$#@(^
M(@-!$!'Q`1#5D(Q<X!1,I'$DNJQ/@!!#@(4H(<P^(?#5@\):.`5<O&?%CWJK
M2,:H^L;UJ]7$?6^2;CZ?6(`_&`:4_$7EB4B!DV"NS;BF(#Q`1X@/$!XUX@//
MCK'E&(<@!U34`,@X&2N"0`)P`0"@A0>',.=!](5U*.`TC"*H`!))Q+*K(`5$
M:!7JYT#[X`ZOM^.@A\3B5.?ABT<!V*M)R_H^'4HI0R54'(/B#[FI*:J2<@_H
M\=4',]RHX*\A\@/B#6/']X@KZ7[WXP^[K+X!(9*J+XZ@425:C\HGQ?ZD=1E[
MI457I?)'^N'[NJ1]*:JA^1]K]O3A[P0<U4AR#X@U?Q52YD^4']'AIIC-5(?*
M^R&I#-/FN[3.2B,UJ'<?^;_F?^#*]O\`N"\UJMX_L%;_`*>K_-"R['_N%+^/
M'^<%?,^(^T6!OE0I7S=EON^A*>GJR3E\-?('Q#GY?0F[3Y;?6/\`(7VM\"Y^
M7\8^FJG+>+;^L":TG+?\B..MY=/*=1JE:<NB2:#Z/@U\.=!;AYG6VU0?._HC
M_B!?KW\8]QU_";J.#Y[+>#_@S7H\Z_1=?A<C0A&A":JWS_GT]FO]*G<C_(*W
M*Z$DZKH34+OWFCCN'QB`\AVQ,P-\7[^+K7I/PN__`""7^YE\RUNZ?N(_QU%2
M9U`%41_ULW4%>=!'J#E\`Z^@)Y1'\&/S!:#ZQ/:N2XBL=-L7QHHK_P!C#@`?
M9-J/8@JJI3AZ.&HJ2I'!>DZ;CQ3'I/\`UIQZ`^Y]O4AF"H255J*FJ5$?/547
M#Y`U3;?UI:C7[0:EV%1"[G1/,0Z2_P!F*45$@]*A"U('Q=0AH;@,T'(JH;J%
M40*H6M#AYQ0KZ?44_9#0[A5KD("NNFW/P3(/GKT]%!!O3XQ#3[$*M<E$Z1S%
M^4ETK)5Y51]8/"G(-$AX4U6E.51$AB\C%(8@_P!2/5S_`-%72EC%8Y]XKX8A
MEEDD@^00OFJT_<D&OV..D<F4P<%6_)=(&_UHW4V/\(*`4R7[>D/8FKLF("3A
M\KKKQY=/R>/V"Z.':CO7:W`';D3FKY28'0+\8E$51^P0P:A(XLJY'%5L?U`D
M"1N!FYSHC_IA.3C\*1]1.`9"NW4*2/F^%1+]NNF,`Z2Y-TQ2,B;F5;J(KQ\3
M"8Q>?HIHR0KLGTB<H@`4`1`.'P#_`$M)/(=J^\%5:%#@W&IOAZ__`,^@Y=R%
M=T$T^8)?N1J/]5QK3PY:%"IP52!"UY^/+[.I1`=5=JN27,?Z/3I)Q]Y7)'D/
MQA]S43[I4*O%7DG)/XA^YK'/TK&5<V^6'QF_ZW1'-"KOZ8?=#4H9H7>GR'X_
MZ6K$*X)_+_TNFJ:O!7!/D.C@J>"J4N1?L?=UC'WBK`KN3]O]K3"1S58E\D?Z
MX?N!I30<U<D>8?UG[6IQ]TI35Q2Y?T>D=5JDYA71/FG]G4>)4ADJM/Y/V?V@
MU4<U$YJM)\H/L_<'4/K)#)5Z'(?C#2G]"#D5<$O#XQ_U6G]58I^E7,G,/C#[
MNJ0K/JGN5W3^3_1Z1TSFJ8JN1^]^(?N%TPH2XJM^]+\8_M:8S3^JJ]MX?UO[
M8:A4456E\?B'[@ZJ3"KA^47[/W-714%6D^27X@T<5'BJI+F'QC]S04'-79K\
MC_1#JF:IG[P[E<D?[(&D%1',]RJB>/\`V0G[6IC)2GDJ\/'^N'3"(>ZJI'F7
MXQ_;TU(Y*L)]]]C]O5)^LJ5<R?V/[?W1UC1_>)%<B_>_&'W=9?`)#)51?'4"
MB2K4?E$^+_4CJ,O=*BJY/Y(_UP_=UCGZ4SDJGP^P&I4_>41D%5AR#X@UD<5!
M<R?*#^CPTTQFJD/E?9#4AFGS7=IG)1&:U#N/_-_S/_!E>W_<%YK5;Q_8*W_3
MU?YH678_]PI?QX_S@LQR^A[3;>]%N(5\[9S[O<2GIZLF9=#[HZ^-?BE4\KX;
M;W4Y;97/\@K[+^#<_+^*W3]3]'=;<_RPD)9`MMTVLV><,4FPO469%6?M8JE:
MB[(X0,W]I,B4ZI6XK`'6)`$P%K0*Z_.GX:[F:OQ"V6F_O;G;CUU8K]2/BON/
MF?#+?X/GM%T/^#-3PL:GRR>'>CF!MCQM<'SFH$<3&SVY'T.,/[,V%([Q6YX^
M.>EDA>"L!BD(*7E`00'J$P!^JJ_&Q;$T(1H0FJM\_P"?3V:_TJ=R/\@K<KH2
M3JNA-0NO>:3%+N&QB)C`4/JQ,^)A``_W\G7IUZ3\+O\`\AE_N)?,M;NO]E'\
M=14%5$DUD''644^@$5@`Q1$1``5(-/1QU[[,XC^*/F6B.:[6J=`.N)@$Z]3G
M^%&M`+\=0TQDDJD`X!0.&DAU\43,HDHGTCZQ>'`:5'3"1(5N\U1RDFV+P76'
MR%C<?Q!"_P!FZ?A.74&X<4U<R%(0H$)P33X!]S4TEVUZ?6]''[7'0HL52-U2
MMBN$S"`E0JJ6@U_%&_L90IXE/Q^#3P42JY@F8""H<**J&%54>/K&'@`\?@'0
M`R4O=5Q*(`8M1X5#J_K1X#^QIE1AFNIJ)6Y5$3T_M10W4->9!]<M!$>-0,(?
M'JL^Q.3JXL0&BBI_[(X-YIO^Q_ZP'IX$$=64L^U)5:R?FI&)\1@_KTP%4@_$
M`DTZO!"K`<@+4'(?+5Z>',?.4K40#F(`8P:I)Q?BRA('TJXM4P2`B8?*`HBH
M(>*IN*@_9-J!#**[R%$KT!,%4EB%+R&O4F`#]W2Q9"K0Z5EDT>14Q%8P#\'R
M>>GCF4\U<U0JF)J?($%PYUX#2GQZ2#BJQ%4"I>8<*@8*E]/5R"O'TZ$WXJL1
M"I:&YJ@(F'T&$!J/V0T,70J]I0J90J``"A@Y^CA^SJ:HJ9,JQ'^R?;_ZX-+@
MH\%<4.5/Z.8Z10,U<6?,WQ!_JM1EGZ%&KG\NQ75+Y1/L?<UCGZ5C*O+S#0,T
MI9*L#Y`?$7[H:E#WD#)590J`4]`:L"%7)_+_`-+IJJKP5P3Y#HX*G@JE+D7[
M'W=8Q]XJP*[D_;_:TPD<U6)?)'^N'[@:4T'-79#Y!?L_='4HYJ,O>5<GR_H]
M(ZB<RJY9JYI\T_LZAQ*8R56G\G[/[0:J.:B<U6D^4'V?N#J'UDADJ]#D/QAI
M3^A!R*N"7A\8_P"JT_JK%/TJYDYA\8?=U2%9]4]RNZ?R?Z/2.F<U3%5R/WOQ
M#]PNF%"7%5OWI?C'3&:?U56H?>_$'W0U&?N^E0.:KPY:H4QDJX?E%^S]S5\5
M6JTGR2_$&CBH\55)<P^,?N:"@YJ[-?D?Z(=4S5,_>'<KDC_9`T@J(YGN563Q
M_P"R$_:U,9*4\E7!X_UPZ81#W54!R#X@^YIJ2J2<@_H\=4',]RHX*\A\@/B#
M6/']X@KZ7[WXP^[K+X!(9*J+XZ@425:C\HGQ?ZD=1E[I457)_)'^N'[NL<_2
MF<E4^'V`U*G[RB,@JL.0?$&LCBH+F3Y0?T>&FF,U4A\K[(:D,T^:[M,Y*(S6
MH=Q_YO\`F?\`@RO;_N"\UJMX_L%;_IZO\T++L?\`N%+^/'^<%LF_T!<MMWC>
ME?.VD>[S)T]/5D_+H4^SKXJ^,,_+^%/4%3EM-P?53*^OOA7/R_B3LE3]'<J!
M_EA:#RC;8M\?W0OY(`",;YE:<0Z%T35KR\-?EK\)MPU_%#8(:L]VMA_Q8K]%
M?B5N(J?#W>H/GMEQ_524WW7[*+\K%;%9N&0=DCUI:-2?J+D:ILE'S4CL[I5#
MVI-L1L94%C+J-OQA2`7J$GK`%..A"J&3]C)-B/(YXU?M%!4*FZ9.$G390R2I
MT50370.HD<4EDS$-0>!BB`\0T(36N^?\^GLU_I4[D?Y!6Y70DG5=":A<>\UI
ME5W#8R(<@&#ZL3(0K3B(9Q=B-*\Z`'VM>E_"V,I=0E@2/)EP[%K-U86P?])1
M2G#1-=06Z12D$B`+&,`^J4P``E*(AP`Q@Y!XZ]ZFQ8#]$?,M&Q.(Q7:@V:+)
M$4&O4(=)@`RG`Q>%*%&@#PT!F0TEW>PM_O3KE]%##3[`FXZ?<RCI*^"T*7FJ
MX```1J*H`%`YCQ\`T:D:%;FZ"PK'4(LJ3SRBJGU&3"@EX5"HAP$`U#CWJ6DJ
MY^0[_P#7QOLE2I^QQU9BH8\U]\E__P"O2?9;\/L_!I&0;-/U*F<%<F=(E.=(
MP%$@',!!*F(G$>D%1#EU#Z>>H\>Q1+OV*]%^<:'$I&@B``4"E.H0X4,4!X\>
MD::FX2+A=H*/0*'6V3$:AR7,;X^90#A\>D&':D'.#*B4.N9ZD4&Y@\ZGFE*J
M7B4O$I/6&E34J`<Q`!TW&29!99"1VJ``8S%T("6A0#R1H!>%/6,741/3EFJS
MAFNTK\2"'4P>%*)R@803*H(DX]90!$3B`B`^.C699H&*Z6CQ(%CD'SP0;*'5
M*0$S','F"'2!PIZHE$.6H28'$J,@>2R1.39U]8QBCS'S4%2CQ"H\``.`#J+@
M_6"@Q!50N_:&(0Y%TRF1/YA0KT"("'$``YJU-S#0)1R<)L5<6+MF)05%='J<
MU&IEDP$A`$1*!JFJ7E3091/$(Q?)79)9N8IP]I;\0&@^<F-0H/+U^/V-)X\P
MGV(;J$65*W`Y.A"HF$#`/F@(U*!>/K4K7AH!&6"&)5\2H)2CXTX\>/AP^P&I
MB<<W"LX+M)\HZ?@H7U.'R3>(CZ*UU'7%SB%0<,U=42F``J4?D\>`_P!`5T]4
M6S"H)>2N"7`YA'AP#GI:H\PF,"KDUX%X\*A0*\/3J$I18XCY,H5<<E<T_O?Z
M/#5&J+9C-4,1B<E6(B`"-1IRYZ0E%\PH$AE<`XD``XC0.`<?1Z-2A.#YCUH<
M`8E5R7'EQX4^SPU8)18XC-&J/,*X%`>'`?E>CXM2U`\0J9XC!59`&@\!^UHU
M1;,*LX#%520"`%J`ARY@.L8R!D6(4P1S5T+S^QH"4I1;,*N1XDX>D?N!HDEJ
MCS"NZ'R"_9^Z.I`ATI$&6!5<D`TY#]KX1U$D.57*0?,*Y)\T_LZAJBYQ"8D.
M85<0A^GY!^/+U1X\/#AQY:J)#J!G!\QZU5D*;J#U1\?`?1J/UE$3@V8]:KT`
M&@\!YAX:4B"@S@V8]:N"11X<!YCX#\.FX9N*QS*/,*YD`:AP'F'AJH*S5'2<
M1DKNGR_H^'0<U3&43Q"KD0'U>`\A^X73"4E6!RTW`S*>4<57(\P_H\=5S((P
M(S59(!Q5<&JLU($-F%6\S%IQY_<U<)1'$*#A5Q`'I+P\`T:HOF%$YJK2`:AP
M'F/A\&F2$B1S"NK;Y'V?NZIFJ9RCJ&(5R2$`4"H@&@*F.&?)5:8"-:`(^L'+
MCX!Z-&6:E,$QPQ583EIQ(YA$`1'$+LH/H'[6I..84E7IE'T#S]`_!J@RB"<0
MJ#DKP7Y`?%3[/H^/5,014Q05R*`^KP\0^[K)<$!(9*J+XZ@91YA(D*L1^47X
M`X_!ZH\]1E[J2N!`'IY#\H?NZH/-,Y*H$!IR\`TZ<HZG<,HC(*J#D'Q!]S5X
ME$E@0ZBQ783Y0:DX1D<54@/K?9#3U1!Q(3YKN#GIF<&S'K41FM0[C^&W_,P>
M)L97L!0\1'Y@><`].M;NP,]NK2AC$6]5R,6P"RK$@;C2!(?7'^<%N*;1!W*;
MI6].H%]J_N[Q``.(&ZLI9<"GV:Z^'OCC(TO@YU+4R,=ENOZHKZS^'=3RNNMI
MJ<KZB?Y85LS[`'B\+9*DT(YS(+1]I2CU&/9^SE>/E&J0+)LVIG2[5H#ET8@$
M3\U5)/K,'4<H5$/R"^#&Y2J?%KIN#^]O5H/76@ON#KS<O-Z*W:F^=A7'_#DI
M*N+-P>1\B7:WMBY=H>XC#D6NQ?NCWQD=]@1Q:[59HEYB+!=+'^;;YN,7<B;U
M$>B/.EU?+.0..OW27YVYIEF8V9;O)]&ZHN0Q<[E;HNV[+^2BLIRKC&41,VCE
MFY\J8KR!<^9_GN%N5Q<*&('=MV9)1-K.DB.;M:$DUV:D<PC%4FS5HS*>!V/V
M!<V/\5W`VN+'3K$:,]>YYF`QJ^-;!7EK1C*RK)M*2,NSLN6G+58?2B[K7DYP
MA&;M;S4I,J[CRW:JZ2:0DZ[Y_P`^GLU_I4[D?Y!6Y70DG5=":BB]\O:GFO>#
MO*QQBO!5NL[GO!/:2-Q'C7LPVAD_FV.S>N5RL1R\,")C)BH`]/"NNRZ'W3;]
MHWB5U?R(I&E(9EG;!85_2J5:&F&./),R-.P+W+B$$RN(;<%503'4'Z=0!:]8
MB8`H"@@`@`TIX:]@A\0^F]`:M.'A&`QX+3_=U>0!9L$)]@GN7(K*E##UNBD<
M.LM+Z@1`IJ4$*]0\?'4_\0NG!_\`<5/4H_=MP^7SJI#L%]RT``/WH+<Y?_WW
M`_T]+_$+IS^\5/4C[MN>2I7'8)[EZH))$PY;@)G/U+&&^+=ZNDHA4O4(U#K\
M-/\`Q"Z;_O%1NY'W;<?HKDOV!^Y9TIF1P_;H"E0Y2_3N!KTAP%,/6I4?1I_X
MA=-Y_:*GJ1]W7'+YU5!V"^Y97_>AMS_=W;_X6E_B'TW_`'BIZD_NVX^078;L
M(=RL"F$,/6Z(@`B`!?=OU&@<@];QTO\`$+IO^\5/4H_=MU\@J,G8([EPM5.O
M$%O><H)E.-]P/4`B(>47Y?-/I_9T?XA=-_WBIZDONZZ[?4KFCV%.Y5TE%3$%
MO5$A1/\`W=P%>H0$1`?6Y@(<=/\`Q"Z;_O%1^Y'W==9?0JC^84[DWAB"W0'P
M$;[@*?9];2_Q"Z<XW%3U(^[KKY!4P=A#N4"DHH;#]N@NH;K3_N\@0,GTF`"@
M/K<!`M?MZ/\`$'IMG^T5'[DI[;=$,S^A7D.PYW(__-#;Y2])0``ON!-00#UN
M'5PJ.E_B%TX3C<5/4E':[GB&7,.P_P!R(H&,&([?$0*(@'TX@!J8.5`ZN(Z?
M^(/38_\`N:GJ1+;+G@']"Z&_8<[D:*B!OWH;>$%04!S6^('F8.H@G]?ATB6G
MV=0/Q`Z;)!^T5?4H_==U^B%>4^Q+W'2@7JQ);M1+4:7O`#01KP-41&NE^/\`
MIO\`O-7U!([9=\O8N2_8G[CBA2)%Q';P`<Z?G'^FMO\`R`*;@4>K@(5TOQ_T
MW_>*OJ2^Z[SM]2J&O8I[BI$BE6Q!;AA+4A1->L`)NDHCTB-#\^.E^/\`IOC<
M5?4C[KO.WU*M#L4]Q#UA_>BMD*`/04+U@0^P'K^.@=?]-'.XJ^I'W3=G/YEU
MMNQ7W$TE_-4Q);PE4"M"WM`^I0:4'U@H(Z?^('30.%Q5]27W7>=I]"N9>Q?W
M"BB-<3P-?2%\05*_%YFC_$#ILC&YJ^I/[IN#G'YUV)]C;N'@J%<5072%./TU
M@J</A%0=!Z_Z;_O-7U*$MHN6PB%=2=D#N&<:XK@0"E*?3>!#T>@^E^/NF_[S
M4]2A]T7?(^I=Y.R%W"2B`_O5P%0$!K]-X*O_`%VE^/\`IO\`O%7U)_=%UR/J
M5U3[)_<(*-1Q?`AQ#_PT@.'_`*+EIRZ_Z<(_M%7U*)VB[X`^I5R?96[@I1XX
MP@PH/,+T@0X?`)3=6J1U]TZW]HJMW8J/W1>`O&)U]HP]*J@[+6_^O^]C"?9O
M*%'[?KU'4OQ[T[PKS]2E]U[DV4?U54I]E[?Z`@)L8P0^%`O&&#EZ?QOCICK_
M`*=&=Q4_549[3N<@S1]2JR]F'?N4.&,((*__`!RAA$/_`%34O\0.G/[Q5_55
M7W-N@RC#YE4D[,N_8`#_``900?\`SSA__P!IH_Q`Z<XW%1OXJ!L^Z\8Q]:JB
M=FC?D`AUXS@Q#T%O.&I^PIPT'X@=.-X:]1_XOY4_NC='?2`JQ+LW;[$Z@.,X
M4/ZV\X<P?#_KFJ!U]T^2QKU&[8A/[HW7DJXO9VWV!3_!O#4"O.\8C\,-/\>=
M._T\OU0E]T[LJDG9YWTA3JQO#<A_\,8<?'_LG/4AU[T[C^WGZ(LJY;-NA+D#
MU.JU/M`;YBT#][>%#G4?I?#^CX%-,=>]./\`OZGJ43LNZ'(1_55:EVA=\@!0
M<<PH?#],H@OI\.OX-4RZ[Z>U87%3]5U'[CW4_5'S*J+VC-\9>'[V\+_7?32)
M^YYG'4?QYT]_3U'_`(H3^XMT;W8JXE[1^]D`+7'$$(TXTNV*X?&/G4U4>N]B
M<_MZOJ"B=BW3,1CZEW$[2N]H/_)Y"A3_`.-,0%/3Q%;CPU:.O-A;]_/T18I'
M8]U_1'J583M,;U@H)L=P@<N5UQ`#P^$%>&JOQWL6/[>MZDON'=.$8_J_E527
MM.[TQ$*X\A^`\QNZ-#_]=00TAUWL7"O5]2B=@W;]$>H*X$[46\\O_D_A@_\`
MG=&?=\[3/7>Q-^_J>IU$[#NWZ(]0^A5:7:HWGE$HFL"%'TA]+XP/B_UX=+\=
M['PKU/U0H'I[=2?=C^JJT.U?O+*7_>^A0]-+NC#C\054\-+\=[&,[BK^J%#\
M.;N3A&'J*[TNUGO)*8/[@HF@!R^ED87]GS0KI2Z[V,C"XJ_JA1ETWO!#:8>I
M5I.UOO%^^L.'_P!%=<8</M`L&JQUSLO&XJOW!(=-[P![L?4JHO:[W@EYV)"#
M_P#.>.]/_9N&C\=;)_3U7[@C\-;Q_!;^*JPO:_W>@`_W"0@#\%T1W'_U6NE^
M.-D_IZOJ"B>F]XX"/ZJ[`[8F[P*?W"0_#T7/'5__`$^E^-]C_IJOJ"7X:WG]
M&/J*JTNV5NY+0#6%#4^&YHOT#Z3&\=/\;[&!^^J^H)_AO>1D`_\`%5P1[9V[
M4O.QH4M*#_WRQ5?MZ7XVV(_[:KZ@HGIK><P`_<JLG;5W8@(B:QH<W@']TL5X
MT_8#2_&^R#*O5`[(A+\-[YR583MM;L"B`?0J)H`A_P"$D4`?'6@Z?XVV,8^?
M5]049=*[O,8TX'O)7<7MO;K@,/\`<1$_*$:_22*#Q^(-./7&QM^_K>H*'X2W
M73^ZIOWE50=N'=9PK940`AZ+EB](]<;(W[^MZ@H_A+=3_L:?M_*J@G;EW4%$
M:V7&?)"M+FBJ#Q'A3I$34]&JOQOLAP\VJQYQ'R9/\)[N,J4/02%6$[=>Z0"4
M&SXP!_\`E`PX?"`E,`?L:A^+NGCP_E*'X3WG^BC^L5VD[=VZ0M/[CXP1]/T@
MCQ_ZX1#0>K]@`<9]Z?X3W@?[./ZQ567MY[HRUK:,8'#D$_'?="@Z?XUV27AE
M4F1R(#>M+\)[Q_11_67:3M\;H2_^",;QY_[?1_#4?Q;T]P#?ZR!TGO7&E']8
MJI)V_-SP"%;08"`<JS\<'V^(:!U?L(Q$C'M!<^I$ND]Y;"E']95(=OW<STA6
MSXVO'_P@C1]'A4::D>L]C.=:H?\`5`5?X2WK^AA^L5WE[?\`N7``'Z(QH4]%
MP1]?_0B&G^,=@(:4YS'(X#UI?A'>S_LH#TDKF78%N6`P"-I1U/\`X?8?MF'4
M?Q?T\V#C_6=,=);V,/*AZR%W_4&W,`H42VG&@%:C2?84#EQJ(\>7V-,=9;#3
MQA*<3V8H_">]Y>5'UKL^H+N6`PB-J1@\?_?Z.'[51T_QKL<R\JE3U!'X3WO+
MRX^LK0^ZC9!N'M[;5GF9DK88)1L;B6_'\@=*;8&%-JTMU^NJKTD'K5,0I!$"
MAK&O.K-BKV=Q2$YDSHF(?#''@LFSZ8WBC=TZDJ8`$XDMCQ"P5F@+R\-QK<Q1
M`R^V/W=5(2\##Z^5<M`/P".OC[X_R$/@IU5*.0V.[;__`)27T'T=/R>KMOJ/
M[MY3/\I;JW&6I[-@O*;CI'\39LLKQ+^X1ZO3\&OQ:^!UR#\9.EX@Y[[9C_CP
M7U3U=NGF]+[A3YV=4?R"I,NOZ``OC!&FA&A":JWS_GT]FO\`2IW(_P`@K<KH
M23JNA--AW!_GA,?_`*`-T_QY%TN*#[J<\TT(T(1H0C0A&A"-"$:$(T(1H0C0
MA&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$
M(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A
M&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"2COL_,OW4?P!Y2_O/E="8S4
M?JT6X.LH9V;C2BVW+W<U,:\J&RQED!KKQO\`S#R,?@7U;(9C8;S^JDMQT]4\
MK?K2IRN('VI;>[*WVD=MHS?(+JH-V[+&]R.UUUC)HHHHMV*BJJJJIQ*1-),A
M1$QA$`*`5'7X>?`6O5/QKZ4C(%OO^Q_KX+V[?MS-79;N#X2MYC^24];:-]63
M?[!Q*6+=]KWG&,W9H]U(VI/Q-Q,&[\B*+@[)=Y#NWC=%V1NX3.*9C`<"'*:E
M#`(_T3!?/"RO30C0A-5;Y_SZ>S7^E3N1_D%;E="2=5T)IL*X1IWA,?\`Z`-T
M_P`>1=1)8H(\*<\`:A7TZ;A"^Z'"$:'"$:'"$:'"$:'"$:'"$:;H1I$MBA%=
M+4.U"*Z-0[4(T:GYH1HU-S0BNC4.U"-,$%"--"-"$:$(T(1H0C0A&A"-"$:3
MH1IH1H0C0A&DZ$:'0C0X0C0X0C02`A%=+4.U"-,$%"-!D`A&@$%"-#H172U`
M9NA&F^#A"-+5PQ0C4D(TG"$:'"$:'"$::$:$(TB60C2U`<T(U)"-)PA&APA&
MAPA&APA&APA?*Z6L%"^Z;A"-#A"-!("$:!(%"-#A"-#A"-#A"-#A"-#A"--"
M2COL_,OW4?P!Y2_O/E="8S4?ZS5?)RCG=;EY>W#W=`]?1TY5RX:O[&O(/\P$
M=?P3ZIB<CLEU_5E9VV2T;E1GRJQ/M2W=ULLD]VVYM9+`DLBZQQ<S=9%5,JB:
MJ:L>H0Z:A#@8ATSE$0$!`0$!XZ_%OX(6D8_&/I>0&(WVR/\`_(@O1-TO=6WU
MXOG2D/8GM+?M>VK4:K,;7MZ#MQDX7%TNS@8EA#M5G1DTTC.56\<W;(J.#))%
M*)Q`3"4H!6@!K^@->6*_:$(T(356^?\`/I[-?Z5.Y'^05N5T))U70FFN[I4!
M+O`X_/01'Z@5T@`!R_W\B?:UB7EU*UI:@'<LI`.&3EY7J@`("F7@(@'$>0#3
M]SK4?>=U$L8/C\ZM\L')<O;C_P"QE^V/X.C[UN?Z-'E#FCVX_P#L9?MC^#H^
M];G^C1Y0YH]N/_L9?MC^#H^];G^C1Y0YH]N/_L9?MC^#H^];G^C1Y0YH]N/_
M`+&7[8_@Z/O6Y_HT>4.:`?'J%4PI7C01K3QIZO/3CNM<D"5,Z7Q[DO*7:#U.
MO$I_M!_3UDC<Z0+F%3U#_P#R2\N78@[X@%'H*<3<*`(``<P\:CX:E/=:6DZ(
M3U=H#?.@4I<67260$1XI\AH(`/'C^UK&&\/+1I+GY<T&DV*91S%[PWVR,$Y4
MOW#60LI7FROO&L\ZMN[&$=CFX)1HRE&8$%=))ZV**2Y2@<*"``(\J5ULXU*I
M`),0X=0;L*5CB_NF[+<S;8\C[NL:Y42NC#6(XM_+9'>LHQX2Y+01CTC+KMYJ
MV7!49!F\.@43IIGIUE`:#P$`IA=S-4TVR&:&#.D'Q_O-7:4D7#1$F:;Q:(NW
M"#<LB^QE<B,8A[0J5%-=T\*10C=H!QXJF]0``1K0!U94N)B.H?1^5+`,^#IV
M'(&\;;GBW`8;G[YRG:L+@M:!CKD8Y"4DD%864B9<J8QBT4HB=0[]9ZHJ"9$D
MP%7S`$HE"FL>-[4D6`4C%@Z1'MC[YW;@W=94B\+X<S>"^1)\ZB5MP=WV[+6?
M])EDTU510@7<NDDV?KJ)HF$A`,4Q^`%`1$`&56YN(#5`1([<_I0!'C@G<F[@
MJY1&E#`(`-./[-.0:ML[O[33)(:0+(E'255:S@7#J"--"-"$:$(T(1H0N)A$
M"B(4J`5"O+4*IE&F3'WF3&:MB<@85/+,0/5&AA`1\:4I4..M)2W.J;@49C#B
MIZ0V"N@#6@^G6\U#UJM?=2.2%TK*"F03E`!ISKPX!XU`!Y:Q+JM.E2\R`RYJ
M40Y96.1N)I$1[Z5DCIM8^-;KNWSDYA!-LU;I&7774.(=!4TD2B81$>0>G6IA
MNU63'2&=L,U,P`#I`FTONK;,][U^Y`QGMTR,YN^\L:++)7-%NX5U$@!6[I5F
MNO&+NC>5)-DUTA`5$Q$M.-=9=:\JTJ0J#27X?)U&,02W).!A*]0T!,HCP"G6
M`5$1``#C3F8:!\(#X<=8<-VK3#B$64C`#CBNMQ-I-&R[QUY2#5LDJNX744JF
MBBB0RBJJITP.4A"$((B(CP`.--6#<J\BPA'Y>A&@,[I**>_3;8]P+DW<Q!7V
MG=6',2.KA8WC=%K1[R9\I[:QTDYMK%,D4RN)=5FHL4OXD!`PUH/#5WVZXCC.
M(`?A^<!1TA8!=G<[VG63C[;;D^Y+MGF%H[L9J*M_"[HUIRPO9N4FE!28MI2.
M$A74(8Z@4-YP5#G00U9&[KSAK`&E(:3WI=Y9E,Z:2I`*<BP%%,2B)J]:9E"U
M`H#01(0?AUBU=SK4YQAH!U%G[E,0!XI,.#=[.#-Q61<VXKQ?+S<E>>WRY`M3
M)C&4MN5@V\=,&463*G&O)))%*70$R!OQB-0`.=!X:NJW]:A3$Z@&()PQR[V2
MT8LE1EDS&I1(*C40"M1H'B(%ZJ5\*ZQ_O6X()C3#>U2%,'BM'Y3W0X9PM/X_
MM7)5ZQ%LW-E.X4+6L"WW2W7,7/-."**`UC&*74LL5-%(QSGX%*0!&O`0U.&X
MW<XZXTO"HF`R=8>XWJX/:[IXS9JK+38YVEK(>9#9P9+<DU(,ULLB.E%G"MR$
M3&,1="1F<2H&-YAJ``!40U9]X5O*\W2[%F3T8L$I_P"<S?[$'V#5J%*@(=-0
M$!`=8\=VKS]V`9T_*`XKL;R!G!Q3(0*EYB:H%'E7I$`&M*\?0.LBVW"M<3,(
M@`CFHR@(JX4/SJ%1\.-/L<M;/34(Q9U#!%#_`-3^SI:)H<(H?^I_9T:)H<(H
M?^I_9T:)H<+D`&\:?8U*,9@H7+5J21SO,WU;?-@V+TLQ;E+CD[7L-Q<4;:R,
ME$PCR=7-,RPK`S0]E:B4]#^0:M!$?0`ZUM.XGY]2F<H*19@F_,6>\4]K'+V0
M;4QG;>;IR)N*])=I`P#F[K#N*VH)>6?J$18LW$T]1]D:'=K*%*05!`HB/$0#
MCJ<KBH`2",/EP=($.S%/7DE05`!2*54HE*>H'*-2'`!*<#`(E$HUH`U$#"`T
MK0=8$MRK:M,0_P`RL$`0_!?1E1``'RN!J`7B`=0CP`M1H!3"/#C2@CQIJL[K
M<"6DTP%+RAP*^A)F$0+Y(U&E:U*!1'@`")P+0PC0*<^/QZD=TKQSA'Y>A+R\
M6"TKCG<YAO+E[Y1QWC:]X6\+LPO+1T#DR.A5Q=DM2=DVRCQM#2#I,HMRR96Z
M8F41`PF2"G53PLGN%S3TF4(M(.,_R)"$2=(.*W6$D8:B5(I@`0`>DY1H(UX#
MX`(4_9`.?`*Y;I<1Q,(M\NQ,4P0N`2HB43"B):!U"!JE,!:B`&`!#UJTX`%1
M'P#2CNU8A],6^78CRTF*S]ZN#[ZW-91VC6[+33C->'K8@;NO>'6MV3;0K2&N
M-,BL8HPN%9,L=).3$.`J))B)D_'D.L@W]?RO-$8B('R;Y!1,&+<4I[YU'J`O
ME>L-:%K0PT&@T`:!0!'B/(/'6/\`>U=VT1<_+DI>4N(2PB;I\H`'H%2HFH`E
M`1XAPZQKTC2@>'PA51W:O.9A&`U1#_+!!I-FNTLB8U?Q5*"(<:A40IP*(@`&
MJ(\PJ`ZG3W.O*0!@P/TI&F&S25=NN^'`FZFY<TVCAFX)&>G,`7RMCK)C9]"N
MXLD5="`N@5:-%5NH'Z)19GHH6@&X4`?#)JWM>F,HDJ,8@]A2IPE!$1#RJ4YB
M(](5H`T#JI7GX<*\.>L7[TN#/RQ".I3\K!\60$J(THE6H5K0_#EP$.FH&XAP
MI4*Z4]UN(!YP`^7<@4Q+")<KZ$F80,((_)K4HUZN']3T\:TX4YAQY:?WG<:=
M6B+?+L0*8*XA+5`1\L``M.KJ$2=-:?*`P`(?*"O@%0KJ`W>L<H#Y>A,TFQX+
MD,F<I>H4!Y?)J`F#F'K``T*%0I4?5^&G'1+=ZT8F1@&"7ECFJYLN*Y.L2@4.
M%``:_LTH/#T5#6UL;B5S2-60`5<@Q9);WV?F7[J/X`\I?WGRNLY(9J/=!J"E
M?^X94!IY6V;W=92OHZ<HY>'7DWQXCJ^#/4\>>RW7]65;;RT7,)<IQ^=*6W)3
M`K8$RTEU@(*6+.E$*^`M#!37X[?!:WT_%[IH\M[L_P"O@NBN[PRMIQ?.)"D4
MZ_>$9+ET::$:$)JK?/\`GT]FO]*G<C_(*W*Z$DZKH338%QE`_>#Q\`T$`V!7
M0-!_AR)JNI3A5`C(<7]B"X`/).=E2(4*=(<Q$>'B(U'4?L]+DFZY=!/W(?:#
M1]GI<D.4=!/W(?:#1]GI<D.4=!/W(?:#1]GI<D.4=!/W(?:#1]GI<D.4=!/W
M(?:#1]GI<D.4=!/W(?:#1]GI<D.4=!/W(?:#1]GI<D.5P43*)#<`#A7D'@(#
MZ/@U1<6],T9:0`?SIQ...2QXY2J'&OJ@)P"E"\Z^KT]0&`!`>7"NN7B8SJO$
M92"OU8,H'>V+<OD7`G<`[KS&P]@4UO4)<&Y/VET^C(N%DFMF+)Q:#<C1R,PT
M>*H*/`+YGJ"`4"O`::Z6I+1&,0PPS/S*C&67+Y?-[5NO%VSS<)BS8SWN=W.<
M<406W-CNRQ7-3%B;=K<%4&MF140UD%W+UTT,1-%FNZ4>%#I(81$XJ?)*!0U7
M1G2,SEJ;V(D,0SL_M6B\7-^Z7DCM*VAC6P>W-M;N3$US[7RV]`9>D$4'^2)"
MSG-KNF@7PFU5%-4ET_-ICN$3`I3VD"5#675EJIM"`+CEBD8AV<^D_0E&6[:>
MU7>_V&-F.U^!W)I8;O:.O-I9N.G^7@0;-)[/U@W"\NV=LB>;H?."#NW"/)T2
M,RD`1!IY-0*(&`-=!QA*!8GYO]*G(G(.01\OF6K\Y36Z/91.;;,A=U/8YMCR
MGAG$^5+(9V5N,VZ'DK&O>SI+V^-1A)<J<8Z@D9ULT=,$G0MG)/)6*)@$!`U-
M7U0:D=(&B0CQ_,HA@?"<">_U`J<C:LHUF86-F&1SF8RL='R3(RA0*8S1^S2>
M-1-03>L*"P5XCQ\=4[;`PIR<@^/Z%.>)P62AK;0]U5+[J:$:$(T(1H0C0A<3
M?)-\0_<U75_=GN3&:QLG_;*G]>'W`UR5/^WJW@LD+R+\0?<UU@^JJERU:DJ5
MV(%0.)@$2@`U`!I4*#7CX:U]\T;8ODI1S3&W?OWFM]H';NRLZB9!5AD;,C4N
M)L>^S&.#Q&0N55!.6D4$DE"KJBQARKFJ0#&J(!3CK2[=1\)U!PZMF0V/$>I1
M+]N.[39;LXW4=N?)VU^Y[C7?)VBCB#=>A+6I)0K2X).ZE'!E;E</7ZB;===K
M(2@%ZA,0>E.H`(ZVLZ0,3&66"I!(),L!P3W?<SN+=+F+O$;/-M.V_=3?.`[4
MRU@6YIBX).UG@.XD\45Q;J[E^UA'*;F+<3"C9Z'D+G3$2"8W$.H=0I6L*43X
M=0!&7:I2D2`S+2FV6T-UKC-G<Q[762=Z&7[TM*P<5M,@6-F!W)'<9/@U'""4
MHNS;2K@_JM))!`Z#AOZR92'$""'#4_LX#$1..(]"@9$1U%G;Y?F2=>V5B6],
M.]C3N#Y[B,X9$E74U'90@82SWCU(]O6?)VDY9I*7)!MU$U#I2LZ=X`N1.)RC
MT!PYZ=7RI$&((#`8HCAA)CQ[5W=PY]D/(G;8[&+R-OT]OY(NS(5BE89$E$FZ
MXP]Q/%ED6\\Z242.T4/'JCU`'0`"!`"FI0B(40`"1CDI=@"6`LEO([4_<!V:
M6M=F\_(.[/%V\Z;4M"]+/R,HW=.;=G'$>L^)/6VV0!%**CDE&`$1*F%"IFZ1
M*(5K55HQE&`Q%0<T"0.`PR6/X6WK9;V[2??ZS$WE7=VR^#LI/4\?1,H)7+&$
M?*NYAC'K`DD"1#MF2YO,.40$!$HB-0&FKIVT=$)3(,6^E2$G9LB%J>X\']Q;
M'>PUMW:D.YQ?TQE-K9C/.$AB*1>-APM(PCSRIM6PVT0"8(D<>RG%N4"%)Q\>
M0ZA.WMQ5<1[4M4G8,`$F+?%C:_MYVZKM0[C7^?LOV!+[R$;<<I6["/B-VN')
M:.C9XLA*V"FN*@L!EUH\XFZQ/^+4&G`0#3MIU!;R`CAJ*B\B####_3BGDIB_
MLA8P[^=F8X^FUQ7/:=C]ONXIUPPE%D5/I!/6Q:5W'+)RGE))&7=O%8XICF`0
M]<P:0I@4B`025,'`.,4AC;GC?N'=S3&68>X-;W<1N#;[=$'G*];5QAB%"6-#
MX?MJWK)N-=BWC;R;=+E<4WR2!*=0J`IZX"%*4J-.,(:M$L<,&2,F.*F,8+0O
M1OC2QD\BST%=5\%M:*+=5RVR'1`S<V""8/)"*('0'L;A0.HH](>@.`4U381B
M*L@/>&?K"E+)^!R6Z=;]5(T(1H0C0A&A"^#R'ER'GR^SRX:$*,#[TPI*I[',
M4'@HUK,3!-UN%E(N'?EJUE)(DN[%DQ=*5ZDVKMR((J<_4,.M-3B]U78\1]*L
M.('=](30'<V;=QK(FSNW0W&]OW`.$=NMB73BR^LDY<PNDR>Y7M^QH1=B@]D[
M<65,R(WDEH]Z*GF&/T^:!:^G65)A3(TX]R@"-0+OV?()R/N#;HL8WK=&SA%3
M>-N)MC`F0\`0.2+(VZ[3X9R7<?E`)R/4/#7;=MS)G.6'MDC1!(")F-_9TE1Z
MAZQUB"V!(+./EFI/(N8Y<4V7B+NQ;O,(;+NZ''6[?64)AWA/-^*L0[>9?<.T
M:2&7,8P>6)&?8N%[\?MU3E>3<+'1_P"+$YCD24$@@'$:7"WI@DS!PR1J<#3Z
M4[_ME[?^_#"68L&7&Z[F,[DZP]P&*)QSG.S<JW![3/&F;C@8M=*7P,U;(MRI
M'B7LN)T5!43`GLY`$!`PAK'K4X3F!"$F&9+9<6_.C4?0?EZ$UIVC\;WWM%R5
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MUK3?JE70<REB8Y7N,PI]*:2AW,HZ:""IS")C&4$*T`!U;.G$V\B&;\C%/*(Y
MX_D2+L7X=[B&Z'83.=W5SW+K_L3*#JW,@9CM'#L`Z2:89MZ"LN:N`B%E3,0<
MIR'=/F\&)"D,4W4"A:FXCJGR8B8U0+Y`X,_SHU<V9<]YF^G=SNBV==C'+&,,
MRR>VW+NZO-DI:%ZW'`/E(RV%)9JY-9B\S+QP@HUE(119$[LB"Y3IB50.`<=7
M^31I3G)GD(GW>YD:BP&+?Z4I.WAW<=JKN?[2,#75O"OW=CA[>V:YFEPV_E-T
MG(W%:%S0CACY\W#)D3`(N'7<S`>24AA(9-,:@%`U7&C&)?3(-ABW#Y=Z@93E
M'$X_+L3>^UC:AN2W(9.[RTWB?>!D+;/:&)MQ-^7L:,QOY3*5O.^XEK=DI&J7
M!,^6J];V\UC67EBV;J$`5#5$H\-6W%.,]`C\BI$C4EQ6)ONS!EWLI8;ROFW>
M`YP#=,ME*6QO>F3+=MP\YE3(,!;LXG'I0MB-DNHOTJE0/TF<4X%-4>(:Q842
M:V,2P/!,DN`'Q2:-J6^W(^#NXM%8_P`29!WGW=MTNG:MEW*DI9^\U1M*3]P7
MAC^R+MG6,]9!2"1S'P\DYAT4P(;I#K`P"`AQUF?9:4SXPP`)Q[`_!0>1'APR
MR[2`L?M^U>X3N.[>>>N[*EW'<B8\O*<)E:0C,+PKQ!GCJW;*M6[IBUBVVW:&
M26&,N)9I"D4043]<%#&]8*B&J6HB(!B7,FX,I"6.D8!OI99MN-WZ[L(+MT=I
M;#5A9%RPA>N[2'<N,IY4L849_,\K%0I[D`8:U'4NY:-SR[YVW2,=8YTS^40H
M`(!PTC1HB>AF(Q0YS"<+[*]\[Z;3S_F+`V;VVY:\-MQ;9B;FQ;?NZ6%A(O)L
M',(F40?P+]:&E'XO&KI(Z1B]9U!`2&XA76%?T(BGAD4X3.#MJ_*I1,=P0\>?
MB(B/Q\?VN&MAMK"V+)3S28=]GYE^ZC^`/*7]Y\KK:*(S4>%J?RKNW**<NC:Y
M[NX;_2Y.R^.O+?C?'7\(.I(\]GN?ZLJ$I:#JY$?.ME;C7*,K@?+46[\X6TC8
MD^Q<>0Z<LUQ0=L5$%?(=LU6[MJL*9QZ5$E"*$'UBF`P`(?D?\'+,P^+'3DN6
M]6G]=!3J7>J)CS;CVA2+<289L3",`_MO'Z=W)Q4I+*3CL+RR5DC*$B,@LS9L
M3BWF\G79>$TQ9^SL4Z-4'";4I^HX)@<YS&_<));5T(1H0FJM\_Y]/9K_`$J=
MR/\`(*W*Z$DZKH338=P?YX3'_P"@#=/\>1=+B@^ZG/--"-"$:$(T(1H0C0A&
MA"-"%P4&A##SX:IN"11D0'+)QS6.^6)Q.%#!ZU>7.@CZ>&N-I0KZY:8E]0/J
M60`!Q&2;\V>]O6R-G^9MV.9;8O2Z+HE-V&1FV1KDBIQ&,396U(-F160,H4[%
MFV6,U,0@&'SA.:M>-!ULZM:M5B8FF6<'/D.Y0A`1.)&24+NGV^P>Z';MF+;O
M<LS*6[`YAL>8L:3G(A-%64C&DPCY2SMF#HBJ!ER`'`#E$M/#6)3D+29JU8R`
M.&&*E(:@P(3"EL^[H2MLV1%XRB.Y)N\98[B(8EMM;38/K4CX]"W00,U/#MO(
M@2F;M3M3F2]2A@(;G6@ZR!N3AJ#@CG$_E4=!XR2XYKL?[,)O8E:6PI2'N9EC
MVQYDUXVU>L?+@WR#&Y"7<B[>WLA-^08A91XN:AR^7Y8I^K3@&G]NJGWB^+^Z
M4](S'O,WH26+,]W4Q0M>E@36X+=9N6W)V/C&>B[CM'%V0+DB26BC(0CA)Q$A
M)(1T0W<2+=J9`GJG.`F`.(ZL%Y7J'5IU!FXCYU$TQACB"I'4,R1CV2#-LF5%
MLT22;-4"$`A$&Z"9$4$2`'WB2:8%#X-9FW1G&!UYF3I29\%>-;8!@RK1IH1H
M0C0A&A"-"%Q/\D>%:A35=8M2D1R3B'*L!4C%<5&M#J`'+E3@(\^/+7*TZ=7[
M9&9B6/R^E7%@,UD`!0`#T`&NK$<NQ4K[J:2HWP"9`Q0#Y0@']/@`AZ-:_<1*
M5L8Q#DJ</>386ZOMJX_W>[FML>?LJ7G<SR`VR24G<%OXC3;QJEF7+<,@19()
M*X0<-%GC@&Y%/53*H4*U^"FCIRNJ0$8QQ5I#OB&*S/>%VZ]O^[_`5YX*N2VH
MZR4+I0C19WC9D'#1]RV](1+]"08/XMR9DH4IT%D`"A@&I>`ZL->\E[\2?3^9
M1E"+-$AUHFT.U%:MO[E]JNZ*;S+D&Z[\VMX>?8?AT9-G"$8W=&NPC"DE9T6\
M>FY+((IQ29:I'(!BB/"M!"4;J]A&48PQ+>Q+0'<LSK8V/^VOCRQ=XNXO>"2]
M+JE;BW&6&TL&X[1=HQR4'%1C=N9L=>/61:D?F<*)J&XG4$`&G#AQE]LOO"!'
M('UE&@<2$EW"?8_QI@W;UNTVS6]G?+DEB[=,25*:$EE(5RWQN>8646?KVJF6
M,(4RRPF+45_,KT!JB=6ZE+5.&*9B2&<+OW%=CG"FY+:GM*VFW=E7)<19NU%5
M@,).P)X9C<-T(LBJE,61<'C546:YQ5ZBJ($()#!7CK(C?5X4Q3$$>6Y=PK;M
M5[$^&-O&XFWMR5Z9MS7N%O''K!2+Q2RRM.LY6,L%H8I$D3,"(,&ZKITW;@8A
M5%#"-##JN-Q<$F1@^'/_`$H,,<PV"4+ASM187QA<V^"6G;AN3(D#OIN%W-Y'
MM6XDHU*/B$7XO?:F4,JQ:-W`"?VP1!10QA*8H#\&G*XN94XTS`N(MG[<D:`[
MN$WPW]VCV^@^9VE);F-RTKMQ87"2>:[=GEV1YK*Z4W97:,4LX3BB2"L60Q`3
M\H3T\NH<^.I?:I`C7`OW_F3TEL",TN/>UV?\+[PXS;NC'WQ?F#YG;$^CUL7S
MF-G#!NXBXY@B=NG&&1D&3M+RO(4,'64"GJ81$1T0NKR-*4(1>)/J')+1$-B.
MU;(8=M.PT-]EI[[)"_[QF+UM?`I\$'M5^G%G@YN+<1LA%O9V47*R*_4DG:$B
M<Q@(H1/KKPH--1C7N8PTB'B?-TA3B^>";MR3[MUMYO/(5^R]K;@MP6,L194O
M0;[R#@2T;CC6]@SDZY>&>R7DE6BU7[%H\6.;U"J")>L>(^#IWM>/AJ#43Z/R
MJ9@,P0I!6)L<VYBBR+4QO:#59E;%D0#"W8)NX65=+I1T<DFB@55RL8RBR@E)
M43#S'5NVZIUIO'2"HS#`8N5M+70*E&A"-"$:$(T(7P>0_$/W-(Y(39?<T[>5
MI=R?!\5A"\LA7?C%E!W];60XZY;+3CEIAK+6R=PHT!()1H\;`7J7J`]%0$`U
MSM2XA2N:DJNJ.HC(/DK6UQP;)-<2GNY[3(,>UL_,W<!W;93Q:HXC/G['<K,V
MXQB;@C8Q9!4D4]4:015?9%@0`I@#PY4T?:S/]T)2'J3%-LR'2R<V=FW&5X9G
MPWN"P%F')VUG+F&<0,L"0EQXW/"/D)#%,6W>-(NV7\9<<5*-:L4)!8"+$`JE
M3`-?5#4!=7%'+`>D]V7H08.&<?+-:RQ=V#=N-C6MO#L.],E94R[9F]5K;3S*
M36^'\2XG6]\VV\>23>^X:>8Q31TA,'D'?F@4X'23Z`*!>FH:7VVI,O4<GN(0
M8%F?!F73M+[#>*-MNX'&6X.[MQ&?<_3N"XQS#X/M_)-P,%+?QY&N"`DFBT;Q
M<<Q6?BV0(0A/..8.E,M0$:B,OM-SH,8P]*DPP!.''\RW=A/L^XCPANLW.;CH
M'(^1I>UMUT=<Z.4\&33B,7QX^D[M1!M+2R::$>A(>>#8QR(@=4WEE4-STI5K
MF9B3`O$-FEIX$^%TD6P?=Q\#6!>\(1AN0W).=OULW\MD.`VY'O!JWL=A+G?C
M))L_:FL8C**10.!`ITA4`3IE`*]53"IW$L!I(*-':$Y2Q[>ED1W<+==P=M>5
MR!>+C!<?@I.PS(QPVNU@HYW)ND7Z"H-@DP=",F8!`5A*%*AI5*M>=`T80(?B
M_P`OG1I`D[AE:[.[;N.;8WK;G=YS^Z;@N68W2XKM_$U[8]E6T<-IL[?@HP(L
MQ6`HMDWYPD&IU"JE654]4]`Y5&?G5_)-,4R'XO\`F1I#YAL4V5/>[5[?%Y&X
M[8M3<IN3L?;A==R.KCN#;C!W<P"QG!7CLSYY$MW#B*5DFT8LLH<HD\P?Q9J5
MJ%=1JWMS.1(CX07"-!`P(S6B^]QL:M2YUNS;M.QQCJ]4<"VSN73L.<2QW'RZ
MZMC6,ZC86.4F',[&LG000)&445!XX,4GF")AYA38;?6EY9JU1XS$@^GBHD%V
MCP'SIP+:5V.<+;;]QC'<[>^9\U;DLH6>S5AL8R.7YR/E$;"A#F4`&S)&.C&!
M73P"&)14PB-0$1KU!3$KW%?6=!^MEV=[J0C@'."4?M?[9./ML*F]8UO9`O2X
M/KJ7K<EZ77\[)1*8VD[N2.FXY=O`"V8)`=-NG-G$GG>9Q(6H#XQ^U5C(&%,@
MCM_,HZ'S(^3]J2PEV&<`I[+<:;0ULHY,(IAW*4OE[&^6F9X5M>-O7A*R99$5
M@0+%FB';1`4P*":B`UXB(ZJ-Y=4SJJAG/`.I"&.>"MK7LVI6/GRV=[MV[C,W
M;D,]XOQS?UJ?,5[J6NG"Y&M27M69BV^/RQ[*#:H03=T227)YJ(A^,5`PT`*#
M+[76N8Z:4B9#,$$/W8]BC*!$6)#?+'T*)5FC%%EOH7.V%K.VK=SW']^Y!NBY
MA@ML,>@60V\0E_2\HNHUN$MVMK<04?P!G+@[GR!5*0`7IQ$O5K.C'4Q9F/R^
M6:@TP,<OS_+L4K^S.SU9^X_MD[,-N.XM[=^-LM[>+<B9RV;WL21287;8=W'+
M)G7:I.G#5V@NF5K*="R1@-ZY>8<0UCUKJ?FEH2&'/\RF*<3XG2M-A':RLG9#
M<EZY%<YGS!GO*M]-FD9+7UE6>2D7#>(9>:9&/C(UFV:1[,IU%SBH<""8W`*A
M36+7J5Z\-,8GTE2$0#F&3L$>04T3$$.(#\0"//@%1$/LZVVV"8MS"88@J$VU
M8),.^S\R_=1_`'E+^\^5UM5`9J.LH;R[BW.J<NC:K[O`:O\`6Y-R^/[6O-?C
M+'7\*>H8<]IN!_PRL6\EHH3GR'TK(\Y2'7B#(I!-\NU)0M*^E&GQ:_++X36>
MCXH=/R`RW>U/_&BM+"ZU5(Q?.4?G"E:!RU^RZZ-&A"-"$U5OG_/I[-?Z5.Y'
M^05N5T))U70FFOKF5!'O`X_,-!_Q`;IH%:5IG(@_#Z=8MW<?9H>8SY]BD!J#
M)S$)`GWQ:"`B`T&H<!\.&M=]\P&!B'[_`,RD:;<4?."7H_9_ZFC[ZI_HCU_F
M1Y?:CYP2]'[/_4T??5/]$>O\R/+[4DK>[N]@]E.VC)FY.XK4D[PAL:Q/SL^@
M8ARBV?/$@6(GY:2S@HIE.)3U#@-1X:S;6]C<$N&'K2E!F[5&9)[XGMZ4,'3M
M6RF!!`!`3S\*4W*OR12\?CUGLC1)"OOAV!4AX[3LJB3I(?K+.Q!B@4P5'J,1
M`Q2F#T5U8:8''%1TR/+UJWG]\AV[E,(!M8R>(`%:C<,17T4H"`A41X:K`<LI
M>7)?4??'<`.#=*&U#*2PCU<$Y^*.(=`5-4`;"/`!U9*FP?%&B2ZS^^1;>B'!
M,VU7)H&'ATFN.'*:O*G29O751#X$8)^7)=B7OC6WHYP33VJ9,\PPB`$"XX83
M&-^Y``0$1,->&JQ0I@N(HT35<O[X;@1H8Q7FU+)K4Y?O5[CAR&X@40X"W"E0
M-I^7#DD(R/<JAK[X5MR=J%2-MER$F8Q>H!4NB"*0#4KT]1DRA7]G1Y<>2#&0
MQ5Z_Z79MX(CYZFV3(9$Q*8Y3_2*$,F<""'7T'*F8!$G4'#X=(TZ3M(!NX),5
MC3WWQ+;:V6*1OMCR&\1$?660N"'-TAYQDN)2MQ];U:TUDBRHRAJ`]@_*F(U"
MNQ/WPW;XH90&VU3*2B8*^4F?YZBD_,/0!ITF;AQ^*NL?R:<2PBEIEQS5./OB
MVW]/BKM2RFGQ4*'5/1(5$@B7@(H``\0T"F`=0"EHD53C[X_M^`QBCM2RB4Q`
M`1`UPPX<1,`4`?(Y=(ZL8\DO+DO@>^/8!'J_Q3\I"!0$PF+<$08`(`@'480;
M\`T,D(2Y+B'OD.WRHE^JKDWJ^]#Z1Q'K>-/^U^=-1)#MBHD2!7:G[XW@%0X)
MEVI9.,<P])"$N.',<QN'`"^SAQJ.F,5(1D0ZN1O?"<#IE`7&T_*380`O4"]Q
M0J(@)Q]0"]:0=0#Z=&*-)[%6(>^`X`75\KZKV1"&X<377;_1QY>L)0T>M&DJ
M['][OV^))"JKMER04M0`#!<4*<A@$P$J!BIC]^--`!D=(&?R"0!7;97O<>`;
MXR196/(W;/D$CJ\[NMZTVT@>XHE1)HXGY9M%)N%B)-S")&YG(&$`'D&B="C3
MPK/&LV`'^E2$9LZ=F[J'>+L#M=6]A^X+WQ5<N0DLN+.TF#:"DV3!6+%HT%V?
MVDSDBB:@B0.``.J:=34=(X)")*9Q)[X9@)8P$;;4<JN3??`C/0JAP*%1./2F
MF8:D`!'[&KVQ8.GH(S96]?WQW;TD;H#:KE#S!$P`FK<,,F?@-/D^2)@X_!I2
MIX>(%D_+DND/?(-O1C=(;5<E^97I`OTDAQ,(\>``#>O"FH>7#(#%&B:YK>^-
MX";B7VC:?E!`#!U`*MPQ!`$@C0#%ZFX5`1T>7#DC1+@NLGOD6WDQA`=J^2@"
M@B`_26&X@`<:?B`#GH$*?+!+1-7A+WP?`ZB!78[4,GD9F#_M@]R0A2_!Q%*E
M*_#J,O)@=,P=7#!TFD[<5Q_Z8=MV`#";;)D$@AT@!377!`;B/$1#RZT`-2%*
M)X)F,UD2'O=FW=VEYR6VJ_EB%)UG\JZ(%8R10IU"<I2B8``1U"I"B(#!ZO)0
M)E&3'W59Y+WPC;9&&,C]6G(QW(!4&X3\04YN%?D^1U<N0TXZS*5C3E$&.1[/
MSJ>F1]W$*R)^^-;?#^6*FU3)9"G&G4-R0U0+X"(&0*/&NJ:E",)&+9($)\55
MF]\+V_B!E";3\HJIID%514D_#J)ID+S,<2(B!=5&A2)<Q<I-,%E;P]\@V\5`
MI=JF33&H8:%N*%J'36M0\BH!0-,48#`#!/1,AUQ+[Y%M[4,!$]J>3%#"/3TD
MN2&,-?10$.>K_LT-+@>Q1TU%R/[XWMZ1$PK;4<GH*%'Y*MPQ!!K]E`/#6-Y%
M(2<QQ">FIRP7PGOD.WH1K]5;)0";E2Y8:HA\7D5'4H4H1D91#)F,FQ5U-[X;
M@8A$E5-J&4DDUB@9-16X(<I#E&@U*/D\>`UU8EH+M@N:?OB&WDYR$':[DD`4
M/TE-])H*@!Z3"9,`#1CR*>B2R1'WNS`*I!5^K%D<4@`.I1.Y8)0A>KY(&,4H
ME#C\.A08K'I3WPS;PP]5';%D5TH43%43"YX,AB&+40J'ECP$I3?9#4@'P#NI
M:)'%23>W]O1M[?QM;Q]N=M>T):R(:_RRQVEOS3A%T]:%BY1U&B<ZZ!2D.17V
M<#5H%!$0XTJ*((4<=3%,3;IO>GL$;8-PN8-O<MMXR%<TYB2^I6R'TM&S$<@S
MDEXLK<3O$4E414334%;@''ESTF<%3$),^"3ZI[XC@(G2!MIV4/7'I`33T2`"
M-*\Q;:AY<3P'J"-$E3#[XYM\3+U&VHY/(6HE*89^(`!$.`@`^S:/*CR^9!A-
M4Y_?(MO`4$=J.31$?3<$0/(*\_9M!HTLR'1IF@OOD.W0P!_BIY-ZJAP+/1%/
MM^SZB:%&6&D)Z*B[P]\?V\T]3:GE$?2`3T1P^'@@.G&C`8`(,)KF3WQK;^H`
M_P"*CE"G53_O@B1]'A[/7GJ7E1Y)"$U=4O?`,!KF2`NT[*0**F`J8#/1`"8>
MCKX`*`5H`:K-O2..G%#2YJI4][SP\DD*Q=GN6%4J"("C/Q!QZ0YB)2MQ$-3%
M*`&23'F%8R>^,;?A=D9K[4<H-E3#02K3L64Q1K3D9J&K#;09VP1IGG@RK5??
M"-NRBJB#7:KE%V`)E.)TYJ',41-2I0_$#6FJC;TQ]52TS"MKCWPC;Q4/.VG9
M2.HF(#TJ3L/4A@ITF"K?U34*'$*>&IQ@`&`P*7EDXX.N@GOC6WI$0`-JF4.L
M`H!37#$``!RY%;T`?B`.6J_L](2U"/B3T3R7(??(]O?AM3R=P&@UN&*X?:;:
MGY4.2-$T![Y)MZ&M=J>3_@Z;@B>/_L?AH-.(R"0A/DN9O?&=ORH$$-J.4*4'
MJ_N@B!H'"H#5J/#AR\?'2\J!Q;$(,9C)=Z/O?NW]V'GAM,R@94X4*I\^0HG.
M(\*G-[*!J4X>@/#4B'#*'E!W(#K)8WWNC`[PRR*6U+*`'1.`*">=A"E*;H*8
M`$01*`@!1``'T:K-&F3C'%2+A#_WN;#S!$[CZH645VY:B*B-PQ!^7,1`K8>F
MH!P].IPH4FR9(8I8_;=]XTQ-W%=S49MGM3`%]X_G).W)JX@G)V58.F2",,LP
M252411034]8'M:UX`7D.G4A"E!P^*9C+,LR>6WRN`7V7;JA`M`+@/*(A4>(U
ML^7YA0*<M8EE=&[E*+:0"G*.DA1U9`XDE]TIP\-J'N\@\/@R5F$=<-\6AYGP
MPWT<]KK_`,PK6[H=-C5ERC]*M^='3Q;#^2$F"[=L^5M*839.7;=1XU0=G;&*
MV7<LTG+)1TW26$ICIE61,H4!*!RB/4'YJ_"^V$/B/L<N6ZVW];%<5:W)E=4H
M\ZD?YP4I_%$3F2'@G[?-E\X\OZY%)95:,E<;XUG\70[6$%HT(BP>P=Q9/RJ[
M>R1'Q%U#.B/T$S)*$)Y`&3%13];UZ(MHZ$(T(356^?\`/I[-?Z5.Y'^05N5T
M))U70FFM;P`P]WW'X%#B.P.ZN/Q9Q)6FM5N\)3MVC[S%2B6+<TY*!5>/4W.8
M0,8*E*(@-!$`XU]&N<%&L`TJ,Y'F,E<2"<T<N:?2/B4P"`A\85U$@`M*&D\C
MF$,CA^Y#]G^GI>'D$V3,?O`@B7M-;LA*)B#]#T/DB(#ZT@W`0KZ!`NMKM@UR
MD'8!1F<8CO\`H7E$S<4"+-!RD8P&4,R3*(*G`P^<4!6$``>9!'AKI@X8.I`O
MWI:&--LDY.XHD;G?.VI&H'3E6T>NY\I^X9M8YV<2`%05(5P9'J`!Y<AUZA;_
M``YW.ZZ,/5=.32C,^%L)TQ]>''UG):*IO=G'>([67%6<28GAZ4BVV('YQ;SQ
MSI]/E+,R)><<2^3[2\5`2")JB<Q0)0!+2M=>9P#SB'S(6\E(18GW>*WYMTPK
M<.4+O96Y;40YD))P]D&RB"*:IT5?-0#RB$.4X'`WJC7CX:Z;I;IO<.K:\Q:R
MC3L*,":U23M3(.#G)LEK-UWG;MHH3NKR4A;1BY;$^@+665L>+6/>XVVNF9-^
MR)YCU!3J+Y*B3U=%9/\`&B8XB`HB//E76LW/:+K:;^=E=D"43)N<P[1,?1B5
MF6EU"[M87E/]Q4]WGD^/H51CNPSW-D6#MY$"+F?KO%/5`X`BF@4IBJ'*3UA`
MO.H<.&MCTOTU<=4[Q3VBUF(5)@ESRB'.78E<W="UH2KUSII`9I6FY[;C$V?C
M&"R"SD&2KAZ]2C92*;J"=\GY*;H"/C@H:A05\JG+Q"FO0^M_A/#I?IZINUE<
M5*US2E`2C,`1:18D,`<,&Q7-[1U/'<]WK;;3HSC0IT]0F<B7B&[SJP[DWPM#
MD3,!3!T$%0JITB"`KD(4H"!#]?`AQ$0"H<*\->+2$C3G*CC.,S$/D2"!]*ZL
M5'@9<06"7SC7;;+W)83JX7!T(]JT;)2:+1R;S#.F*72N8K<YZD\QR0"@/@-!
MU['LOP;OMYZ8EOM>MY=SH$H0#:98$R=P3@P;'CBM#?;[:VFX4MOF)&M4]7#\
MJ0^A"EZI$2D$?*D5D^?%,2.2`8"B4`]0!'A6O&NO)3&M92G;U90E4C(@Z7P;
MGCQ70R!B6XLN^0BY1%VT(@[<`BI("1.ANH>H52IID*`!S,8P!\%=40!K7-*W
M@":M:>F('-0UTX@"3ZC\R4I=6WV\+=Q9"W)<;1=%12&EIH!;D$QE&RRYO83J
MF,`F((E)QJ//T!KM>H^@>H.F;"GNE_!K*3:N)BX!6LL=WL]PN:]&S+FD6QYC
M`^A)<BHI5W$K.1!<ZJ:YRF,<>DP`5#KIQ\`^YKAW+"6<2Y#<1P]:VHEES(2@
M\*8<N3(<%=<E#Q#Z696];)I2<700,=..9BJHD99100Z2EJ!1^SZ==1LO1O4'
M45&M=;7`2MZ(Q=SX@';!:K<MXL-NN*%"ZJ1A.N2(`\9.P'RXK0ES0'S+=#R*
M`/,]D4;@!B&-TU433,;KX_>]5-<S.E*$Y4ZF%2!(/\8%ELH^,/DK_9EJGE;V
MAXXIA#YP6_$])CG`JPF`"I_*I4:".K[&RN-PO*.U6K'<:\P(#ZK')^U$I","
MZ4;N(PG]"[?B)PJB:J;E-%N<Y%%#JF7(8ORT^@0*>IO#AKT3KKX:;IT7M-'<
MZDXS,HC6/T2P<!F[>:U=ANE.^N*E"W!,:;N3S&:1<:/5#CQ)TF*4U##4#&'A
M0.(B(U^QKS'5X=0<ALAG\G*W#YD\/:G&K(VHKRN"YW),E=+*+DXD[<65FN0.
MH_EHYRF'4[:'.)J&3.(F$!'D7AKUZT^%E[<=,C>J@N*5[.C*K&,A'2(PB98X
M.^&&*XF\ZK-#JFEL$*)G3G!Y3`/@/`'AWI.FV*%\K<7@X$4C"HVSICLRBRG6
MF`D+>D8F*8")S`?UB\N(_;UY5HN!KC<B,C&):7'Y!=H22')SR4S_`-[Q8E?X
MTV3(G*'49U,GH!A*!A+`G&@"(CZWPCK7V<8SJ3)P`B3@JXYX9J']M0P"RR9,
MSKR?N!6V8>#CID&[PA`5!Y.IQ;U9I$J>8)A*1T8I2=0>)JZ]1Z!^'M]UIME;
M<Z4M`IRB&PQ!DS^@8K0]1[U6VJC1-G1-:I4E$$,<C(`Z6X@<UJO*>.C6;DZ$
M@E$F]?)06<@50R@*^:)E0ZNH*5$.?QZXS?;6>T;Q7V:KC.B2Q[L%OJ=7S*;@
M2`T@M+,.,5B3.TCN[J;,6R"BRK@JZK=!FGYBAUQ4*)4SEK4I2E$>/H#6NM[>
MM>UZ=K:A[JI(1B#D2>Y2E4$8ZI>Z,UNW.6&)*S+0AI^4:@@9['M0:&\5!46H
M;S"&J9/H$:</'77]7]#[MTC]GE=,:5:F"3R/$+6;;NUKN$ZE&CJ%6G+$')N:
M2RXC4B1Z9UNE)<H*G!,2\5$R$"O$.1NH>'P:XV,8RD)`G[,8R)/%P1A\ZVSG
MT)RJQ-M+"7PBQN1Z1<@RK$',6J+=0S-4P%,==/VD!$HG+X!PXZ]IZ&^'.V]2
M]-5;^XKF.\R!E"'AT^$<7#X]ZT]Y=W="^I4Z5/7;R!U$.X/!N&2;:E(8&LE(
M(%`W0WD'+,1\LYS%$J@ID(<>`%-4/#P`=>-75M5MKBI;7']HA(B0&0(/#CD0
MZW$9Z^!#\TK+:#A6&R7>;-&[W[B(LM!ZDUGG[:HK@F=4"G!"@#U>62HCU!2M
M.//7H?0/0EQU30OMPMP'MZ;0!&$JA=@99:7S;$!<]U'N]7;-OG.UI^;=P8B.
M.(XY8\F6([B\;P-C9EF+=M9RM+6^P$Y8J2?E!)9TP$`!)=<IJB"GK</"E-:/
MJK:KGI7<_NB_$1?F,"T3JAJE",B`<,`[<^:R]BO*M[M-.ZNX&E=3!)ARQ[<<
MEHM]#!Y;FBB*ATR5`Q3]12D$*@/440#K`*?!KEYDRGAS9;<'!BEG8?VK/+LP
MHMDAK--7LA+2I8,MG-S+&DSLSD.L:2ZBTJD4@4&E*:]+L/AK=[ATU'>Z58?:
M#3-73AI%,!\>.KTLN;GOEP>I(['&VG]F%(S-9O"",=+Y))'S&W2R#<4<BU2!
MLS<2C=)$AQ53ZFZ!@`H&ZA]:H@/$>==>6B>H"0(T'(K?ZB8`XNRV_MQV_7+G
M7+$3CVT6?FR4BN5R)B%2609M6Q#J/%'1@*-.E-,>D`H:O'PUGF=O;;7>;WN4
MY4=IVV`G<R$3.0IE@\`,'QR+\%BWM[;V4(FYJ1HQJU:=.$Y^[JJEHZF;#FKA
MNKP'+8-OA:T[A_%2H`T<>4*9R=+-XQ2=-UU2FJ/4;K`H@%*5#5=>>UW%C:[Q
MLE6I7VN]I"=$S@82+YN[!G?@LBC<4_.K6`G3KW5"L:9-/&#QS:1)!"34$/Y[
MB*#K33*X<-D!Z2`8_4H<"&H0!`34`:@`"`ZIC3J59BE;C55D0`.TJX@R#0S.
M3Y>E.1W)M,BT]N+[)!KCCD9J$,0$K;7.H$F]9'1`QGJ!1^0D@8/6ZN8<M>RW
M7PAO++9C=W-2?WB;4U_"WE,`^@X:M7I7%3ZKT=4_<,*4I4>-0<\NYG";-/'I
M@7I`PD*)%#"<Q^8@8H`4I*")C&$1I37BD34-,NWFPG*,N6#XCU+M3JRCFZ5C
M@/`]T9&:$(V52B8TZ#MPM+/S&%@L#4BJGDD*/4`*!Y=*<^K7>="=#;AUV95+
M)Z=I3DTI2].7J6HWG=J6TT8UJM*K-YQCX1QD0/I6A;PM/YGO.Y(E8Z*H1BRR
M`F+0"K'`JA2&(!2EH4W2/`=:*_VT[/NM?;ZU2$Y4:LH89^$LY6TIS,J49RC*
M,I1!`/(Y^E>J7[N.@!.TEMH*/`H-;KH6@!TE^D\J!0`/0//X]:>O4U3+91R]
M9/TJHCQ]KKSM.[FP=CW,=\#A)7RNG/MY*`(`F`"!$F)E!$QBB8#'H4`#E75<
M?=)'-7Q(8)(^(,-Y)RM$W3,6_!/YV+MN).[D'Z*!U4&!C]5:B2@BH0"5IZ-)
MR$IR;`9K5$M;[J-N^8M@[E95"+)ZPJ(])BK@P0=*!TB%2]"J@E'X`TP7*!/P
MOS73!0CJ2D7+8@"[%`6"9&Y2_CU3OE12`$4P]900.'`.>I9*1+*HO:TY2UG;
M=)VW<1X.73ALFDY0,DKYC;IZ@%)0H&+3K#CQ`=+AAFE&3YK'R%?IN&*:7K>U
MJ()\"@)C**GZ*>@?6TG(4RS8I1-Z8FOJS;6C+L&'%K&N62JI7B[4!36!/D>A
MTQH)J\-,1E+)4QD)%I<5H<+RN)(K9X51!0[,R:Z8`W1`3>:44Q`P`4.`%Y?'
MH$9`D'-3,(LP&*WU9`9"NNUG]Q,X*0D8V/601<2\0S!1LT,MT%%!<H%Z/.`Q
MNH0_<CI'#)4RT@X+0,A<,^^6>*N?(\Y!T=N9<&R)5"]"O2!1$$PH(5XTX\]2
MUR9F5\8Q`PR58[;/(X6WE/CID<.2(B(%Z2D*).LYQ$"\BF_8TG<NF&.!6[I+
M$%W-,<1UY3$#,0S!S"3\HRF7K)5)*248$7.@4JH@*9B+>6/2%`,```UTB<<U
M4)D2['6@XR-</(<KXZBIE!<G*<P%)7I3134'IH6M1$P_!IA6:L66PK1LMU,1
MJJZ3<7YS1X/#F0147%F!U3$3]H*F%4^05KI*N=0`L."UQ+1CZ*G'T6J)R'9*
MI%$"]!@$JA`.!RU*'J^M3T\-296@Z@XR6>XDLNY[_OMG:D,U5D7SGI%NS*D!
MO..<3`)3=)!H4"EK7X-1!=0F6CAFLDS-8EZ8FG_F>62=0[I1VHD"!B%#H*F0
M@]1/4`*#YE0TLBE`Z@TABM5(W-=3-Z0491T3VM1$5Z)D4,<0,5$I2E`@B<Z@
MF*``'&NIB$I%HY*1B.6"4AD:Q<L6?CN)N>8BI:&9S4:UD4GIS"5%8BHAY?4D
M8H"7J(;J'X=+&*JCIU]A3R_NN:3QQW3+9>OUE7"H8DO$P*&Z0#\8^A>H`Z0`
M:&Z>(#JNYD30?D?H4IX!AEC\O8O14WO"(;,MUY:U_P``64!$P\Q'Z&RW'T<M
M:?9I'S9CM15&*CL3`],ANJ-^YVF>[S#]K)68-<Q\5`_PUWN/#[LK_P`PK3;Y
M+3M=>0_0^E8[EYR8V,;W+7G;SX.?I(&OSJ^&M$#XA;*?_<[;^MBO-K"KJO:$
M>=:'\X*83K]51VKUU&FA&A":JWS_`)]/9K_2IW(_R"MRNA).JZ$TUW=(G+W@
M+`,4`&FP*Z:`/*HYQ)S^UK"OB8T@8^_C\RD&S/!.9`9W3U2T`>(4`*<>->-1
MXZUHJ[E,"43$!L@/SJS33"ISMUU#"<Q#"8W/B'HIK#J6=W5F:DV,BI`P`8%<
M?95?W!OMAJ'W?<(U1YIE[W@-%0W:;W:ICZIBV8F8*A6OEOT#4I7T#K+VN$Z=
MWY=3"!.*4B/">TKS&MJ.VRZMV^:8#$UNN1;)?B)*3<E,50[>-1`OM0I@8Q05
M4`E1"A1`/0.NEP);@B4Q$=JEVI]M`RUY2=M.+'916W*S;1CX4)A!P#>X;A:N
M8(\<J_!SU![7.EDO,6,F5,.FE!*(<_=9=8;98_#;[CL+F=2_E2$-(+B$<`1$
M`..UR<%CSI6TJHJ2IT_-#M)O$.XJ(KG;",[MHS/F;$KE!T]0M:YF)+?7=)>6
MK(VZN^?.(9P"11$W6Z9"3J$`"A@$:!R#PFK^Y`IG_F./9VJR1$@`<F*=HV8;
M,[QQ?M+)NAN]Q<*=Q9%OU""Q];-LB49E&)*S15/<<@8@JKM$'"QS-TR4((F+
M6HUIKW#X*7\:=Q?[+4^SBQN)"53S`2[`8.)`"&&3''BM7N]E9[C1$;R!E1`Q
M$>(?CGWI,/<\V?71@]SC7-GLDM]&LEVFS4FX^92*G*V]<:YC.#M':A!,)TW!
M1*<@F`A@.(@(C6FN$Z^W*GN?5ES6UTS*G*,8"((CY<1*(,7)Q+XER"V06PMJ
M=&A`6MN"+>F`P/#AV<.Q;![.&UC'NX?=2X7RI(+A`6I803S%HV<%;HJ2[Q-D
MFU1DE@)ZK/J.83$J41`.?"@Z/9-[OMBW2A?V-3RJT:@!D,],BTN/$*52G"K'
MR9QC*F3B)!PWY>25GG/9BI=2M]8SR`+2S4WS6<7Q_*K.6QH]Q<+&920@FK<Z
M2AE?9W4>LJ-##3J*(B;EKZ6ZZWNIUA\/Y1V4U:]>%6'F0#`M&,B99.SL&[5I
M=NLJ]G?UKJJ("TJG33TALFS]`*CU1V+YQ_DIYC:XU6K&4B,@L+%G#J*"4S=<
MTQ\TNO+`H]2I4CE,(C40$*4X\=?*`J4Y1)J2\FK/4)0(Q$W#D<O=8+>2C*C$
MPG$@'(]JE29ZVC-;<9V#C[!-GNYVTK6Q'"1DI.PZ2IBS%S-(MFO+K2JJA@*D
MLDH=0"5*`"%>=-?4WPLZNV2WZ=IT]ZO(Z8GRV+XZG#!^/SKG]VM+RI.%W;TJ
M1JQEB9!RV#,Q"CK[E]L=\;85V"5ZB1FK?5QS86O"J%$'HVXS4;N$YWS>HQ3M
M7#AP9(*!3K3-\0?-.[PH0WJ\C0`T_:9L><<-*Z*)F9-,-(1"P/;?BRX\X958
M0,8Y;M(ZVWS>=GG[TX%:,8<)))NJNY$P"4Q154*4>51UONAK2%_U;8VE01+5
M)U!AB].&MLV:3:1VK$W2Z^P[=6N8TS.=.E*8;,Z0^GT\#SX%/QYMVM)S&*G=
MMQ]U+OIR:0DK7@(X@H+&>`4AU8Z3CDFYSG"&75]4`,`&X\PUW5I\7-\^+-OO
M'2]]L-WM%G91G*-Q7QIU#`Z!2AA%I%M0.(8KDK&TM=HWNTG97UI?G<+2->I&
MWU/;2FY-.L9?7IY3`XD,HX<W!7'83N4M2>9.(Z>AIUU$R<68AA<E>^2"1$1`
M_3U'.8Y1#GP'7B\`T(1Y!B_8Z[H&,@#$B6&?#`I\O;1MAO\`Q!MULZ8OTTI;
M<KEQ>7,K;@(BU45M!B1!V=>1=&$J2S=9OU*IH#4Q^H*:^E_@AN56IM-[MD(4
MXBE4-2)+C5(QPB2[&.(?+O7*=24-D>ANFZ0G5E1EIA$1?23)]?'$$8'EP3?F
M_7:-?^WW+\1+H1[R<L+*]OLKVL.<91ZA"O8;V1N>10403,H8BT8OUIG^`M=>
M#=4T)VO4-W0J1B)BO(G3DY\0;$\^:ZF%02B)/@0.SAAZ4HGL][,6&[3>.PAK
MV?-HFS,>08W@_3=*E1:2A&XBF1NL=3I,4BZPB4`I4>''6MVJO5LMPIWM&33I
MS$A+B#R!Y=GM493A*+'+VIRG<'L]MO.<EE?$K6PYC'@6F^N61L:[6A7#AF^4
MB57`H-"@J!4W+=\")01%(U0KQKKW3XD53N/1]CNM6_C-X@U*;N[@9!\\>U8-
MH8T;B=&%O*G&9QEACVX#BHOS''DS*9++C!8BS:62O-.U713D,*B2Q7QVZAC$
M`>LRG241\!#EKY_$R")4\,7Q[OFR6QUC2\7P?OP4HJ^-LS*SGMCP=M6>+S%T
M3;-LQ]PS;Q3H0>BKTLIU9TJL<@`\`JIC)$`"CRX#KZVZ'ZBCNWP]J6VY7-26
MY5*4XB/-XLT`V7#BM1<V]S]XT:]&A"%$P/F3(\1/`R/YDU=D39U(;3MV>#53
M7`U>VU?>XNR'U@1Q!.9P^M8;WAG;2>(J"@I"U`ZID3``5$Y/"E-?*VZT;JVO
M*U"X$H74/JG]'M'-O]"VI>,1B#3;`A2/_>^WJK3%^R54`#K!><$:B)0$!@U2
M"`TXAZOC\.M/9RU3(P]W'EP1#,'F$V+LYPG;N!>WC9NX-6SF%VY-R3?AO;TK
MECU7+:`MY5`XM/*:&$I#K/@3,F!S":@'X``Z]O\`A%;5]PW.MM4+VM:6402U
M.8AJP<`ZHR#$X9+#O[G[+:BM3I0J2ID"+ASB0"1B,>([4G;NL[26MF7%MTW+
MX^MMPPA<QV"PG[_AV(*'C;7FDD6AQ.4BIS"S;N0>'$J?AT\QY:X'K*SGM_4M
MY;U)^;+7A,ES@3F?S+)A4E5I"K*$XN,Y'CZDCSMP[?D=P>XZ>?7!+.HNR<7V
MO<5[SSML03*NQ8(*BQAFICD.D"SY90@!U=7J]04Y4Q>FA7EU-84K?PUC<1$9
M-J`\)))`(9F/%3G]6.''V!TY_ES8L^SGCR1M\ET1\++!8\ODZSC,1&7,+*!$
M[E6VY-JF`+-GCE-#U/6*`&-R'7T9\9*=2[Z<%S"1,K>48RU1(!)`!T^@]JX;
MI;J2RWB]N;6UH&E4HU"\B/>X>K!,-7+A=_;=XXVL:Z7)5G-RRD8WF$6("#B-
M:2CQHFL@X,)A.1RF@J:@T`>/+AKY7H>"D(P_<ZB,<3P)==T"?%(X,%-ELC!V
M,<6XVLS'=O8V8SEA>S,[>78W%$KN'0N%F`+KODW0))%;"Y3-\KU0J`4IKL-@
M%Y]V7EY;WMQ0N;>'AA&8$2^;@Q);TA7TO'&60FX8\<DP+W.NV59VT^SKBS3;
ML;=+."R1?D:GCUJ^JFQCDY!8%9)HJKQ!=%)5;\502T*/$3:Y.<I5)>?6D36F
MQD3Q)"Q8&I$Z9RU,5O'MM;6+!=;`<D98ZW$WEF<OYJBQ@VR`K/'4)%.Y!!_'
MQOXLYB*J)E+U&+S$0UZ=\+.H9[5O8VZ57R*=Q2J@SD3Y>O#0\7`>)./-86[T
M*UQ8U86PC]H(P)#GT8K7&[S9#`7KC^[<\P$%.XM)8$<11Q$S35=:2EQ1:MB@
M@7S"$$B)W)A'J,`@!0II_%.M=FMMLMRN+6]WF!EYU:C#1`Q.HP:.J1!C#3$E
MR\@_8M/TG:[K:V+;S+47EIY^\6<N>'<F`&ZZLJB=))(YWKHS=/R$R@)Q%4_2
M']C*(@'FF`.`4$/177EM+0)`R)\F58@'BQ+^L/@NK#@D2YX*3;M2V^Q<1@FP
MYAY/LHB813,FO"**(-WR*YFI#IE=-%DO/7%^*H@)@,4"E]&O5[WKSJ?I3J#:
M/AUL&QW-[TQN%B)W%[+Q"F)CQ@2`C&,8@Y$$]I7!7V]B7WC"-T*>[VDZ/V:U
M%.4C<@R_:/(%@`.[/BFC=]^V!OM>W035O6\Y!_;UPVFWOEOY!TUTF2LZR46>
MM%CI=)0%J\,8@`%!"G&O/7FFX4K>A?5Z-KC:QJR$#_!!(C[&7=B8G3\QFU$%
MN3\.X+<?;"Q1?]\#G7+%H2+F$)BJ`AY(5XE,_P`Y.'3^4;1SD&QTS`)O9HY=
M150A2B)BAS#CKTCX3;_:6V_RZ:O*=">S7[><*L!,3881\6&E^!!7/]4;;2W/
M9KFE4!JF`!IQ.6H8ALCAB!CR6ZM[FU"3R7:^1\PVO?KN\I#$\7%S<H]<-%U%
MK@:23<BCQ!%4W4";J(`?+%,0]4`Y:Z_XWV%G:VNWRMZ,*9HP$(TJ>F-.`[(Q
M`((YNW8N?^'M:ZJ;+(75`VL?,)T%VF2[2_2?B[\4WEL-V^6[N:W`6[85W33F
M&@6L&]NIP=FB*BKDT6LB9-BH8Q5/*(X4]4P@7J"O,->!6U;R;BE7!TF$Q)^3
M$%_8O0C4A$B4\(_1V*08GL(GK\E9BQKDMFX;=M!9G<*2DL9,!:NHM1%;YE4B
MNDBASU$P5XFJ'@&OJ#J?KO9ZGP\-G:7<97U6U,6XZM(!;B"N4L=JW&.\5MPK
MPIBU)\##'/BY/!N7%1HKZP3)VCN`OC"S=TLNK:LFZ8(*K-5$CN&B+E).I$5"
MBHDH")P'J&H"(>&OE.5$SMC3B^H$G`XDD/B>(]2ZB6,'X=G#M_,GT\)[<K.M
M'"-LL;?,=Y*(,73J7CG#A1&37E%7J?E$*Q.F=55NY2.8#*%,`&&H\*<?==CZ
MNZDZ/ZLVKIC:-NB>B[ZPC6N+UB12J:#*0,HD1`D6C&)#@G,KG:52SOK;<);A
M>5:>]V][1C:6OEDPK47CKJRJ91(Q,8X9)C?=5:![+W!9#@"KC[.:7,Z:E1-0
MB2;JAQ;TJ<#"W,J)0XU`0'7C^ZU!4WV^N"1+5=U6J'Z\2<#'D`,\\PNE!>9+
MZL!GP;@.SFO3R]W-+T]I;;27C3V&YC5YB(&N214'T<NN@?%K6D,9'FJ)>_W+
MSP.[HA(ONYSO(A(ALH^E)S/UU-&;4GK"LNX59)))D('2/F'$0H-:!34QX<."
MMB1I!.04HKMN]K2X<,;,X3]]5*,@KIRP9S<#Q!9L07;-@Y:@#-NZ`#B=<JA7
M(B0G/J"O+AH;#Q8.J92>1(Q41/>AAR4VZ[PLZX[?R!)TL6^=R</-))"FVDXR
M0CF#U`2E$O24S5)SY9BAR$FEW9JW`P$>U*B[16U^:W`9[E[UG;.-)8QLB)45
MDYYZFDE'-9H2I%A2`+@>E=4550ZB@41`0#EQTP7]"50MX5>N\+M_N+'62+5O
M9A:3MI8ROSA%N+@202!J>5$Z!2&7(W*0B(."F]0XA0?L:89T4RTL>*0/M-P)
M>FZS<9AO"V.V:#F=N.>CW#PZP=#2.AXY1!S)R;L3*%`Z#=L(F$*EJ80TB"<!
MF^"G4(`/)2G>X=V];ME]HN07.*X=I).<7M8M5RU8HI)K.(=J8&SQ^@!:"4B@
M)&,/RO#5@JRCB`&!^7%4@8@E0O`%7H=1XM1(](=&.%+@*HO$EQ1*ET\*&.J8
M`'X0U&<C*1D<UDZ@0_!3,MG_`&Z[CMK9CB>V+L@H*'N[)%OR=P.VJ*B1C.7,
MX=R>"&5.50ZAW?LQ4NDH&+T".HL2W,K&D0Y/!1-<KXGOK$.0KQQQ?L`K!7&R
MN!RD5LYJ`"J$D"*?DJ"'KI'\`I7AH"N$@W<%L#;;ANZ=S6X"P,+6XS67-(74
M@$N\21]H"-A$'A`D'SDI0`"II)`)>-`$1TL!WJ)\(<9D*;OGKM.1>8-B.6K"
M@+QC;7N''5CN;SBKA5A@7ZD+4:=3Z-`B9TO9`FF(*I'#A7KKS#3(&0.(Q5()
MP)?$LH"<;(%86JF`)$Z"OWR7M``;RS"V013Z?6`#!YO2)@J`4Y#QTN2OTO(2
M?@I3O:<[>4[?>U-;)5TV5%M'>0G9A@7L@1(SZ7@`(<J(G272-TI*>U%'J#I#
M@`AP#C(8XJN1\6&(4<[=7AN],`;D<CXNR)`K6[.14X=1%JY*)0-&N#>:S7;]
M0F*9N*1:`-1#[FD#PY*V!&D`)UCL2[2;BSKG+)F9G$8LO9.*+=%L=0S<J[5Y
M/2*2Z:1$S&(!1]F3-U^KQ+Z=648"4^P!U74/!9%WI=G=UV8O'9QMU$TI:361
M*PN`B#?H)%'4;%*5<W$#=`J(])AH-1$-5RS?@BF\9,4SQM6Q@]S=N.PO8,8F
MFFVFKRBS2#IRU4>,VT<U$[AS[20!2*H)Z`4A1$*F,'.@ULC4,!@V*MGA$CFI
M=/<S[=$W>NV:[F.,VL<2[;#@FDZ6%*T*W<O81FF<PD1**G2W$C9#K`E/$=1J
M$RX!PJ(XD'@D`>[.6C=UG=S^T&EVP#^$7=8BN\&8OFWE%D2%DH5,56R@")3$
M`#UZN(".J+AI4#WJ<B)9+T$][WYF>Z_GPP%E$!^$0L^7#A]K[>M-LP:M,=OY
M5*KF%'5GQZ76Z\?1M)]WH'_[2,PZY[XH!_AUO(_]MK?S"M#U`6V>Y/\`X?TK
M7^9G3A'%5_*LVOMSI*V)11JR\]-M[8X(@)D&OM*H"DW]H4`"=9@$I*U'@&OS
MV^'$&Z_V8_\`N5O_`%L5Y1MM4G<;<?\`CT_YX4MK%%UY)NZ#?O\`)^*OWHYI
MO+*-&,!].(&_?G"+*U:JIR_SI;R#=HU\UTJJC[.<!4#R>L1H<NOU%"]O6T=-
M"-"$U5OG_/I[-?Z5.Y'^05N5T))U70FFO+H'_P#&!Q^'@.P*Z!_^W(H:Q;F(
M.E^?T*0]TE*UW-;CK'VL8FNG,.1'CA*VK8003(Q8(MU92;F7Q?*A[?B$EU$P
M<RLP\`J2"8=1C'-2@\M1C5,*E*C$:ZM6<(QB,VDT2>Z)\1/:RMI495Q(N(QA
M`SE(Y:1^4I%^#^X]?M^7G)6/F7:AEC;[(/;-E[YQ])76D@_A;QB(IN5VHR5D
MFR!&\1-"U4*<4%*B`5'67.,A:W5:D":]H)&42P!`(&!]JQH3%2O0AE1N*FB$
MLV+`N1R*47M.WGV!NCQ'C;)+5_"67.Y*8R$C$8[FKAB/I4HTC)%W'.%FL<*R
M3UZ0QVU0,FD)?AUDWUK.TG"$<3*C&H0`Y:<7#-FQS4L3*J`"(4J\H$\,#]*1
MWWYV8/\`M8;M$#^O7'3E8I0+4PJ%.D8HE#B/$X<M<W"<_O2-"9!B#%RS/DY5
MS#2)<'*\]CL49JL3`W</Q[<618(+@MR:A)R`68"F50B#E4A"H.5$SE,4J91+
MXAXZW\@!)^`14RP;$?G^A3Y-\.-<JYBVFL93;,@XC[MMVZXF^V5K0Y%2R5PQ
MK%VDZ&*;%;%!1VL"2@"9(`-YI`-4..NX^'&X;%MV^FCOE*(V^O2(U%@!J!&H
M/Q"UEY*Y\B)H$>?@Y(<>I0=>]JEE$VY).^,H61&8[R1,XOL\MQ6W&IE;I,9J
M.9M?+%ZS!NB9N[>H#YIP-ZQ3B)=<[U%9;38=07%'9:QN-LE&3$%VPP\2RJ4C
M*WAYG[U\?7C@I:/:GM7!N3]L>$SV[,#?+IEBZ,F)MD[8(.HDDJU!0ID&ZGF*
M@>6:.R@8R72`E$P#K%JTKNQI0N[6<O,JQT$0.E@2Q=LV&)5D`->@$1&H8G$?
M+@F-NZ1>EPRFVS=9C_<!:[X,@L+FB;LL)X[CW#=?'3-K=[>.;P3\#H%3,QFX
MXB0M5`$H]74%!`1UZEUUT[L=#IJVW_9JD#3MZ=.E,OJE6G*4`6.8$7?B[,M)
MM>[WE[N][97]L:1HS`A,81F'Y9/GBFU>T!DN:L]WG&*LW'D[?MUW%9%NL@/`
MM74E(V\U,Y;-W$J"+5-1;J*4X@D`T*4U!'6C^&>R;7O>\&KO-:%"UHD2`DV8
MQQ?-RME?U+H6%<V-/S+SRY"`RQ;Z,T[E,[4MP4"QB\S9UQGD!##+60?1IWTV
M#U>ZV3.=:2)XV5%JHF"R!&C],E%!$.GJ*%>.O==\ZJVP6-YLG0-QM]#JF<:8
MIU*^F-`D5*?F1DV'BH^8W\(!<-N5IU5=]+VTSJ.XT9/H@X(+D.6S`!8][\%&
M,C9&(F=\L?(HHO7$*]W*1E&KLAROI1FWNE-(0>I&X%<J@B(C6HB8:CKYKZHG
M:5.K[VKMU*%2V\Z0.`:,AGI/$&3F)XC%=IM7VN>S6AW`R.X>3'S7.4],'('#
MQ&2]"C(N*<L1>XRW26=818K`TOC!![<;CR/+26EI.$C'B8K-DTR)"X**9TRA
M6I_-'6XM)]-'H>I3K&`WZ%82$0P8B1,?#[.U9AE4J#RYGPCUX=JA<=XV^IZX
M=P>/,:3[$B#;&,'/1=O29$3D5?1+^:>R)6:RIPZE%V;A8Y1"HT*4`\-<_O%U
M9WU>-:VHFE4T`3+N)'F!P]"R)2!!J`O)L5K'M?JQ1W.YRW6=J25V9"NBQH&/
MM1.,*99S&,6MQIRTY)D;D(=1ST-F`EZ`"GKUUU7PPIV\^M;8W%2-*E3$I.>T
M$?0L6_C=5+*H+>(F6&>6)`."E0[B\1M-LFV[97F*(Q*_43O)&T)/+[A=BX+=
M(2Q&#=TK",S"W4/$I27LZINFI>HWAPUZSL-Y'JCJ'?-FN;N$:%'5Y)\,8MEE
M@)2QQ)QR"QKN`VGR_LMI3%>H-$C&(<Q(!S`?%0\]W,]:U[[O;\N6'B'4%:,_
MF".>MX]]3VUBQ<G8`L@L)2E3\](H"%*<>>OFC<K+[JO*MK*J*M:%1B,AXCS6
M=3E(Q$-(A$19N7?VJ</:&Y[95YF,MM[Z+8W9%*VO;#$<A7"SC9*+MZ^WT<T:
M-[;`5SJ&0(L*HI&,4Q1`2B4`H&O5-M^'?6EOT_5Z@VRK.&JF9QHQD1J@/>+C
MB`Y'H6LJ;M8?>$=MJS>J7>&;'@<>:P3N7OML$+M%S0TO)_;<=FW"%B2:.+8=
M-HP)),HJZT0!N2.%80/[,Y37*8H)A0`-PUYW7VK>*MD.H*\#5HU"1)R=6H88
MG_5(6P`GI8EY$GZ0/H4>3L-RF.6^<-R=UY0GIJ+:VCAV'NABG'+>8I(!'R+M
MPM#@CUD_&.UT4RF#CTD-6FH;5M-YN>Y6^T4(AKFKB26T1/!QFW-2G_R\!.7B
M[L%(9C<SW=G3:WD7,UEX_;Q5Q6/=":\7&D8.%22UKM%1<"BT5!L0RIC,Z%4X
M#ZXZ]3O.@-MZ?ZNL=JOKOS=NJ@:Q*9,('!QB2/"V2Q;;<!<VT[Z$9QT2(,3F
M>W\BA=,LD6\V[@C_`"@>'2B8I+,PS#J">$Z6I9%9TJH+5<BQ2AY8NCC4*4H&
MO,>H;*TV?J*MMD)>98BOI$@<(P<C$_+)9D):J(G^ECW/S4O>PL#Y>S1@3/3S
M(,"-O&N:ZX:\;%1.HI\V*QB)6K\4(L1*3RV:S8ADTQ('2)C:]JO>K.E^G]PV
MFIL,Z=:VHVIC49FU$$`R[02^*P*]"^N]KNJ4ZI%QB*38=P(XJ/'NVNZ9E=[N
MT#';D\HM;^.+^QC&VV:81,B\9M5KWAW+I@!U:^>BDN!Q*8!]8-<G\8:>U_?-
MM?6DQ._NK0SF8X1$3$EM(P!;BM=TL-YH[-&WZ@B*>YQG,&+9Q;P2]F/-/T>]
MXLSR=D[$(M$.I62N1U&D`H]0F!W'E0`M!#B8>H/LZ\6M81>42YB8L6PY'V+H
M"0`9<&3@>S2T<7M,98"VXW#9[::=(68F[GQFHOVJ&1%FBFZ;NU143.AYX)E,
M5,.`@8==G9V%_8[5'J2VNQ"OX081P)!EH'J<%2\H^6:N&D<._L2$O>(5+)Q]
MA&Q[%CHYC%KOYQ1&$<L")M&RD,Q1:E(V*V3*7I02Z@"@<-:*YKUKJM*YN9&=
M>9Q)XJH2D/"YT<G6B_=?MO6,,D8_SA=N0C-O.+<J\>DW*DD8CQ)!5V<6KDZE
M`%JHB(^J/`:!J%.56E4$Z%2=*H"")0)C)^PCL4IRTS!9V/T*1\&TW;_B":?9
MBA[`C(V$<HN&LXJ!"';&B3(J>U())G**#=%Q7U@+0O'71;GU5ON\V4;#<[B=
M2S!&!S+9$GCDL2E;6U"<I6].$*DLS$`$][+SB]P]T0=W=P6[Y^U`*M;)MQJ+
M:%:("0S9"+3DB$*T3`E2E(BDD)0`H4+KFCF2,CC\RS.!!S*],"V;7LB<P]$1
M:3!@,K.V=$/943L"%\DZ3)--J9!P!!.DN`$"HEH)M60G.GJ%.4AKAI(<@$''
M$<U7+43JY?0HA/O!>XV=4P)@[:_+11E#05]7#+LYLYS$\QBR.T(W*8!)U=1/
M9C=(5YB&H.[`\`/9DK*8&KY<DY5[M+C?'>5]D,5=<^*$=-XUO*X&9SJ($<A,
M)N)!^?H635H0YTRI%#J$!$..I1D1*,A*0,).&4*@.H@*L[W<E*V3MOR:C8D&
MRDC3;,[)VF5$B9RQA_6663!-,?D]!2\N&G4JU*C^9(R<DXEV?ER2`>3E0P^W
M!=F/8/=#CR%RU#Q$GC:]IJ,@[M&42:TCV0K&.W<LEW11!LJ"I@#J*(#P#56@
M"$:>.B,G'>KZ@.G#@I\.`MK>W6]Y^1N6$L]N[A)U56-AGB"97_S>S]5!E(($
M`#)`L"10$#%H/H'75CK/J&-I"RA<$4(`QBPQ`/!\VPRR6*+>W%0UA3I^>0'D
MPU?K,_>H]'O)V&L;87W*X9:X]<^;(SF,C$N1F7\6=4J*<L!%U"@)A)UB@!NG
MTZY4Q$?!$O@KA,U`\@V*W][M7CZPKQPEN#E)IXLWG(F7,DUCRM4U$Y8CE$J?
MDG`Q@*HFD41#I$#`):^G4XDQ,90D85*?NF.$O7FB9,9:0'BZ>[W#8*P]9^";
MS;/[5B8Z,DX&X)2=9QD:S16=&-&K'#VMLD0O5YXT$*UIK-O]RW'<I0GN%>K5
ME`8:I$\&Q541&,R8C#V>@*&WV1KTL.TNYG;C&6A&<G:UV-K]M-G%/DD@;H)O
M'X*(*@50IRIB@0@`4?`=8$2-8,@^'%7U(G0!Q^7Y%/1RE:\-"1</=5J-4!80
M,@DR:L"H@9,S9H5(Q&PF.`E63.)J&X>MJ<J5(RUM@2<!D'Y!5:YN0Y;O4#;N
M%,I>T^Z;=5SO[>"WV5_)L7#!)-IY+,47YF;=8Y`*F1.HG&HT].JQ+23$.Q?O
MR;-2?P8<&4C.RYNSK8N*R\6W!CU!PF]LY!XTN1A#HE4%!*$(M[&YD/(\SJ/4
M?6ZJ@)J^&NSVC:MVN^FZUU'<JT+"B(P\DS)$@9=IX$OW!E`@2B`>;GM(Y\VP
M90T=^4(_B-S>1)/V,S:W9BYI4UM&,*ACE:MWARG3,H<*&$#*AQ`1Y:Y&$!1A
M*G(ZCJ&.?/+EV\U?382D1A\N"]++W<\/_P`);;./+^T+D'AR_P"^*1-P^#CJ
MG,8JN7OJ`COFC$9SO=[@8IVZ!DS'=)/&<2!PJ1F@55BLLJI40IY9""8O'A36
M3;6\KNYA:0+5IRTQ'Z1*L'EL!.>D,IV^U"Z[!R]8<<]M.^YC)EL66UCX%U*2
M3<4!:3;!H@HX2:)D<NDQ:I`3H1.-!$0Y!K;;]TSO/3=>%OO$!&I4CJ'<SK$M
MZ]"O3U4)B6)=N]0_/>&FN/8?=7'P5CN(N2?M;*EIBZG+9FW;R0/Y5HQ608N5
M$>I15NT0`I*F'P'AK1$>+-7P)9R&+IZOL2;?;4F]B-A9&:7-#FELA3<^$I9Z
M**0&.[9O"HINEA3-^,*D9`I2`8/5$-(1\#@XDY)2/B9L`'=*B[O.US"7U!MQ
M$U>;@6=WVMCIY)0$>JFVH:<:E27:+E56.`E.0Y:`)0K0::>`CGXDHF6H%L.;
MJ/U[M/8M@Y"R+D-F_"$;94MV#:NK7?@BFI-A!321$96JX47113'I$/+$0Z`I
MIC-N*LJ`^]BREQY=VY+7#9^1;+:7T[MF0BK5<JE\E@;YNO!@=(Z:C-8IU4P6
MKQ$`$#``\0XZE&F#Q;Z5!SAA@_J7FA8SQC&/-\B>-KI0$L4QW!.(N2(JD($!
MFTNMVBH0Z1@"B8=!3<>`T#4"SOPP5Q_=Z>Y>B#/8T'%^+K=A&$B20<1$>T?L
MY!,YSJH(U3,T43`PF]C2*D4"`!1H6E0YZE5IR@'BJ(DD.5$4[]%J8MLS<';,
M;`*A<>5,A6/`9.NF79/TEFEI,G8ND6<4T;I]1UGTFLR5,<P](EZ@YTU$X$*=
M,D8\,EEG8.?8#Q_<N<LR99D9%*YT7EOV#:C.*!H+T)"[)$_LSH5'*A/*1.=+
MJ.8O$"CK=].].[GU->?9["($(4)5)2/'2'P"<B2P'8IY-J8P,6P[@MB:F/FV
MU,H6+<+*0D'0`((,#P+B04<.'`J^6N@=NF)!#J`!"NM-*$K>-2E<%KJ-32S=
MQR[B51"4O,TR&6*\LO<P>TE]P5[QT'"1,59;#+TM;\!%PJ*)(YU$1<NE$H.1
M30*5.KH2]1AH/56HZB"[E7Q!Q'8O2DVH[?+S@-L>"HHA(V*CIBS;1D89M#HB
M*;*)/;[%RJU(4I2!4Q%"F.`<]!A)QVA5B<0.9!4?SWG+;9:JF(;$W.D7@!R`
MUNUA:4ZDP8-$I9^R2\I!O\YNDP!<P%,OP*:O`*:69=U*!,9:>'Y5O7W?"PFC
M/8]+WW;\K%LUI:ZUFMP6VT,49&0DSI,DA%PBGZYD"H&]4I@$"\?3J<9&`,@<
M1@B;:])#]OK2K.ZGAW#$[LIW&&O&?7B9B*L@TE%M3$110<R29"KH)IE.H01.
M4Q@*/"HTTCI((?$*,=6H%L"HS7NZN.[4R7GR_(*XE$!?Q5NMKFMH3,D73LDE
M&N$6Z:1%3>NU3515ZQ$O`-.(!+%65`<^Q2N=PMZ6[@>=B)[*D[[3:UUN#VO<
M\N=`',:TB'13@],X*J<$U4D$%#%-U"`$`0IK?;'TWN?45Q.CMT=4J<#.7'`9
M_P"E8E6YI6H!J^Z6`X8O@F1^T'E"V\M=^NZI#'CM)7$ULV)D&WL=-F2I1CB0
MD/.0[1NX:IIB*92N03!0::T-[1J4:-05HZ""0..7'UK+'`?6_P!"FO;WA$=F
M6ZZHU_P!92_O1F.7P5USNR2,JTW_`$ORJ=3-1T[B&CC=A^B/[O2(_8R1F#6C
M^)H?X>;S_P#'5OYA6@ZB+;+=?[OZ5KW*O5^]S>-1_P#<-WPH'H+K\_OAVWX]
MV?\`^2M_ZV*\?VL_^IV_^_I_SPIF&OT[7O*-"$:$)JK?/^?3V:_TJ=R/\@K<
MKH23JNA-->71_G@L??H!73_'D76-<?5[U(>Z4GGOT0%\R6T:S)VS'JD6WLK<
M=@^ZKKFRQYI5.W+6C;F2-)7"XC@35]I9P]075J4X%`E1*(5J;=(TNJ]FJU9"
M&WZZT*LSE#S*7@D>.$HX<'S!P5H>6UWU*(><J#MQD(G&'I)=QCAFDX6I<$WA
M#.UFV1B'=K=F\*VLZV'D&7RM;MVR5JW"3&[%"!%ZWOR`?P#2,+;T>9TH#7V0
M53&.14*$X5#(J3A5L-TVJ=,PI4+"=>G4)]Z8F(F+OXO,),F+Y8,%71U&K8W)
M.JYJ7=&F8L,(&+/D&TZ0'&)XE()M;:3A.T>S=8.[J,MQZ&XVU;HB;KMW*WSU
M*'N&%_PNH,20[#H>)QK>!,V6.F9L"!BCUC7ARV>X`;1OFQ6UK/\`9FI84IOC
MJC6%,58EP<).<<X_5(3K2%U]\2N@\(SNIQX,8$F)\+9<LCQ!3X/=^4<W%VK,
MYOEP\UY)X>C)%UP*('5<Q[%TO4/DT$YQ'7,[A"%/JFK3IX4Q7D!W"1`]BQ;*
M4JNW6\Y8RE2B2>TQ!4('L$;6XG*N<,L9?G8\KIGC1PA!1OM!O[72>RASJJ*G
M()RE.LFD3@%!``\*ZVXS[`LB9P'<O14Q);458L):\>=9])L92+0D&:IC'!-B
M<B)2@DD<M%"4((%'C40X:F:<-`'"$2!V`_+BJA*0D)#,GUJ`)[RF_.KO(R=(
M*)'+'BD@BP.LGTH'49Q"!E"%$``Q@(-.?'[.JXDQPC@&`R5D<Q\N*D!]B'!C
MW!&S?#B8"Z<2%RL"7<^0?',=)%:[@(X*T*4#=)"^4F2@!0`^,1U&<1*+2<@]
MIXJ,VD)"61'S)7'?)P';-Y=NC=G/J,(Y*X([')9Z3=MVJ8/CDA7[*0CO/<%)
MYBI6JY!Z`$1`@&&FK93J&E&@9R\B``$=1TL"",'9W`+G'#$LHPG/W98Q)=^+
M]^:C;^Z=PL4\SKDE=VT$'4_CUZR,]`@^NHU=-/(;=5.@`Z2`(\M5R@*EQYTB
M?-+8@D998`@>Q63B(81P"F]Y`QTG>#AW%3B'7`PQDG@19^E5%\X!@9-(JQ*F
M,J4O7U@!JA4M/'C::5,2U``G4^.+EB.+\\!D^.8!5<92@'B2Y7F5;J[`M6PN
M\>:%@6!T6#G=-;LL>-*C1L"\I<`K'!$@E$2%%1(1H`@4/``U40\GQS=W9VR?
MFW:K8Y$\S\OG7I9Y>A8M#';&0$#N9)O;$.44^DPG32<,620)D(%$Q%-(`H-.
MHM.`AQU*(C"9K!O-?/U>@J`D1X8Y'\Z@;=^3;\VMNZXG)T?&N2$@[R0C';HQ
M!.F+*?;B(K*\1'I%TJ%!'D(Z4C(2,@2Y*(Q$2T<B%B_NUN'&MVY@RC?SM!P#
MIM-05FQ3DJ1#%;B9TD]>^6<2B50QRF*4P#4.GXQU$QUO(DB6`<$@Y\P0I50"
M^>39G(8KT/R6E'W-"S=NW/%-9R!@HWSV7SBU;.V;AR6)*H0?9ETSHD7:+&$I
M3E*!R\:"%1U;0,[.L:]M*I"L1I)$Y.02[''''B<>"@)2U"H_[0<\6P;Y@O)[
MW=V`XG-X]QV>@G\UJW9G;YO0$I@3!N@XE3%*9$H"":9!31H`@`4U7(ZM6MSJ
MDY)Q+\WS4H@1U2&9Q]:G<X3[;^V\]MV;D>[+6.O,VA;<(_DG*<J^;1CY_&B6
M12FI%H54K<[D%$CFJ`4ISJ&N^L/B/U32LY;1&O,P,-`&BG[K,`^AP.;''BL0
MVEE.Z%Q.G$UP#IEBX]1Q]+IOOO3;44<N;>\C9/M)LCY\1;19-@Z8K`J#V$CD
MBBBB9P!@(Y10*W```0&G337)U+W<[:RELU:<A:Z]1AA[Q)D^KWAGD"W8LT&8
M(%0^,>CV)MKW3S&$+DK>'FV2N./;24;#XFCFAXEZB"[-3K?D:N?/05ZD5>I,
MH@/4`\O3K`,IZ@8RD)1.H$2(+D\PQ^A$VA+PJ>!D_#UJQEJ*6E!047$0:R#Y
MT=M&1[5DU2;D+YBB":#--),04J-0Z1$=%6K6K&,J\YRE$N"9$D'/,EU&5:I*
M3X<L@/F"\UWO)[6FV!-]J4O!1I&-KY1N6V+GB$DTBE3]J&1<)2G2D`B9(55?
M6$!`H!U4"@<-0R,\R:DM4B2Y)/%R_JR[$XGPD'DIYN&L>1MP[=;%5;!TI2=B
M0YU"":A0\N);B8J8*#ZA2F"H%"@!Z-*5.)CH#"GZO:,53J<M/FHH'=DPHX@=
MQ^U#(D/;PJPD;N#QO`R,T`!UMP/=L6FBFH8#!ZBKH]`$2^KX"`5TJCR>9,B1
M!@\B6`#,')X+(!DQU$DMQQ]IQ3G7O+4)'3V0.V'&2IB%CELC@JX!4.HIJ1JB
MQ"B%#`8!5`*!36'9GQR/\'\B0]W#E^=/([;,5%9VC!SC9!=,5ACRL166*<U"
M.4P42#J,)P2%*G`1I3EK-%,0C&$3+RXLP<MZGQ]*@3P[4U?[QOC"$''N.;ON
M&,:JBE;EX)D;U$I&[E-E'J)KD$AP'J$U!KJR7/@R0.!;-UHSW8K$CQ/:;>5V
M1H&<'N:]Y!RX1!9,R(B@[52(FI4?4ZB*5H42\M2A%Y/P=2J2<GY=BDZ9<QK<
MUZ8?G+0BX@&J2S%9H^2(JF102"A53V<7"@DH4!Y\Q\-.HP:(&*K&1.:\PC(^
M$$\.=PZ,L&/;+29U<^INF[1T":ZQSK/`.=(`$*G`.L0"HB/'4:,:4Z\*5Q/1
M;RD`9#&402S@8CU@J^(G4(IC(X$_HC-^6'(C%3+=IFYK<SDW,\1;YXEE*V,Y
M%Q"S\7&P8L4K*C8MLJ@W0<N7#9!RF]*=$IB^:JJ)P/7B%*=OO&Q2VR[O:%W9
M?9]FHVU,T;N4R9UJDP[Q@)F+8-+]F`#DRYG;-R-]6E.=20K0J2C4H>68QIPB
M1IJ1G(/4E)\HR(#9!-W^\';26\QA&W<M)K*FE+3N>7>KHF$@F01=K-B)@8W2
M!3@).(EXAQUPQIUJ<(BN`*K!V+N_%=*3(3=A&)R;C'F>]+4]V+BF,MV^7K>&
M;"D[/?$F5X:AR)*KF=R(JJF,80$>@PB(@40#1%V;M554D5'*5COYPRYR'C:[
M8]2-2?AUKQQ^DM"*-A15(KY8*'Z:"(EXAQ`0YZE2E3)(D'P4@?K%>?!MHVU/
MLE;V6N&!;K-"6_D677DD3G(1=!G$2*ZB21C\P3Z4^8#7X=*H(ZR(JZ4O`.97
MHU[)+%G<5V6RMU)`PI)(-!BU`.FX,";4P&`1`@G.`C0.?$=+$%E26.:CC^]!
M0$>MG+%5Y.U`0EF-@E(=N5/HZDUE)4@`IZM1"BH^.B6!?L1!QX>U*P]W<PXO
M9^S&6O<[1RU>Y$N-S)(BJ*?]LM3K))$%'J`3>6"(B`4I2M>85U$GEFIS+S/)
M/0Y^LUS-XKNY@D9)5^G;TB*RCM,#&]6*5*4AC"4"&`A5*4-4!TW)PXJ`;-0?
M.T#BAK)]S]@A-^S-SVU>UR($;@'3UE<N`*0X`%1`AC'\.`?!H&)`4Y2:(YLO
M0NN_'A?.:1#M93V1%JHX0:ATF;"L(UJ/`P`!1(6@^C4\6:1X*L%GTC!U"Q[X
M6.'!-TF'+L+'JMQ$%H]BO7RVSI9@]:G!#S""43@L<H<QX>%-764+6M>0C>U#
M2MB^J0#L&/#',X9'-61CBQ/A3Z6WB`E,D1=FN[\@E84KZSX9N19!(P'%%2'!
M%11`2F./2(%`:UKJR]IVMM5E"QN*E6AWL_#(,/8I2IB)(B1W*+SWX\`Q>&+B
M@W39)PV.]N1XYCCK$I[5&.BI&,<*@-3%'B/(:FXZPH^"+0]UW13]YSFRFL^[
MD+^T=I+;4I4`HQN0O30*$$+@D`Z?3P'TZ6``91/O.H<3;$\3EKWAG=2A/M_G
M")M+-5[SKN-4**B;_H3:MP16`M*E,*M.?#4Z52I1K1N*1:O"6J)Y$<59&9C$
M$,^/`<NU37=KV)K>QQ%2]LXRM%E`V\^!ZY=L&@*G`)!<I4!<&5=KN'`@F"?`
M.OIJ'+6SW;>MTWVZ^U[K5E6KZ0'(`81R81`&'=CQ6)"E3I1TTP(AWP[<U!_]
MX0Q#(61OQRW<K@%3,)*RX!L@<#%!-)V:W(M5=,G08.*ARB(A2FM5+"1!5T#D
M."D5]CFS6MI;`]OZ<*D8CY_!25W+)J!4#JR4@L94Q1K4.I5,QND!Z0ZN`4H&
M@/IPYI2;424[/N;VQM=UN`,KVU>$>FT9R%D/A5,X.!2*H>PG6663#S*>JFAP
M`?M5U)A+')++,N%%<]W%V_,+3[@NX`T(JJJWMJ`GK3C#)"`IIL(6?;H&6,!J
MD,J*:0@(TY&X:4&,AR3G)X-R_*ISE_6,>=0/+2J31N#"-<D,<`(`+AY2OED,
M"8U-UC3U>0>`:D)8M')0)P8XNO,F'%S!+O'9SMIVV`I&F=X5ZV02*("E\]W0
MW.!`"O`ITG'Q\?3JOL[58?=!*FZ9X@Y&%M,T6S;"NZ.U4;)5`HF*@"($*DJ(
M</+(<.'5XZL-6HVB1^91SBXR4!KN:PRQ=_JD(9^YDW,?B>`35.N<51169Q-Q
MKN4$CF"HHMS$$24$0`1&@ZK(X*>=/T_D3KG8&V@0%]8ENW)-X0:-RLKQNL01
MB5Q6(D)+=DW;5-5)5!9%<BH'2$0.!P,'AK/VW<;W:*XN=MJ2IUF;#'#DT@0?
M4B3B6'H[%-0R+;;QWMSE?HRE\RQUGX^FT&;8QS>JBC#/4G2!U%SJ*GHAUI@)
MC"(AXZQJ\Y756=Q6+UIDF1R<\<!@/0%`F4IZI8R.'H7E*;@;=9HY0>1=MA0[
MB_W"C4XG4-_;;V<2\NACGZQ$BG(3"-?&NJ!B%9$8$=Z]3[8RI=T=@';VWN]X
ML5.$Q3;#<P*H&,!A/`1B):&1+4IN@!`!`:\/1J;D,J2,R$T%[Q9M,2R3LQE+
MRA%Y<#6S>Z%Q"@0_E-Q1!=B/4]3]2H>L;IK\&HLSR*<)R?!F9)_]V-L=VKMI
MRFMYIG`1N2'2IVJAPZ4VJ<8Q.@D2@@?@H)AK7J'Q'0'S3G)\N*="[IFWMMFK
M;QE*-*BDD5[8\BH5!(/*%1=E'J=9!4,)3F$525^5^QHS+]B4,/"5&]]V1PVD
MSW#W^[,F=&5_>[N2.4*;I`4PCYULW.)1"H%$2I`%0XT\=2@3JP4JA!'J^=/"
M=Z2QWU\X3NF&A2JL26LRF7RJK,>@%'[9@H1TD8W50"N"DJ(!0`$.%-=/TQU)
MN73EY7N[!M4[>5,C#'5PQ^?/M6+<VE&[@(7`U1$@0'.8RR8J/1[L&@5+N=V\
MG43F3QE?:!SB4I#`))B)(H`](%ZN*8<1J(TY\]<E7\\6DIW$=$JDI2(<G,N^
M))&>3K-SEJ.;+T(=[_YF6ZW^`#*`_;L^7'[NM+LH:M/FX^E3JYJ.C<?_`&QN
MQ_1']WI_C(S`.M%\3/\`]>;S_P#'5OYA7/\`4G_9+K_=_2M:9C>M8W%E^2+Y
M8C9DPMJ2>O'"E?+;M6J(KN%CT`1Z$D4Q,-`$:!K\_OAU_P#GFS__`"5O_617
MC^U_]SMO]_3_`)X4J+&6\;;+F6ZD+'Q=F&U;SNYRS>OV\%%?.0O%6D<EY[U<
M/:8]NEY;=+UC>O6FOT[7O29RR)N8WN$G\JIS4;FC%E^QV:+]:X'L1W%6$\A+
MR?F3VI*V5CJ.0L29O=M><*PQA=%WRZI))9NHY>G6<T*=M[,U?<DG5]C=Y3M\
M8FG9:1NZX[]@$+X68V3>-U**NY>;ABV=9CVY`4DW#-@XDT(7)SV?C4SG3#R"
ML@;%$2(%T$NFD\;Y_P`^GLU_I4[D?Y!6Y7223JNA-->71_G@L??H!73_`!Y%
MUC7'U>]2'NE.27!;-OW9#R$#<T/'3D++LUF$G%RC9)XR?-'"8IJMW#=<ITE4
MCD'B`@.G*A2N+?R:PU4Y`..[$(A.5,ZH%BZT'B?9QMEP<I<2^*L-6593F[$G
M+>?<0T4B@O(MG=/:&BBW%0&JG2`BF40)PY:RZDY5;?[+5.JWP\/##+MP4,16
MC<1PK0?2>3K*`VVX.#%:&$?WM;8_>H;E*5"R/82!`DZ7XR9"E9\"ATOQ\T/Z
MOCJ-8FXK4:]?Q5K>5.5,G.,J1!ID?Q#$-W(QTU(_5JB0F/TA/WG_`(W%(6[Q
M0Q\#VX=RR142-X^/QD[9MT"%JD@W1030;IIE*'`B1"E``#T:T=2<JN^>94)-
M24@2>9.)*G2A"E2C2IAJ<8L!R`#`#T*$QV<+_N_!=KY)LC(D,[QG#Y1O*(NB
MT[VGEVT:A,><*S,44TU%@<"0PJ@9,#`%:UUO6#D<TI,?%%3J\&9MCD,9Q?SH
MZ0D(EJDR8$FUW*":C$'"?2=0@+J$,J!1_<@--2!F<#[K*!T`"7UE!G]XMR]B
MS*F[UMBZV9)"2=-+NBQNJ3B"'>'91$DM%QK\Q_9T3@8P-^LX@43=(EXZC+,J
M<,`#V%3.=F"./FF/X"R[;=-RQ,#%V,U@UB*``*PK:%8G07#J*4!34.!@,(<A
M"FGP(XAE`^\">U*GW78_L7.FV3=/CBX9$J=NW7AV]K<FWI!(W/'D0MJ2=@_3
M,OTE*DS5(103CZH@3GJ&>*8`B6/H4,KW:^^K"QA>YXAHHE(RB%\7M9[E<`*"
M[MB:['$3;ST2E]<Q#,VQ3]0>J(&KJ0)SXLI5"26X,IMV5KZM;'*%SW"O(@K,
M+M&J$?&JN`.D9RH!6R14D4^H].L>LPCPH4=6D2%*,I!B_K4'^KP^9>;_`+S`
MA;8[V"UQ7B<P1[?*=B2C:1<,G3*&>3!EG+R10C':J?L[U..=+@D84S#TB4/3
MJF69/:K(X`<EZ%D;?#+(>'%;P(E%F9)0R1)!THK7YN(FV2!)0@`J81ZDDP-\
MGA35A'+`%5.`0"Y91,N[!?MOY#VL[K)<&"-T2T==MGVO;2<8JBX6C?8/8)%]
M,+I]8JMT"(D.8YA*'#D.H'V*89UJ?W<^0MJQ=N:=WB[%K+.L^2S2X2N$E$%T
MD%$87YI?(BLDFHH@LB>I1H8!`1H.I!O0G4'B<*;+=E^P=OXJGKFC9L'<4J1T
MYDG+(`<>QHN&:@%$A`]9),5A`#"-:"/AI?6+Y*!P8C->9)N_LAQ=_<PQ;9-B
MO:3UYY?M0S8ZYTP3:KO)$'#A41.9,@)BUZAXFYCJ.>':K![I7H<QMLN[9S!;
MFW!2VY>8M%UB@9"Z;[=)D:VT@N1(8U&%0,("B[D'2#@1\OK$:&X:W]&AY6RR
MW6%:,;Z-8"$7#YX`CM58C$5!4+&#/VNM8;IL.6*;#5T8<!=HPAW^/Y^(A8XR
MR)E%CJMWBH"H>H%322$X@`#2@!K475>[NJQKW8$:\F<#N4Y5/,D9CQ/FH[GN
MP&-4<?;N-X5I-99%G)1\*\@6QR"B==-(LD8?-*GU5,!#AU%$/3K'Y\V2)<#T
M?2IJ5RI(V_;?L\G<**BD+#G<N)*6`@KN.%#K"`B`"53I'U>>@,X_1"1&9.94
M'COS0=NRN;]N-Y33QD*D@@Z?-FR8)F%1%"><(M'0MR"=1!%18@B41``&M=!)
M.*,`,U)+VB9?M"7VCXBN-L=N_+]&E8^0:"X(`B_;L4V:30YP_L)`6H:@AIEL
M$A$8\W2$-[UN6_?.T.`F58:,F,CR^Y3&,9#0!EF2#R/(SOB-<JR2!S*E$@-&
MR@*&,:G441U&<3&D>X_0FXD6[EW=Z6Q[&OS==VIK5RE*(P%MC>DNNY<K.$B)
MA+LH+^U&2AC]29R**'-QY")0IK#LHM5.K`$*1+##EZT[IC2X86U7TI8*:Q56
M4-)-D&3P1*4``ZHD7.H<0Z03.D)>@0H%?'6>)8F)X%1D.(XIF#WC&ZH.5Q"S
MA6LLU>KPN/[LE?9SJ%.=N91BV!%2O#J,KY?(*CPT8MCF@8R]2W'[N18-DXU[
M6=AW:K/IO?IA.R$]./FH@/S2Z._.B1FN"8&,`D\P0Z1IP'2!(&?/T(E'QEN!
M];XJ1"I,PQ4G8BZ;G9F8E4,<RQ"HK$41$2K$4-ZH%.F(?9U+'CFZBP&2\]7=
MW9=CQG>QQ<]3\MW%$R(WG9=)BE[8W9+!(1)VYW9VY#@0IR]8U'GQU&61I_5.
M![E;"1&1S_.IXX%QS'6J%QVO$6U"(S\DF\D7D5'M6)I(2(D$SARJBDF*YQ*6
ME35]&LBK7N+@C[14G.,8Z1JD2!'D`3DJLH``81)/I.?RR4?'OA7%9EU[%KYF
MG=P1-OQYYMY'Q22QRA+2TT91J1%NW;\%3-P4Z.H0+0`./'6-@SCG\R8B(DOR
M6A/=D<X6.UVI!BAG+LT)=M<TBX?I`!R+`\.[>E.(F.*1`!43UJ(B&IPQ\**@
M:1E).;;L\P6S8Y`C+AN**BXL\VT"9DY%\W;-HUB\7%(QCJ'.":@B:G`*UZM0
M``D^2&#=B9>V%[&K7R?O_P`X9\L8\>K&6[!RSYBW9KL7;:X'#Z6?D"1:JHGH
MJ!V_2<>FM.H=2S)ERQ4B<=)XGU*5-A##]QVX[2<R,:DI$GARK(_((=-ZJ!3%
M(0.H1`"C4>6HC`^A(XANU10/>DL9(*NFE[.G8(O&%LV\T*CU$`[=)S)+-U2H
ME`1.<02./(!YZE+%CS"E`X]Q3VNP2UK*Q]L,V?1MA(MU(52QH-_(N1!,[MV]
M7;,UWRJY"`!Q$5#F"HAR`=$FTQ58U/)\$H?-UW6G$VE=*0&3*>4CW8="IB@F
M)3QAC*$XE#I*)PKSH%-)P,LR4_%QR`7G[[&LYQ6,NZ-<MVNB@G&.[VN!DV>$
M2.NP0!!X006671**:0"9.E1$``-(8,0K2`8Q[77HRM=Q&,)6T4YYN^8OG4E:
M;)5F9-XBHR*#IN)TUDGE10,("(]90&O334B54V"B?]_#/=DS=\;<,5VY!J/Y
MFU16NR[+BCX=PM%QWM)F1V\>,TBW%D87"1Q.8GFB:I1T2P:)X!-L#(<2I$&V
M^:MV[L$;=;PC$D',8QL.V0DY1N@D8#`JW625255`:>J8:\:CPTFQ')1:+G](
ME1:_>JI2TW$CAN'87+"2USD>2<@:,B%TG"C6&6:MO(,Z\@QP(J`E#J`1^4%*
M:<G$F+%6TF)P=F*DX>[A(@GVC=L]1ZA4972<_AQ&YY4M/M%#4."#FF"MBF)8
M>\^]=W5;^DG!".[,OV[08(?B_-/U'9J*F*4XB?@'H#EIQ#OV)$^$#@ZE0[6K
MOBI19\5LX2*9*WR>U)EX$,Y-U*%,!C!3KZA$QN/"NI`]O!53.D>E0I?><;GA
M76<KA&/=-5E'YXI-4R3@%%:L[9:HJE$B8"8`,KS_`*W2EFX4Z))(=2(.SL6Q
MXC9GM!5@)R/DF+_""+>14,\3.+:>;D=*.T52&$!+ZPEIPXFTPP`(XNB>+@X8
MA.Q7K=,:RP]D5O+7.DT97'C>=%J+$3>>R4;LE2@W\PO6":JB9J4$`&@Z>8QX
MJ.1:/!1M?=^%+/A-X^8Q:.B-E+J+DTS!%R<@*F58W$EYA3*&$H@;R0ZZ#01Z
MM0#\,U(X#2<G4N"5O"U'EZ0./U9E-S)/&#E\+`$SG3<M4Q4-YOG@`H`8IB\A
M&M`TPPB?TD#5A(^ZR@7;B[`LJWO>$=P3&WI!F]B']QX7N%=1HND9&(G7BK5:
M7BC`2H=<:Z0'J*/K5X>&F<)>E2!>F'[?H4JG<W(Q%KQZ)7;@//E;>,MUF#UP
M44\PI%!+Q$"@8.'*FI'`NH`Z@R@5=U>$A;3[BEIG06(+Y[M_BGUP"JH0Z;9_
M(P][IMP5,7AUT.0>(^`:B0`K07ID\'4O3LT[<&.%MD.TU--9%9_DJWEKR.J@
M=%0BZ,S*.72E#I&.`&(9<:@(U#3@!JCVJLDX\A^1T]KF=DE;.W+-#>552:-3
M65<I&K@%"%Z3+1J[=`U0K05'1P)\(FU<8ACW'YE4)8AL\/G7DQYOLN2:[GPL
M*(.L\F7V4K8CHLB11657>.YU$R8)`41#J*92O"E=8V6'8LB.6KO7K![<;+E8
M'$.,K;N7\9)1-A66W=(@7I.ET0K%)0IR`81\TJB`@(>DPZG)]+',,JW8@#(N
MM9]SK&O[X>R7/EEMV[4J:UDJ/H^HD!<73-5-P(AYAJ]8%1\-0#D,AHB03(/N
MU-ON[4L#*%L21@30D)@TJ":9B'4,HF1)N)0(!AXG(EQ_K=60Q+'DE(,&X*19
MEO$\?EJS)&U9-T#&-.SFVR@I$337$'#=R0@KJ@-.D2&K3X=6U(Q`8!E"F3F,
MV48GL=8FB\3[UL_V>S=>:C;Z%Z0#=R<R:0.1<SZ+HJ:/FF*!E.D.?(0UC##!
M6D8.G1-Z=FQ-PV-EFV)55-!=\K<#%%,X%6<N5WZ+E`B20)B8O4<2T$>1=(P$
MCXO>&28.1&2B5>[?6_(6KW?;AMMPT612@;>RM%@N9%51L`-KE8$*0CH"`V,J
M0G,`/P$-5UR31D3B74SP93^][WYF6ZWA3_`!D^G&HT^ATMSIR'6GV;]])LL/
MI4ZN84=.XN*^[+]$?W>G^,C,.M!\3/\`]>[Q_P#'5OYA7/\`4?\`V6Z_W?TA
M:[RJ/^#F\?3\R.ON%'7P!\.O_P`\V?\`^1H?UD5X]M@/WE;_`._I_P`\*9CK
M].E[VC0A&A":JWS_`)]/9K_2IW(_R"MRNA).JZ$TUY='^>"Q]^@%=/\`'D76
M-<?5[U(>Z4Z$7Y(?%JZG^[CW!1"^ZFA%-"$S!WZ)*0CNUWNN<QJQDG'T*,B5
M4I`44*59X@F<2@?@`$*'Q"&M%#_N`D<]1^=79,.W\B\Y_:?"/,JY&<W?FB_K
MI7LG!ME.LFW"9"1>F7^:[32Z(>,B8X79&B"SEXY(4P%%,!``XC2FM]Q4"`YP
MP6>9L[E&[')GL249D^Y[$M&"<BO`6Q:#L(U`S%-X#EHI,*(G;&DG21"E#\=Y
M@B`4K0::,\U&+#N28;DS]EF_[HBLBSSF!<WU$)O8\]VN+>C#R=R)2#T7)EIY
M)9H9"1=E20Z2JJ"H<@"(%,`:'YIX/V)_SM?]U;*;^\)VU,O74U(A#6:P=6.V
MAHI'^VHVSDW:DRR=%12;B1RHP3$X%H8E:<>&@>+/DEE[N:S;<M[QO+9QL7/&
M*HZP+MLBT,B0TMCZ*NJT'#)C<8P2T<[9'D'/2Y0]E&2>*)%4.F<5!;B?CPH+
M&>08I,S<PH]NWO<WD/:DRA)?"3HUOW['76I+2-UJ&!Z>1C"2?MK**>M%`,@F
MX42`J9U2@(@(B("/B$NIYG'DGVNX#W?<]9'P/M\NO%2<QCV?RS#.IJ<O)9RF
M\29FM-\XB):,9I'.NFB^7DVP+4`"&%(Y:C01#1J)BQ+A0#8DYIA:_=R&5,G7
M_;&2<Y3S[++RSGKF7AT'Z:3%RWD5:N$7*SA"AG0)/A(HH!S"4Q0&H#RT.2I#
M'!.6]N;N<[I@SZVQY=&5)&6L3-3YW:?T5N!V`6C$SKAJJC;18\3]98YC[8)4
M5>E,H'Z@`"CQTFQX.@C!CEZDTOE2_LO2EV92:79>=W$E)R\YSZ3PA)N6;QAI
M)L_69*-E8OVI-%5%%)N"92'2Z?)I0*&IH3<.`5MS'>\O=+C2%BX>T,DDA(V+
ME(.4)"14'%QL<Y6AU6H-6[E1LV(HJ4[=`$U!.4P"`A4!`-"3OFZ?:W!=X7.-
MP]NBW)3`\E,6S(S=X!9&9)E\=@XD85?V994Y4VA//4;Q3YWU"D<#)]9*`)?5
M"C&6''-)@9=O!1X;?RO<MP9XL#-N4+_GF$_:$\VN(MSP+-)S<+92+Z#,4V;(
MZK9JNHJJ%!.8P&`@T#2SPX*;YX*:-B#WBO:[+3>+X&YHZ_Y&Y)^#8VW<%P2+
M=BTB8V9;BDA'NW()RM6P.#%)UE(02FI0=*8I59/.`E+M;,9'T*OQB.E\'^02
M*.Z3WE;MLO+:V.<96^27D)*U#.EYUX[;F9Q;"?B4E(Q2-%`50!<GM74<.DH_
M".IDG5JDVKYT1BT>QTTIVZ>Y8WV+9LN?.<[;EY75>E[M*W4X8.FJ4;*']I$X
MII,E'1$B*($IZPE`Q^'&ND"!P4B'4F7<;WT[%NW:HAFN&:2L*]N6UUB0ME2Q
MVS>8N*0223270;@1P<09E64H(D'@/$-!8CDHMCBHGF\GN(Y'W<2]JW([L**M
M-W:D/\U1#E-V:5>D;%7.N5$4ET1(1-)4:@0#``&]8..D<<`R8B",2R5+VV.X
M1N"M"R,O6#)S;BY;2LNS;@R-$-I/I`(.2CVIP*BV44\TXH'>$(()\$P'PT8^
MA,QTE(CL_=MN6S/N&Q":_<Q7K(0-Q9^QK,+VB$T[1@FZCN\6"8(H-TG)6PD]
MF]4X>4`"6@<N&H3]PI^'TLI;_O.&2RX@0V+WRWM"-N^4AW<HK#DDG2K4L4]3
MC4EDI1DX0*)4W:0)"4I@*!@`PT&FL2SS+YL?G4<_4FGL']]S/EW[C(YC?-N1
M#3'N2']O6DDQA?92/H.2,JU8-WQEC(MP5(LZ$ISGZJB-1H/CG%B23F4@&##@
MD4]V+?-DC<1N'N.PXN:N"V[*LJ,5L*4CWQ$S&DW)#"@Y='636,=1JJ1/J*8U
M3"'HT8@XY)A@'/O.E@[#^[[;';MVK26VIH[N#.C9Q,1<\Q9-(I&.86X[D#(N
M)2-.]<O`.\:HE4'I)TB03@`T`0KH!8,V:#GJQ=.XY-[Y]HW!M2NK,F,D9&8E
MXN#C60X\0Z&#R`D9!=%J5.6,U=&!)@EU=0*^L(4'EIN3B$F`.*B99RWJY`RC
MEAAGBW(I;&^0BG36FWT2_P#G-*75:'1,U5!-V`%332(F(=(`!3]0B:O#4>]/
M!^2>QVV=ZG/]A[&KON+-I[AR-+160D[>LN=8(,$6%%T4EPC7CA44%>E$M!Z$
MP.6E0$.6GB8^+)TFQ32V?^Y_N,W(6A-6+D>#LZ=M]_(OGD2T=H@5:"2=@06A
MXQ))C[.G(MP*!O-`2F`:`!M(D=B?A`8E(NQ[N5SQBYDPLS&=ZRF-6,<Y,^4=
M6:Z4@YIZN*HJ`N^>,1:K.Q$Q^'6J>FI*>F)&IRZ72[WIWSNUL<<#;FLBR#3V
MB.%.W<ED<K%<KS[1<WS:TO)5!1!9U'*`(D%0YES%.`&`*\=(,0Q^90XX9IPK
MM=]P.[.WPC<&/[]LPUQSL65RS97''3Z:IEH6115%F507(IC,1QQ'S4A.-4P/
M4`KIN!PX)%G?+%2HV7?(VY61M>BL\9'2E6@.V`LV4#;X,9-^M<*;83$BO*4?
M-RI&6.'`1$:`(TT#3F4>+,$>E1+^YKW,K.WW7+&WG;#5TLRC#L%?H3><*V-'
M2C5DLL/LKLZ+AT``D90#=`@)3B&D2"4@,,\55;5N[WN1PW)V*RE(F)E\,6RU
M"&''T&P0;MXU@H?I.O%F71)T%:H#ZJ8"0I0#U::`2>Y,Y8A;M[EG=+RZQ6Q>
MOB.)=Q%D9!B#7.YF)UHU7:3,>LU!HXMR-5*#HJ#ID*IB+``E$3!U"-=`8=R#
MCWJ-[>E^BUN2?N#%C)]C]C<Y3+R:*3@7\JD[<CY\D[;2:BAW30CYZ%!(0Y0`
MHTI31@I!C@0G%-MFY[->1<#7QM73S%<5O7`XBS2.'Y,TJL60D7[0ISJV2,P9
M47S5!XW0(FATF$G4?@`<='8H_.FV<IY%W#(_2"Q[_O\`R&]7C@50?PUTRKU9
M6->,1!,#-W<AYCH_E)B<A!`Q0.40TV&2L`C+-.\;6NZ%GNV.WADG#%A/93Z<
M8>@6TA]+W\V)ZVY(RI$&HL4S^:L5PQ(OP'I+T%`0`::,0&X)&($N*8]S/F#*
M.:[C3N[*]XS%YSZ[<Y$WTJZ4<^0W/ZX(M4U3G%!(*!P+0.`<-.("L9AVKU$/
M=S"F)VE-M!:T#V.ZJ%Y<!NB5]'$.(4^,=0(\/H^DJF1\9':H@.<.X?<VQ'NC
M;][@Q]B:*D9&X\Q7Y#S,FYD5P&92<L6S=`L@Q<%5:G3065ZP$"B:M/1IQ)S1
MI#,3Q[DL39CW]K!CR/&N6(Z1QK-MXUPDX]G;MY&'D7@)&3*D@X%9.AC*#3B2
ME!Y:8T@N4I1<8)B+N"Y/SON/R+=F1;LM9L[L>6GO;;3NJ'2</6QX=RD!"`ZD
M$D5"H@1)/I,01H0X<-1?%RIQT@^A;NVM]U//VWQCB:RHUG;#+&MG*I1DG&03
M=-N?Z.KE!%VHBG[&W(#I/S#KB<O28QZ\1$-/MX*)`XYIP/N$]TW,UR8CLZ1V
MM7\V<6!)FF+8R#.(%.21CYJ5CDC0D:Y2.*QT#.4Q4+YO64>L/'4CV9)1!36.
MU#?==&TG,6%[RMV7G3E-,N9/.\D\<>U.I9.XZMIYM!H++G321(V\MP`52**M
M!^5QTL%(!W(3_FXCOYY2V^[BL8-+.QXTF[!6L:/NE:<N`K%2[7-M7*1X6/5B
MR'(N0RR;8I3F`ZQ0$U0'3<`@CW0HD"0+YGY8*-?'[R)&"W79]W./GEW7'/W]
M?$A=5LK2XE^<'+]26=R<:G+F7=K)LFL:W5*D7RC&`O(H4IJ/%E8Q+,I`>ZKO
M'R>0=GN-,\VJWC)2]7[*%M&:M%1R0[R+E`?F:2+F4\@%2-VJI4#BBH?UA`X"
M-*ZE(DEU","/",U'OW"YUQ5N!O29R_=*&6FV4IDC*+!)XYCI:`;VVV(HFI`Q
M+@7XN4U&T:Y7\D!(4$E#`):#4=1=\4\6TC\R?YV>][C&F-\:;4]M^.6&0V,]
MC"2+:;5WD$C(S!]:KN52438`\+)O?97Z"+GI((EJ8*!73$F&&8^E1E$DF6+?
M2G9NY-WB,`8SQ(MBQ_?=R2&0+]2.23MR!2:/S046:/"32;2*AGZ0H@J<A#``
M%$IA&O/CJ1(8ARY2B#V,WI=0G+'<9#RANIB,R8P8-94;3OJ!R$U2NJ1;QIA1
M82!7B:"PN2KD56413H!3#0HTH.HY?QE8&8@YKT?<7=T#"\B^QU;\W>%LQV1K
MRQ[;TFTM)&28O7)'S5HW).1QB)+E#VY&25`J0<1,0?E!T@`LF)#\2JFQ<9!T
MECN)]RN`0QGD''5I3$4ZR;=&-I0]H67(NFD>_DA7<.&`&3;K*"7V@ADSB%>H
M1ISIPU$>$`#-2(=1]>UMW3L:[$KN/;.X`M\6],3SHT=(I.8=NY:MGD@D8H/6
M[@7Y&RC%DJ8W50"A0?M2C(1..21C)L,T]?O>[XEK[4\,1-[6<U<WJ]RFX$,=
MH,E6DB:207CG!CRKWVEP<S5LF=0"B0O64AA``Y:#(\.?%`B"<?9@HRVR;NXQ
ME@[A;UR#G4;HMISD>54<?.=B`V;EC5GSD!$'X%<1Y02,C4.LG4;K+741AFIR
MB0'&3)PW>WWH(G%.7<9)X^@'63[4D8E:XI)&4?-E7Z[.23%!!XNJJHN=P\72
M/U@!E!`IJCU5'3#`@A4TQ*0(.:UU[OWN2G\N]T]*.9V=`V1:,I9>0[A2B(V*
MCU)%5Y*S<4Y66E)LS<CUTL<JGXSJ.?C7B.J;@M0(YE7$9'Y9A3C][_YF>Z\/
M1@')X#PH`#]#9;@'P:T^S_OY]X^E65<PHZEP!5QNP`.8[2/=Z`#[.2<PZT7Q
M+B9_#[>(C,[?6_F+G^H\-DNO]W](6!980ICB\S#7A!.QX!\!?AU\$?#VTJPZ
MZV>1&`W&W_K(KQ_;)`[G;_\`44_YX4R@!`>0UU^EX7O2^Z:$:$)JK?/^?3V:
M_P!*G<C_`""MRNA).JZ$TUY='^>"Q]^@%=/\>1=8UQ]7O4A[I3H1?DA\6KJ?
M[N/<%$+[J:$:$)F'OWFZ.UQNK-X!9E1^&CUMK21_[@!_"/SJP<!V_D7FS[8,
MJVECB[YUID1D_>XVR;9DCCZ]THL@'>L8B:$GLTFW`3ICY[%=,#"6O#GX:WHS
MQ4)9D<%093P3=V-NEU5O=MC3"7M5NWS;1SR$-)1*H@HR,\%(H+1L@=*AE6ZY
M2G3'AH(9+MX+2Y%$A3(41$I4_4-0:<!X"/"G"@CI))2FT3*<-B#/%DW9</46
MW'"DM:UQJIIE4,UA[JC'4$\<@!A+_P!K>V`<P\RE`1TP6+IG)8)F7&,QB+(E
MPV7.-">6V>NWL'($4!1I+6Z^=K+1$G'*B`>T-GC02&XAU%'29+YUJTY43A04
M0-4P#0W`.H.`&'I"HTT>A-V2P,5Y.Q_>^&'6VC,,@M;D;&W&]O/$>1T&YGB=
MG7-)I`TEXJ?;IF%RK;DND90Y@3*H)%B)CTA41TL<D-CBOCG9=>OD'?!DW"7S
M&9`'*4N:^/[5,U4()BG%M[&=Z0ZA"U,F)*E&A1XZ8!]",%J9.U\08T=(OI3(
M\E<US0TFV>L6..$%$6*;^.=I.T7/T@?@T.5,KI,AB"0HB(E$=/!#DK-LK9*Q
M-GX9^^FL$RQ[EXS8[R7(\%9>(O-*/013+)MW"1C$;7,Y2((+$$I04-0U1XCH
M+%28MV))""O,:<:T'P.4:`)B'])@'GJ+@%DC[5O##>5&V/)62C;FB`NK&MUM
MTF%]6@LMY:3]L4X>SR[02F**<Q$CU&0&I1.)A"NAU$=JR7+6$FD1#(Y+QG(E
MO+$LZZ+\WR*)16G;7<<:QMUQQ2@9FNGTB0#@8P&`0'4FX\$W=)\+Y728R8`0
M:IF2.'!4#`*G2H4!XE!.I1"@A0=1R1FE?YFAV-Z8.PMG)(`<W(LA*8XO54AQ
M,L*]N*G;0SQ<@CT@8\<F4*\QIQU+!GXH=DD1T0BY!+X$'KJ'@`\>`\^6DDEN
M;PW+=.P=HMOH)E%K$8)C7R:8%*'2]EG)G"ZQO290Q:"/,0T<NY&12&E5>'*G
MI#P`0KQIRXCH3&:WUM9R#`8]R'+Q5RB#"U,FVI/V!<#T#<&07$T708R"QC#^
M);-Y4R1U#!R*4>`\M)2..:MMAXZN3&6Z7"EM7$R,G[+G#&0QDFB`FBY.-&\X
MT6+N-<CTBL*K54HFJ`4U"K[DNY./M4N'WLC_`'OMEE!Y.ISEP`!"%X"%?CUB
MVV%60X,$L64+ED_7:.&KYHJHW=Q[AN^9KI"/F(.FJA5V[A*G'S4%2`8/A#6:
MHXA+DNZ/MG=%CEUDJUX\L=FG&%OH'RTP7.)?WP(ILW\E.[8@H&.4TBD#8XN$
MQ`@%`X>G1FF6SXE(=+Y29_,(0P&,5,2D,4``H#ZR?QG$`&H?>B&A)*'VX97;
M8TR`U0GF!9BP+U*%KY!@5"%,C)PLD'LWF#UB!2NF"RQ54C<#`)>`Z;^I#K%\
M]V+'XURG>=EQ[@SN'CY`3PSHWRE8B00!RR.(&YCY"I`^QH1WK=.6YU:*VE[;
M<?L0%*$D9*\[TDRTZ4GDO[8#!$ZI@XG.FD2@5K3PT/@R#FD:^/3PH!3!ZH]1
M0X"-`$>=*Z.'I2/-6EPBB)O-,``H3@GP#T\>.H_[1D\A@J8XE,`@(4`INHQN
M'`U.?QZOP32B\232K@1)(NEW9UDR-$CK*G64!)+S"II@=0QC`0A!H4.0!RU6
M6=(IQ"-AE,A;.\L6A#-P4F<:WG"9'79AQ<N[>%H];R!V(>MU&;&`!,'``\!T
MN!YH.(";@3\D$A`H!T@`4J``/"@5$.74--136:V=<!HA][.4*MGE`53-ZWR@
M$#&"O(!IQ'G30$G8I=%LO6V><+7E@N[.EPG8<!-Y,Q5)B4"JVU.10&<R4654
M`\T8R63=&`Y3=105+R\=2Q0[=Z:HDH7J3$O2`]8""O"GK#Q]',!'2&:%8T55
MX=9JNR579.V*J2K-V@J*:K9=N8ID%4S@8#%%$Y0$M!X::$JV.N`-T%JSMBWH
MR9N<MP%N25PVE?8`"+^>;0+8Z[JW)X4NE-PHNV((IG,4QZE#CII@NW-:.VQR
MT=;-]RMGW`\!C:V4HJ3L6<4,%2-$9-)8L>94>'KQ\IP,("(A30ZG*3@=BTI?
MMIO;*NF=M"82`K^WI%Q'F,!0%!=ND*H-'Z!A`!,F^;]*A?@'5S-")'&03&1/
M!EZB?NZH`':;VV<AHWNWP#A_=3+<*>'+4;D`3+9,%5];Y=B\_3NLGZ.Y/O6$
M"@`CGN[J4#PZ65>/PTU0<"RD>";[<D3>IBDH8"`-*B(%J/A0@TX&$!H`Z.*(
MEBMN6%F;(V-H\T':USNVT"N4$U[>>^4_A'8*'$3E78/RJ-Q/0PB/2(&I40U-
MT.<^"W<WRIA7*+5E%Y1L1''MRG+[*3(M@D!-FB<M2HK35L^T>4HT$3B*ATB5
M"NAPRBSK9#O&SC$VV+/I[EEH><MJ_+IQBTQC+1#@%F%U+-7SZ0>3"`=)3LG+
M&+`OFI#ZY#&H-=`!92P=WQ`3?SEFDX<).$NDIR"'G!P$%0,H'F%IQX%(`4KJ
M/'%)\&2U=P4@_P`Q8?PAF&#:"Y;8_P`>QV$K^43*`N865MIVLZBGC]*M?FZ5
M8/A(1:M>LH\.&GF@>Q(7E(]*1;"0W`P%HFJ(@)>H`J0!$/EE*(:,N],$Q+K9
MN$\DJ8G-,1LK!L[QLRZVJL;>%KO>@6TDU-Q0=,E3B"C.4:*E`R2A1+Q#B.D[
MIR.HNLDO3&=O?1W]\S%,VXN"P$G:+66CI=/R+ILR27,GY2,PV)5-:*$J@>6X
M*8W6(#7EJ]@!Z"D7XK3:2I6[IN^2`P*QTDSE$?*H"GFL7";DOE#4M%!,GP&H
M<]4#`]B0)2R=ZMNO93*T=G=N@HO8&<;,LRY++F/,%PW,#6V(:(FX1TH`BFVE
MHV:B%JHA4/+'TCJ<ABZ'\+)(2B1#F`Y%G9##TU\APLB`@7Y(&!,Y*B7P#PU%
M)UD<).2]LS4/=$+*RK&>@GC1_&R:;QP+MJHS73<D*DL90RA2'%*@AR$-`1V\
M4L_N"/;ANO-]J9,FKADK@9WAC&TINSII=51+RVAD7*4DV8J(%3*0R4LDJ(_#
MQTY.[H?AP2)9.1F)=)@62EWLFC'E5*B:0<>T*)I*B`+(!YHG5.*I?4`*\S:B
MF"E:9+/(Y@VS83N>+1</W.#4;BM"\F:)S=46U>RKAU!2Z[<QA*5NNS)Y?5P&
MM-2S':AS''FD-RL4VDDA(($243$GE+)\RU,40$`Y"!N(#X:6*<9&)?-*OSC`
MLW6$-LF0R)(G>O(&Y+$D%BF$ZJBMLN8]5(RPC7Y*<B(!4:T"G(-3B,^Y1&`P
MR3JGNS0!_.DVX`%$H!B:\B@`\O5DH8-0N@/L<CQ3!/R]"]!'>]^9ENN_@!RA
M_>=+:T&R_OI]ZLJ9J.O.AU/MU8>G:7[O.7[>2<P:U_7D/,Z*W.G^E95!ZPN=
MZF+;'='_`,+Z0L-S5&-GV)L@L7S9)TR>VM*-'C98GF(.6KE`47""Q#B)3I+)
M'$I@$*"4::^.NC=K\KJW;*C97U$_\2*\6VFJ^ZVP_P#,4_YX4LS%.%<3X-@G
MULX@Q]:V.;?E)52=D(>THEM$1[N86:-&*LDNW:D(11VHS8HI"<>(D2*'AK[S
M7T,[K:&A"-"$U5OG_/I[-?Z5.Y'^05N5T))U70FFP[@_SPF/_P!`&Z?X\BZ7
M%!]U.>::$:$(T(3,7?J176[6V[(C5!9TX/9=$T&Z1UUE!!XAP(FF!CG$/0`:
MTP!^WQ/#4?G5L,_4O+6;Q\W^*`8>6_L9.`Q$@'WH5`:M];EBZB8E;+LC(.5,
M>K^T6BYN>';BN91:+6C))>'=@("``XAUT2(.B&`>-!"H#IXI:2MD.[RM'):A
M27YCF0LB??F`I[TL2`D&\:J[-ZH.YZVEF9TS)&4,!U.A4H]/4`<1U*(>0!YH
MTG@%K&[<?7%:KMF11F^EH^0347C)R.C'JT9(H%$0Z2*"B<&K@I>!T1$>>G5I
M#5J28\%O.S\P#*VC'XPSG9-S7M9T8J*=N7:T;2"=]X^07(5+R8ETX9KGD85N
M8I3BQ'IZB`?I&HAJL(+G$A8+D[#,I92;.YK8<R5ZXZN-4Q+;O-O"OFHG5*3S
M#QTNR\I16-EFA@,0Y#B`&$HB'/4F+X)-ZUJ96-DP2;BG`313"B!5CC'/SI+'
MZAHH``V]4P!P#X-62;RVXNJP#YN7!42D/+C\J%E>/``")D*5^RWU4ZM`*H%(
M:9#C\RRXA7U?+B7]>`A4##Y&H2.(38E4)8>9,?A"3@]-#"/S2_X"`5_];ZW&
MV6\:LY5#]6F?:D7!9516$P)AK!3H"(C_`.Y#_P`/'@WUIH$R!=\"1[4])50$
M=,A3IAYDIA_=1,A4?_8_/5B>DK8&/;VR)C27&6M9K-)E7(9"3AW$0_<PL\U/
M0%&<K'J(%(]1$.%2B'3HQ"6GB%L>3C\>9.%1_&Q$UB6\5%!.M#GB)%]94FJI
M7S$H\X-6RL$4RG$2J&.`&KH46+<DJ3!\'-*83S/MWNFVI9Y*78FTNG%T[&Q[
MI_$K3T6159U'@_!`2)"Z0&O3U`81+3CI!,@Y)NEQ`W&R,[:OH&X&SQL*B+IN
MK$OP4173,)%4C@"'$R9RB`^D=`2()9*UW1H3#^UMM2PP\P<Z&$H%J/3&/C=/
MDJJEZ#@"(B4P``"(#J1R#IL\DCL\7,`/&$E`'G_[4R%>/I_M?2[DV*MKB*FP
M-3YDE#5#_P!YY$P"'P@5O40^[I-+ZN$N">DG)*?VJY-R5`YEPK;#V)D;DM=_
MEG'29X>YH&1DVK$YKMC"D<1KQ=`IX]1$INHH4]00`1'AK-H1M1;R-<?MV+'^
M%P]JF*1`)Y!2P/>S&;UU8>S%1BP>.0*\FQ,DR9N'1R`:$$"@;R$SBF4O5PKK
M3T(M.6'?WJ`#CT*%26-F^KA"S9?'J^:G_$`\?^U]9>"6DK<6!9R9M#*]F2(1
M<XFP>2J,),D/%2!05B)JK%^B(^STH=-7QJ'#0!BGI,<>"QG(=K2$'?5W0S:%
ME_96-P2J3(J42^]1J#M0Z/2)4!*-4EBB%-'>HL5E.%,6S60,@PD4ZC9>+MYB
MN6<NF8<Q3SV6+@XD3/7BAP.DF`KJD1$B7'Y8^.@#U(Q79G2Y'.2,JW;=,'`3
M:4$]?E;0J3J+?F73BHY%)BPZQ!L0#><FD52E```$--T,5N*T6\EF?!X8@^99
M9&_<:R4A=-BJFC'Q4YN!=ID+-PX"=N'2Z2,05"4-R+RT')N*"/6DC*P\ZF8R
M2T%.)G2,)#I_-3^I%"B/F$'\1S`]?LZ1#I`$*@4B)<2@/S/+EXCP-$O^K_\`
MA^//4H82!*;%4:T/,TH$--''A0H1+^E>?'\1Z-9E.EJKGDI1=WX+85HLYUC'
M-U48:;2437.<2A%OJ@(`'"GD!4!U#<:-IKB(?VKBE+WCWI96%,Q7=8-R1]R1
M$7*(RS=$[&08OF+\(Z<B'0>2]8/2>S@(M';83%,''B.L:3B3**S_`"-MZB<D
M-9C).`6,JT3`I'MQ8ED&CD+A@E!'^WW<&J5%(LA$HG,(D+Y0>6G4`$=1(X\$
M@`M6X]P7*R*+BX)M^2WH:-,**\Q-MWK1@W=TI[)Y/00SY[U<*`(<1`-`S36<
MS^2;=QO9-S6?B=M<]S7;>;%2WKKOEQ"2#.'86VN85GT5;#51L91<SUP4@F7,
MIR*(4'GJ3AF2);)(\/$S!T^CYFFJE`1*/S8^-ZG*G]@X#J";+&7]J3*]3EA)
MNH`/#YJ?<?`/]8#TZ80MS;=(V2L:ZKERG/0,RC#6':4ZX33-%/@]OFI2-7C(
M:/`1;B/]L*N1,-`$:!HQS0DCO(JX5U#JGA)4JZYU71P-$2)O)6,NNMY8F!N`
M#[.H<"E](A73,->"FS8+=1BI9@B86*NU%Y;M\VVU08QUTR<,^487'%I@4C=A
M+B9`@MWK02E`JG6/2`ZRZ5*E"5.=3W8S!3`(?DO2Z]W]M^3M;M=;?H289*,'
MS-&Y2G253.F)RGGY`Z;@GF`4QTEDQ`Q!I\D0]&K]WKT[JXC4I81$`._$GZ56
M?>/RX!>>OW6F<J;N4;UQ)%3!TCY\NU1)4D4^6;J$,1D`&3430$IBC3F`TUJV
M^=6,6"0&+"7H'^T\M_\`R:1"OHYM]/$X(TE<BQ\Q3C#SG#P3AY'E\/\`:^AD
MM,EW$C9HI@.$-,!0JE3*0\AU=`D%,Q0_$!3B<!^+0V*3$)8C^]IZS\#X0M<;
M0<3]FSXWP]O:V7T*_$DH\6D&K5-ZS<"W,$=*QS8PF05,4]`U+@`C3XBR3Q=5
MGNHQ1K*6_'S<A;$X*CF)<J0KXCR/.<P=<1*B5$?.D&12F`%J%\TI.JE1TDVQ
M8<E=,=7]D7%[YX_MQE(*,I1'V.X+?E(:1>6_<,881`[6:CO)*DX,)1]0PCUD
M-QT`G@C25L63M"R,OOG#NPH.6Q?>)VR2JEC2[=\[MV:?"B+A<ML3!FK08Q=8
MYQ(DW$#B/`!K3B)`%N23H^M^XXYVJQ?VU<+!ZBH=)PU5AWX*$,01**:@`WH4
MQ1#B'ITB,@AI'+)7.!&Z8IE=C5M#SR36X+6<QD@DE$R`-UVY54E_[9*"`5$O
M4(_8UF"B/LC\04L=3+'4X^8H`_-$P(TY!#R`B(CQ`"`+?CRUA]G%2TD)0.,,
M\7_C^WE[`FK+3R/BIZL+]UCB\8:4<0L<].<2G>0*Q&X?1]Z83&-U]!Q$YA&M
M!TPX08X?2LR<WMMPF0,=?;=D^VW0U.JG;]TG7:H*&#UA:H.;<H5%/C3B-0\=
M&"1CZ5B"%BX_O%5RWLJ3O.U90XF&-MZ]85P5F_`WKIM"3;%JT;(^93I$5"B!
MS"`>.FR1!CBMA69E)6'M=SA/<'CNY[PLV'=N5+8>LVSQK=>/W;HI?->P;I9@
MY;NHQ0Q:F3Z2`J41"H5KH?@AB1DNPVV:*NZ.5D,/9+B[J`J1UBVW=D<M95V(
MB4/,*BHB],HRD%"D$`ZDB%J/``T,$-S6`6^&=MO\ZI-M+4N>/;/0/#R3)_#R
M3NV+H8JF*=W'2)D6_L[QDX%+D`^'5R#42.*,RRR"9L*'S8I<%T8MM5Y8\_'-
MDY21Q@NS>"FZZ4?+?/[-7%LW%5H"AA.+<2&$GITV0Q9=-T,+@GMJEA-RL)4W
MT$R3=["18'B'_M<=](8Z'41\\H(U#S#M%`$U*"9,=7T*>N4C_`*`XD&3LONS
M\?)M.YQ:IW43(M4$\87D7VIPP=H(#U/X3RRG451*3J.%1#CQUN[^M]GZ=A2&
M>EU;)B?1^13_`#>T`ALOW6U_\P64`_\`\/E^'QZ\^V.$HU)/Q*C,NH[LL7JE
M-TQ?3M/]WD#[>2\OZAU73\WIB]I<96TA[%SG51;8+L_^$?G"MN9&XEQ9?9O1
M;C\>(>@@<=?.?3FU&EO]E5TX1NJ1RY3"\+V>H#N]J.=Q3_GQ4O<.0:^K5])!
M?=":-"$U5OG_`#Z>S7^E3N1_D%;E="2=5T)IL.X/\\)C_P#0!NG^/(NEQ0?=
M3GFFA&A"-"$@_N+;D['VF[2\NYWR!CAKE2U+$AR2$S8S\&16TXW]J(F#=47[
M=XU`.LW4'4F:M-84;BA]ITEQ(<E)B6P=U$70]YUV'.C=*?;-M@Z].)"%M`XA
M4!\"VQPY:V,(U*@$J8,@<F#_`$)RAHCJEA'F<EVO_>;]B\=0'_;#@&_4%0%5
M*S>@2F"H"!OHV`"40XU]&EIF3I`.KDV.&?#@E&,9^Z7]*MY_>?\`8>GT`/;)
MMP!4*04_4M`!.FI3RSD_N:J8I_O1#GX:!KD6&)[,_F3%.68S5X#WFW9,>-34
M'MD0(QK9PJ5N45+/,BFX5*7VCRB?1T>)B4K348R,B(Q#RPP[\O7P49DP.FH6
M)#XX8<_EFK*'O0FPNIJ=LNW:D+U#T)V@8*&J4I_^]OI$@&^W3AH)E!C/`$L'
MP<\AVIZ2LFA_>=]E4R@:W6G;:@"1AW*LF9BY7M%%B9R@F%'B:)K;*F!Q3/0!
M\:_#K(LH"[K>33JP@6)?4!EGR0(`G#$A4S_WF38G#BV^<NV5;[=%V"HMU@3M
M$R:O2<Y!$!^C8`/49(]!Y#TB'@.IW%G5MXQKR>5&H^F;>&3%CIEE)C@6);BI
MFEX1(<3AVMGZN*I&_O/?;\<*BD';9MXABB(@(-K2/ZH??4+;0CTA3GR#5$0)
M>]*([V"CY<M)F<(C,\`^"N$K[S+L'A#@F][:=N@84TUR@1"SS527*4Y%``;<
M`?6`X#]D-.4=):)<\N/J48@3]POBWI5J#WG+8<JK_:G;(MM1+H,8RBA+.0`!
M+X>M;0@)M.'F>*,9",@SAV/9@I:.:K6WO,VQ9?I\OME6L*@A\@JMD"):UZ0$
M!MTI@,:G#TZC"%>I5%$/4K'(#Q$]P`)1H#L<U3N_>;=BS)0Q7?;&MQN<G@J2
MSR5J`B'$;;\0"H>D-1(G&.HAHCF/6@0!R=4)O>?]AQ:=7;+M<`&G$_T0+S^.
MV1KJ+EVP=`IOEFJL/>;=CHMP>!VOH`S43"7SR)6B*8"%>`G^C0%`PB4:!PT&
M3,"0YR[>Y1\&6H8Y8YJHCO>J=E4*)$(WMQQL6"+@%RIMU[31\I80&BH%+;E`
M$H'X_'J?[2)T'"0X-BGY3GBZX)^\];'YIRJJ/;,@G;IR=1=50_T15565.;K5
M5,;Z-B)Q$WRAXT'4!)W8@MGV/EZT1CJ?27(^6*KI?WH'9"8L6C.]MN$!)NT%
M&+!]]$^A%F4X%!)GU6V`&2`XCQ+4-3,*@P(+@8X9#FE`"H^@B3'%B[*A9^\[
M]OYWUE<]M^TVQR#TI@<+-$5`ZA`.G^YOJKI`3,=403$<0,`GY<FYJY2/O,6P
M&,4(B[[;5L$442\_H!&SP'HZ>L.`VY6E./+D.GIG(/$')\N'-`A(AVP!;TK<
MVT_W@;9!N4W-X6P-;';SMFTY;)=_05KQ-T&;6HJ$%(R3UNFC*`FA;R2H"T4`
MJH4,4P]'`=1URG3E!S[N#=J)0,1J#.EM]VSO=;?-D&Y./VT97VB)9^?1=G0-
MX,)J07A#,8Y*?;B<B#5I*Q#WV<Z90Z3"4Q:UU51D?*!/NCC\N*-#Y9)J]?WF
MC8RW`!5[8-OI@8>D!,6S"EZJ@'3U#;@!4##3AJT:I81Q/R[$@('`''O5(/O/
M&Q=FLD<.V-;Z!R*@)%BA9]4U"'`0$!^C8"!RF#XP'09&)TR82[4Q3*X+^]`[
M&WZRSA;ME0CA90QSJKJ%M$ZM2T**AS?1L:4#P'CIXF0B/?)P'/N1Y;#L7<V]
MZ,V2QY71&O;1AVB3YN9NZ!(]J))N6PB(G14`+:#S2B/(/2.H1F"2($$@L6Q;
ML/)+0^*ITO>=MBJP%\OMBVZ>G,.FSAY@`!3IMKB%"T\>6I8G`8DIBF<RKY&>
M\[[+F#A-_&]LJ)8K%ZB)/&OT434`QRB`D(8EM@8>H.`@%>&I-4&+9=GYDS3&
M172/O,6R-0YCN.V'`>:JH8YA$;+,)U%1ZA.8Q[>`PB<QO'QU",Q+(@]RCIB<
MBZOR'O(FR%;I'^;*MM,@DZA,8+),4H4`?6_N>&E/'3.;\OER2,3P"M4O[RSL
M5C4_,)VV++<A7Y(*V5U\`];I`+<,)J"%.''AHC*M$BI0F&!?,*7E2!:42/8K
M8T]YVV*F23\CMD08**&`.@B5H=%0'I#HK;51`*:<ISF34F29$\4>6?0K@I[S
M9LB1'S#=LN#(<!]4]+0`*@-1`!+;M*E]&HF1!$3A(Y<SW)B`)T@^)5#3WIS9
MW"G,_CNW&R8K>4=`Z[-U:B)^A4!3.B8R5N>L4Y!Y>C4GF"V12\HG#BK6Y]Z4
MV5.&@-7';5C%6)5A=(M5%K342.NI_97`)?1LR0G#[X>8>.FU1G;#N_,CRR%0
M_P#2A=CA:4[9$%0>%>FTN/$0X4MFGR@IJLU`'U2`;/L[^2/+XK[_`-*(V-B/
M2';,@!-^Y#Z(U\/#Z,@/CJ6(S1Y<F?@JA'WGS9$J(=';(A!`:<2C:0T`W(>%
MM#2H<M2TU-.ICI'%L$_*(Q*NZ?O.NR\\<Z;#VS8L(QR*3AP@)[0%NN9$!*BJ
MHF-N`43)EY5Y:CJ.7-+1$EN*N#+WD+9.^33`G;"M](JQ?,3%5*S1*8QJF`.%
MMF-40"M*:CJ;$Y)$`98E6F5]Y'V;1A3F6[6]M*-Z@7K;_0\QS==2%$"?1CEZ
MW'X-3IRU28$.EI$L';TJ07V8NZ?CKN<8ZS*]QI@U?!D#@BX[/M<+<%XS<LWG
MTOCIR6249HL6+-!H1J$0<HD`H]0F\.&BJ#$^(ET&.DY!S\O:F=-X?O!>S;`>
MZ'.N&KO[>\%D*Y\:Y%F+6GKV63M0%+CDH\K;SI14SJ`6<"=<%`KU&,-0YZB"
MX4A`G',%)K5]YNV)I@`_S85N"`TXB6RPX<_&W-/Q=BEH5`/O/NPNHC_-C6V`
ME$:U+9P_!][;6C$\DO+/!=9O>?\`8A0*=L2VS%$:5Z;1#AXT$;:\`XZ,4M!5
M0M[T5L963:M%^VA;RC9F94&B"I[2,FAYPE\X4$C6Y0!/0/1RTWEE@CRRNTOO
M/^QE1(&)>V5`%145!8J!OH>5$ZI0-TJ"4+<^44H#I>)'EE5*/O-.QEP<0)VP
MH!43<>HB=G#\(CT_1JO$=#GL3\LC/)7N/]Y3V2O1*X:]L6"2%NL0Y5BA9Y13
M52/^+524);8AU$.7GX:'(S491`_TKOE_>3MGAU7#Y7M@V](G5$JZZYU+1.X4
M$1Z!.)?HR)A,`!70"9%W"0`;-8<7WGK8LD\,S5[8UNHJT$CCJ"T*E05]4WF5
MMOU0"OK5H%!U9IEF"I"F2,,E=%?>9=BZ!@KVP[>`1IT]1;,*!@$*ATUMSD)>
M/Q:@3VH\L\%2#[SEL1*)@4[8EN4)03BF%EG*2O+JZ;<X5KH<I"F>U=!_>?M@
MZ0A_^&3;U!`./E6;XU$.=M<AII$R9/RI=JXF]Z!V#^I_^&5;P#U%,43)6<`5
M*("!JA;5?5'CI`R='EE<W/O1>Q=\L+AQVSX%=4Q2D%98;/.J8J8B0H#6VZ@`
M!RTWD<T>4<D)^\\[%#&JCVQK>!6O3P^B!3^CU>FVP$IM#R3%,A9.M[T5LV>Q
MJ,.\[;D:K%-EBBBS<N;45;)N#@8I.A,UN"!5*G$`^`=&J61R1Y8=^*JF7O*V
MSUJZ;O8CMC0:4@B)O*.BI:*2Y.L#`8Z*A;<"A0*-#?!HU$'M43$'!U8Y;WGC
M9Q$(.V$EVPXUNS>+@N[3,-I`T<O""H8JRP!;0D/0RIA`P\NH=64A5E+]G*(0
M(`G/'O4A7LY;Q-N_<-Q'<FXO%&V&UL#O+3NEQ9/0TC()257*5$KA0Z,C&1C(
MY$!$H@)1J`\!KIWE6M2B(UIF43GA@W>EHTS9A@'"7YOD535V7;JP3()*8#RD
M(@(<:_0^5J-/L:U=E<T:TB:`8`Y-Q3(([U'7D`ZIK=$7]UM2]WB#[>3,O:IW
MBGYVTUZ?&5(KG.KBW3EZ?_!/SKHSPQ<K8:R8BT=FCW:MGS*35^1!%R9BY4:G
M(@\*W<`9NX,V5,!P(<!(<2T-P$=>9;9M7E[C0J"/NUH'U2"^?-BK/O=F'_\`
MN:7]9%2D,06;DJR8"0C<H9BD,U33J74>L;CD;(M"Q%8V+.S9H)PA(JS&K2-=
M)HND%5_:%"BL85Q((])"Z]@7U*ML:$(T(356^?\`/I[-?Z5.Y'^05N5T))U7
M0FFP[@_SPF/_`-`&Z?X\BZ7%!]U.>::$:$(T(3)WO`[<J_:GW9D,'RK,3&O'
MD#]`?NZT<,-Q/:5:<(Q]*\Q#:[@USG'*0V+%)-3/7T21-B4JQ6R:SD?+(8RZ
MZQJ(J$-PYAS^'7KWP[Z+VKJRYW"AN56M1M;6&KP'@S\N+YK2[_O5GT]MHN[B
M-2<7Q');D[@&U:9VS/K+MJ1(T=EFTOG)*2:JE=MW)T&?E&9JK%]5$[0:@`<`
M/SH.J.J>F]GM-L&_],TKZCM524J&BXB8U(FE(`2D"!A6#R!X@8+6](=4T^I[
M>K7IB,94A'6WU=>3I#%PQ"?S9"+"!"F]CADC&+00,(#0X=/(0*`<0UPX)?`.
M>3M[>'?P76N2)1CB<6X>WZ5(#-VU+/+L_+EQ"93C\C*PS>_`<)OF[BV5H8S(
MC4D`:/,EYR+_`*"F4.8!'UQ#CSUM[?JS;X_&:W^#-KM5Z:-.W\B=_*C,1E<Z
M#6F1)M/DB!B(R;/%><GJJ^E>QOQ6LZFWF[E1E:&0\Z$&85P'U'47`#L&P"CS
M-HH"*RB"JA?,1=)(F%$4A*H9)^<#G!,W4<4A+R`.8A36ON:-:VO:]M!JE2WK
M3,7Q`8%W[@Y7I.!A"I(@"H"W9A@/26'I3MO:TVD8ZW*SUU.\@-GSV*LIRLZ<
MMXQT+9RX1.5-DU3!0I#&Z$EU!,)?136=U+U#6^'OP>N.MMAL87G4XW3RJ>N)
MG2C"8E+7,!O`,G?/!<#UCO\`6VFI;6EN13-<.9GE'$@=I"T]W--NUN;>LRP]
ME6<H[&WDF7M+-)VO[0X0(^1%\5-0@%*4#%,\$*AZ=;>YW^IUK\.NG>LJEH+*
MI>TJL31$3'35A(BH8@XZ:C:H\PMITAOMSNVVRA>Z37I52-0R(X8\V][M2!+(
MM$+GO.WK:*?I<3,@SCB&'U#(&74$@F$X4Z0``&M>`AK!Z:V3[]WVVVF6$*U3
M2>8+.&].?8NCNKJ-G1E=2:4(`G2<I8?1F.U.Y;R.W9%X4VH6/FMG<#F7G!7C
M$+I*GTK1!F,JV17BO9/Q!%>I(J*Q5C=72!@+3EQS*]CMU]O746P]/6]S2H;#
M&AKJ5@0:]Q,UA5-(D8PAY46;]+M"\YV'KRXW;J@65<4XVU:%3R81SCY;8RQ/
MBD2_H33RUL_V@5T0">4DF1(XJ"I_K@@8I@IPH<1$`](EURL9&O+S@'G*$7;T
ML5Z1"J"P.,C$$GM+N/0R4'M#V_?6"S;%8T;+>R#+>R><\0,F46;)-<#.7B`K
MG&JB:74)@Z1`0*'PZZ_I+IP[[6O+FH:GE;?95;@0I.:M2H(G3"(#N[,W-:3J
M?>(['LM;<I$1,0T7^M(D#0>0Q=U==ZV$"82N][9*"CE\2&NQ^R2D7)$P5?-6
MQ%V[=RHL@*:104(EU`GSH8.&K.L^F_N&QL[FA3K1L;VWI5(^8&(J5`\Z9Y2B
M07!Q".FMZH[]M5#<8C36G3(G$91G$L0#QYOVI,4]$H`A%*JIE344)%(&2`Y3
MF`5#%$#&$G`*](_#KBHTZMQ4A;T,*OF@/WX>QUO@--6/+$GT</2G2[HV7P45
M@NQK_MB?CYJXYHTA.S5L+N4P1B42@J5D3H(0@D\]-/JH)A#S`,%*@.O>I?"6
ME?2N+*TC>6][:V\)BK4&JVNC*E&H138.#&1,)'G$]B\[LNM[FXZ@J[;<4Z<;
M(:?+P.K&()?%N*:;6A*3<\@=(J8-%7O60QR&!$Q5>DWK@;I$O7\CF-!#T:\+
MN+>K;7$J%S",:\"1(1?2XX!\<L?6O0XRU0$B<_DR5[LEVWQ&X*_;FMF4FDX,
MT5%?.+216<E00%Q[(KY+18ZM4_+<N6X@%`XB(Z]'^'O2=CU#9WM>\IUJ@M94
MW%$:C+S2>7]&,^3+E.L.I[GIK;X7UM&G,&H1(<6'/YEK;<U8<G8=SP=LR_E)
MGA#/XPG0*1VRI6[[RB]"R0])B'IP'Q#7+]7=-U^D=VN=ME4E6E5@33&9T/X7
MPS8K?[3?4]RVZG>48:#6@)^L.?42M'6M:1KIO"#MM`O]LS+YJQ:BB/4HF4X'
M%1<M2F#@!!-40IQUK^G]FK]1;Q9[51D8ZRU09$2`Q?M[%D5JT;>B:\O<@"_:
MG%=[FT.UL#V)BBZ8FY5KBFKBMU%2\D1<-781LE3RF8$.V3(4G602]0"(@(UX
M:[WJSHRCM%G=W=.WNH;?:W4*<9D$0N-41^U$N`C,Y`C$,N#Z-ZHN>H;^[I7$
M3"E&;P#-V^E5?:2CD6O<?V2."K`)%,[V$!1`M#CYCE$I0,-`#I$R9PI0!]77
ME].<-08C`YKOYR</\LPG-_>M&[E7N@NU$5GB":6#+`,)FRB90J#%02]13%$P
M@(ZAMXA.VTR8Q-67J\92<B!,?>3-.)]KF0,C8[G[\CV_MUMVS$QDI<#EXN0J
MS5"473(`-4N`G.H:G(!$`XZZW:>E)7MIM]2K5C2OK\U!1@2TJIITY5"(#BT8
MDEN`6NOMXV^QNX6,Y0C6D.?))$+")FO"=B^DZC9LM)`@"BHAT%34'RS&$1#U
MP'G77,W%&I;W=6A<`FI2F8E^!&!'>%LHS>F)\"`W:LRQ/CE]>-S2,:R3<+2#
M$6IF:"9T1!1554O4!O-`4_62J`\:#76VZ=V'=.I-PAMVTC]O4SFV$(C.1.0&
M0)[0H7->G0I&I4(%,!R3DJ[-F/9"S9-!O(0;V-<G>J%4<+J-S(N"'*4Q2I';
M&$M2"`A76/O&U;GLU[/;-R@*=Q3[&,P[:QSB3@Z=*>N`G']V0X[0M-O8E9%@
MDL0JB?FI]9#>92@>:"13"',0]>OI'IU@T1"%S&K5]T1/AYRP9NU7/BW%+SM[
M;E,1$)&SJ_D2C/V/VGV%T;S@(BLT,H"IBDZ#@(&.%!J.O1]N^%'5&Y]-#J2U
MD8UIN33EFPR+-DRT];<J%.Y%O.41,A(,?QJ[9V^;KE53#S79TNE8IRI%(JHE
MT@`*B"8$$M.D>/$-><UZ$Z-4TZ@@*T7$M/,<QS?!;HP`B)#BE,;;\$71EB"R
M/*1<FR;HVW`NEQ;/'!DW,D8@"(-8\_48B2H%+SYCKKNG>A^H>I[25YM#2MZ<
MCJ#8Y#Y!<WOG4%GT_5MI7$*DQ7J:<`X&3I/H6TX3GW$<[1%LJVZTU4U%%CF(
M=(H@("?D)A$O$:<=<K=V=>QNI6=Q$"M&1#98C/#FM_#3&&H$F,L0^;'$#T!?
M6C!XX26,5TZHT55Z$TU#I@3H`:B4Q2"-2E#QUC.,^'Y/DRF2'8Y%+*V\;9KQ
MS%85TWM'OV"$7:S,3ODYF0!-PZ.;S2M$HYN4G6Z<K]`ATEJ8PB&NRV'HZYW2
MQ\\2,1<RD*<6,O-,?>`DQTZ>(<,ZYC>^I;'9+JVVV4*DKJYJ,)`9`D`X\\4E
MR9MP6.4W5NJE.=NT>$:N$:G('6#4YSE,0]#E$%!KQ`!`1IKCZ](6=:5H6&B9
M`Q?W28Y\>]=-,C'2?"'8\2`67=;UBR-S7U`VU&MGJCF9>+LFB29TQ$PJ`=,A
M"@`B)O,-0"\*B(:S=@VFYW3=8[9M!E*4@^F?$XY/P5%:O"A1G6JD"E`>(\`_
M-*\W+[,LF;=L?6Q==]P9VB5RQ1A8.&:Y#%:O`5.L1G(%$*-W)D`ZNDX]6LNI
MM^QW=O=5-DNZ-[7VZ6FOY4A,VI/U9@>\2<'+LN=V7J:PW>\J[?IJ1G'&!X2'
M,<PF_P!./=F:D61.[34$PE`XB4`$Q2"80J`"(B7GK0S,:<3(.6#_`)O0NID6
M&KEP2X,)[7<BY#Q=<F1XDJ3ZW;5BXR:E2J.#(N%4'#DY5D2"8@"`E;EXTIT@
M.O1-G^&]]N6U#=Y5)",Q(TZ;XU3`/*,0V+`XKF=TZCVS:]TH;9=F7VNXEIC^
MB"<G/>D<W29^WN.:9MGSYLV^<7*:#0CA0R2:`5*)`/T"`@2FN!E1J?:ZM"42
M)4I:6[03AWLNF@`1JEG\W%9UA^VLBWM<80\.N_<IMT/,,198_ED()3%(81Z`
M`HB7Y-1#[.MUTQT_N75.X&PVG3YT8R,I2]V+1):1R#LPYE@J;FO0MZ4JM0@0
M`))/`#,E6.Z(:^(*[G5O2CZ727;/5$5T!71`"B543%H)BTH)0$>6L2_V^^V>
M\J[=NT(B]I'%@V!R)[^',)TZE*K1%6+&$H@@\P<B.]3QO<U6QVN%]]/F^9YJ
MN4,**#YHAUFK:U\T&H``"!@'AK!J'Q9\$JF8;L44[NGLYR=[JN\ZV8L3+&D,
M_P!XBBW12*54Z@)L1Z2J"4:&,(4#T:J.8;-681@"<TA_+.,;KQG%H2$]$/8-
M\[.R21;/"F/YB;TJP^TCU%`.@1*4`$.`#X:8.+)1D26*U"[8.$H"/F4CF%5P
MD],N!D_4%1LX,C0OJ\*`->?CIN&?ZJLB7++?<=@VY$[$&[YJ(<I6Z4\:!;D1
M05,BF=V`"*'5T&2$@*"`=0>(TT`2E3\Z(_9`L_#Y8JLU,<$G,&K@SF13*LN=
M1NNY33`"$((`DN*11,4P5*82%XAX:`1(.,E:^#K<F%L7WEDU]($@VAY0[-=T
MV=)%$IE46K=D5PX?!TE$$TD?:$P,81X=6E)0G(#`9JRY:@W=FW!'0K,'<4H2
M";&D6X*E.87Z#A9%910:"*9_5X@-*Z`7S1`Z@YS=83`*7.[N*&@XMS(.3R3Y
M%-HQ364*9VLX7(1(@@0G`JJPB``'HT'-DY:0'*VQG7&V1,87BE$74G)Q!I1%
M!^V1]KJ1%%4?+%.A?$@T$0'E7CK*MZ$<3)1IZ2,O$%K56+=M!2<5(Y4$_DE(
M\_&E4*`")C*JI](B`5KSU$RB\AV*<9!F6Q;&MRYLA@HBWASR`HO$V*81!3@H
M4Z*1JB8OK#TB`:QL`2RK+1/AS6&77`/X.\VMG20`EYGL`/BJ%-[0W%T%%2B8
MM/72Z@X"'`=,2?!2$GQX@*T,;<DWUS(6XS;H.'*YW:*9:'3.<C<_040.;J*1
M4X!Z-/)2,@VHK9&3,7R&/(I!>7BE[>DEVD>X09OD514>).B*"JX1.J6G0'J^
ML'JC72!4(S)+'(K21C.6K<C@IR'`2G.>J0"`"'#I&M`XF'F&FX5J5?:&$;^D
MK02NZ2M=XE;!7("ZFVB+98!1.Q!5$"ATF$*NE"EK^SI%8YF'>*3>XG;@(Y>-
M`?'(#5^X32(+-CU_VJL8J!5!`M/,`"4$/371W*UHY@+;F(F66,HR$W$6ZW6F
M',=%.'?0FW9(E;E3433`ZBI2\*F/0`\1T:9'$!5R$6PS=:PDWEZK3$A"3SE^
M#N,449O62Z;0ID%T5C(N$S@1,!HF8@A4-60A*,@9`@*6F(8C)>BO[H<V,WV$
M9<3.(?[^$L4M.0`FR,7C\8ZKW,B5-QEH/S*)_>CT*0OO?_,RW7?P!92_O1F=
M:#9?WT^_\J=3-1Y'!>JX=SA?3M6]W@#[>3<O:W-2GYM$T_T@RY7K'#IF^/\`
MX!609R:]&'\BFI\FUI,>0?[%Z=:^GM?ES$V]T@^I?-W3]0'?K(?^;I?UD5*Z
M#D'Q:VB^ME]T(1H0FJM\_P"?3V:_TJ=R/\@K<KH23JNA--AW!_GA,?\`Z`-T
M_P`>1=+B@^ZG.3*$+P,<H>'$:<>`T^/CIH7`5T0"HG"G'C0:<.?&E*!I.&<9
M(7:4P&*!B\0,`"`T$*@/$.`T'30F4?>!@,/:EW:F*(@)+)$P?$#QO7[5-:*.
M.X=TOI5S8#N7GZ=L/"[6<5>Y;DF\RXC6%Q1L=.#;J3MP^BH1=NJJ=Z+1@FJ[
M`H*-R5Z"B;B'#GKW/X>[EN]ILV]VW3!HTNL:EKILA6(T3GRJ.6/I(PXKE>L;
M2XONGYT*-+SJ[AXA@=+XD&1`]J6KODP&UW*6+(2F.T'3N<LYI=ER%DT33'S(
M$/!)D6C&Z\E+((I'D'[%(YEBI'$#'UKK&M\4;GX;W-G\:_LM+?J5S2E:TZ1I
MDF(!UB9IRG'3`L*;G41B<4]MVWI;:=ZJ6_1$+_\`#4MOMY3E>`"I*\`_;"&G
M_9@N8:@,$TCM(VGW'N]N22MB#D&C=6PK5B;SD(9=,`=2T.W,=N^(W=FHBW,@
MZ`"]1SEH)@'D&N.V6%C4WBTAN0U;=*YI"K''&D9QUC#'&+A=4-.MI/I)8\V)
MX=K*0_#W#9.0[>Q1MAAH6<B$V$C'1=[%D7"K4%THM&LU',T_-,9^J^Z1%(@%
M$#5Y#KZ$M-IZWZ>WS?\`K7J.^H76R3I_\A1IT(O1B1'Q2JB.!T?LSXGPY+Q3
MIKI2[AU7]X[G2IQG3E.=1B/VF8@&;A@2W%U&MW3XOQ[CK<[?UAX["4-;\?D$
MD$A"RZ)V[]NU?3J:":29SD2Z#JI.3$"M.)0I3GKYHE6G=SK74"--6K*4L>$0
M9&)[)`,>PKVF!#^/"`D".QB#]"DHX-P=;FU3+-Y82M>WY6PE[YM''-]H2[5R
MW-)13!W;$/-/_;UEC@FBPDBN@5,(B/JTIRUU?Q5Z*CU7\"+2_M-VI[%MME=3
MKUGE,4:OA(CJTM.4HR]V,7<X`%<7?[O;=-=8[?U'N.T4-^MY4JM"%C5$I1G.
MJ2(2$88ZHN`.UG2)N['95G9!AKURI'N&5SECP@F,'/Q3P57L'+P+)JTF&;\M
M"D%C*(")R&*`@<Q`H(T&F%\-M^V[K;X'V?2FUWIN>J.G!KKSG"4#.E(U0*D#
M.(<'4'`)D-+F/%;;;>D>LOA_N7W+UGL];9ZFZ/>6L*L=&NG4D<(.<1$,)#ZK
M`%B4AWMP[1Y;.5X7MD*+MY>YXW$T';DZX233ZFZ+R>4-[%&.DRE,(.7"*)RE
M.%>@PU$0UN/AWO&U;+U%:W5Y`U#(S$IXG1(P85(]L20?F6SW6A4O-MN;&WD(
MUIQ,06=I/R*?$W;.2Y+Q9';3GF+YZWKEG75OM(2*G4$V;1DFY1<MV*#9P"A4
MW"(BZ3Z3C0#4XCKLOA3\,NH=DWSJ#J_JG?ZF\]/;B*I%"42!3C#68&+@'41-
MI/\`HA>5[?TWN-IO]A7G9VUE<4*<XFI&KKE7)TO.8D?#(MD.9=10LF6^6R;P
MO&PVERH7"RLA\ZC'4I'E51;/)%ETB8G2N1)4Q6K@3I";I]8Y1'CSUY!$PI3J
M0ML;36?+YB))P/RP"]ATU8@"L(]A'M3@W:XL]ZPDKJS80C(Z<.]-9MOC*JK-
M8P+C?QYG`*/'W4FF3H;JF%,.K@<E1H&NIV:IU;'I'?Y]$4YRZP-M2%'28B6@
MU/VII:I`>9&+GQ$`AF<X+#K671^X[SMEC\1+BYM^@:EVU].A$RJBF(@Q$`Q]
MZ0$9X$B+L'2Z-T.T=[N@B+BE+92BW-W6?9C>[KKEX&1.M:<5.D6<%%%9\`*(
MBLXB")'5$5!+YPGX\0UMK676MY\&[>?Q1>GU/2OZ@MQ/2:U2WT1,)U=),8S,
M_,&!;2(\71=V_1]EUCNMI\,IW5;X;4Z@%G5NAIK2>G3,QI8'3&J9QIDQ!-,0
M?%TRY@_!<UG+<;C?#;=0QS3$LU3E7354RJ!8V(ZU'ZZ:Q`-4A@(`=7$.(Z\X
MM*XIW5*I`^.-0&79DZS*4Z42`'$=)=\2YS4G:)V&Y&E+.1MR(PY>*\O#3`I2
MMV+R[-*V%K9*\,IYB"*KE,RIF\101(0!$#5J`".OKFT^(FWO.K5OJ%3:)6>B
M,(PF*L9Q@Q\>ERY<CDX7E5'I;J:?5,+B,J4-FS^KJ;#5@,1B[>A1^>XWM3':
MSN.N&!B8>78V3<\"2?A5)5$[8#.E&#->3(@JJ!"J)H/U#B`<:E$*5#7R?>5J
M5>]K5Z'F&D:LCXR3)B7Q)`)[.Q>J@OF1@0,$Z=L8[;+Y]M+<;@;,5NN\[QR"
MG:4VWCHY@LS]GA2N'Z,ZR8*N03*X\@U#]=0)0>8Z]3^#G5U'IW>IVM]4IT[&
M[IO*1Q#A]`8.7]&2TF^V9O\`;YTH1IRO(XTQ(/'T\'5XW2]N"=R#M7R+=R-A
M&2RGB60>W"W,V?,'=QH6LF0%W3:Y6359<R`$31$U3E#C73^,E_:;GO=*_LP9
M1G#1"H(R$)2`<C40`.#.PY%3V>SO+3;Z=+<F\V%,ZXP8:2<F;!NYV3?W:7V9
MW!N@S!D=_$0+*7=8IQ*XE4F,CT)D+<$BS51;*"582"FJV$IS`8:`%.8:\^Z2
MW.>R]4T+\^&$;G5(L_A,1B6?V.ME.EY_[`X4I.S]P`?FG$YO`]MSU[16'<\V
M$NSC%(HD2Z*T$TB=V^D'"C>*FFCQ([E%(A'G2!#@(D`2UK3CKZXZWJV/5G1-
MP+(B4,9,V@ZH#4PC+23B!D"N&V/:3TUOLH[G<:#7!-*.#2!=L1D_:R;UV"66
MTQOWE]NN/HQ%\U@+/W/P41'MI5=%=XD5C-"4@G,F%3%,!_5,%0IRU\6:*=*L
M:,W%6,B""#@7/8N[=XM]=@?0_J2\/>J5W0=TP8IBBHY>RN%L;,VB"28JJK.%
MD0!)$A0*;J!10P`/"@!QUA4:4YV1A$!_,(QR;Q%\,<E(1!B1VHVW;>HNPHG&
M>`,BW]<5N3N0H6"&\$(M(CN/C_G`0>,VDF@CYIE5$DC$H``8"B(5Y:^J.BKL
MCX?V^]QL:%8;33JFA(1\>J4)0EI,V8M(N[+2;EM6R76XTO.<;@03$OA@/$,'
MX!,H;L,(2NW#=7ES'#HPOHQC,S[^VY8I2)I3-OKK+BP>(E*'RU$B5,`T$H\P
MU\W;E>2W.]J[E,>7YVJ>GM)>>6&#^G@MS$QC3C3'U6"4GV\L!71?:EWY+!!R
MQ35FX.R[&(X1,@QN"?>D%=YTN%`*D9*.9H'.<PCS`.FNO2_A!NL=BN+K?K@M
MMUM95)U9`/(4Q.F^D9ZN6"T75%[9V.S5JUZ#*V$`"`[EY`-V8D+?N]C8Y>\A
M:ERSS5\V6O+&K=K.N(%H856LS!R*WE&<M!.1,H+M5"&Z@-TB)0X5U?U_U'T_
MUWM6W===,U95]MN-='7.,HS>!U$$2`.#\EA='[K;;CM\C;TITH49"!C(ZB,'
M&()&1X)FNR++F\EW;C['$24$YBZY="WT$SB4/)<JO?*%P/54"F0+U\!Y:\IE
M5K4CJH&#C-QGR;Z5UI#`U![PR[0IH#;81BC][JTH91C<#DC)@E$S$W&."'?.
M"$C"MW#@Y#HTH1V80*/*@:]:VCXK[W8[1/;C*`:&F.>*Q#1L[@BM6I@5`>04
M0+=-AAS@?</>^,3NEWD>TE7:T6]?=/M2T:HX5]G%P0A2`"Y"EZ1J7F%=>1W%
MQ<7,S7N#$U)''3P<XOVXNLR,GBXX8)U+MK[8EKYVWW;DYLK-&<J7BZ9`C&,E
MWS<S=F#FJ!DVR)Q`'`IB!JCQU[#\*^O9].RELWECRJ]4-(LV.!X\%@7NWV6X
MU8_;HB4*/B@_Z7%95N#V%QUY[6<B[A<7XRFH&],>S:*MWOEW*C1FO#I"=NY6
M2CW`)+%$RO2(@%?6KK#^+73MO8=00WBUJ1-&I(&407`,HN2%=3J&9>0:(/L&
M'S)@)*1=^S-RI^8<[QRZ*D7@3SEW!4@2*;U@-P$>%1H`Z\GJ`">F&`.7SNLH
MLSCW5)'V6;<W]@XK1F)J2MQ*3MF'B+PG8"Y3H$^<3/4C2;6+02(J'MK0Z1`Z
MA*!Q*<0].O?>A*VX['T]:65K;W=W/=:U0DTM)IVL2/WDS(C2).Y`Q8%Q@O.>
MK^KCL.Y4-N^R4ZTI$2C.4-4AJ(!T%L"V.83=?<(P7)8<W<(3[)BB2W,MVM&Y
M+BDFJ!$48E.99.2.XH`0$2HD9*(4*`@`TH.O#=SL86.XU[*1U&C5E!SB21(C
M/BX7H$*L:M,U`&C+$#D#BL6[<6$[FSQNUMBVH=VM%A;[6>FS2ZB1WB23UO'N
MEX=F)1(8XG=/D@3+0HT,>O`..MMT9O%/IO?Z&X5(ZJ3'6<](:0RSR/!4;C94
M]PLJEK.0@*H#Y\.Y/'9EP5N3WDQ&4<(7@>2C+BQ3;,]=QXUQ#F;F2>V^U4]E
M:K@H2ASRZ+DGE@`^N`U#AKVOK':.A>C^@ZU]T-965K4W:<95)4J>@UWU%Y<7
M<GW@.)7!=)=,#:=QG<_M/!3TQUER^&7M]BCB6YBG)=W2I\<0%G3CZ^VRZ_M4
M&+)5FY20;*BV4<@FY!$_2`TJ8*A3B%=?.$@"")$1!&>8'!SV8KT=P[D`ALBI
M"N.]K%\X)QDOBB^+T<6==I;3M`J]GG*J;Z8GNA@4Y4@3*`I/"-E5BIB-1`I@
MJ-`XZ^M.CNH[RALVS6`VZ-Q92M)QKUQ*E$6\X1<$QE.,I>:^<(R9O$R\CZH/
MG=66M(6T9S-2)B0)$1Q#E\@S<TSMOPV690V=Y69L;[<1:K#(!)"=MLC)VDLY
M38D10>]#E(@B")R>UE#I'CPU\O;_`%*=UN]U<VSPI&ZD''8[^P+UZ.(T\'C\
MR4MVV,&QMW8[RED.;FUHQXA<UM6G#-T&"RZBQ7Z@K24LZ5;)*K%;L4:B(A3@
M7I$->J_"?JJXV4W\*=M3K5?*G4IQ#"565.!(@)$@`R(`Q("Y_J3S([95E2@:
MDXP'A&9QQ#+(MWFQBXG%R/[ZPO/MLD?,#1"0NM*/`K9JS2]E4<.G!GBPHH%,
MV22'J*8W7QISUH>L:ESU)M5OUMN.W5MIW>YG*G7MJICJ`B?!(:92!!`.()`X
MK$Z4W2[W"SJ4[JF?*H3$*=328@P9V(+%XY##@I+GN<KPS[$.^PYBF3%#*&$V
MJA!$#`59"U;Y(X*4P`'44JE1`0X#7A77FG'M;Z%TTPQ`[DP)E[#EY9X[]6YV
MU[3BB.48;<!>DS<3Q8*-F$,Q(R5=++F&I5#G```H<1]`<]'$*<CX$Y%WA^V1
M>E][1+7S-A2UF-S/L6R#4MU*,':9)J0C79!(*1(T`15?*-52=(4`1#PU+22\
MN"J$A$CF5$:D+;NHA87&HVZ^;7H[E%;?+`.D#).RR4E()H(,3HFXI@9=4@F'
MY)0XB(!QT1EIEYC./T5<&?4IHN".WLG#;5K5QI>SJ,EKNG<:($=M'+!%]&1T
M]Y<B]0*F`IF0$\6X.0QU0,81`@``CPUDW-V*UL*-&&@$EQVOGZOF5.1?-E#[
MSM@N_-N>8,A8IR0@Q3N"-=O':<@T52.QDF3IVJJWD6ITA$J*;HGK`0:&)P`>
M/#6-X8-&/`>U7`N`W!2`^QMLOG+HVU[@]REW6^FO:\I=$9;%B(';I'>2Q0;*
MHS<DU*<#'29D5:%2$1Z`$"!2NC,&7+@JZDAK;G]";Q[NFTVZ\"9*LW(B+1`V
M/<C0KAF@Z;I)H*1UP-'CE5W$R90H'G';G*8AZ4$`X#73`8]JG2D"X6)=IG;%
M$Y[W+GO"^9%Q&V-AN(:76JW28E=K7)<*YS)0-O(MU4SA^/,D*AS"`4*3B(5X
MHXE.H0S<4[GW0.W8XR_CYUE;$RBJEVXXE6B4C:@-")!(0CTG4JY:](%564:.
M%!,<*\`#E35D+ASICGR54)F$L>2BU+R#E!7V20;`DYB7)T)4ANGUG:2@E.B7
MB8!/U$$.%0$>7/4,"2>:N``#\%),[)VQS(USGO6],F6#]'[4,,#+6^_GV;;J
MDD+@(9VV=MB."'`6AVPE$#4`*#0>/#40S]BJF7D\4D7N_=O?,^V+=XPO-Q8A
M4\79C.SF<>S$<\9O&:R<8Q0-,I"@BH!HLJ"C90P@<I"&KZM1'1D4XR&G'Y%(
MRV88=NG/6[RRK2LR/:N2Q3]R_G7;M,XLFT6U<*"L+A0`#H\\1H7G7T<],$,F
M?<924.Z[VX+FR9M`C;YQ19T%](L/,1=WI)NB`UDW-OM8TRXD:JK`W(HD040Z
M1#J"GQZ1R=1&8Q4/V!L.\[W9,8NV;9D9-^ZGFUME,U8&4;H/WZR#=LV=.2E$
MB(BH:HB>@4\=,]JM,F/H4W'"?;ID&VU9;$,TA"N;[DL9F*DV4()V19XD.+M$
M5712]"2OM+<"=8#7AP&G'0W!4/CADH7>?L(Y`P1F*],9W["E93\/,/B%0:&(
MY1.FX,5RB5N=,3G4ZTG!:`(U'PT!9$2"&R(4C_LV]OV>0P_?63LG03!BI>I2
MF8!+,BF<Q$2B=$4T/7,4>I[Y8*@`"//P'5E.4O,$(@F4G9ARQ/R*HD=1P34/
M<TV=77M&SZ]N=T]C)>R,J.I&?MI5CTB=L"ZYG)V#Y$HB5LL@5VGTA0`$:\1I
MJ0J:X^+W5./B&A3,O='U3K;#\MJ*$*FH?-TNH<I"])`$[4X\.``/V-8UXWDD
M#M^9(AJK#L4@C>_^9ENN_@"RE_>C,ZT>S?OY]_Y5*IFH]8%ZKGW+E_=;6O=W
M0^WD[+VNGL*?G7=*G^E,!<EUL6Z5W`_^7E\X69[AFSM+!V5%6*"+AZG9,XHS
M0<K':MEW1&AS-TG#I-!VHV045H4ZA4E3$*(B!#"%!ZZ[VGR[6I4_1@3[%\P=
M.5GZAL1SO*/]9%26<8R>6)6%>KY?LZQ;*GTY-1*.C;`OZ:R'%.88&K4Z3YW+
MSM@8[=-)`[PZQ#-RLU4RID(?SA$XD)PY7V.MD:$(T(356^?\^GLU_I4[D?Y!
M6Y70DG5=":;#N#_/"8__`$`;I_CR+I<4'W5G>]K=Y>>W9_BK'.(,5I9>SIG6
M:F('&MJRURM+,M%)2WXQ.5EI>ZKI=MGQ8V/:(JEZ2D0454$!`E1"FL+SZ];<
M#M]I#54A1%69)8"F9Z,'S+Y@8@8E7-2IVLKJX)%*,XP#8G5/)P,@_%([?=U"
M_;1PSN`E\HX':VCGS;:YM%&^\>,;W:3]G23*\5D!CIBV[S9QJ17C8R*P?BCH
M)G*8#`8`X5V!A0J1L;JTJ'[ON;XVM0,085&/8[%CCDIVEM*=U*WNL*GV>56#
M$%P"1BV1<'-BR<WQ%NCPGEN1<6=:.1K4GK_@(M@[NVTH>7:R$K`*N6Z9U2O4
M$#BH1-%8_0)Z`'50/'5M2D!.IY+RI4YF+YG-G_/WK7T:DC2I&J&G4B&Y.8ZF
M?N3;_O`9@'M1;MA"M#6*80X>EXC3A\-=<Y`'[Q/:5FF0,('Y<%%)]W`N&!5V
MY;EK,<VL@O=UPW!'1$!>2Z(NUHQ-PT<+K'134`U#()%#UJ5X#375;?=TJ5_]
MKE&8J@<)M\Y"KF#.;!M+9<"I.^Z&!L7!.P^^O8\=6F,#'X3E8QFF:!C3N"N`
M@Q8JR8&38^>Z>./.ZA6.H8P&#3W#=+G=ZXKW<ZLYD>[*98'TED0J38FIH,OX
M(;`J!+VJ<RS&&-Y%NV\TA%%T<V6G<6-91JZ1H=C&NY,KX%0(HD82$*BF(%4+
M2@#P'CK#A5G1D*U+&K$N.\8CVI3<Q*F?Y([9^0[VN*SMQ.UM+'L7=$I'P"[Z
M/N:L6G%S\+*`Z1NJ)`B+QHJJY:B*3I-0I!4`/DFKKV/I?KZRH[.>G>IZMW7L
M8Q()B?!4U?5D'U-$X!QP6BWC:J^Y[C9[K1N/(-O,:Z0!_:1#X$C!0F>[[;5Z
MX][CV?%KJ9Q+.XAE+>N98(9N="(7DDI1-8[N,0(U;E104?HFZ*$+0IN6O'[R
M%E4KU!M]$TK/S7TZLX`XMCAX?R+?QU>4`[EP_=Q]BD-8^VZ;L<MXWCMX-Z,R
MY#@;WQ7:47-,XJ25^G%NPHVNSCH!1C&%214=LX=JP(4Q$S"!RB`4$->B=9?A
M3XD_#`_">A7.W[H#1KTYF$I0UPF)QA)F#3(8DG!U#:+G>.FNN=L^('3XHW%Y
MME83^SUA'RZD,#4#3!CJ(]UQGQ";[S9A^]+9VY;BC+6S<4K&!;#/S#.X%^Q9
M0R!GZ;IM<#I:0;H$;RH`@=`B28B84UU.H0H`#PWPW^$G4/PVWRZZEZDO+3[%
M+;*](4:-34:]:J--/7"/AC"G!R\LI&+9E?1W^9G_`#$[!_F&V_IW;]EV.YV[
M<]KNOM%>\N#3\R`T5(3LZ`IRF)4IRG"I,N`32@!'`K>/NPTE*ER%O$M%TU,Y
MLR7M&PW4B1%$ACA(Q8N3M!2,*2ACF2$X',4!*`%+QYZP=O(MQ3,?<AX9$9X1
M&(&9)/+DOG.4]505<(R,CGDQ.9X#\Z>"[C6!)I&[K2S%8DH#:]K5AC2+M-='
MSD9IQ;J:;Z!\TR_F)QRZ9S"4Q"E`H_#3AZ/TY\3KC:=EO-AT2JT:]*<14_1)
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M\DH\<K';*`8H)E$J91`1``J&N3WCJ7<NH[>?WS7E4J4Y$THLP`.42V&&./:L
MH&A$&%M$0@.088-BW;]"@P=I_,:&&M]>)+R=6^VN92>CIF`CF+]JD]1^<'B*
MKALJH@NFJBFD*@@4X@'`.>N9I436G"$XRC2^O(`X>D9^A.1@,2^?!>AQ<-K9
M`R7M(NEQ;C1&R;TNNT;F9(MXH03592$G'.@;QS)PD8I$"KND@\M=.ABAPY:Z
MS:#LEAOL)B,ZVW"8UF3QPP=HG'#L&*JG%I:Z!TUS3(!X.79^`]*A`=ZUIN"0
M-@"T=P%OE9SEI6;.1[*7-T*/W\61!,S(TR]32#VEU[.`"4QSF,(4`1UD]<7&
MQ7'48K=/@QV\P!F#$AI:1@`1CB,Q@J-OIW5*UA"[(-S]9B"/>/T*2#V0+RRW
MG/81MJ@[,L2";6_C2;>0-UKW"9"(<2MM.2K-&SR&738KGDB&=H',9$XC3F(!
M6NN<VN&SZ:T[^$J=R*8\N0)+SYX8`#B^#+-AY<(U/,_>8MQP6CM_F+<PX,SI
MN4+C^/NAM-999OU+70C$%GD#<UK2L6Y0N"%<L3('8"T8F)U`H)"G`IN%..O?
M>FKS:.I.C;&AO<:4["VHR%:/A$_,@7@0<"=>1(RXKA-ZJ]16W55M4LI2.T5*
M35(YC5P!/`IG3L%)7NEO:RYCA&5EK7@;SQ4Y97L>%.4CXCEJJH5,&Y3*)"0!
M,*A!`#%Z:<1UX':W=*QNY53$2H1D<21BQPTO[S89+NX5(18GB<.S+!2$=TNQ
M6[;7F(6Y]OIH=5:;LY6!N.'NJ4?J/E%4P<*,I6.DGA7QXEVR%4%2^6<I>L@<
M==[M_6&R[_3HTNN)W=`VU[&O0J6DC'",HR,:\8F.N%73HE%I8$N%SO5.Q?B;
MR;D5O)O*!B!AG$%\Q@HL.V6RKML;OIX!@+X>)/KA;[BK*4DE6[L7R*AW3XCD
M5?:SE(*J@"?I&@"(T"NN.WS<K'<M^KUMO@VWSJ$P+-@_+WO6%O*433H1@3J,
M8`$\S@G)>_FVM!UW[\*HWT)?HN;'^,3R)%4/:2*%38G5*043"0IQ$2#2HA0=
M<Y:FK3L2:7[T3+/_`*WT*^1B*9E(/!PZ?!P5L2V_YOF'6X%U]*DI2!=H(PZ3
M5T5O'^Q$9`Q:.WK8'G2H=!7I,4"U$0"O`..O0MK^(6]VG3T^FH")VTAB8L&>
M6.&:PS:V7G1N-&FX#Z7+L"&4:'WB'&^)\6[D,.Q%@RKJ:N!U9MP&NZ152!'U
M3BU%@S,!SF.=9'S5`^'CKA9:&TC$1<#NEFLF(+EQW)P+L$8=PCN#V4W-:-YS
MI@NJV\A/DP8I(@24@U9`ABLYN$?-WR:[)^W.D'282T$AS%YC36?M._;AT_7$
M]MC"=.3QG3F'A5C(-ID&.#L<L65%W0M:]&5M?417M9AI1?,8%L?7GF$]#+[&
ML`80PKE$V0#7+D5]+0THY=WG=)S/9A5)%!7V1@4RCT0;M&Y2!TD+4HB->8ZW
MF^=1'=!3L86UO9;91!\NA0CII"1]Z8&F+$\>Y8NWV%AMUO\`9]MI^51=R"7,
MCS)<\,%!9[=R%C'[EV)CRD:WD+-8Y0N4$8IR03HI&/<!$8U-4@@8J8^4!BUX
M@`"(B--<D3X@^1_,MC*6F$<\0O1:AK:M".E+BNF-LE&/B8U9'V2#4;I.XY%D
MF"8N`%)3J36.LJ81K0>&H^9$DQ`(.KE@HC%B69E`M]X)?V9.]P=M*V1:J=JL
M9&SVZKQ!)JBS;.I`'DA[0LF1$`3.0`$H>GAJ4@Q;Y?(JR$L&[$_O[K>6S@VC
MWL2\48A>(;WQ))NFLJU36,\=^V/@;BR6,511,$P$W6)0H/"NG"!JB484YO3:
M1G$X@'+(@JNIA5;-RWL2T.Y7".+.P)F&-QLC$M[?OVV)5%U$(LT$DWXKJF<$
M6\A-N5/K2Z.`@`"(<=9=U=75R84+BYE4C(#3&4GDPYYLI28%A%I!>=%CV"CH
MK,F-H>\D2K0;+)$*UN%N8#@BJQ&6;`Z1&H`(`"8CRXB'#6#*IK/CPD<N[$*9
MF#%FQ*]-W&.S39_NEM6W+@;8[3%O;T!:3&-6BG[F*=O`0C$$RF<^R.FJ+IDW
M*B%05*H81&G'EKK=BZUZNV&A]V[7>4XV!,A(2CJE&)!:,2V`X+#G;VEP?-OJ
M<*M:!\!,1X<<,2%',]Y$QOB?#^0\#V]CI0X7(6W56TTFY4,NHW:'"1*WCD!4
M,8PMD"I@(=/`*CKEJLZU2<JEQ+57D7D>9/O'TEU?`>`"0Q<^@+2WNRC"S9+=
M+F;Z:VX]F56EJ(/80S=(3"SG$2NCH)@H`ATD6.``'&E`TF$8DS]UB.2G-PW/
M_2I>\]:<78K&3RFE"QWSU/+.!O1\1NDG+S,,V%1P1HY=F34%TFU9)E2*8X@`
M%+3C361*_O[VUI6-:YG5L:/NP)+#EZ@[*!K1JR(T:)`>A0-)?<ICU#N[,\W^
M0X8XF:YO1MF1@671'IC;:C%5H\9&(D1N4Q//)U>L40$W'6-(1D#$X15F##7B
M,_H4^N4P-B?(,>M?XV9;5S+Q"35W:TS-QB$G,QT`N9%U%-TW:B:BQC(-1*(5
MJ4@CP'6WLM[WNUM#9T;N4;<`#B2V(+88.&531F!*<8><[`L'$>&*BX>\Z2=F
MRJ^V,L99[.+F6S&Y6\C<1&R13OO8XYNF+90Q"]0%+0HAP\-:FB)D>35)DTC(
M$!S(L<^*E#/PAB_-.%=B?:;CZ9[=.,\FOK6!M?CZ5FY8DN**"S.9*X?.TO,E
MTE@52<MF[4>D`.F:I1&FKK6K=63-*5.)(E&64B'X8@OQ9.<]#56>,B1ZL2_8
MS8K1O<6RSC3:SC+<&QGK.A6J=W0\O;T$A`Q;:.*K/R1#-DG0E:HM#"50SC@(
MT`OHIJZ\W7==SF^Y7%Q7C3\-/S9`D1XX`D#L?%)]9TTWIP/U<-)<9X+:'N:Z
M90PAOB4J;J6RAAI8Y1*`%+YEJ7L8A0XF,(D$:5'T:P2/%Z/7X64JAQ'H^=)9
MVKXS@KK[QO<]N^;NKZ-MH#,5T-TTT$?.?OCJI,!(U*)5D3HI+*&`!&M*5U.G
M`S=L@HR+`-FZD=S%A6\GCE\WNUT]+CX(QPYG6Z"RQ2G;&06=D<D22/T>:B9"
MH&&H`(^C1AD4B,<.7M7G@0%U60EW/+(G[A=B-A'W-*0<B^<,&[PY+;D)]*.;
MK?C3B(N$>M,0-P,',!X:@#@Y5D0X/RQ7HG0N'[*:,8II$2Z,O!PC5PT;RC0U
M%7T>NG1LJ<3''H4%-80$`&M?MZD1B0,@J1B`3@2H0/O&%D8JL;=C9$/C5XJY
ME5<7.WEZ/G@*"N>067;.&C4Y#'4,)FR9C`4P^K\.D6!PR5U)SB<W4@3LWVO<
M=T[`MN\1;98J)MB7BD$R&,8Q_;9E=>3)+G>MTZE!--5JHIUJ</6"FI0C*I.,
M(9EV4=/O%GQ2.._%CK'#;;3.)Y`FW#=U9LJSFK(5B1,#IU<#Y3V,K`J:JB22
MS-5,1.8PB(E+X5IJRK3E0F:53]Y%$08R26_=JXS$5T3N?;-NYNZ=7Y'(8_OJ
MVTR"91DI'LHSV-XD],8Y%#-3NW0&`I@$#<P#T4D@@/S"<B=3GW6*?(W.J/\`
M&=_S*3.Q4[PQW.VK<B,X=E)K1[^#E5(EVFT?1Q2"4'2:*P$-T&&GP:Z.PL]E
MN=INJNXS\O=A$BC$"1!/`F4?"'[5&)'V<AVJORX+SE+N470D[T9KMU47A;F=
M"L+D:J)4>K>?UB`B(G`IRTX^.N;BP&.8&*NQ,7X+T^^UOB2)=]O_`&P2MO7<
M,HO=N)K1<7`@^`KJ4-)Q!?9_)\Q51PH,<1+@4M2T``J&K13G*D*L?W9S6/(Q
MU$$8C\B2A[S-;%NV_L0M3);R937N>$N>R+`QZDW`&SM$D\_6->#AP3K`I.MB
MD=(*5$I1KP`-5R((!.>2<=).GL=(+[(.!L,7WMH@,L6HA!Q.;E;KF<6WH6,:
M%923N*A7/M<?)KJD,H8RBZ;XX&-0HF$.(C329@_%*1Q;@`%(FW=[79^YMK>3
MF,1?JT.PA,/W.X=MVY7%)L6]N.#)QDDG00./G%+10U0`2Z"#+%\`$A./NMF?
M4H$/9,N*V)'=J&(LHOV[&!OJ0F)%D+]!N=JC=EMG57CU0`Z8J=8^S%``+P$=
M/`E73#Q!CD`I_;JS(B*4MAL1VDU;W(=DR6G")J(A&-W@%9D5.)0`PE1!6O#F
M!M#D`$YJHMC$9*`5WPL3J8I[E$U!N+G1N./F'$&^.]1.H8O2$7%""E3"40)Y
M:G@-:AH.$B%9#W21R4P79[9M@S/;QM"^;=D)-RNWM@LU,MSG4$ICPWFM':+;
MI7,=8RJ;8G0!@`H&KK)LJ=6M<PMJ-44YU"Q+.1$'$@#%L0YX*J1TQG4(\,($
M^CB?0HTG?6R;B3).*-M#NR?I!!WTW?2[*^[2N0J)WS)7RHT[1ZBN153S&;LJ
MIA*)>!1`0\-;K?>F:_3\Z8%>-S8UA(PD""Y!&IV.#.`QQ6'L^Z6F[T/M5E+7
M1!(=B,LPQ"D.^Z1=/U$,LD(7H!/-<F00ZS'`3E9G*>G5Q`.K7+77[DCO^9;$
M_O03V*0+O?\`S,MUW\`64O[TIG6FV;]_/O\`RJ53-1["&Z+IW*G'D7:Y[NV/
M'EQRAET./V]=KT[3\W>K6GGJK1'M7&]>2T=(;E+E:S*V/G]T4<*Y,#U?6M"5
M+PI]\C3A]O7L^];9Y>T7533[M"?#E$KY,Z6NQ/J;;X.,;VC_`%D5*,UX`ON!
M&A"-"$U5OG_/I[-?Z5.Y'^05N5T))U70FFP[@_SPF/\`]`&Z?X\BZ7%!]U),
M[NGT0N?.NT;&^Y">>XWV=S;N^YV_\J0TD[MV:BLCP<;'%LN`3O*,`92U&$JV
M>N!662$@*>6!1'AK%V^E0J;Q>7-[(T]%CY5`_ISG(2F.X19C^D&PS616JU:>
MWQIVX$O,JGS0>$`/"1S.K5Z./!-*Y&B\<Q.W_N"8KVW3DED?:`G$8QD87)TM
M)2ER3,ED:7EFS>X8!O>DB0LC<K%I&%`Y#F,H1$WJ`/`=6PMXWMKMU'>1Y1AO
ME,4M,B":8IEI2`PD3)W')L5=M>FVW>K7M#JJ3VRK&>H8"9PAI./IY.G&,YX0
MQ)MZW9]HN>PUCJWL?2MS7[,V5<$Q;3$D=*W/`.<;/W3F.N=PV$%)<AGB)%>M
MR)Q$XC0:ZW=A7G7ZPW.RK$"A]T5ZPP;]IYND!AAW+0W$GZ?LZT03=B\I@\M`
MB$H[O^B)NU-NL(-!'Z&H)GYT$%7K8.%>-*ZX^FXOAJQQ6U.+1'#Z5"I[3^67
M6/\`:9<<)8-XC8.1E\LB_)/J,#N(XT0Q;J'=JOW`(KG29$17*4>DASUX=/CK
MW7X4]-VF][E<7%];1N;:W8GGQ<`9'UK2;]NEKM5&E3NJ@IUZ\],7=GPS(=E-
M-G8EOG'8G?*<E=,/D&43Q05I=DK#%72C%YM>VP7<.FC9PBB9NV<J4.!>D*!X
M:\]WFRJ6V[79C`TK:<WI";.W%V=CV+<3@:8:3<E"+V!X[+,]URQ8!^R(HA;=
MKRY0$$Z%!PHY;-65.DHE`ZZ0'(`\./'6HQ2?PL>:]'K#C)"Q,?MOGM8&D5%K
M"T%0>I=-!$4DCB*IDP,)"E$:"/@(ZE[L<%#WCCQ4!SWD7",G(]TO'3QNP3"W
M,J6Y9;IG(M_[&Y9$F'SM=(>D`&ATT:#P'@/AIZ1*;$^$X_2IP,A`CB_TX^Q2
MTMK^W',;BT\`1##(,OCNUK=MVR;@?,(>+8KIW##)VJR2C(0DBJ'4+,J0=;@!
M*%#"(!7GKLSNFS6MK5E3M(RNYT80$R>(&*R*TK<D"B^6/>ZR;O.6A,7%L&SG
M:MEPJ3^1C(-M-2J_DD!))HU4.0YESI@"JYA3="/0("''7$'56!,WA+LD3@^(
M^;U*B<ZDSC+P#@W9G\N:CD>[GX:5GX/=-:#B7>VC(Y*M1BU;3T/^*FHMT99V
M4KMD-`Z5$O*X?U&L[;+J.V7]"YC3C5HTIZM,N.#*FK"=6D80J2IDAG#/[4Z[
M=6T3(>)(:5+=^69K("LZM*04';+A11:)B22*IP-*&=/>IXN\<I'!18`]4IRB
M!0IKKNK.K[;J"EY5G84;5P1.<6>639#ZK$CO6OVG;);7;?9YW-6ZF9F6NH`)
M8_5PP8*`MO%P#=6U[=9E7$-Z)D3>,;E4N5BHF8#)O82YP%RT<IF,)3`93J,4
M`\!].N(IF$*<8$:A$Y<#BZV^,J;#Y,IM?NX=J^7M7L\RJZ#F-NBXI1S&MT!Z
M%XHT.@T(L@LXZ"F\PRR9CE#UNH3<]=#OM]M&X&V^ZZ'DQIT!&H&;5/5(F6?(
M@>A%0P`&C,!.V]VW&,9?6P;/<<[,5Q)C:SEHV5<@)%B%2,=)$#]044.!A^'7
M.$1(+*F+@]Z\ZCMU8\R>.Z:')C>V27=>>/H1<C<7"/M,;%+2;H&)))VD!@`"
MMR*B)AH(_!QUVG0NT=/;MN-0=1UJD;6G!XB,F<]HPS5=S4NHQ'V41,B<7+,.
M/!3K]A5X;L[IR_?N(<IQPS>,K5A&+M"_$8(;9C"7`N9%`\4DW7.47[9MU+`1
M4I:F$`&G'72]9;3TE0V6ENNTU/+NIRE'0)/[I(!/J4/^8^T2HUB!2\)#8E^/
M<F-O>IH-Y!7+B]^Q13-;IH%\R!Y03U=@R3(<A#$+TD5$Q34`.&O)B9$#47FV
M:RH`$ALGP4F'L28R86%VO-L1?9P*O,V06?5,(`*M7[AR8!$U`$3=("/P`.E(
MD0'I]N"1:4GXX/\`.E@[H+-??O,Y*>PJ?FSKNP+N8LW!D$5%FB3N*=@8I3B0
MRGEJUX](E'X=/P"GY=.)C3(Q`D0#WA*!J1,HB9\OA$CB>W@H,G8TQ;=TEW!T
MY).;5MY565NA:>001!4\W&Q#=VFXC%"F^2DJY1$>?(`UT&UW^TV>UW-M=V_G
MWLS^P)RHAL6/YE"49'%31,F0T>:*E%/9$#R3]P^B41,)RF*FLF*1#HT$>)"J
MTX>(:Y^4:9!(&)P5@)S.2@2P^,;AQ3[PWA&VI]HX;BYSYCV38"X.<YU6<@Y3
M<)*`<XB(@4O#X-64?+A@?>X*P$>6>;_2$N'OO6DTN_OM8?8NFXK)?0/&P*B%
M!$H"P4!,H@/#UA&GP:Q+&I&-N#+$>;],OH2E[AB<E*%[?<+>$9CYE%7):8VT
M@Y=R3,&IU2K'%DBY<-X]VH=/J3`JI*#0>0AK?[WM]G8>1/;9$QJ@ZWS!X*$S
M&H>R(4<WWF/;I$6QDR%OU%DAYDO;RK_STTP$W4U40(LF3U0`H45&@@/'6EDQ
M.";R`Q2=O=Z;3A<<6)F[<!./GR4&6:,I*(M2KK)(,8%-4Q3%;)$,"CER<$B\
M`YFXB'$=9>WV%SNE_0L;21C4JS$1(9#`G$G(8=J=4@0E4GC&$=1'$\,.URI8
M6`LTV1O?QQDI*-Q[>4#"VS'O8UW)W7&)(0LL<S`ZX%8F!5114QD3`/*@5YZZ
M/K'I:\Z1K1AN%Q2JSFWAA/6?4P6NL[REN-+S:,9Q`+>(-])4(S;Q94KA/?CD
M>\\>69$W&K8]Z3DDUMY^1,&B[..DEWCA2JE.CI`H<>8".NJ^'G0%AU9M=QN&
MZ533M1.$*8BYD_BUZ@,@/"V../)87475%GTS:B[O"?(E)BP<CDP]?J4Z7&-V
MNMQF%K+O^W(MG:*5SQ?SK<T,L!3F;/#G41.@F=(Q_P"UCG('0`\@`=<5OVUG
M8]XNMKK3-6-*8$"!P(?');BB]2A3NXM*C5IB42.(/TJ"S[Q+9LA:^\/&2[E!
MN:.=V7(D;+H%*4HK(.W/6B>@?+`QJA41$0US9,A+Q."KH2`!;).%=@+#*V6-
MBN1E)67E8N-M_+:YH(\6X.U.+Y8)$?,.).GS3HFXD*(B`B''6^V#?*NQU95;
M:A"O5J$"49EHZ0>>./H5M.N:%0RB'=./$P_D]*#ORRLA9"E+_9DF%&EK,Y9,
M`=QT4X;BH0KA4I`ZU*JB%.(4'GPUUW6-UM.ZVMK?;994J-2$?')VD#B[`#'V
M*C3)S/@2H;$Q@QW*=P@V)&\>W77B<H"R;-3FZ&_MY7*RA17`2U.GYR9:5#PU
MQ&Q?=M:_I#<=0LQ)Y%L6=\,4ZDIT[>?D`&X(\+Y>M>BEVG&>2X3'CVTLHVBA
M"2T5(FBH1ZV!+R'\.V(=$5@(B81Z4RD)S`.==;KK6TV6UW6C7Z?D?L%>EXM6
M$M1#A@">7-8M#SY4Q*NWF\6R?V*+;[T5;+KZX]B3`-#`RC;+8^TN0+T$`ZB3
M\@#T!T_ZXJ%1UR1B(EAR65'W<>2VU[MKABZT-O.Z;.MD1[)W?$O-2-MV*I)"
M06:\W'18FAV;@PB(@FZ=+=/PUXZR;*G9UKVU.Z&8M*<WJ:<21P;)^WL3J2(?
MFS)_W`$7NVOK#UX--T<%;,"^5BG;V):PB0I2R!#*+MW#>X&12"U1ZFYBF3\L
MQA,2@C3CKKNM*'2T+F-#INI(U<#)\`P`?(ESBJJ?G2M]-P(BJ^#%\.]@H!6Y
M?`:4'OQ9XV:HIJ,[NS5"*I$*GT"JFJLNHMY9:!TB8$S`(_#KB&X<E=')N#+T
M_<.V`YM^W;3M1%JY0:/;,ASJ20D3.S4*VCV3<8\#^8)RK`(#0.FGPZN\HTP<
MF5,I:O%Q"C->\J8AC'&.,.LE8<H2DC<,]&0CPI!("9W":"*P'.!1$5%$CCP"
MO*NJ9S.EX-J;CEZ4Q(XZ?>X=[+:W:,B]W6+<?X4LR4C)]3`R=C2GM(/6,<:Q
MVT(+%P,>YA7:8ED/I`K*H@"Q#%`O3XC6FO0=VM.FI]-TYV=.W%6A;TI0F"?-
M^T3J-6!BY\&AV+XG@%IK?[Y&\U9UO+^ZY4XB($CJU`!W#,WI3:??W1<W?BZ\
M)^8039C&S48I$-U2D!0PHN44!,D0@`%!(`"%>/'7GS<3A+V?+FM]$`2`2\?<
MYTBH88WN(A41#(N$CG$W`1.I:=\G-7T4$:?8TGQ]?S(FY+]OTK06U*SV,YW2
M>YW(+K%*HGN2F6:C?I&JA"-8Y<HG4#P$1U93E&+B7$)%P!)2=IZV7.0MOM]6
M^/DM6;>R+E8+N2EH95%6'6233`P!4ID_++Q#E4=+WL\@JRT2XS*\SG'.VTUV
M]P[&&"G3H73>2W#$?NG:JAR"I&,ILDB<HF`HG'H%+I`::K#8#@KQ)@9#->C)
MC.SC6?"(Q#0BCIJXCTV:(&.<?*,BW0*4J93`/4)S)>GQTR<P,E4`V+J%![Q;
MC"/@-S"%[F343GYFV(]LZ2`X=)S&1;EZ.DQ@*4*FKIL8C$8,K82QPR4QGL7X
M`+87;UP>G+1C5Q(2EKQDZF50#&19M)6,<+&20X`!3KIOAZZ!P,-0KI@D:)T_
M>!.:K,I1EC[J1;WXMIL3FO:O<#4S!NV5M*WI&X+:5$ZR1VDC`+&5(HNJ4E5`
M40*8O$1U.O4\VK*I+,G!2U$DGUIC/W:?&QD]R%]R:J%7TQA93J4(?J`J4"+,
MXT&M#D2\D0IQJ(:J`U`Q2E+U/\ZE1Y\M&(2B']QNFY7C]_%*@59:H)()'%1(
M]6Q/5$3`/H$>.IM'/44BY[@O-0SSCPLCN[R;8A@*Q3?9.1**=.@I6\C.-DUR
M$``\43^J%.>H.0&X*X2\#\UZ:W;GQ!%86Q7A.";$4480U@,O8D@6.*70Y0:G
M*F*8@`5#S1&G+67&[J&W%N8A\500[GM31OO66/9:\MON#IE"1596[;.0I18T
M<WZDT74B9B\=(+NB%`2J`D@X.`5^^IK%F^'8HP!&)YI'?NS>,)%A:N3<FN70
MKH71DU=!JR!50R39&.(L*RQ$1+Y:2BZCD0$0Y@4-`("G4R+9,ILKMBPO:R;S
MMCR`)'/K6DHQ\*B0*%73>1RZ+@@\1ZP,F8P<::<2`6.1/Y52`X<9@?,O,GV?
M8$AWW>%LZQH`@,XB&R'<\V1,XF4,0@)O`\HA0H(>LA6E*:B,V602T#WKT.)N
M$6F;?90[EHBDUA?96;@X%IUE;>6!%`&E1]8WVP`--Q*&GM58ECVJ"'[P;BYQ
M&;R\8W,Z!-4LTHG;[E9(!#S`181IFO4%`"I6Q"UX\PTF8MQ5L2X)X,I37:IM
M\ZW;7QS;J#)N]:N23\;("J($,JU-+2;8Z`GZ3'$:KU"E*"`:MMZUQ;7%.YMS
M&,H$DDASPP'82,>Y5C27@7`,2"1R.8]*C`]_O:?:^!6&))ZW2/G#F2F'YI-W
M)O5'SD@+J(>6V*JL(&*@B3@0`Y5UO]UZEOM[C"%[&E"G1$A"-..D>)C(D<R0
M'6-MEA9[;3-O8TQ2H$DL.9S/I4@CW1XXCL1RX`@/#.,L!2T"I2>S'$H"(#QZ
M2\^.N5N,:)[RLT_O/4I!.]_\S+==_`%E+^]&9UI]E_?3[_RJ53-1X'JGE3FY
MU01H!=K7N[(U]'^%/+>O1>B*?G=6[;2_2NZ8]JX7XCR,.A=VF,Q8U#Z@KIN%
MGV[/"&4'CA0_L[6SY9ROY""SM;R44?-5\EHT37=NE>@H]*:1#J''U2E$1`-?
M5_5NQQH]+[A6;W;.J?5`KX@Z&OZE7K+:H%V.X4!_Q(J3]BS+UD9FA']PV&K=
M"L9&RJD,Z-=>/<@XX?`_2:M7IP0A\C6O:DP\:>0]3HY104;&/U$!03D.4OQ0
MOT46S="$:$)JK?/^?3V:_P!*G<C_`""MRNA).JZ$TV'</#O!X_'P^H%=(?#P
MSD3C\7'47\;,4'W4X7>%D6M?T0YM^\;<@+KM^0*!'\-<4:REXUR0H%Z`59/V
MKMJL`#U5`Q/'GJ$X0F1K`+9/P*8E*)\*QYGA[',;:@6)&V'9;&R0Z:6@UM^-
M;6V`D."A3!#(M"L*@<*A4@T'17-6M*-2<HSJPE$Q,OJMQCFQ'!.F?+?0X=W(
MS8\%?I*Q+7F'EN2$K;T')/K1<`[MAZ^CVCEU`NC(':G<Q*ZK4ZK%?V8_1UI&
M()B"(<`U9"1IUI7,)?\`,3IF$I<3`E])+XA\U#2#`4C^ZB00.#A,]^\!D.7M
M4;L*B4#A9[4>%0*(@];]73P^376HA`_;H.1G\Y5T2V)XD>Q,Q]A?%6S#+O;^
M^9KEMJSIO+6/,FR$G=+&0-'/KD76FUT@8.G4<<@/!AW+0@E%,Q3IB-..NPV?
M?=XV$5!M%P:(J'Q,,6R>.(Q6/.G2G.,IQBT:NJ+Q$@&=\^*DM9NG,<V/MFS0
MWAXR`MCR;(?`\BV;>.BTU#_-Z;<ATVC5)'J!%,X$(%*]%.0:UUP;FXJ?:KFM
M4JQ.6I3U2(:8!DZ@U[6[A<8U[B\S>+&VUUK2EX.V6ZM\$13:Q,-<,2X"6+&+
MR"@@@BH\;%,)J"(<!KRU4SE@CL4Y#&F5[)O["5Q/POFT8^WT&7SFXGI"29`Q
M([Z"N%RO'9W!&:[4%4P`:"(@`TYZ9`)[%$NV*A?]ZK<G;6=MY^W6Y\67WBNY
MXK!EC*A?BS&Y(T&,:V:NGC1^HLM[5Y!`!JZ,=N4!$YC%IT@(TU7*(F-)XC@I
M<"#GP4GK8/OZQ)E;;]BB]8*YXZ7A8ZRR0AW9I`I(YI+P)E(N4:&=JF*W*+1R
MS&@=5.@0U.`A"GICJ)43&0.!`!"UKOO[C>,\>[&-V.36$S;N2IZ:>(XQMFTK
M.>(W>NXG)ED@0[5XP@CR#ALE&,"+++**%(FF)`$3:.!.">+@>E,*>[S[KL?0
M&Z";L:[;NMUK+7+;UP#&,B/T1>KO(A)>04AO8SJ`8731-0P"``/`*!IQX!,A
MHZCFGSLL;N,1N=UV'K5N3(EF6^16[U9!&#N&>91;MV[4=-Q0;*,'BGF*HH-P
MZS%\LU0&GCHB7.D_62D#")D,QBH/_>DRG>^XC?)E_.;[&UQVKCLDBRL*Q)Y]
M;\BT@I:-MMR9F238RBK)LV.W=K"H9(U:&*4*!QT8NY5T=(#`XE2D.P-F*R(7
M:?8"D9*0[:0M*^IB&N*VAD6AI$4)`C%9C.>0*J:[=-VHJ8M3E`!Z*@/'2&`#
M<U4Q+ODG9>Z]N"QJTVDW`Z6EHU!C*7'$1)'[V80:-2+/D7BKDBR:HD%0B8H&
MZ@XAPX5U(,V*@'R41/M39'M7#VZK--\M+@QR:WKU*U0CUUYJ*!Z5!F\;"=,K
M$'B;@$'*J8])P"E:>G4-6H&$HQ$,""'=^WZ%+Q/V*;7%9F@$XQS/QK=T]/+P
MS<S9O'3*2Z;=Q[.=5-1`PF6-[*92AP*4@\!^4`Z1A2-45=#SBQ`)P?N[3[$B
M"222`^':HUOO%.5L<Y,P-C"QIE["P%Q3LXT25F)5PB<D,D@8YG"AR@0JB'M!
M!H8WB(\AU(RE(/,`'D$X>!M))9/A]J/>3@I[LVP_BV$OFRG\UC.P8&`E&T1<
M$:^61)10K9TZ9-G"KA!-RCQJ(!3QTRT@.##Z4%W)'$I=5W;CK+71N%Q)*-QM
MN-M.:<K@FH5922;^Q.$T2(-B&455"0'U40Z:FKJ0PQ'NA18D,^)4%7MZ;T,:
M8@[I4:0XKVNUO6^KWA(ME,LW+$6JDLXD2-VZZ:B:9FYSJJ`6@AQ\*ZA$D$'@
MK&,GY.I-69-_6!,8Y.QQ#Y4RW9ME')<WM@Q,O.,6+SH*NHJ)G"*RX&2(KT@4
M!4`"C7B(:>!P.3J+'2\<2%&<O[+D/N>[]6W;<-$9&L"68O\`</C^U[6LFV'[
M.9D&%KQKQ-HVD7L@P7.Q%9T1J)^D#C0OV:$23-_DRGD"!V?.E?\`>*A8,>^O
MBR7EI=LQ(?%]@BJ"JZ29$UFZ8)M1,4YB@7S>O@/B.L.S+6\3P\T_/)(XA2Z=
MJ<U:\G9K.,9+-5E58QLFN1(2`J1TW(X.J<PF,83E$M#`(>J%>>LP0A#"!D1Q
M?Z%`NSLH[WO*DU:,]CAXDB^27E+-M&31$`$@KD=*BDH5`2"/F"8"(_!I$`!@
MF/$7RQ64^[K;>8&TMD6,9Z07C7RV6'5QS#]-4[5RR/YBRYTVRXG,)#+@!@`Z
M1BF&G"FG`>,51*<9`EM);'O"E*6)BP//N4H&U[5C8^V5(9LQCXYB";IJ5HQ:
M-6+8$S)&3KY#8"HA4!J/B(<]1N)5+B[%W5#U\`Y)D2QPQ*C&-.,--,$0S8*&
MG8^VK!-Y=R',&);\E)-@T=7^X4]MMV6"%?+(2:X&^;U'J;=<I$5Q4,!@Z1`:
M`/AKLNENN-]Z5M[FSVV411KU-3&+Y/IXAF<OS=8EYMNV;E3%/<:$*U,,0)8A
M^U^QU*$MJQL4X#MZX(BUW*$?%&@V,)%PJCXBY&P,#JD!5(>@ISJJ&/43`7UA
M&NM'?;QN&XU1=WTHSNB226;'Z0LV=76/+A"-.C$`1C'W0.Q0-O>:F=IVMN'P
M);,/=C:<N3Z&2=Q7'&I/47:D,I*NU#-&[GRSF,@HN!1*4AJ#PUK*IG5(E)M3
M*,(Y\OH2Q/=S-R-J6EM@NO%>0GS6T&$?D9W+PCF?*:(CKF7>K/"?VG*._*:/
M#LEC`4Q2F$Q1'2B=``&8+IR!!)&+IYO<UFRR,01[?(%PW);,(R<O6;N2>R,D
MT;L311E0;HJ).C*`185!,0:E$P=/'5@N;HP\JH1Y7I2EC'3P4;;;G8V-\]=]
M!5:VKEAW=NS%W)7<C+,'[)[&/3NFSIXFBS<I*'0.!C!4.->(!35)C&H/+EA%
M^">,:;G$LI].!XN`M2-]D<NTBN6TK(1R)U0\HU5U^":@])?6$2!TB!A"FE*C
M2$`03*I'`/P^3H`)/+`*'I[T&1D_N:Z[E2<$*M;L%;D0*9!*<?.7=]-2B7J$
M*IGX@(@.I$$9YLB!$BXR=+T]VP@\;K]JI*.93":-SSV5KA>3@HU+)H2I?8P9
ME1`A!.B`(%JF8]"F]/'3#D>GY>M.<C&H2"G[[INQ9C;DW#S;9FXF/H^NV<O)
M!0K9^JV;(^2W<'`O0*ZRK<H'$0^]I4=1$*=.6NE3@*C$'/B>Y0EJDP!\*\_3
M<];#M[W8[&FDV*XVS:-UQ,W(N^@J2#0ZQ5@2XKF("J("N`F.7J*4`&HAH.)?
M)3B<&7HQ8<R/9=T6)9:\?)QCN13M9FX`C1PW7)YJC-(3')Y2A_,`IT^(^%>-
M-3D9$X8A5X`%,%>\,WG8B6!]M'TG?,6]TN,PO',8U6<M0<F:-6_ER*WEF5\T
M[9(IB]1B@8@5YZKE%XL<"@>]@E];#+GBENW;CV[DW<<Z:DCW[=LD#Q-VV(V:
MR9R%\E%(QR$54H-2B(5"E:>,80A&8G"G$2`/BX_-W*>IPQS4:OOZM(R\=I=U
MY3,JWBE394MNWX!F@GY`RR9'0&?@@D%2G%)-/URD$:>.K.+E]1]2E#-GR2H_
M<[5B'Q%OF*54%/+R?A@O"O4`?1N_1)4*<2BGT\0TF^GYD2X>A=FSNPRM=_'<
MTO-ZH1,CW=E,L"E\Q$3BD2,AE`4$H&ZBDZE:5&F@$#TJ)+AN*D<1IFC;"=_H
M$<>2S:-)'VM0:=?DG9JE,3I*(F,`AXTH-=69`MS5>)(?-E!IV^XLBEN]1C]\
MY5(T86^UNV]!ZNDIE02DDB("("7IZP\\#<_D^.JG`(':K=7A(4Z:U(^!4B&Y
M@,@#B-MM684-YB)2%,J8R9%@,<Q>KH#T?)-SU<(L/0H'#'@3]"@_>\_66Z;Y
M:QG*,ERNR7@PB(B,ZB$4=**N_FHI#'Z5!'S3*+=("7J#CSTX5(1BTP75D6!?
ML4[;8Q82.(]G^VO'CE0B+^#PU8R#TC@4TG*CWZ.Q[A_UI]0&$[998Q!'P`H5
MU3(%\/=4,W)S=)R[E=L05R[8LAV4"R"LQ=%GW2SB0,=)5V45&;I4QFI2]7`W
M1Q^#3Q,6*![SJ(?[OI?5N8BW1_1&Y!9^=-8[NVU6B8N40=LGB;D5P420!03G
M\P@!ZG,0`=.&;\&2F21@I2-T3MLW;=%CV`HL1=ZNX?NI)9.BYU(M(JBXJG0)
MU%`E"#0IAK0.6HC$#-TY8`G@O/\`-_C+#]Z]T+/4YA^>;I6S8X(7"19%5%%O
M+WC:3E(LE'-2!T"N(.C%H0H=1Q*(!6@598C#(JT$B#+TC-I./)MICC%;J974
M,+G%EJR39-4ARG$KN)C5S4J4"A0I_373]V6/)4:A(..?YDT_[S6R*.R.'<(-
M>M6#NX'_`)($$QEFAFWL:SD"%`5*%.IQ$0I0.>D291<\U(!BW8$D[W;6':0^
MVN%,[3-U7%/3\B=!0@^8"ZXCP23Z>L!1,%!J`>&F.7:G5X@9J5_.2X6ECHR\
M1`.9B3ET@C&48T3,5P\>/$%4T3J>J!BHE$!$P\_1J,B000H1BV!4%#!.'%,4
M=\X[J59LVDC&>R22K,KAN8$7,RG(HJ-E0(8#$4`XT$!`!KH9IIR><&&2FSW+
M%L7UJW&0R+9G)$31=@W%\FS4,05!4.<A3@"BIQ*4>@"E$!$*:F!@7S90TL=7
M!U$]]Y7VV1-K8>VGYM9RJ2\FZS#'QLN@^.DF^63DXEPH@"1AXKBB5N4IBUZ@
MJ'#42`"ZM@2Q?)BG4>SF"+[8M8QG3_R&#6\+A:NOQR8%3\J4>.1()3F*!*]-
M:>//3CEV.D>+9LD?=^#:9'[B]CN1\R1DRVCIK!ZSF?;(NRH>3,1O659<C590
MQ2F."3:@`!@'UM!'UN13B3`B+*\^Z(JF4V#96.(`'5FR4'H\2U8F$?6XU#CP
MUCW/[H^GYE8<:OJ4A+>_^9ENN_@"RE_>C,ZT^R_OI]_Y4ZF:CBWDY]C+NT=U
MI[/M+]WA5J'"G3E#+@U_8UZ;\/<>MMJ_ZRG\ZXOX@4_-Z+W2F?K6=0>Q:DRS
M>GM>.+N:><(^T1"B(AU#_KBJ1:?#SU]H=:1?I#<Q_P"1K_U<E\:]&;7Y75NV
M5&QC?43_`,2*FJT`-?G^OOE&A"-"$U5OG_/I[-?Z5.Y'^05N5T))U70FFNKK
M4%/N_6`)>?U`KI^U^_D3^EK"O:\[:D:L%(1U!DY25XN4*>H/$?3Z1K^SK0'<
MKH%G'J5VB(SS7+VY?T$_9TOO*ZYCU)Z((]N7]!/V='WE=<QZD:()FKO[%.[[
M4^Z\IB=9S64`E`O[H'J'[''5]G.=Q<1F[$'%1F`&[_R+SR,);TLC;:;$9Q6W
MF!B,?9#G&IT[SR6HL[E)6=*F'^UB0Q;I4\6F1D4>D#='6`<AUT^(':J,,N"=
M6SKW7=P>6NVK(W`]>/T<J7=?<)AK(-YLW+84A3:,32"4@RBTR=,?\]L$.CJ`
MI1$WQ:M-1Z`@V+XHC$/CDF#92\<@7`RB@F+SNI==L)CK>R3#IBHN\Z`;HKK@
MP51\]<J!Q*4QO#53IDZ7XA.F6[NGSC*=L7(6,X&[):WH?%-QVO;$B^82#A68
MF8.]9#SW8R3M0QG!S^T$\@INJH!XZ'<-P48R!QXIGH+<`C=X[*9T+F0(0CH5
M'+A=5TV:J%7(1X=<3F4$RM!.4U0$-#E3U<DX5LBW7/,5MAPQD*Z;CA\#W22?
M;R#:W3$:O;<F9Y,4D9YJHEY:@(H/EA66(!ND0\-+OR42V?%8U<#O<'L>R9<$
M=:5]NIFSKN92;J&N98P7/CO)<!=#)--662%^@Z8*3:"8%254)19!5(2\`$=,
MN^"DX6%;!2O;9W4K9.8'<-9W'UC9(R)%&9])'DG)Q-MOUVK<OE@'68CKUE"`
M'XPG,*:;D)N#%BM"9)R7?F5;TDLFWY=4U.WG,R3N8-,K/%DW48N[4,KT17DF
M3&+(W\SH("=.!0U$'@DY?!8'<E[Y`FK>>6U)WU=<W#OW#=VM$2TNXE&RKAJ)
M2I*)D>&4]E.4HF"A!*'K#XZD.?)2B0""5EV,,BY:P^]4E,99!N.R7[MPQE%$
M8IVH$<K(,"@+;VIJ<3)*D`Q`J`AQ#47$DC(&78G/M]N\3+VY#9-M<C;N5(1C
M/W',.KG=L':R;R=N2U#RL(NH]12$I"-W(D!8"EH``;EIDY)1(QDFB$H7V%RB
MYC%'L?)@#-NV48O'35R15)5,S9(@H*%,J!W(E"@]0C75A@U+S7'=Q0Y9CDGS
M-RN_S<]AS'.)\(6I>R%HW@GB^(=9`E(=P+V3;.9&+2^;XU55V!C-9!)F)#*T
MZ1`QJ?*`=5"1(<8!18:L4TS?6<LUY9M$EHY,R!*WG!H.BOTDI])N]?`X`ZBJ
MGE21D@=D(H=4:E`W`*`&FF^+C-9MLUW#W?M9S/;>1K6?NT8UG(L6%V0AGBXQ
MLO!G.0BK=XW54.B;R"KBH4:5+0=#E*6/<4L7>KNHWGQ&7KM<AG.YV%AY,C&<
MY8_T=,5K`JV1))F=QC>,423`HGCB+`DH(&$2F+0=(XE,$#,8)K`EP7/;=\6S
MD(DY).KHB)IM)EN=006D@<DD/:SNEE5!,)ESBJ8.K^EJ0Q4XXN!DEC]P)C*R
M>>5KRN"2?W%'WK:%K7/;DO)N5GR*D7)Q:9E2LS@(H_BG0G`XDJ8@\Z:CB,E%
M^2[.U)',F_<EV8F11*D3]_RQBCT&J0YP>F.4Y@&HF-^-"@U\.//4X>]BF9$C
M'Y8A.Z>\C70:R.[NE<YHHT\2,PCCE;YI^<7445=9`A5T!*]:F!5M11,#").(
MTIR'6):X6O\`_M/_`-21]WM?Z$H[M@]ZB0EKHD[6S`Q/:2%BVA<-WH/XGSY-
M![;\&V]I>LEA]5506S8IB]1@J)AXCK*!!/BR42#F$TGW`.Z!.;W<U7XLG;I8
M_#<K,O&J:2)@:R\O"-EE6Z#IJ910Q6RSM`*AZP<]!+ET:=,<\4M?MW=XK&^T
MK$N/L!1UHY$^8XB_UWL?,W"X8.FUJ1TOYB:J?M";GS%&9'AR&J("(%^#0"P;
MM3()+OF$^WO([_.&]L=CV?"0KB7O[+-U,6]P-V%M*-WT<SB7Q2I%5?""P%)Y
MQ`,-*#TZ;\3C)+3(N,HJ'3>&_3/UY;N%,WXJ<OK5E;IR%#3+.U!(5ZN_=^WM
MT4F3A=0AU?)>G6$!*`T(`A34,E+`@\T\3O8[X>6+-R?;UCXHA&4C)6Q&Q*V3
MSSQJH$NTK?J?Q#$R'F$502&G4/``'PU+5B6S2BV#Y*/CO$W%7'O`R07)]\V9
M%PUWE\Y->4BW;EP9XV.H8Z*2R:YS)D3;E,($`H!T\^>ECQS3B1'+));A)N\F
M:!+>8W=<S",CW2[YBP:RKIHV8KG6\Y1=!-!0E%3&XB8>8AH.2L+-J3B]PY:R
MGO(VY)8ONJ^WTE=^"HP).$A7#@Q5+[L],YRO$W1B44D)*(6=D$`$!JD0*^.G
M&.OP\E7D726-E^XN<VE9U@<SV_#.;GEK;?L7"L<Z=+(@'LXF*J)5RF$QC)E,
M8H!XTU*I$QDSY*<V+,P&*F@[/>_+B3-L-?DW>C:0L"1L)![=,U`JHG>N9**C
M6CERL];J$5$R()+$`*F`M:AJ($3[V"J((+%1N^XKW%F6]Z=O%]$V[.`QD+B;
M2;`T^8@LW[!DZ_$(O$TU!.0AT0J!0Y5T$N7*!'3W*P[<^Z?NDVNVFTLO!K2Q
M\?P*-Q,)^391,*5PA+>Q$3(9NO[<"WD"X3)0YTZ"(:0)`P*"(DMFG=LX=[?-
M\OM(A,UVM;1(+*]]3#[&3F<<)IOX6*D"-'9WSYLU5$Z:2B[=N0R-"\`KIO@X
M]XH`#M]4*,#E#+F:<FW.G>MY7W-R=Y*N%5CSK=TI''1J42E(`,@1`Z8`8:%$
M!`/#0ZL!CBZ>XP1W)=U6UO8/#*L)9.8E[FO5_9&-KKGWJRL\W@F$<P/.J)BL
M`@Z*Q1>%H8>KUAX#H!(&'%0P)[$WUOUWO9&WGW+BN3N&:N1&+QO8@6VS1DY0
M7`+W&Y;E"3F4D$Z)(^T+E$0'Y70`!I%R7.(3!#%+C[:_<>SI9&VK*NT.%>EN
M><:,Y.Z,,.)E^H0Q9)!!=T_B``#!YYS)@H=(@@8#"`!STQFP1,!P>Q(TOGN0
M;D;]L%'%>8(FQLI0<)=LA<3:.NJ),@M!3;@XI.4D2LO(%3V<]2E%2I@$ND_`
MY),,SFI37N>[D7^,=^S\&+>,([RUAQT1DT$/9FQ'%L7TIY*13`)R)IB80+Q&
M@4#T:!GZ"G4P;CE\Z;!RIW&+1V=]PGN#VK<%NWW(&N'.UWR!'<*FBZ8`^;(Q
MQ6@%2452$BH@F-1#A2F@##T(T\>:=31[OV/E-BN1\Q,WJKB/E+2>,6L<[702
ME%[A51(BT:+,P6%9(#K^H(\AXTU+5X?2H@'4ZB/1O<)RQ";BD-S<-`,F$BC$
M+03Z(H0XK0`%:/'B2*AQJBX5.UK4.)N7+1$QB7EBIL`-+C4ZF&1?=MQ?C;;'
M9>=<F/7)HB[+3A$BQ<.];.I=W+/D"KJP7LB"P`1RD`"(I\^@W4(5U94F)$$8
M191;DHPW>BW97%NUS'C_`"!;BJ+#%BL;:+C%;Y=VV/\`CFY(\TM\Z`@<YV#F
M%=E(18AZG*)1'EJHXD\F3B&'')2J-MW?EVN*7!M<Q9EC()&5RVUC-A:ERW!#
MG27LAY<)8.*C3J/98RJ9$RKN6_,X4`:Z8;`G@H$2Q;,_,M0=S[O`6!@K(]FP
MSIB\OX]VVI<KB!0L]VSD6T7!R[%W'-I9<!7*@(F!?J2](\0TG(+ELE+0""QP
M4/3"&X9'"F^''^=;<5NI]:$!=K50L(N?V&8EHU\X*Q=LWZ!%/(!<YG93&$!I
MT@(UH&D&]14F`@0,TXYO<[CV\C'N[>:/;ET-K-B+?MN/:VY;[1(BS*7M>YXD
M7I5W#\R?M`KB1T8@*$,)BF3&@Z;EU'2&:629VG<@VW/WE'7:&.T[;G@!^M)2
M4',/W",M<2SHKM&5DTWBIS+DZC#YA!'US<:<-3\O!WR"EE`@99J??L;[[.WV
M_<&[>8&?OJ!MS(;*RF=F7'%S[M"/<-YF%.G&(I)%.J4%"JH-:D+2M!#47XEG
M5/ED=@3>?O$G<6AKDM>P\(1<?\_.K[LA&29.&ZA%&9(US,BFJ[7%%03$5Z2"
M(5#Y(@.D_P!53`)RR=(5[<W<ELK8A!VSB*YKR4O5^O?J:T1,6HS*:$M>&G@3
M.HQG)!R9,%%4'2Q2F$M2@`:'(+A,C5Z5)6W,=[?#>U>U;#F,@7,Y?7=>38CB
M#MB&;L94$XP6_F(32Q$5@,@V(5<AA-X5KJ3\3FH@'@%#ANW?BI8^^*Y]SZ\[
M*9(FY"1).Q\C:SA'YB&'4%5:/B7Q%_+5&1;"H/7TU#B&H8N_%2`YY*37=7?1
MQM![28/</<-G/Y)_<*<7#0T!&R:2TK])$12=*L7:8NNIIY(=`CU5J!OAU)WB
MYS0!]49)C+NF=V2SNY'A7"L.A)3F-Y/"TJUO%>RYR*!8;MG5E%&RJ:<J0YR"
MJS9U,0M`H7XM(GUHB",,RG`^RUW$K:N+&64<!K.B0DC:\BZOF+92CE!DDK;X
MI4D72*BBH&,)5E3>%/6`.8Z<7R2,3'%)AW:=[K%VXK"6X/;3*QEYVC:,Y*+6
M[;5Q,&*#]60CV2[QHX<^6#BB*3LY2@4Q@&I1'2)<,FTM6:>D]T;;LVNQ',;>
M/<*.F*6=YPK594`!4Z`-5`2,J4!'I5,0`$P<@'6/<_N?7\RG_M<>Q2"][_YF
M6Z[^`+*7]Z,SK4;-^_GW_E3J9J-+EUS[%:V])W6GLVS?W>U:OHZ,E9>-7]C7
MI_PZ&KKC:A_YN"Y;K&'F=,7\.=M,)!UZ7N1>V)5%5P!$U$D"*'.?I(1,7:'6
M8YC'Z2D*4*B(\``-?:G64#^$=S_Z"O\`U4E\T]-V$:?4-C(#*[I?SPI\<?>E
MGS3D&$+=EM2S]0BATV<9.1<@[.1(*J'*W:NE51(F7B8:4`.(Z_/E?728^S)O
M@SUC>[LIH65G"P<FP&*W4[=;9!O:=GH.[OFF>3,48UN#"KB+C5',S'V99SB_
M7XQTHBM\_/W\,[(L[70;*"=LCBG-=GF1;VR%CZYQOR[&U^R]JWHC`M[V;Q4+
M"C<+"7L&Q,@`*S"W$&L"FI`/KV7B2F;)$ZTH\@K=3@5CF"A)>WS_`)]/9K_2
MIW(_R"MRNDDG5="::VN__._8_P#T`KH_CR+K6;M_8SWJR"<C\1^,?NCKF)>\
M5<<T:BA&A":)[ZR#MWVNMT[9FT</'![+#RD&R"[E8]':!S"1%JDX54$`#Y(`
M(CRYZVNU#_F!#F7=1F<`#P^E>7@'FH`FDLDLBL4A*I*D.BHD/2%?.*L"8I?9
MXZZAECI1V"\TVY9+.ZL>92M1W?6&,A'CU;K@(]RFTF8.:B?-&&O*VG92B(2T
M>*XE.0Q3D63]7U>>@89Y([%DLAAK"MT.TSXLW(V8+5R<QV\'DME*V9<<:GUB
M8C=RX6;FAW*R!3=!CE7I4*\M#I&.'8E([?<37Q94G=>*KW:0UZ8=SW`'LB5N
M"P[@B;KC[<N9%8KZR;D=FBG*SYH@QEZ>:<R0>H?F%-`!]"40(CFF^;VM*X,>
M7?<UB72V4C[AM2<D(.4:J``]2[%11L=RGTF'K9."I%%,PB!S]7$H4TLE)8B4
MR)1*0*IT,/A2M:U$!'@4?CKILA*3QKGM:$MF/Q+ER!7R3@M60/+%M)9RHTF;
M>?.$W*(W#9$TFDHXCW:8KG%5NH"S98HF]0I^DP&+=B%V7+'2.UG*=C93Q3<L
M?>5EW&P<W?C*Y5D`.2?M1_YD?(6S=L<*RAV<L1HL+1^VZP,4#@-0$=#$9X%#
M*QW>TVVY-=KW':MUOL)SDE[0]FK,NV)E92UFDVX-YBJ-LST:DJ9&)57ZQ(FN
MG^+(8H`<]!$)PIZW8Y)\<%I2[,271;K%.>8/K=O2W$S$.[G;/E6DFDT3$1`3
M/F95@D&A2<*B9+[&H'5'P@.$SB%AB3@!*!0,>I1*H03T*`DK\J@":H"7EQ#2
M$64>U+6O]1)]L9VYNT$P.6/R1E2,='*'K)._;W+TJ7I*8S<Y1#X]3$7'I0W!
M:?VU1$/<V?,31,\*18I:[&[AP!SD(9<S%JY>,VIQ6$2`#AXW(4:CSIZ=52A+
M7GX<,$\L5C67[LFKPRE?MP72H92>D[LFE7Q7*9TSH*)OEP3:=)?41!``\L"<
M@Z=2R2;!^*UX5P0P`%2E#T!\GT?)KH0O@"B434*'KG$RGK4*<W3T@(A3ETZ$
M.EQ8JN`=P^)GFW>Z'+4UZ6.Q?W'@:7<406'V5(SB=LE=T<2%51>HI%4:E,)A
M!0!``&NF.2&=(C?('14<M7B`D7:J*)KH*@)#(J(J&243$E.H5"."T$*`):5T
M<48\%NZW<Z0\A:$=B_-4`ZN^R88SD+6GHU<S:\+$.N'`T>J<.F3B"K4.9L8H
M5#J`#`(UTL0"V*;<DJ7MYXW4L?N3;&9:(F$[QLBY<X60\M:\8Y(Z:+YJ62`A
MF<@W-YA64JR.F(+(G.!B\PZM9%"C.J=4<QGV)E]))X#Z4X%[T`"9>YRY4H!3
MJX2Q]4X>@6IN`5#B%1KK!MHD6K_^(?I2*9*VZYH#!63HZ]EX7Z30+B)F;6NV
MVRF\E::M*YHY2*GF;-<0$J#\&ZYE$#&]0%0"O#CJ[BEB[+8>3L!0B+%SE7;]
M+I9!Q/+*.9IPP854N_'!5C"Y/!WC"]1W[4K#S.@'!2BBIY8B7QTVPP1CQ27O
M-)TJ^L)A,)C"6G$5O+'RO6$I>H*CZ./P4IH=`2XMX"-OW1`[;LFVZP0!A)8A
MCK6D73!/K!*Y(%TZ2D4'J@`?RW@D4(/0-!$OP:E",ZDA3@'J'@@$@,,BK7L:
MMZ$N3<)#2<XW,Y;6';=SY'9-0`!4=S5JLB.F"1@XF5;BKQ$M.8!Z-*49TZAI
M5`TXH!Q24[EN![<MQ3]Q2*@+R,],2,J\5,<5!%5\Y,O0!&@T(0X%^QI,'Q0[
MXK&%!Z"GZ>!C\.H0K3XN6A"QY=-$BXN`)^/,D"9C%'I`W.GJT$-)QZ$W8,K_
M`(^OV4QO?-O7C#'%-["O"*B`B`IN(\YR(R35PF8I@41<M5S`8*<@#T:G3C5,
MGC%QWJ3.'"R#(CJU7M_WA)66S3:VW+S;N2CFOK>6V3?F%THDG3H.8B3A4X%_
MJ0#15<5#JS=1/L6<;?<M$PKD1&YG,1\^6Q/P\K:=_P`$B)$5YVSYQ,K.8015
M,4Y$GJ3<PF24,(F`0ITCJ(PQ2./H6_;NV>.9B#7R;M@>#E?$JRA3DCVZ9VU]
MV@Z7'UH:X(9V)5UO9?,`@*M_/*I2H`7P;/DAUB5G;,MPMS*'<.K$D++@$C`,
ME=-Z'3M^#C6X!ZZ[A=\*:R@@`T`J:9A$1``K70Q2[`KEN+O6`C+#L';?8KQ[
M/6CC:6D+CG[U<1KJ/9W=>LWYOM3B+;.TDG/S="MUSMDE!'I,4H&X5II=G!/Y
MDD%XV(X;F1`!*)1`R7"IBF(-2@82F$*'\.(AI(!2W-QSA<FWO9+!(I%"):XV
MNN7.81ZT1N-Y+1S>1-U!TE,Z,V2*4XUJ4M!IQTWP;@C)(MZ2&!,QTRJ^6H!A
M%3RNFA35$`,*@<*!3A4?@'04)0^SVWI8=P=C2]OF58M8*>;W#<DT9(Y(VWH6
M/;KN9!_)JKE33:,A:IC43<^5!'0$R^'8M(YAG(BX<L9.G;=`OS'*9`N=]%5#
M@JR7F%S)KIB!4P,@N%3I\*=)@T$/DFWS*:O[G?TFQ%OG,0@$ZLFX3J!?3]%;
MX`1^.NJX3)+$8(GF'^6*BX]UD`'N0[TP"A1_?\NT:E"IODL:B'F=8`(@%.%-
M3=$L"M-XP*J]VY[H(@AT_9V\19<TW3$Q@*T.%S^6J+=,3]!%%2K"!A```1&M
M.&GGBD"Q](2<#&23C7+%-%!<CDY#"JNF4RJ:B(@!>D@@(DX\!XCU:B@8%^"5
MI@!!EE3&67=N$BX*E,S44UR?AY9P<3)L;\Q^DJ\E8DBBARIIMY^UCN4R)A3\
M8F2A3#J00_$I'SUF=Y'H-UC'/[$=5RW:*"8Q4EU0'S!*F<1(@X$WRA`!`:<0
M'0,$"2YLH]N+-`JJ8>:FV4163Y%,"JIU%1,4G2'F]7R3``4\.>C@@D.2EJ;C
M%X/)N*=M68(-N(/+9L3]X_(2)C&,)KJM$YI*.?BFOU&,E(Q3X#=50`3%IQIH
M?!#AF&21;+,"O%$E4U%&SQLX3707)ZATC)F&M>D0`34+TE$*=(>`Z$1+'F$J
M+<#.267L78ES."7M2]I026&+[7`QC+DDX)RY?6Q(K<.LJ#J(>D2\T0Z3'2,'
M57AHR"!VI%A%/;7:;:HH`<W6?RC<1,%:"!J!\(:GJ8.IMIQS63&;-&WDO`2`
MBL<JD_2<I@(.DEFAB+E5243$M%!%(:\/6KJH2Q4'.25UO28.'F:XB\!DI*2M
M*[<78XN>QTGSQ5V5G$R-GQ2;INQ$1`2)$EVJYSB-?7`0$-2+/@I##+-)=>+"
M^<*CY31L"C5)-(J"1DB`L!.@%`$ZARD.H8`J8`"FC-1&`2U,XV:;*V+,.YKL
M)%Q<,9`65'8^R,T:NW$E,V?<\*U2255D&2@G>-8N3!J<Y%03%,O2`")JAH8M
MG@C(8I%;]D5P42%(0JP$)3I3`Q#%`:$,`'(0`4ZBT&I`T)!\TK!-@XE]F*ZQ
M6JCB/M7.R_SFN)43)$6FH"%29%5$"E$`37;&$H```/$*Z,61B/6DL$;MQ\PJ
MB1#$4$A@*<H=)1Z>HPT#I'I$QN0"'QZ&=!5^Q7,)XZRE;UV@JN>#3DVR$_&(
M+K-#2D(Z<MPDXPSA#\:+11$HJB0>KBF%!I6IAQ3,GBROFXS'R>,,O7S;+)$B
M$`I,*3UJ';E(JD>U;@5/*PARG-Y@JE*S<`%>H:"`A6H:&(+8LG@<%.L]TA*!
M=BN8Z`!>K/$WP*`@`%]F4`H\QY@&JKD'R3R8_,F3XQW!2!][_P"9ENN_@"RE
M_>C,ZTVR_OI]_P"52J9J,5N`6%#'&^E8.'E;)_=]CU]`%R-E\:Z]2^&V/7>T
MC_SD%SW4PU;#>1X&A)-,34NC)1YXYTFB[:OUV+1RV<)D60<-W#]LBL@LBH4R
M:J*R9Q*8I@$#`(@/#7VYUI%NC]TY_=]?^JDO"MCMP-ZM3CA<T_YX7HAVE@7!
MU@S*=QV+AO%=EW"D@X;)3MIX]M&W9E)L[)Y;ING)Q$0S>D0<I^JH4#@4X<!`
M0U^=[KZ0&2JHK"6&H)XE(PF)L:0\@A/K76@^B[%M>/>(W0X06:KW(DY:12*R
M<\NV<'3.\`P.#$.8HG$!$!2:S*V[8MNSHAO;]I6_"6O!-%'2K2%MZ*80L2U5
M?.UG[U1O'1J#9FB=X^<J+*B4@"HJH8YJF,(B(38^^?\`/I[-?Z5.Y'^05N5T
M))U70FFMKOK_`#OM@#_]P*Z:?'^_D2@?LZU6[R`M3'B?R*R"<D]-0,`]0\BB
M(<_2&N:'B\1<$JZ18\$</ZO_`$@Z>F/:HOW(X?U?^D'1ICVH?N38?>*MO*%U
M=NW<3`X<@[FG\B25L%2MV'M)HJ_G7SGVQ$QDF;1)-0ZBAR!4`IK<;71G&H*Q
M&`R[5"<AZ5YZRNTCN+3L>9G>VQK*5UJ*$*`2:N)I.)F"ATA\M_&-DC+&^$Q>
M.NBQ59<JPRO;?W@RC([V`VB[BH"0;`05("6L"9=M78`'K&CGR;;B`\^DX!IL
M0HX9K!1[<F_H0`H[/L^"4```*./9H2AZP"82E,@)2]0!3@%-)#J[06P;N-6D
MY3DK4VM;DK9DFWKM7L+9MR1ZB2I%`535Z$"`DHJ4X``"8HZ.*EJ*6!GW9'O+
MS"^M][);1<U$R&]Q5:\N^OIK8TL0T]=C=J]/.1-W$(W!,9-8C8O0MQ.*I@"G
M$=,A)N*1F/;FW]&"BFS[/=0Z2G*6P9@Q@.!:*TZ4>)!.`](AS#CHQ2[%6&[=
M_<`<@W26VBY]%)L0J*(&Q]-)@FAUU\OK!#J'UC5`>8#J4"8%V=/+%;IBM@V^
M"YL#7C9TYM)SLG<UEW(UONP%5;%ETA<M)KRHRZX1IU(\`7%-)<$@X5)6GCJ4
MY:PS`([TFA;MO=P'F&S_`#X-3'*"86#-^6D2H=`B3R*"MZP@(^`AJ$)RC+2S
M@J3!L$,>W/W"8H[I6/VE;AV!GB)V[I)G8D\DD[04J*I'"14`2/UC3JJ41'6\
MM[:R.WUJ\ZH%<&+1+8YOQ=1\4CV!<?YM[N!F*%=G^?"@)0#I+CR;`0X&I4WD
M\:`;]C7/Q&&H<4#$)2]K[$]_%R[=KMPW);2\WQJUHW7^^E:9G]B3#<7R[U'Y
MMFHF/,+<#&<'35*I2OK"%-61)`9/#CFD]QO;S[A46^82T=M`W`,Y./73?QRZ
M=A315&SUJH55N<%`0#I-4E!X@`@(AJ)!,G1@E*WGVY]Z&<VKO(47M-S39F2$
MV"[N^;3DK(DV49<KY)(IW4_`N!0*V]M>G`#'0X")SCTUT$'@@MFDQ$[<._WQ
MV=Y]J`C4O[WLU4!`1`0_L-*`(?9#CJ+%)=G\W!O]'C]3[/P<:_[WLWP_]0TV
M(*>"R2!V%]QBV[@MZYHK:3GUI+6R_92$8X0QY.(]"[!4#H"H":'XP!)4AZU`
MY1XZECFD6X+:6X3MW;R)^ZHZ_K%VB9T38Y!B$KBGH5.P9<JMM78J<Z$_&K$!
M&I4U'A!.F(`'46HB`5T,24\/D$G-3MM[_P!80%;9YGL2]8"`CCZ9H0`'U1(8
M6XB`$'CST1$M0[TWY)T7M;[(=Z5B;A\!N,@[:,NP-J6[N=QA=9'MP69*M&L`
M@1TL$Q+`NNF4K./2+0ZPA0@!Q'CKH;2-*RM+FO*=.50T9-%\BW#Y9IFH#'2R
M5C[QSM`W59N[B:EZX>V^Y5R9:1\0V/%_2.S[4D)B)*_:-C`Y:"Z;)F3\]N8*
M'+S`=<I2E.E#R&<&3OWO^5(XC!,*?S;O<`X`&SW/O,*B..YHU>/$0_$AQ]`\
M?BU>X=)9S8&R;N68ON%.Y+-VI;A(I\N=-*51_>_FOFVX&0#TK1L^T.V%O(,7
M21C$,50H_*X4TP2Z,\UL'+O;=WD39(3)5@;0LX1K*Z?,"=LLMB2POK6N)(!4
M?@DU!`!+%OU>M1$P`!2A0`X:9!XI./2LOPML[WG%M:4PSF39]N(/BV?D22\?
M-1^.9A:9LBX^@B82L=5$%C-7!R$!=,H@`E`>&I0E*G+7#"8R/)!"JK0V#;\]
MK^?8B?B-L6:KWMV+=`DM(P-DS"K>=M*=*1-\@J4$#&274;J#YJ9@$0$-1D:D
MZAJ5"93/%+M6J\N=KO?':U_2[&W=K.:)NVY)R:8A'T98TPX0:Q\H8SE)D[`B
M!O)=L1,*9R^%`].F0061@V&2UDZ[<._M(YTD]H.>ERE$0!5+'TV*9QI][5L`
MTTF*`%8U^W!W`3`(ALZW`"/+I#'LWRXC6OL^D`ZEEFK:';4[@JIB+#L_SZD(
M$$HD_>[FC!TB?U@&K>OKEH&LFE`Z1+S".S#\J>K!AB%=$^V]W`B%``V>9[`0
M.`"`8]FZ`E7B-?9_`/MTU55'C+%^U+O6PH_8)OAA&:81NQ?.DQ+=)15D9NPI
ME=JW4H`];9@#84C%`WB;G3B&H'M2!"NBVT+NH*-ACV^WG=%#1]`#YKMNS9^W
MXLE#]0_VI%(MB*"/*IQ..D)%&"R:,VY=WR'8#%L<,[M"Q@EZ18.K4N"2;&)2
ME#)2*+I,W#T@.C448#%<U-LG=%D^E*[-HV8KT94`JS6X\-F7,H3[\I':$:BY
M1ZO"@C30Y1@5CEU]N+>?*LPN.U=G.?($Y3)HRML*63,J^R*KCTG<QA_(JLT-
M^XH`D^QIXLCCV)0L!V_MYF2=O*-AWMMVSC$SV))63N>R4UL<3@.WEOS238DS
M;K(ZB!"*+F,R`Z9:CZYN0:&+)/P*TW"=NG<8Q<D<SVS[=S.-D1!0&;#';AEY
MXI&J*9G)JBCUG#@-!-H1B%=[NVR=PLUNR]A8HV*YMQ=8,^D5M<",;8$X\NV[
MV@'*J+>Z)\[4'2C0RA*@D00((5`:AIE\N"E@.Y)E-VV^X#4!+L\S_4I:$`V.
MYHI0*'3P$XH5`*!P#PU.D!J\62'#]BF9>ZL;><Y;=L7;QX_-^*+XQ2^NG(F*
M'UO,;W@7L&[EF<5;]Y-W;IBDZ2*+E!N==,#F+7I$X!IW%.$=)@7<_0Z"7SR"
MC:=RO8=O8OWN`[O+RLK:WFFZ+1N/-MT2=OW#"V5+/HN7CW!6?DO6+I%$R:S=
M02B`"`\=5:3Z4Y$'%:MV[=O?>VLMD7&]X;5,ZP4'E2QY*W4)-]8,TBS:7"U,
M20MY1PIY`="0/2"`F$0``$1'EIQ!R2)8]BT"[[:W<#CWCIBMM!SNLJR<JM5%
MFUAS"[=<43B0%T%R(=*J:H<0'T:2>8=;BVZ]O7?I`YLQW-OMJ.=8:.BIE=])
MOGMC3+=N1@A&OC.$C"=`""+AN)D@"OK"I30`79!R<K5DCVZ]^CN5EWC/9YGT
MC5Y+2+QHG^]]-B*;5P^<+H)@/LX`8`14"GHIH8I%E>[3[7?<-NZ52AXW:-F9
MFX6\PPN)BTG\4S(B'$RIW#LB:8='4-2UZAIPT,4B.*WSECM_;PK-QE:V#[(V
MMYYO)VTN1S?>0+M:6!._-"ERN&)(EK;\(91`?:6D0W2%0RP4(H8]`T8^E&6'
M!)>6[<N_X_5U;/L_"%?#'LU2E:\P0](\=&+H6UL.;!-_35S<N/I_:=GAM8^1
MX)[$R17MA2XL6,RT26?P4RF51O1L[;ODBI]84$2F$*ZNA3C(8ED\'2>6';.[
M@:+L%E-H&?:)I"(4QY-B0Q@$Q0*!Q0J("%*#IBG"0;5D3\RG*0(8+*#=N+?Z
M(&*;9UGT2B`@;_![-T$!"@__`+OZ!UBMAZ5#%*:RQL&WU7?@K;"^+M2S>[N>
MS;>O'&<]'%L>7/)MF4-<TK)6\[=I%1%1-D:*<BBD(A01H`#J3-BA_6DU%[;_
M`'`*C79YGT0$*!7'LV(%`>7#V?CH26P\>[,.YWBV64F+%VR;B8%PZ1!M(M28
M\EUXJ7:E434*TEXQPV492"`=%``Y*](B%=/$)NP6[WN`-\MRI"C?_;'N.XS*
M&#VB3@<4SEH3"@`(";REHU#V4BAC<:B2@5T\4@"2MJO-A6Y1+:'F:)LC;%N#
MC'MUWSCF7C,>3UC3*TS%2<4[4"8(S5(W`CZ.]G$A2K!ZW.H:;$A)T@O^;HW\
MF`3#L^SWTC4"E^@$T)@`HB'K?VO4M0`*:BQ3*MB_;CW^GZ@^I_N!Z`H<H%Q_
M-D]8!*%.KV>H"8AC:&*``E%3&P+?)G>QK6CKGVJ9MMW*F-XAI:L+(R5@S"+2
M^+2:B"<>@_?"B1!"0C2@)0,J(]15.?#63;F)GHD0`5)PV"F$>[,;>,V;:MH6
M7+(SAC:YL;7.OF24DVL/<\>K'N73`[90H.FA%0`5T/,X`<O`=/=Z5*-.,:$M
M1E$GU,$C+Q:N0">?WP$4+LPW6&.7IK@+*-`^.T)81YT\3:YW:*$Z=61J!L5*
M4M6*B\[EU/*Q+OW4K3HV/>[]FK6G+(>8->F_#1SU[M`_\Y!:7J"(EL]U'G1E
M\R92))BHZCB=50/,0I?E!QK+,@Y:^Y.M8_\`].W7_P".N/ZJ:\?V>B!NUL3_
M`$\/YP7IY:_.5>[HT(1H0FJM\_Y]/9K_`$J=R/\`(*W*Z$DZKH338-QE`_>#
MQ^4W$/J`W3P^$<Y$X_L:JJ4H5?#,.$W(C@G.@13`*=!1^$0"NH_9J'Z(1J*^
M^4G^X)_I0T?9J'Z(0Y1Y2?[@G^E#1]FH?HA#E)PW8;@(?:IMXRYN&GK=DKIA
M\2V;-7E(6_#+-&\I*M8AL=PJU9K/U4&R*QR$H`F-T\.8:NC"('A&`'!(DGWC
MF5%N+[XAMP%(%2[0,]*%*`"H*<S8Y@`!X\!^>A\/CT\.WU_F4_*/9\O2J%3W
MQS;8F4Q@V>YZ$"#0HA.6$-?A$H3G'GX:;8Y?+U(\F3Y#U_G7(OODFUT`)YFT
MW.I#"%%"?.MD@<AOLS-`#X]$C(1)`+@<_P`R?D2'R_.ND??*=KWK%^J/G<1Z
MJ`/SS8M!+Z:?/51'4:9J3CJ(*CY1.0]JX_\`3)=KHF$I=H^>#"(U+_MO8E>?
M$"_[=E#U0K3T:8<\#Z_S)^2?E_I7(/?(]M(G$"[/<_&*`\#!+V&/"G,1&=&N
MGB^7M_,GY)&(;Y>E5J/OB6W1W_8-G.?5"A0PF^>;#3`*"'(?GL!$0'PT$<,O
M2EY?-O6KHA[WWMU5`M=H.>$U#"``52<L`O4-*^K_`+>!4P_`&E@.WTI&`["N
M#CWO/"+;J,GLGS^Y3$1$AT)VPU:E`.(]))<PD'QJ//495*<<)2T/S!/S*.GD
M`?2K(A[XKM]4D$8YSLQS^U4<KIMDP6F;')Q./$QS&E0`"E`-/R])U>9"<3PC
MP[W)]&2EIDSM$#O5<I[XCMN3.J1+:!G=8$ESHG.E.V,J3J(-!Z3!+T#3`;#Z
M1^1`I?+Y%6Y;WQC;>F90WU.\^&$/D],U8IND>(&X!,`/CRX!IMV>U/RI9,/7
M^=?0]\CVO"4G7M*SPF<:@<@RMB@("%>0?/?#[NFW9[?S)^2>7R]:Z#>^3;6P
MH8=IN>3#7I`OSQ8X@)?ZWY\$HCZ@<::CZ/EZD>4?1\NU=J?OD^U@U13VEYY,
M;]R:7L<H!\8C,>&F26_/^9+RC\O]*X%]\GVU&,)2[/,]'\0$)FPAJ'I``G!&
MG#0S\&2\D\L?EVJJ2]\9VX.#`1+9]G<PC3@6;L+J"O@-)[PTM=)V(D_R[$>4
MPX>M7%'WP';L)#4V?Y\$_6;I*,I8M!.-#</]O2U"HCQTR`S_`$H$`#P];JB<
M^^$8(:D,=;95N"!,@=0JDEK',3I"M1_]NZ`'V=1U4S@!+U_F1H'!G^7:JBR_
M?!=N-Z7O9]CH;1,YQSV[KFA;::NW<S9!DFZ\W(MXM)=1-&8454(E[34Q2@)A
M#D%=/3!F#X<B/R(-.8Q/S?G2YNX][Q-A?MOYTBL&7OM]RCD65D[!MB_DYJTY
M*UVC%LTNAH1ZUCURRTDU4%RU(ITJ"7J#J`:<-..'-T:#(X9?+N3?)_?,=LY>
M6SW//3XC\_6#4`#QH$]Z-+T%`IGD/8O@>^8[7E`-7:-G8HUX`:>L(HT#TB,]
M3GH;BQ]?YD>4>7R]:X#[YAM;*7\TC.X"/`?[H+!#J](#2=ZAYUT/V>T?D3-(
M@=OR[5]#WS/:^(#_`(HV=.`\:3U@U$1X>$[QX:;CE[5'RY<C\O2NL??,]LE1
MZ=HF>3!X`$_8/"@UX",X(T'T#X<M/#D@4Y/^4_G7:'OF&V7F&T+/(@/@,]8`
MA]BLV--##DGY4NSUJI)[Y5MH.-";/L[#PX?[?6#3TT_]NM(-R*CY4^('K70K
M[Y;MN2"I]G&?`^$)NPND`]-0G0TV<\64O*(S`]:I0]\ZVQ]92'V?YT)U&Z!,
M:XK%$Q*@(@(I!+#4#"'@>OP:B8]Z/+D[,/6LSD??"=M+-%)RWVE9R>MCHMC'
M62FK&)118*B0`/,5H7J^,/'3#-D7[_S(%,R^7YUCZGODNV<@T^I_GFE>8SE@
ME^#E\]$J''0WR=/RI<AZUTE]\NVR`ITJ[0\[$+^[^?+#Z?@`:SXAILV.+]Z7
ME27:/OENUT/E;1\Z"`\J3=@_MSP`--)SP!0:!`X>M=0>^7[73#0-I6<R\>?S
MUC_C\'_?!XZ9/84"D7R]KH5]\KVPDIT[1<ZJ"/[F<Q\`4I\$^8>'PZ3D\#Z_
MS)FB1\OSKI#WRO;&<`KM`SR:@@;I&>L`:B`\./SYU<_L:#W%'E$JM1]\@VSJ
M"'3M`SR%1*!2!/8_J(UX!7Y\"G'1GP1Y4AG^7Z5W+>^,[=D@%0-FN?3D`PE,
M<DW8)QJ`=730LZ`C0!KH]'M_,H^6QX>MOI5I6]\SVSHF$%MGF>T?`!4G;#`1
M`.=2#.#2H\-(L^14A3/(>L)\#M*=W3&_=JLW,=YXZQ3>N+&N';EM*V9-K>+Z
M$?KRRUU1DO*-G+`\*[=%2(U)&'*<#<:CZ-&>`<9Y]RA*.G`YDC+O3;>Z3WI/
M`.UG<)EG;Y/;9\OW3.XJO:6LJ3F+?E[,+'RCF*!`5'[0CF6;.$VZXK```H4#
M5#3&3M[?S*0ID@\N[\Z3\X]\7VV(@7KV@9Y`PB;I`\O8)#5)3D)YTH`(@;PK
MH8'A[?S*7E'@WR]*HP]\AVT(F_'[0,])%,%0'Y\L42C2M*=,V(!6O(*!I\,`
M5'RB3P]?YUQ5]\JVO`'K;1<\F#C_`.[-A!2H4\9XH_;U''D?EZ$_)/R_TKXG
M[Y5M?4*!?JBY\^]H'SQ8-*!P#Y,Z(^C1Z"_R[$>4<OE\Z^F]\GVRB-"[0,^F
MZ1#UB3-B!Q#E4?GT*4'T:,\"/;^9,42_R_*NYO[XWMI4.!$MGF>3'./_`+]6
M+Q\`K2:/4=-FX>W\R4J,LC\O:KP'O@^W<PB/U/<\$`H`)NJ9L0``*\A-\^`(
M?!PT89$>U+R^[Y_I7%3WOW`H@"B&S'/CA$0*8!2G+!-U`(`-*?/(\P'GPU$`
M`OCZ_P`R-+'A\WTJPO/?(MNT</EN=F&X%L(&`3&<S-CIA0:AT@`RPC2O+C34
M@.3^M(0.8T^M7XWOB6V0WLR26TO.RCM=$JBK4DM974W$Y"G3`Z@S)2^L!@^/
M1AV^L?D4O*DS\/EVKH5]\+VUMS`LMM"SVFF:I>LTO8Y"B<HFJGU!,@6O54?'
MGH##(>W\R#3)R;Y>E4:_OD.VI`H*#L_SN)#<C&G;`Y^(<9T*4#3/:Z7DRY#U
MJE-[Y7MH`/5V?9X$1$:?[>V`("%!$/DS=1J.@#L/R]"/*/9Z/]*XD]\GVVJ5
MKL[SUR`0$)RPR\1YEH:;*%*!\>AAR/K_`#(\HJJ3]\<VVJB0B>S[/9CB;Y`3
M=@G,?A][2<$P4'[5-1+?HE`IGB!\O2KHC[X1MZ4J8FSC/HI5`#*_.UB`F4_`
M!`QS3@!4*<::;ALCZ_S(\L=GR]*J@]\`VYF(HH.TC-P>4`B8!N*P"FX4ZBE*
M,_Q$*Z'''#Y=R6@`\%=$/>[-MSM)$_U5<RI><4JA$S7)8@J@`A7@5.;,(&`/
M1I8.^/R]"B8D'N[5:9#WPG:U&U`VV',BBQ0/^*3G[)%03)$/4AA^=C#U@<H4
MKX5TF<@DG#N4Q"7`!N].;X=[EUC]TGM;[R<ZV%CFZ\:P]OX]S'8RD1=CN*>O
MG3EA83E\+Y`\0X<H%;G3>@2AC=740W``IIL!DD0Q9-([I3=.&M_YN5-C/N_P
M\?#_``AYA]'HUW/PS#_$#:7_`+[!:K>_^TW/^ZE\Q3$`'.\<1[1)VX9*.I:(
M;)O6GD>ULSKRC1,CIK[2@Y;>T-S&`Y/,343Z@#J*8*@/W/UM`CHW=3_[=<?U
M4EY3M8_]3M_]]#^<%Z<>+<?3>.H1_$3V5\C9>=/)5212N#)@V.,S'MSM&C8L
M.R^@5DV+%?-B2C8RQ?-:JN/-6/542=!2?F^O:ELS0A&A":JWS_GT]FO]*G<C
M_(*W*Z$DZKH338=P?YX3'_Z`-T_QY%TN*#[J<\TT(T(1H0FP.\V'3VP=Z1@$
MU1P9>WB/"L2N%`I3A34AD>Y)_'$=J\B&TOG-^_C(5NP15%T@=<2H=:SI8B2!
ME!`"=5!&H!J$Z@IMYT90?T_,KYA@_%9'=L#(6]"LYT6C]N#X5E447B:R2(@D
M8HT$1,`5)6@A]]K*KVMW;1A.YI3ITZ@>+C&<6PJ0_2B>68&+JNC+S#.F2-=,
MM+O6`(M%I&-4F5#)@NM*&8JM*E*!RF:E<"=,PUZ0Y@'V-8\BP/%AZ_8?F5AD
M`,<`!FMT8WPQ>=X199V/L6>N"(4:.S*NH%K[:9I[.84A<*>4DJ"94UB"!BTY
M<:Z]"VGI0SVJWW'<1$VEW4:G(5H4AIR('F#QS?@&556^V^VJ^5=U-(<RP&5-
MAIE+DY+$E85DJQ'^/+K);;DZ+DZS!J^16*D("0KXW2"2Y#@'0HD0#`-?O@U@
M=:])3Z/WG[MJUQ4$J,:D&&)$CD<LABXS2LKC[9:BX$3#Q'`MXH\#%C\@L5@V
M<S*W4SMJ/33<.7;TT>U33;%,HHJ)RE2+TU`#&-7CRUQ%>M"A0J5ZLA&$(&1)
M[`ZV^U[5N6][C0VG9Z$KC<KBI&%.G'WIRD6$03@'YG)*^=[:,BHP?SE'?-J3
MTK18PQ9G,>=VJZ(H0I$R-RJ)U.H7J&G54.D>>N+GU]LHN30_:"#`B1B2,L<?
ME[5]'R_R@?&"GLTMUKTK"%W"F)?93<T_-)<_LPQ]]O$S9`I*;N6N9JL)'8-P
M>0SE(1;"V\L4G(&.V<I+%-Z_XL:A2@#7TZ[.-:B80K0)G:RCJ,HC@<`&[R%\
MS7EE5VVXJV.Y1E0NZ52=.8(),9PPE$CL.#OBE>XKP-N+RC9,W=]M8V?S[*+C
M5Y==^S439ILHI%(R@O"@J8/:3'(0QB)%'S#@'J@(UUZ6.F[;8-AL[[?HT?MV
M[7=.WM85*D8&<ZK^7I!!+G`%V&(<A<_<;UL]K>0L+BOINIT]>D#46!^L![KN
M,3EBDO(%NPEZ'AYE5RV<QKA85F+@I06;JIH@82*>KZH"14HTXC7QUQN^[7<[
M/NE6RK411J0D08YL1P)XD9N,&(9;>$Z=2@*D#&4)8B0XCT\O4K7:J,I*318Q
M!HFY!P#YXJ1HBHX<%(V*<5/+2*8"B83`'C4?#4=IVNZW:ZC:48U#4D_NQU,P
M<8=IP[%,LY<@`1?N_+]&:N5WV\_MADG("B]3<+J]7D+H*(")5`,;J\M2AR`'
M+I$/#4;S;J]C+[/?>9;7H!U0JTS$AB0&QQ!#$'OY*%.K&K'`#/@00W-^/RY+
M#V$3,39&J[%!1W(/G`-VK-),3"JH)342#@`E,(@'&E-5[;8W^[7%.RVZC.K=
M3FS#D^?I5OA@WF,!BY];)2>5MN$GCC$>(,AR1UFCW));B1<1JX)'/'.X)Z1L
MH0Q4R`)06\P1)41J`@/AKK.K-AVS8?*VZ)J0WRE%[JG.0D(&41*F(M$,X()Q
M.!7-[/OOWIO%UMQ@U&WC&0GBT@?>`.3Q29RQ9BB8@+=8\C`*0<PYTI3A7X=<
M0-!&L!HD>EVQ]JZ1P3DV)]3X>QE>X^+'VA(!.B)2%*94#)%`>FAJTY\0$.?'
M0:M"A<TXW.J5`CQ-G]*A*6&&:V,@T;>6B9F)6IPH50Z@"J4P%"G5T$\O@8`K
MSUNKF[V:K#_TZWK&39RD#_\`2%1$R).I71&#4<K-S&DV2/LR@K$+[`%%#C4*
M*_C*F`0'X!UI7#N1EP4L`^"RI=JHV26.+U$!,@((`@V*F0''$!$P")QZ!#D%
M=;65WM<@WV>J!SU##^2L4T[F4WI&(@,P1C\X6,XR5DCYVPR5TLT<%_?8QX8I
MP2HJ/G75'$,01$X@)0&OAPUKI4XU)FK0.FV8L^9].'S+,BV@D."R>X]Z94.C
MW&;01(D=0I]N>'D2`40^4-OMJTH`T$3!41#F.JHA3I@$%U&W625*T7=>L7V<
MY45"""I>I40,8X%.(`0`*0*TYZ;8*PE@RL:9U7Y%3@D"94`#DH-3=5?6$:\>
M(:BD,GP78P9F>J='EG*!52I&4`#FH8P"8`H!A'B`:``<$-S&"[9-@M&"@84B
MJ(N@,**GFUJ!#B40,`&]4WP:;`8A&'!4JCD[82%.W+Q.0H]*A@]4U1^]$>=-
M+%($`K,`C'2***IFATU%:&(5SYR;<2"43%$C@Q03.(TY5#CJ0&"-0RP5C--N
M#$$A&22?EF&IR+J%'U1$*&`.'AH(9`Q=7AA=JCS\1\WH)"FB!?:#+*G#J3X"
M)B==#=0Z0<YI"+XE6=S,N'[Q)!5FP.(*%Z#BF!0'I,7UC"4.-:C]C0<"R;8J
MZR:[OV]R4$?4*Y$Y"`J()D!(1#I*'JT*6G`*<M2`92&2NT<S=2#=LH=%T47A
MS@D=,JBH"BF'XPY2D`?,Z##Q]`:'[4B0%C+ERLH_-$$*52JG0"W68"FYAUA4
M0$`&E:?#J+G)#Q(R5-Y3D'R;`B?G**N`;I`"AAZC"8`$``H\^&FV/%(MZ%E#
M^TI)DP*_%DZ0_M$SY<CY%9L3R2J4ZFJBH%!QUD$!``XAI'#)&J+X,L126.5`
M[@$2C02`4!4,(!U"`>L%1X"/VM)U(+,+=9*2S91\=OY35)55,5PZ^@5"I@8"
MAS'@;@(^@=,$J,B!A@Z['LHYA7"3=6+8+^<E[0CY;P53`F7A4XD,'0(\Z4TR
M2D`)<2N++(*\69=H,0@M[0Y`Z8F=*T3!8G(/BKPXAI#Q=Z4H#`]BK[INYPV3
M;E/!-A3.B59%5\W5ZSE,4@U(*I.E0`,(A4HB&@AE&,1P*GA^YD"5Q@O?0X\A
M%L"F7L0G*DW*()E`UH78<2EZ@'U:CRK30/H/S)3.(]'SJ)IW?E5F?<YWP+(J
MHIE)GF[E:G1ZC`84F=2]?AR^Q71%Q'TJX>[ZDE"/QA=,I#.)8EOSCF.C+=1G
M)*39-BG0:@Z3!0#+F3('2F7I'A6H4'CIOC@J];'TK1;`SB2DG#%RM5)$CLZ?
M2)C"8R2)E4AJ)S>J(AQ#3(4NU7&"BG,N\D$2&2(2,BR2;H3]1`%'S4T5`(/'
MUNM4*<ZZCQ;%,D`@+)[^LUW:4=&2+A!S'*2C@/9V4FV$BYV2B!%47;<PE(#A
M%3J^4%*!HQ48RU<E@3I9=@U;."*)F\]-8Y_Q0"4IB*]!2>%>'CXZ>04^Y;FB
M[3DBPB;YY'^0J9-JX.[30%9%BV<B0?,>`0`%.B/4?F'@&DY?L51F#)EKQ2Y9
M4SA^R:+,EFOM+EH1P#(2J*MT>H"*D$YQH*@``\0'AH.&2F(#BLBL"Y[UNVX(
MFUHV)),NETS-VS&.:=#Q<Z*)Q(/4)C`!0`E3#32+J!C$9JP7),7BUGG$#/)J
M,W8.E$'+)TW*19MTFJ"1B&`PIFZ.(CH<\.84AI&,659=,>JUEWQFRZQ>B,9+
M"5(H%#SDV:05`:5`.'V]7B$=+EU*)!ABE5X-VQ93R[:X7';L*$]!QUG2$XZ$
MQT2*G7+[24Z"`*&`#NB"7A2H_!JG@_%4DERV;I&23)0ET.(A=958B,@JW.D)
MU"`0Q#*$.F)#5Z3E4((<N9=#GT*YWAJ[%F-D61(W3>K:V&*;M1X\:*JQK5/\
M8HX=`LFDV;E(/R_,.<`-2@\?#3."4I1C%\RZ43N%VN9'PS9:<G>%HJM1<'8.
M#2T?Y:[6,3?*$(E'2!TA4!)ZH-1XB`T,`=.D'XJN,CJ9(Z>19RQ#=R5$Q3`#
MD#J@/2;I2,7RP*(4,!C5$-,X9*X,[)U3;QL"OK+NVR3S/&?.J5N,&*ZR#@L:
MHZ8R4@@9R91$7`CTHI(&;G(<P^.H@$JB4O$3QX)K9Y%&^D$FP<-RME$'SE!5
M,IBG*BHD<R8E(H7U3`825Y:8`.>*O&(=9CA'&%TY,RM!61:C=9W-23Q,C9)L
M0R@@0R@E4.8A0-0A"!41IH+!1F0(K*-PN#YO"F336?-K)O'P.%U3F22$J@F*
MX`JR:B=.!B&J7EQIIL.(2@1(=RG+]@AI[)V(-]1.GRQZL\B!2T`"@.-@H%/`
M0IJ*KG[RX;K!IA3N"F]&Q;W?\?B_PAYAUW7PR_\`V!M'_6P6JWK_`+5<_P"Y
ME\Q3!\8J(S$"%>`W#;X?_P!98Z^[.MQ__3=U/_MUQ_537ENU'_U.W'_C0_G!
M>J('(*Z_-DKV5?="$:$)JK?/^?3V:_TJ=R/\@K<KH23JNA--@W$/3WA,?B/R
M?J`W54:AP_PXDYUII?63PTXISLIJAXUX_L#2O#AJ3,HN^6:^U'A6GI'@(</@
MY\?@TD(ZOZ.0_8`0XZ$TV-WF0ZNV#O/`?'!MZ@-/_@I?4AD>Y1.$@O*0VWQC
M=SF6PC-6@F32246?J-VJ;H&;%9(B"KAV"8D(FF)@$0`?W.O0OA5L<-[ZLC87
MU*57:8XSU.>'/AZ"J-QJUJ%C7E3E&-S&+4]182GP8'#T)X;>YA_;K=>W)XWP
M:>[KTR39S9G*@SCX"<4&48)`G\_RLE&+QQFL8UCR!U%!JIY9A-ZP#T@.NBZ[
MVOXI7>YWUSU99;%#H.VE4^[YV]2I&]IP@=%.!`D*<HU8^*42/"S!LEYQT?N>
M_P!WNDOO.G5B:[RJ.:!A&0`EX#3EJ9RWC=TPK`$:(VVHFJB4RAY*A$'!3)K%
M<^Q`82`-`.@LF)1+X4'7C9UG]V=-3@>1X'T%>K2PEFP`S+$#O!(!'>0#Q+*0
M-VZK/RO<.UNUC89%"-]DNZ;+=\JXDXR-DBRIT$TFK0%2^8X4AE&1Q4*0PF*H
ML8P4Z@#7E7^9*_OK:UZ?C>T-P_#MM9D4YB,A1E<RKRQA*&D"HS!W<#%U[K_E
MXZT_RX=$[EU'>_'`PK]1W@I4+6WG1J5J)L90>I/2-=`5!(^&4M)'`X)"'<MM
M5>WLP0Z@VN#:(BV;*V+@NYHR.5K*7TR<HN)]E[44E")@`IJ$3,-:"(@`<=?1
MVZ_BVM\/.FZW5YA6W:5GKE4(B*M,2`\NA,@:IF,")>82Q[277SW9W6Q7^Y;K
M?]'1E'HRKN=>=E"1D33MR?V0!EXB`,,7P/,)#F-G["VLTVE)2RB#%BWGBN'3
MU4IC$1;*"006$B8"(F(F?X..O+.H;6O>;-7M[:$JEQ.!$8C,G@%['\$]YVK8
M/BCLF\[W7I6^UV]]3G4J5,(1B#B3\F2UIEOCR0=M7D1E2(,Y3E6+\R2K27$1
M;(OO:EA34:G6*5T8!Z0]4"&`WK#X#Q5#<NH(;3*VOMDIT[0VTJ?F2$092!B<
M"S@^$E\"P(R*^FMTZ!^$=?JRGU=T]\3XSW>>\PN96U2I+RO+,\(P-)ZFHG2`
M"-.G5E@DNY*0:FS-?+8\*$FW-=!U5H@G4V3>@,BJ<R9E_+.1HD")RB!C]/,:
MZ](^&U(W(VRC=V]2K3-2)-$$C4`8X2F^$0[GF0OG#_,/`Q^-G55U2`C0&\5#
MX<1"/AD&#1QF^H#2.93\MEA.K;;[8=8^/*6VUM`6H7[9#1RM[0W5>H`%NW`B
M1F*(R$0"`J(]?JD2$1$*^8.M?_F\VG>]LZ]VO>MWF1TU7H>79SI2)C;7%"-(
MU82`/ETIEXF!P-31)F,'7H'^0ZO\*K[K?J/H3K_;[2YZGWB$:EE<W5.G(U;>
M7F0N*%,U`2*D-43"%-IU'+OH@`TMN6L@S#-AL@Q\4A&VY=$8R*J@#SVU4DN1
MKY+UR<>AN1#YQ>)'4*GY9>@/$U==U#>JGQ)Z5H=;[=(5+NUA"UO:<FC*-6D"
M(S`&<:M,QD)#`R$Q]4MY-\6?A+U%\&^L;SIK=Z,AM-:[KUMOK:#"-2SE4/E1
M`.1I#PF)\478YNK1V_V&.76ZFT6-_E;-(8S:4,072JC>-/(`@NZC49=TB4_L
MC)Y(II(BJ8.@@&$1X`.MUT=NNZ[;;[U7Z7I5*_64=JK&SHQ8ZJ@B[0$L)5!B
M8@C'!>*=53KQV=]4H6YJP%:I$/*G0,HBK*(!$B80,I'3BP3G'<0V\VO>..+C
MG+,B;4OC)\+[//>3B%%U(.F-J)M3.)T]UPL<D#1!.U3+D0!ZDFG[20`,(C6H
M\5\/]X^,/4G1UT?C/L]S;6E&FU&^NXPIW&LR?2V=02!)`E[F6*Z3J*Y^$5#?
MK.S^"M;=JVR"!%W&\@]M&4!H%:WKS/GM7F#4\JH2(:F`TLF==LTO8,%+QJ]R
MO6L895QY#!S(=1FH.1,`F()ERE\AR!!$0ZNHP<JZ]R^#&Z=+;?N-0[E5$;P$
M0I'M(SY8XL^`6#O!KUMOD*$-=73+(MD_L3C/<*APG,?8Q<V)`34C9C@2N+7=
M1;%_*E<F9M&Z-R/`2;ME19I'D&QZ?NZ5^^`1\AZJV7?*_P`6^JJE:<[[R_L<
MI&,*A%/52!@#ITP+P$3AKPSS*R.F]PZ5C\*-BLB:4>MZ.X[D;X2J1A(43+_E
MACC(:9`EWS'),[+0[]H;\8R?H+'4#J([:N&G34.KI.1RF@9-0U>0C6OHUHI^
M;28UJ-82(?W2(XXX$Q'/EADK16IU?W<X3(&.D@M@`,1@<`KI%0DC)K`6-AY.
M35(1(798]@_?K-^HAU0(X*Q9ND42F+6IC"`!]D-9-O:UJI%6C'_DI9SG%XB7
M&`\<,CAFJ*ES;4P!4J@53+3&.`,B[8`^(O\`P<%D;>)DR^85.(DR](%JB+)T
M90G,#$,86Z8)F(/"@TIJ^>T;E2+RA*,#D8@D-W>:?G6P^[=X=X6ET2<FHUC%
MCD=6C+UJH.$@T#S#,GJ92E1\SVM@]9F*"A1*EUF,W63**BH<.=:#3AK'C9WE
M2G5KTJ%S4HTJGE2E"&H>9GP=N[DL64?*K?9KAQ=O[H_2XP.O1,88OI54_0NH
M4$.F&EB>TH><V(K"RP>W(`F/XYFJ=%N@ND0@"83%$.`<ZZP)>0":)K4HS&$S
M4KP&B7")@&G"1.`C-R25;;6-U>1E7MZ-Q5MX%I2I1,],CD"(PGV<N]=F)8:Y
M4,T85DY.!DV\4KE2P4T9$\6[39@8+GC:$]L.@JV\P#%&H":O/U@\5"XI7A%"
MQJ0N)42)3$"XB`<26.0'`NBO`4B;6J)T;T8F$X2C(CGXB/8$]S[T34_<GQLF
MF55197`N%`(D1,ZBJ@G@V9?+!).IU#&$W``#B.KP6=^)/MQ5=,GRR4G^^]IT
M`;;#=TH2+>)2[2W37$FS+:K@9@KY)L1T)C+E2!8$_`0`:4YAI]J@Y"8:BTDT
M4G:;E-8ARF*D*)@\M<!(8P"!B"4#)*E&H"4P!]C261%.(=N_":V6[LNYXK;#
MV6B+>&-7%X:)6D8=LZ6,=+R7ZOE*MS*=`UZ>-!YZ%"H<<."L?<,P1%X4R?#,
M(2VIV+C9N+"4=2+QNJC$.7ZJRA3$BTO9T46Z2?3Q*0:4U+L*5,OAP2%S,A>R
M$>T:-EG#A=>/22;MB&5<.55CID(B@D0!,JHL<PT`/'X-$AA@ID`!U(0SML\6
M0VQG<1=IRS^X(^VHB4&*+%-6\FV$Z95%UE.A+S@#H-4`#F'$=+$8J@$C+-1X
MD6I4W#EHN1=)RFHNB=!<IBF(9(3=95"&#J(<HE$!`>-0T$DK(YMR3AW;OVYI
M9EE<D3;R,2=1EN1"2+=>0:%<L#O':IRBB'F@9,%N@E0$.(5T@ZJG+(<$GW<G
MA"X,(95=Q4K`R$=;[]XFZ@Y!5JH@Q=HKB151!D\IY"IDC`8`*`@8`*/HT\\U
M*!=GS6J;A%FFZ=J\#`<[D2B4Y"CT`-1$YC=0=0B8:=/AI@\U..$<4^7VO]L*
M>2L=L[VNBV5TH\L@K$03R5M\KQE(H2)SE<K-#/>E)0I2%``5+PXU"G#2#>A4
M3PF2$UKO)Q,TQ!NNR'8S.'E(>-9R:+F,:R#$[119%T3SQ6:)FJ0T><X"!!*(
M](</#0#CBK(%QCFM<X:MT+FSQBFW&<8ZDU9N](ED:-9-A=.W)7+TH+I(H4$H
MG2;5$#"%`#CST%W14?2I(O</V-1+K;A+7/C7'M^7I<5HMVQ&L5;<8DD]@^AD
MLD]._8QJ;MV[:L%$NE4HATB80&FF0/0J8N"HLPQ;B/;OX^2BG\;(,EFZ;QD^
M25:NVRA@4$"N&RR*2R/68`'C2G*GCJ+.L@$)\KM@[16.6\!WOD>?@E'+4MV'
MMBWE'\>DZ92":S0%'RK`7)3)JK(@H!.OF41`>&I!B[*JH7FFOMW.![MP/FBX
M+>NJQ;CL^->N'RUN+RC%1!G,18'ZB.XIZ)`070H8*@41I7PX:,\U.D7':L,V
M_8CDLU;@,=XWAH23ECSMQQS5ZVBF9Y)TG%M2E7DGRC8/5*V;($,)S&X`4!YZ
M,L!Q3J%@Z=J[I^TXEA8]A+OLFWW#VV[3>,X26?,8QJBE$-C(D1(*J;$G6'6H
M@;K$P=)1XZ"&[55$A\\%(T]S-%$<![W_`"3`:F6</`:B@*`/]Q=SFZ^H"@'K
MF.(T\.7AHR/H/S(J,X/<HHO=PBY">[H.\RW8=JB^EIG<!<C)HV.)$3'6<G9I
M$HN<IDT^/B:NC*('!7.P?@I*VSWMSW;:^TBWXS*E@D9WW>L$+=NR&7:.(Z68
MOF@H,$W3I1JF54I`4`W0(T#X-$>7%8YP/#2H?&9\-W5@+<QEC%60+:0M*Y;-
MN6;;NX94Y#(M&+U`LC&G06+T$617C72:A1H'`VC'(\%:X-/!+W[7.Q3(>Y:_
MI[+<A9B2F`[89'C)B6D5@;-Y269.&Y6,<R)T`=P)WP%%0*B7P&N@.2HS+AB<
M72L^^%MRD<28TP!)Q=F-R6TXD)-6=N%LR0-(0QU$V*,7%NW"2`"UCS@<Q4R`
M)2!3@'+0<8J,,"P4?%:"?W#]'X"WF(OY24=(Q,8S03`2N).0D_9VS85SF`@"
M93J+6GA72;!BKP6))4NY_P!N!S96PNTX0MO6/%YRO*`9OKO+<*R;AT1)2/0%
MNBDZ(DJ;H0$HC0A@KQ`0#1D.#JAG[G41V9M\UI7U<UK2)FP2T!=4G#.`:`)F
M1CLU7+9P=#K*!RE(9,>@IJU"G/3]X8JYR1ADR>K['&S&XLR7=E3<)+6B63Q5
MC^*>6LE.KR2$<9O=SQLDJ5-`#AUG,FS<@(B`^J8VB(&9]U0F<=(S6E>ZCLIR
MS@')4#GAY:C4</9%4(G!7(Q<`\(64*N=NJRF$3451.X*NF1%8?4.80Y>(W'A
M^1*!?PGWDV->TJJM,J,X]%1PO*,HY%LW00%151PNU;)%;))D`QU3K*'$```J
M(C0-2U.%9$>%SP4XSM2;'G&'-HV%YK,K!%.Y+VCW]PO;=?P2RH0\5+K/_FJ/
M=_CD%#.RM!*JH0X"`%&M.6HA@`>"IG[S!1?>Z)M%G-H^\ZZ2I/(V9QOE:XI2
M]<<R["/&']GBG+Q0?F-_%'*<(Y]&'6Z#$`0Z@H-/$3(-P5@(TD'`I0W8TV+W
MCO6WL1-T'6"-QQA)(]WW:\(*5'BC=0JC*%2!S^+,5RJ41/6M`#PIQ;<@E,B(
M`4BONS=KMWGS:]D:=Q"ZEQR18\E#S$%:-NR$=\T76D+U))ZUF2H>61=VV3ZC
M)'H/1TAQTRY!/UE7$Z2V84'9MB#(4S?;'##U@G#W*WNAM:MR>W'(+>!5D)%K
M&J.G#P#@W-[,#D3?Z#TC74?I5QD,9C,KT0-O6QYM@78M9.W"T[J?W!`*66M)
M7RFS5;+S;M6X&[B347!=!+RH]BLO(&!$Y#5\OF%=/21A\L51@3JP9U`:WC[5
MLK[6<LS<?>5DOX2U;DNE\%I3*BYGS5VT.==P@F9^0*>W%;G`3$$:F-7T#J.6
M"R(%PR?*]W5V0M\G7KG3/$I\W+W+CYJA`6-'O)9JS%JX<I/E7[QPFN?H5.*9
M$RE`0$0H(\-2'Z0S`5,SJ('!)M[X6$VUGY*LG*+2*E&,NK,SL%>1RII_-1%4
MG**B+M-=-0:B<X*@`@(=5>/'2)]JE3))(.`92!.PPX2==B??4J@H50A_W^3%
M,!"D$`_>Z,``<"B8!-T@'$>-!U%*7O,5;=UW^\CW!OT%?=__`.,3,&NZ^&7_
M`.P=H_ZV'TK5[S_VNY_W,OF*C_MBNS/XLK%1!)Z::A2LU7:2B[1-T,LS!NHY
M016;JK-R+4$Y2J$,8M0`P#Q#[MZW(_!FZ_\`QUQ_537E^U1;<K<M_M8?.%ZA
MF+V>7F4(^3S-/X[N&XC2BAXUWC6U;CM&&1A1:M2HMGL?<UWWF]<297I5C&6(
MX32%(Q"@F!BF,;\V%[$ME:$(T(356^?\^GLU_I4[D?Y!6Y70DG5=":9!W<P>
M=KG[E=O6]MSO6VL>9.E]A,Q'QUZW/%&FFEM1B^?F834FQBQ0<-W\LC&BK[,1
M8HH^:)1/4`IJBH*LJD!`F-+5XY!G`;@#[5;3E"/O@2D?=!=CWD%4^")[/^V[
M>O$;:[IW77QNFL*9PI>&6,OSF2+;Q_$R6')F*=QI;>5;2EDP$$@VB;G%P\,F
MT>%55*DD42"!2#U9EK4I2VW<;BO`1H6IIFG6)+2G(EZ3.Q>`$@0'U:AP5=S1
MJ1G;&G)ZUS.4?*#/`1(_:##(DF.+N0"K#8^\[<)E_N+V%$0TP6`VDW7BC)*]
M@V\:+9%FK]N"S)F(CG=^O'[ABH]0@C*.54614EDRJ4$QBB%*+;;>I*UW&I>N
M+^-K"K0IR8"$92`<LQU2&+2=G[$[TBE"@:+&D;L4YS'UAH)(Y!B&P;+-:"VD
M=W2\[!QU<:FX#&VX'*UM1>Y3(^/+HW$1%IVPGCO&S%>]#P5F14J=%Q#OG[-B
M55))59LT5%(354.(\1=G&G?V.VB'[*M<6-"9F<ZM2I(@X'`2.31`#<'4]UIF
MSWC<K>D\J%"L=`#>&'E@MD^?&1)QS3C/>/=)NNUOO&=H*D51<X#NYRBJF8#I
MJ)K0JBJ:B9@X&(<IP$!#F`Z1A*E*=*8(G%P0<W!8K&C.-00J0]R6([B,%YX/
M9%P*.XR_LD6:M<!;1B74(QCKDFF=J)W;+&BUU`5!G&I+-UO8G3I0/6.0R9R@
M%`,`5#7H_0?7UGT5:7<+BA*O<U/</'NP;`ELUJ]_Z=V_?YT?.J5'H2U0\1B`
M>>!#^EU.;P5L3VY[><*WLC8UMO7\C>\4YL>X;]NV2;R%Q3`O6GE"B@W(46D"
MS\]8W4F@'4>M#5#6FZKZTZBZUJRM]Y$:.VQ+PIP\(?/$Q;D,'(X+8V=M1VZC
M]GLXQA4XL`YX%R7)7G9=Q+;&SVD[D\O8F:SR$FS)<X7'&HB;^VH5O./E*LW8
M*()@)DP>!T"`=()EY>GD`9@@P]\'#CCPS68)$AX^\I9VWWME9$AMJ6#E<`J&
MQ_EUC8S=9U(+F$EJ9)A)8!?NWTB1P1VT^>6BS@2)*>4!P`H`4P!PUVW3&^]-
M;EL%3HOK^R&X=+BN*@I3,V$P1(&,XSC4BTL6$P.89:/=-@V_J`M<B-.ZIC"H
MY<8-Q)!!&#,W%G7?W,NWE$63VBIZ[+Q:04G?6&$I'(5WW.G.F(O)9%G).*0D
M&[TI$DA=/&HJ^0D!AZ>@`X#QK@=9[]#?]Z^U6KPVR%,4Z--_#",`P`XL`.).
M3YXK86EM3L[>C9VK>10AH!R\/<&$G/$@GM4'6/3@7.0+?-<3AXT@7J=O.Y-P
MR$?;",WL>S<N!0#B7J(81+4`H'H'7&7QOQ95)[;I^VQB90?``@9]_)UV?1MM
MTU<]2V5OUC4G2Z9E<1%S*(>0I/XFP+$C!\PG!6;5&/:W&MBV*L]VQ0@R%B5F
MX%E;H^<"O6!R+/6LJ)O4\I501Z"`0#`4->,5*TJ\[<]0U[SSO.U2@7%,18@M
MI;B1QYK])MIM-MV':][W'_+_`+=TS<[#;;6]I5H:KK=#<B5L:8JTZ^H:'G4,
MVP$X4\$B`7=S.;TG$YI1<TU).THRX'#I$&KM#V^;9_.B_ED*4B:B*;HQD^D"
ME+2@``!KVVTC84*5&.VUJM.T@-5/2<0[8$Y^LE?FAU35ZGK]47UWUF;@=8U;
MN56\%6($O.F')D,HR?4#!FB&8!>@9#=OUM+86PED*>N2<QXK;V*;6M^T[AM)
MO%N6<YC9C;C99RK>44]:J,I!X1(Q!*HX`YU>HPF,(E`0Z^/68N-LK]-]4V$=
MVV6ZG&?DSC*3U($G6#$QE"6(Q!'+F_)WMC;[AIJUO,A=49/2JTI2I5*,S+5J
MA.F82B=6((.84?CNO8$_>4P3;TO=DW8,B_O3(2;+&3:RT09SL@P8.%>N?GB(
MJ&:`BJ@<Y3`B!2`8.(>.J*=O\/=AVF]M^B+2YL:UW.$[BG4J59#S`):=`J3F
M1$`G`88A@M]N?4'6>_4;:GU3OU]N]*RC*-*%S&F](2$(F,9QA&<G%.#F<I$F
M+YRD3I[W=7!+3,6ZV_U3PMEWK(69#.%0M2^&HR+*5C#-7:IRJH'HDHB1<@]8
M]0&]76DL;Z\LIPN[2I.E=@$ZXG3+E@1E@PP98(JRC4C6I,)D',`MJP.;YC!3
M*<;;0L006$\G9&Q[BNTXRX)^<NFV9UA'-I$WMS)V[5;2L/$'D'S\Q(@%#=)$
MJ@4/+]6@:W&Z=5=0[[2%ONMW5KT,/#-B/"&&#,X&9S.9<XI>?4IPE3\`I2'B
MB(0`).)+"(&?JX+SD=U.-X[&VYNY<=^Q-V4:URH1B+4!$R#9)^^240*<E3`)
MD!.%`^2'3K5[=7-I>PO?+C6E2GK$23$"0XO$Q)[B6[%4(DCPEFBP[BI<FUK8
M7N6E+3@'>.\G/;0L.1C56[%Y-PS.?B!E2H-Q64\AQ&O?F]BZ,<3CY($J%1$.
M.O2>I^K/AGUMML*/Q!V6%SN'F1E.-*=:C*1I2/EF52VJTIR$8D,)RD!DQ&"Y
M*[Z+Z<O;LW=;53O0)/(9>-GP+@NW$$AL&23>Z[VGKXQ5MCR/GW(=\P=W7';Z
MK&2E7L.@PB&RSAT!DF"[)%!HR,<H-2@`@*84$!$0$>.LO>?B1M&Y;!'I_9]M
MI4MLA$0HF1D90`#!Y&1F6(^M(OQ=;78]FVW8+0T++5*)=BY+XOBY/$ILKM79
M);8I;+N3)-UV5QWJTA+I:'CD'IW\"LBUHZ(J=/SDW31PL8A2IT(<@>L!N&L[
M8/ASL/Q6^&,^C>K;&4K*WJ59PJPG.#S+M/5"<2=&;$F+YA<MUY;&%G2W^WK&
MGOEFQI`X@-CD7`]2>2S3#;2XJ2:HRMLQT/=,V5>6BW#091-)206]:/&ZFS:1
M%JP9NUU"F.":1#=`F`::_.'J[ID_#GXITMCZ9W>XW?HNVN:(NQ.0_9PA/]O1
MA*.DS(B""T@0&TD'%?9?P"ZO_P`ZWQ1^$>ZW_35Q1.P6=H:=+S*%`5:\H#`6
MLO(>52`;3J,H/F"F!-Y&;[P/==PXG;6G:]L-8-C;SMJZLUK[0TD44))`B#UT
MNZ4>K?C2GJ(%.4M!Y5#7Z5VEQT_T=LEU:?#^G7J;=>3M[^%5Y7$(QGIC(C63
M+26TXR<'B'*^6H4=[WS=JN^]=7%U7ZHIR-*J;J%*G6C./OP(IPA%R7+F.KM9
M/J;>+<MEY;<3&7;(VA?44C$03ZRWTTV-$22L@I&MU9UE&@5)-=U%L1$Y"=93
M`L>I1X:\M^,EG_E\WGJ>UM.MHUK#KRZ(A*-IKBYK'12-UID:8J"<@?=U.!XL
MES=ONGQBZ$I[CNWP8K[K^'!JGN%:E$3H0G$$Z93G3E".G`EF!#X%:CWGWBR:
MIX\@,?N8-&PX/(V/HV5MEG#HI#'STC=S%-`WM1FP+^:LB8W$IP*`<::Q^A>D
MOA/\.['J3I_H^WN*_7EG1E2NJ]Q5JS-6C6_9FM"$JAIB$-0,3&$9ZF<E6;=<
M?$?JVOMWQ(^*?FU/O>C+[OKG2(U(T)"-6,=`B\HG/4"25D?>1MNV[@[UN'Y"
MZ&A7\5:VW'$4T5LN4#MUGZ4"R1:@N0G2!B)J*"/'U1\0USH_A%RNZ<:6B[/Q
M2NF$[.N'@7DX;1RJ`@HD,,M'M2-'#95%9,I%6:B(I+H&3^46E*:L<NZBRB4=
MQK%:%D[A9MVR%JW<9!DUY8(5DR;LVT:H]?@8A4BH))IE2$SC@%!&@:AS5],X
M%\E)4V*[=+AQ?MQLVW$H:+B64U!Q%S/U60@<9-5X@5?SG:P@9PHY+YM0*)N@
M.(TT!P%42YQS29NZSC>XIG;JZG']IMGL;9Y?/CY110Y7:21GA2N405`P&,D!
M1J`&K01T')T1][-,D]LS%BV3MT,/(-8]O+'LB'&YD(=V4'*2[E)P0$`,EP*J
M*`$'@-:UT@22RNJEF?(J6JK:ESRLFUC5Y$J=QRK8P,Y-VBB#!0BQ2E4CEF:B
M1FYDTRCT@`D&@!PU/,LJ`\0Y41GN-X>'#&[BZ[5<M8Y%P_9_/+Q.+4#V,[EV
M+L55$TTZ%0`WE5Z2@`!JF7A+*R)+.,D[9VI[7?Q&VINV;0)2I7O-R$T]N84E
M5B4C'+AN@RH0P@F?II6H4KJ4"0H2:1+K8N^>PV5ZX'N>W)*-1=(6.(W!$R2Q
M4C/H]=8YSJE*L:BYR',X&A*B4*\M2/!D`L'"CJ8#QJCF3->.,8J,'+Q>Z)P&
M`((B)/-,4Y!(6@U."9NCCQXZ)-Z5?(D#L4]3%NW>:M'%%F6?)6VNQMRRH5M"
ML8B'2,1P8Y44S"J<J(I@<?,2`1-7J^'07TXY*@''!1R.^Q%34ED_#MR2-KHV
MNS:0Z=LMW1&ITW[]1F:0`BKMX)1.X.!"AP$1TB<<5*G@25A78?V\DRONQ6O!
MYY2[FP.M.`,<I3=,NNW=&*J9)2OKHI#P.(4+S\-/,J=0\.Q3"[SL&[(F(>(8
M^,L].HN[3N=8!\L'J`&.9TD\?])A0!14W$2=(#3CIY=JJ..&3*#%W$,8()[[
MIBR994;>C[T?6VDNZ9]#M1N:0$4C5$Q2><`JC4#4J(@&HXN>2L!>+QQ*F";6
MMOL3A3:SC'$45%J-VUJ*`\6\QLNFX63EFD>5U)O5CG,)A=`AU%&OJ\@IIAL@
MJR7Q3-WO"V()O]['%&0E8>72MJ$74;V[,+^<J1VS<BW2=(&4.H<@(IJAZO+@
M&GCGP4HEI8)$/8XPI>&2,_9?NS&;]A&W9CZPXPA$)/H,Z797&H"$BHQ$Z:G2
M<K90X"8M#`'CHQ9XY@)U/=`ED5)1O[#$:R,CB^Z2P"D;?;/YOF&LH0%V:P((
ME7<BJLXZC"/GG'U^KKKXZ0Y<U66`<YK._=:+9AK,F.Z=:EOMF36$MW<WCN(C
M$8XQA8D:,;<O%ND#;J.<PIB0@<Q$=($^EBG)L._Z5%\W&8X?93[]FXNWV<<K
M*(,=QD],2+)(`,=1O&JL'!P`@C02J=/3QX:0),65Q/@Q4Z!S=<A>-H6RVNFW
M9&S[7MEI$1D%;B2)`D2NSIIM(UPVZ#"1<3N$@,;K,)`#PIJ<CJ(<,%1$"(+8
ME0'N]SB^Y;#WZ7/=ETG63E,GVJA+J1DBH@+]DA$13.%3,^*D"@I%=,FP&(;G
M0P#I,0[YJR#:</=4JKMR8"A,+[-L&QMLLT'EIS\&QO&3%I,N)$57,VY(Y>IO
MBCT@BJ5X8P@(B(@!@`*!PT$,`7P*CJQEFX2=O>$[>N:!V2.9.3MU/Z%SD_#.
MX-XHL5.01(B^9I@U`QAJHF*ABB'WU`YZ`,&X.B+&0YE1A>U3;\#>.\_`.+KB
MC8F7+?2<JI;C>3.1NFUOEN"4C;KU=P:@D,FFF8@$$12.8P]1!TP-1[74JAS[
M/F"]&7/V/GL%CVRHN\(.&!ZE;[..8(1,<@'LQW#0I'97)A(99<6JH&$3!P`H
M<*:'+^)E6P/NDJ#;WY=J%I82SOB'+=FO81TEDAE%0TJVB&GS<U>24>W565E1
M9B0AE'!Q5,D<_P!^8E1X\=1R+9A3@7!X8)Y_L)8@06V*HY%:2\2A;4[=5],Y
MBW49-=-^6[T79&Q7;V+2*)3M"1Y$P`3UX!P#38Z7<,[)2(UZ<76=]RG'-G79
MV^<\Q$Q,M'SFW+.D).WX::,*KE:8BEUY)%&W'@%]I0.U52*8I3&Z0X5"G#5G
ME3T.<@'2#B;CU^A0D]OL<6:W-X#821/[5=W/:GG4`!H")6IP<&+3I$41+U<0
MZ1$O$*<-5$G&/)6GW2'X_2O49;V&A`Q6)XV!D0N")0QK`RR;V0$7:ZLBX1`Q
MER(A^)!(2FH!>GU0#I``#AJ3,7&*J'B=^2C]>\=X[PA';9[.R*M=Z#S,TM=,
M2#2W5FJ;9TR3\T"2"C4"I`(%J!:EKZWCJ)+X\4X@ZF;#YUICW7K'CV\[>SA<
M"=](VF6#DTF4A'IT;EF(\JKDWS:^731%5/VDI!]8IRJ?U6I`.<3AA]*)G2<`
M_P`@I4UEIV>W)/SUZL'*%FB\79.D6HO6B3)HU3`PU5.IU.D%#!43E,!N-*Z0
MD)%Y<_8D0<HYMES*\SK=O<=D1_<1R#,64]>IX[#<I'.U%$55DR*12=U1YG)#
M)+*B95)-N)AXU*/C6@40.&/!6@>!R%Z5&T^W+<#'-GQ\/<+N=L;(=BLI$IWR
M9S2#!4C!$[4B+I(Q3%:@94X$`3"4"@``&K`6(8O&2H8',-(.HVOO!%K1=P;1
ME5$[5.V?8VS)#KC=A3'(9\U>@[9)(J$*(E!N":H`8P%`>JE1U"1X<BIP]X%U
MKKW>[%4W?N'LNP=D&<#<!\C'D+N:I2)FCUU;94#@B=LY.)Q3"A#@/2)1XAQT
MGP*)$&3G(#!+R[F.,\)X\P=?RV7(N)^89.S[@D6+"XU7+]\C=+!JO\VE0?E<
M)N$Q<.!$#T4`!IIMABDYS'!89[OZ*:G8=WV.$D4T2N%\^JE32KT%(;'-$REJ
M(C0A``H5XT#CI(E[Z[MUH5PGW!0].Q;W?X/MY$R_KN?AGA\0-I/_`)R'TK`W
M4:MOKQYTI?,4P=&ITF((>8_2&WQ$?BFF/A0-?='6LWZ.W4?^W7']5)>>;;0,
M=PHD\*L?G7JC:_-U>I(T(1H0FJM\_P"?3V:_TJ=R/\@K<KH23JNA-,"]P)YN
ML:;^V9=EUNVK<.?WFP.;CK5)>DZS@8&,:O,]-4IB8.Z>@9$7[&,%4S8#@=/S
M^D3%,`4U@W0KFI#RV^SB7[20]^(;ZAX/Q['610E2TRC5BX.7>L9V^[9=X5Y6
M#DG;GG/;`3;A;6<+=F'>6]U>-]T\%D?/%PWP^CB^;+D!_8+I(J3Q8ZJ:;<Z1
MFK0@$32+Y92B.QJTK2^LX6Q/DVEO.,Z488"4A+S!*4>,C,F<C@\B9<5C0KU[
M:ZE=&/GW%2.@F>.F`<1$3PTAF5-9_:/W!8NWD8%R=#;U=T.4<28KQY<%N.1R
M1?.,1D&!!=QHQ5D,8>W\:00*6Q)MVIC.S@43"*9>-=1M;T"I?U[V`E.O1`B^
M)G/E+F`?%PQ+JRZA&M8T;2G.480NQ5(!+,S'UN5E4!L%W%,>VWGS;.[A[73R
MKD/-=[7M;30MSI+0Y[=GLBQES,SNI<C$J!7"D.Q.!T0((@J-*Z50TZM#IZ(`
M$MMA:FKPQIU)&7L(?NXJZM5%6_WFZ@PIWOG&GAEJI1C!N.!&"4OW:(YU#=H[
M='$/2D3>1>V:6C79$E!53(Y8VHFV<$35$I!4(55(0`PE"H<:!K/W"M"YOKBY
MA[E2K.0[I3)'SK5V5.5&SMZ-3WX4X@]XB`?:H=?NGKZY;;RQN7N-!BS>PH6M
M;\<J1PU!0ZCU=8RJI6JYO536*V+T`8.(5'6'KDQ)+^'Z76?4)!`[1]*G%Q.,
MK.N'#LI`0P+L':L\>XFS=N[,ZD$I%10IRJ%.N`"=$#>C@(>.@Q\T:9.0[^E5
MRD=7F?7YKRRNYO$95NWN!;D+;OUY\X7?*9>2LJW'<HH#1LNT=W`K%PY0=AUD
M*W2`4`4'Y):"/@&HN8Y82!5D28Q<=Z]&W9="9$L#:U@VT[[,G>F2+)QI`6LJ
M+<'*,6\4*;S1DVJ91*@FV9@L`*'4'\8(!3EI`DGRR'P9N"Q9@521+W"4UY[P
MR3)MO=N++T':CM(D5,W#:<M?B'69!I(LU+DATI%XP:U*`J5Z0`:"`@%>6D*<
M:<!"'N@N!VL1@K!&.H$1`8,%`RLZ!CYW)^.(.1\Q6,GTH!FL"9P35]D%'RBI
M"J-/)-TI@-0&H`&M)U%=5;/9[BYHMYL*9D.\+TWX/=,;3UI\3=FZ6WZ-6>U7
MU_"E4C`RC(B1YP\0'-DH4]FDCH^WY1@YDR#+WA(0#EJV.#<Q(^.?I)H"FX%,
M7!EQ(I4#&,("):@/#6LK=0?>$[G:[J5O.A2VZG4IRF'&N3:@#P+GU.O5X?"N
MCTK:[%UEL]3>+>KN/6-;:ZE*C.4(PLZ560U0E&`JPG/2,9$QD'+.`K7;%OM9
M/<S.6X[<KOF8RD@S!5\L#I5<K5\F(K*.!$YUE#`0.?&M-;3ITUJNP6E8Q$3*
MGBV1QCZS]"\S^.EI#;_B]U-:4I5JE*GN<A&I5J&I4(T185)EI2F!]8XYJ<EO
M\N50N.=AEIMU'\M8#O`IX=U"LYCZ,G+/2T5:C*'>/'DJ\9-)1@[2JAT]0@D?
MK,`<->N=,;5U%==-;B>CK^WVOJ&-U;R%S7MS<0%"F9RK4P`"8RG$C3+L*\5W
M3;+[<J=N+&)F8RE*=,5_(-0:2(_M'!&B;2(&)`;BHKO=MM[*UH7UMCQOD91N
M,-:4!*(LF<.Z6E(Z-=/Y.5<M(I63-ZKATBR.)5%`J4YBU*8P"`ZTO5FX[/OO
M4%WNFTBI]CJ3`:I3-.3QA`2D(G$4Y2<P'!Y<UEV5.ZI65.CN-3S=RA3`J29O
M$``<!@[@EQG$A\4J?W7NRB+[E<^7@=R].JR@4K98(,G@MEBO70NS@X<'J`JI
M"DXZ:5\!USIB`S#`!9=3W0,&P7H$V4S96QBJ;MI)BK&/&L',S9S@1,Z!%E4G
M+@7/2J`(IK'4$1$W,1&NK(Q##N^=4RX\05Y4N[7'<S,;[$;:>/57<G?.;XI-
M%VNJ)E#M9";**G48*D$J:)1Z1"NL:I`:FD,`KH%XKT[<4VQC3;IMK8-)VZT6
MUE6=;Q)QQ<$RJ"2,6J5FBA(%<"7H\\"])RH$#US``@`5UD6-*ZK;E2M-M@:E
MQ.!\/83B3Z57*I`PTU)&,8N\CD.3*,WWO-S.+MV&*W>'L*WE.?155@I(/+R&
M%D(^W+B<1C0PI6_'M7[<K]PV2<F$SAR(4`2T)4!X9^ZU-EZ,AY77%2=7=[^<
M:=M;6PIBK1F9`>;7DY>FS$0+9Y+L>@/ASUA\3XWE7X<6UO?4-KH2JWE6I.4*
M5.F'+QFX$ZY8Z:8)<`N'3%6S"Q;;M"U@N96\8^WKOA9=A.Q\=<<+,R$-=2[%
M,A?FYNO%1Z[:/=*I)$(47%/7`*^.OI/HGISJ+IJQK;#>1G5Z;OJ/[&K3G&-:
M(K`&<H@$&)B^(`PY+R_J7;]NWRTK;37NZ-MN,!I&L@:Y!P8$G$CAAGSP2S+U
MLVZ,U3[N_K*,UFWMP.4"2MOIR3()FU9!QY22S208.5$%4XXRH&\EQ50@$YTU
M^=GQ+^$75'PXZ@N+25CN%YLM>XJU*5>$3<RKQ,Y2CJ-(:HR`($M0!)XK]-_\
MJ/\`FX^#727PQM?AS\0[FCT[U'T_:Z2:L)T[>[A'$3M9T_,U3(#SC("1)\$)
M<&DL\Q:L;N8GK$>)M9$\A;%N0CI:+4!RFA(,7JRKDK98@`5P3I1$!4+4.HM:
MB`Z^O>@8]0]*].6_3=_3E+J"_P!CIFUCI)\J,2\1..!#-CW+X,Z_ZHZ:Z^^(
MF[];],1K0V#<-WKW,#6]^<#@2"PT1/`9LW>GAKA*Q0MBS#88N26?V%;=K13:
M6N>_HZ'B)&V+FE$#I3]MVS)E0/(23%NFO0ATBB8!4'6UZHVCX3;%NMEUE\:Z
M-G1Z^T#R3`U_+KFEXHU*EM`D&49^*(J!HD!C@N?V&VZQWBZO_AU\,QNVX[9N
M\8UK_;["1E&H8>(3FX\N#Z`X/`9+1^9+D;W78.),?*R!Y2ZK0S?C2Y#7!#J$
M)'S,6VN)F@C$2AU&C1S(J,6IO,\\P?*`0YA37A>\=4]'=:_%^\W'X=VM44K^
MQTW%:4*D#6J46G4J"$I-3B!$$N!J`!9EZ=N/^5?XS=`?#6'Q*ZUJPL.G[2YD
M*&T5JAG<VU.XPE48#1#Q,\8RU8NS,4Z3W*\+7#>O=LC,D,VJ:EO6YM<P\V7*
M<!5\Y\O#,#)AT@`^:#<R9BF'P'67IE&9HRQG`DR;C\O:O+@1.$3`-%;WA[1-
M<E@/T9Y@DPN%NFLO&"@H*GE`0Q"H'*`=0F$"5]7T".IO@HA0X^XFYN"8W%'A
MI!Z*LM'3AXEBX23$#E,,FB@B)6Q@$0.F)0Z0'F.H]ZNA@)*6%M(<7-;^&;%C
M+N4<&?H6=;Z#8ZI/[.0C%$"=:91$"J"FI7I&GITPRJXKYOFL*4R1M%RS&L6;
MA9ZE;+SYH;)E33:=1!37546\WU>JA1$!#C73SP3R+IA7L58W*IN1N"7ESG_M
M2TY`AF!*@X1>1[GRE`,8@"!DUS"-`#AZOPZ66*G,ZB!\L5)SR82$&'5]J1\M
MXP>`\9G0,9-9.M.'67U@*4!H(5T%F4'/M4*'N,1]UJ[Q9QU<:SA<TZS3-$KK
M$7H1@?VM`I055_LH)@81&@\A#46#XJR)PQ4BOM:1ZUL;+K-:.HU5W'NGTL11
MV1R)5#G([<"44TP]8I`,(U"G'4C@,L%66)<)*'<_EW\)8TI*6>T4<(I%*UG@
M.J?RSHKIG$.M,#%KY)Z``CJZ-.E(>*3(B-4@#D2F<]BMIY(?;Q<-NK`9JNYN
M'?,YU<Y$S"FW8&("BZBA@XA]]RY!JJ8`+1Q5TY/%NU>D1AZ"GI/'[!Q-K'=S
M3E!!=NF414`'H$!10A@$/D`(4`!].HG)E5@.X*(%[RW<]TGW0X?QW(Q[>,C8
M^T6$V`,A.*:TBN:3;KF*4?5(90`ZN&I3<G'`J5,#,9,L<]W;L":/G+(V24))
M\6V[722@YI@U,H`J!-,G;8BJ@%"@J`*P<1IR#01BG49P5,-BW"]M?.$61L[<
M1\J"BZ`J]1O[64,)U"+UI_9.H1&NDP'#!5^E0?>]S986WO)>7C`,'+9Q+6W!
MR#1!90RA/:(^7:>SB@<O2"8E4+0H`(<!TG]2G`@.'^6*F+[&;WN[(>TO%4_E
M,63RXI"P(8'2J:0I&$#Q;9-!L<YQ$ZJH@4#&$>==-V8*`&;)L#OD0-P7-LR<
MQ:(NGT9!.E%FR`)ID0BVR=3U2*MZ*>`<1T.0W)2?Q/VIG;W>@ET1V\G(3Z+>
M^S0DAC8(^33.D)NOR6#90JQC_P"R$.(B40\1TAB<<F3F0`/EQ4C_`'9PI+Q(
MT8L7"_FQB:YBN.DQ#D./0(F35"@E!2O'CQIIX9*!=WXJH]UJBF<*_P"YY%LU
M%%TV^X?%0JK*&$PJN5+0NP[@XF'B83JB(C\(Z7=R/S(/#O\`I2$=IVW!+)'>
M![FF4T7R+.=M/-5PQ4:JJ!1`B+E%BHY\NI!$HJ`>@T$*AI`L.U62+AFPP4F>
M.(VDK3E;?ED$W#X63==%T*)RK(D8*"4C]N>GXHZ)E`,7TTTP7#<540Q<9+SH
MN\FGD>X.Y?ENW;VECRSPD9`Q%EG,4P)MX>2MJ-*R+0:B)O,4JI3[X-2EGVJR
M.%/!3+^T_%N\>;+\.P-TI/Y@26PC&N$3$,Z%<[2BZ=#JE$G%4`Y_N-1&6*@7
MD'&:0S[S-;63[QV967<+::1@K,M.:C).4M83G.>8:/W+!NU*`%$Q$%6KD0.;
MD`:8=G*<9`D1#X*''MS7OJU-R6UN6QM(ND;\"_[81@'S=$BP(/%IMJB()E$.
MHY/*/T`(?>:."F29`\,5ZK*LS<%VQB[O)T0[//QUDP;!B9VV5;G3EEFP&>RJ
M+8I1(H5>IP'QIH?,D8A4D9`8Q.*B2=^[`RL_C?$&7T_/,-D910@&B"RHI)$C
MI(XB[31:&`.M`BB@TIP#EI'+4%(8$\TJ?W:"W/F':=E1W=#A.30:9>GW,8P=
M"NFWCD7$8T+Y92B%"I**^N/I$=.&;I3+I56YNV+(N&QLIH74Q24MQ>*N`B[1
M-4PE56?1ZA'KL@&*)42E24XF&G(=3%2>1)8!,X,W-0RMKV,+1N?NAXPQW::Y
MALM.\12A3B<C@WL;=`.D"GZ>E4$U!Z`H%`IJ!Y\74R'I^E>F'C_';FR%+&<L
M3GEF#"WFS0D:Y/R:LFQJ(D`GJD2`U:$&G'4H@F195DM%_0F!_>=-OR%[[:8W
M-2D.>.>63<;=XT:I&,0$FZZC110JQ"EZ3>:"8B(5Y!J)(./%U*!(DQR"QKW7
M+#;:+VWYAN+S$W4A?-X13]<>D%4`4$CU5,AB@6J/0DH!`KS#1B06Y@*,SB#P
M#_0I568K,A;KQS*1"";`C042L'A&!DRIM3`5,'2`^4'4"AN=!#X=,A^Y0B2X
M'%>6+W?['C[,W?Y$AX6`8V^R:R!",$T`\LSE51RL0LHKTE`#J**@4QC<QZ-)
MO$5D4C@8GB%Z`7:=MR>MS9/MP0NJZF]RWC/8=0,V7D/,(9PD3SE6:2!#4$JC
M5F*:9?2!0IJ47'>RID1D1@ZQ;N([6V^8MD^X)W.P99)-M::\JVAFK>CA-[!.
MF[@KL"J)FH0OE5J''QTL""3[S.F<"(C`.WL3/ONQR:EN*[CXZ,9B:279P+\W
MG*=16:#@'WF"8M0%0X4XTY"&E$!B&?!(EV<\4M[NQ8&)N0QG<5EN(=5RFYA+
MC/&JI&.4Q9%FT75!TB0*E6#KK4H`-1#3.?H3R&:3#V#XTT+V,-_D(IU^T1,C
MN!8..OI`XJM<<@B83$*!13$>@/5$*^/CJ"E+&2X[J`ZL+]P$/3L8]W^Y?PAY
M@UW'PU+=>[4?_.1^E8E]'5:58\X%,*)U9NXYV5LX="UEX=P5JU(11TY%&59J
M`@V(H=),[A82])`,<H"80`1`..OM_K*H_2&Z#_V^X_JIKD[.U$;JG)LICYUZ
M?&-<@.LB0[Z6=X^R%CD[.2/'%B,CQ$3#3#PA&S9R$DS;P\]<+92-4%QY93F6
M(<54CAT```(_G0NV6Q="$:$)JK?/^?3V:_TJ=R/\@K<KH23JNA--@7$0AN\)
MC_J(4W^(%=`^L4!XAG,E!XAS"FASEP.:#D_%.=BDD-*IICTC4M2%X#2E0X<!
MIH8(<H\I(:533&G+U"\/BX<-(@$N<W?T\^]'!N"^^63]P3_2A\/P?#H8%";`
M[SP`';`WH`'``P;>@``<@#YI7U8/=/<@YQ[U$_\`=:<97PGAG<GEAY'.8RQD
M9J&:0DPY:JMFLRNBFH$D1NZ#H!R9H<>'$U*"/#4>!D?=4IL3AFZDF[YV>6[H
MVCWG)[;)V]8W)41#Q2A%,<RSJ.FW<,BZ;GG!CSQ:[>5%P#00Z#-U!.!0,!>>
MNZ^'5SLL.I*`WR%&6W2B&-2(E$DY.)`AAQ=47?VG[ND:<0*NF3%F+L6Q[UY[
M>\BQLA#E?"5R7&QNR:O>ZLK6VU>C.-Y-W>,M*FN)NHDW?KROFRKN4=K%$>M<
M3'$U*CK:_$*SVFZ^(D-KMY6MML]3RP9480IPC&4H@S(@(C`$DD^E5;7*L+*!
MN7E=2HEP[XMV\5Z9>&YU2-VKP>3+IQ_=%K34;BY&7G\>2*!5;U2-!-S)*1YA
M1307.:0!IUIE$`$O5XB&N&NK&(WW[KV^XHU+?S!"-0@,.V7/TE9,*9E,$C!\
MN:9[WKWFW[HG:\WEW!9F'[TQO.6#8#Y6)B;P1,LXE'5K':W&X7AU/*;J+(HQ
MR!A4.!1`G2(>.MOU7TS4Z3O(6%Q=T+NK6IB8%,1>F,_$W`C`=JM\K3(8X`^O
ME[5YVUO+W"VNW%<C;:*3FX2QT62-9KE*<BTM'NU&*B*H',0!$ZB1@&H\``=<
M!NT+*=A6AN&H6AA+48C$#FN[^&-UU-8?$#:[GHRA"OU1"]@;>G(M$U7\.KLY
MA.-MIW*(QJ1OI7BP)@G4)(,R:)W`OA/T^0"I7GEE5*(5X<S4`->,FVZ??S)6
MNY&VDP-9Y"/EOF_-V'<Z_3>CU-\=:-B!+?\`H&.^4Y@C;Y1:<ZIF92@*HKM"
MJ)1&.D$LV9"3C@ET^D=U\.]NA,&TC*S<K\[H%1%`J+PIC%7:BG7\4F1=,!`>
M?HX\=>T[50M;?;J$-NJ&6VPI_LXG$MPD3F?RK\NOB1N._P"]]<[UN'55$6_5
M%3<:OVJ$01`5=7U'>6EG]XN0QR4VK<[LKR;>EIX&W&J,+@SOB=M@RU[;;XLB
M9;V>3Q_-(P\85)Y;K51STNVSLZ2ISBEY*A50#JZA'AZ[TYUG>6?1MQTWT[>V
M.T]4SJPG&ZNH&I2(!),:@@TI@Q):,B1FO(^K]GW+?:EL=KG*G&G+&,3I,FB?
M=+-&3@$GB!Q4?WN*8(D8;:_:U_2ET.D)_$E]0Q;NM>4ESS,DLYNDZK5I$^<X
M7.N$A"LG!`63)U`F)!KSUJOB%OMKO74E06@IF%&$(>9`1`J'0"9``:FU&3:G
M.*Z6T-:-A0MZ^-2G2B#+](MB7(!Q..+G'DG"?=N]MTGCC;AD3=Q<[`[5KE#+
M*5L6DX*N!C_-4*HP(O(%;E'I\E0[M3B(<PUPI)!Q^6*O)>7:`I6FZ;"N5<WX
MK^:,?YAG,46DU.PG[DDK7*Z1NF\[7C8M91Y:19=D_8.H=!^X5J8Y#U.4O28!
M#AKH=FWK:]DNY7%W:_:[BI'3'4!*E#^%*$@8GMP=%%G>8#-[?I7G9;E[25-W
M.=N=LP"2SA:2RQ:#=F@911900"733.99P<YSK*BD41.:O$1'6AJ5)5JTJDXB
M,IS)88!OX(&`'(#!`F)`F/!3NNZ=C7(*&TYK8^+FZLK'(2MN2N1K6BV7SA/3
M5GP#A-U+N89$H"Y,L0_699-,!$Q!XU#7:_#FYVVCU%.=_.G1OY6\OL]63B-.
MJ8$0-1SI,=3-$^%\6=:_>*=>KLEU;6D2;VI1D(#.,OTF/U9@>ZV*BV&@KMR9
M>EZ7!&VRI<;5>*-:=OGF(%R\MNSD%F)8L'<D@\;$9QSN&32$2)#0WF@(_#KR
MSI+X1;[/KFXZK^-,Y_==I7J5YRJU"9W\G/DPHRC4$M`CI`C'PL&`P7T)N_Q:
MVG9/\N^P_"'X*U+S:>H:DS4WJ\HZ[>H(>,SHSN(M.K*M*0PU>X&+C!)#M9K?
MN)V"=C.GS%X-MR[]J[(QAFZ\+-J@],M[/)^<DJA,F$5!`4E.KRZ]--<9\2OB
M1UT.K1=VVY;A9VM*C_R].G=5*4*,""P%.$Q`M'2"9QUR^L20OJG_`"J_`_X"
M_$_X5WM;JG9K6^ZDG<U!7JUYQE<T)!P]*;FI1!BQ$HF)S+I8$]'VO;=C$=9!
MMNR3WWD%BU1L:`LUBYMB?@5I?I!-Y-)L'"22S(3N"F!/H`@"`E`H:]G_`,O>
M[?YBNN=QM^J+S?;BA\.[.J(UXW-"C4-[".#4)"G&<&`:534=3N2277YZ?YAM
MH^!NW]9U/A]\%K+=SN=A=SI7=Y7OOM-K*4:@'[.$Q(@@/$ER6#NM`]SK8Q:.
MT/)^R^\XC)?TOF,OXUD7DW&.XY&+/%OF+HZWEH]+UWYK0#J"F"BI2J"`^`#0
M?3+WXGVU7KBVWL6A%>VK2HEJI_=8G20S:<2=&,7+MB5I)V=+[O\`L)DS!CAS
MS9@&#X^A;QOVPKJR#"6=;[&/C;'E;5MB+6<X^?O&,&WD@=-R+M;HM\0]E9S/
MSN0`$XE()@$O3U:^4?CCT/U91ZMN.OMKC?[]T]N9>G<4HU;JI;Q).JUG3/F2
MHTZ8/A\O3#'W0OJW_)G\=_AE\`K>^Z2^(E"-CO&X7)K0W2,?--:@0--*M(C5
M$08E]1?BM96UAIY'SMJ,+H(Q),2ETVT8L4W50E%X!@C<;/VB7F2-^I*,!,WR
M#G,!Q"G'GKJ_@-T!O=/<KOKG?[6XL]IL[.I&D+F$Z%2O4J0D/#&32G&(PTRC
MI((!P7:_YL?\U/1_Q1L+?X7_``LN1>=/&O&YO[N$91HF-,B5&C"7UI2F_F8L
M2,0SJ:]>.S.V<AY=F,RRC=NLK^])9=ML5!2(/M01<:V`5"G$0#RP32$0X5`!
MUTE41\^I6#`SJ2;NQ+?F7Q'$F+0B/V;YK&I_9/&L8(\Y`,$P-'0*TBH":0`5
M4X(*K="*11`M3"3B-*UU6"&![$.Y(XJ"9NRV57??'<(82!8Q=*'^FR\K*@HB
M<R8I1\J10PF*(@00`1'F&@YJ8EX6"DSV/C`(N!MU-".3,T*R:$5#R"4$B+-!
M(I@]40`0`!IX\1U+(*`QQ5)NM:?1G:_E>:2MH]R-(BT)5PY9MQ\DJ3<K<>JA
M2D.4@DJ(B--1+LZD,U&D[+<B9/-\A=#9BM#1-PLY--N45C*J%*J[,H=$JM0\
MPI1'B'(*AI<<42!&6:D<9%?VZD5PFZ1\]=9J)BT`H'$YQH4PA01`:A73.D#%
M+C@HP_>+M$A;]P->:!6J9I55>`*<J"153>2Z0,*:J@%`RE"N`YZ1X*<<21V)
MXGMXP:D9M+Q^@F(%43=SJJY#=72!?:%A`Q2`-`'CZ-2&3]JCAEV)&O<1Q_(S
M>*+Y6B4'CEP_16>"W1J!2I-!-UBH"?$2B)*T'2TQ9R$1/B5\]WUVXN;]W#3&
M2I&UW3B`MZP(1BH]58*^Q"^=I.4U$2N1*)45O`:<1Y:(@OAD$$^$CM4]O&^#
MK-B1:KL$Q3329MCG9G4,HF4YRE,<I43&$I.-?#3.D8C-1Q(8\U!0]Z^L]&,W
M;XKFFQ#MR-[,A4ZD1Z43E,O*H%(14*=`AU5H&@N3SP4X8!NPI17NLF#Y%WB#
M=9DZX6)5[=DKBB8^/262'S%58E`ZXN2*'4]8"C0>6G'B3R16(!`"DO7/:"2B
MI9"*<)K,EVJJ!4Q*!3,C>SA3K+U&`_0(<*\-1)(.H9*(Y$8J')WF<+KRF;<6
M.^M210E"K1#QZ=,?)26;N%I1!$0((D$P>S4*'AH)R;)&(P&:DN;18B-:;5\'
ME(A[8@2T8XZW0`U!=O',DR$.8OKB!#%#I]&DPU#N3QQ3>'>5LFZ;PV-9DN&U
MT7ZA+4B';U9%!%1809)$$7)@,3U@\DI1XF`:!IG''@F`-0":,["\8R#*<NI%
M^SI2[K#J,D!G!DTG3Y904_.*FF;B=0"%'AQX!32'O%LT'WB^3J07<MO.,@WL
ME9[5R*"PLE%))1N90RU5B"4J8D3,4$`2\::9(#.HD9KE[MY:"EAY2[M5JG4\
MX(C<]C-!-4IQ,51,;4N_H*7J$P$!/E3TZ3#V%.6#=X^=;+V![<6Z>Z+N69`E
MHJ01E+KW'WV[AY)EYY&Q&<;$POXATZ2,4ISF.(B!*\!'EIQ`+.,42E(9,R<K
MQNH^D[2EY)B@Q=RB!'<6^++D2,)8X@E*8@><4_0JBH6I?3IAV)&>7H2PU@2R
MS]*@3=^:U8QGW%;`R':Z0D-=C:)B9(A2!QDH)FR24*`%"ARF%,`Y:18DLIQ)
M$"#FIA.Q,@H[.<&NV\<A)`=JH5\R01$S[VDG3]Z0H@F0?-]'*NAB0`,E7Q/`
MX+CWA]H\WN:[9F9%+=2:GNZT+!?W9'P_D%!1=*WS(RSMFHH02J"X;LV9Q*`U
MXART$Y#ZP3#:G.2\_CM@8\7S'W$]@%B^2L0763X]R\33,?K3):\D#Q\05""0
MPD*=@<#@(T"@A2G#41C+L=6%Q"7,XKUK+F6CHIJN\7;1\@9PLE$1*#MNT.#<
MY$S$,I[0HDHH;RB"(]/H#X=3U%G6.0-1'H3`7>VVOP$WL.6N98X3;RP91&X9
M)LR$Z3KVZ1>&>MY$%4U!523;(<"H_),`5II8@!\V4QI)+.D3=B>^+5B]MV9;
M::N&*DH[N,)>-9K&\M!1NHR;HO!,9*@^80Z!O+,/WX4U91A;RB?M,M`[V02=
M3<$X"G&8NRZO?%L2K0@69(69<+*X9%VV!DE''5BG(.P4=*%*)G*13@)1`P"/
M+40`9G]'Z$\=+<0HDG:7PMC97O?-L7M%#7);UEN+S&Q),SCRT?.9.2*MG3@P
M*'%84$3B2H"(G,/4/'5?!3+LQR7HF.IZR;5NIK;<;<-ODF4`*R7A7#]!-<R@
MI`LN)V[@Y"MCE#@40+4_#TZD['!EC9#$E^')-0]Y]2+RIM1O&T).6@Y)NX*=
MQ)LVCYDZ".,W04!$%T4JB7IZ:>&HEG<9YJ492$FX)(7NXL)(XM[>>5KVCGJ3
MJ27O]4\0JZ4,Y;&3CU9%-NW``%6J(()\"TX:D"P)XE6'$X\RGMH*_'REGNKJ
M<HA;C*3EUT702*QP823I5HD+MZ";DJ:ADB":GJCPIPT!F)9DN+Y_0O/L[],'
M$R.\!@O`G2<KW2]M=L'2V.W(N9_-JMFQRIG.<Q4C'.)@$>)BE'0<"K(GCQ9>
M@9LUM6TL>[3MN\9<'S(M<5K8NL[K?M@3=+,?.A6ZX)H.``56AP(N4#$*)>//
M4QAR<!5.\CA@</4E`Y'G+4N;#>7(T[R-7!YCNY#KQ[X4`(#-6)<IF56;J^J*
M9A.`\0YZ1.3<?R)^%V+L/RJ(A[OC*L[2W!YQASO&[6.NN"EVD=50A6YB1K^3
M(@=L8IQ*"GEG`.HM!I0-1!8XX)MR4B3+4!:C9Q8,U*F8RR3X58A!CY@*BDZ=
M.>EPHJ`]0@5<AC=8TXUXZL%2,02PD0E'Q9YE:8L+:]C/:OL2[EML8K=`:W+N
M1S9>BT2FH51M"2,IC-,CEDT,F<Z9$3"EY@%*!0`3<M1J&)DX#!2!?O37V9L<
M9"RM8._>RL6V-=F2;T>[#.PK(Q]H6/!/KCN:39P%W9LFYE6-A(U)=Z]&/B&"
M[A0J9#&!)(PTX:Z3HO<;3:.K+#<[^?EV="XC*<F,F`XM$$GT`E1J1UQE`\0R
M:5B]C^]YU+P2!=E^ZIOUST%U.'N"[^9LT"%EV1U%W;MS#I-VK9%,HF.H<Q2$
M*`B(T#7U!U)\5NAK_IV^L;6^UW-:SK0A'RJP>4Z<HQ#FF`')&)("PJ=E&$Q+
M#`KTA0I2H4X\>'CKXW!<.L_L7W0A&A":JWS_`)]/9K_2IW(_R"MRNA).JZ$T
MV'<'^>$Q_P#H`W3_`!Y%TN*#[J<\TT(T(1H0FQ.\R%>U[O7]/[Q%\4'T?[4+
MZD./<@9CO3%'8YWI8(O7M&FQ#"$BX*]L)IM8;(D0P491CXQ9F:=KM;HD`_M1
M0[!9,P%,Y,(^L<H<0Y,:3%^10<)GD1\ORIW]AFH^),8O4HR5M!G)C%@H%Q/9
M0ARQ\"1,16DVKM4AHX"+@'`W(.`Z`^D")`(R[$2Q/B?3R4)KN/;DH5UO+V[7
MU$#)W!$0FX&S;[G[H8L/:8!XB2ZV+=<B$RT24:NU5$^H2D3+4X\@KI2IRD=<
MY&4AQ)<_Z$X@-R#8*?Y%[@(2ZKZ4/%71:01!+(CG#]FM<#1PHY9NVYWA7B+$
MQ4G)/9>H2J%.2O5PY:<8AG@P&I1+Q+%]0[,DWGN*WOV39F.\U8Z=WACQG,9)
MQ)E*T\6V*>1@H.Y;LFW%O2#$B#5JH+*.;E42<B)E%C@42E&M:4TY"1F:U0F4
M]+`DN?7RQ3)+9N003Z%YQ%TXPO\`VQYOL".SE%I6Y*M'1KK.PC)!E<;9M!3$
MBM*H';NH$SN/4_%O2@8$S"8%.'@.M'OE"M<[56H48B564"`"6&/:O2O@[U)M
M727Q*V?J+>JIH;9:WD*E28!)$1FVF,B_H6TED<&_."$U&W[/LWAI1*1,W>PS
MI=N9$KLKM9NB5)LV5*<0J<IA4H`%$!`:AKDZ,>N3:':*UA2G0\KRQI./B\3M
MDV!'>R^BM]I?Y/KGJ.GU;LW4VZVW4%/<Z=[(FC6JTY-5$I4M,XQ`/'5BPB0Q
M=:YMNZH\VZ2*N5G)-F<5-7T86TM-'&/CDF<JX!%!W(*&%0[1HB*OF'-0:`&N
MLZ?MKBSV6VM+N`A6ITR".YE\[_&'J39NL/BIU%U-T[5%?8[_`'2I6HU&T&43
M_`8$#E@.3!2I]E_?*:$QWE7:+<K"8D;YQQ%W,CCF7@R$NR/R0G;J3P%#6TX!
M%,69HY)NFHD8:=13C^YUNX1@7,@/4O,VDVK$#_3\ZC^GWWI9UA[]QUG/%*E]
M061<EI75:,NTO-6SYFV9/H,P9*R;A)L*#^/.N4BJQ%#4*`&"@\]9U*D)1D2V
MK#O]:F6'>G=-E&^_&';SV,3&`LZ9=LO(4TPR^[NBP+1PA=R5_34?`3K=F669
MW`T*@U3ADX%=H)3F3.<PUKK7F$8Z@<WP58U/AD<T[4_[U&+5]DN1,GPM]*2%
MIJ6XXBX=LUEVR%TEDSG,T-`!%KA[0B_063.D83"4>D-2P^A`&8/-0H+]W6RE
MR;ML0[D+%C;E=NK6O.WIUA;;IF!IY%9@_*5XP020ZP=N7;<#>6`"/KCI$'/D
MK8@1B77H%3/>4VH7K^]%:E[7=(XYR/D.VT9.)@K]C?HY<\:JJDFB]BY!!6A&
MRJKD``GFCTJE-UB%#<+O)C*D9CB<</EZ%4'$0#P/SIJCN@=P['>(H2+L>`>-
MX:2OR2349N(@T<HT5,+8U;AFF\4W!`K-,5BF46XB4.(\=1J^;<@1N)SJ".6J
M1DS9,Y+>A,&3&,<CG^?FF+;,RK=>"IZ53R9FRRI2WY=Z6\&5X0<@C>44_?2A
M1<^4QAWJ!%QEDVJ]2IF$!$X\?3KT[9K#IF]Z&^\NL]EVC==NH7)C3A7G"E7$
MHDC4\Z7BB6&!)#*F,[FWN*IVFZO=NNJM/34JV]:K2-2/$3-(L0SAL#BG?L?9
MAV11&#KEW&QLPUS$_MZVD[IFKQO0OEW?&7(U:F.WMV*MU1P=M#G>R!@(D0$5
M`*`<.0:P-[^)6YWNWT]IZ?-+:]EI0$!"&D0A$8",=(`D(@,[`$8JFPVW;-IA
M`6-*1G.9,ZDB3*<CG*1DY)/,ESQ3&V^W?[;.]VYL9Y"4MB]\=S^+L>.;5MB&
M=2R$U;;^04?/WKJ8*NF<%FQ7A%"E``(!0*`4#7+6]#8CL-U6NY7/WYJ!&'[#
M(8B7`EB<%F$2U=F/SIW+'^X:V;,B,6V!N+P+"9KO&XML;3($?>S>;&1=6!`L
M2.URE9(MG[<SARDDWX`<1Z1'6=M?5G5735G"WV2Z\JC4/F:<P?X.1S94UJ%"
MM_:(0G$8>(`X=CA,Y8UWUY2C-T4(]QD=I$XVOF_[8LP]J7-#-I))_;SZ[X=,
MSQZ>02<NV+A(#G`GXPH^MX\*3W[J_?.H*<9;K<D3/U'8'^"V'8K[:C;6]"5.
MA"-.)&40`./`+U`;\W18TQ)"-K?N:>MR.FF]L6@X;1+IZBV<NB2\:B</+9'3
M`X-:!0H@-*"&N4S>0]Y_EZE!CA$@Z?R+Z.['%+VPIR1"9B6C-C`2*[HJST$T
MVXIM%5`;%5*40/P"OHU)HYOBEB3DHUNXG*V)ELO6/=<$A&O'\Q(R*JBB"`N`
M>MG+A(QCF<%&@E*4U=1QX9E3(#XY!+8Q?N*P[>V/WCVV;DMUS]&C.FDPNLGY
M;&)<,DE"N&RZY0J0454:5'A4-!!.11D$TEOS[@^-+?V@YQ965D)K<[V;,[L-
M-*$9F?(KRSPR9%62"Q"&`A44%>L1&E0'2=@W-,!Y=KIA;MK9@7Q2G"SMX-UX
M&T8HCEZC=:JK5-J@=1R)W8+)C4Q"I`4!,!M(.R<FUE2"\R[M<&I8R;9+A<@V
MU<3$8U)="0B#(JD\DPAY@K&3+T@9,PB'1QJ(UU/PL^<E%R[<%'0WMYH3W:-;
M*O#&]UV9*VIB9XK)RT(I,HQMW(+R#Q#ID0A5DP,=L`(%`J@F`H](A][H/:I1
M&G-\4[IV[<Y0Z^*Y2UYB[X2$>68R;RSJ-6D4UWQ&SXAW!2@DF8Y"D=`<1'T`
M.D%`GAQ6IL\[DV-Y*Y.86.X3NQY;]EOD`L^/!NZG7[AZJDT27C(LOXQTBF9Q
M43"/+XM`(9/NS3ION[V[BPXS"^:<$W5%(Q.2[$2@I]2/]E:L+B.D@"P/4G2-
M/:A,Q%(1$IQ$1KI_5(2E@7Y*5G:V?<=JQ45<"!712S*+=#RB$`RC,R:=5E5R
M!0`$]:Z4F(48@@XY*%3[UUF#%5[9-PE:5MF0<7BA#LW;U]3R#LVB;J75*9U4
M1`R0`&F6P;-E9`%R>"3'VI.X9C#8'@.=LC+F9X6X8_,,HPG8JTL;LY&X+@MY
M%%ZD@\&["F12CH]$0HKU%-7H*(CX:G2K"T!$L2?IP^E$@Y?)N:D/WIW*-LS/
M;BMF]CE%DG9B;$6JDJT,V5=%?KI+F%L6+2JZ]N,"/2)?`0X:J+2^7-`&+#WE
M%=WA[W,5[F<CX;=8QRG<<TO;\H[?GQXO9;IJO+/WC5\V%RI..2T*=!JL(@GS
M#GHPP38L20I*>P?=A9RFRZW8=.:;K3EJW++VP_3'RO:V#Z.;L4DV+A0Y:!Y1
MA$##6G/4@V?%U#$'L98ONMWLXOP]V_MT4C>K^UYQ>]X"XK)@&SB39R2TC=$P
MR>HMH!G'%*81<"98#UX"4"B(<AT!F(.)1B9ALE$_[<F[:`V[[H[!?R\B>+@[
MLQ\:/>-F$:K/"VE7C=<T?$I(M2BLF8IT?+]2@U$!#41@74S$@$C'%/"X\[T&
M!CWUF&%B8N;M_("D=)PN.I.ZUAMV"G+H7,Z:`R7?KB=>%*@L4#`*Q:B(\-/M
M;%E$Q.!X)QGW2VY;RO6`[E5UW]($E+NG-QN/WLX_2=%>-UWIH"]2G!JN3@NT
M3`M$SB'KEH/.NEQ]!^9.?`\V^=8Q:7<TP?L\W<]P3&V>]T=N,K<?YSO>X[9@
M;?;W2TO"TYD\?&(DA'#8(I6-DDWJB(=92G]7Y7+CJ0D`P?#L2E$DNRW98O=@
MP)<F,[GOC'E[Q5P6\PBIA]<,L,LE%@R;H-7"SATNT<)%5^<%.@>E/I#K,%-(
M,`2$'/N40S=]NLQ]N\RQ'9Q:W?*0BN.[G<+,<;S+.LS=D854Q%I2UI=O1JJL
M9%J)BE.'B&D64VD'Y*2/VE^ZGC/*N/QQ+'S<[:-P6&_EGK:+F"I.)5Y"/%T2
MMWJB#<HIB6HB3K$:>H:G$*:8D>&!"C*+$ZA@4X1NH[QFT^)P3G;;DQW!8KC,
MKR&,)>U$2W'.KLF\9<,\BK%K/)QTU9.@HBFL(F13`3E,/2--!QSS41$OJ&2@
M[=O[.6-MG^[W#&<K[NU59YB*6R1,QCVW$3OK;O`#O)$J*$3(F0;OV9Y%5R44
M502`!3&AAXZB"Q[%8Q)PS/Y%.CV>]X3".Y[$EZY*B+D>+OQDFJ]W6?,K-FDE
MCQ`6GFN)-4KG\7T]1A+YA.GAQU(,`>7S*!!?'WOE@D>;RN\'LLR?L<SS@&/W
M(6(EDQV]2B8=)Z95\M[**JS@B/MK,BH2+CJ2,B'2/J=7.@Z`(Z,SJ007<,RC
M)=M?N+W7MYEMPB]XMY:X+$2LJ3=L5;?19MTH^3!V1*':',DEU"F^4,4H5'KJ
M/$-)@^.(92E$8#BMD17?)S.]FL@1-ZV@>W,=9"Q]<&/F1;->,%;JL)S=,>YC
M!O5@#Y`&LM,,&;@A_9A.!O4J`\=-R^/)/1AAS2/-F^9+#VU=Q.RLNV[EB\TK
M4LUVP5M^[G%O*NKFO=_)-&)U(F?C@45]C2EGBZ@+'J?H$G(.&C'2P3,28]BE
M>9*[M>RK.>XY_!L\DE@KS=_0\R%V3+@T)9[UT,:R-,1$;-)&!1N^BU4CHKD.
M4!$P#X#I'2[<56(RS+9)OKNR]R3&^/[OD<'8W;KY#O$($R5TOHQ[Y=IQH2I*
ML4#*KE*,LH*`B8%:5,''QU93;S``R8CJ#G`!4/9/[I]A;$\"9>A]PN2L>C;-
M\SKNX[/QF9\ZDKRAE6AUE'C96`"/]G!J]]IZ4`\TH#4`X:=7"7A3(!(;$#!.
MG7WWJ=KF7L&WCD6SI9.3CK1A5W3ZW73IQ&2,,_5$"1\=\S>32/5=.#D`IQ"M
M!XCX:KSS46E$L,`?:HBNY_-Y]Y=Q8_R-8$'>7[\1+DAT)JT9?V%Q`QC*WGGS
MC"3+&7'V<B4><ZICKBJ`%`I!KSTBS=JDVG/-E)TVX]VTL?*EQ>Y@5)W%.*\0
MVN7+&XJ#F?,Q[;M_-XQD>=@ES/$"ME_FYZ51N(MCF$#HF`"A0:`S[&42#Z4W
M3OQ[_$W?L_<UH[7D9J4AI&.<P,E?3YR6+8OV*T8+59*&CRMSJ*-C*@82',4H
M'H(UKS..&2E&&`)X)/7:VWC8YVPQL!E_*EX&:1]M/@MNZ8R/:OY*:3<R@F5`
MSU-,"]953@>E:\AU*!\0;-!CB0^*>PW<=YC!UNXAA<O8DF(K+T(:4;_-]K6T
MZ=L9.$>*BDZ.E=9UVQSQZ9O&E0`*^C63.(XMW9>M1Q?3Q2X.WANL3WF=JKN*
MYY"'N"W#W07-B:T'.R;631C#,<7I-01B5&J#8"L/4K0Q`-U"-1Y:QYC%#:2Q
M2P>V4'^.7N8`:#3MS=GOQJ'_`'D;J.0CS#5:.*?0IX>&A"-"$:$(T(356^?\
M^GLU_I4[D?Y!6Y70DG5=":;#N#_/"8__`$`;I_CR+I<4'W4YYIH1H0C0A-C=
MY$R1.V3O,463(NDCA.\%5$#G$A5RIQRQS(&'P*H'`1U(9'N1R[UY@;[>A?TA
MB9]A^P;/Q5@RS+FA(V#O0<8P)&%V7G$M>/L%UW,LLJ[D2J._7]!0'2QR&2DP
M2@,D[J<SP?;BQ-@^9R+(2C')5V7@\+[:X77F2XWMPT>C'LC2X.@7736>#Y=#
M<!`.6C')``,WXIMR*O"_6%KM+69W?(LH"+E(FXH6.4D5%D8B7B#&7CY"&3%7
MI8R+9QT'`X@/2<H#X::D=+\5O3%&ZO-V.,WVWF=#*MTR%QH/F[*X9"6GG,BG
M)0RADV[QJ^;%5(FJF5F8P@'$``*5T:CF'=(B+8A;,[@*T[<NY&:N&]9IM<[>
M;@822L23&I(]6S9-)1PR=L2E6,`$35<'*?B''2)+HB2(D!(RF`.M$M4DI$SL
ML:=91ND\>"X4(5P!CG!`QU*$;EI0A>(@%-,9IQ..(5U;/D0:I"*R'%$O4/FD
MZ@,`?)H)J^G46(*CBZM[Q%F_:N"&=(IF6(9,IO-2J`CX\1J%=&*8<%\62B^W
M8G(L=Y.'DV2WE&8S3P[KR5"%)\SH,EE))<R@&Z`3%J!A,(C0`YZL`):(S/K4
MZF,!WI/QWK<]XR)FH-3(&N&:.0I0)Y:K965D"IF-U&"H@B(<>0ZR+>%<QD*6
M!#.JY:1GR5J9'C&H51)&ME`543,*!$42E*10>H#"01,H)N5`YCK'GYXE^V?4
MF7*6?!6XO$;(LN3TU%,&D1>%^VRG9SHR+0%7KEH14'CF.4(<3>6GT_C>%0\:
M:G&J:=/M2X@G$I'UJWC-V+<<'==LR#-A,VN=56/>@8%%".C)F(+AH!5`\M4@
M*B`"6@AJAS+Q<5-N&+E;7QB+S,.X+&Z5W2XW`]G+V@0FIF=D59)PLD649.I`
MA5WBAEC`=$A@(`C0A:%`*`&I*+:1CQ67;M;UB[WW%Y!EV!R),6LTE;D8BHMU
MHMXZ$8(Q"?D(K#T)%HUKR`>(ZBB+A)VF2N'L4WAXA8RGDF.JG'M"E.J\646Z
MO400`3")C#7U2Z!1$BG'`N4XA"6@QP=M#E&N7[>5;RVXBY+>28QL>"2DY:-C
M0J(N5KF>IE\XC5X^,YH1NMT*+%"@E$-29L5%_%@4@>;+!ED))M`R?MD,W6<(
M0[Z1*FU?*-3@4&Z[QFGY:21@`*4*`"&DAB[E9YMMNH8G(TI;]U7R\@6-UV;)
MV-'W!(2;I\C&ED$5BL61%2F/[*Q>N3%2$OR2`<:B&FQSCFIR`(!"K[3QO>5B
M[@\46_<T(YBWC#+V/13<4(Y8R3%.ZHXK1^UD&1E6KI%TU-UIB)Z@(B'C36;2
MLXU*$JD_>$20.+J&L`L>*DJ^\.W)<$5O6MN.B9R1BVI\!XK7!!F^,V(54L`W
M/YP(]708W5QU@2+E^*@!@'36<UF;,5X[:%A7R3<\@QLNZVD+<S!E)JM`&"?M
MDRQJTBNW."[A,RJG3Q]4!IH<MCDE@%J2S,_W7:,1+L59"2DB2<46/C7#^:7.
MK%-U4S$ZV!CG$W09(P5#CRT@0^":VAM_S*\+.RUD/'\D2W;X@IZ/>,6TR=!L
MO))L%G+9V\;D$2KF,LCQJ'$!'4P>":3?;&Y.6L6TLH8Y<VK#7-`7TU?PSEF]
M<I*-XN304Z$YUN"QA#VQOY8<0"H@&@<N"!VI#-TG>NHF&8D>+BPB2K`JS^<>
MM@FHHH53S_90.4HG.`#X<*:!CB<U;!L76U<,W!%G?%Q1D2[IF)Q'=Q#-WK6.
M>F/'Q4TX+TQ\FHT$51%$7(%`X``\1KPT/Q2D,I!W=:9R-CU3'=Z3EG.EFZRD
M&[,BUD""0@/6(A5HZ+4PATKHT,%/`=!R<JV)<.ON%+CDK5RO:;E@^=LV[RXH
MII*HLGQVA)%@Z=II+HN#(F`52"4P^KXUU=&C$PU.`5&8CI)65YQ;J6GG2_5+
M9>OHU5I<95&,@UD5VSMJ59)!RF*+XE%"@113IH/#G7630I%G8F+'%DX")ABR
M=JQE=.08G"T(YLA"W-L<7<A5#99W4W$Y,6_+T3.=(XPUO%,Y^=)&/!(W08J"
M8F.*@^L(<L?1'SR265`9EE60>\AN'M"Q7>)L)W@@$=%)LXLV9)$ZY[LN6-8%
M!!4J#!RN0K%O(E()ZB0#%`0KXZIJ>]I"!$$XA)$SQD6QMY$"7/-^9(DH3.MI
M6M'P<A:\P^/(0MXM62Y$!=P3XY1.R?G!4RBJ)C]-2C0*:C\Z?B!;@M08!PH]
MRE-N.A]'VU9-L)A-7U>\@**$3;T$V*91>2<B"A3NWIRD$J9"=1SC0``=#$A(
MDK9&X_-&/+P:6GB3$#95+$6,4ERQ4Q)]+&5OR?<AU2MT24:4B*2*#APHH+,J
MA`.FD8-'<@!B&6F,3V]/WI?,#;UINTFMPRLB#",=$73(9NZ<&31!QU]9>@$2
M'ZJU"E.>@)2!]*VQDO)]S8D^?=O&+,JSR4/;EPRKC(-X0\B9H%Z7@L=-I)E:
M)D$I4F#$$1`A_6ZNK@(TU++`*6!#K&<%[DW6(T+ELN]+8@,V8DO99<]SV#?Q
MTY<`E5DUD27-;L@X.!XFY2><)B+!U4$*>.@29-G2-E[C3AL@I77:#4]LFBIU
M.0MYL#P#NX9NT="I&,CNRC0QVR)`*<P<Z_9T#)6X:6.:5!G(EGY6M9+/%G-B
MQTLH_8Q.8;<`Q!8,+D=E(#2XXP1`I@;S*J:AC!ZWXSF.D(ZZD1P=0B2)8J9/
M[FLW(WPKOK\ORQ15R[B`4P(<AC#Y=J7@"AS%`:IB8PCS#CSU?<@>8)`_5_*H
M3EJ(]"BR=UU-F3N7;W^L6R)E,]WAYBJ@I&`"=#$!ZRG,`@`#X\M8^*9)T@!:
M=@(5C:.US+-RSC=O$%R1-6[`V0U=ID1=2JD>X4<RLDR1-14K--(2AY@E!,15
M"AM&*/KC'@DD0*#9,PO57":8DZ@02,HF-*\`,;CRTRIS/`+;>&<IS^&,E1]]
M6;,N(.58.6!7JS%^5$DM"N'I5)2*=@4P`9`S4IN%>9OL:`[J))TMBLGW*P=N
ML<_95.@+==K=%RC=K114Y3"5E=:`3+<&QQH(D(5UP-31)`);!:+EDTBL&"35
M5NH6'3<I(E7\E94R2YA5.`CU`)J"?A0/N:$Q[V/%+9PY(GLC9KN0OR&G74-.
MW;<^/L412<>N1JDLR>IFE;C%PF40%7S&!>GB(!H&`*1][%(C:0<$S2\A95FX
M#J,NHNH1$5Q5'I,3I$##3C41IXZ6*)2D^"VQ@Z\+5MNZ[ML[(\D6/Q]E>W5K
M:F+B:)'='MAT4Q5XB=5:H"95PDS<MRE5(`5,0PZ;',)Y@%4MZ8'OR(\Y\Q)&
M7M`E$KAE=-ERC6;CGS1,W%Z1LV<&E6!B$+U"D<G4->7/631MC=/]D>+/PXC'
M\BCJB,UA,@+`)4GFIM47:35@90AR^4LF86A"B4Q5!`Q#$'@("`"`\]8^FH!B
M"V*/$S<%3N0CGB*S9<Z(I'$Q@/YJ9E4U*>J=+B-#E'B`^&HH<A*FW,=%S1>V
M>_9%5-"8G\"P#*<435(1:24M]TK'1SY41$3&\UF0`^QIR*0.8"2XHG&@L3V7
MR#.US"DH"(E7>*E.(%.1(B0F.*QZT+P'B.HXG-,&0[DO.S(AKB;:;F^XKU<$
M@KAS.[MVRK!LY]TMI>:8PD@VD9:Z5F1Z+(QS8QS(D%4I.LR8B41U(^ZHYL."
M2M:UR7&UAYRS;;EV,>E?)6L7-JF6005%KYJ)0*$@=0OE-"F.(G+6HTU$.AF+
MD8+<>X62N/'J4!MB^<T6>.\>0\#.!!Q[A(&5P3]T1"%PO[AF11/Y4FH962.5
M$W$.DPU$1U(D\<T\<XYI,P+LA413(J@@0RZ95E4O9B]"!C$%19-(M"G,4E0`
M@U`1IZ-($@Z>:&+N76^-P^6,;7G:V.\285LQG9>/\<L/G.=N:2.D:\<I7W(H
M-&\K<%QK?BB"R3.S_M='I#RBF-3Y6K*EO&CIE'.6)4A+#%:ZQ9F(N,UKCAW4
M/'W38M^LTXN^K5.N5NK)MD3*%;/8Q^`B6-ETO/4\A4Q3EX@40IITJ=O/&\!E
M2Y(T&04X7LEM,;-.QYOF5QA.SLW;CQMG9T9*XF*3*1B')\<T-&JG1(FF[\D"
MA^-*``?GZ1U;7I1A,1C[C8=RB1(2\7O)T;MG*I(;QMSBZZB:**/;A[/RJRJA
MBII))IV-NI.HHH<P@4A"%`1$1&@`&L4X'TJ)S*>SM:[K4OB&;W%95S6_=]ON
MU'"32=MB9CI^&=*M%U&KI-O*13EVR7.V=(G34`IQ$BA1*:@@(:2%>'#UFT.T
M3=.VS91^Y]C8D<+IHF>.Q16<@U:E4,45W(MVRBG06INA,QJ4*(@(53H0C0A-
M5;Y_SZ>S7^E3N1_D%;E="2=5T)IL.X/\\)C_`/0!NG^/(NEQ0?=3GFFA&A"-
M"%KK)N,+%S%8]SXSR9;$9>=B7E&O(:YK:FF@.XN9BWJ?DN63QN?U%45DQH8!
MH`@.F"P[$9)O1/LG=J],H%)LCP:```!0+08API3ET^C0Y[$''B5>97LY]L^<
MBK;A979OA=_%V@R6C[99.+4:"A$,7*I5EV[,!*/E$44+4P4XZ3RX"+(?M*M?
M\RAVL/\`D38,_P!R++\'1JER",>976?LG=J_H-39'@NM.06>RX_!P+7CH>7(
M)DDYDK)K@[0W;=N]I;+&YMH&&I=O:,0$)`$>6JT5^;XHIA.DQ24.7S`;HF$>
MD@\"UX:'ER"3XYE8[_,H]K$/^)-@W_<@R'_4Z-4^#(QYE'\RCVL1_P")-@S_
M`'(,0_U&C5/BR,>91_,H=K`>>R7!@_':#(?]3H>7()@D<2LDM'M"]MO'LXE<
MUE;/L,6_/HLI"/1E(^TF2;I-K*-Q9O4"*`0>DKEN<2&^`>8:<92C4C4#"<<O
MSH))&)*Q%'LG=K)$Y52;)<(`J!CG\P+09@83*&,8YE*UZC")AX\:ZN%Y7%24
MXL#-GPY9)$/Q*^#V2^UAU`(;)<'!0W5U%M!H4>L3=?5R'C7QXZHU5)$F1<H]
M:RV1[1';@E+4A+$?[0\/N+/MYXY>PT`>V&QHUH[=J"JX<E0(7H!14XC41"G'
MGIOAB`Z7I*Q;^9*[5OK&'9'@P1-S`;08#3X:`6FEJER">/,JNA^S!VP8"583
M</LQPE'R<6Y3>1[QO:;4BK9TB?J25((%*/4'IT:I<@C$\2N+_LO]KZ6DG<K(
M[*\(.9"075=/':MHM#++.%3]9U3F$@@8QS&$1&N@F7((=@SE998G:6[<>,W[
MR5LS9WA&'D7:?DJ/$K*BUERD"M#MSK(J"V,'4/$GK:-4N01CS*XS':>[>MQ1
M\G$7#M3Q7,1\O+$G)!&1M])Y[5)I$,F1P8RHFZ.DB@@!2B`?!H!EV(+NZPT.
MRCVL@$:[)<'"'PV>QYUKP`"_#H>7((#\RN"G9-[5IPX[(L&^(<+/9^/CZI:U
M#[&@2D#JY<E+4>96Q;6[5W;]LEPP<V[M7Q4T6C%VKF..>VF[L6*K!8KEF=J+
MHBOLYFRI`,GTTH(<!#5HNZL9.!P;+FH&(/$@NZSC,G;VV:;B[K2OS-NWK'>1
MKM;1;.";SESP*+Z02B(X@(LF"2JQ>LC=LD4"D+R``"FJN..)_*F7)=\%@D)V
MJ.WK;T;/Q$1M/Q$SB[H0*TG8\MJM3-I%%`!!$JZ1BBF(D``,4W,#`%..FX8X
M!DF?B583]H#MKG(BD?9UA91-NF":136FR,!$R\`*4PE`U:!\6J8TQ&J9#(A,
MMVJMB^T=VX(5^A)1>S_#+-ZWZQ272M1D4Y/,3.D>@@40#J3.(#QY#JY^(`=+
M`9$JQJ=FCMAK*'55V8X3,JJ=150YK19B)E5#&.<QC=%*G,:M=)Y<HLCTE49^
MRQVN#@8#;*L'&`XU.`V@RXCQ_P#2N//3U$\`C'F53_S*':Q#RA#9+@VJ9BF(
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M:M0^AS$*B(<^)/ATW+9!TL>975_,F=J\$P2#9)@T$P'J`@6>QH`^F@!6ND\B
M,@Z8<%W*R]GVC.W#'VG+V3'[0\/,[6N!9NXF89O:K1!M(G:G*=$KL"E`RB9#
M%KTC4H^C3U29F".+N5BI>RKVN*T'93@^@4XA:3(`X!3IH)`Z@IXZ'/8@]A*R
M.V.T!VUK)EF\]:^SO"T3+-%!4;O6UHLB+)&,`%,8ABAU`8`&M?2&C4>`BECS
M*L2_9=[7KYXZ?/-EN$EW+M=5TY76M)H99=PX4,HNJJ82CUG.<U:B(\1'0YX@
M,GPS74;LH=K$_P`K9-@S_<>PX_\`H!TB3P`2Q'$JE5[(O:H6#I5V/X).%:^M
M9S'PXA3I)7GIN3F`F"7=RKPU[,_;#CX29MQGLNP@C"W"#4)B.+9[,6ST69S*
M-17(``!A1,8:#X:'(R`1VN4I3;-LLVQ;.8NZ8/;-A:RL-Q5ZOF$G=+&RXM*+
M:S3^+0<-8]R](A0%56R#LY"B/R0'APTG)#'#N3=\>*3_`'SVBNW'D[(%Q93R
M!M"P_=F0+MF5K@N2Y9BV&CV2EYA8R9EGCQ=<`\]102@(B(T-31J898HQYX+O
MO7M'=N'(KZ.>WEM!PU-GB6"$7&(N+2:%:L&2`%`J#9L4"-DB%`A:B!"]5/'P
M;RS:*BS8.5B@]DWM7^&R3!8<*<+08_<Z0#0YXLGCS*ZE.R5VKC@(?4CP90P`
M!O[CV/$*\>0"/$-&H\&=#GF5?I_LZ]LNZGS:1N#9GA63?-(N.A4'3FT60JEC
MHAL1I'MS'$@=16[<@$+XT#2U2XB*/2591[)_:PI^9)@WCS$;18B/IY]->8:'
MER";GF5>2=G?MGEM5W8Y-FN%OHH\FD;A=0IK1;"R6FF[86J+\Z0D)U*I(&Z0
M$*CIO+(B*3XX$JR$[)O:P`..R/!@<``*VBRY`'H`HT$-#GL0>\K@KV2>U8?@
M;9#@HP#S_N09#]G@G41U$OQR0#WJZ0/9J[9=K/VLG;NSK#\0[9F`Z`L;;2;I
M]0#7UTDS`D<H^(&`:AJVG=75!_+(,3S00)9DKY+]FCMAW!*OYN7V781>2<FN
M9P]=JV:R*HJH8?E<$RE*`4X``<-*56I+`H8<RK<;LE]JX0$/J1X-$#`(#U6B
MR$!`>`U`"UXAJ.J39!T/VE7J<[.7;.N=&#0G]FV%I%&VX-&VX-%S:K51.-AD
M#&419-B]!022(8X\@#2>7$13?M*RBR^U#VY\>+(N;1V=8+BG;4Y5&KHEBQ*R
M[=1/B0Z2JS8YTS`(<!"HZ>J7**3=I5!>_:1[<N2I]6Y[[VBX@N6<41*A\X2=
MLM'!TT2F$Q44$Q`$T"`8PC0A0#CQXZ6J?8GCDZPQ3LG]K$Y1(.R3!]!`*_W)
M,P`0`P&#B4*]0=-0X<Z:'ER"`XXE9)<G9Z[:-Y22,Q<NSG"TM(MXN-AD73RT
MV9EBQ\0T38L&W4):^6W;(E*'/@&C5+E%1QYE6+^90[6/CLFP;_N19?@Z-4N0
M3QYE<3=D_M8&"@[),&B'_P`D6/[9=+5+D$8\RJ8W9'[5@C7ZD>#`I2@!9[*M
M:@-1$`#D(!JR%>I#()XGBLFS!M6V_;2>WWNUQYMRQ7:6);-D,-9:GGD!:$:E
M%Q[J8<V7)(K2"Z2?JJ.3HHD*)OW)0#PT3F9EY9I9G%(&V?65-9%S=O3LJW5F
MI)B>[9/9_;,VT@NJTC)CR;0W0.W%M2[I%-<[:&NEJV/&O%/*7*1LZ4$R*Q0%
M,T4<4J^^,4[P;AORTK[Q?CBYL+0$`YLJ<5Q?$9DM&$MOZ'V7/7+*WYB;Z)V9
M<YK`>7IF"="%D6<ZJAY;:/;N&3M^U376:K"%IBR=GF\IX]L[(&5WN5)F5+F^
MYLC739*6YN=>2D/;J$!CB%Q$RL\ZE\$L>WI"R).9NMW*HQRK5M-,4E6KL7R;
ME!N<="<ZV:V1EG'N"("V<U+RSN^FTQ<SAT]N.[Y*]KLD(UW-O%XF2O"9=W5>
M44E=4BQ,5=\UA7H0#1=04XYNU;%3;))"5/H0FJM\_P"?3V:_TJ=R/\@K<KH2
M3JNA--AW!_GA,?\`Z`-T_P`>1=+B@^ZG/--"-"$:$(T(1H0C0A&A"-"$:$(T
M(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A
M"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(
M1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0DH[[/S+]U'\`>4O[SY70F,T
MU;L'O^S<7;GMV%]7_<#*V+3@.V]V>',K,O\`SC(-B*V=NC;()D1;).';MTZ=
M+D210134665.4A"F,(`+*1S*<C_G'=EW_GM9?[B\D_\`B;I(1_..[+O_`#VL
MO]Q>2?\`Q-T(1_..[+O_`#VLO]Q>2?\`Q-T(1_..;+O_`#VLO]Q>2?\`Q-T(
M2/=Q^8,:YRW=]F>^\4W8QO*U%=WFZ6&"78(/VI$Y6%V*;F&4K'N&DHT8OVKM
MBZ()#D52(8.`\A`="$\_H0FP[@_SPF/_`-`&Z?X\BZ7%!]U.>::$:$(T(1H0
MC0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$
M:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C
M0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A)1WV?F7
M[J/X`\I?WGRNA,9IB[!GYQ62_P"!#W;S^.#*^GQ2.93J[G>-?]AV&RS7D"&M
MNZ,>9)92-[6;95@P;N"O/$&*+,:*N,@7+DF\+FOR2B,DW#$)O8\XQ</"0CE%
MPHLU3*\%(7`IL48\5@VVON2.LI'VSX]G\3W5)7[G*WX3V*[XM]:K*UY9>W+2
MN!UF*]5XL\F20MN"M:[;)E62#-0AW3X10.W(9-3J`8(6P(W=WE"T\\7MB?*E
MJP0O'ES.9BQK780S>Q"V9M]M^2NA"XLZ7?EVY\I7!:^0852$B$7P,6<+;4@P
M63=-10=>65R(R'*3W:/=WM^=RDQMA?"V:UD+E>8_MT+-C,97O(7+C]1W>-^0
MMXY$N<$+3+(A8ZT._LUVU<NFS)CY$B90KD24,H,$<%JG(0UWR]O`W#CW3=^/
MVOJ)9\IH2XI_O0FFP[@_SPF/_P!`&Z?X\BZ7%!]U.>::$:$(T(1H0C0A&A"-
M"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H
M0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"
M$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A)1WV?F7[J/X`\I
M?WGRNA,9IB[!GYQ.2_X$/=O/XX,KZ?%+B4L&#W@=LB^;W@6MRXF&T9+(Y)'+
MTM+7_:UML8J)N>U[NNJTFC"X8EA>$N[6O:YUT#23:+C8]\,I'RK=TX()CJ@B
M8A&!2TX=7MV84>8_R&RN#;#B61NZ,:RF,)^:NFQ+%?R\6V@UK0(K925Q2D6Y
M!!&(F%6+E)FF40.X.1<OG'-5(6J<EW=LAM#*^1[+'"\9DO+\#=F-KNN>%M8;
M`DKRE<E9,ENBR(4C2[;^@)5LXE$KF%\H9V5I;(-GG2JX%94$#-#X)06*MM.T
M:>M"P\CV'@^Q&45<[6T<IVT]5MQ%"6,=['C/6V\D5%5'#E51FWFA,#9515!,
M_2'2/E)]*0FQ,B<-\W;P_P#RIV_'^0EGO0EQ3_6A--AW!_GA,?\`Z`-T_P`>
M1=+B@^ZG/--"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A
M&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(
MT(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&
MA"-"$:$(T(1H0DH[[/S+]U'\`>4O[SY70F,TQ=@S\XG)?\"'NWG\<&5]/CZT
MN*<*@]FNR7+-\[=9G'&:1D[PQ"P;Y2@D+)NJT95WDV.LB7LK%J]ZW0V^:WYW
M$;%RN*64"NM&@Q;D<MU$Q`%Q,;1VHR2L'VQ?;W<ML8_MJ^8:Z;R+C(+@"U9,
M^0K^L]V@6Y+E=73(`^;8\N6T(N4I(N`!,7*"HD33`M>)^I(6@MU&W;;K$9,9
M9MRKN3D\$3URW9!2F,W3MQCAC'0F8H:,L6%3NN(7NRU)1Q<[]U:^.XEH:(EE
MGL,D"2CA-L1=9143YT,E28HS+MGMJVL68BL3,UBS*<>0,,V''ENV*D)F=F,7
MPS*(DX%($%2F?3T4R:IBZ*4@#U&`0#U@#1VH34>1/SYNWA_^5.WX_P`A'/>A
M+CZ4_P!:$TV'<'^>$Q_^@#=/\>1=+B@^ZG/--"-"$:$(T(1H0C0A&A"-"$:$
M(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A
M&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(
MT(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0DH[[/S+]U'\`>4O[SY70F
M,TQ=@S\XG)?\"'NWG\<.5]/CZTN*W]?O:=RO&VS'&Q+=%N%GI?%$E9EZ,5+@
M3MEU&2RCS&%S0;?'%T2]B9$C;=C8_*UFO;L=.EH1=RNI(.6:`-CK(O6@Z.U+
MZ@MK&8'6*\W6#(94>X[N;)LW;LK:&1;,N>_I*=QW!1<V236L.+6CKHL.?3B4
MG39\^*LRE6!#K7,[;^0#=N4BX>Q&:S"`VR9"AL*XYPI<^8IS*R$=E&.NO)%]
M7>[NIW<5SV?"33Z^(^U"_3"\<A3+IJ\N:,B8YTDXEC(FB3.`*!0Z4#(>U"1[
MBS8?GBT,J6Y>DTKCL(E1KMRL>X$V%SR[EY$6MM:E\+2T#=\>DK:S9.:D\GCB
M(R:L28[0L!\X%-[9(>2)5!"T]D3\^;MX?_E3M^/\A'/>A+Y>Q/\`6A--%;HT
M]R.*NX#C;<?B7:Y>&XVQR[5+AQ'-EL^\+5M9U`7.ZR>6Z&H.@N0U72*\940\
MLM`'F->&@`.Z"[,LH'?)O*_599T'EQ#+^*J5IQI40&E?@#4VCS]B6*/KR[RO
MU6.=/ROXI_"T-#G[$T?7EWE?JL<Z?E?Q3^%H:'/V(1]>7>5^JQSI^5_%/X6A
MH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL<Z?E?Q3^%H:'/V(1]>7>5^J
MQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL<Z?E?Q3^%H:'
M/V(1]>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL<
MZ?E?Q3^%H:'/V(1]>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS]
MB$?7EWE?JL<Z?E?Q3^%H:'/V(1]>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.G
MY7\4_A:&AS]B$?7EWE?JL<Z?E?Q3^%H:'/V(1]>7>5^JQSI^5_%/X6AH<_8A
M'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL<Z?E?Q3^%H:'/V(1]>7>5^JQSI^5
M_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL<Z?E?Q3^%H:'/V(1]
M>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL<Z?E?Q
M3^%H:'/V(1]>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7E
MWE?JL<Z?E?Q3^%H:'/V(1]>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_
MA:&AS]B$?7EWE?JL<Z?E?Q3^%H:'/V(1]>7>5^JQSI^5_%/X6AH<_8A'UY=Y
M7ZK'.GY7\4_A:&AS]B$?7EWE?JL<Z?E?Q3^%H:'/V(1]>7>5^JQSI^5_%/X6
MAH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL<Z?E?Q3^%H:'/V(1]>7>5^
MJQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL<Z?E?Q3^%H:
M'/V(1]>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL
M<Z?E?Q3^%H:'/V(1]>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS
M]B$?7EWE?JL<Z?E?Q3^%H:'/V(1]>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.
MGY7\4_A:&AS]B$?7EWE?JL<Z?E?Q3^%H:'/V(1]>7>5^JQSI^5_%/X6AH<_8
MA'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL<Z?E?Q3^%H:'/V(1]>7>5^JQSI^
M5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL<Z?E?Q3^%H:'/V(1
M]>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7EWE?JL<Z?E?
MQ3^%H:'/V(1]>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4_A:&AS]B$?7
MEWE?JL<Z?E?Q3^%H:'/V(1]>7>5^JQSI^5_%/X6AH<_8A'UY=Y7ZK'.GY7\4
M_A:&AS]B%IO<3N:WMYDP)F/%$1VP<TQDKD;&UXV7'/WN7<6G:LGUQ0;R+;N7
M)$S`<R"*CD#&`!`1`*<.>DT>:`D-QUX[=]O.ZO<#BO>Y=.1<0-KEV6=I)O:D
MU95O9><2P9&VW_O\3TT-O7GB:UKB-&2ECW8O$G5JLF"@+%*`'(8U%QP2)#I1
MGUSNV+_R_P#?!_NCWI?\&NA+#FCZYW;%_P"7_O@_W1[TO^#71BC#F4?7.[8O
M_+_WP?[H]Z7_``:Z,48<RCZYW;%_Y?\`O@_W1[TO^#71BC#F5K&+SGM(REO6
M[5F.=IF1<G9;<6ANLW1Y<R=-WW:^;W$VU"\]E^X:&<7+<MZY1LZ#1<%?3\BT
M9HD]H$2B=,A24TDW'!25]":-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$
M:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C
M0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:
J$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$+__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>v367027_chrt-line.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v367027_chrt-line.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!1`)&`P$1``(1`0,1`?_$`.@``0`"`P$!`0$!`0``
M```````("08'"@4$`P(!"P$!``(#`0$!``````````````$"`P4&!P0($```
M!00``00+"`X'!08%!0`#!`4&!P`!`@@)$1(3%!465I;7&%B8&1I:(>76%Y=X
MJ&DBTB.4M-57V"DYF=D*:C'4E;6W63HD-G8XN$$R)3>G>4)2L],F46%#-#41
M``(!`P$%!`4'"`0)"@<````!`A$#!`4A,5$2!D%A$P=QD:$B(X'1,D)B%!6Q
M4I(S4Q87",%RHC3P@K)#TU2D-5;A\=*#DZ-$E-158W.S)(0E&/_:``P#`0`"
M$0,1`#\`RCA$Z';K<4_7F5MDGGQMN*5#*@A[1S+$)!E,+9:65)O`(K*[65)/
M.`"*LD@CEA!+.;('H<,;!!A@X6Q_[:`M2]7GVG]H-XOWG"R+X3J`>KS[3^T&
M\7[SA9%\)U`/5Y]I_:#>+]YPLB^$Z@'J\^T_M!O%^\X61?"=0#U>?:?V@WB_
M><+(OA.H!ZO/M/[0;Q?O.%D7PG4`]7GVG]H-XOWG"R+X3J`>KS[3^T&\7[SA
M9%\)U`/5Y]I_:#>+]YPLB^$Z@'J\^T_M!O%^\X61?"=0#U>?:?V@WB_><+(O
MA.H!ZO/M/[0;Q?O.%D7PG4`]7GVG]H-XOWG"R+X3J`>KS[3^T&\7[SA9%\)U
M`/5Y]I_:#>+]YPLB^$Z@'J\^T_M!O%^\X61?"=0#U>?:?V@WB_><+(OA.H!Z
MO/M/[0;Q?O.%D7PG4`]7GVG]H-XOWG"R+X3J`>KS[3^T&\7[SA9%\)U`/5Y]
MI_:#>+]YPLB^$Z@'J\^T_M!O%^\X61?"=0#U>?:?V@WB_><+(OA.H!ZO/M/[
M0;Q?O.%D7PG4`]7GVG]H-XOWG"R+X3J`>KS[3^T&\7[SA9%\)U`/5Y]I_:#>
M+]YPLB^$Z@'J\^T_M!O%^\X61?"=0#U>?:?V@WB_><+(OA.H!ZO/M/[0;Q?O
M.%D7PG4`]7GVG]H-XOWG"R+X3J`>KS[3^T&\7[SA9%\)U`/5Y]I_:#>+]YPL
MB^$Z@'J\^T_M!O%^\X61?"=0#U>?:?V@WB_><+(OA.H!ZO/M/[0;Q?O.%D7P
MG4`]7GVG]H-XOWG"R+X3J`>KS[3^T&\7[SA9%\)U`/5Y]I_:#>+]YPLB^$Z@
M'J\^T_M!O%^\X61?"=0#U>?:?V@WB_><+(OA.H!ZO/M/[0;Q?O.%D7PG4`]7
MGVG]H-XOWG"R+X3J`>KS[3^T&\7[SA9%\)U`/5Y]I_:#>+]YPLB^$Z@'J\^T
M_M!O%^\X61?"=0#U>?:?V@WB_><+(OA.H!ZO/M/[0;Q?O.%D7PG4`]7GVG]H
M-XOWG"R+X3J`>KS[3^T&\7[SA9%\)U`/5Y]I_:#>+]YPLB^$Z@'J\^T_M!O%
M^\X61?"=0#U>?:?V@WB_><+(OA.H!ZO/M/[0;Q?O.%D7PG4`]7GVG]H-XOWG
M"R+X3J`>KS[3^T&\7[SA9%\)U`/5Y]I_:#>+]YPLB^$Z@'J\^T_M!O%^\X61
M?"=0#U>?:?V@WB_><+(OA.H!ZO/M/[0;Q?O.%D7PG4`]7GVG]H-XOWG"R+X3
MJ`>KS[3^T&\7[SA9%\)U`/5Y]I_:#>+]YPLB^$Z@'J\^T_M!O%^\X61?"=0#
MU>?:?V@WB_><+(OA.H!ZO/M/[0;Q?O.%D7PG4`]7GVG]H-XOWG"R+X3J`>KS
M[3^T&\7[SA9%\)U`/5Y]I_:#>+]YPLB^$Z@'J\^T_M!O%^\X61?"=0#U>?:?
MV@WB_><+(OA.H"JV3]#MUHIXN^M7#+*\;;BE+[*VAU<D*7E*5%39:6<7BQ5I
MAJSU62Q-MI8<DYI(H:F#&&)0883+$7$NHF,;>YR6N!:G_":?JXYO^?\`[+_W
M7&5`=/M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`
M4`H!0"@%`*`4`H!0',%M1_JKN&)\P#8#\'V(H!_":?JXYO\`G_[+_P!UQE0'
M3[0"@%`*`4`H"'DF;;VCK;#7#5CXF9,5K[!''R#::!2A))B)JV9<4R!)=T0N
MM9B'5!TOQ4[1[`62@BQ4$L2&%."G+9`@E38$53?%+"9Q4U+LMPL18FG[E&VO
M(PW/"9*HCJ>SW/:A,V8Y,>AIXPX+&S<3X_;LD19KZ\7*S311UN(R?2D?_P`3
M*I!@<(O<#TCG$5E:/B+P:L]:KI<<S^,W];W%!T/M6>+2$F2O?:69<H#8C2<+
M_/Q$PK1P^(]DHP1"?H(:2O(Z`FJ`1X@IK(&`_0@?06X@<S*KB!U[0]9H_-;M
MD9@>$9.V&U'9!;38/;S:8\+1[.ZK,138,#793>:[':FTI@:::G=''(*D*Y%N
MQ$R5*!E#IH`#"#_%8<*RPUF38HUE$>K4A#71,V3W)(N.7PF<\X,0>VJ8V8\8
MTCMOH\:/U*G68V$MZ]//,\E74VP0%*)0&0"@(,I$2XP%MAITMDBBE7&?<"*G
MM\\"3,%%H^IDB*68!4`L1B(@1\T,"6SQ-A9VR#Y,OL[7]SEH#'?C9BO\I<?]
M^3<_&5`/C9BO\I<?]^3<_&5`/C9BO\I<?]^3<_&5`/C9BO\`*7'_`'Y-S\94
M`^-F*_REQ_WY-S\94`^-F*_REQ_WY-S\94`^-F*_REQ_WY-S\94`^-F*_P`I
M<?\`?DW/QE0#XV8K_*7'_?DW/QE0#XV8K_*7'_?DW/QE0#XV8K_*7'_?DW/Q
ME0#XV8K_`"EQ_P!^3<_&5`/C9BO\I<?]^3<_&5`/C9BO\I<?]^3<_&5`/C9B
MO\I<?]^3<_&5`/C9BO\`*7'_`'Y-S\94`^-F*_REQ_WY-S\94`^-F*_REQ_W
MY-S\94`^-F*_REQ_WY-S\94`^-F*_P`I<?\`?DW/QE0#XV8K_*7'_?DW/QE0
M#XV8K_*7'_?DW/QE0#XV8K_*7'_?DW/QE0#XV8K_`"EQ_P!^3<_&5`/C9BO\
MI<?]^3<_&5`/C9BO\I<?]^3<_&5`/C9BO\I<?]^3<_&5`/C9BO\`*7'_`'Y-
MS\94`^-F*_REQ_WY-S\94`^-F*_REQ_WY-S\94`^-F*_REQ_WY-S\94`^-F*
M_P`I<?\`?DW/QE0#XV8K_*7'_?DW/QE0#XV8K_*7'_?DW/QE0#XV8K_*7'_?
MDW/QE0#XV8K_`"EQ_P!^3<_&5`/C9BO\I<?]^3<_&5`/C9BO\I<?]^3<_&5`
M/C9BO\I<?]^3<_&5`/C9BO\`*7'_`'Y-S\94`^-F*_REQ_WY-S\94`^-F*_R
MEQ_WY-S\94`^-F*_REQ_WY-S\94!L"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!S
M!;4?ZJ[AB?,`V`_!]B*`?PFGZN.;_G_[+_W7&5`=/M`*`4`H!0"@(\2S!QJ2
MYCU8E,!Q%T@OKG(DB/@ZC"IHAP9U!/F#9(B`).*G<#A?!)$3C+\P/9"9ACV$
MP+7"MCC?.V>(%=*SPMGI)#:MKC+TLL58TZ80VXIZ'6RU6,Y4>8\!=OXVGZ&;
M)#[=9U['6R*DP9$.SCP;Z6*1(]9<6)DB=.7)&20ECH&1+N@FRLO9.>3)ZGJ'
MU#8UN-_5]!@-W1_$KN2X];JMJW/&&Q.#]D)HK4EG%A=.3V]R)`BXD4DHEBR$
MB$K`IQP<R**;R`^@EHMLNB2!;;5&E>"Q-S%B8'N^7<74F`_[P`<B]]05%$$"
MPNBEBKYP?:?VO%X+:CE#<8F8Q@^L$SI?(B6*'\.I`:\&X6TTL^.7K%L2[!QV
M22MGM:"FNFXKK=\4N(RX5A847E/3XD.<X,2DJ1<$IHNQZG]F'86!0E<5234O
M"R4-B9,7(F`%`"X!<C6/70TR3$=;(:KM9B<"F@$VN[4)-="&%@C`X`)>5TY>
M+*)848@%A:P8F>.0F/\`3SN6][T!`'5K5[6A0<&V^!_7>"SN"=MH\DY/P-Q(
MP#.)!/"C&(1PB)/$9OYV*DPQS(F>(6'-PMF)E>UN7*_*!+3Q3=6/)HU_^1J.
MO@Y0#Q3=6/)HU_\`D:CKX.4`\4W5CR:-?_D:CKX.4`\4W5CR:-?_`)&HZ^#E
M`/%-U8\FC7_Y&HZ^#E`/%-U8\FC7_P"1J.O@Y0#Q3=6/)HU_^1J.O@Y0#Q3=
M6/)HU_\`D:CKX.4`\4W5CR:-?_D:CKX.4`\4W5CR:-?_`)&HZ^#E`/%-U8\F
MC7_Y&HZ^#E`/%-U8\FC7_P"1J.O@Y0#Q3=6/)HU_^1J.O@Y0#Q3=6/)HU_\`
MD:CKX.4`\4W5CR:-?_D:CKX.4`\4W5CR:-?_`)&HZ^#E`/%-U8\FC7_Y&HZ^
M#E`/%-U8\FC7_P"1J.O@Y0#Q3=6/)HU_^1J.O@Y0#Q3=6/)HU_\`D:CKX.4`
M\4W5CR:-?_D:CKX.4`\4W5CR:-?_`)&HZ^#E`/%-U8\FC7_Y&HZ^#E`/%-U8
M\FC7_P"1J.O@Y0#Q3=6/)HU_^1J.O@Y0#Q3=6/)HU_\`D:CKX.4`\4W5CR:-
M?_D:CKX.4`\4W5CR:-?_`)&HZ^#E`/%-U8\FC7_Y&HZ^#E`/%-U8\FC7_P"1
MJ.O@Y0#Q3=6/)HU_^1J.O@Y0#Q3=6/)HU_\`D:CKX.4`\4W5CR:-?_D:CKX.
M4`\4W5CR:-?_`)&HZ^#E`/%-U8\FC7_Y&HZ^#E`/%-U8\FC7_P"1J.O@Y0#Q
M3=6/)HU_^1J.O@Y0#Q3=6/)HU_\`D:CKX.4`\4W5CR:-?_D:CKX.4`\4W5CR
M:-?_`)&HZ^#E`/%-U8\FC7_Y&HZ^#E`/%-U8\FC7_P"1J.O@Y0$@*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0',%M1_JKN&)\P#8#\'V(H!_":?JXYO^?_LO_=<9
M4!T^T`H!0"@%`*`4`H!0"@%`*`A_J?\`[Q[A_/`>O^%<-T!,"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@(>RM
MOGJS#LJ,F$75)Z>H2R^W>@LM/8;/*''BOHJJXCH*>0%=Y=O@G0VH6ZR:!YV!
MW,(UD&+80,',.V>>.^PNF=:S\*YJ-FRU@VK<IN<FH1:BJOEYJ<VY[MFRC:9]
M5K"R;MIWHQ^%%-U>Q;.%=Y,*M"?**`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%
M`*`Y@MJ/]5=PQ/F`;`?@^Q%`/X33]7'-_P`__9?^ZXRH#I]H!0"@%`*`4`H!
M0"@%`*`4!#_4_P#WCW#^>`]?\*X;H"8%`*`4`H!0"@%`*`4`H!0"@%`*`4`H
M!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0$/=J=[M:=.T>YN8G\6!=!HH(:
M08T;(>+AD5R98X\H`9!NEA<+)I8WE]B&=4QB"??/['I[9>Y6^T7IK5]>N<N!
M:?@ITE<E[MN/IEVTX13EW'U8V%D9;^%'W>UO8E\OS597'=6XFG$=#SQ;I<SP
M]-55@,"X:XHX&SNPL@H9C[ITZ<&'DBK"$14"V(8F&05T$&X(_-P-J8-\\:ZO
MP^D.DW\5K5=:CV*BL0??O3:[^=U7T8,V%-.P/I?'R5V?57Y?Z?0BP753A]:Q
MZ@%+&XR9-EA_F;"Y+,NOP0NZ)-6#!K#FG1+.`<H`$@ECO_\`,62@")8:_P!D
M)AF)>^=^7UKJC6-=ERYESEQ5NM0]VVN'NU]ZG8Y-M=CH?#DYV3E.ER5(?FK8
MO5V_+4FS7/'QB@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@.8+:C_57<,3Y@
M&P'X/L10#^$T_5QS?\__`&7_`+KC*@.GV@%`*`4`H!0"@%`*`4`H!0$/]3_]
MX]P_G@/7_"N&Z`F!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4`H!0"@%`1[V&VI@+59J9N^<Y)0622$"$S24@<;(^ZW*,'>V'56PU
M$[`TOK@O2Y8XYY@`9`%[7YXX@0=LL[;32M%U/6K_`(&FV97)=KW1CWRD_=7R
MNK[$V9[&-?R9<EF+;]B]+W(JIOLKQ".(<+FEZ?L`UJ'K>?,6!'V7ETB%>1'2
MB"8Y6S,Q^V.::!!ZX6SSL&(FV.88#AX\BT2SO?&W:_A'2W2RY]>NK.U9+^[V
MG[D7]N6S=]JFS_-R-E]WP<';E2\7(_,CN7I?S^IDOM5>&%KEK*J!R$H%%2<)
MZ,F,U):G"6QQ'(YQEH;/I!U)`33Y@\F-HQ<2]^89PZ=5YF5\13HMJT6M=8ZM
MK$/NL&L;3$J*S:]V-.$FJ.7HV1X11\N3J.1D+D7N6.R,=BIW\?R=Q8Y7)GP"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`Y@MJ/]5=PQ/F`;`?@^Q%`/
MX33]7'-_S_\`9?\`NN,J`Z?:`4`H#CLV`XF'$ICWB-;)P0@KTM7?=Y.0&AJ%
MJ6E:B+3JBUY1NB3EJKDFOPY-*.QC^"FBS9!+AD@XXG$?<`)-CYI>0>&!4R$7
MMF!V)T`H!0"@%`*`4`H"'^I_^\>X?SP'K_A7#=`3`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H#6$N33%$#,XX_YC?[9CIHDL
M^AS6',I!$L#1NX0@P::E%/LSZVKCA`YY!$R80YH6V-^8'ER7K[,'3\W4[ZQ<
M"U.[??9%5HN+>Y+BVTEQ,EJS=OSY+47*7=_AL*@5/?C;K=U3.,OAN0V8:D<9
M&#B4K;=3JE"H[4*7`&S*&C3&1!@%(J<-%1L.7&V9=8/VQSMTZ85RMS\>[ATS
MH73L%D=6Y"GET36+9=9/M2F]C7KC'A.1M5@XN&N?4)UN?F1W_+_@EWLWGKSP
MH(@83KPF?91SN#;_`&(/7*G5)^3`**N-E'40.04+!K,U4'42O0IHO)B4%4A#
MN9:P6&13`G;[G;6ZKUMG9-C\/TB$<#2E5*%K9)K[4U1[>U1I6OO.6\P7]3NS
MCX..E:L<(['\K^;Y:EK.....-L<;6QQQM;'''&UK8XXVMR6M:UO<M:UJXHUI
M_M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0',%M1_JKN&)\P#8#\
M'V(H!_":?JXYO^?_`++_`-UQE0'3[0"@%`<=&X*[M.R-E-DM7AEYNEYGG[B`
MPELQK=N4H<22&HI0-<XF:YJ/$=G1^XM973)C>E84BS6$,Y40RURC=/I3Z'61
M#`=C8N-LP0.Q>@%`*`B$C[V:P+TK[$PZDR21/.74^.2DG;`J0!8P*V(V01U)
M])QP@LK(>.5LW$AVCM2,'R8(8N94OB'EG?G"8X4!K%`XE<%*;'D9Y.5E3Q&1
M^/6_"KN+QW(D7&4F2Y$:FRCU/1IKLMQJUDI57.V$29)(3Q&^FIHPY-:(*]\"
MRL33<Q0^>!]%^(S$XC833!"+-@U:73\OK\$&-8DZ/D<2?4.36K&J?,[E2%Y'
M'>!>/DU'1XB6DYQ76KN/)$-D%9/P*&S!H^4+#`>*Y^*3K*WVVU'NF$)>>[%5
M82;.R<AO%G1JI&DG7R!G:K.A!29+GHHM&T)P,I-"7&&XBQQ.+DE%<3[MQ5$,
MD0@$\R*&!8[0$/\`4_\`WCW#^>`]?\*X;H"8%`*`4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0&+/1[LZ.&PKO1_NA!9C202N9U9<CF52
M2*C)I;"WNBFU`^,`6"YU^3''&^7.SRO;'&U\KVM6;'Q[^7>CCXL)7+\G11BF
MV_0D6A"=R2A!-R?8BG-[\3^4]C'(KQ)PQ834YJ7"8F)!>V$?1`VV8:9`@F?-
M%,@`+5D<57,X%<KB@7/#DL\\L.4$DH87YN7>X_1V%I-J.=UAD+'MO;&Q!J5V
M?JK3;L?*GWRBS;0TZUCQ5W49J"[(K;)^K^CUHRB)>$ZGNMXDYOX@4K+>X,T8
MC8G"S>6!S9*$6=>^80]T=!9W1D0EI*"-!7RZN(63D<?'+FB)7.MEGGASNMI6
M+#T[I>Q'`T^E')4=Z??*>VCIVUE-=D^PI=U-QAX.#%6K/'ZS]+_YWWEOR4E)
M:&FD49$32".D)94$BF)243+IZ:G$BP=@BY,B1*!@E2A4N%C;'`,/''##&W):
MUK5PDYSN3=RXW*XW5MNK;XMO>S5MMNKVL^^JD"@%`*`4`H!0"@%`*`4!K<Y,
ML0)QPVGJ$JQN0/D#(Y,\1./EL%3A,X5%R`,E#98=4P&+F2XV&6`@>>-LL,K7
MM>UKVKZXZ?GSBI1L7G%JJ:A*C7%;#(K-UJJC*GH9\WQXPK^6"+OE`:?XVJWX
M;J/["]^A+YB?!O?F2]3'QXPK^6"+OE`:?XVI^&ZC^PO?H2^8>#>_,EZF/CQA
M7\L$7?*`T_QM3\-U']A>_0E\P\&]^9+U,SE"<+?="<&KME<1W$DBB"A!*B$I
MDE=.%%`SN&.&&=3QS!;,0$2W-SM;*]\;^Y?W:^:[:NV9^'>C*$^$DT_4S'*,
MHNDDT^\KPES=2?FM+6QC#A[5)IRXT]7V>RG?(SM<&RR;$JZH`N]D*C^NF-%J
MJ\3.-!.G"2*D"!X"J3A2B8AG+&PHQ8+G#8XR#03RXN*NG$IHD9@Z]M%TP)!,
M>Q;*+M=;VV5;L1S`MM*2]?6%L<&$R84<D<J!%:<Q!FOXN2+D#3H(=?6`LBMA
M0KY8Y4!N5_[\RP#+<\L2!]:&W-B%JR399N;6^=G<_'^TJOB[XN9TRY7U]U@Q
MA)YCRT72V,_$\+$56=#/Q4W"">1D^QH^1&#H"S^@%`*`4`H!0',%M1_JKN&)
M\P#8#\'V(H!_":?JXYO^?_LO_=<94!T^T`H!0'$T[VVSHOXI.WS)!;7`)FI6
M7]PVE/CC=FY#"V$D/:R%"4UN2$V`@L869P=:UZ(&@Y"[\7D\5N-[%T_^!*"\
M%87(('*^88';+0"@%`5G;.:9O78M^;NI>:BFMY@[3<,ZVF:0Y[GL!%)&>J^L
M[.EUM1,I6)4T,&FI*++Z:8#'Y@MA1+"86PROA>UP(RR1KEN=LR[%'99]0BSX
MBEJ&F_IR#%D/F);;KD2Y<>D!;3D-CYS%%=[>+*R>TF(^D=ND$)A&3V8"J"=&
M'.KA$J#@&6R`^E(U^VW;>Q)OB'!:_%U>1W?+\DEUO5,M+<>%GFVX$>FMFNL/
MHBI@_39\**E:6R4E:T)ZJH$@US%'";:Z."7,F5`CA8X!IU-T6W.B&(IZC)FQ
MNPI$<6^^I1B))6<A>3DQ):&L<\OR1]M7W(;A.@+Q%"<LF0DA%-L<@$BR,5%<
M1HRV;XC@!!*6(Y$"]!RP\U'='21&"PJ2(1;J*30214^PY5DJ(7AF&W2H10C<
M5\0ZZF`ZPPQ@PK7,@`FPBIF_N"!98VMC8"N;6#32(5-?VQ#,O#:T+%)VN>"4
M5NG[X;Q)&8I4&,XD,X"J0J3L02$65*XAO.V9PY<<YF';`/(6^`8>.($KO$>A
MCNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>A
MCNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>A
MCNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>A
MCNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>A
MCNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>A
MCNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>A
MCNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>A
MCNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`/$>A
MCNUV_P#VA._7YRU`/$>ACNUV_P#VA._7YRU`:#EEC:#P5@/>7MIIP8!H#&^>
M2.X.)SO`7<8UK6YU[$VP%M`,XC^=L?=YH!43+D_[*V>#HNK:E3[CC7KL7VQB
M^7Y94Y5\K,]K&R+WZJ$I+N6SU[BNYS[G:!GU4RU]=4[B>;5.X.W(63HFV[XB
MN":+G>^6.'61E[8\BY@01<\+VP$!1S-LN2][>Y[M=59\O=7C!7M5NXN%8XW;
MBK_9K'UR1]T=(R$N:_*%J/VG\VSVGA?%-Q')\^PA[7*:]7FR?^Y@.O8CB><0
M%?<9+#+DYICM>3MET=;3S%K7MEG@9;)O#&U[X6Y^5N6LOX5T'IG]_P`^]F7E
M]6Q#EB_\9U3^2XBW@:58_6W97)<(JB]?_*2!A?@OKSA.)ZWOYM-,6UI='43*
MLWXI5Y9F%R1^A*!P$$$UG9SR(\%EZF2>88>.&("?9$Y>CM<7,>V>>%1=ZTQ=
M-L2Q.DL2.'&7TKLO?NM>E\U/EE-+L2WB6I6[,/#T^VK==\GME[:_E?<6$-;A
MXZUL5#)-=C&MF62UTS',-+;#.WIWC:S;2@A!,A<@$M!0=BD])32_29WO8,`$
M/"W+[EK5PF1D7\N]+(RIRN7Y.KE)MMOO;-5.<[DG.;;D^UF0^(]#'=KM_P#M
M"=^OSEJPE1XCT,=VNW_[0G?K\Y:@'B/0QW:[?_M"=^OSEJ`>(]#'=KM_^T)W
MZ_.6H!XCT,=VNW_[0G?K\Y:@'B/0QW:[?_M"=^OSEJ`>(]#'=KM_^T)WZ_.6
MH!XCT,=VNW_[0G?K\Y:@'B/0QW:[?_M"=^OSEJ`>(]#'=KM_^T)WZ_.6H!XC
MT,=VNW_[0G?K\Y:@)?T`H"M9S<(+AUO!QK[M<.NP1Q><ZRIN!;.`2I-J8";5
ME@Z,H*)D-.2I)))A'`P<,9YV"+@A`A\O)AACC:UK==9ZZZJQ[4;%K+I:A%12
M\.RZ)*BVNVV]G:VV;".J9\(J,;GNI4W1^8\3T+_#3\FW_P!8I\\*=9/X@=7?
MZW_W5G_1D_BVH?M/[,?F'H7^&GY-O_K%/GA3I_$#J[_6_P#NK/\`HQ^+:A^T
M_LQ^8>A?X:?DV_\`K%/GA3I_$#J[_6_^ZL_Z,?BVH?M/[,?F)M0'KM#>L#"M
M&,%LL)B,BRRHN&Z*&MN1PYB+*MB6P4#XZJ[%E>6C`HX9,+"ULS.6&&`>..%L
M<;6M7.ZGJN?K.3]\U*YXN3RJ-:1CL6Y4BHKM?8?)?OW<F?B7GS3I3L7Y*$1%
MSAIZ]2SM)L/L%LG"D&SL4E`C#"6P4Z0V2GO8XVTN.F<>0G"F+B8YTDR@FDU:
M5C.(X9>UC0(@=K]+C:_V-]>82*&R_#-DN7IEW#<21!'#VD1M;2%660:<N;!(
M3H7YJU^P0(!9$-7/,MO),1GL#^3576KFX4<`@\V\)<WGAS31(;_:,0/SV<X<
MFPL\W>T?.Y@:9;#E%!-(H\`;T3>M.)@;OZB%;,E(10%1HE8MUQ4S,K.IAOTN
M?<R*I@R2PCAL8]@5.B7N!D;'`O,3BPQ)/(DS!TPI&"A,L6'43>(&)I0&`!P"
M%.F<2P0!;$P:SPN)G8/##"V65^;C:W):@/LH!0"@%`*`Y@MJ/]5=PQ/F`;`?
M@^Q%`/X33]7'-_S_`/9?^ZXRH#I]H!0"@.(G:#6^&U+8+>+8\.?-I47A[-[B
M`H$%;K1<V=>88<9<])<MR+K1)<\.=I34Y'T!(Z3!39GN*&`5<HA1N&U\AF,:
M!1NE)V&N*!V[4`H!0"@%`*`4`H"'^I_^\>X?SP'K_A7#=`3`H!0"@%`*`4`H
M!0"@%`8<^Y$8,7-PX[Y)>K58+63[<IQQ/%?2VXC%[WM>^`>:@K&BA7IA;VY,
M`[97SSR]S&U[WY*^C&Q<K,NJQB6YW;SW1A%R?J52\+<[DN6VG*7!*I5*_.,?
M$ZRXC4=:<Q#+>YLE!WZ/$O'39649B$<KY9`Y&59T**.;6@B``V-[W-!)`B=F
M&'GGUO#"UL[]KC=!9UNTLO7K]C3\3_XDDYOT132KW.7-]DV4-*NJ/B9<XVK?
M>]OJ_P"6O<>7;>;B;,W'&\A\*U;7\+!](,-&TV("F(&%>P)GGA$41%D',P,$
M3&YO0=+AF(/:^/.PRQRPM?\`=SH_(_NNM1C_`/,LR7M;AV]M-Q/W/3I_J\E+
MTQ?]-#],>+D[6ORWE_AS;PQ^$%GR#FDR-3+C(6P#&S!,"E5!;*L8D="#RS!M
MCGAGT>>0E[<ZW)C?./W&L7O[AJVG77P=SE?J7.UVC\+C+]5D69?+3\E3["''
M/T?L;#3WD!.,8J&0=A!B+\B@X`<*?8#<_$P6;2LYAN4(V!F7ROA;/'IL;VM>
M^%KYVK/RXZCY>;'^[7H\87%1_I*/9M]!#T;,I6'))=TOGH;R;7%QX=;JQPNG
M[--@CGE:]\@W*V)":.0>6-@N?AGFYV@D@WOC<:UN7'/+'+DRYM\K8Y7MKKW0
MW55GZ>'-_P!64)?Y,F89:7GQWVW\C3_(R0C:W2T_>%PPVUM)KZKF!;\F!$M,
M#!Q4^6XV)?'G)8R\$HX6$'RMCA?(*UL[Y6YO+RVY=7>Z?UVQMO865%<?"G3U
M\M#!+$RH_2MW%_BOYC?J&YVTZ"]S;:<*&X2F.`0F1E#5B"L7M@/<2P.=QB!@
MP';`:X.?-OR\F7,OR?T7K5W+-ZR^6]"4)<&FORF"491=))I]Y[E8R!0"@%`1
MQES;_5V!^M!2Y/<7,A1)\_IF\I.U*,.W[GR])T+.31SSJ-='?W,NB)Y\W*]K
M7Y+WM:^VP="UG4Z/!QKUR#^LHOE_3=(KY6?1:Q<F_P#JH2:XTV>O<5\KG&OU
M[7E4TV-:HBV*VJ=6%\<216,8Q5RB.9RSOE8.Y@99#"=Y(,6^/V-^P0GN<M[V
MMR<E=1;\O=4M05[5[^)A6>WQ+B;7J]U_IGW+2+\5S9$[=J/>_P#!>T\GX[>,
MK/WV$7ZOPIJ6UU#_`/K.6='@*\':2PR_HSLE)5KG2HH>-^7+$XU,K97Y+8_T
M95?\.Z!TS^^9F1G7E]6S'EB_E>Q_)<)\'2;'ZRY.[+A%47^'RG\WX9>V,T98
M&MM^)%-3B('>=V78,$D2L6-C+'.W)F$$8*B!MX]C?#++'&XS9QYEK_T7Y;VJ
M?WOT33_=T/2<>$ENG>;N2_Z2^2X/Q#&L[,7'@GQEM?S^TW]$W"&T#B;,`Z%!
MB;(ZZ'G80==F!55)%S/YVOS^>=;BT8NQLLLL[WRRO@DAWSOER9<MK6M;5YW7
M74^=6+R7:M_FVDK=/1)>_P#VC!=U3.N[.?ECPCL]N_VEB#::K79B070&>VT%
MIH)3EZJB-I'3T)(+<N..-^KIJ67*DP>7'"UOL<+>Y:W_`.E<M>OWLBX[M^<I
MW7O<FY-_*ZL^&4I3?--MRXO:>]6(J*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!0"@.8+:C_`%5W#$^8!L!^#[$4`_A-/U<<W_/_`-E_
M[KC*@.GV@%`*`X#]X9@A=>XE4W+35UJB_-(@K:<W)NW4,.C9_8Y`;<[E(ME3
M6&%(O<"IK:SW@V884]K)YE!T&EUF$#Z:?3'*WFZ`:4BBD.:,#8@=^%`*`4`H
M!0"@%`*`A_J?_O'N'\\!Z_X5PW0$P*`4`H!0"@%`*`_@03`+#,47/`,,/#(0
M003*V&`>&%KY9YYYY7MCCACC;EO>_N6M1*NQ;P5P;$\6#2?7,4ZCJTH@R8]R
M>8A>["AP$N_5NQT*]P\R)U5*'"S.1CH(W)@(`<4P#.&7+;H[WM>U=3I_1VN9
MUEY5RW'&P(QYI7;[\*"BMKD^;WN6FWF2I3M-EB:1GYLXPLVW63254ZMO<DJ-
MNO91%1$G\8?;B;1S21!K+:6JS)$YW-?C[*C2))(Y7"][W%2$<RC=K*><-@6^
MQ`,IHP6.>6-K'\+6N);S/J+SL_EXZ`OO#U369Z_KL73[MID'?BY-TY?&A)6'
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M83%35TP<2W)GES[\E[^?:CT?_,)U9==_K#J_`TWGWVM-LSR;D?LROW?!:X)V
MLF]%;]KV$XOF/Y*:;+Q.G>D=5U6Y'9]XUG)ACJ:_.ACVGD-KM<;^-C2[%1.I
M^RQMIM;HPXDIB[,MP*9(T,#8IK4E<F**G+"V3`MG?"V3C$#,$5!PEB6'.&3U
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M0@24BM\\1+ECY4`X7OGA?EPSN"8P$#OGA>_N7Y.6U>FQG*#YH-J7=L/.$VMJ
M-&N/5#5MX8WQ=FMT"N7EYM^<N1#'ZH+AE@$*"&(&,=;XPH0H00V>.&>-[986
MROS;VY:V5K6]9L?J,O)AZ+LU^21FCDY,/HW)KT2?SD>G-PJ^'L[>E[*ZMQ\5
MZ:PEL^UDPZ&5R6$#P"RZ+M-<"#T%[8AVOC?#FWPRY<L>3*][WVEGK3JFQ]#-
MNO\`K<L_\N,C/'4LZ.ZY+Y:/\J9H9<X&^@"@8ZVW6A)$?&L!,Q"IEGRL[,S!
M+/+/'+"Y49V&74+A<'#&^&-\KY7YN5^=>^7)>VSM^8W4\%RW;EF['[5N.WT\
MO*9XZSG+9)QEZ8K^BAC^/!N2FM</*(MZ=YHUL#B'B7#+2\$9"*VPP&+7#*V;
MR2S!02^)#/$`/&^>66&%KVOEE;+FVR_O].]_?]-TV]_U7Y>9S[=I/XLY?K;-
MF7^+\]3_`'+A^<0AIAW&COBO26H"XVO8(A),4D'0'?*X7+EF*KK3V<V5[9#@
MAXVQZC?H\,L\K97ORXYQ^]'2U]TRM$LI<;=QQ]BA'\H^_8,OIXT?DE3\B1_.
M<*<;Y(MF22]Q]67@6,6%+Y+;MC4)NK)`,6X>5CY)-:T.F4@P>*\[/$,(:]P,
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M\,I2DZR;;[SUZH0*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`1
MHG7;>$]<GYK[&TI+JHENK9B1,(SC(JFH"FM%;K@IE$1P%)T'B`(I=K-<P[W<
M@-_!1-WP+Y+SC2R5K]*<#H"1(ZFFE3Q!,,J!$NI*F)O-,3QS9<(\HX$`PQ3V
M1`H()B.;Q)!#89#7#QRL'CE:^7):]J`BZY]T(2;+`/ROB9>#ABY+)NX50D)M
MLM<.M0FKL>8TR"'"TS"D;`(=$[`)$/C`@D\L+9&BJ<<,@Y9@@\[(#?RF]TX@
M?9!,DG+SE`?+N56<"L--*%<"$USB.U'JZ#RL]U4AGF6:[=P'8XR/8X/?H^SY
MXB0O:PQK"U@/-?,LQS&S6/O5Z.U+1VNENAKLI25\;CJ8)%UO1WH#";2";!2`
M%`T`H*3N=*>2YF0=NAS,XY"WP#MEGB!Z""^4M:)'CQP@N-$,F]%UC%PGPF"-
M8RLJB*OFFZ6/H(*EGADK(;H-%>F1S07+BI%10Q0K7MG:U`9I0"@%`<P6U'^J
MNX8GS`-@/P?8B@'\)I^KCF_Y_P#LO_=<94!T^T`H!0'%%LG.N_R'Q/MFVHEQ
M++C@F-PS7%]]3(\(:2-]ZZ^+;+A^;M7S<02NX)Q#CX\"I=F8)791Q<+Q5G%<
M_'YC$0LFB)0X(&.(':[0"@%`*`4`H!0"@(?ZG_[Q[A_/`>O^%<-T!,"@%`*`
M4!C;G>309*?=6>;J;;12K<_E4W.N)B`GVZ.ULL^4XJFBA:W,QO:]_LO<M>M=
MJ>L:1HN/][UG*QL3%_/O786H;/M3E%>TV.FZ1JVLY'W71\7(R\K\RS;G=GMW
M>[",G["!$R<5S2&%01[+4L6=:D!AF)V&8:.=73IG'&V7-N1-FK)2$?L)EA>U
MNA.9VM>WV7):]KWYS1.N=.ZMR7A]!XVH:_D1ERR>#CRE8@]FR>;?=C!@]NZ6
M2G3;NVG>2\I.KL*TLCJ-8FD8\E5??+T87&N[&M>-EOY+'<MNPARC<57:K:`8
M=,T1T5=#K31112Q27YB6,D..B@F&680@AS`O=NH0V93FW$R+AN7K>=L;XX@W
MRY+7]DT[I2>%%9/7.1C8"I58]F[]XR&GN4VK<86Y+MY%?@Z[+B2J^=S]'T/3
MWR+-G?N+>U;\./\`B5E.<D^QRA::[8NNR'VQ,33D]\CEN([Q)VZVR0EQ!#&M
MFNA92<^8>-KCY!(:RTFV`TD0`SC:XI;$XLAF[XVO>V1W.][UM;/[UYOP/+32
M</"M/=GYT9Y%RFYN%E3L0B]THRCDW8K9S8[HXG(ZOYN>37E\F]>OW<K4H?\`
MAK,H0FY+L<E'(N)-IIJ5JPJK9=CL9YL-:0DG?B6#U7U#=G8$R':P<W[5.(=N
M)Y@`2U[!*Z*VVGB@'38%KB!B8X!GW,5ROS\,P<\+96K@^HO)OI;7+_WGSLZG
MUCJ.\I<WW"WD>#AQDG5*.-AQQ[4:;OB)3:2YKDJ[=)8_FG\Y];MO&\D>F-.Z
M=TZ:HM1RK'/?<'LYE/)E>E)NM:VO$BFW2"ILL>B_A!,JY@JN[#R$>?ZAC?`<
M5F1ZFDX[880O+]T`'%2RQ=84\+X^YTY?%)'O:UK7Y;8VK<:-D]&=#VONWEGT
M_I>CQ2IXT+%MY$ENK*[R\\G38_$G=V;*G%:KT7UQYAWUG>=/56L]03<E+[L\
MBY;PX.M:0M*2C%5VKPH6-NVA:/&,*Q-#"5V%BR/6LQR.0>`9BZ"E%RQ]0MAR
M<S-65\L1%98&MR6^Z&AQL_<M[M:_4-6U/5KGBZE?N7I]G-)M+^K'Z,?0DCM]
M#Z9Z?Z:Q_NV@X=C%M4H_#@E*7]>>V<WWRDV;/K7&\,3?+$9TEM979+^;B4ZV
MHNEKE55$6"V)DF9#Y;9!B8\O-%+&RPN-A`!PLL!P!<<1`\\<\<<K?3AYF5I^
M3'+PKDK63!U4HNC7SI[FGL:V--&OU32M-UO`N:9JUFWD8%V-)0FJI_TII[8R
M34HNC3329S\;%\/XYK$KJ$@--K."8]<AC`JBOIB`H9IDSPR#C>V>2VWEH($T
M7<"4C8XV%P$.%#9;$''/$T`!G:RG7S=8>4OE)Y[0?[S8=K2O,%_0U#%I8N7I
M]CNN*Y;D]B2\:,Y)T\.7^;.3Z4\T/.[^6&]X_1N9D:]Y1+];I>6Y9"Q+?;X'
M,^>W:2;;\&4(M55Z"?QB1T)RAM.W624D#7R04C=R#P>CP/,]T#9HDZLC*P%A
M14-5P','E3%4)XVQ"#QL86,1\,;B%BF(.6(E_P`[:QTG_,1Y)9<L2S./5?3-
MO:K5YN.:K:[;5Q\TKBW)4E?>]>!;=4OUETOU[_+?Y_Z9'5+'-TQU#<HI7+*4
ML17']6]:5%:EO;K&Q'<_O%Q4;F=#F^L$2JHX--;45"(I)"'P('F#*)>S:4`U
M6]N3,B05#5\$HZ+D-]@$")F7.BWOC_L^-\K8UT/1_GOT+U3D+2LVY<TCJ-2Y
M98N:O!FI_FQG*D).NR,6X7);/AINAKNK_(SKCI?'>JX5NWJW3KBY1RL)^-!P
M_.E"-9Q5-LI)3MK;\1I5)KU[0>-"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0"@%`*`K@='#/C=UN5P.@_L!MD5.N-;5%TV5(2PB8$"IA6/#GA
M2Q$,TQ39D,D7S'O@%B(*+GB'C:V6>5_=OWN/Y@9^-CPQX8.F.%N"BF[,JM15
M*NEQ*K[:);>P\8SO)+1<_-O9UW5^H(W;UV4VHY<.5.<G)J-;#?*JT56W3>V>
M%Z*^+/*'V]^5IN^#RLW\1]1_U'2_^QE_I3Y?X#Z%_P"\]1?^;M_^G'HKXL\H
M?;WY6F[X/*?Q'U'_`%'2_P#L9?Z4?P'T+_WGJ+_S=O\`]./17Q9Y0^WORM-W
MP>4_B/J/^HZ7_P!C+_2C^`^A?^\]1?\`F[?_`*<FM!$)HT`L(./D%WR$]DX)
M745@-8DMQ@N=Q8"*=P;BD@CQ9-2"P"8!D#S@@0P,+8YYYY7OEEGE>_(ZSJ]W
M6\W[]>M6+-SE4>6U'DCL[:-R=>+;[$NP],Z4Z8QNDM)6D8F3F95E7)3Y\FXK
MMRLJ5BI*,$HJE4E%;6WM;94GNEP^MI=X)IV@=I>6`M>6FW838VO^L()IFL.2
M,WL?2EEH[.+TUDU#)T#K47B9[$H+32.C%+E%+,2-0#MB]RPA48SJCI3`2.B$
MM2>H33MC(VI#-8FYDH<17A/;"MM=$78D69'CN%(A87"X1MJV^V9+1WHO!HC=
M90<>3*A*"855K&'2GEC(98)3+J2=<X!%._#+FI)U_E>)8ITL268FE8IWTB[-
MBMI5@R)F_+"[(_$/@J9(L,-LRWWJF`%4%XZXLC$H055#!.&2RJ"&GCXE<@2(
M(H$D,]+)Z>3_`$9[:UZX'M%XPRV56'2SXP/6@IH"Q$ME^%1O]K&J;09,"'GZ
MZV:F9.R;9R8+<Q2T8T>4S0#<#612^!,88S@!I)Y\/A;D2%7BE-?AA$X89S1A
M?4-LR5KTX2VLSM&V@F2%]H(UD5Z.UM$$21'&T'LH,:'$-WI)9WNLVCK;YP>@
MA0UC;`OE:@-JN+3.1418<:U,_#]/;D1&ZW%Q%$Z.-=22_`P0,=NC8G9PC(,5
M2(J6>\EH;58:;(D588I@CI21#3HC\,GF&&5PLHFL,0.B!FI@J*T&JC&"/8L=
M);:&F#)O;(L/+L<*03"I40CVWN$$NONKJF85P^R1X/`X>YO3C8V$SRM8#)*`
M4!S!;4?ZJ[AB?,`V`_!]B*`?PFGZN.;_`)_^R_\`=<94!T^T`H#Y3IXDF$S*
M@I'"J>0)@B&#AXZ8"*$RI<+&^0HYDR/F&"`"'C;ERRRRMC:W]-Z`XY9*A>0#
MO$4V#<NP6GN\NT&:EN*67H(G1C<1]M0]%S,@L<-@F&6T`8!*SZW>@;,;K^"K
MEU:Z7F862>5A!@;##Y@V`[)*`4`H!0"@%`*`4!#_`%/_`-X]P_G@/7_"N&Z`
MF!0"@%`47\338J:&+-[5AB'W#L6XW*[(X37.CQ%`D=BX&3UAE]PHQM7594('
M++R8`9$3L<!.JDE$(E@%;(4,+I.?GQ>O>3G7GF+G_B6%UA^[O1%N"MW+=JVE
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MU+-(4DPFV4X`(Z'84')32D\T';+#&RAG>]\J_2%W!UG&PH6-:S</0M$A#EAC
M8RC&2@MBA!0W)+92W*4?L(_&&K_S#:AU/F7<7H'3L_6L^4GS7N6=JPF_K3NS
M3N/O\3PDZKWMI926UBWCV$+EPMBY^38*CL0$("\,Z[%,"!C!*MAB!FA'W*&+
M8,L#B7QMA8,0XX2=L,;6L';ERY.9?4/1VAM_@.#+,SE_G\EU5?SE#M^2-J7>
M:%]%>:O6CY^M]8CIFESWXF`J2:>^,[M>W[4\B/=M9*F%-&-8H%N4/,R,TI2<
MQ6X8MGJ]/_R]UW-AW#O8^5/*^`I-$-Y9!6O>Z:7)8<O+>V-N=ER\YJ_6/4.M
M5AEY$HX[_P`W;]R%.#4=LE_7<CN^F/*SH?I-QNZ;@VYYT=OC7OC7:[/>4IU4
M'L_S<8+NVLES7,'H0H!0"@%`*`K!FW29WL1[F=B]'5DC&<L!]*:=489]&5C6
M4RO/N8-)PJ9EF$E)"@>OSON6=@B0@^6(N`A$>US5_0](ZNQ<W#6A=80>1IFZ
M%[?=LO<G7?)+CMDEL:FO=/#>I_+'4=*U.767E=<C@]0*KNXVQ8V4M[BX[(PE
M+;L=(.34D[4O?/ACV3-9M]L#D5;!Q228FQS2`%37&Q706,-U[$3)#'I3AIA.
MG'L>X#B1CE?K`B?F)84''EN,`,!C@8%\V\TO(WI;J'%63KF'CZEH\U\'+@N6
M];BWLCXUNDX;>SF=J;WJM8KU;R6_F0Z@PLR6EZ7E9&C]5V6_O&GW76U<DE[T
MH6KJ<+BIQBKUM;GRTN2_:^N&W6L/..:O2UC+<>$<><%",QC!BG"I($2V0::U
MW!<4D1"SYF6?)8$=#!]WERP&RY+5^9_X=>;7EG6]Y8ZM^+=/PW:;J#3E&*>R
M%F[6,4Z5^C+&CQC-T/UK_$/RG\RJ6?,S2OPKJ">_4=/3492:VSO6J2DU6GTH
MY,N#@JF?1]Q#(['7<6!L$U'+K9)(.?0F$Q^ES':F9SYV.`9@@[,B9/``F9MR
MB8C'"Y8G;#DYAD7EME??=/\`\P73T\[\!Z_Q<GIOJ-.CAE)^`^#C?Y8TB]ZE
M<A"W3=<EL;T6O^0/4$,'\=Z"RL;J/IUJJGBM>.NUJ5CFE62W<MN<[E=]N.Y3
M]('R*H2*J28=***<>`"-$CY`P";)'"PV-LP3!4T7S$`,`"X7M?'/#*^.5K\M
MKU[W8OV,JS')QIPN8\XJ491:E&47M3C)5336YIT9X1?L7\6]+'R83MY$).,H
MR3C*+6QJ471II[TU5'UUE,0H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0',%M1_JKN&)\P#8#\'V(H!_":?JX
MYO\`G_[+_P!UQE0'3[0"@,#E&,&!-4=/6))5:R6^(VD9MJK0?#/6PQ14ARME
M<*B$E9&4@P101<R9XH+D'G;'/&]\;^Y>U`<%4]@Z2/7BP3^3F&:^&AJG*46[
MKMN.&G%#FT\E^?Y7E!";H<;J+'D4_.+4D(RRDA^/;)6['#$,0"^3944^Y<X6
MP'!%MD!_T$:`4`H!0&"J,H1HD([]<*M(C%2T"*S1DC)ZXHNU`)(\<'22`D.L
MX3?JF94`B3/-%&LX""D*&H9E\PT\\7,96L",'GD!K`YM_J6G0ZF[$*&T6NI'
M7]9/`)B1.9R;(U*PZJJ1HP,4+)Z;)H[FP91X\8-EA`@P@CN0F8@>6-K7OC>U
M@/==FRNN3"/QDEOJ?X39:G-0A0*&TYV2JQ6X?EH4^"6,D`HR*+"\3,/P0Z7.
M`B`XI6)NXF`N&6/+;+&]P-V4!#_4_P#WCW#^>`]?\*X;H"8%`*`4!"38UG[L
MR$]D]IP3(T=0]$AAOE17"_C*>869(NKCG#Q943$E/,$SI(,,(AU<8N(#DGBV
MROG_`+9CE;'"W7:#E=(X.)+)UFQ?RM34WRVTU&URT33DTT]]4T^9;O<>\\PZ
MST[S.UC4X:?TKFX>G=/.RG<ON+GD\[<E*,(M2BJ1Y7%IVWO^(G1&OH[X9<&H
MZWB]II67GLO(HO,%.N.65HZ?2A#-LNDRR!;6!P8,P3N)D)?$NIF50/'I,O\`
MMYM[?=G>8.L7;/W3286M/P.R-F*4J?UZ;'NVP4'L-1H_DATMC9/XGU-<R=;U
ME[97,N<I0;[K=755K[MR5U;7W%@Z(A(C:2R:&W$=*0$5/"L`02$1/*)261!M
M>][`DT\B"`4+!6O?_NX88VKA[UZ]D7'>OSE.])U<I-MOTMU;/7\7%Q<*Q'%P
M[=NSC05(PA%0C%<%&*22]"/5K&9Q0"@%`*`4`H!0"@(?[2::1SLL3)KHA@['
M\Q-G`(9BR^U,Q"#G0CA(2YI-`4!2@Q0582"QWD$P#R$#,E<KY9%1@,L\[Y]3
MTYU7G]/R=E)7]*N?K+$]L))[&U6O+)K96C3^LI45/.NN_+;1NMK4<IN6)U'8
MH[&7:K&[!QVQ4FFG."EM2JI1VNW*+;K&>*MQ)+U^>B7KYOD2`;ZH8M8G'VQ!
M/#.[`D`F#F&7`R<*B&7!*IRC;GX6'.98`=!<3&Y\$MR]8%Z#4NE=/UO$EKG1
MC<[:VW<5_K+;W^ZJU:X1VUH^1R^BN(T#S'UOI'4[?2'FO%6;\MF/J"_49"6Q
M>)))*,MW-.D>6J\6,/IRL6?D:1I,;<P1)`:3:?;=-!7,$L%8D64<`+&P;6Q4
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MK,<*Y)D[DP^Y(.<0XF)0L^4DF:<<9KHV&66`QHH;)9*!DF!SK>YB4'6,,<;7
MR$%#M[E9].\^<SIW+AHOG#I&3HFH2?*LF$97L.ZUOE&4>>45W6Y9"2VRE$PZ
MAY$X?4.)/6?*'5\;6]/BN9XTY1LYEI=D91ERJ3[YQL-O9&,BP=I/)IOU#*.9
MDN5#=C>/6OU19;RF35DX;+&V-Q`K&B0HP6!@&^5K"!97L('E]CEC:_N5[_I.
ML:3KV##4]%R;&7I]SZ-RU.-R#XKFBVJKM3VI[&DSP/5=(U70LV>FZSC7L7/A
M]*W=A*$UP?+))T?8UL:VIM&2ULC7"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4`H!0"@%`*`AS+W$!TZ@1\K\;R_.C98KP::2DKSM3U9-=(I%I(:V2
M&4DU:=;@3T$XW&TDC)A<0SF9/&P`02P>8HN6`>.65@)&,R36!(IU[I[%=J*Z
MC4<.9*9SVP13>)T-ON5<CMB2TCI1HR%:Y8492C:3D!9!S!S$"S)*H&=LN7*]
MK`9U0"@%`*`4`H!0',%M1_JKN&)\P#8#\'V(H!_":?JXYO\`G_[+_P!UQE0'
M3[0"@%`<<4W2U/\`IGO3L/A&L^\4O7N`9=W7;SY?:<SN#;"4@ZF+D@RTL1G'
M)H5&VLD)3N<-(<CJ!5-3A5DK<J,84C&0H8(AX3+(8#L=H!0"@/G-E0#Q4R2-
M!]*5.%QBID+G9X=(`8#R!&#YX>6`F'/#SO;EQO;*W_9>UZ`YZQ-<"L'ZX;H,
MMB0Z[DZ$V3Q=-=YO7(X1&F]G>H/77UH./1>1)B7F^@Y%5YTR:@E[H"XK*9<K
M90R6`TL^2M@9SRS*B`8^W':W4'<0UO`NM=_%M%G'MC-ZHR7`)#4HF4Q.DYUZ
M,ZP1>1V1LQ0&2.Z&XQ7@Y(YD5GEG&(G@DE%;7,Q,,L[KV!DT!&9(9ZU%NM^S
M<>R["DN"N7;;AL)<3Z),(&%Y+5%U"R5)BWF<\6ZRE0DIJ&/B1DR,$.7HU.'"
M2F*D&$8$H6,"#8X-P01/`Z@7*QWLZXZ2&J7F!\1>\`":#V7D6,TV,5%P&3Z>
M5"P5\"I*7(TDQG63UHU;+(2^:-UC''DZ+,&_+0%<VL&N\O'5_;'`MOAM:D9$
M=KG@1-"I[/T=%S630<9Q(-FLJ5E;313#"4APQ\`L\2>)0G8,#"^(&.=Q,Q`)
M7>+3,_\`F$[?]Y6@OYCU`/%IF?\`S"=O^\K07\QZ@'BTS/\`YA.W_>5H+^8]
M0#Q:9G_S"=O^\K07\QZ@'BTS/_F$[?\`>5H+^8]0#Q:9G_S"=O\`O*T%_,>H
M!XM,S_YA.W_>5H+^8]0#Q:9G_P`PG;_O*T%_,>H!XM,S_P"83M_WE:"_F/4`
M\6F9_P#,)V_[RM!?S'J`>+3,_P#F$[?]Y6@OYCU`/%IF?_,)V_[RM!?S'J`>
M+3,_^83M_P!Y6@OYCU`/%IF?_,)V_P"\K07\QZ@'BTS/_F$[?]Y6@OYCU`/%
MIF?_`#"=O^\K07\QZ@,!DK15P3&UC3(E3=?:9\M(\*",:15EDZ(AX=,!>_1F
M"*DEZ4IRVBG\,,\L<#9$T5-A8YY=&+CRWO7WZ;J>=I&7'-T^Y*WD1[5N:[5)
M;I1?:G5,TVO=/Z/U/IES2-<L0R,&XMJEOB^R4)+WH379*+37':R!,JQUMOHB
M<0PVQL+L(H:3I1DYB:,16B:_.&2(V*J8Y3`H&O7FZ#Y>+8H2+8+*Q>R=9*2C
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M??G?6_\`+]J'O:CTCF8TWVX^9<E3;79%W;,-NU?1V*B7=&I8U_XTZ6=S-E-X
M1G*6L%CAV,0FIJ45+97MC87(4N,Y-/44[B9RYEP_N@V05LLN7F<GV5K<_P#-
M!IF^'2^HKN=^#?;LJ\95^JJJE7M36U5Y/Y9-2W3ZGT]]ZL32[-M%D.GUG1UV
M;&GL?DY)'%L;5\<G2^=G',!A>^68[(7.'4%U@,,3#(6P!:VF3K/@9W!%MACT
M@-[Y9XY98XY8VOC:/W]\_P#3=NJ=&X^3!;WC9MM52:K2//?DMCHJQWIM)K82
MN@_(34=FF=8Y&--[EDX5QT;6RKY+$7M5726YI-I[1:5=PT6][OIP<49#!"O;
M$P:;<=:)O(D#E83,#+_;L.'PADLL,A^CQ#RN)C86V?+C[EK<XO/+JW#?_P"\
MZ&ZAL06^5F$LB*VT^EX-J.^B3JN:M5V5/R0Z4S/]R=;]/WY/=&]../)[*_1\
M:Y+=5M4?+3;VT_JVU1%/Y,'CN9Q-F`+:V-A;.N".'V6"PSO;+'['(EJ">&S#
MS,!YA87R#PRRRQORXX^[R3__`$WT-C^[K&!KN!/M\?$BDOT;TG2J:6Q.JVI$
M?_S3UOD;='SM#SX]G@94F_[5J*K1IO:U1[V9XC;%P\L\F/I9-OTH>_.OT"S"
M^H)'DQQYGV5S?H^14ZW+?/DMCTW.]R]^3DMRUO</^8SR>S-GXMX4^%S'RH\/
MK>"X=OYU=^RAH\S^7?S>P]OX5XL.-O(QI<?J^,I_V:;MM3;J(X60X<@\$SC"
M33THN5L`@5'T=2(.*)D+8'`((!:TI3QA!1!,K6QPMC?+*U^6UKV]VNMPO-GR
MRU!J.-KVE<SW*>1;MMNM*)7)0;;>Y4J^PY/-\J?,O`3EDZ%JG*M[ACW+B2I6
MK=N,DDEO=:+M-NHD2N]R\SM<XGFRC@Z3H^C[")G#N5>?TO/Z+F=0TJ'YW2=%
MES>3^GFWY/Z+UUN%KNB:E3\.S,7(K2GAW;<ZUK3Z,GOHZ<:,Y/-T/6M-K^(X
M>58I6OB6KD*4I7Z45NJJ^E&5^+3,_P#F$[?]Y6@OYCU;4U8\6F9_\PG;_O*T
M%_,>H!XM,S_YA.W_`'E:"_F/4`\6F9_\PG;_`+RM!?S'J`>+3,_^83M_WE:"
M_F/4`\6F9_\`,)V_[RM!?S'J`>+3,_\`F$[?]Y6@OYCU`/%IF?\`S"=O^\K0
M7\QZ@'BTS/\`YA.W_>5H+^8]0#Q:9G_S"=O^\K07\QZ@'BTS/_F$[?\`>5H+
M^8]0#Q:9G_S"=O\`O*T%_,>H!XM,S_YA.W_>5H+^8]0$OZ`4!7TY->-U5%PK
MJBA[LW1T4^L*1U)2+Q,W1+I2::.##DDWI.L9=+8@6$Q"MER_96PY?<Y>2O`=
M1\OO.?(U"_D876O@X=R].5NW]PLODA*3<85KMY4U&O;2I[WIWF!Y-X^GV,?-
MZ,\;,MV81N7/OUU<\XQ2E.E-G,TY4[*T/%\6O>KRZO\`TC;O_P!^OC_AQYX_
M\<_[!9^<^S^(ODC_`,$?[?=^8>+7O5Y=7_I&W?\`[]/X<>>/_'/^P6?G'\1?
M)'_@C_;[OS#Q:]ZO+J_](V[_`/?I_#CSQ_XY_P!@L_./XB^2/_!'^WW?F)A0
MDSY-8[(P0Y:D_P"-MV655`WVU]KA%L<Q,,=!8FE=03\\PANIY!B9=-ER9Y=+
MS>3FX8UZ[T7I'4NB:*L+JO4_Q;5?%G+Q_!C9]QTY8<L&T^6C?,]KYJ;DCR3K
M/5^F]:UIYO2NF?A.E>%&/@>+*][ZKS3YI)-<U4N5;%2N]LK56M9-E94W$WS'
M:,]/S6V)9):^O#6,J"5!K&=PDBE\8E74%SJ3!?,G(ZP@%E1M8';DQ>A(*A8J
M:SQN8!RR^YWZTY,BX4TN=4*O_9B2H80-HVZXHZXG_"JCN"R#;?D\@L5=U+1X
M<X1FO^P;MQB])6P(UE-GWB$L^T5XNE1250,D`UC.8YHL,@W$*`1-*R5N2')4
MONN(R^UK`D25M9N(TD.1JO9'W0=28Q-C4C!"D*#T)7E*=0".GY&2F@UFRXP6
M..Q$!':2<"&73Q5$XGG4_`V!][X=+S/O/;-BZ6/[==/UM;['X8KGDU'GH#B0
MO%V,MG/&4N(RESXYHRC]?=+1W$LWW8NL9DEGP::!\@?,EDQ6OF.(`1%!Q`NX
MX7Q24"6LI@O)+B?3G3\96D;**%206-+T?JUXES4RV3;+(R+L-),H[`&&*75;
MJ%FZ:>1XLL"HG5<0RN"?@2%&`L5H!0"@%`<P6U'^JNX8GS`-@/P?8B@'\)I^
MKCF_Y_\`LO\`W7&5`=/M`*`4!SB\6[2ABL6.I5W`F;:+B-SI$ZI.^L83ET1"
MVT;<:ZIK@,G[/0G%22WL41*@=P/%,8[07785<%TX)4ZP>%3NK=;+V'Z<(#HZ
MH!0"@%`*`4`H!0$/]3_]X]P_G@/7_"N&Z`F!0"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4!^)@N7.%QRAL`$T5-`BES)8P%@.7,%Q\,@Q@!P1,<@Q@1@\KXY8Y6O
MCEC>]KVY*F,I1DI1;4DZIK>F5G"%R#MW$I6Y)IIJJ:>QII[&FMZ*JI2U!E+7
M1X*NP&AAP%*-&<L3LB:WG[YB,5^E`<\QA\FT2S-%02"@#CGG<(G@(`(';/.Q
M`P!>]BHWI&G=4:=KN+'1.LTY16RUE+]9;?VW1U7&5&GLYXOZ2\$U[R[U[HW4
M;G5WE1)6[DO>R-.E^HOI;7X<:I1DMM()Q:J_"G']7*4.KNX\;;-IQY-(@G&)
M*[:Z4N^8A=6?576W3I(6Q51$*!F`20RRCECW*%D/B"$,!GS<#(!<3+'"_.]1
M=*Y_3UQ7)M7M-N;;=^&V$D]JK2O+)K;2K3WQ<DJG=="^8^B]<696+2EB:_8J
MK^)=V7;<HNDFDTG."ELYDDXNBG&#:1+JN8/0Q0"@%`*`4!K]:B>+');.SBC2
M/UZPEN02RTS6ZJ6SMT5P>3.QY-'ME;H<KX>[_P##?D_HK09O2G2^I5_$=-P+
M]=_B8]F==E/K0?9L]&PWV'U3U/IU'I^I9]AK=X>1=A3;7ZLUV[?3M-2+>F.J
M;@Z3K\!QJ!TEL[9=A&Z6;7);/#'"_1]KG8KHKVQPMR7QY+XWY;VY+WO>_)YO
MDWY69]?'T'38U_9V8V=^S9X/)3Y-V];3J\+SA\T<"G@:[J,J?M+KO;MNWQ>>
MOR[]SV&I%OAG:<K'29%XU44`82^>60R(^7MA]EGGCGS@RRHO*A(&V-L;XVQP
M"QPM;*_N<O)>W)YO\M?D_EU=O3;EB;[;>3D^Q3NSBN%%%+;NW4ZO"_F0\W<2
MBN:E;OP79<QL?VN%J$GQJY-[-^^NO3V@CTB87%RZB;`/J/'`5P!Y[/?RI=S1
M^X`RUQ,2Q!1`!3<L2I<N")S`\AR"G</&WV%@\LKYVY^_Y"ZSTI+\2\I-?SM/
MU"*5<?*GXV+=2K2,TH>ZDG1.5J]1?146^8W]CSVT?JJ'X;YL:#@ZA@2;ID8L
M/!RK3=*R@W/WFVJM1NV:OZ7,ERG^)F\DE0F?)-7=2%EI@=*-8B3E]AE1W'':
MV-C?DQ'%*E,SPA(3(OATH@90T;-7OG[I("WV-F-YW]2=%WX:7YSZ->P*OECG
MXL7>Q+CXN,7)Q=/>:A.Y/;^I@M@R?)3ISK.Q/5/)O6;.?2/-+`R9*SEVUP4I
M<JDJ^ZG.%N&S]=-[2P-A20P910@G+';P;[R0Q>9:Y]OJ990P+BYAV$L5/A`Y
MW,)I[##+[,N8P"'#O[F6%K^Y7ONA=1Z#U/@K4NGLS'S,)_6M34TFU7EDDZPE
MQA-*2[4CP77>G==Z9SGIW4&)D8>:OJW8.+:3IS1;5)QX2BW%]C9FU;HTPH!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!CKO:+7?[3=##>Z`DNMEO9NK;1=[67B
M("FA.5KN1-,HR^@+2::P$+*"2L)1T4N9`$QR#%!$RQRM>U[VH#4T$:PP=K21
M<A.&V4(VQ7B<33KK7%ATO-_.]R9HA,1/0"RV]Y$<3K>*DEMT@,(`FDA3V1-.
M"%SP+!!8YYVR`WW0"@%`*`4!S!;4?ZJ[AB?,`V`_!]B*`?PFGZN.;_G_`.R_
M]UQE0'3[0"@,'DV.&?,4;2%$<AIAA;8$IL=V1P^48HLKK<-*[/>Z"?;+F3"S
MA:ZDBN9!,'T53'"P.IQPH>*Y9V%+C!"XX9X@5$H_\.[PA$-;07"1U@>`BFV7
M`@NE&NJ[:[HKI`NNMA7)+Z$>'1US8=11U'L<L)P`^(1D`8'+,.W.PRM[E`77
M4`H!0"@%`*`4`H"'^I_^\>X?SP'K_A7#=`3`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4`H"#>T>DK5G12(RBP5H>(-BFOF`>:LKMKI21@Z;(`]"2(N\(AD$*
MJ%.@QL!B;MRG"X%K86N*!:Y;/L.G>KLG1K;T[-@LK0KFR=F>U)/>X5W.NVGT
M6]NR7O+RWKORQP.JKT-=TFZ].ZRL-2M95NL7)Q5(QO*-')4]WF^G&.SWH>XX
M^L?B&J\&GSL1;[-A5CN2&^`%DE2&VT`^N,N3$C'/J^"Z0!0RHP@!D7DMEGF4
M"S*9YV$QSP)C8=6K>9G0UK6(+5.B[D;^!-[;4Y*-RU+?ROF>U?UGS;J.:?,<
MAI?G#D=+79=/>;%BYAZU92Y<BW;E.SDPW<\5!.C?:X)P;JFK<ER$D$/B+:5.
M&^%B$^-DOTE^3'LXD.YL6M?I;`_9W<K=2;!VY]^7ERY+<W[+_NVO>M!>Z$ZM
ML?3PKC_JRA/_`")2.TQ?.3RSS/U.K6%7\^%ZUVT_SEN'_-MW&YD#9O7%TW#Q
M;T]0XKC"<G-*$I)9XIZU\LL\<+"$.S%CH.6=P\N;;,/&^5K<MO<K57^GM>QM
MM_"RHKB[4Z>OEI[3I<3KCHS/HL/5M-N2?9')LN7Z//S+=VHV\F+*0ME[&T95
M35<KEB'G8RF'BI\O?`;"P@65ABHHH=\10[VRQOR\F6-^6WN5J[EJ[9ERW8RC
M+@TT_:=%8R<?*AXF-<A<M\8R4EMVK:F]YZ58S,*`4`H!0"@/A4TM,6T\XDK*
M<15DI0`S*GTQ3*%SZ>>+"VY!"YPD:#%+&0!+>YEAGCEC>W]-JP9.+C9N//$S
M+<+N+<BXRA.*E"47O4HR333[4TT9\;)R</(AE8=R=K*MR4HSA)QG%K<XRBTT
MUV--,K^?G#T98"_G(&MKX=&MDB87Q$P%9QHR89*CEAE?+(NIM?,T!D"5'M]S
MN"7,8$+87RYY07EO:_@>N_R_:-#/>O\`EQFY73?4*VUQY-XT^Z=GF5(O=RPD
MK5*UM2J>\Z'Y^ZQ<P%H/F+A8O4?3[V4R(I9$.^%[E=9+?S2B[M:4NQHC#,-H
M=IM:,K)^VL/BOYCE.>'E.L,EP#I:P`=^2Q]R-['!.(D<1<LOLLQ<$.V.-ON8
M`V7].F7F=YH>6S\#S8TAY^B0JOQ/3DI*B^M>M>Y&->UR6-1?1A-FX?EGY8^8
MZ\?RJU=8&MSV_ANH-Q=7]6S=]^4J=BB\FK^E.")QQ'/<0SHDY*\6OI$=6``0
M8Q]-+CY%5])Q%MCS>R[?/8%EE-QOGES+9B@XAYY6O;#++DKV[I/KSI'KC%>7
MTOG6,J,4G*"?+=MU_:6I*-R&W8G**3>YL\4ZKZ%ZLZ(RONG4^#>Q92;49M<U
MJY3]G=C6W/C2,FTJ52-OUUQR0H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`Y@MJ/]5=PQ/F`;`?@^Q%`/X33]7'-_P`__9?^ZXRH#I]H!0"@%`*`
M4`H!0"@%`*`4!#_4_P#WCW#^>`]?\*X;H"8%`*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`^%03$U6+]454\BIE;Y<^Y90*%SI?G\S,/G="9#$#YW1B98\O
M)R\W*]OZ+WJ\+ERU+FMR<9<4VG[#%>L6,B'AY$(3M\))27#<ZK<V:A7M:]=G
M1TEW%!$.K(@EL[9&%"-6<9-XW$PQ#SS"."(]S0`M\,,;<_#/'*UL;<E_<M6T
MLZ_KN/\`J,W*@N"NS2]7-0YW+Z*Z.SJ_?-*TVZWVRQK+?R/DJGWIU--KW#PT
MN<?2=D(!:9?I;YWR[`GG.UN2^>>(F71]K"\D=#:V6%N2V'-MCCRVMR6O>U]K
M9ZYZLL?0S;K_`*RA/_+C(YO+\G?+3,KXVD8ZK^SE=M?_`$KD*?)Z#42EPFM/
MS!FQM"19`9AG"^=P1VQ(:WTQ>PF6?/L`,X+KXN-L@!+A7Y<KWN'_`$_97OE?
M:6_,OJF,>6].Q=CPG:CM_1Y?3Z3GKW\O_EU.?B8MK,QI]CM9$ZKT.YXCW;/1
MW[3R;\,VR#:]HVW#VT8]N6]\,;2/<V&';(#H1+6Q0R[3RO;+HPK?T\O1A\V_
M+[F6.3^(/C?W_2M,O?\`54_RG/O^4^=^2/W3_<O4?4.+_P#DUILI]16N[Y%3
MO7]WT]W7;5\QF3Q#G>?O;ES`)ON-4Y>QL)CA@)AB,H*SD<F(H8IK#DO_`+):
MP85^;R9^[;*/WIZ1R-F7H5J/?;NN/LC"'9]K?P)_ASYFX59:9UCDSX*_C1N=
M^V4[ERM7]C8MFWM_V\>\5UN<F:=/6N$BA`WOE<-V-`TVSAK'#.V6&%@FNQ"1
M2V8]L\L<[=8!MACACS<N=E>]/OWEKD;+F%GV&_S)J:7Z=QOV,?@_G]A;;.K:
M+F17[6R[;?R6K$5M[?>5**CJS^+21Q76[>P:EKSKO(88/,PZ5I//-M&C5L<A
M`LQ,A'3()8M802_-%Y;%PL;8<MK8<Z_)C/W#RUO[;>=G6&_S[?.E^A:;[M[]
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M,J-]E(!E[H`XWF!@.LZ9YO1(Q%QIX+C^S_[G2MD\*4<!?I+^YCTA;'G7M>UO
M=M?DY3/T#6]+J\_%OVH+ZSB^7]-5B_D9Z3HO6O2745%HNHXF1=ENA&Y%7/EM
M2:N+Y8HW?6H.H/YSPQSQRPSQQSPSQOAGAG:V6.>.5KVRQRQO:]LL<K7Y+VO_
M`$U#2DG&2JF2FXM2BZ-$');T!A.0%6SS8F*K!,GE1;'$Q]14/DW^@/X6RMB9
M.-XD*33!<LKYY9""%+D#@N5^7(>]N6U_$>K/(3HO7\K\9T/Q=#ZFB^:&3@OP
MJ2XRM1<8/?5NWX5R3WW#VOI3SWZST'%_!]<\+7.FI+EGC9J\6L>$;LE*:W42
MGXMN*W6S3UY(WHU7Y`95993:F*B7/Q[?X_!S(R,DIX7+EB:7D0$KEF;ZL4PR
MS$OF4%PY<>452Y;\M^0?4?GAY7>YU3APZIZ5A7_[K%7+EVX+ZUVVHUE2-6ZP
MDOSLGCUO[N^27F?[_2^9+I?JB?\`X7*?-B7)OLM7'*D:R=%2<7^;C<)80AMU
M`NP(0(+`>Y/!QYX6N.R');!OO(L)8*XPP6",<%Y%:Q;"U^E%3Q3A?"]N2XE>
MK=$^;70G7\5#0<V"U%K;C7OA9"=*M>')^_R_6E:=R"_./+.M/*CKKH*3GKN%
M-Z>GLR;/Q<=JM$_$BO<KV1NJW-_FDEJ](/.10"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`<P6U'^JNX8GS`-@/P?8B@'\)I^KCF_Y_\`LO\`W7&5`=/M
M`*`4`H!0"@%`*`4`H!0"@(?ZG_[Q[A_/`>O^%<-T!,"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H#S59&2%\@.E+J4FK26:QYAE-5
MB)51(&,?_E')G`ABXV/_`.V6-ZR6KMVQ-7+,I0N+<XMIKT-;3#D8V/EVG8RK
M<+MB6^,XJ47Z4TTR&<D\.?3R3K&15"'41JJ8]L[X*T=CFV..7$$M?G#!I:$,
M7;8XM[WY?NY$:W+[O)_375Z?UWU3I]%#*G<MKZMVERORRK/U21YKK7DUY<ZY
MS2O:;:Q[[^OCMV&GQY8-6V_ZT&:1MH;L#%5K":S[MRDW2!.UK)K*EDL5D!MA
MXXV^Y@XYC6NC$`L;6MC?HT(2^5N3^CDMR[?]\]$U+9U!I&-<F]]RRW:G_P!)
M_+<1RZ\J.KM!5>B>I\^S:C]&SEI9%OT;?<BO18=?D/Y^-KB;PSGS)$U^C38Y
MN%,>09PP\XQ&\XS'N^[GDE'L<SQL3+#&^5L"S<#QM?W+YVY<:?AGE[JRK@YV
M1@7W]6_'FBOE6Q?+=?H'[P>>'33IK&D86LX4=]S#N>'<?^++WGZ(XZ78WN/:
M0N*=!A)2!;TVL>8]>7+?EQ,D)'82M<F$)C?''.P0B2":7A`PL\K6SR%3`+8W
MO;E]SW:Q7O+G6)VW?TB]BYV/V.U<C7^U2/JFSZ<7SXZ6M7EA]3XNI:/F]L<B
MQ.B]'(G<V=K=J-";,=3U"LN!!"1I*C$>@HH=A>QZ$Y4LTL@8WQY_(<0NL8K)
M`2V'NWP'`#SM;^FU<CGZ+JVF-K4,:]92[90:C\DJ<K^1L].T;JSIGJ&*>B9^
M)DR:^C"Y%S7IA7GCZ)13-53AI7`4[C"K+A:MVR^.?@.6D-BBAMIV`G0<K"`'
M#8Y<$1.6C`6>&/-S/%S`N&.-K!YX<EKV\7ZV\F.@^NIO,U#%^[:W5..7C-6;
MZDMJE)I.%QK91W83DDO=<=C/=.BO.3KOH>"P]/ROO.BT:>+DIWK#B]CC%-J=
MM/;56YP3;]Y2VD:;(^^^JM[Y(*B4W%B0CTG,1E<09,EY)3P\>DM8N=$N>4E8
M?#W`L+8B+>8EK7YA4"U[<WS;[GY\>5NW!N0ZPZ3A7X=QN&?;@MNR3YIW&OHJ
MCR6^RU"JIZ,\OR+\T-F=;GTCU7.GQ+:4\"<WLVQ7+"VNUU6,EVW)T=9`0=O)
M!LVJ@30P4E&.Y,ZQBGCQO(A2S?7\U2UN04@DCBYY)RP8L-CEC@`&+B>O;'G9
ME\.6UJ[[HCSNZ(ZUREI$;ES3^I>;D>'EQ\*[S]L;;?N7'6J44U<V5=N)P?6O
MDIUKT9C/5G;MZATWR\RR\27BVN3LE-+W[:I1N33M[:*Y(F-7L!Y$*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`Y@MJ/]5=PQ/F`;`?@^Q%`/X33]7'-_P`_
M_9?^ZXRH#I]H!0"@%`*`4`H!0"@,55GTR$!NCO!=>+516D5&ZN:="LX4A-;I
M8QV0[$=`.MG#@*8"-V5MU7FY"VRZQ]SY.?\`8T!]"J[VF@G&\G+CH;J,H.X]
M=,:A%56TU...=2Q`N:R3V\5.&01UH]8M:XEPBV(HG1VYW)R>[0&14!#_`%/_
M`-X]P_G@/7_"N&Z`F!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0"@%`>*OMMNNQ,'1'2@HKE1C7)UE(7TLBLIACFVO:W3D%$`
MR4&Y+97Y.=A?^FLMC(OXUQ7L:<[=U;I1;BUZ&FF?-EX6'J%AXN?:M7\:6^%R
M,9Q?IC)-/U$)Y$X:FGDA""'+1:$PEC+/I`5B,U509PA,2V7/QS*(I,49IA9A
MYVMEC>Z=>^-[>YR6]RNNP>O^J<%<GWEWK7YMV*G7TR?O_P!H\QUCR3\N=8;N
M+`6)DUJIXTY6:>B";M+N^'L-2>))M1$V?3ZV;N/G!.+X]&19$XD`7TB!@VOR
MV+V5#`"P1(`B8VYN754,'/'EOEAECER<FS_>[IO4U37](L^(]]S'?AR]-%RM
M_+<?><]_##KWI]\W175&4K*^C8S8J_"G#F:G&*[/=L)]J:8O.W$EAZU[2GJV
MR9U0B=KX"..#7,83UHT'A;[,QVOF+KZP?,VMRY8A@HA/`2UK8?8Y7OE3\&Z!
MU3_=NHWL.\_JY$$XKNYERQ2[W<E3>/WJ\Z>G/]_:#BZKBQWW,&ZXS??X;\2<
MGVI*S!/=L>T^9M;M::RO*[#*RQ$SIBV=""^CIS0$E>+A`%\DY#QS!/1BA)P(
MV"HH`%NR)G'$'-0#*%P1N02]@[XVSMR>O>2>)EY=KJJ[B:9J.7@_$M9,.1W;
M:@FZJ<E&3Y?I**E-)T<5S4.TZ8_F8QH6Y]&7,G6-'6H-6;F)?A<C:N2N24>5
MQ@YI<[:BYRC;JJJ34:EJU:4]$%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`
M<P6U'^JNX8GS`-@/P?8B@'\)I^KCF_Y_^R_]UQE0'3[0"@%`*`4`H!0"@,-D
M)B(4G,IQL!S&W<10'4FB)2J;8<@OV*G@"4&SPS$R0)$BYRLZ0&F>O<.UK&DI
M3)&K8WOC82V.65K@<Y\4I<'1)KMPE36UX;';VGL;";?MY;5-@S)(]%[.FLV*
MZ$2`UJ37#)XQQ,)&#4<!/Q*3E9?,WZRKJQ<OTHB@>*\\"(78V(FSKC-[>V5;
M2"2>$E\,YOL_A.ME^M\H3D@\3O,>[BK!45ZTICA*E7&B;`MMOKD/FQTXAU==
M(%0D,P8SQ!2AA"('66Y4N9S\=)!%C/2.V?*6)-![+N5^1PORDS\S0)4*SB#"
M:+6DZ%U(00Z:YW5A\5<$,"WNY`"6O;&P%<VL#/WB%7]L;).Q&J1(0+:YX!+&
M:AII+RG@>6+1G$F0YY-#+;X)&22FB%<P<,"@N1T7`0//.YC*PF(88$KNTK?K
MREM0/,>F?]X30#M*WZ\I;4#S'IG_`'A-`.TK?KREM0/,>F?]X30#M*WZ\I;4
M#S'IG_>$T`[2M^O*6U`\QZ9_WA-`.TK?KREM0/,>F?\`>$T`[2M^O*6U`\QZ
M9_WA-`:@G!Q;]0RRT5W_`!\:@.3LQ,&O<4=C_$SF='ZO\?$^QI!W9[K?C\*G
M3=JOQB=E.J]%CU[J?5NF+]+U@(#;_:5OUY2VH'F/3/\`O":`=I6_7E+:@>8]
M,_[PF@':5OUY2VH'F/3/^\)H!VE;]>4MJ!YCTS_O":`=I6_7E+:@>8],_P"\
M)H!VE;]>4MJ!YCTS_O":`=I6_7E+:@>8],_[PF@':5OUY2VH'F/3/^\)H#3[
M$<6_3VDR<HZ^/C4!,^)AP,A"[,>)G,YWMD[<H]0'YUKL?X_!3L/V-[.=4YG3
MFNFZ+I>=ASNCQ`W!VE;]>4MJ!YCTS_O":`=I6_7E+:@>8],_[PF@':5OUY2V
MH'F/3/\`O":`=I6_7E+:@>8],_[PF@':5OUY2VH'F/3/^\)H!VE;]>4MJ!YC
MTS_O":`=I6_7E+:@>8],_P"\)H#3\_.+?J#(:D*6_CXU`=':&WQEWM?\3.9T
M3LKT0Y<'JO97Q^%?J/.Z?EY_5AN3DY.;[M`;@[2M^O*6U`\QZ9_WA-`.TK?K
MREM0/,>F?]X30#M*WZ\I;4#S'IG_`'A-`.TK?KREM0/,>F?]X30#M*WZ\I;4
M#S'IG_>$T`[2M^O*6U`\QZ9_WA-`.TK?KREM0/,>F?\`>$T`[2M^O*6U`\QZ
M9_WA-`:@17%OTL3[)<'?'QJ`7^+N'X/E?MH\3.9QNS'QS/381H=@>PGC\!=C
M^UOXA^L=:ZV/USLKT?0@=6YY@#;_`&E;]>4MJ!YCTS_O":`=I6_7E+:@>8],
M_P"\)H!VE;]>4MJ!YCTS_O":`\X]&>\BH(1%4]@M+U$5,-AGTT4]HC+QL1//
M`Y6R".D<S'$$$R*&PLL;7Q$#OCGC>WN7J\+MVVFK<I14E1T;55P=-Z[F8;N/
MCWW&5^W"<H2YHN44^62W2C5;&N*VGH]I6_7E+:@>8],_[PFJ&8=I6_7E+:@>
M8],_[PF@':5OUY2VH'F/3/\`O":`U_+(N_47Q7)<F>,%J`N?%W'[R?783Q+)
MG3.S':BW%)?[%]DO']4.Q_9#L?T/3]7'Z+G\[H\^3FW`FRRELPYF:TG(;"!+
MFG`V4%;,@%^?U<$PJI14^,$!TN8@G0AB&+VQYV5\N;:W+>]Z`R:@%`*`4`H!
M0"@%`*`4`H!0"@%`*`Y@MJ/]5=PQ/F`;`?@^Q%`/X33]7'-_S_\`9?\`NN,J
M`Z?:`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`
M4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0"@.8+:C_57<,3Y@&P'X/L10#^$T_5QS?\_P#V7_NN,J`Z?:`4
M`H!0"@%`*`4`H!0"@%`*`4`H"&&_8+&%UM71)4GUR:ZQ*4>D8'93=C+NZ`7L
M^&,6D!O"*D%L\\P3Y&1R;@GDQ8!IA8MG$RXSV"MF230!39H*U`4:.-D[5Q^I
MZE'(<!>FKT:SQQ@F5GJ9"^S:T^I(78FB+T:VU*<_5F2V&5DX1RIK;?<BMA1>
M2-&)ISD\DXSB5Q/9HALT9)I8%V>A\\RM-35V`;<U&66M2)K;M/*VMJL]F"VE
M1DMN1"#(3F@YV\\PV0L.A[&VBJ'6\^2I4^3Q5SY?(\4%'!S""&P+@@3GH!0"
M@%`*`4!S#\6/>\'#8J'HN`EYZP?&NJF^/#I.R(F);>D%+4MC'0Z]F(0<+X3#
M*LEMT4FKP%#T,+I@8Z4!'&L[':HX`!X\K=$!/@9(Q]E-L8+.;R;$-M^Q:Y]>
M6MQB6#":A$+O9#Z<$D.EJ;&2'I]!*HJ-N51)*1D2,2K#O,)=414<-K*H`PQ,
MWUH;D/!AD@.E2@%`*`4`H!0%=W%DFB0-?.'5M5*T6&G,FOQ#CXHBH*XRNQ^+
MT:]WX[&Y'ZD\6:*KFB2.7=S-1W0854P8X*&3!/$PLQ\K!8YT!1A-HDDZZJBE
MKHT6L\M;Y_6]DN#3*#*CL_N)+&X.KSD079Q!4Z*[2.INYZ,"+IF:LG/5?3<4
M:5T7`<1(<:623S)`P>,W4CF8%\.F\X3D[Y;W$URG]>CM_/#5A_Q.DI4J1NPE
MJ*DQ\M>8H9:TJD@%>.UE_2A=#7&DJJYU.Z<NM#@'R0982X((]AND`G_0"@%`
M*`4`H#F/XI)V;Y!V-W43H@C>3=@@M=N'NP'.V5)D[*.+6T#2*=7,J["N,K*C
M50TQX-G"=).?+,1TQ;M8+H,TLJRBB5<V'BO#<P#%4';+:Z*#_%(V_BJ9HPDR
M#H;DS0U^GVQ(\9/E0=$Z(3_X?^ARD[[-!4)R2T$779/6D%V#K9'`)"<&6;A5
M1,S18($L($?`ZFJ`4`H!0"@%`4M\21K1^ZI93V^OJ^P.P,QNS7I=;^K^C^O3
MM?<=JB!(]G6H]F]M7Q([,D!E-N,T%)-J+=1BCO>!@@GMFY`W@D#'5-3S3\P*
MT^(UM_*4=QO!NL,L;%.IF2%ILO<+(]L_(;6;TAI(NWFP+HGK6(&4$E!7R+8L
M2,P4THO65MUK^-A`!UYQJR0G%\N<D+!`R!O1-V?VJA-=XHNT,;R#%KFUZC#B
M<P>@&HG?S&?KA?+\;4PP+PZF6YTUI2%:2&XE0TBMIO28&MH@.#<6NM+PIOKH
M(8.=["`=+E`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`<P6U'^JNX8GS`-@/
MP?8B@'\)I^KCF_Y_^R_]UQE0'3[0"@%`*`4`H!0"@%`*`4`H!0"@%`:3GK7>
M(]F6:G,&9FZJ.1LI#L07RE%T5[/R/E5,=K7S,"M]<(.:.7,TG,3.)0QK,0+H
MSF.%A.;G?&^6&%\0-;,S1O6EBY,H1(9SN6!XXE8G-S$-R!-$X2J>:DH)[`?$
M7%70BGI/D=WG">6##DA;3\B>.?4!,3^0N8&0^`0N`&[X]B6.XJ'D(U'[8*ML
M>59&6Y:D`0L:435W)(CC341(6W.9LH'#F)8T?36X2"R"+V!+8V+VOB'C>^5\
M@-C4`H!0"@%`*`US)L2QW,:0W$*2VP5=22TI&C:6FZ2-FE$I@F2)$#W1)'C=
MSA9IAPB,*::SU;A(^$$)EF6%$+VP&#$"OEAD!KI3U*UV66M(;*4XR2S;7E><
M&QLC(*1FJ./`%RS:S'?'C];+^-#!+.!HJH)+NBAO'<"Y<0$CGFF88Y@9!YC8
M"`2+H!0"@%`*`4!B+_8++E1C/",Y';"*]H_D!LK;->S/<9$%30'0U7(G&$A>
M05E/,8Y@'$U53#8@(P>5N3+#.]J`BHR^'7J`Q4X<BFQ@M.(T9?T*248=,GR[
M-<RR$,Z-<'@2?T"A"2;+LBO>1,FC$;P(8GD%N]E.UY.%$'L$2QP,&,10))M:
M)8[93[E"36NV"J2^IH/--2DYP@FE$8P[#K%;!5F-0P;+&C@Y`GDC-@D$4PL5
M"`QSPPMD);//ERN!L:@%`*`4`H!0$1)RT3U@V,>!M^2HQ7(;=*RSR,=O$^R)
M?FF(2TGQTF&EPZF1W,R/$,AL5%FN/TTRYU/(NB.TNM)8'9(W;`#'$R-;,#(U
MO3G6=PMJ=&<JQ(WQ&MLJH-!4FQ!*FUQ,3'N<8+%8<:,ZXI9+5B>""7;[$C%!
M30`$OJ(%@$T.]\+YY"99@28H!0"@%`*`4!$28M%=:9XDL:89%:S\$D@RRVY'
M9QT,>>9_B4P?9;1678X6PWU(C$TGLA*4B:&MOM9,EKC@""!BJ0][9?9WH#:K
MIU]B-\1*VX->;6&=<8M(U$A]%0'$Y78LGL%&"G@SG_%BHINI073#O7U9L/-@
M)"C<TH'S1@^9*<X[F8L(-80#&ES4K79R-J9V@MQDEGVWL+*;?FR9$L14<883
MYE)K$(O2T!W'Q0%D(R0.)I"&&P'B"2S+%<K)(=\PLKB#W%`D70"@%`*`4`H!
M0"@%`*`4`H!0"@%`*`4`H!0',%M1_JKN&)\P#8#\'V(H!_":?JXYO^?_`++_
M`-UQE0'3[0"@%`*`4`H!0"@%`*`4`H!0"@%`*`HGC7BI;P/C<4WI<N<*8\SY
M':C)C26Y//9[O0FO)S$AJ27LILHJ_0<B+.+E'6:3#*"?&S1R1KL@+B6MC;''
MI<,K@2A;G%7U3:T+(4O;73GK!K9@ZGA/K=:9(/91K24W'4GP`_+LMT&FT\`F
M\R^SSH(=?2^RR$43QCB0J*0:;SC(UL,Q0-S0IQ&M#MCWZ;BZ!]N8"EB0B#!3
MI0-M%D22VUQ:!82D0)*8;CR*E3N5\BI$@I%A3X=KW'3,3`76PP.DPYP'L:Z;
M\Z5[=NE],G6':"%IU=D:XX#/1!C1]HKH4$<@(;ZA@LAA)YD2RLW<C]\0+*1*
MY@ATV>`?3<_/&UP/AFOB%Z.:XRXS(%G;:N$(IF20.Q.36CIZ/U$1G.<!7SV:
M8@FSY$P8MV`3UU0#S`)&5'(J`;%#SQ"SSOAE:P%3$Y?Q)&H>O6R^\L.OI&2U
M:-=%6FV"[K?#'F6.EB8I=G!;=+);+BAR&=?'!FTPG(7BXVYSY5TK9IVDNQ"R
MBC)^1'/,0,6@+1W+Q-^'JSGG#4>.?<K7A$>FP;;93QAMO'I.;09Y]M.2B190
MCER)G(=R`*H<@%#@62&:-YEP5:XF.)7(7*_-H#9*!NGJ:ZYX.ZO-C86*7%L0
MEFG:26(:0W<F*L@H9IBIR&KNL%>;A$4<\A9(Z<Y"0N?6\0;"8C\@?/OCG;$#
M73IWGC&+IEV.9,X.Z"XCBK7AAP2\%R4G%/K?Q<1,U.;D46@ADI&BXXW$H>*T
M,XY@R)%#532P=#<)HYD&$"!D#]T`C-LUQMM$80TGG[=*+)KBG9QO0<O`QYBS
M8OE%M6.NZ8E848)L1N76>8JXIPR^"4,GPCP9,Z&,D$#9PF&<Q`OAD!LV,.+!
MI4X2^MK,EC976"+MC-CV&P'<WH-0=AFE)^."E(B:GGFVB(#\3T]MI[E)N,12
M"#03PQ%+NX<1,,R0&?/QQH#=#CXAFC+/V%QU/=.V$$-_8_(N`->'E>1FZ1>8
M1@V3#4B2,83QSF`99T*"8-@:+)`F>*H8*"8#AE\@L\<[@0_B3C.:V[.1PU)-
MU?/,AWHBAOFR-'W66EZ:&%#YPD:=[O46R3D..LD;*52<FG'BGI_91CMKI4A1
M>!3.UK"D,K7H"7B1Q$M%%[8HYJ2B[:P(J;)D%`RC&H<(R2VS#TQ<)*P]U!JA
M$`SV01EX)MBHG6D<(3-3*]'ETH&')>@/C:W$AT'>TWI6M;1V]@!QSVMJCM0D
MN)T>2FX>>AMP,134T=V-S%(!.Y"AN1&440\'FGYWQ.Y]2,9!A9X@"Y8`>ILO
MMJ6@25-18,;K(^,J7-OIH/QXT6MDY[-`HW(Z8+/5I'G28U=8S;[CP'2XM8B3
M;,%-Q!#&65A0($,!RUC&9H`#'6SQ*-&I#E"38'BC:*$I0GJ*4%YK;FB%GR$A
MJ;KQS818R,ZDLIB5%,%5%2;PY7,%2!*9F1TW/#/K`8?1YVQ`B_IWQ<6[MT_M
M*V(G0>M,<7<G2Z1-QDQ2.OHBNAL)-C^2&]'8S#/%@&PEY+YY3&7[&L3X>90,
M+$*X=P,KY<ZP&W%7BTZ0MO;^=-+7?+"2RY,USA(I/$INEU+;*28V0VOT9H^X
M4/-9S=HCC+NYCMH(NM+1<TDEBI)(4"H]C(G2WQQ`]QS<6CAH,Z/2<KN7>#7)
M+CI3D)P14CNT62$09+7G\TBR(<=B`WLBHPX[AR:I9R)^:F9)8#DT^QP'IQ0^
MDQY0,RF_B3:":VD8L4YSV_@"-4^;D=,<L3G7%)#=P+/MI+.`0B8]D$4H<-8#
ML,W@-A?%=RO@D6YUN4S;EH#4Z)Q=]%%C9S9?5<Q,;?;[OU1B-#FN5'RX'&Q2
MD6XL<^7&..4RA.,J\#RP8,1H3R)C.3(VFDBJ>$J$LL!AK#?8@,N,YPH,+J?.
MXA.J'-1W@B,11$M,33R!`<KA+'3:6!B/B?N".EB`IICI5(/+--*Y@9X#F`\\
M;XV`W?*_$'T>@R8F)K[,&UD%QU-4E]AKLN-G5(;?3'0KX.0>Y5LC"D1C?(D%
MW0;MT*6(=R+!J0_W,M<7/[&@/,?'$AT'C29"&O4@;>P`SYP47PG1L7BUP24W
M$YYA/I82T=82&TH(Q@[@925!6(.%/N5ZU8'`P*>+A!Y9"CA89`:7C?C#Z#R,
M]-V6A>:VVQ2F@CD2V]/#YD%R,9#8G1*/8].'<335R+O5SQ]OI#V4;-<UF?*)
MIKMF#S(`@#"<R^8$N]:]K];=Q8_&E/5Z:8_G%@%%PXV5!RQ^O%UHHE.,@7*'
M#:"L@8=&>15@$BH%S'5C00(V1<P$+;&X8F&60&E+<4'AW92I)D(X[G:\7E6&
MV^_W1)[+M);>NILQ$BA%5G'*)E6%ZWU"QB-T%`/G%XL&,(:2"Y`SF:#"Q`%O
M@!]6D/$+UXW\U)2-RX.-N8M%YT%W]G6^ZR*'E(K%5&.(9S7FV\FZQG&^4\BY
M@TL,!0")%3YP80D>+9VM;,6V%@(KZ=\6PYLM/49P=*>G4U:HC;(0J]=A=4E^
M473';A.2W&$?KJ,DN,-YLUG*Y]R0L_@4]Q$U0)'5<#`>9'/.V1O`SA8OF!F4
MS\7_`%0UEW4>^HFSSZC_`%[3&Q!\2RZA3')\E(C=0'HKRN]GDSRK"26Z>(%S
M81Q`"9HJ@<4.MBE@2@E\QL0`P\A;@22GWB'Z+ZLKK#;&Q.V<#0\X9.(E%=BH
M[XD=N(YY?03^8@1%T`@"'<LB;1.C!9A@JYGH4P47#+#$>^5KVL!L]9VDUQ;R
M@_DI;F^,4U0BR&0]B9&+&'@C8YLR"!BRN<!EYP7Q-98)\>C%$`Z+@J9WZIF&
M5$RMG>V-[T!KHSQ`=)2DAQ_$@^TD)_&?*A-A*4=,`)]HIAW/!(E!MJKPC]<1
M$(N8%433?=381#)TJ?Z.Q/(`.V5Q<>>';(#1OI5=4I8C7999T?ER%MTYIUOB
MUXRBI0+'<NIR4O.Q-98.8IXJCKI1ON[GE5(QAB1)J95//IF:F:*`"C!8F<1;
M`35@*;6%LG"$2[!1<HB*L=S1';1DQF'1PK`&\V^\D0DNIP*@5MGG<DJ%`#M@
M30&5[Y`&`\P\OLL;T!MR@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@.8+:C_
M`%5W#$^8!L!^#[$4`_A-/U<<W_/_`-E_[KC*@.GV@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4!68Q-6I8;_%PV"W&42:'C"LC:209!+:/!+0(KA%?[!E617<X2YQ`
ML'8P42PT=RE<@C-\[XBB7RQM:U\;T!5]IWPHMGHCFSAAO646O')IKZJ2SQF'
ME+&(;I2UX4BD[O.=+/0@,@D1"=[+)I41@C(:I@'S;I^(F0>=\K9WM<#0T1\#
M_:LCK5PK8*<(;`C-=UZTTXONNNQ3Z:3I(&5%FN[>9B#M.(70U3"43+G'@(F*
M"H8/&A@;XYDA;7R]W+.][@;YX1?#*V?UZV#B23=DH<4H[-ZR:G"ZS(,@J>\C
MCV+(R28/F&V64"$01.38C22(I@47!K8K`*4O&15%,4<BP!<L)8,0YB!HSB^<
M+3B+;G2]Q`$R(V,S3T8['1CK(@0NY6K,L:Z_-\Y>'P$Y4>:=MJE)$4J<T;&/
M(B[;'[,<!17PVJB)9K"V5PQ0[A9`2&W,X6FUFP[;_B`$]EIC(337$93]$3FM
MH3D>)0ID=-:Z0[&S?D!*>F:<7506H<R<31,DR6>68Y8QEE@+<7$&]Q+`13VK
MX1F\,_[)[0/Q>@KMV8'$<2]3'=)S<(\0AP1G&VM+QC>+64SY'C>:6T@Q/V=V
M<:<>N%`,&62L-TJG#AAWPM<J7OGE?`"ZSAW:0O#66?>)#+DE-IHB*>S&VV,D
M1:^BYTBX7PLQ&GQ.Q&JE%W0M"`9K2<:#<R>L#7)##B7YQH0:][Y#97N!7IQ(
M^%;M1M&_.*DM1R@L%50=O(BX8K(BD!Q.]/3L551U:V?2I2F(JY29HJ-@DD0&
M85$N3N+;/`^-?HK6M>]`?CO1PI=H)Q`X]):)FU'@!;B#1/PW6AKB7,.I,;X"
MDLZP@KI>3L'6%B3Z-JER!<X7P(B"VSL;PQMCAS;8VM0&AMM^#3M?)VXFY.*4
MPEJ9->=YIVA:8Q9'QWE=4#-*("K$0&,D+*9,$$(#%5G3*B]'YUL&1V$;05/"
MY,(0M@,*5MAGA0$LXMTFW<AK9Z;XR*:HZ93EKQ/'%)7N(H9W`V&5D]_+,;,Q
MTW0%H1A-"!>QJ<]".RL5'4?-*83O"5LD1(+Y!&!`N6P@60&JVQPQ-W"<:LF(
M%EBQD53HH_B$&+Q&D-YILL@*6+VUF%V`=<M.I5&;QEKI)EKO%M)"H7+A)&9@
MZ*H#99WQS"MA:V0&N(\X6>_2.TM:-#%R%H)3H7UGXG(.^>?$7*3("?DF1V0F
M3F[)Q+)A&(\6>7D)!V1<1)T%VL?63:@(BE4U-L'B.<#N$+8#;;,X3FS+>C[6
ME)$:<;%G9&_\0@]>(Z_#Y1S).)@;6M>6)L&)JP:F&2P'5GB(E.M"#S2KY=-;
M`OCA?/D+XVL!-S>%*-1UQ3N$7LLX[FL8G'-;8Z?+JX.+CV$8\J[(,!GN&$!S
MN%NE%+Y2<Y8C,M4$:V&(>:L>3`,Q+9#!XY@5!:N<*'B2M_9_2:69QCQGHZ?K
M8Z.(1G)?:/-46(L%BF-K(?F!FLY7U9U6C",(\:L4,,PY7H1-N`PKG#;N438Y
M@P.'GT?W4";W#?X9FTFLDM\,=XRFDLLHBZL<,R8]6I9S17@36#!.6'K-+.?"
M&30RX)</):0Q$%%'R$.X7QP#%M;"]N6]`?MQ#.'GN%.&R_$$>$.,B.73&NYO
M">SU#07*MRD$TE]E3.UG'*"^A$%)I'&P>P6&ZZ;N\H%=0#4"^!"W/SSQ$OCS
M+@:8W(X3NRA5YZ03#K9%QE]IL+Z'*6F,GZ_0UM,3TQ54!;5@6<H=OC9?8+(<
MC6=+-7!$<VB.Q+%#+&5!,#)"!8FKA7!Q`CA/W!KW\M%K,U]AV.F+>.`^%6XM
M2DT:--BV]'2FR)D=SZD%\.-A31.+[B!?V4GK69OW=I7!NM=//)#>43140%13
MT\N;',V`W:M<+'>O!F[EL%(CN,U%)VNX*NL>G::OFY>3TQ58^R&O,2+D?F&<
MJ-W!NJ!)8:[K4W48&P70%0,N3!)X<H0V0][``9U-O",V)>]]T<FPQ8IM>9N"
M-!NB,8W%7$(E<*?(]P<@:LF&+]CN5#:I/#L1B74K?<LK$P;8XVZN'S0(G3IP
M1]R'!+TXH(4;&)RA_<MAZ6I#P5P]Y7#`;!AU8@&%X_BIZ(<Y1:B1^X5^=&VW
MU-FBJK,&;PV!A.Q'P`RQMESQK`2OV>X1^S,GQ?QG&ZT6XP%=X;J[-Z#23`*^
MX':GXK*RQ=;EG78R^3+Q<!XL944)4*E&&X<BH)@47,T(9RY,K7-9WN!ZFQ_#
M4V^?:YQC&VGP1"\PQ?N;,FK&PD."+NQ#SBAS.$_#;:BM!<C,3E-EHI%:B&4&
MR>90RRV'(;-JB$(J%"Q<\0$)CC"!@32X.6LVXVO:)M*M[9X+206EZ7FTZ8F:
M,I29%^P>R*&WT1AIC><I^==EHMCN.4R7S2XX2U\D#$Z`=4$9&`#`,&AALQ,K
M@59:X\+CB,HFZFFLVS3'S33&YKCNAM=+DC&V#,\6MF"#K0G%#D-%:+EUOU2C
M>,&.GL\,8FO)@CJ4W.J&WJJ*0(YC/$ST^=[`6^<';7+9W2;AFQEJY.4>,4I,
M&O)63FJTBS0E#%U-:54PPYG`^6DYA5T1J(@K&Q<2JZ!4\0D.7.BD@BF)G,3*
MXURX0$1N&!K5Q$VEMV_MGN(UK(PW)L#*;3=S24]L4G<$@^$"(HOLX\7.S=<]
M>M6"$0IA.-8SS.`E[J!T1U*BNH'RV1TX9'R'R"Q`S7<3AQSG.>RW%$EELMA@
MJB+M'P<EO2B#U)<6TL!7QF]2O,QG%.4L#1,8RV6R*HNE$&S4.=<*XH&.=\><
M7QO8"'ZGPZ>('K^:F+.+-9=?]NBNZ/#`U.TA>MI*FU*86>JDBP+!ZM$3GZR2
M7V>O@23`#N47)@X#Y)`'#5%!32<<>@`^XFA`,/D;A2\0^#FV\8H@1CQ9LZBS
MOP,6/PMGG)CLG#XJ+Q9)T=M*06THO/%O+S2<"R\V6XDQ[=$W"Y7,`4L,`$`H
M9%"V%S60$V-.^&/,L4SQ-4IRDPX:5##FX76D>H\;+#D.6=0"=*4.Q(Y&C+J,
MK8(=DYU);"47%FE6,&$TX5,*90O;(+/`0,/+$"%.AFK.W?#3>;LV:V68^,#:
M9:D:13$B.MBO_9]D[>(ZDLI!]&=J$W--5Y9C8A/4`0MG9$4<L6XXG*LCG!#B
M>1L4,FK7,A@73<%V!'_K'PK]'H4E0JI)LAM2#4-2=J&L6RQ5FNK/E059`%9R
MD%EF)<`\S<'3BE"A6RO8+,G?"WN8VH"SV@%`*`4`H!0"@%`*`4`H!0"@%`*`
M4`H!0"@.8+:C_57<,3Y@&P'X/L10#^$T_5QS?\__`&7_`+KC*@.GV@%`*`4`
MH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@/C/)R>I@X%U
M(B34"X9@L;P`/%@38.!HF/@9)F<`A\!,,3!0R%B('G:W.#SQMEC>U[6O0'V4
M`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`^,^G)ZJ4%(*A$FI$1^CZ<D?+`G"@
MW1"X#!=*6,8"`B=&,'CGCRXWY,L;7M[MK4!]E`*`4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@%`*`Y@MJ/\`57<,3Y@&P'X/L10%3'!RXG<G<+/7"6=;97X6?$VD
M]QK.U<TRT1=,5ZTN`TU14!Y6:Z8FE@S#DR03PIS#)LBB998`Y`Y!BX7PSRY;
M\@%LWK+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<
M7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO
M_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*
M`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-
MA]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3A
MQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_
M`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@
M'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8
M??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<
M7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO
M_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*
M`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-
MA]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3A
MQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_
M`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@
M'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8
M??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<
M7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO
M_4X<7[S8??R@'K+_`-3AQ?O-A]_*`>LO_4X<7[S8??R@'K+_`-3AQ?O-A]_*
M`J9E3B=R=*_&,U@XEZ5PL^)LCQ7J]JI(T2N>/EG6EP!2.[%]^*KY0T\RT0B^
M0[<,$R-Y0+F3&)@\`-8N2,Y8X9<W'G`93PG]2^);Q4H"E+9)1XXN\<#]K^SD
MP0Z083=/KSS3`4QD=KBB24054W*39$`Z<-S=#8O8MS0L2^-[9WYW)B!9]Z"'
MB.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'
MB.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'
MB.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'
MB.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'
MB.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'
MB.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'
MB.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'
MB.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'
MB.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'
MB.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH!Z"'
MB.>T6;__`-@JGASH!Z"'B.>T6;__`-@JGASH"+&T_"YXD6M!*#C0/'WWT>N4
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MPE(3DQRYG-SCEVT%=E2Y[^$T_5QS?\__`&7_`+KC*JECI]H!0"@%`*`4`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0%6W%)_\`\?1S_P!P
M6%O\.IIJ5O++<_09Q60P"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!4+O%#II(FS
M350;<[;5M`#8[=0M%\FH+0V<F9M-89D&-8-F)'$1&PVTAW%4=G!=ML8HYBV2
M:$6SQQ`S#M?F#"XY"3SIJV@MHP^Y_1FZV)MG?."M0]1WNDME][&JJP6>QN<]
MMYZB0N5+B/AKN113)#*FBEA#;A/JYW!630$U,N`0"3[&Q8W`_5Y[][D,A<VA
M:JEI]!IQP:DPBT-F9,S3MM'3FA*D5/5(D171F@S#YO6,FI*DM9WAUTE\L3A)
M/0,>HE1<CV/7>B`59-$8U+G&':+/4Y64V$BP0KL;7]J,1U2>ERUM$U(8G%[B
M/**FY-*FV-?(G/M1R@/Y=9T=/)+%SS5%9#**Z\*(BE!.F!'-`JBA<DWE])=3
M?0W0@F\%!#<B.F+Z*?"ME8,ZDK!(!13C8=LK6RM@9)F,,[<MK7Y,JDJ>S0"@
M%`*`4`H!0"@%`*`4`H!0"@%`*`YW]BO]2=P^OF,S9_\`4FRH>]%OJDM/X33]
M7'-_S_\`9?\`NN,JQER?_&1W>V2TABS4$YJN0U_,REM/O_`&F0:KLNCOQ9BQ
MII4X-R4!<'>K!QR^&&XB/8%Q--.$',V,F@PDZYJW51!<@L@P-=\//?[;V4-W
MME-!MS$K41VR'"T)QG/2%,VD"E)!F)Q4%^K(R$+'[[1Y,<#M76W(8(N81TH#
MD=#ZRFXY#V!Z/,/.@)AO?B=:<QNH[NI#ZD54:ZIP\FW'SOVA(*S+=98PU&W*
MK>,N>/59L6NE7PD(NZ4PO:Q>R)D=SL9%"+YXX#BAAY`1UG'CL</77AYDF7)3
MNEX`4DP8ADR57&VX`EMWM#75HSPF$%B)S6PR^W&NH@1>I/!,4@A@$\SB(?PQ
MRMT@.%\P[9@:R$XR+;A[9?C(I>U1YCL[4#AJE^',;9,DQ\SWTZ7^NE=V8X"5
M%,R]0TA?=9-VEPI$64LJCYH:.F8E4X?/,U<SS;F,0)[ROQ&=/X,E:98<EZ6"
M\?NV`-<"FV,L&5]ON0)M-B$3[JS91%Q8N(JE&DY:6#SGQQ)ED8AD95S1@0,,
M$L((*'CD!'N#N-?P_IP;LYN+&1'Q#OBZQ0'/DFM[86))#AQX%H(,7N$2F)L-
M-TH(*X^&&?.7#*@F$@$X/D<-%0.AL*<*8#@;4U!XH&K.ZL@N&(XP$F!DRR@Q
MNB346C.?(/DV"GF[H-<RJ&AMN;&&E2,W42SRB];5QPRX*F1S%QQ$&"L+B'TP
M5\P(*39Q79(:_&]C#AO-D%ML>!&;K0J[`['R*^H7EM65%<T,75#Y)-:4B$#"
M='[$C!L-K,@>4'NH@FV[BL8'$$4X"JAXEK`2-ULXW/#]VKFIG09%[\D8@X98
MR=V,!.^1H5D^-(NV.[0KF>W"T&2&\FVDM][C(097+,0&PA<P+C[@(8F7+C8#
M96F'%?TTX@$@.V.M6W6_'XI,1MK3A=Z\?BE_-%F(1A!>83(/M,RZ76AI"8.]
M+'3`)W%.`R%%R2QPS7+;#.U`:[FWC9:`Z^;$+VMTDON1"CC9#P8D>2C(Z%#,
MEN>"X?D"30DX9C,R49@0F\=:#27%W!8*7Y!1LP"G3_[4(!T0_1`;(?'%@TCC
M=D;BO][22N-]$T.DQKQ)LD5.,!Z=GVL\WRKHJ(QBR`WPD815>Z>\SJ^6[&&D
M@,V";#RRSPOS<,N0#5<K<<'A[0O.BA`K_D1^)JLU'8S8]E:3"<12&J0/!DD/
MZQ/M:CR:9I(H8S#8+L%$4BX9P$P;R!2A1;AGA2^8)G$$#*';QE-"63M$_P#3
MY>DEV`35$AA9SETH!%S_`!V;%;<;T3')H6WV_9!Q0K,]`8Z>RBMKW/YG,K"G
M1<2X6`F>`W1`>+K-QL-`MIUU[-YG/N0H].LN#ES9\,S/,.21"B0]=:6WGA99
MGJ/UE]M]+3'3&I(`8,>YH,7`SD6RR&Q`N&"/D$!A<%\>[AP[!27%$3L]_2LV
MW7.IITBPR-*4`R_%[8DIHM%O+;I4I+:[P>C326R/'.:(W3@N*D,:!Z','HS`
M8`F6&.0&>:S\:?0;;*<V]`$2/U_8NF1"KS.P<ZGW#\C1U&.QI2.LC/;T+`<@
MO!OI*#(^38!)##CAEL\!1"P(HP.(H80F6`'V;A;V2-K?Q#^%UJNC(C!-1!N<
MF[[*TUN)?1G,HOYL$=4]>T*7F:)&YY(=*6B)N2FL*`P2MBHI2QD9)XXX%K%1
M>47(#8C)XI6F4A,?3"16M(2\=:F_SV7H]UA/#1^]"0SS=+:$70E<DKDC2*$;
M9P(&;<-VQ&5,"H0G,MS<K\['E`B(I_Q%/"[1W"31E&2)B`2#3^?<2B/\/6F=
MS<=EI>8-U3$_$H;J),0R569*6\DK+L6CIF)XX;Q,%L^9A@9`RS`^9Y\9:"I>
M@J-);UBFQ-BDYAQ`88TVF%J[&Z\3%D_VZ[GFH&\5>'5.-4\-#<C&?3K3[A=B
MW"<ZP@IXH8P9J]QP3`((&;2;Q\>&W$<I2!$[UD64":G#LV#0%-[Q)0'+ZE%D
M)OWLL40$R\GR64:0C1;C?<2Z9S*)QZQD8,T(6'RM:P0.8E@,VV"XV7#\UEG=
MPP#*,C/8);CU:9;<FN1&M$TA.^$->U^1>K]I*/.DP(*$<9<>GEZQP*_-,&<[
M$\<^4W<O;`2^`'W;!\9[1#6:7'K$<DN^4#8L1",$'8*3F!!4M2-!VM@LK%TX
MU&84\RZSFFKLU@B/D%6+7(XB&!KVZ;'INAH#X=DN-EP_-59J6H-E.1GL976*
M18JG,[TCZ)I"DF*->T^3[D[QV:G22&8A*[<C[%X`*)<<I@.(()8L8!&%Q##&
M"RS`^6=..!P[]>)J583?\I.PX:9J@PTF7)49$7/U]0%!*E*`10>/B<T34V41
M08C'$<Y=0`$#R%-"AE@Q;9FL@,<<[X`>;LGQS^'MJI+TR0=*+REHZ_\`7G*,
MCLWEX\@"7I(0(Q:,KLU(?C<D1T.MH--4;A=BE6XX4_,X<",BB!CG0BX80H]\
M@\0,HVAXT6A&ICC9[6?K^?3X4W3$R9L"IW@N)9!FTG'.ORP'@939OE$U'R$L
MALN.3:??,V&9'YQ@0F%D-@!D'</+,#%YQXZW#?@9S(K>7)9=T@$3<<QK,#Q?
M4)Q-(LP1O#\43(FD%N*I`F-[L9OJR(PD%_-]1!44[`P)D=$3Q0C.0&`(Y?,8
M"VM!7D1U(2*YVRKIK@;CC24Y>;Z\C'2ZDD+:(L$P5!*5TI1*""E#Z:I$#`8P
M`P6>08H6>.6-[VO:]`>M0%5O%5.$T]O:1'3YHL1)E^(%"PA@V<'"+%@`[1W-
M%KYC#C98!!86O?\`IRO:U2MY9;GZ#TOC!87=NT.^5&_KM9##1CXP6%W;M#OE
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MF']G>]!M,P>^O\//=V[ANPU,Z81,;A:W,#6]R%"ZLUQ`6<B,!-GY-)N1#S$/
M<\^JJ&$^G,A0C'(#C=/!YO\`W\Z#:1Q.:(LQ%//`I$>WR9%+/EQ`CQ-F0@39
ML1.E['W"PHK:$+COZ'Y!7QQ!X<>#QCU@HY92'Z@N!!&R=CY(,H?$$,Y03\A:
M(1>D=)I$FG%'JU,"A`J7)%<!78FF1,"Y4'``'$0R:41C)C/$,.UKYB9YB9W]
MW*][WO>I(HSZ_C!87=NT.^5&_KM!1CXP6%W;M#OE1OZ[048^,%A=V[0[Y4;^
MNT%&/C!87=NT.^5&_KM!1CXP6%W;M#OE1OZ[048^,%A=V[0[Y4;^NT%&/C!8
M7=NT.^5&_KM!1CXP6%W;M#OE1OZ[048^,%A=V[0[Y4;^NT%&/C!87=NT.^5&
M_KM!1CXP6%W;M#OE1OZ[048^,%A=V[0[Y4;^NT%&/C!87=NT.^5&_KM!1CXP
M6%W;M#OE1OZ[048^,%A=V[0[Y4;^NT%&/C!87=NT.^5&_KM!1G/CL*Z&R/\`
MQ'>@BT`XD(9&):/S06.*P2NGB)A0P*+,^(0!D_@8N5`&$N-A;''/.V5[YVY+
M>[:H>]$T?*31_A-/U<<W_/\`]E_[KC*L9<G]QB^'NZN(XP-(8M2T>/W+'L1<
M1_6O8K8AJ2*K**4E.[7%@HLG-V6VJE!IJ6I"K#@7T1\8E@"(F1,(P&(+;(R%
M>UKW`FKJWH]J+I,BN9`U/UZC*"$UZ'B*B[[,%O`)I]SFTL(R"E9+RP+D96%8
M%)#.CV*!#CYA%>G%N%CA<43G`4\\3W@[R]N5O+#$RQ2[F*V]<YE9L70OQ*6.
MX5`^FK<G0_K_`+!L;8>,NTHBGMY3*+;N7#J(>;Q\<^9+A%TFQ<.V`V.670@1
M$XJ_"'XD&[LS;X([<%CF0(=GQDPB#JLZ7=MW-<+,77`"-TQN=O[*=&JD:,Q0
M8TWOJ0W,EC9DG$Y31THCD+!F`_\`:,"Y`J!FNSO!/VNV#9G'3;Y!?B=M&.(O
M&?"G*Z^=D'.KF\RCMT1835RD1`D6Q1MW!;1-RNYIXIR6=*B*.&0!GK(N`=L+
MAW`PB?.$#Q'^)&]]Z),VU3]8-:5;:GAZ1;K/'3;BV37U*`++D^%-FF1L$U?C
M$5#+*1>L-MUKC'SZ\<2;&[IZ:H!%\2QT<L+F8`R6%>$)MLX2FTSUDS5K2J)I
M->&E3FU6C"TN[<\0O?H625QRNE+<[F(R`J3-.IIK1SK<X[(8-B26EH1YWHJP
M/V4`/X9%NK&P-_<'WAR[KZ@[+O%\/-*+ZN:@6@`I&9#3-"W4ES<UB+LZ%G2B
M*64W1M>5V>C&H488#9)&B!1&S455:O<QS#)H8+'&^($D-E>&A)^QW$IG[8%2
M<C;;.NT\<$65.&@?6$Y5/C2<WY/E">UYZFG(1;-DXLG"MM*8RYD*$;LJ!CY*
M`=@NAQQ^ZV`A'K]PX^)T]7)PJX*VR:VJ$8ZW<)%T-%V(<NPQ)+S>4B[,JL/1
MP/&</%T5G*C,;6$<HYI,"",.NRF8R$41<\A``\;_`'"@+0^#1IC*^A&C3:UW
MFL1ECR$FRQ/+X4S+"5C:X@&$V2);=;R;F5E,^C(1LPH!-Y6*AF,<B]K!"87#
MQRSQQME<"COB%<'/B9;>R]N-B,)&TBM>0]A8GF36Z4'AN%-D?,F-H=8[A91D
M:!R>G#.9)F(C\G8`IQL<T^5S,Z(8""SZ+_;#=A0`)Q[?\':79_XI\9[(LITL
M5O:7RTYM7Y=WWC55/FPWO)\L:-7DY2UY+)Z(70#S><3171W4BIZX":.@BX%T
MO,4,3*U[`"@08G7@1[0*6P>Y[6:<-Z[;$:][Q[:N':$U),W[G[[1*UHC(2<Y
MVRZI-8<F:?:U2Y$[,G)20E1'-"M91"52IO,6Y+(^=#+E@29,"SV/^'5M9&4@
M<<M]1D]HSC]V[\MN,2&H;X&/J;G-,]P1WK8XHL3%.3R"NWE,1.+IST4PA0LN
M5?RL6RS,9A#B6R`%`J,CC@K[5DU.2YBV\+(<-QVO<(W9/3J=7H#MIL'O)-AF
M0UU.`7%78@0B]VAAF3;:_FCFCY5@,ZPX"<%B$6"P-&38_1@0JC)?EC?_`&3X
M)FFZ]/.ATW,>%(&VVAPDX]"'B_9&>S;A0UIL5A4S.&PZ8]V^RA('/*1,HDE4
MMLFBR4?-K61JV8`5LD\O@!:7PY.#!M1K_.VG:?/L$ZW#L+1T9R'$W9:V['$`
MF%UR0J]KRB@L1<@36!<EYIP+KRI#%3`8+H+J:*JHPQ?(0-/(8XV#Y`+;MV]&
MI9V2XAW"WV4:2BT4Z)]1D'B%H<SYJZJ=`=]L-J-;T2(X^,LE"!2C!%PY$G$2
M%$4<3!TA8`M;'+"XN5[XV`INU(X47%.86?"6A&8FIJ8AP+PK]D'^^+R.SY>?
M#@D6<&H\S#V.E7&E,XVP"".T@T<-RXELD\V<S-GA1.EYQ3`#F&0-P,S@V[<(
M&LFE,1'E*'[NO7[C[-3B6OL0!Y+8B2-KJBO^2W,<)(!S)H!C*$D73G:5M@F"
M!%RN0MA,;G+6QM?(!,G!MVX?DF[+NY#4H?P2I:XT6GV_;6Q//);+FPX,@M`.
MICU**P(;0'P*/P4R8QZBGX9BEQ\>6^9H+^B@/\V*X-6VLI:-<<37AL'X=#D/
MB(;\HVRD"F5-XK11!*QPG3#`C[S+2$I@L\T;;SBQ1HX4[8%2Q=0!Z?,+'IK6
M$RRP`TSM%P.=IUS9[=@>-8>U\V.@[?&:R<SYNR<-T=[8):T)F%P)%SDQJ2]K
M+K%*$;-S85''.$!A6X8`42Y\'*X6)L;`N$&`&!]V\/!JWB>6S4I2'J+',)1D
M^7RFP<@09O9"6X>R.J$H0T@1BUVNV%-.V;A(B2EM`V7R*%$<8FE'R9T!7&2\
M`>R!D<7E!P`D.OZ%<5_7K8+=T/4T+3J:XYXB;F@]]O6==GC2IDKP<\F*QT9E
MRL8<\$D&>J(,OH+ML1,G&XGECI<LFBCX!&,+8!Y9B`14V#X$VU-]@=ODV.(D
MUVV7A'=N54*5!7K-&X6\.NC.ALT>3F^!)S;E?5#5*3(Q9LYH)PZE##-JY(^5
M-$[Y`A&!0RH(0`8$U7MPD-A3:OQ^0F@9BL!O<1O5S3N"]5L#3K=&`Z6I:_ZD
MN2"G/C)%U9,<BNV$<5SGRN1(:R@OFS)/"XI@3(;&_/`U>7X=O%&U"E0_*^F;
M4U(FQ:V,X=FI^G\Q)NP3^<J"@P3+FN$8E8TQ?B.FE&*NA2M#BDG7S,&4>V)0
MZH&KY]*!B%CC8<".L^\#/<U.G/81Z,..-:ML4+=&(=?&M)5W9M/N+HW%T3RE
M&L,DXBE$PY(`U'?#*0IIU]?V9?)134`4YV31R9@5+"O@%80P=`ZQH#BXA!\%
M0M"J6512*9$$2QS%R<2;=W7DW29"/V<C-,H50<GVZGT^,D4N72<<"MUE<656
MX%L>MGC9CI#`@&VJ`J2XO#.:,@L+35EOUJMQ[LYQ;\PPGN!IN]#3'*VETAG'
MLS"9D5A"62IU+4R>>8>.5PAPL\+WQM?D]RU2MY:+:3:WT-/>CZT)\B'4+S:X
M9^!=9*(Q\\^+]8]'UH3Y$.H7FUPS\"Z40YY\7ZS&6[I=PUW>9=))IZG:.N@X
MQG,.RGL4;L$P(MF6>\BR0CKYEI.D!-:ID5ON8NA.)/.YD#=@36!0\7&OA8,8
M/+**(<\^+]9^3:TSX:[R//),:FH^E+A4([=>3%?1-)UZA(Z8:;RP;K==N;97
M@@6=EDFK6+8=J8?N7$YHG53X`G)S1,;W40YY\7ZS*_1]:$^1#J%YM<,_`NIH
MASSXOUCT?6A/D0ZA>;7#/P+I1#GGQ?K'H^M"?(AU"\VN&?@72B'//B_6/1]:
M$^1#J%YM<,_`NE$.>?%^L>CZT)\B'4+S:X9^!=*(<\^+]9#%NZ1:7C\0V864
M-J)K`,S4S3'6UTIK2%@**1&RGN9=F_:Q)6W&10<VG=**+JRE-U/+&C@86)@P
M7(EPQ,\L`0[8Q15+<\^1.KK5]OH)G>CZT)\B'4+S:X9^!=31%>>?%^LUO)VK
MW"JA-%*.69M=^'U$;=/J(".17Y.B37)A(IU7-<MRR64574WTHB943%K7Y@&`
MF0N?)[F-ZBB[ASW.+]9E(NDG#C!:XCWSU!TJNS@D#-U9.D+7R#QT"[9P3KJ]
MU\-6!:`A$9'NEVZS8QAGD%D!]G;*^/NTHASSXOUGZMO1SAUO!NH+M:VG&F;@
M;#I14MQMQ>2==(4.I:V@K9$!32%=-.`LW($VGJ2>:#&!%PO?$0/.V5K\EZ40
MYY\7ZSVO1]:$^1#J%YM<,_`NIHASSXOUCT?6A/D0ZA>;7#/P+I1#GGQ?K'H^
MM"?(AU"\VN&?@72B'//B_6/1]:$^1#J%YM<,_`NE$.>?%^L>CZT)\B'4+S:X
M9^!=*(<\^+]9#'A^:1:7O/5%@.-X:B:P.QPG'3-9<XNN6`HI75DV72IUDI(2
MP#*HJ-,T='!34D@`5+XY9WQ!+@AAX6MAACC:$E0M.<U)T;]9,[T?6A/D0ZA>
M;7#/P+J:(KSSXOUFI3>NW"4(2D4@T_!?#I)38H$<5,A#QN,=:"TI'4W(O@;Q
M4"D?#(F#M,D<B@F(MA<"F0=P\K9<O)?EJ*1[ASW.+]9E[ETSX:[-/,U,=>H^
ME+>4)$=>+%8I-6UZA(D8=CRS;KB=N#900AF=CDI+638:2F?L7#YPG52`XG)S
M0\KV40YY\7ZS*_1]:$^1#J%YM<,_`NIHASSXOUCT?6A/D0ZA>;7#/P+I1#GG
MQ?K'H^M"?(AU"\VN&?@72B'//B_6/1]:$^1#J%YM<,_`NE$.>?%^L>CZT)\B
M'4+S:X9^!=*(<\^+]9#'B!Z1:7LS5%_N-GZB:P--PDW3"A<FNMJ`HI0EDH75
M9UC5(5`"RHEM,J=`!4DD^.5,8XYVQ&+C"!YVOAGEC>&E0M"<W)5;]9,[T?6A
M/D0ZA>;7#/P+J:(KSSXOUFHI.U[X1\)&6Z3F:#^'+$9QWFKD6F4DZ--9V"9=
M![$0,*Y-N@.I%215HU84;#&X9:PN?.SM;DY;VJ*1[ASW.+];,U=^F/#5CYL*
M3V?NJ&C;(9B.$6'5W:[X*@-M-A*`.&BY$F,I+RRUB241"-GC@0(>0HN-A!1<
M,,>7++&UU$.>?%^L_A]:9\->,6:YI#D/4?2EF,9F(I]QNQV./7J$DM!;J"E@
M9FE%75U$TS@RQ)/)%@\LQ1<\K8X8VO>]Z40YY\7ZS*_1]:$^1#J%YM<,_`NI
MHASSXOUCT?6A/D0ZA>;7#/P+I1#GGQ?K'H^M"?(AU"\VN&?@72B'//B_6/1]
M:$^1#J%YM<,_`NE$.>?%^L>CZT)\B'4+S:X9^!=*(<\^+]911.VKNLZ'_$!:
M00LB:[04CPX]=,I=<3RB9+B-@)\9NUP)9F6ADQ=<S#*-\%K+RRG#(Q/,`T:*
MBC@Y%`;X96N%AS:M*J)YYTWOUEE'\)I^KCF_Y_\`LO\`W7&54).GV@%`*`4`
MH!0"@%`*`4`H!0"@%`*`4!AK:CJ/F8HKBNSV(S6HK.8UD><BHVFPB(2BX#N8
MF0N9Q<.I9$J95C68N=\KB#Y"9WRO>_+RWH#,J`4`H!0"@%`*`4`H!0"@%`*`
M4`H"K;BD_P#^/HY_[@L+?X=334K>66Y^@SBLA@(G[I2=-$602L*FOL<.V1)6
M<RX@,5NB--M%7B)'`+H.7*+<OK+4,'B.;H2HV0\#"B$E!9<JNI!E"`F9<`R*
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MJ,&(;GEI*!58W3';`&E:ZCLEO"B!XAC8J+SD!<N6MS!+FC1T?H^6W);%4C@?
M6ZW+L4O$N*[(S=VV5H\7XGV/)ZW:\MZ1G@WF5!L?=N4):>+V0PBWFS5X\2>S
MR<TGF$IO*"GBJ)Z`KJ&!D(EG<<S84225T"D)XX2;L%`TI@;*,^26,W8?D8Q$
MNPDB,*>RS4;<@"R*WRCLC38%D+*RJ.UI/Q88!N^20Y,$Y41S:>-<N5P)F<,`
MB#+1:DJ03;'ZS.;_`)BFK'^/^XM1V_(7?ZM?UG^1$[*DH4M3ZWIKD7BT-]H,
MIW0HPTUJ</81UQ\ZIIBX_-(I-:=,\.IM3@GQPP`9.B\H`>5V^DLD-Q+-SH@A
M1*Q"(V!SLI]8)QVD]AL[6YW-][<)I<66NQFI'2(3A;:)HE6U'Z@M*<<""L!Q
M2ZPS[HC$PXE!56`8N?JBVQEYLEAC1CJ2$I%"^`F>`6.5W8'O(%LI^3KIO`ND
MSKCB593F17DKA;["R>K1?(2H076.J2#`NL,3R?#I)@-%/2TT)AX):F?%0\"Z
M:,'BHIICE4.N'L<#N+<3\YN-QON3X)(ZGN*/-JI4G8[MMKAL4ZI(S>;J3'8D
M*!AFZH+TVMK8Z*44JF%246IB)(J<DH>*8W\"C>$`=A7`0IF8!`'L!X,R;;RT
MD0GHN<;<TJ)=[R3PL-M9\>UT]6315ERO-EZF1@ZV=)"D6P#$$R'1WVJ'314Q
M;#`#(YF+:ULN;ECB'SGH.Y*VK!:&GS?9<US3LNJ/*!7=/TZQ0U-F&%KQM0]G
M&XDR$"C;D2+U-306\SSD,Q:JFU,GFTL%-ND;J"\2$4#:G;+,$0"U/2J5$^:M
M5(.DE,=[W?P*\R"A0T\)+;2`T)$7EALFSC47SCY0&F8-L\H[;+B(8#4!$845
M&-&L,QR&>1,4&]Y6XA[R4="""?#7_P"3B-_^+YZ_ZA95J%N+W/ILG94E#EO>
M9215:.)@G@AG%E]6%7C+LQY.6/E$H=%W7Q>49[C1W"IP)J22%E@UFZMJ,M,`
MD>1&J.ACKHD=&;I`2X%F<+9%J]_>6^8M(XF#44GNZN&JU4EZ.:/3:SQ%$`N(
M[6;FF`NA-3PM.MRS*N`B&U9/5"::>6$D`<EB<L!F.3L9N.!?`<,//&60B(R'
M*\SB2AXFZG/LJHL4#\3^2-9;S(?=0`DS!Q6W-"X_VK94(@2\?(Y+@+A>LFN@
MX0++XN>;E%0R%R`1W(\,&:N)[^X]Q-GN96#L2RM>TV:GD^HLCWBML'7TF_W0
ML$5MS../7WPZ)=G9PP,_WE8J$*]SD=2_DFW#.FLLU:]LB!,X..:+"Y".T?,8
MR\)UFF6I27HU96RC\9S:6..8:U7%=,;*;9,K"+"[>X8]Y5>42H1]41EY+30L
M);1SXHPF0`IM-5KB"87P&!QMB^<'Z/R49PB2?'Q*#VE*<'AKJP-I(>B-M3#`
M$X1X_P!@10A]>B.-EJ`MI]5'EVMNY>=;J>*R/V?="*.YG0!FOECR?B0"#N4R
M`Z!ZDJ03XE'_`"<21_Q?`O\`U"Q54/<7M_31.RI*%3^RJ80<$ZSW&^NT$E)W
MVCG37]A1C,STEE4+$=<M?(/,B2:6915\*IPBJ+"D.Y%AP+"K=C-DD>4EZX09
MM1S32G53N4=O>25?<2]NR.S=75;6!]1QLBZM?=)-:H!:L?2>EL_LFSMC9U1$
M%B(^<N26X07`*,2:T2HQ6P2:G&+C9'GJIFSAG#E1DHP-#X$K>6U<45Q=MO"9
MW6<_8)Q-CL]J+*JIVO.Y,["NA&ZXR3XW8Y>2>G,]CE4KSN:,#TF?,SM>W+>K
M/<0MY#O:>6-@M(W7/C:8NP<F/^QK0<>;E)VS*80WN!'DF)6P;"B=SSFW$6Z,
MGH[40&TQ)"4%Y0;90,-LX]A"_1$@<<3'3QN)WG@[PR/,>F:-L`QH.V3F:1"Z
M_P`,?:O90PI2$^"TAO>'),AMQ10C1S,#:=9Q.Q-HJ++&$BKI?)&!MBAX&FYB
M,EE"80!S`0_Z!O,XXENTLKQ[(\\-*%IJ.-,VUN&VJ3"F$FX>3%#)LOE6V?BU
MG-601$_[KEUDTV#ZB6+9"98A&2UQ;8\O_>L;(1_.U21LE&K]R8[$F;8V>8VA
MG63MV?Y")-F(ECG<9AOIX2!+"X;V.>K.?20P(WFE@FD!$['-MNYJ"6A$1F^<
M)X)AG#,#$N)1<A!C_297A.'I205T\Z$.2HLCY_HKF4V_DTU)Q)+R:20XDY=4
M&ME:V3:/*Y-1P,"I]_=)B"7!_P#@J2"C+8K_`%)W#Z^8S-G_`-2;*A[T3]4\
MK^&]W69FM^CTQL!P0WLY(Y\YNSL$Z,5Z$H,=$H-``NK$F$7#2C3C0\K$P'`3
MR3\LC)._W0'`0.]_<SM6.C,E.]'0+Z56,/)<W]\T60?MZ4?`47%#TJL8>2YO
M[YHL@_;TH^`HN*'I58P\ES?WS19!^WI1\!1<4/2JQAY+F_OFBR#]O2CX"BXH
M>E5C#R7-_?-%D'[>E'P%%Q0]*K&'DN;^^:+(/V]*/@*+BAZ56,/)<W]\T60?
MMZ4?`47%#TJL8>2YO[YHL@_;TH^`HN*'I58P\ES?WS19!^WI1\!1<4/2JQAY
M+F_OFBR#]O2CX"BXH>E5C#R7-_?-%D'[>E'P%%Q0]*K&'DN;^^:+(/V]*/@*
M+BAZ56,/)<W]\T60?MZ4?`47%#TJL8>2YO[YHL@_;TH^`HN*'I58P\ES?WS1
M9!^WI1\!1<4/2JQAY+F_OFBR#]O2CX"BXH>E5C#R7-_?-%D'[>E'P%%Q0]*K
M&'DN;^^:+(/V]*/@*+BAZ56,/)<W]\T60?MZ4?`47%#TJL8>2YO[YHL@_;TH
M^`HN*'I58P\ES?WS19!^WI1\!1<4/2JQAY+F_OFBR#]O2CX"BXH>E5C#R7-_
M?-%D'[>E'P%%Q0]*K&'DN;^^:+(/V]*/@*+BAZ56,/)<W]\T60?MZ4?`47%#
MTJL8>2YO[YHL@_;TH^`HN*'I58P\ES?WS19!^WI1\!1<4/2JQAY+F_OFBR#]
MO2CX"BXH>E5C#R7-_?-%D'[>E'P%%Q0]*K&'DN;^^:+(/V]*/@*+BAZ56,/)
M<W]\T60?MZ4?`47%#TJL8>2YO[YHL@_;TH^`HN*(`;]\0)GRR'IVC-K6W=<D
MIH.[<4.O$FX]8WPB#+P*8Q97)B(;9P,WRR6W0:R4\1"Y$*W2C!!"YV]P.]3M
M3JRT55-)K<;N\;=8\C#B"^:-(OVE6YD8_#?%>L>-NL>1AQ!?-&D7[2G,AX;X
MKUF.(.PZ4UC;H4&QH/O&W#[X<63P>AU!TK>20;=[MS1$1LYNET&4\D7&<#BR
M;C934^YXWD,9N13RP'/Z(`+'%S(>&^*]9CI^5X]54A^M]4X;^X"D@RHN6<TG
MHA_1!P'$B1W)9+;Z'9P/U-,)(A)X+ED1I)1/K:A@8'ZJF%`N?T9<''!S(GPW
MQ7K,2=*W!3XDU"FAY<+G:ATRXV<TH5!DMP:!K:L]TP=!&R,-TR6<IY'&5K&F
MT8$S$3!<A;B)H@HF1;(*X@E\G,AX<N*]9X[Y`UID]]&I.DKA-;&2%(9XB33C
MST?'#L-.QR'BB<2&3$X,ZJKS?/FS>:<EF!2A<03+(0`H+F!AEB%GEA=6(\.7
M%>LV4:EYAG4B0V^=X<NXIM!EU0/*TL(AK11QF$B3U13;R.T5)2D--%2LR;U4
M%!IMU/2QQE+`R(*G$2Y;*]P00\,7,AX;XKUG@0Z]HDU[1E1OP7PTMOHB1UQ0
M#55TC'FBSH:8:ZI@%0T\JH+F:,G%!E@X230`RA<0SD+F7*`A@!WQ!#PPQ<R'
MAOBO6;?\;=8\C#B"^:-(OVE.9$>&^*]9#%N[-*@7$,F%RVU0W<%%/:9:W(>3
M5`UC?0KU(!I<W[5G\'`IMG'#KQ%K*^2QD6(GL_N1HV1-A8?9%\Z<RJ7\-\B5
M5O?;Z"9WC;K'D8<07S1I%^TIS(IX;XKUFF9D=D-[$)R*DSQPRMN)A3FV<-J#
M=+21H@Y'AB@G%$K8@ICHN2XFG1$O)63^4L<L!EA8V5O<$:V865\+N9$^&^*]
M9L(GL(CI[1+Q^0T%WA(L,HWL&D59)/2EXEFB6:@:?9(#;)=M@DL$8%O!I5NJ
MXDL0;%K%_N=L.9]C3F1'AOBO6>83FIGIP[#-)_#OW.(FHL0SC9C$R3T;<Y4>
M.6VH)J:C*#>88P";@(T$,\D(Q,H,43[EP!2Q0$++"^`6&.+F1/AOBO68%&2S
M!$+.)SNZ(>%OM-&+H>@0Q9U.!A:!+346%XF8/9*IE/4%!$1R1D9,,JXF9P0K
MSK%Q#H@AC+"XPF>>3F0\-\5ZS%FBWM4&"85S;)X0<\M4VO)CD0UDVA<-WL<:
M4F^\"1A-=3<-&"S:P&$;;A338I8XG<[J0Y87,+,*X>66-W,AX<N*]9E<GK<%
MS4WFFTY<X7>U<D-IA<EF*AO+0=>7TUEA]CPD?,!IE5!)'#;I4PC`XDA@2=@0
MAB5NKB8Y`\N%.9#PWQ7K-M-[94NT4%%:K4T3WM;#7;:400FZVV]IF^$5!041
M**A$4M'14=-*ED]+2DTD!@"7+@!A@@A88X88VQM:U.9$>&^*]9['C;K'D8<0
M7S1I%^TIS(>&^*]9#+A^;-*C;U18".%JANXZ<"SIFH:RXS-8WTY&X:N?G22E
M#($FLD<+EC)A.R-7+&\,?=`.`BA9?987HI*A>=MN5:KUDS?&W6/(PX@OFC2+
M]I3F13PWQ7K-!YG=?199PG@3A6[/9S5@>Q5<95RX?:K=_=FL"ET\%?R='87L
MN(XBZ;ED5"4<A;G0B@F8&`N(0F>&3F1/ARXKUFV5[8=*=)MKJ#GT'WC<9]CN
M+%X,LZO:5O)7-M!VX(BVV<'2US*@2,#-]Q8MQS*2?8\4R!,V(J!D#G]$.+CD
MYD1X;XKUF#.E\Q&]VX^V@\.&9MHYFM*#D+O.2&^MZ$KJBDOQYDDYOI!%Y.\D
M92!`'"[D]+:227+JAJPI\N"ED\`Q<;%@+8.9$^&^*]9CYH[K^=B(M`1KA9;2
MC0F3/`JI**KZ!+>+$)K1=4R7`%\FVL$C%,*N()=SR/XJ(8>)VQ[*YCI>FO?.
MG,AX;XKUGIL]RP;'B<AH[`X6FSC'26R]09*;:6S^'F<;*<WY&+LB\9EW^ADD
M5ODBR2]0(XO=OX*H&(9[%$OU&PMBOW*G,AX;XKUGF*YW7YP2T3GI<X5^T*Q-
M:>:25`G*JGP_U@Z_0%1`+XE&^LXN<PC"*UUQOD\>@(';BW-D@+W#`$#PO?&[
MF0\.7%>LWYXVZQY&'$%\T:1?M*<R(\-\5ZR&7$#V:5')JB_T<75#=QK8&73"
MHUUQYZQOIMMPK<A.D:J&()Q9/86+%C"CD5L6*89>Z.<&""Q^RSM1R5"\+;4J
MU7K)F^-NL>1AQ!?-&D7[2G,BGAOBO61BDYN:E38[CL@3+P=YHEM^J18B347M
M)W#+3WZ[CY1+*AD4PJ=<CJ:*JLFBR<2"P!`PS&RQ!"QMAA:V-K6I6)/ARXKU
MFWQYA8QF."<.F>'/N.8B-.;B,ST^+!]%7&+'!%I-TN2*-]K$V0(EY-DLW$(H
MFEPB9'`KB6*A@!XAX8VPQM9S(>&^*]9[;NV'2I`:Z^R'[H/O&]V6ZDHXA.AH
M.[2MY.1KN1$40<BZ@CKZ`LDCJ2L)1XOG<,8N8"$!%PO?'+&]K\E.9$>&^*]9
M\JA/+<5W`.[%7A][L*;I,M)08)ERJ&D;M.N`PQ%<Z`I*K*'63*>(HBM)342P
M9@PFY"7)C#AXYYAWRQM>SF1/AOBO6:SCA1@&'D1YMJ*N%CM#';=D4KDG/U"9
MO#^5V\D/)*ZH=3PT1RIR8BERBR@%$U2,%2Y`QAF3+%1Q`0@L`LLL+N9#PY<5
MZS'6B@:IL)*7$-E\(:>VRDN='%;KF(H_#?N2!<C>&.(JAF@.&P3:MDN(=CC;
M31,2AJXI?"Z<4YN%K%@+8*Q'ARXKUF23`J0)L$>052=.%KM-,"DV`C!5`4))
MT#6WD=3$\[GB*?2"YE?2#PW8)1&PP$,D,KY$S(@>&8H6>6&%\7,AX;XKUF\@
M-L%$J`"6+:5<0`N6+A!@%RX&H4A`@```X6#"!!"#"Q#"""#QMCCCC:UL;6Y+
M>Y3F1'AOBO6483K-ZBJ<?[2&3,]?=HTD=M::2ZBA1:N08ZTN:'58\8EK#):9
M4:CX]FW*WD_%1OF:.`6Z,#`J8RR]P'*HYE6I/(Z4JO6;U_AH/^12:OGS;$_@
M4?U:.XI+>6R[;;%/^`L=>4.+8M9\KO[8K8,A`C<2'_*RU#C003)F'YCE\RYE
MMW-V(YL6LP"Z?#XQ,,H`A"9"C'L,[BAXAY6RD@B5*/$GE&``=CFC.6LC019J
MA#7IK;*M-MQSL(JR!$\IL!RR.+%@I>TIK,!Q\[V(NH3LQ##,ESS+'L.%GD(4
MR,X!"98Q44-Y(VUTZLF=XNA/:"`(NC@.:FW*"Q';V@S8AU[`)UU2(V\5=SJ0
MG>WG;K;KXZ4/$5LC"#E#I`JL%A#&&!82X0PX&.<U%.!KJ(=W]C93CZ#=D4_5
M1MN#5O85:CC%KGXKF-=DW86/6%*RZF(+1DF38D28=+-+),1\UHN;>1!%=2B:
M91+`T*/D>Q)'+@15[Q0L279!9#8<[&9;B=2&BNR3#RZF1\WU)0`**CR4FR@'
M74X$]NE1LL1%0\D-E-,GQP@N<)@3+BBWMS`\[XR0:D?.W6LD;$UHZ^)PCQOA
MMZ0QHD50#*^6'40I1+-4B^3D>%DDEUI44GD09:D`K&$XL",:+IHEC(F&(/+G
M94FAM]B/UD2BSV](,;NUNOMC.Q."5VR[VDL$%]N+R8-?+$,ZE*Z8.9(G0.DP
MRPO?#._-SQRQRY,L;VL(-9S5M!KYKIV&QFZ7&7'!APE5911D]P*F."LH(Z!U
M3MB<`*.4P-*EFRV[*!>ZDIY`XD$ZQ@*Y@8+I,.55$G@2%N9JC%19JFY`V%B5
MM@/QGEY"8=S+T1C0KZ8IH,,<!WLHNG&3AAVMP0D+8UUQ.Q,@6)XY&+Y6`PS$
MQ50H:C=_$4US0)E9,%H+X9KJ=TH:S2!LY&J^6?;:*QTZ6PSQ6O=!2\7@7,*M
M@L7ZE.`RJIZB7*G"5DE%/F<LK]#A@(J*,P%G\4&!\9!=S`G!S1=".;<B?7.4
MDQRFY<(.IL.@A.;(5'<NG4Q8P;#>(EH_CD<H5+".D<3!+/!J)8<7J/2AA"*B
MA)\QLNQ&ZZ9Y`D-T16Q(Y@QMQ:YU60U.6D'+(%-DH@N&@33X;QM/3`8\3[F$
ML$%'''4#ME^X^5P<0L@K8"*@TS+O$KU(B>"!=AOC2;KR8I688OA!0";BPFEU
MQ&?<FNYM((:6X$=?,)!]NGFLUW#FZ%$H>#+G+-TB,:""$M<*PBJ%&;)2]O8H
M)MV:'U)#WBEAQU%<NI,7)3P+RFEN8%R9.&-XN?;:P6DX%(2C31D)QFI)P+$6
MH'=44#9.Q(X"()V1#+@JBANZ+98C6;62E2/$CV;LA,9;S/@)KE:ZD`IIHQM)
M/F$I73A1`<ND)JJ.JDQBIPH-B&9*&0LPAL,!,,L;`;"H0*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0$1MFO_`#/X?WS_`&(/\/I@JL]QDM[WZ"\JJ$GQJ*@12$\\
MJJALNGIJ83,J"B?-BX`%21$D#F9-FS(XE\0P2Y8N'EGGGE>UL<<;WO[E`5@0
MAQ+3<J+^L"P[]:)`B*`MX3BRGZDS:XW@SU<1\GL6&Y9<CPI)4=IF8:Y$1B:X
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M[.XE+GG!L0=XL^IDD27)DL-.<7:\6<^GFU8H9D'>+=+UX`EIGR!+%BSX0E.0
M+S,5.HK=340HI!K828;4!3!%/"ZS<":6J^Q35VRU_C78-EHKB;2#(R2?-V;3
ML!(`N)N+""NJK4<[?5,TD\J(QX9$<Z$<*XG")HR0/!A8F"PPH`H>>0$@:`KI
M:/ZVS8/_`-NG3O\`ZE]Z*%OJ+TO^@L6H5(R;6[,)FKT?MAR69#DE)^29*#&A
M*&XH:1Q%2EZ2)5D,Z8!0T`)><QY,;3:1TI&35%:5U,^8P`3T5*-CXXC"X!EQ
M0,?UAVE4)T<DV11(D5*D'3[KLX&BDRA&QMU([_0AT&16UVTQS(T?/]"*II9V
MQ^]2150+%A3:>D*I912#Q8V0+Y`X7%`C'(7$]P9"W,3S(ZYO=SZC:XS@G:^3
MQM`4>S-3K--[X*[8;C_=#7B(Z)VW/>*(0<SJ#3G@L8&"1XJ9)G<DQ-5@"8XV
M`"0N)[@R%N8GF1US>[GU&UQG!.U\GC:`H]F:G6:;WP5VPW'^Z&O$1T3MN>\4
M0@YG4&G/!8P,$CQ4R3.Y)B:K`$QQL`$A<3W!D+<Q/,CKF]W/J-KC."=KY/&T
M!1[,U.LTWO@KMAN/]T->(CHG;<]XHA!S.H-.>"Q@8)'BIDF=R3$U6`)CC8`?
MH_.)@ILD\^9`MK(^%/4J*=ER.JTF;#"/9LI#@2GR+)C9A1=?35A4\3[//.'&
M3+KFLAJRJ$IEE;G$39H@DGR@6(V8%J=`*`KIX4'_`")Q5_QQLA_U/3+0M/Z1
M8M0J02GC<1[,:<K:VZ_ZY.+9>8$.&0-@)&2",B,R*V\Q(W6G2NLQAE!G,\;&
M0%B094<+,<`#?2L`02>=D$T*HJ"<!<$44#*DW>6!S^CPO$#,*#@2H#)06K3V
MM6447(-[(C=;S?.K3C:AYLX&,\LY`1#R:82!4T(82XBN#<N$)GRXYY`1K'XG
MP<0=MGCL:YOC4OL9JO)NX+/ZZ]6;+';E&4*=K'QP,?/M/$)]AIWC_M];W6&U
MAUXJ?[+X=CE(YT!KH0`_$^#B#ML\=C7-\:E]C-5Y-W!9_77JS98[<HRA3M8^
M.!CY]IXA/L-.\?\`;ZWNL-K#KQ4_V7P['*1SH#70@?1AQ,348&'03W&UED35
MX\2U8D_<!C$,7<SYB./R-H2P;0DP,((!EYE,DJ>V!B^F_P!.V@^O%3_9?"Z>
MI&[%S5P0-G0SNC(3GGQDZ[;":QN+6][S##+VG6%1C$DM23DYTM6,5B,T236@
M\LF\02#3`E5C&I>0132;8-421RYK/(JJCB`BA8@6`T!73Q7_`/D3E7_CC6__
M`*GH:H6A](L6H5%`54-WB>X+JRQWP-KF^$S3V4-F!-3X]VH&>K-'#6)),R.K
MPJU'>JQ$$)9V(,,2+-B5BUT%=S,C'S)LZ4-&4PHFF,#EP)2;1;1#P`>A=A,J
M,EB:YSV)?BJPHABY*<2.RR)[-KLY<D!]/1ZOE?#,IS.8#%:3?%&/G,"JB>%,
MF"A0F2-&#.`=`1;*\3W!91FZQVWKF^%'<)<V8?FIYW5=1>K-21&G),91P!-3
MS=[HEW`12:9>&"<)JJ.Z"JZ4+'#YXHX$TJ$F74AQ"8('Z$N)SBO(S=8S;UX>
M!G<!>V7D#4TYJ^N/EH(@32D^,8OO.3L=#KEXKBMMP*',(5.I#E)K:>045(Z3
M<"<`&E==$,%BP'U)?$F6'RDM9I1-J](3RV45IYF37%Z0PK/%J-UH0X_H$;91
MWR&MRA-R8&[FXF1Z:;BXB&D`ZGIZDJK6+B3\,4P$6YP,F!*[4W9=-VGC);>X
M+)<$;.=C2I*L'2<P'$=2%HRT94A=ZJK!?B.FNAO&3;>=[?P6TC,4@ID\[8F2
MHN'3!%C.(Y4`"3=`<P6U'^JNX8GS`-@/P?8B@(E_PT'_`"*35\^;8G\"C^LD
M=Q26\L8WYUU6-D5?1]O!-EPN)DL7=%,D:6!VP\EIA*K:C\EK%M`T<7#@Y6NY
M&J[286#W>:*2RLEF[&L^NVMEC<#IKVDA&GMPM!H]1=*]O6AK'#"@XIAFV/V^
M@J@YMXN%ZR?(I9L.%/.(S6-2/+CS55\5,1R(QW(@2,*X!$KF,)<.P>0F5[PT
M*[33;-UP636SNO\`*FJ>GTS:C*D=BR:5F&4]@7LW%)FO6+G/%3U2D*(,8S:F
MQ,F.-Z&%":!6LX,S=@4@))+((O1GKC&;`9J;=@[#1B7JXY3648NJ"="9DT<W
M[%DR'%J:9*A)WMF--/.L)[S;)Z>G`X4!KS@O,&8H>>[23%FR8DB-M5=(^9HD
M$;"(#YCF`XIW;2?R%K^_<2O>1(:;3[B!LYNZ=]:)=C?9*&FV7-IB<<=:]'*W
M8)ZQX6458P1)E,Y5B!:<;9QR$-%`["JV&0@N.&-^6S(17LLZER1'<$ZDN%PL
M'9$*>PG3.D]3M.VG3^8>4RPWL!LT(`]Y%2L8IDAOKS*G>)5E=6C#<,8B@FC:
M.2;R1D`1&!$',$8H23NTE5MC&G&,3QK/4-**6XUX"=7@KO\`0F]$#%16XDA2
MXH'HT(RVQXU<QEN(TZRNRG.&NKX36+G4`)<"4N>8#SR#Q%E5[2&:;V_;6QA[
M:1!6&4T9U"BPWKX&UD-X:G(&L!66'C*9I_N!17XLF*5Y[0UEQ1G"Y)N%D542
M1449+)CJHJCD=,B"A$BH\=H1I;ANZR31&3GT@<$HQ(K,T2%.%ZHZR.]0<-F[
MF>;<LH<VL&RDW"69%44#8R>XTAEC*10X6YQ,ZG6`$RSMEG@'8OZ"6:BAW5_8
MV,6KJ:@KL(O(0P5X8^]NJR^&ABM51*Q_*TE27#4B1PBNT0%QAA)2$XFW&Q\N
M5/%^L%`CG5RPF0>0V%`?5"D<['ZY&IJ1E_2&3I6SFG0'1Z#6VL-,[#)]#'D^
M)X">;%>T5R8(YG^C*#=:A%>==NG5K@*"-8,,W:]^ER*AG0^<\Y*T1V;C+J(V
M;',S!C`%^$"X!DXBOML`?8FVF\=/5GS&79@SL54,@(ZVVMJQ5QI`:Z*C%U!4
M(%@^L!Y97RPB@J9OL3#<^SMXWVR30UZDII([T.<+M+9T0K8#139AE@IIKN7C
ML!+\KG&:"Z#15)/EH^<N:(@IYX^7657%O"8]5PQ%3^GGO'<>P+!,],R?'+M&
M9@M\OMCM;B:OG8G&+42S+.2$O19(W#;A_7A&EUH-U9=2<GJ3DC.32"@2'2<C
M0"QD2NH#$@QQ0RX)IWCLH6?ZHX.4ZQWL\G5`25K>>DB89%?A*/@\D2[T4455
M4P2"._I;";*DMMPE*;_(I6*HI%2AX[U0(P`"8%ZV&8PPDADGZ$"@%`*`4`H!
M0"@%`*`4`H!0"@%`*`4!$;9K_P`S^']\_P!B#_#Z8*K/<9+>]^@O*JA)@\G,
M<K)L;2%&QX\82R,A,=V,<XI%`PQC2<5=B"?03!XL$-R`BF"@)^XF&.?V.66-
MK7]R@*/X>C3:R4VKPJ]6)-U??T.9:#/:-WQLE-B\MQT=B-T'=8H`?D-L%/U_
M,(3Z7G8]RLZ/QR)JZ7S.II+-O-<N<`4[`*V1<OD!)^=)2EZ4F6QT2<.'U-3Y
MU4GN'C&4J1>RE9G*6R,,38@/I'5VPTY'2VE.3=(*C!=J(6Q$`4VBH*F:6JI_
M-4A`B!NPH(%5L?Z*RRS$+4M,W'U%G:?=3XBB+9MMP7KY&+];#OEC41:DS8=R
MJ$)LR6C[:EUEKTG'D+3M00F+V81EMQ(Z(?23F)C[D.$KY`;?:S%XA$,ZMZ=Z
M<#QGMBRHD0XUE%3EYX:C'=?W7L<T&:+,BYXLVI*9*3_EAIMQ@KT?0"9))KU>
MZ""X50^=3P\491*C#"*]`2L64R[+@F)M=2_#<G)5X>SMAY>:BU#[5/MXWLW$
M<JLV5@51MEI13DS8OL@XV3+A,`1:#<"&NK:L$KXW'7Q@0E`40`"3O"\AB3M?
M=*XQB:44!89!EL."6<HWBYS.9+>SMAB`UF7'PNZ]0H\7JB*[@1G6[(EA920T
M$^<*'CQ:Y@CD$&:-8!V,C`6!T!72T?UMFP?_`+=.G?\`U+[T4+?47I?]!8M0
MJ5\<0F+I/=R-JM,41,14E=UZ@[?Q]L@?B=O*;:27;(K%O'$NP+)20RC+R7&L
MU#+T;[`G927TLDH*R6`I'$<,IUC',?#',#2L%#3J0V`W`WF6=69B24S8,]I=
MKA%$+JAZ,TN8<HEA-6DSMBV%?*"._1T%FH(3FV37C.2.85+N/M?;&`UTT,X:
M#*B`1`EW7S:*VNV_'#2;VMLC.D#<_9[8QRQULTEJ\;!P2VX#W@EDQ+<NOJ0%
MI1?9!ZMI[0&-)+H30V[9N&3R\,FI@B;@H`&C8Q4!+NOFT5M=M^.&DWM;9&=(
M&Y^SVQCECK9I+5XV#@EMP'O!+)B6Y=?4@+2B^R#U;3V@,:270FAMVS<,GEX9
M-3!$W!0`-&QBH"7=?-HK:[;\<-)O:VR,Z0-S]GMC'+'6S26KQL'!+;@/>"63
M$MRZ^I`6E%]D'JVGM`8TDNA-#;MFX9/+PR:F")N"@`:-C%0-A+8$]SYL^I.7
M<35G>-XQ%%&PXXNMD"1:5U_1=60$^+Y(O:)-EIN4<]B$:3)V>BB80"#R3TQ7
M)EFXT\A"X02$<5B&*H(!?=0"@*Z>%!_R)Q5_QQLA_P!3TRT+3^D6+4*E4TFE
M)FU<WNF39UF:XRULM&.SFK4$1@HIT+#QR:>C"FC6%][`+#42EM*?[]CLN58L
MM-?8C($%7"$/%TA20ALE$0H5,@B4!'(CI[L6H\+)R<-U3CHPC3&\=1)%E,:6
MKKS74(%0]I)!EMR2X#KN94BRUB^3I-&?J_B`.K@I5R`C>"R'#-7-WQ"N!K7<
M[7S:+BL9VL4UMD;4S"&M+MGD1MY;"*\;99O?;J<;Q#VA1@FX1J^WS8[$K%M%
M1[MD=6&0(!ZZL0[$]-T1VX8#<[7S:+BL9VL4UMD;4S"&M+MGD1MY;"*\;99O
M?;J<;Q#VA1@FX1J^WS8[$K%M%1[MD=6&0(!ZZL0[$]-T1VX8&W93>.Y,VS$Q
M-M&%HM+D?.'2W43:,VRHJF=P1057)KVZGXA%K=9\/MD5D2:X4XY&<?)S$5#+
M@=&9PB54LU!/P2LQ>C.7#`V=H.Q7.7FQPRW/L1[PNC:-WQRHMQQ[,[-H\%-"
M+VPS<EMMK9^$H$BB'9VD)*AU@J[C2RJEB2#3SZHJ"IP8RTN*!@N7SL!<+0%=
M/%?_`.1.5?\`CC6__J>AJA:'TBQ:A44!SGM77S:$75V!.%BI:VR,EID3[@Q*
MXGOM,:5XVM!Q_5?73<9*VO93_:*N6?9QZJ$HR@V8\0VUFW1&WB82'"HG1S(>
M"66`.&0)D[$X3DO3AJMN&W-89<6"FIDV;6PR_P")2"A&1R37O!DI-7M*2]BX
MF2[OXJB.-',.Q@MY3+HAI1(N$1M*1W/J%U$`(D(!#9NZ^;0M;:(#BG*^MLC&
ME-Z;@S,XG=JRAJ\;*$XLS5=XZ<P5JA'[_P"Q&+[LREJ4<'-K$BN5:;I)R&C!
M=O.4<`N&,J$+DQ`/S<NN,XKYR1]RG[J_L,WWA-?$,#GAOHT!29'J!N3J1##-
MTR:NG,>R@C-OLPZXQE!Q2,0CB^;V8HJFLEPFV\,<\21M11\RMP/<UM@O874>
M&W_VYZJ2U-,,[O;0[637M7&?;\B2)M[&Z-(;8C!@0:Z%]1)2XBMAX*SJ9\4"
M''\E--14#*,K.$L"B!=33C&.0$W>%+`KUUX@B5F>KQR\(2BAP[.2W(.L4"2(
MZ$UXO^%(#=X#7.$6B[EI*=C])A*#AD\)TNDLG]FU,9'3G"6(#C6'+"!!@6=T
M!S!;4?ZJ[AB?,`V`_!]B*`JZX`Q?;T;4"8,M>5?6Y/8UMQYXQ.@3,W9.6'9D
MZ+%V5V6%*FF0Z$-'P0<P;E^K!Y@W,8Y6$Y^>5KX\EXUH0^3MK4O%ZEQ,^Z71
M3O(G_P`(-3M[B/A_:]@ZEQ,^Z713O(G_`,(--O</A_:]@ZEQ,^Z713O(G_P@
MTV]P^']KV#J7$S[I=%.\B?\`P@TV]P^']KV#J7$S[I=%.\B?_"#3;W#X?VO8
M.I<3/NET4[R)_P#"#3;W#X?VO8.I<3/NET4[R)_\(--O</A_:]@ZEQ,^Z713
MO(G_`,(--O</A_:]@ZEQ,^Z713O(G_P@TV]P^']KV#J7$S[I=%.\B?\`P@TV
M]P^']KV#J7$S[I=%.\B?_"#3;W#X?VO8.I<3/NET4[R)_P#"#3;W#X?VO8.I
M<3/NET4[R)_\(--O</A_:]@ZEQ,^Z713O(G_`,(--O</A_:]@ZEQ,^Z713O(
MG_P@TV]P^']KV#J7$S[I=%.\B?\`P@TV]P^']KV#J7$S[I=%.\B?_"#3;W#X
M?VO8.I<3/NET4[R)_P#"#3;W#X?VO8.I<3/NET4[R)_\(--O</A_:]@ZEQ,^
MZ713O(G_`,(--O</A_:]@ZEQ,^Z713O(G_P@TV]P^']KV#J7$S[I=%.\B?\`
MP@TV]P^']KV#J7$S[I=%.\B?_"#3;W#X?VO8.I<3/NET4[R)_P#"#3;W#X?V
MO8.I<3/NET4[R)_\(--O</A_:]@ZEQ,^Z713O(G_`,(--O</A_:]@ZEQ,^Z7
M13O(G_P@TV]P^']KV#J7$S[I=%.\B?\`P@TV]P^']KV#J7$S[I=%.\B?_"#3
M;W#X?VO8.I<3/NET4[R)_P#"#3;W#X?VO8.I<3/NET4[R)_\(--O</A_:]@Z
MEQ,^Z713O(G_`,(--O</A_:]A&38(IQ#K2'I-9?<&F`BAENK%^+*R1V?.`),
M%Z79$HW3!G1@=?(XYEL8DK&K#A%,@3>0MPKX"6QMG:]95IM,D.2KI7<7!=0X
MMG=9PZ?D^V7\)M5'N=XZAQ;.ZSAT_)]LOX3:#W.\=0XMG=9PZ?D^V7\)M![G
M>.H<6SNLX=/R?;+^$V@]SO'4.+9W6<.GY/ME_";0>YWCJ'%L[K.'3\GVR_A-
MH/<[QU#BV=UG#I^3[9?PFT'N=XZAQ;.ZSAT_)]LOX3:#W.\=0XMG=9PZ?D^V
M7\)M![G>04;!+B9^DSF_`LY=%+25;135G);,CLB?\F-FQLI_W#LUP$LD'(.*
M^$[`E_%8R/BC&,R8A/,GB"'@)@/EG!;W.3MI7YB=?4.+9W6<.GY/ME_";4E?
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M'^)`X?@+G6]41=D,](YKRC9106M+P$(EFC;X[>S@3X15!X&'V=<>97%2L4$(
M'RY;$3(M<3#*V(MLP]SO/Q_AH/\`D4FKY\VQ/X%']9([C%+>3HXF\PKD1H^G
M(!6;7S`#-E'<I%C.5G_'*<AJ3LPC\?6[9A\V2$X)>8\B%P<3KV8J*((($EC#
MVP!OC:^.&6=ZENA"*\)7VKV'8D<;XK4$;(SS,>O,8ZNQV]&7L5*L2-UN.F-M
MB%>41T1R1]&SG!@N,T:7DX>-L@E<_81*7<D$\*`6ZQC<Q8H%%220D2[)*:=N
MG`\.1'M7L1.K9E2/)V4W\PMO8J)1&5+GF`VDM;82M$+J7M<X#=CD>1A;'&!5
MD=+R<1<!OX&5`V6*7+%QAI[1V&D8"VG>:@M:_I$N;BS]K_OFYY#C4A-FL&XD
M2YQ3KE)1M6<"6!*L-P(L&(<R9HH02*,HAQNK-5UJ*RKF"R>(JY'L#@]ZC\H_
M(7635L&DP>]M=FRY6RK'&_L%+8D*@/<D9)XI+%>JFR74[&,$Y28M['!4]]*;
M3$1"HP'+8)4-E<!+<T;G8R00R>G%&:*(;2DEL1R5/*3WV;G/6F*5R1Y79\0Q
MB^U'7%,#!E%WY2,OE%0BD$0W\646TC)H94\JK1Y*,C``V*AYC8144+!X??BU
M)L;M=[N./'1%*\MECO9B/GB,CFUUMJ*:J'D@V7$46^?4T-93#8R?<RGGR@XA
M=03Q@#(?)B+;&T@@9*^Q&R#1XA9J%(EC@],[7&TM;4K78AUYM:-6@@N3&<7F
MUUES'GJJH2ZKYN9;0RI,BF)F!<0H:R`$S&%)AAB&*=H[#TE?B(B+,5Q1+$/P
M:HN5MR/'2Y(:RLS%*3"UY9C`--E?Q:2W$BX_'0(X4`[-Q=TECY+%'`OV,PNF
MCC&50L!D`*-%10(_$2%E]N0X<U3U_>$Z/"6M9&OMP89ZZ\6I$H3%B9YCF$UG
MI3D<RQVQ)@DF/9PI2HG(R66P%3C(Z*>%,J1,J$&8%5%#1:QQ-GZR)\EA3D*#
MWXU-:FGH[JOL,@-IR$D1JSV7D?8*1I18:&QEY@.0RD*2,^7<_DI/9`:(?-EP
M4M82A#8QGJIX//!7U$T-F.7B=%HO:&PA^9X-/M=_P/$;=G<LR8_E-DR\DR9&
M+B=F+(%':+P;X*;D4>31=&09-;23Z:7Q`$.$\R1D^`9L-@J10_EV;UFHBD-X
M.6=&',,>'VWJ8SI/'UV3UN+'V%FX7YLNYX7B]`25%O=&&=FN2%@9&3LP<7"(
MVB69\(OTV60(QX144/KE'B3J^O2))I;8369X,^3V-&[0F)JQVQ'^U),+RK'C
MGF%EPFIXLYV8E&J5!?;$>,@(X:RDG2A<MCV4)W*'C@0V8H*HH:SW)WPEV.X!
MVT:YZ.7%KQLA%\!H$_1J.B.=HRL2=<>*<E$6,?/-Y1`3"Y/![ME6QP(K*09(
MB%B^:L2S*'#H8UQ0S8)($-X'@F+\Q,*1=69,;<KQQ"+:V#:,8LQTLF3W!)C#
M=CG<;*3D<H=1CR8B-A_(SJ;URZP4-&!$@F`8P-`*ALN&8$!FHH:H*\4UNH^,
MZ-A_Q+CC+\/%M?KH$=PQ,4<S<FRNM[1RBK0E#+&;#V(C-$DWY`.2HDY)RTFK
MA1/LD%1@U#$8T0RZ>T5%#[73Q,3D0.J3X\V%UI>T;R#'D3Q7):(C-A_,>1$.
M6E*;I@P@N+V'&;GR$:(!APK<DF`DTW=9+HV"<+?,86UR%@CHRO$4)$:Z;9&9
MBD>1H3D".2L62]';69LB9)"%)36EQE.Z-WZINA"1'*U'NVP$DP(HI#@9QX@M
MIA]+(#IP]RV861HL:`,92"9-"!0"@%`*`4`H!0"@%`*`4`H"(VS7_F?P_OG^
MQ!_A],%5GN,EO>_07E50DP^0WHFQPP'Q(:R$8'2&$SW,]%4`IC;(T,FM=%.K
MAX(MCER8Y&!"I'*V%K^Y?*]J`I5AK8/<]DH/#-V7G&>R<G,KB&O!ELN5=?`(
MOC9M,V`%+8F#GS-\-"P6\6P@)<F*Q>-EEJ$FJO7=JPY;KY91&5`.QN8&);("
M8/$:VLD"!XG6(]UO+I*[MO(\<RFZ8Q**P`"B@Q6PXR;&:S)6R$B)PUA`QF+%
MP9PB6)E!,;XK[L5T='MS0SHY@L!'"5-ZIL;G#LUO/18=27WOAL?I4@S,BJ*L
ME(V""Q$]"@IMOJ;=I9$;B62)(91BQ\J+I<,FF`E02BT[%I'10@P0#@HQ4#%]
MK-KMY6/P?H8VS@EQ1%\:"GK%`LG3=)LE$AK.-/-/IKQ>9<+BB^.T!E'8X6'<
ML*+E4!,"ZK9/1$[*X66!4P';J^(&R>([M<[86V`UAAL78!_ZQ1'*D9[&OEW2
MC`D,MO9&?SC\B@>)!6"SB$3*\2S\=;T2*""YW&=<+GP92H#8X13DFR@C&U`J
M*:`E=PXIUD/9G1_7">94-M52?$F,'%P*:TS.Q02$XR'9I7(-MU=C41=<J6W%
MIU-@D3451'".C=A%0T8(96PS+9!X`39H"NEH_K;-@_\`VZ=._P#J7WHH6^HO
M2_Z"Q:A4@5OU-$K1HW=<(Q@]RIK"E';7:E@ZU-Z3%1M)[R#C)'/,:3IHD1YI
MS461,$)=<Q6+H66RB,$H6%(!JYPL,8`,@A9EA@,?T_D^9T[8S;[3R;91/3LH
MZ\I.O$K1S,KA:3%9;\<L3;'I4G)J.W)*2XN;K,C92>S0?<%N/'-314)!*'4T
MV3Y2`(H8@@P$"I8VVV])PMN]Q$6G.P;;AS2W92;6`C:FX1;&JHQY,@_3Z3LH
MIV)47Z_U5!-3,!+;X5F2Z3K6/(:\CHJ*#8B";25:^0@MP$L;;;>DX6W>XB+3
MG8-MPYI;LI-K`1M3<(MC548\F0?I])V44[$J+]?ZJ@FIF`EM\*S)=)UK'D->
M1T5%!L1!-I*M?(06X"6-MMO2<+;O<1%ISL&VX<TMV4FU@(VIN$6QJJ,>3(/T
M^D[**=B5%^O]5034S`2V^%9DNDZUCR&O(Z*B@V(@FTE6OD(+<#7*%Q(Y2EV3
MI*DQL[4.:(60Q-Z5K5UFQLXM0'<LZ5"LN-YX(P6O)FRFW($*.)<8,XSB923J
MHU#9)XMY";';"@$UA+-BF;9C`=*%`*`KIX4'_(G%7_'&R'_4],M"T_I%BU"I
M5Q*KSV3V"W:E#5:"=B535UFZXZR0_,#U>S4C"+9(>#[E;9!\S8WXS;1\M,#:
M>*`5B]D(&O:B<6"Z843UE8%6@P0%9.N6L)F!AY#B%R&3X/*]ORL-%KGIP:,&
M/T51:)3L@68"OL)'[E7X=,%P;9&LE4E':U,*!<6UNL9F0$<;DZ7(3'GW`C9M
M/MMM[PO>E^->=@]S/C3TUV.D1A=NT71K%W:7MG`7Q5]@T-*^*!`9O2:]R?\`
M&SGTI)8[+N)"[!X?^,G.N9=$!N1S/;B!:R3(R=?,-@6OMY(VT>I&R[DAA1F6
M.(_B)LQUN'K\EQTJ(Y,0>$FHW#@NN$@DY),"C)RF$M.5(N@!AV6C5SV60($3
MWWQ&)RT]D;;^,C^QBYN(XX&T,D&=%0A/,)-#7XZ@;4H$ELJ+V"T(>NR(RA.T
MM:X.E7=1XPO*!0NZQFP$23<!'&,(J!X9`3_CAW[2ZW;C:[ZZS[LB<VG:.T\$
M34XP7`OQ7%T9K<93OKZ8BQ67BC,"BIMM0J:AN16C(ZAF53UW!:744XA`8YK!
MW$Z)8,"U>@*Z>*__`,B<J_\`'&M__4]#5"T/I%BU"HH#GU:VVVWN4`0EQ,%F
M=@U"$)?V[C6.ES46\6QJ`Q6CK#/.UI#4N,5QO2`40"\V'9S;0KV078L'3C@,
M()[/$TF`HQ7"V!JX$_=S95F/":-.]3X0D8:%7%LXZI>6GQ,R8U&@]7<QXD@>
M/`W2Z"<=(,AHSEC^S^>#L<S?32QY:2E@BG$!3ABY`T+@%A8"++#EC>*0SDTZ
MR'9^;;..ZB[?KD<[,[K6:,3(;^`U85-5F5M-%;M;3$=C<7()2Y@5A9=1&TOJ
MIE`,-U-)(Y]4Q1\<C(0)<#0T+;G;5SZ;AW6IB;'9'TN8=P=JF7&_$!2(MBXR
M[I@TTUBB)C/D_),>M0XR[:^*LA.&9)"LQ"[F*MDRTCA!OG%@FDB],$%B!YKY
MW3W);[P\3XS)<T+\I0UOF^X:DV?M=-7F-*4I2'KQ?1Q,VLB(VHQP88[GAYE/
M11<<W-)$7E:R<DI.78`P(`&1NH6!"`N%TAEM`F>`DEU(LW/J>3Z8ZGNSGFYI
M4C5#AJ5VJ_&FY3Z0[(ODZ*$)D1R$P7M'*F#DF&R(Z.5,98@X#WR'#&#,"@2Y
MH#F"VH_U5W#$^8!L!^#[$4!$O^&@_P"12:OGS;$_@4?UDCN*2WERT[P%\=CM
MU>=/;9VL^+;L47GWJ/8+LSVY]!"<V0[VI]:[,I7:[SOCB[(]?Z,_R=CNK]7_
M`-HZ<"2#\-O8`,[2ZV2UK^3>($?')-;@*(4>9IM"/$LWC)973%@`\8:X3B:(
MJV!85-MAF!BIDLLL<[\@N-[4!H@_J1.\PR#$SMVNV)CA^-N$'(Z'VP63KSK^
M\M<[&'^YXN?\/6<CN=[JV6V$=:@$WV;)RQ<@42#"%A8\,$.8S,8@XA5%.(J:
MU.:,;+OJ)X_UCFW:U@R=KRP''#ZB:7!]?E\GLU)#<A1X-I[,Y">DLJ4[KS()
M.DTJLU/"6G00:6"BK%[CY@`IIP3KE*=@J3&VOU^"V=@MV1*"[!8]<QP^T'C'
M,E%D,!R'8TE:,GD@R-&#_*(1A02++&35?+6(&AB>)TED=+8"E^L`V%N)C(1&
M==T2<2'KGKQ`$5OV+EEMPFT1VH^F/LG!*7-\.[%&5=,3[.)[R*SK.IK.%%D,
MP[P#J\54""P(5#-+"@":)G,!PLRT4%38NI.ISUU.9,71<@3(BK46L\A,1]VL
M,C%&+:2%)ZRC)(DAH-HIR$?[@$AJ((J!55-&0V?A9;M@E#%,1%'(0ID(9E*@
M;/#F/5N?UG:@':K7[86/(R73&NY379;8DH0*L2XV%!/`D-=?I5^EU%NS7$BR
M3<+?-K?(5)<[,F9##&"'RY3(0Y("/(?"O'9CAAM:BZ3HN5,HV@6T&FSVQ^N*
M1/BTBJJA(3QE%Z3M#EL'\P&U&TMR2YWN<Q7.F355)/8`)>8I80!)ZB>B@J?O
M$/#KGO6]GPB'`&RL:MR3XWU?0].WH[7W`*\^6P](HCIYNUR0J\TEH)\V,\TW
M91C<N]5/(QTZBHHJV94#&.90J#T%@5!4_>7N%VI2V*N([AGLPZFP\].=>-:G
MLKRFQLI,D==D352877.L23@KK:L[BC8=.2]([P%-NM`4DD4LI@D\"X!@L&8$
MZ*:"IY_HNU5S1AL.SG8[]9XW7YNC9LQ:CBZN:=-B%F4STA#=A%WK3E7$L20G
M+($@.9X*:66QS`'<Y!(3"I8$,`H(/B,<,Q05-_;*Z$)&R<BR2_5>3E9HW>VO
M4:0^WRZ$VB!I78S[AZ?A=C8XEPBL*:H.GJPK??Y1-$NCC)V`8V)"_*;MTO-#
MF@J0KWQTSV5D*$)MEU]R.G2UL4;CJ(8$AY&UU@=R-I#83,4-K82DR1'N78K@
MD*:G2[W@L*+!258_?)0`2DU+;P8/5\[8&3PT,)DAY*X>TG["H4\*&P>P;+69
M6EB%&]KRT'-&<&JC)8D;1PAR`3D=:4+,9Q3(^G"Z'A(;H32QA1%S<9,D2+E"
M90L7O<L,;/*"IFNVG#^OM$[)9==I9"9=Y-USC2!K(9Z/<7F@87C;8'*>K&WF
MGYO1N8/R/'Y>W:VY&M>Z=9403!L"Z@'UGD#EH)D.I9X>3O8*/-<[.-S(JH=4
M(JUK3VO&^CVH"<VE>'Y$U6V2#G*$)!B&+SLKN`:24AE+SD43[K130QE>=!`K
MF72.J\XLD7BA-36"'J]+O$5FO9!Z3*\@E&/3VOVM3+BB3#^F\B07&Y25XCV)
M7I]222'!.R#K7GU,;-1U=OD,W<,JFB:0KEUP1%)B6ZL8,8-XW%HVI&H2EK\Z
MI"D%T7UR(.)\(;8:Y%IZPZR-K72.FPC-HXMGC1X:]G&_)!>;F=QU5"$.C*2W
M=.)@D2P!(B#GB:-GI(J3KH0*`4`H!0"@%`*`4`H!0"@%`1&V:_\`,_A_?/\`
M8@_P^F"JSW&2WO?H+RJH2>6N(J2Y458;B\0+JJ&OI:@BK*8;PZ0JHI*J4&(J
M)`SARVYY<X3'S#SMRVY<<KT!57"G#GEYDJ>G[(ES9YNRUK9H(I"K.MD=IT(G
MV7)R\KH$:.B&H:4M@Y5.2^\D60S4)QB\CY4E=&;+:LLK'5U8];IBV`.0&=R;
MPSXIV0CL,WM?=HS+M>8@)0@A:VC;S-<T29GTT0R\%5%-DXN:\H'"))!07$]#
M2@&D#*YL,0?//G#VMG;F`:W3^"WIB'KFQX<66$DK,E,75I,UE3YVQ'?R8N#$
MD]*7ALW`*W2<D?9I(L@.M3<(:&,I#E@!CN9?`;HK8Y6`V,J<-IIX\,L#AOLQ
M^=IR3A$#*C4U*':NI.'K2\W1VTHN%[]I2J^NL@=MBRAC&>QN*[T)#K?1A"Y8
M!8VR`SJ<M6)F5]F&[MQK3,<;1Q*I6#CVNSS;<V0VX9DCIV1X*_`Y#05))!9<
MP0J[68\FLY1S8F0X:B?(*Y(>Y0P4#%P*GR@&WM/];4S4C7MDP4G.M0?0[?5)
M#=[G>BBED4$1U2#+\F/&8Y,<!)MI@@Z>U4-5D-_*@R:D@"CA)2?F"4Q%&L#8
M7,"2]`5TM'];9L'_`.W3IW_U+[T4+?47I?\`06+4*D4MN]:3^RS)C\LTI`!B
M>6X4F5AS]",EGFA\8*(TY(8ME=)O@Z6)@YF2:>#->#%=2VWE@@66T8X,F+`_
M5SQ4>P8N(&E8LU#V%8ZQ-\T+.RS#,[3;%2)`ZG(3_0-?C)>+FY!<&CXEDG7N
M/HT<$P+S@*%SC?7G1CVSJ#C.&\%MS&%/`A@$&"FX@::D?AFR2\0I\A%O['M5
MM:1[33R>GR;(9.P<?79@Z=ZN)O/&=8GC^:`Y?1VD@1K/SO33J@J9GV4J*J59
M852Y8<:Q\L,E`)'X9LDO$*?(1;^Q[5;6D>TT\GI\FR&3L''UV8.G>KB;SQG6
M)X_F@.7T=I($:S\[TTZH*F9]E*BJE66%4N6'&L?+#)0"1^&;)+Q"GR$6_L>U
M6UI'M-/)Z?)LAD[!Q]=F#IWJXF\\9UB>/YH#E]':2!&L_.]-.J"IF?92HJI5
MEA5+EAQK'RPR4!XKJX7LHJC>F#6QK[',=LZ)SYL6Y-B9$BP2!C)^=TNTBRN'
M-\O0TPID*2LDL5&CN0I*%-C@'3C)/K"`DGS"<6%%_P!C-D0+EJ`4!73PH/\`
MD3BK_CC9#_J>F6A:?TBQ:A4@!-^J$XJ.PRGL]JC/<?P;);\@]"U_EPE*<'*T
MX,UV-=C.MY.^)WPBHS>F*%CJ+)$6*LFN6Q<4X:5$Y5)*G5#!8.P(0V`&%IO#
MA(%M5S6C"E,"@KZHJVHB_KTOML5D$"LN*TP.M6455R;/6ET%P7`).A0.JQA0
MP1<$*Y8!<SL>Q-7QQL6H#6SNX9DD[.YN;+?C8]JSE8/5*7=48R#AB#C\!X-`
MO.EV?>39_6;KDP3-FLSJJVCI!LF"D<DI$0;%#/5B6771.8!Z*KP]MC9E6E%Z
M;.[JB*TE-+623];]>Y$U?B1<UI<D2+4OFV4=?NR!PZ<FF63B]-:R)&B"`"$1
M'1D!/(@GBP1/+!3'Y@'FR7PTY/V[4E$UOIL!'LG)Z1K=/>N,;IFO,%+T"9H8
MNQ)%F)C[FQ?5G;-DWJBC(1,FP4W)#3"8A%#1S88AH0,^/U7,D!NZ&=1I\!V#
M8.QNVVQ;#GMX0E##RA:%DN,X'4H-;Z5\9RNQE*5)>?158F.81W+*CY)1HC)^
M%B`B.BHY+`[@5)WN?$R#`L/H"NGBO_\`(G*O_'&M_P#U/0U0M#Z18M0J*`J#
M;O#,DE(*QQ`RAL>U5+1*)=G26T#,@P"#SY.7S1QLS`H[!QI"+JFL>8%!HJT-
M1C-(A%5)!@L@LK'4U*(I0YJP0`Q@X!N^7M19ZD=6C*6$[9%DI^Q>OL_3))<#
MO=7@,P;CTA"DM([@9YC6V4(_1)=0%I])I5C*A$`=T$EY%/F%M&)*MB8=@\R`
MH$4I`X4$O/UH`@+>S$)O9\2%M.Z]MMJB$T:EO21=>MB'P+'#8B6(6*I0<U-N
M8G62<00.Q&4D`H[=7W8[$]144LJH*`8YD*V5`2+>.GNSSX2X'D!9V)UX2-H]
M7),=;FA1]QOJ4_&)!8D4O>,;1J[X/D6$%W;B276M):^6&S.65TE[(ER!LBDB
M`D+]CQL5`#$6?HGM/%`YB58OW(:N&R4A3K)<X[**3S@)84]>)X%?["CZ+&VR
M_BB0IP07\PDF#H^B5MD&6<Q>RN9)W*',SV!^ZF/;`"66HFM!O65AOE,<L@?&
MK)\PS)(<^S)(A=J!,%$<TDR,<)6/=J;""7G7=F,]O-Q%3$A,("JRJ;P)I^`A
MHZ:,B##B`2KH#F"VH_U5W#$^8!L!^#[$4!RAI7H..R[\^*KUG_L-\8KQ[/?$
MEXH7:%VX=E,^S_4.US_9>EZ3H^3IO]JZ#HND]WDH1L[3W/T0W\VW]&.@V#]$
M-_-M_1CH-@_1#?S;?T8Z#8/T0W\VW]&.@V#]$-_-M_1CH-@_1#?S;?T8Z#8/
MT0W\VW]&.@V#]$-_-M_1CH-@_1#?S;?T8Z#8/T0W\VW]&.@V#]$-_-M_1CH-
M@_1#?S;?T8Z#8/T0W\VW]&.@V#]$-_-M_1CH-@_1#?S;?T8Z#8/T0W\VW]&.
M@V#]$-_-M_1CH-@_1#?S;?T8Z#8/T0W\VW]&.@V#]$-_-M_1CH-@_1#?S;?T
M8Z#8/T0W\VW]&.@V#]$-_-M_1CH-@_1#?S;?T8Z#8/T0W\VW]&.@V#]$-_-M
M_1CH-@_1#?S;?T8Z#8/T0W\VW]&.@V#]$-_-M_1CH-@_1#?S;?T8Z#8/T0W\
MVW]&.@V#]$-_-M_1CH-A^.?H<^L)_7_6O>M]>#[`=FO%.ZUV>Z(;JG:SV2^[
M=LW5^FZ#J?\`MG1=+S/L>?0E=M.!D_Z+'^;\^CI0#]%C_-^?1TH!^BQ_F_/H
MZ4`_18_S?GT=*`?HL?YOSZ.E`/T6/\WY]'2@'Z+'^;\^CI0#]%C_`#?GT=*`
M?HL?YOSZ.E`>=AZ([LN8Z'UM+MM['%.R/0>*UV[]KO63W8;LIT?_`.1]JO9+
MK_4.F_V+K?7.A^Z]/0G;R_9J>C^BQ_F_/HZ4('Z+'^;\^CI0#]%C_-^?1TH!
M^BQ_F_/HZ4`_18_S?GT=*`?HL?YOSZ.E`/T6/\WY]'2@'Z+'^;\^CI0#]%C_
M`#?GT=*`\Y)]$?U`+M4];2[!\\QU7M+\5KM<Z?K(W9+J?:]_X1UGLITW6^C^
MRZYTO2?=>?0EUKMWGH_HL?YOSZ.E"!^BQ_F_/HZ4`_18_P`WY]'2@'Z+'^;\
M^CI0#]%C_-^?1TH!^BQ_F_/HZ4`_18_S?GT=*`?HL?YOSZ.E`>:K>B/Z@+VU
M>MI]@^D+=:[=/%9[7.GZT#V-ZYVQ?^$=8[)]#U3I/LNN=%T7W7F4)5:[-YZ7
MZ+'^;\^CI0@?HL?YOSZ.E`/T6/\`-^?1TH!^BQ_F_/HZ4`_18_S?GT=*`?HL
M?YOSZ.E`/T6/\WY]'2@'Z+'^;\^CI0#]%C_-^?1TH#&"GH4_C`4.R?K2OQU?
J%N+VM=M'BG?'%VE]N:#V2^+;K'_Y9U?KG2];ZO\`[)V/Z_SOLN6@/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>v365643_chrt-scatter1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v365643_chrt-scatter1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!%`(X`P$1``(1`0,1`?_$`(\``0`"`P$!`0$!`0``
M```````("08'"@4$`P(!"P$!`````````````````````!````8"`0$`$`$&
M"P8&`P```@,$!08'``@!"1$2$Q05%M87MSA8:'B8&2FI(3>XF=D*(B,DM7?7
M&(BH.6DQ0=665UDR)296EQHS--@1`0````````````````````#_V@`,`P$`
M`A$#$0`_`.JK5S3C42U8)94]M#5?7"R)T_;?[]^')I/:.K&82QY\%[S[%,S9
MX5D<AC#B\./@YG;DZ0CNQP^XIB"R@=@``AX"1_T]M!?8>U`^6FF/(K`?3VT%
M]A[4#Y::8\BL!]/;07V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y:
M:8\BL!]/;07V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]
M/;07V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;07V'M
M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;07V'M0/EIICR
M*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;07V'M0/EIICR*P'T]M!
M?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;07V'M0/EIICR*P'T]M!?8>U`^6
MFF/(K`?3VT%]A[4#Y::8\BL!]/;07V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?
M3VT%]A[4#Y::8\BL!]/;07V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[
M4#Y::8\BL!]/;07V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\
MBL!]/;07V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;0
M7V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;07V'M0/E
MIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;07V'M0/EIICR*P'
MT]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;07V'M0/EIICR*P'T]M!?8>
MU`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;07V'M0/EIICR*P'T]M!?8>U`^6FF/
M(K`?3VT%]A[4#Y::8\BL!]/;07V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT
M%]A[4#Y::8\BL!]/;07V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y
M::8\BL!]/;07V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!
M]/;07V'M0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;07V'
MM0/EIICR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;07V'M0/EIIC
MR*P'T]M!?8>U`^6FF/(K`?3VT%]A[4#Y::8\BL!]/;07V'M0/EIICR*P(L;T
M:+Z2Q'27<65Q33K5B,2F,:L;!R&-26/:^5*RO\>?V6I9<Y,SXQO+;$4SBTO#
M2XIBU"92G,+.(.+",`@B#QSP$I]'OS,37XO^H3^GULM@2_P&`P&`P*RNM`N6
MMG2;ZB+@VK%3>O1ZC78H1KD2@U(L2J"H4YB*/3*2!EG$'%BX[(1!%P+CG_9S
M@<NFJ.VA6I;SNI>NMLHUK60F&]-RI'PQRTKEER[)ZK06\7'9&/U\&0;%1JT9
M;7#`W[!JV">EK$/>[\Q,J",LCNK?5J=O)"I`$DX)UL]Q)1#P1NS-CM;-=(W%
MMA]NJS5[S2:AS;6KNP#*6I;5RUJ#JLB$5-;LBABJ:7ASL"\'$JXT\N/$A:XP
M`N.%JE9Y@Q!\MI]23>+6RU>HA)FR_4LW<7B_>G,D*C<RAZA!"M4->[ZTZA,]
MGVQ,"IZ][(JQ;6E6M=B@+AIHY.H8VHB3.@G"1"\*`6D<AM2-]1O?W92`OK%,
MI!24-B;9TA]LMM[-:R*@YE#??:JM+IN*DH:MC"LNR1IH+%K9@3,V.[@8C7R%
MO"9W8+48>C5)UI88_5G6$V38-EM$Z"B+]42:IWIRZ:6OU@4HX5>SQV1DLVTF
MKD&G#_9<5>E]X#MU0TQJ6R5,@9',J%D0D00!;^7%Q7]T[4,SK24V05^[/Z#/
MJ-]LXF!.!^HQ&W$LK5?-AVRV:?+-EV$C9AZC+Q"3#9TC.3UERK"ZJT'(E*=A
M$N'V0A"(80R51MOKUJ]`)6[=+FTI57VI]C;4T'4UO[7VDRS"_-"-3V)[I6R9
M5*++UT;'28-*TP3Z^QJ.L$P<5SL""M$E?49Y_/"H:HHX/*<>M+LY7]85E8MT
MO5=0R$3K6;JF@JVZ/-1)8I!-JKLU<FD9:-.K.K&+29:^2*-H=@J^&ND*2*FJ
ME0G<D)JI(+O'@G@`>3#.J3U"I9/X](>+3IQ#60-E.CAK.\P`VB0+I$[*.I7J
MEKG-;(GZ:>E3YN*:%%<V':RUX8V[P2H)/XX[T5&C3<`"`(BUYU:-WM;M$M3U
MR#9>!W=,5+7MP^7"JMUL)F^Q)M@UE>:5@BE#M*BU+4JJ#V[,T$7=S%Y]=H)H
M1<:Q([,_#2V\-A10E(7L]1K8B45U=73&EL1CC&2Z3)-O5-$:B;Q==Q)X<YPG
MIPWQ:;%PA;U:U(8PN@GAE)2.B944<(241R<7`!\]N$,,Z5.[>WMY6Q7]9;03
MJK[-2W5TK-*.HS&'F!U.HJA=7KSL2\3V)2:KEQ/$YF:.:-Z;Q-3N(77D#89W
MXI4`+2E)N2220IEIVSMPYO;.F+*BWA\9]BZ^W#Z[T3=);:D3YMIWJEKK./+U
MT8B,KK,5EQU:`MZB"-.Y1AN=5I"*/L[ND[R2GMY"8LT-UTSUR>H);NQFED;4
MP"IXI&;NA>@CT95HX@W$J-AHYLK!8N\[%VO54C>[B3V<C;Z:D;\X)6Y*S1F0
M-3.:PF\2)<$A46H+#)NL[?4]U*ZL%7;BPY2_+$NJW3S42]]BJ)8X'LLC2W1<
M-O:R1Q`Z1LH_P>\'<VY<$15INW)$;RM0)R^!<%#-`,(6ZA[?;+].^CI]JNU7
MU7%`0RG[PZF"J,WYL)5<_P!B$6RNPFO&QJ6LH/IA%G%+8$0/:)!,6<D3FH$4
M<X2AU)4$A:".Z%*AX%E%E]979N`3:15[9""+T%<LZE'1A=J?U_FL+4J)@@AF
MWSA`6C<]I"H6DD&R9/64M?G".C=C."RV9V)+3BYX4F%%#".:CKE=0%N9MPPM
ML<J^TY;7L#6RZ-#JNIS7R%T`UD[9UU2#Q(+:CLEMV![!55((+3\U520^'6O#
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M1GD"[],X7+FD?(=<.`P&`P&`P&`P&`P&!R@=>)YK-%U!-#&VY'_49GKY=J]M
M\:,G=ZT[(JBBCY*1.]="V<\+Y6/9?E,^3I3U7#:1SP$H282OGD81!#V0@1%N
MKWMYIUIOHW"X1-$);W`-3J]MN;Q#9"%"DDCOULDFXU@TJM50>Q+(NB`V[(JA
M)K",@>XL;&XM('9GC*EM4R->EX%P4,)O[`=1;;VV(AU-ZXCVTT%I:W(!4O4S
M88GI[`->[@YVGI6):RP>7**3O%LV!B$A7-41?KR:HZ2XMSN[IVA`?S(4W,54
MGN2(L!@8C6G5VWA;-I-0=>HS,*SN6L9#&]#V-F?'9DAKM(]R(7>D,C9^P5VP
MR?H+H#,'!XI"0.[@TC''HR^M2-UC"LR2JB`+>!D!\K!U`MZGBO.GQM]+&.KM
MF;DLZK>KG8U1U)$*=<8J]LCGK54$R0PN#LSFS35S=9B[6,ZQ!,-TX1H4BH\@
MWO!`G$H[0\\/E>^M!MXS(8LVQ;:C6RWJLD=WZ-1>7[UQW5V7QNJ*/>MBP7F1
M?>NDRKERL]=Q*Y12;57K-).34KRV.K&W+A(WTPM0,)A0>')-OMTMA;8T/MR*
MW16C+.JT@?74;*WV5;*-?553;3TWKTWZIK*\O6+TNX6F@0H$]IH$0TI2SAW<
MFD'/"M8V`,3*$@@AET'ZZ^VM@;(Z5-[,JJ(43NM=TXHC:6O)M>LT=D8U.[.K
M,+N65S:&2R27MQ;:AI8+`G!#6PO1D.3P@00@1&N3@O[KR$-9Q'KF=01R8K/?
MX](J6O.R&OIU6!M#+M>(3KK,8N_:B7ZW[AZU49*ZGL7PU8PGR=AUJJ>T7F1.
MS<I5LKDK`D[NL$4D4(3N0LQUTW.WEVVZ2?4&LV)J8_.-AZ^C>R,,U1MJGVAA
M3JK?-:J3;9-"9'&VFLI[:<`7V@Q320*VA"9&7US9ECBWI./X"GOU,6$.JSV3
MU&UMHRRKPZ3)U_71?4%TV@;M?C0L<+DM_71CDSO;M50V5V9MW$9`^<3-PVUJ
MEKD,CE"UI:%#;)E<<8'I,LY((X3]J&TXOU=[]C++$Y5)+QIJ\-487U*=>*`F
M?41A]0+ZVI:T]<;;UHM&?V(8:C52>916,O5/WJWQR,+90TN8V@XYR2H>2REW
M?7`PBX1UC^HE/:2D]TUW:E+1Y'4V@VY>[[VV2C7Q3(R[0-UQZCE^Z[0JO>"B
MYU`W6`-LHJ2!-*9R6]JJ6DJ"CC2TY:@[D9(9=)NH=M[0DLZECTS[3P-=)#M^
M]=6B)5GL.Y<(F:@=;;;U:C-EF/%;R>6.952TTQN#LF&Q,SU8*J,5LYNS0Z&F
MK>7]P"G,">-N;CV#<_2+TWVAE\2:3Y[:>U6CC!*&N;UD="&TY2Y[NP*LG*6L
ML(1V78B5`E<DJ3EXCK@DDCNVKDYZ5Q2F&)#RB\#%=,>H5NM8FV>N,;MN>U1+
MZ6VAV#ZJ5#-,`9*@.B$LK5%HM8DG(K^7\V*GG3D7+GB2L[1X-7IC&=$E"F"4
M:'CE5P:<<$$=SK*V,5[P;=TZ;MJN/>([UD>B.=KS5<Z*4O;!642LI-1;BGF,
M<K5).8Z\*ZA031T-:GY&TGM*"2NZ58<I5E.2D\8`\*\.MOU)ZJ`57I"BE"7R
MJ+<WTJ$Z^)#4S(T0?:^V-2-E!T[`ZC3QB2WU$`UR\3.'<DNCVVQ-3*I8J-7I
MQLB$9:964,)A]?&5V06X=)VTV)#)(M-*RL/8G;9R@C4].2%:H>]4]-IUM>;`
M7+E(-M&]%F.=4B;S4IQ?<UG;"*&5SP8('(5OZJ;FWS1L^WDO&.60PUC$MUMM
M=,+4L?:6V(A)K9K+4?7K;>HMH=D:]GJN"%2B,(FAE%%E,.AK<X.2I+'6TQ<G
M4N8S31![X"7S[UO=J*ZJF33RXWNMH6P.W3RZGLPUAM\=2R2)P7;K9W5BXFF-
M:N6E6D5E*UZ?FF.W-305,K,BQZL\DY!P:Y`-+;."A`#-%_6,W78MNH=6;>P5
M];L>D$1K@F,T)65?&&7I,G^3:;MMRN3K*(?-YU75LM$9<KE="2$EB0N.S2L$
M#$<6@6&A=N[G)PE%T/NH[MCO6\W`@V"-KB6L$<K.GK`*DT`B+#"5=6VI/SY6
M7/M>Y.S1:V;B2@+B1+0E.;"GY6S39($*H#RV@Y&E,Y").F/4OK^J^D!>M:T=
ML#64OZB]-H>J%9$(U\5/J&=V[X<A>TNTUH1T2ZK^^SY&\H4T"+2N0$W<^>V:
M^0"#QW/M<#TG7J_;(W]>Z2M-1+YICFNY]N?T\-;X3;O-3EV6P-D9V0TAV?N2
MZ71O1>,D/+F#HUVG4:+P<:%>6F2&)34H^32^[%\AIJT^MCN[']3ZXLIXLZ@J
M$D16I/42LI-:$HH.43*-[5;+Z<['VEKU#Z`KME)L1(TUC)I/"8%X\.(##7<1
M1QH1%%":$+F'`ZQZ%E[S85&4Q/I&-.;(9Q4]=2]^,2$!2I3'F2P]G>G0:9*'
MD04R<:Y:/D!?'//``]CC_=@;8P&`P(@=0GU!=X?A`V6]#$UP&CWYF)K\7_4)
M_3ZV6P)?X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$.K-T,UJN&Y6
M:]+#C<Z?I<SR:L9N./<73<[;4C[.*4=`O=/S.4TBUSU%44EDU<.W'*EN5+&4
MT0CPDF*.[C2(A)@F+@,!@,!@,"/DDL>3-FUE,5&E-1\0Z;Z^;-6._$#2`&X&
M2:K+'U)C,3-3+N1=T3(R6NXGK@\GCCG@\8RA<\\=RX[(2#P&`P&`P&`P&!J>
MS;ZHRE4X%=R7/4]2I3"TIQ:FS;%A\#3C*7+!-Z$T!TJ>&HL1:QP!R04+CGL&
M'<<@#V1<=C`U]+J[UQW3B5&SX;W';@@M:7-"]C*:FE<3TMVB1]E58L?6Z-R%
M!(X4[G,\I;6AP7+B#THCE",PX(@&@Y$7V.`D6L<VUO-;DZ]P0H3WA=RV-)*Q
M6G3&NCEPB6N7+>W%G&`&N7<-S<H4=Q*X$9W`@P?8[4`N>`^P8P%@$88((``"
M(8QC%P$``!XY$(0A"YXX"$/''9YYY_)QQ@0DUATMU+IB1D7_`$(GD4I<IM6*
M.)0:P9%?EM7TQM5'R1[362AB-.KK%L2=L$6K&1R$\IZ"!B[BG7?R;LF&)4J$
MI.$PSY)'4LB:X@I?F5/+'QE?I(R1<]T0DR)XCL571MLE#\ULAAX7)P98VY3)
MH3KU1)0R$9[JC+-$`:DG@8>U@,#X2W-M-<E;,4X(37A`A;W-<TEJTXW)$VNZ
MAS2-+@K0A,Y5)D+FJ9%I:<T8`EG&)#@@Y%R49P$/NP/A)<VU0O6M2=P0GNC8
M2B4.3:2K3FKV].Y=\^#CUJ,!@E"0E?WD=W$1@0A-[D/M>>>U%V`^-VDD=853
M`B?7YE95LL>O%N+)'9T0MRJ2R+AH=Y!RPL"=8>2:\O7#`P+UW>J;@P_O-$H.
M[7N9)@@A[6`P&!XL;DD=F4=89?$'YEE43E3*UR2+RB-NB%\CLDCKXA(<V1^8
M7ML/5-KPRO#:J*4)52<TPA008$PL0@"XYY#VL#Q3I)'4\B;H@H?F4B6/#*]2
M1IBYSHA*D3I'8VN86R1/S<R#/"Y+F5A<I4UIUJHHH1"4]R2EFB"-05P,/V0/
MC*Z+'IN;'=K<7"-.!#3(D*!P2*UC`ZJFEM?TK8])4YIA[4X*6)Y1K2R3PEF#
M2*R3N..2S0"$'J8#`B1LUH_KUMV))Q=S38CDF#"Y;6;XVP>\+JJ-GG57STQN
M-FM:60S53/X8UV%!Y,8T)^^4+N2K!W,`RP<@*/4@."5+8V-S*VM[,T(4K8TM
M*%(V-;:A(+3(F]N0)RTJ)"C3%!"4G2I$Q02RP!XX"``>....QQ@?=@,!@1`Z
MA/J"[P_"!LMZ&)K@-'OS,37XO^H3^GULM@2_P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&!$":^OUK3\(&\/IGZ>V!+_``&`P&`P&`P&
M!17;55W_`&?=?%@QR-7RY/=:[U69,)2^T`OU82V;7,?K_5P5,:VP]L;=OG<F
MKI%74E@U_/LV.`4F7G-SX^G*"2"5QG)Q0:I9]1>H]%>*8BD<1^`'"LY1%;`.
MLZ*VPK0Q^72^>VE95[7A+K996^X89&Y7/)S9<[Y;[#3H*Q(;Y(T*W)R:G`OO
ME+%D(?5/]-MQYK&JRE\0KVV8A<T'A-ERMHE-K[:G6T\->U":B^*O9[G708FT
MD=<Q1=-.;4G1+20P.ZYM#X%C(%:*.H5"U.VADC9IQO:[5A)"'J3V$UOA\9VT
MLRIHBWW=8D.%75[2^&:[U9K(V2[OS:_85>_,,;7QJP+!?&<^=2>-\/[\4<4:
M8JXX)*#$[MI[<"$(E"P3=?2J72^UI)0SF.-;0.R`R_ZNLS:NL7>N6FA&=)97
MBI3KE36C,#DB<N0O[?$WA%,1#&)2K*<GB0*`V$/139Z1R)_FRPZR(R=&5%:A
MUCCQNT$[-?:6BEQ;BMTIV38Y!,$,_?'"4/$$U_JB'/?+<L5OT;,?E"QH;.'%
M$C2FFA'F1(=KZ3?O.CMTKLJ`UA>4FH,FT:C8=CUC"LGDF;6/;R1VE5M6R=TV
M>GY,>7<V-S61Z0A!)XP*;5ZA7QYO:.%1B6(EAM;6[5_J/"F^JZFR)7-([`8]
M'Z`L^1.L@LBPI0_090;PX6[L)4LH>C]FHTMFUAR^R)8X0=0&0U7*&H<%`G/)
M?6YQ2$HR@WQ:^G>P$\VOV!MR)L[Y$E#S("Y17\['=4EC<,L-NJ335K@&O58S
M-@@U@!F""")]F[MGSX_-?#2F:UQ;"E.4E*^58>#@C2S:R=39-5CHSNZ"528V
MQES22^QYUM^;1N5-,CKNKY:WI)W,>`[^V4U-3;>$_F("GTZ/3%];D:&)LJP,
M%Y6+5O#:&,R#2+J$)#GQ?#4$P5/MGEQ6*VE+II<,A=)K,55;Z?ZO572,OEDK
MK?<JBY"PP^-6J"W7N4+&I:\.Q,F<V]6EC4D)2H'-.$QZ&U>V8YVKI^;;"(+`
MDW%%/&TDI=+W?;L(?(+:CP['AJ35(B"T8EF;L3"#&/6*R9*"0JAL4?,(E@'0
M0?"(77ES5AJ.2T7U"G6R;HD".$3OB(VC8X(V_@=MA7QRE++`UL\EDR3/U2(8
M)ME2,`EM5QLN(Q)G1HW1KK.7LT=?WTA21,`\JT+T'^4_H]MW($M&NFP,IOE"
MNALBI2%31CCVV,Q0FI*G@%"7I8EB*FI7"+,9TLU.G^QMM)*YX7/!_C`;#FA*
MI%WF25P+`TC5-,;\RN%3<F*)+@YO2B62`5Q![A?-HG[BJ7F04IIJR,-CUBF@
MRBQ^%$JFDQW3?GMH<7]];%S.?$$R=Q\,\O#4G2&!,#3/5/<"IME@G6)(E#30
ME.-]G5Y79*%\DO,?F]-)#V:%ZR0=FC2;92:PCE/!ZIC;>OD"E35\!<VZ6D*0
M(53VF<W%P/#&1:L[J3>2.CB_N5LPAWD<N6P>]I0DV5>RH];,'E&Y])67Q,J1
MB,9L=0@J2&U5J96\DAK'SX-CTQY53,X(DPQE+'-R#1LJHO;^FK%@SE#W]P%<
M*V[%,6U5A4RNEXG"D-43;8?=!WM)\F8E4DD<KD=.43K_`'/5CV]MJ\]02:OA
MY+8E-+./:."PM(TRK=9$W^])*B<)$YUV>Y5?4%5OTM=G=\E=D1NA:\1123W'
M+'=\Y"XN\BF]HNS^A\(B"(MZ;&-$Z)SCDJY./`G=@,!@,!@,!@1`ZA/J"[P_
M"!LMZ&)K@-'OS,37XO\`J$_I];+8$O\``8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8$0)KZ_6M/P@;P^F?I[8$O\"`W4'V%M+76OZ:>*
MOG-%5#YQ-@8U6,^O39N%R6:4+2D"<J]L^6JIE8A48N.BE#$%]E$,:HNR*U4@
M(0GR60MR$[@OA;PI3A`[7?J);*27;V.4I*+ETHVTIN8VPAJ2-6/J13=FUX8Z
MGBH&P[DFTS89*^;8[+P^7(Z-?X<TL,Y;T(>\V+B:,)IKSPXK.60(7U8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$0.H3Z@N\/P@;+>AB:X#
M1[\S$U^+_J$_I];+8$O\!@,"--"[10K8:8;!0Z(Q>RHXKUULEGK"4GV3`Y#7
M2A^>7FOHG8I#O&H]+T31*C(R-IEZ<LA:K0I2UP@".2]V2C)/-#0"3J6TJB=>
M7*Q(G851T@[KKI;J_P!E9Z*`@J"?&Z_R17';)7).8W.9#.HI'2TK0Z/C8ZOS
M*V-RZ,,CB[C.3HB`&G!L:UM[J.K)EA3\W\3BT6F:[25SJ,!\JR"R:60Z+6I/
MKRK_`%]6<S>PDS:"`11CA=B6&E;W`]6YEB.<TJML1@4N:8](6&NY]U&X%7\@
MFI;A45MJZQB$\LBG2;V3CK4-9R"[*NK&369(ZZ;TPK"YL1(68;$'&,)WA4PD
MM9DP1F-?)H1#3&J`S6C=Q%=NVJMJASK`Z-.C,*T&=Y>V1_D$UC8)34DU##9-
MX+D0*ZCL<40U0I.*"D5K5K<_B5F!+.8R$QR5:I";V`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P(@37U^M:?A`WA],_3VP)?X%=G4F/N@JL*;3U4BV(=
M8:Y[!QYJV.9]46J,N-^.E$KZTM<@TF$GRU,>U-+>DM[F(*Y`<`9"X^,)G%(D
M'RJ4DEF!E.B2%$V0J7M[:CW6;T"-Z:TZ-#NDG*2/R5.4V<A*(KY,0`LDB,EA
MX[!X0AX#PH['8XP-BR'9TN/[<5CJ@HJJ?!,LVK;5LYLM]49'$M<\@JM96R-T
MBC666\JY2[2(SFR4YAW)B!(D3%E?D..$/@(0U+<.]0*KLFP6-)5"R55+0\DH
MR([&6R5-&]H6UN_7\ZL26.@CL`,9%ZV>M\#CDM9I!*S>7!J-1,KJ2)M*=U8#
MT909$BZ@6O\`,H+:<OI`4^V#>:?A)<UF=;UE`WUOG;1R*5R>%'PA^)M`BN8S
M![6:'Z%.W#G$Y$YM$C:DR`Q0K1$DC)&:&D'WJ7")K..VC#J&=IFS,&DU3[_;
M&-Q=@M;.\U!0=NM,Q=HXDAB,Z.+/.]9*A/5LP.3M0N8ZC4IHR?\`RXM4H1I#
M@_E'U'AK;J9JM20^$NC7(K>YKIG?H_/%SZYG!'>3G3)#(L9$49[1JEQ<8:#;
M"5#4J"V]+&CD:7D0E+@A4*`M.P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&!$#J$^H+O#\(&RWH8FN`T>_,Q-?B_ZA/Z?6RV!+_`Y,K7@D'<+.L_6V72
MV1MVX4[W+>IESL,?U;VNOJ3:(//-G2ILR0!'K>V;I-5]QV0)J$=2(T"`M]4%
M-ZEPYY`D?"C3RG<`=$&DD.NJ`ZV0J*W^M?E5B(9%;*M.DEL_56O,XU6;U<4^
M?:,@DZM!<M=5MC3ZNZ0<HZPOKX:M<3'5W;E"D2U9R;RJ.#[HI0<JKZP-K+-A
M-A1\F3[)V!6LZ;")37SB_,,"\0J@K.H5K6N0--AQ5PF7AQOK\U84>6L9^\SE
MP`"+4!3\\J`AB^]-*P7"/"K]FV988[6L!)V3!K<UD4$!QE]0*=HU<E:9BOE$
MH<;<-8+155O6%AR>.0D/#"Q$(`N2=6]ER$U&("D-E1#IY(H)J1`=-HS:/>=7
MTQLWKM<U*J5,+5.#Y#ZBUQW!J7;&'T5(EZR<F*9PX$@K4Z)IY:<8E6A;%258
MM1.*](J-<P]1'HJ[I[=0.YUN,ZK75HV?E.XK72(JM&&:<7;+X[(T[HF<KCYL
M,QM75@38LO<)BG:01).[A>ADDF/!K:4)$:$X8_7\#B1R51%83$8R>B84<51'
MQ^-LS*<DC#>H.6((XE,;428:=A0JU)AI*,'/"<HPP0@@X$+GGD*S9Y0U6T[U
M'-/)Y6T?<(O)[M<-OW6U%:>73-<@F2\VO4$J[NXL+K(5\?)[C(%YRDD*=*2`
M@8^>"^`AXX#P%L&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!$":^OUK3
M\(&\/IGZ>V!+_`JPZFEV:ULL-9Z6N.F]4-E9.O<(W8B&DMR4,](J,+#P9+6%
M+/4S_%M1-PF\$P:W!"J2(DPX\2=R0>H'RK3AY`%0&J^D'"*S:%6U=A5#6&I%
M`PFR)A6'/%":<(IRKK:(R&*0]S;7B9.$MGVLFIJ]P?)\F6)`":6^)E-+26TA
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M7)FN.(3')[9'-=7LV1I;!E9"5V;3#`HDLK<>2T_*L*!:B"S%(D2H$J9"A3)T
M2%$G)2(T:0DM,E2)4Q824Z9,G)"`DA.02#@```XX"$/'''''''&!5!U=->ZE
MD^INQ^Q+M''#BZ*LH"0\U_/&J83:/N49'&S760,AR)%'Y&V,YJAO>'A2<$PY
M,:8+DSM1<B`$(0A;/@,!@?R,8"P",,$$``!$,8QBX"```\<B$(0A<\<!"'CC
ML\\\_DXXP,!\[-5_]2Z__P"<HY_Q+`>=FJ_^I=?_`/.4<_XE@/.S5?\`U+K_
M`/YRCG_$L!YV:K_ZEU__`,Y1S_B6!2[)_P!YJZ($.DDAB,BW<+12"*OCM''U
M$5KEMJXE)'AC7J&QS2E.#70RUL7EIUJ48`G)SC2#>..V+&('/`N0KVTD_?".
MG[>(+?%N,B7:0<Q:5-I-0EJV^V[^':4*=>'GDQ>X\U#2[P"%2:,<MB;AP2JA
M"2G\N17>9Y_<5':!.W_[1W0H]N;_``S;A_\`\^X&M[C_`'E3H=V?4-J5HR=1
M)T@+S8=;SB#-$Z8]9MR.'J%N<MC#HP():T=PH9$=X4CBIP`L3]H<2+NI(>P,
M//\`"X"D?H#]0WI)](BK=AX1<G5T:;P.N>QH[+(]'(AJWO,E@\'(C3>_-JV0
MI`R?7TE=S,K%*=DO+SP`G@DL+0C`$Y1R$1F!T`?_`&CNA1[<W^&;</\`_GW`
MQV7_`+U+T/X]$Y0_Q_;IVGC\QQU[>&2#,.NFT36^S-W;&U2M;8HRN<NI6.Q1
MN=I$L)`C3'NC@A;B3C@C4J"2>!F!#3FL7[V_TD[?JQ++M@;(E6H]D\O3LV.-
M12RM+IM]24WHQ$#;)&V3BFZDD\7<&EY3J.P$L_E$O(4$G`,3\%<$GGA;EISU
M8>GMOVVSQWU3V4CMBM]9KF!MFASY$K)J4;4LDZ=U5,A29/<T+KU2]A5D,JGD
M0T`%19')?'!H@<C+X$$T?.S5?_4NO_\`G*.?\2P'G9JO_J77_P#SE'/^)8#S
MLU7_`-2Z_P#^<HY_Q+`])IL"!OZXML8IM$7IR."8,EO:9(S.*XT!)8C3A%I$
M:TX\82B@\B%SP'G@(>.>>?R8&78#`8#`B!U"?4%WA^$#9;T,37`:/?F8FOQ?
M]0G]/K9;`E_@<UL(GEFZ?V_):P5,$3YIIZWKLD;%8$[Z4^XBIY1@V+VG?GQJ
M9G7:)MG:&J)`L43"P?!3%.5"(IL6\'MXQ<*1"")2'2E@,!@,!@,"O_8CU[.G
M3_>Z]#K)@6`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$0)KZ_6M/P@;
MP^F?I[8$O\"OS:+9S;*AK'CJ*N])G38*E'8R,F/UK12[JD@IT&2"9K-7SOF8
M,=JR*%IV<MA41R/B1KQ*Q,ZA.ZJ.#U:9202G4!OG6Z[9A?$063*2TH_4\V&*
MB`Q4UULRD[2;YLV&%F=\/;"_T?8=BQ_A"C6%"3C"H4E&B,XY[4/(>.>>`D5@
M,!@,!@0`ZJG^7'N?_0!/?YK%@3_P&`P/G5I$J]*I0KDR=:A6ISDBQ&K)+4I5
M:526(E0F4IS@C)/3GDCY`,`^.0B#SSQSQSQS@0(^D[TLO^VGH!\F^NO]7.`^
MD[TLO^VGH!\F^NO]7.`^D[TLO^VGH!\F^NO]7.`^D[TLO^VGH!\F^NO]7.!2
M[)OW/?I(R>22&2C7[1L0Y"^.SX-DC-I0-EC;,)V7J%XFJ/,Y%1"(:6-OY4=Q
M2)@<\@(3@`#C\@<#P_\`Z;?2/_\`<>W_`/\`,L)_JAP(::D_N6E!1Y=<AN[-
M]3"R6]=,$I=#)-?GCQ!4L<"1C>1J5UEK)E#9$!TEC\!8A!WDWE!2-O>!@^%:
MOOO@"4-:UI^YNU;4$+V\L#96SY]LB;%F&72;4VK]='$ZO)=)D<48Y8^-$?L1
M9(X7,@JYM/%1;4V$(6A.<0B/`:8%0KY4`*("OSH9=!&BNIY1&U,JV<HK8W6R
M<5=+D\)IJ9MDJ>8E7LOD#FP2,3JQN\/L2%2.3KG:IG]L;N7PY*Y%$J2G@H@!
M"8X@SD82]Z</[FV[N:6\#.J'*5$;4%F,+-0R76:T6UQ-/-++D`I7,I:JD$!5
MIALY@S&H+6AY+(6&<@5<J0I^."N#0E-J%^Y::SQF'2XG>&^["M6=J9DMYA*[
M7IT3UC&6R`ITY)+;Q($<SBLR<5\J=%/!BA0`D9:5$'D))9BKL<G<A+7_`.FW
MTC__`''M_P#_`#+"?ZH<"=NG/[N5THM-VV>-J#7"([*\3Q<P+C5VXT$IS89R
MB7+`G=4X4D#626K4@XNA=^'7D:\HGMN%1B<@0NQW+C`FC])WI9?]M/0#Y-]=
M?ZN<!])WI9?]M/0#Y-]=?ZN<!])WI9?]M/0#Y-]=?ZN<#9%3Z`Z(4+-VVS*,
MTHU(IBQV=.XI&BP*GUOIRNINU)7A">V.R9ME</AC._(4[HVJC$Z@!2@(3R#!
M%CX$`7/'(2WP&`P&!$#J$^H+O#\(&RWH8FN`T>_,Q-?B_P"H3^GULM@27FSA
M+&F(R-S@<::YE,T+.N51B*/<F'#&B0O9)`AM[2Y2PMAE!D=1K5''`!J^&Y;R
M0'GMNXC[':\A27)-:M][KL`)-Z1*PG2CY9:T>E\VIXOJ$UJIK-!&T%A-DV)C
M"1CC73HA-E/4-BY[>3P0U>."16XI$@4BIP&$TXP87N8&@:4V<IK89_N6.U))
MSI2KH:?(ZRL95PSNS:VH9DLB3!-?!C4M=$:,M])3,DE2=U4I>#$W!XAE<&"&
M6/@(:QC^^NN3W.UT)6R&00M"%XL:.QJS+$BCQ`Z>L"15%.45:64Q02RY*2WQ
MMZ=(Q.UX&XLL9I'#R,)IS3RO3)U!Q09A;>XNN=*#AB>:V4SF.,^OB`:TQUJB
MW!TP<O/-8\[@M=LD.>R(X6XAC"QO?K(9QN0G(24*!*L`:9V.W+",,#F&_E`P
M>;2Z%O@;(X)AKQ-8>OGB6MI.;6#A9E>U0[W;*ZJ99\-(2P+YPW5PPK%7`>Z`
M;35R4YL`L$ZDFH@!D55;AP6V+2XJ!O@]E1>7$1V:O#OXTIH&8U,#S7MB.];2
MJ"NCA$I_*^WES>Z-'*WCO4"EL-;5*<T"SD9O!7`:UV(]>SIT_P![KT.LF!*"
M];[J'6JM9!;5W6!$ZY@\>1KCSG>6R-AC1+HO1M3B\$QQB.D+DU)':4.R1J/X
M1("S>^%0P<A`'GL<\\!RJ:B?OB6HM[F[)F7S0[]J^@IFII5;57<K+?C5AN]_
M@BSBE1<5C'FI;$:U(8KBD1#HE4-K04J=TAQ)2X9BXHM'W0\(E6M^^WUX*F6Y
MXH_3&0$7P?/#6QUA=JV"2KKUKKLAM$J*E:&6Q)E0NSU('%RY`D\&#1(0)..!
MG=\'\<!+$%ZU;_O!VD[QTR6/J"V;.*[A\T\TZR:2G4V.6[7TFO(J;MDA60LR
M"1J)*WEED;AX>DZ,)K>J5H4G`6=26M4@**"9R$-F=+[KFZ7]3JL2Y7&Y0QT#
M9_-F+*M+H*Y;$KYKLJ0/?*1H<6!P@+:6^$K)TSR1&]DDD"1IN#PN)*E-R5SW
M,LTX+GL!@,!@,!@,!@,!@,!@,!@,!@,!@,!@1`FOK]:T_"!O#Z9^GM@2_P`"
M%V[^N4IV.@M7HHF@K&8+ZENJ/W&HIN\^'3S%WLF8X9/HB175LF,\?EZY$RM3
MM-TLK9UO#*]`;9;&6A88@5EIQ$C#&]*=:)Q1[[?EAS>'T;3"R]Y-"GT&O.LC
MD]/=)5\JAL7''7"8$R5\KNGU$SM&R>ZE</[P5$H\4>@9VE-RF,-2&JU(37>Y
M3&(THCR61R-A8%4M?BHM%$SV[M[4HDTG/;7-Y(CD>)7*"#'I^.9V1:K`C3<&
M*!)DAQO`.T*,$$,+L^\:4I).P*[GN"K:B2RQVX88LIL^P(G`4\E?>0!,X96`
MZ5NS26\NW)8N!=[)N3#NUYXY[7L8&TL#3DMV*U]@,',LV=WK3D*K8J6/4"-L
M*6V="8Y!RIS&I`^Q.1PPR6/#VC802Q@E47<VQ:W<J.%B5P;E2<TL)R<T``\9
M\VAH..G/Q#E9+.,V.-["Z.`6I(\O_"A%)"(TL;3&(;"V.0)284V31E7+2FSE
M8:V-SR@6+`D)5J4TT([=4Q0G6=-O<A6D/)5)56O4Y4)E*<T!Z=0G/:.323R#
MBA"+.).+%P((@\\A$'GCGCGL8%@N`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&!$#J$^H+O#\(&RWH8FN`T>_,Q-?B_P"H3^GULM@;YMR%2&Q:VE\*B=C2
M:HY-(&D:1ALF'D-:N10]U+/)5(G=O1/258U+PEGI^`'ISR^T4)QF%]L#D7`P
MA0]5-\[9UR]&N5B;8;'VGK>P;/V-"95M?_8]UG1T`8K<MG91$RZZ,<#[U,V-
M00>&NSB"&G3%!!CX:U!;AGE.0&\@!W`=$^!$B"4M9-96CN3:D>4P=^<-A;+J
MF;09C>71^:$;4WPJC*FJ)\22QQ0Q]V/2K#U4&7+$G>9"L`RS"`F"+Y$9W,(`
M3'IPW_(*Z24:F?\`7APJRGF_;9!K^HF;;+Y.MD'&UR6>U\A+O"#K8^;&5K/2
M%,W!)$)K>F6.)-@.H$1J@4>([N6(-OPO0.P(1I77^GR2<1=[)IW<?6^Z(99#
MZ<ZFRNP*EH[?>G]PG%RN!4E8$_#OL/+(]#'5M>7<H)J:22087E4:E$X*24@?
M8+16P7&QR(7('2JWG4U+N)/-U#D"XF0K[4D$GL!EF3NY4V^1U:TF08<+(N:=
M+7\Q[Y<#S5C&`MB&T%\\F.@@GC":'IFN'5.^P2LH;%'M,VN#24[LK(C1N7*1
MW7ENCR(]<`OOE4N>W$DLY<J-$-4M,+!R<89V@>P%=5BTZ_03J5Z5S=RON[[*
M;ITX;E+FVNK#<*V50&MBU];MSN4VUZFB=9Q&4IF]M(4\(4_#JZNQO"(H'!AA
MAW`CA!-;;#3C6G>2KT]+[654TW#6"65-,V3Q)Y=I,S(RY2Q(W5`TN_"R)O;`
MZ<G(T;VJ`$')_)0N#N>1!YYX#SP'(QO=^YQ5S=NU<-GVFUHU_JSK"[M\6;;3
MJ18TSN62>+*&<_E-(I%5CB[/#^3(%DI:>T,X1.ZU`2B<`#,X.-)-X))#6N^_
M[FL19VUT6EN@E@T[KGJ6_-L73V16UA2>Z)=.Z_=4"@**5.]7'/:"R#9X3(6P
M'"XM&]R)F`D<1&$EF<)>2^"0POJ4?N@MA6GNE&Y-T]SZ)I'4&;M,-12^+R>4
M3WPW3#LS$%MDU=&AK=")FZ6`ED:-*%R0@"YIAB<U)J0X*-*6!8,.H:H>@OTC
MZ%M"`W14>ET)A=GU?*F>;0.6HIM;RY9'93'UA:]G=TR-WL-Q:U)R%82$80*"
M#BA<\=@0>>/R8%O&`P&!"C:?J.:.Z1O\5BVU^RM;T9(9NSK)!$VF;K7!*J?6
M9O6\-RUQ0A1-RT(DZ9<+@L7(N0\]M_NP*+.N%^\1SCI>R_5=)05-57L)`-F:
M34W.RS.3R>5,I1K(H=$)4<5L8&4C@*IK>V5P*5@&:$)G8'Q^3C`Z/M:K3<+S
MUSH&[79J1L3I<5)U7:;DR-QQREO9G"P8*PRU8U(5"GCA0>C;U#N(DH9G\,0`
M<<B_+SS@;LP&`P&`P&`P&`P&`P&`P&!$":^OUK3\(&\/IGZ>V!+_``*VNI=9
M]IUY"]:V"IY%=32[W%M*Q5A(F+6J/UH];$3J'`I&][*=X[4*^Z&QQJ6*NS(I
MKA-)'MP?1)2Q1!A=T:$[AV5MX#`V-I#X^>*TX\?/[;_??C`W=X?VWO[-WC3W
MMX.%W7Q'_LW?^2>+_=?_`-CPE_*N^>QW/^+P/'V[UT3V?=VA=Q1VJ(O*)W1V
MTY#X_668PQ?F;0&GW.B+\C\C(02IR`3(DL7=)E(&0M6W(3A!4J!DFC)%P5R,
M`:7VGB]NOMQ.5L1[5BR+ZBT@U0VDU(35\6Z4HSKF&6RR=PA8UR16785EL;3Q
M4&PC1&0DKW(D\U8@3,C<)P;>U.%PD"/VG^KFT]>;*I&*^VNRK&U)+J9[IV.1
M^7V,1+(H3=[%3%*0NZ+YFE;NJ]6)74.T!S!)D,89E2AR31Q8E<''P<F%.#^&
M\/NI36:U-78]K3(H[K&^2.`T!M/U<P-^NM/@IQA6PVLMG=O[XF>M=F5]&93-
MX!7R6/ME1*$;,E:T:](K:V6<"X$020F7$EAMW7?ID1I/K)6<'O-RES?,QULQ
MM\FKU`NK:50*M'!PC5>LCK`F-J>X')HE-&F*1JK8JQ)1.Q+NUHCXHB=60AL7
M!`IX#_.L!2;U)-)MC)PU7]>\%98%KQ*$RJK(F]P%17EA%M1:A9R*PC)E7,OL
M!U4.2<P*56<C?F\TU.6'GM@G<C.$%NV`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&!$#J$^H+O#\(&RWH8FN`T>_,Q-?B_ZA/Z?6RV!+_`J0DE6=,AJO)?
M"Y-M3%V!Y77&DGKUIDY;J\,E6.5^/4X26"E=G/6M18J8LQ\D-D+"GLV,]ZAC
M[J_*>7`]I/7'"/&%M^`P&`P&`P*_]B/7LZ=/][KT.LF!8!@,!@,!@,!@:`VC
MVCHG2ZB9SLOLO.?-K25:^+/CK-?%F8S'P+XXS&/0".?^G(!'I5+7'PC+94@2
M?R1`?W'N_=3>T)`88`.&;K0['_N_/6+LZEK*DG6`DE$'TW`W^#)FECT6VPGQ
M3\4^R`#^-Q/6+ZRBHV\Q,,'<N"PEF\"X_A=MQ_LP+M=6.I3^[V;/\:?Z2MMK
M4SM]<\3KFN=<*=/MS2&X5+Q(SH;#FUC+`A>;9H`<=A9+\&.B6&D&NI*0LT78
MY-%SQP+D.E%F9FB.M#5'X^U-K$P,3:A9F1D9D*5L:&9H;$I2)M:FIM1%$(FY
MM;D1`"2""0`*)*`$``\!XXXP/2P&`P&`P&`P&`P&`P&`P&!$":^OUK3\(&\/
MIGZ>V!+_``*L.K.<P+*9HR%/%;0N?NED;/P^*P1XLJW+2I"O:RLAMK"X)[")
MA(Y_3KQ'YPC=),^0HN%QE(G6I@KYE+&=/V_`Q@XY"/W13M$ZPVN]2P.5<G-"
MF*ZO6BPLM:V]L+>Z*/MURUF^2DQMF4^V%M"P'M@LIM7I3FYVB2-,WA9`-R=8
M<8I$Z@*1A>A@,!@,!@0`ZJG^7'N?_0!/?YK%@3_P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P(@=0GU!=X?A`V6]#$UP&CWYF)K\7_4)_3ZV6P)?X'-#K
M%+Y!`+4F]>/%K,=6*B][]EQ>9MWZ2^RUDK4:*4[:V$^(0LNWJ-Q0P^5M=@HG
M@#TDF1Q1J5N\+_QO8+1<E%ATO8&IZUO6G+D=K'9*HLJ'V*XU%+$\$LH$.>4C
M^FA\S4L#5)PQ=V<&X9[<!\(8GQ(>>G`:,Q-W8(#>`&=D'`8M"=IZ"L:T9!3,
M,L1"]6)&SIJE6,X6>2H6US65I(440LUOB4K<V5%$)VY5C+').UR5,R+W`^/.
M1P$S@!,>+@&!E-IWK3E(\P8%M65#Z_4V=8$,JNN6^2/21"[3NQ+!E;%"8C$8
MBSB&)TD+PZ222HB1`2DF\)2CN5"CDI.68:`-<2+<[6:*6%)JND%IM[=,X>GD
M0Y`C$P2Y0SI'2)5RHN"30]-+DD?/A[K8[%4Z4R2J8ND7GR,IB!RNY1=[<=TP
M/9@NR\`L.7QV$L;1/DKQ)V6PGI`-^ACFR(DX:GEZ6`6.W.1J_N9R!RB4U7$M
MJ@(R^"C5!H.2##2QA'R&A=B/7LZ=/][KT.LF!8!@,!@,!@,#4MW%7J=7;L7K
M>NJ5NMGE4U<L2N[FJ8O5=@1<.*;E\"[-\#>6&2FJAM'=N$G)*D``J>0<F<"!
MP(/(0:\'=:'_`-X],#_XUVM_K7P*<.KYM!N51<2UO@^U.SO2DKU\7[CZ16W$
MXN6W7W%92:@JW;:J)(98SFDEEI*N%-1U^Y,X7"6GIRP*"F-*J[B<2;P$P(6X
MQ9WZOTXC$<FD/LSI726)2]A:)1%Y&S5_M0N:'^.R!O3NS(]-2XBV1D+&UU;%
M91Y!H.>0&%&!%QSV.<#WO!W6A_\`>/3`_P#C7:W^M?`L_P`!@,!@,!@,!@,!
M@,!@,!@1`FOK]:T_"!O#Z9^GM@2_P*VNIO+GJ$UE0[W#)_9T$LWC9V$I*Q35
M-2+SLA)9[)CZ^M3EY@+A2318U;%S>(NE>%OBQW&K4JTS(@0&._!290WD.C<&
MC=&MUV8NU97K;=BB<1VX)=8A(60#]HD_ZB1IPG4DKY\LP;,\K4=G7(Q/<TGD
M-AKL[-SFXKFP#R!C7I4ABM8B4$E!<O@,!@,!@0`ZJG^7'N?_`$`3W^:Q8$_\
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"('4)]07>'X0-EO0Q-<!H]^9
MB:_%_P!0G]/K9;`E_@<N,EU0V[O.8O5D,C[L7L&W2G9^THR<XQCJ"6O'M:XL
MZ4OO41(&5ZL?6UUV"@L!0T6FHY$ZUG*H<R0QYD[=)X5W5,A/$X"D0PZCL"$5
M24]/J4MO>>R66"L+JU7;;M2S>M(TR/;1'AO#=']?:<K&6*G0PQ*%$Q+BI/%7
M,_L&A$-464$?9[8WC`K;LC0?9685(Q:^N5/U5-X=0`MQEM92F2VPI$5>#[L8
MNGL8IIPF3.@C<>DD+#7+':Q\OF"Y*YIG=/*XPA-CARH\PI4D#<\3T3M]CTM@
MM!21LB<XN^M=_P#6.\Y%>[NO2^,>P<8JOJ$4%L;8&Q,J<')6^/3+:\WI:"JD
M[HTC5"**=6WAL;.Y,P6PHL/7<=+KBD\\\S$MA\/<];3-X[0W%?+;-L4\4NDL
M.LJ*V"Y*:;,@),5(<4D@XL2PSX^I/\(\-OB`FX$6KY7G<HB0LMKFDZWJ@Y4J
MA+*Y(UZYI"RKW1[ELQF3PO1<32=V&>->\31_D#FM<G"9V6]+UBTTT:Q::K"$
M\TPM.F`2%<MBP2YXWU*]*Y#/KY\Y,%D;AN4I@5=^:Z*0[S;H%-;MRY`V^-K*
ML/>)AX-9S2D/=EH`#.[EW87'`Q<\8%N&`P&`P&`P&!J^YC+H)K62&:\HZO<+
M@#X'\4$ES.<K9ZU.[+^UA?\`QD<80TODH3]SB_*T2/O5*;VZ\)`3.U)$8,(<
MC76%Z#G5#ZP=DT[9-DV9H13JZG8.^P=M;8/)=AGU(\I'U^`_&KEQK]58#B%!
M!P.YA"7_``>0_EY_+@7O:>5UU0Z0B.N='VBV:$.-,4_`*ZJN226`S;8959[E
M%:^AK;$B'AD:)%7+5%!2!P`T%&C*/4E)@\C'QP+\G&!:O@,!@,!@,!@,!@,!
M@,!@,!@1`FOK]:T_"!O#Z9^GM@2_P(N;25[35GM].Q.T9Q)*RF*FY$ZC76P8
M-)3XA8<5O$BK[1"%5`G[O)S:"GQUJ`V7-JA(Z)5;8ZM"U8@/(/[Y"2,-<P+I
M\4G#[$BUQ2*47-;]NQJ;$V,HL6V++<7MVE$T::ZD540QTD;#'TD7@O+;7$%F
MT@3Q]G0-*!B;5TA<7,*(3JI$MX#R]P)7<L+N_013!K5.BM;SW:U-5UI5VBBK
M2J/L%J<Z&OZ9(@KY@M..<6EI;'F%(CN4:-.4-2<4#D:CN?`BAAIW=BT9*.Y^
M*_!L?*-9J\A^FFRVP35.X2_P5I%*;7JN3U^QJ3'U7,([($CHQT&T/`7!R8N>
M?![D*1%^%"#2DQ0,#6VI>_\`L9L+L&9JW.8_4M82]GH%';\AFJ=GFCF>HE$O
MJ"BI6"D6&,NCHVL@;AUQE-TDJ[&*$YK".&!?&#4Z-(;(U94>#7E06U?%A1/6
M.H;HV:GC`CF6U_5X@=D["Q0Z$U?*)PXZB;=;!5U257(5)S"ZM$-;UM>1M6_`
M2-O):GE!`N]C#CT0EX#PS#6:$[>;24(Q6O,K2EB!)>=00,#1.F"\;.@[@[-#
MRW4+%$-W0^$5V;%(G7\G'%X?.)XC(:>"&A\731L3J0GI"1%HPV'U?I#>\8TC
MV*B%=4S$IQ42G7:3HYS9DIOAVCTSAI0"CT*P;="%U:3178ZI&S$E*N[JI$W'
MK5!@BS!A%QR<,+>,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"('4)]07
M>'X0-EO0Q-<!H]^9B:_%_P!0G]/K9;`E_@<B$\<4C7*KAV3AB#IM,%K&]0B:
MPF-T&^*=GE^U3Y+#=LQ5>RR.6UQ'MLXN@=[M?D`298"/I&`EN=&KE.<6<F0J
M..4X=)&ENPKCM+KI$;G=VF-M3D[2BW86M.A#TJDM?2D^G[EL"G!6-64C7(F]
M9(*KM+Q"\9(NN,)"-7'W5&;SR+D?;<A*?`8#`8#`K_V(]>SIT_WNO0ZR8%@&
M`P&`P&`P&`P/C<7%O:&]<[.RY&UM;6C4N+DY.*DE$WMS>B)&I6+ERQ2,I.D1
MI$Y0C#33!!`6`/(A<\<<<\X&MX;>M(V,[BC]>W'5<[?@(SG$;)#;"B4H=P-Z
M89)2A<)M9'=<L"C(,4%A&;R#M`B&'CGGCD7'9#:F`P&`P&`P&`P&`P&`P&`P
M&!$":^OUK3\(&\/IGZ>V!+_`JNZN;_!VW7VLH[8<,JI^CD^V"B\:*G-ZK9>E
MINDI.SUU:EBP>RITGA$TK9]>#G::P1OA\=0AD3$!3,)6T![\*%VG`@U3T9[0
MA$_KVP$L%A%5M"0<'U=M)_E])R>PI'`E$ONZE44VDE1NI5@SZSUC)9=..''/
M#HE(>3..6E\:##DZ=0,P(@N/=8\P/IS*I?&-G>5$:>`2&.*'5L1.)S`_E-[@
MTEOC*:K(.&U/!;6[JTP5)')9W"=4:7P+M#!\<A@K_1U*2M$B;933]6R5N;9D
MML5N0/\`7\3>$3?8+DX*'9QG2)*XM*DA+,G!U5FJ3W,L(5IJ@P9@C>1BYYY#
MVD=95LW.2%Z;Z]@Z%X;)))YDVNR.)L*9R;Y?-DZE),Y4A7D(`*DDDER5:<6Y
MKBQA5+RSAA/&9P(7'(>7(:6IR71)5`)74U9R>"+I(ZS);"I#!(L]1)9+WV2.
M<R?)4JC;DU*691)'F7O2QU5KAD\JE#DK.4F#$<:,8@V,G3IT:<A(D()2I4I)
M2=,F3E`(3ITY``E$D$$E!"62226'@(0AXX"$/'''''8P(#=53_+CW/\`Z`)[
M_-8L"?\`@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@1`ZA/J"[P_"!LMZ
M&)K@-'OS,37XO^H3^GULM@2_P*SH)N_J\^V\^I)[3UBUMLFP6K/M>U#J=J=L
M!*S')%%;+>8-%WECOYCH?B)N=:V`UHT3VF5<.H&U$G7]S4F`&G.%P%E:=.G1
MIR$B0@E*E2DE)TR9.4`A.G3D`"420024$)9)))8>`A"'C@(0\<<<<=C`\=LE
M,8>W:2L#-(V%W?88N0-DP96QW;U[M%')U9T$B:V^2MJ50:L8ESE'W1*N3E*@
M%&'(U)1P..2S`"Y#"XU>-*3.P9;4L/N"K97:D`)[XG=9QJP(F^V#"D_=DJ?N
M\MAC6[*I'&R>[KB0=LL3$A[<X''9[(P\<AFDBE,8AZ%*YRV1L,7;5[]&8LA<
M)$[M[(A62>:R)KB$-CB56YJ$R=0_2V6/:)K;$8!<J%[BL(3$`,.-+`(-<NFQ
M6OS'/'VJWB\J?:[1B\76S>25HOLJ&I;!8(8W-07U?+'F%'/()*VQM&RCX5FK
M3DH$P$PN#>1\`YX%@?5!;SJNRW,IFA4J"\NHVE>\'(.6:0MBEN+:7U5&7EK>
MBGAI;Q,,J9'U$:F7,JWO=X1#!SW=,6'\N!%G8CU[.G3_`'NO0ZR8%@&`P&`P
M&`P&!03UA>OI471\LFG:VLB@;(N)=<4'?9PVN4(DT88DK,E8GX#":A7%/Q8S
MCU!YP^Z!$7_!X#^3G\N!OEXW.J7>OI5R.Q&6106F93NAIE<)U5U?;UJU_$Y#
MPOGT(G$&CB):Y/;RSM@DJB0AX)&MX[5(7SVW;#X[078#ASZ/$69OW?[J6QRT
MNJ99%>T7";;T^L4ZN7N#.+]L@AE2&3V'$6YF<D"[6^.6LW!0JE\"=2N1&G%B
M`)-V1!X"86(0?]+FE+FK78FHZXO:G))XX55;4/8Y[7TI\#O\?\8(G)$)3BRN
MO@.4M;)(VKOU$<$?<%J-,I+[/8,+"+CGC`VA@,!@,!@,!@,!@,!@,!@,"($U
M]?K6GX0-X?3/T]L"7^!7EU(W^S&>IJN;(6UWJYU[-;Q9H3LEQK+5R>W+V240
M\UM:1JM1!(RNB,W;DB4^TD,52R%>-O,5IHHH=/!H@NPT'.!&_IW7#)8A:MDZ
MU<5YNR5K\%=$Q:R2G8C4&9U>*.`3P1\D=MM$EL5IJ.OHDG@PW]`F#'E$G[62
M*GI6N2"-.2B:>.0N=P&`P&`P(`=53_+CW/\`Z`)[_-8L"?\`@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@1`ZA/J"[P_"!LMZ&)K@-'OS,37XO^H3^GUL
MM@2_P.5]Z,W`)WRF-,$3.U5.PS^^J)+$9D3O!6Q%2M#(AW,<IW`YBMUK.V++
MF+#5S-IR\!BSK#$U;*_#;P5R8>F7&##(P!U08%=&MM(\ZO6UU"95#Z$3Q>O+
M3ONK+%KZ+5)'8%'@3PQ5KO2T2L&5M;`B<XTT%NAUB-KL:Z'KQI52P\@]1V3A
M#`(P*YIMK+M`=6<4JMMUSN(,TUT7;]R$-S0NTZRKQ3?LLV/E4Z!3:VNY_%+#
M4V7#7*=S^?L=D2QU=&E)Q&%T.-[Y)<SPH@K`VX;J!=D[T\I9CV"K$FY]UJ+Z
MD.JUM2"ZI87$)&XOQ$/ZB&O%AV[L10CP[#)%45<R76*.*AAB[0!I-8V=$HC9
M:=7PF`8M#UG[52W9S8*FA952LP\3G/J!W+M-*MI"9%626)NM&VC4=EQSF,M/
M><W';Q5B*(S/R:G,1#8R0D1]$<N[[[QX2D*`L*J+3>L*<LMRMQC>9@^3M_3R
MXV4O<A\22E<KDD[D09'*I:^JXI"8NO.6.)Y))1322<3%T(2`G)&HA8(U48$1
M+%8-DFWJ5Z5.-KVQ1\UJUR<-RC*IAU>:^3RL)]"VHVMVX]I16%9,DV;MV.V:
MX(HZ,E*H4ML4B1:I:6-4`A.48%&4%M^`P&`P&`P&!3IU,>AWIAU7IS65A;0.
MEV('ZIXF[PV+@JR<L$3;S&AZ>`O:P3JG>(5*3%:SA8#C@`P&%!"#\G(>>?RX
M'-!UQ?W<;;ZYI3I/6_3JK(-BT#JWJ4BHM*\67<=9QZ7$.2.U+$EX4CF.1+X@
M-Y.\'2@D?*E.B+(Y[?M/_$$6!M.Y?W6'83=76+IR,=D;$0W6>S-5M/FO7ZP(
M$L@GG>*-D:2S+!G!KBAED5L-D934O"67%$]J3WP'MB^1=T_+VH0Z[M&]<5NH
M&GFM.KCE*TLZ7T%3,$JI9,432:PHY,HAK$D9S7I,RGKW0YK)7B3=T"0)2>(O
MCGL<C%_MP)4X#`8#`8#`8#`8#`8#`8#`B!-?7ZUI^$#>'TS]/;`E_@0DWJVB
MDFK=?UJYQ!L@8Y);MMDU`SR^V'Q>P517+@?5UIV<CD<]5-00.3@7)%58`BK"
MV$*4`WB72-H0]]I^%')H0UST[]VY3N''I&.7L$!3/,<K+6.S3I%53PZ/$*%S
ML73Z2QU-=.X';E4IC]G5LXDG\.K;PL7<!9W-F6<F%F+1IR0WI?6S+O2-M:NU
MH72TRF+%LE;PJE4VPCDU?LT%K1T\W5D6$D*>FE?)#K*D+\[IJ[-+2)V]@&U\
M%F#,4N:4PLI.I#%=D-IY]5,]1U=35,,=USM!2=B[#SAKD=KF5(A8:TK]VC[`
MF;X^XDUS9(I/8\_>GE02Q-J@EI:.>&E6-P=V_CO;A0'GU+U$-<;W>D,,J%;-
M)Q:#A"%]CDU2DB*MEFJ>$`@,)L:,2QV-E1[#$&")V2R62PIXP\KW5,S/;BO,
M3$*^3&YU[P#4L#ZA%@V]!J;\VVLQ+7?=RV]NG726DKENQFAC;7[!H]>EBT59
M\FL*T*P@UZ-'AI1)8FSD%-L=;Y$A"Y2`!)3HH0I3'0P-/I^KB2_1<$OBU3L(
MV]Q88^M$V22TF&/N-8O`H;54IDZ6Z'1<F(B\6;5#_8;G$X^J3K5!+[)XN>F1
MC4<K2PI@R?J][0Z_0?2#8BJ9Q;,,B%H6WKI)5M=5_(7031+):6_$'MC7PSL;
MFG1NAIBMT(,3A+,)*-X.`(`@!%QR'@+>L!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,"('4)]07>'X0-EO0Q-<!H]^9B:_%_U"?T^MEL"7^!05/.F]N.Z0
M6S*@B9VA)L/D.WLLV8A-K2R"VSSL:V)G;9P[8UD-D$\;3#B#+>:3#/`Q$J2!
M+/0H`$<%E&FIN^#@N]K;SD^)#!YW_$?SD=[J/&GS;>'O$COKOY5WIX`\9_\`
MS[O?P;W#NG?'\+N_;]C^!VN!G&`P&`P&!7_L1Z]G3I_O=>AUDP+`,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"($U]?K6GX0-X?3/T]L"7^!7%U-R;+<
M*8K5AB$ALZ&5C([R86C:&;U#0T`V>G$4U\XKRSG)P6(J'L*D-B$$];7RU6Z)
MLR\:.*N*MB1.9KR8$2%N6%&!7II6?M#5FQD(A5)3'9VU-&Y):R2+1YMN/1FB
M]5H2WUSQ05A3&U[&2DU)ISJ@]1!="[J10QM9'5Y3I4,\*D:Y"T-"OP*L?0A>
M!;E),%P/E&/KX[/#8HH:Z$%VQPEJY1<$O#^@KRQZX+:7KOM*I'RSC:[*5GB[
MAR2=WP05V!]IVX1!HZYM-%-Q/H9AQL9=-9SDZ(V_5#M,:T;Z>;W9YI"WY"S2
M`^LUA,IJZ6MA1U?&L"8,9D!!!3\VC&I,,4J.5BK@T,?IGI\UI1-]CV'@4VGR
M*7KXZLK)]8S5C8.%.E#,L7A<7IBD4\:X0!2,L5H($"3K8VJ2<EN0'!YD)Z@X
MX3^X<##]`Z%1QEC\1)KFYK6JVP8'>NW5XQ2U8JBK%WDJ,>Z=U6A=]P5TXLL_
MKZ9PQX@7C+98.\"3F[OLDZ/-*@P\TP@[A2$I:4J.)4)4M=TS!>70R*5K$V>)
MM"Q^6`<I"[EM:4!2E_DSH6G2!=I1(EW=5SFL[D7RK7J#3N0AY'SQ@10ZJG^7
M'N?_`$`3W^:Q8$_\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"('4)]07
M>'X0-EO0Q-<!H]^9B:_%_P!0G]/K9;`EJM7(FQ&I<')8E;T",DQ0L7+5!21&
ME3E!Y$:>I4GC+)()+#QV1"$+@/''^WG`Y>;AC6];O<#J7++/VQDCK*MB9#'F
MJO*UV/H^(T86&'[AQZ2P)M<V:&3-DL"$:^SK4!]X95BA4)++T4DBCB4L`:X+
MD1CP'4A@?B6H3FFGD%'DF')1``I)+-`,U.,TL)Q03RPBY&2(PH?`@\"XXYY#
MSQSQ^3G`_,I<B/5*D)*Q*<M0A3C6HRE!1BI&!6$P:02I.`?)J<*H!0N2^1\<
M<#X#SSQV>QS@?H>H3I0!-4GDIRQ')TX3#S0$@$H6*"DB0@(S!!#R<J5'@*+#
M_P"(9@PA#QSSSQQ@?*H=FI(:I(5.;>F/1MXG962H6IB34K4`1@!N:DLPP(R&
M\`R1\<G"XX+XY!SQV?R<X&$Q.X:DGKDG9X+:5<S1W5QWB7I6J)S>,R-R4Q,3
MCX(#*$Z%G<UBHZ.\NW\EX6A#RF[X_B^W[?\`@X$1=B/7LZ=/][KT.LF!8!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@1`FOK]:T_"!O#Z9^GM@2_P*U.
MJ.TMZZD:S<YI?$3H2DXW>\=7[!.TOV7>-1D,QK!]KRSX(WQQ!=S+(8DJ:'B*
M6M,(S-"6D;H@(DG$3&TF'@"MYYP(?=#=HC`F?8B7Q6QJ1L[AS;=;83.)15VY
M[?O&]O=MUG6KRRV7*S;-3S^QG:'T].7I>!WA<7=5:!S0&*WA4<V-_?O!.!?9
M@,!@,!@0`ZJG^7'N?_0!/?YK%@3_`,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,"('4)]07>'X0-EO0Q-<!H]^9B:_%_U"?T^MEL"4,HBT8G$=>H?-(XP
MR^)25M5,TCB\H:&^01U_:%Q0B%S4],CLG5MCJVK"!\@-(/*,*,!SSP(//&!S
M7Q-QI>%[93J)OC;TP++>$FV\QEP;FG^IEMJK<9DMD[/RAO9&1ZV6:Z<)I1[M
M>N[$5CAO#MX=X,;)*F0-SJ?RZF<'+`Z;L"M#5ZOR=;[LZD\D7Q6Y"(#+-AZ@
MF<9>7=ON^Z'Z;@=M8Z)8Y$ZPQ8Y@L"=S5C:9L!8@,+:^5:%E[S.3A`F(1C`2
M%6SM5EDPEJ(=J[H_9&";?UDJZ@;]LG?M-:]RUNG=RN5ES&6J*%30&V':%*Z^
MOH%HW,XP&3M3?RK?6.+Q9A4)9&2RM:18C"$C)!5NQ-UZ8T;(-C8U=LDW(J/J
M<Z<2RSX]&S;@::Q;'".=2O6I18<FJ6#,HV6)V5J="]?VXYWC+RZH'@MFCI*I
MS<U">0$OIY88S*M9EUC7P^U^\TK8#3L9,]Z[OF,]VL;J8D*5D%I)8=&6+#&I
M&DV35Q=37;PWAJ!^8:_30SPHL<4TH0DKSF4)*+ET+"U"E]4E-366X6<KLURD
M;G($MAK92UH60^+,KY*[,GQM@/"TUM325T;S(S&G-4J!'T:LE:[-H7!5P:[*
MRS`%%!%*Q5^R2GJ5Z5IK7B=(,M7)G#<H-4O->6#/)//GIJ#6[<6U'6%&I)64
M1CL9<#X[P0:H*;79W+*6B&4`PPH(3A!;?@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@1`FOK]:T_"!O#Z9^GM@2_P*A>J`PWB7)]4K'KR]JS@YM;7VPR.
M@Z@,TGL':>Z;=V6\T.Q,>?X['U3)N9KQ"!PMSUQE,I4+4;BTI3&!,SKGSB0)
M#"$PD(;]T3ORW[@36S%M@I;&5-S5D]1(N2UF@U0G6J,IKIEF#&I=HTJD#+*]
MK=NX[8[3+@HE(FY_C4D$S]U0+$(NV6(U0"0FC))Y"H<X1!IE<KC\<=+`DG$/
M@S<\NJ)N72^5<L[M(/%Z.)51Q9[P\<,3$M6<IR`C,X3)33.>.``%SP&$6]L1
M0NOY#`IO.YJOJ!/*5#@FCAUDSB.0PIZ&T$IU+T:W#D#B@"I1L2564:O4!_B$
M))H!GC+`+CGD-P@&`P`3"Q!&`80C`,`N!`&`7'`@B"(///`@BXY[/'/'Y.>,
M#0DEVKUGAM?I+6EE^5#'*U<9E)Z\;9T]6!&6Z+ND[A3[*8U,8@U/*IR+1.<B
MBSW!GHAP2$#,.1\M"T1H0@2GB`'B/.X6N;&>H(.L3PKR4GBZI"?$HE.IRADA
M$R;XB[L`X0XPR,/S?/N[L\_85BCAD-<!(4;V@/5<$E+$XS`TQU5/\N/<_P#H
M`GO\UBP)_P"`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!$#J$^H+O#\(&
MRWH8FN`T>_,Q-?B_ZA/Z?6RV!*>0NIS$P/CXF97B2J&9G<W5/'(\!O-?W\YN
M1'JRF5C+=G!H:S'AU&3P0F"I5I4_)Q@>##2P=D?`<FL7@;U9EDR!Z:-=NHU#
MX5+K[M*D5VK$[.T=AL1&8'<^3;+N,,/N.0SQ/;L3@DU7(3)^<TI65X>?%=S,
M3,3XK9!MKF(.N+`8#`8#`8%?^Q'KV=.G^]UZ'63`L`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P-7W9;,?H:H+,NN6M<H>8G4\'DMARENA3&;)96=&HBU*7Q^-88\
MG-)5/C@D:41QP$I'/*@_N?("@C,Y"`05>5YUR-0+@T=N/J$U#"-F+,UXHB8.
M40L15&*>`"8MW,>C;-+IA*4<:?I0R\+H7"(\_I5+LXA4<%I"Q#Y[`NY&]H%-
M;IU--R-R]N]5]W]!T?4Q=NE62)\5;-UI'=:*,=^)&^4V>YF#:ZJ4+Y`XR5^C
MMD.R$EFDA/#JF5-G*56<A--./`0G"^+IN]62A^J4QR>9ZW5/LJS5I%E3FSGV
MK;-<1V'U^[RMFYCACG"V!W:YY)UCE)D:"4I50R^]@)^".Z?QW=`<EX%HN`P(
M@37U^M:?A`WA],_3VP)?X%:'4[:&Z50+6Z#H$4T'<,XVKBK!KD_0V[G36X$0
MN--4%VR4Q^EMX,,*L610>'JZJC\H:E)#>R.2J2'N1#!PG-`ZC`(-`]/JAUL8
MV7V&56=/;^3;-54Y5F?<S<7M>];%T1:T=GM8R!#4JA2\RJH:GEB9=$V<#@IY
MB2UK1`CJ\PAQ3F+270*Q4$Q-L=<S+3N;1FW(K6,5D<RHS:%)*)58:A#$$DRA
M5.JJ.OF-/I+;(GHU'(CV%=-96R@4-3::>8><8`\2<0"##2@TWLS#KZ>+A<;A
MA&L$RN)JD6KNRFI/%>.4TH%B4QY[DL]ASM$K-5#EMJ$,)E'70VQT0GWO52HE
MJ)&UM'"B-GGB.3H`C=J%I1LC5&S"<-TQ-\L354%3OE+L44E%CQV61Y@M!EIF
ME():&U$AKQSFSFVN43W.%&'YM3L1"58Y1<1!KDJ;DA\ZE/>09-3FKUWZP,VO
M$OBNNBZ6LE$[0]6=0DURJJ0T=&G)HJ3;7<*[+.UWLJNTTQL"!5&@)8:O,9T?
M#0)\:G)H8Y<J3][A4I5+:(-PZZ=-6(,&MU>P:Z%4@+GQ]9H6:;1^.21K=85!
MW.1QB'1R;PR$D.,<4-;G'$L/@<>BZ<U2E,3ID491KVE,TKQFJ!AC_6`H<B4:
M3;&3]+;-X0Q+7>O$H2IJZA%@#9*QE9#24H7$@G,7,:UQDC[Y+-X3'\B4EB-2
ME@!SSV>.VY"W?`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`B!U"?4%WA^
M$#9;T,37`:/?F8FOQ?\`4)_3ZV6P)?X'*%9MGTM'7Z9Z<-EL-<[J=?OL=="N
M;PWIS;ER>]VNZ;`W/7#*9(GM"F96S4IRLQLO;E?`&ZUU,F3B;P(!M)B):Z(#
M0GAU>X#`8#`8#`K_`-B/7LZ=/][KT.LF!8!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@5H2%IZP2EU?"6*5=-`464.#F6SI9#6VT"MU$P&J3PMZ=\$CM$EN4N'+<(
M`5/)18"1F=MVH>`\\<8'_/%@>HTYUS4[&:R6GN?LS`2(+?MXU<[5_4])]1AH
MI>4-;%)7"'OTCC<>H6(J*K7PVP5"%2<24``N#$)@0"X$5R#LA^.M5:OL%HZ`
M186ZF[5&&-;>X\GU3$:QZJK/'H@J7OKJY*DS>W5A$"X(1X04K!+3>6[CN9AZ
MD8Q]DT1G.!V4]+*@NH;06BU(074F::(*Z+7)YG/8J]7=3^W[-<<B4V//I/-G
MQWLA*^2Z%R#F0<O#V<G*Y<&Y.K+;TZ8H?;<%A%R'0!4I=ME5W&"[V5URNMD*
M55Q,E=2M\F:J[.6\N*SE$*,-\Q<WF2IDH6CE/P;PJ4FCY4\&<AYX!R$/`;&P
M(@37U^M:?A`WA],_3VP)?X%5W5&72YKJ]C0OOB+**!L^PJSJ^Q(K*M+Y7N8&
M#I5*.U7UPLQVJJ(2$+M/V%9*D4/;^2"T2+F+%$*WCOM6+M$8`][I?M,$B]2S
M>(5J_P!?N<1:)H!P*;*YT+LS0EF;GE[;"C7AP<8;92U8NL60/PTA1JI]*%R8
M+DL)9XQCXXYX"S/`8#`8#`@!U5/\N/<_^@">_P`UBP)_X#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8$0.H3Z@N\/P@;+>AB:X#1[\S$U^+_J$_I];+8&W
M]@;JBNN%'6S?<X1OCE$Z@K^46"^-481IU\D>448:5+IRRQY&M6-K>>^/)B<*
M5)PI4I4O"@T')YY)7`S0!SCR*.0=RL>5()=K?MC0M9U!LC!:[VX);-C]?7UE
M0*-UK\J"](K4,684L,L233S75-;TOC\W=54?D$*F,7%*W5M9SEB+E2TEAU,8
M%96K2LRG;PZEQMEVK/GV$Q_8FG5[+*;AE!KJFC[7+=7Z'<#6&.*!(VUG9HJE
MECZ<0F2(DY1(#S!<C[<\9I@PJR<;5FM9I1V#"K6L2$;E1@_?MXW6-/16#;R6
M.D-$OF`M>V%?2<J=%46?&>77$7`XY5+4@"@<'V"NS@3%EI(3U#@2$D)//MA+
MXTNHNY[4G5H5ML+"NI_IA'+GH.OE;?$XS62Q?U,]9:TENO,L''&XUXM.NX15
M[F-60_'N1B28)G+E]X[#0M1-Z0,.F3)(+%OZ35TFF]@1W=.>;MWE7TH1D2*S
M5;3'-#9'1UDLT/E9L%YD*&#<4PV56J8'1M5A"G:CK=X[F4>%],4E<A9=0&FS
M]35K1>SUEBM*MM8JZO""(ZJB\.)CM>PA)<5VL5S%-=9HP.)OB^PL"EM&@/[8
MGE4Z%$HNZ#*3(4:-,&A+%G=SR3J5Z5QZ?4-YMH+''#<I-`K$\Z,4F/G(0)JW
M;D*!R\4F5&0\0_PDSE%+NXK1C&3W7N(N>1AYYP+<,!@,!@,!@,!@,!@,!@>6
M]OC+&FARD$C>&N/L+,C/<7=[>W!(U-#4WI0<FJ5SDY+SB$:%&G+#R(PTT80`
M#QV>>>.,#FOLK]X]UN@76+A6@O,NKE1K275,B;+.V-)?DBR/1_8MR;$<\A[.
MFE")P5,*F$L\19S69<,@)AADD?RRA#*"W&\&A'SK:_O&&E\8Z>MR1#1#:>"V
M]LG=:4%,1?S;+G@;M6T;FR)P(GUG'K#VUM\&G,L/2JT36H(/"K3OKBA4%A$`
MDWD(;3Z3W[QCH3.=`-<A[F;<US4VS<-A*>M;:8;"<7L,@?WROC!QANL,U6!L
M6A<A6+'6]$\*3N!\=JX+%!78_BNSR$H*]Z_^H=E=4QTT'C=BUBHJCC65BM&-
M;&'2Q(BBDEN9P)0SM=6*%]6+BHYX-)IA]2N05!HB3BG=&N;S>PH+`5R%\#(^
M,LE:&V01QX:Y`PO*,AQ:'MD<$CJT.K>J!P:F7-KD@./1KD:@L7`BS2AB`,//
M9XYYXP/4P&!JN\JK0WE3=HTXXR260Q)9T#E$(%,8&_.<7FT1-D30J;4LIB,A
M9U:%R9Y)'51X%B(\HT'(%!(.SV0]GCD*X.B?ISL=I1I,EK/;BW9Y<^P\AMRU
MYA/)3.[$E-F"1MY4F-A$";(K()8^OJXB)N%?0QL>BD@!)P$+7=3VQ7!O)@QA
M;G@,!@1`FOK]:T_"!O#Z9^GM@2_P*[NI,;<?FFJ]OJ-QGW>3U=*=GM:'TW9#
M+5-[6/7"JH+A,11:EYBY2^`O*>5,]JD1B1NJ2/O*"2KX@PO*=L$:J,`G.#4G
M2G<=DSHG+FG8-3;32>V55JF,,!V(GS/-KR:+7\TAS%?LY7)02V:3.*U58L[C
M8.8\E?E1"E4Z-CXL3)24:@D1H6V8#`8#`8$`.JI_EQ[G_P!`$]_FL6!/_`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`B!U"?4%WA^$#9;T,37`:/?F8FO
MQ?\`4)_3ZV6P-SWK3,-V)IRRJ,L/PQQ![6A[S")3S'W,;*^`9GU(-&L&TNQ1
M9QC<X%EC[8H[@(N2Q\<<]CG`@@3TGJ;&_P`C?WV_]R)?X\615EK6$RRJ^SW1
M@L.94PM@RVO%LQ;@QE-X43L7FV92N"@C*",E``//^_GD+1\!@,!@,!@0?VKH
M^_9W:6M-SZ\/E/H)?0SA;7?S+<Z>:&1M^:K1AB**&=Z*(/SX33.#6-'W4/;_
M`,6/@78YP,?^Z=_I_P#^(O`?=._T_P#_`!%X&G[+MGJG5S-->H?XH:/R7S^7
M`]5-X99B]BQMU?>!J"O"]/&^6"[D9W&/K?,MX!+%V2^RZO:,/;?PNU$&X/NG
M?Z?_`/B+P'W3O]/_`/Q%X#[IW^G_`/XB\!]T[_3_`/\`$7@/NG?Z?_\`B+P-
M/WK;/5.I*N5%@^*&C\Y[WF%71/Q=C!>Q1KP9YR[1AM:>%P`[D=V6^,>-WA1;
MSVO\%$C.Y[/'8[/`;@^Z=_I__P"(O`?=._T__P#$7@/NG?Z?_P#B+P,-L.O.
MHK;4%EE96;$^G#.Z]G;"XQ>9PR4-VP3O'9/'7=,-(Z,KTUJP&)5[:O2F"+-*
M,#R`8.>>.>,"EW</HN6:EUEN$6N'2_Z,TPNQ3%>6R!,$,JAWCTM4N#NY-[4X
M*XV^V>\0:!M+TSL:Q4M3GN+JD++-3\<@Y,-X+*&'&#(?W8_KB19@?).]Z/*"
M&:.,[F_.QZ38G4QV5$MC.B/<%YJ9J:+X7.SFH+2IQ\@3I2#E!PN.`%@&/D(>
M01[]V/ZXDI8&.3LFCR@]FD;.V/S2>KV)U,:51S8\(B'!`:I:G>^$+LV*#$J@
M'(TZH@E02+GD!@`#X$'@.P+I[]$V[$6HU/L6UW3"Z04;NR),/,+D95LUR;-[
M,?&^('#CL=F$\EU/R*P8'(Y=,6-N(<G%8E<A&*5:DPPXH@T0B0!>]7E>=16I
M8+$ZRK*)].&"5[!&%NB\,AD7;M@FB.QB.M"8"1K965K2`+2H&U`E+"6446'@
M``<<<<<8&9?=._T__P#$7@/NG?Z?_P#B+P-5WC$NL#.Z<LZ'5U.](ZPG\B@\
MC;(1840!=)DDA\L4-BCB//K23+FE\C)ZA"Z\%"Y+7)#DQ@.V"/CCCGL\!2MT
MKI'U[]S^E?8E@/6T%9MELW%.+:;ZEM2V8V>P7+5QM6/Y%=^"&5EB$`)K4UK%
M95?/)"CPL@5FF`4J"Q<@"$L00GATMD?7/%IE6DKV;G.O,TMNQCGB>NR39./V
M-&+8@K4[*@H(_!WUDJZ/1F*H0H6EJ*7<`"FY4!,<#`FC%SQQV`L-^Z=_I_\`
M^(O`G!$_&KQ5C/CUXO\`COXOLWCCXI^$?%7QJ\')O&'Q9\,?^;^+_A?NW>7?
M7\I[V[3NO\/ML",$U]?K6GX0-X?3/T]L"7^!4)U7]=Z9L]+JS9MJ4!&[/9J_
MV/BB6SK/65--[JD5*4@;![1<7N0HJYK]2%XD\?DL\*8XPZF*DCFUQIOD9\C4
MI1<,P320];IDL-8L4LVWXU^J&`Q77-SGT#=JGMR(:]2/7UQL8"Z.O!TAKUS+
ME;8TN=MLM)GB3%-LN2$EM*P3ZJ0EAY7M[D::&U][%-BL$QTBDT+N>SH$QJ]S
MJ>@DYKJ'J8>VPZTX[+N)!WP@GJ]3#EUAGH6X;:$12)L?FMM5]N(+@F6@X+"`
M-.;LV[59]^5-#KEVB=M?M:$U([9O3_/Z[V)D%$\BV6K!XH4$>B,BG]?2N,.B
MN50"L)/+'Q)"5JPY.]\$JE2EK7`9_P"3A'S2G>O;2WKPI+6&]GJ$Q16_:S0F
M?V):31!US;*P[0N&L]03BTM*D/+L4Y5BDNVF%UBFV,XJN]S^_(FI1MY+0(QL
MD"T@,9BMA2MOA=10/9?:RX"Z17=2?J"U5;FPTON]11,VD!-8OU_AH6M)1;E-
MF4RFK&)NR^/<&D)HWS%FTU:PM[02$*=9RW+`RZB->=K-G=8)!.D]]I6)=>E)
M69`*_N=_<YP]V#,JK62:N8Q2*^2I6$Z%FH6R5534BF2!DB!W\*`6VB\*DJ!(
MK$<I6A,WJ&5GNA?-#61KGK_6^L$H9+AJ!WA4ILZXMC;6I9UBDJ>N%*%2H8*P
MA6I^Q"22Q\E($I06-1*FU3W0T9')?(2N%)P9!YQNJ;[&^@'ZRS8K]D[@/.-U
M3?8WT`_66;%?LG<!YQNJ;[&^@'ZRS8K]D[@/.-U3?8WT`_66;%?LG<!YQNJ;
M[&^@'ZRS8K]D[@/.-U3?8WT`_66;%?LG<!YQNJ;[&^@'ZRS8K]D[@/.-U3?8
MWT`_66;%?LG<!YQNJ;[&^@'ZRS8K]D[@/.-U3?8WT`_66;%?LG<!YQNJ;[&^
M@'ZRS8K]D[@/.-U3?8WT`_66;%?LG<#4]4[,]4.T?.3WKHWI0Q^;JV)C5BGQ
MGZA>PT?\+JHCX.[L^1[N?2Y>_#<7</"''>C@+O,2GM!]E,5VO\(-L><;JF^Q
MOH!^LLV*_9.X#SC=4WV-]`/UEFQ7[)W`><;JF^QOH!^LLV*_9.X#SC=4WV-]
M`/UEFQ7[)W`><;JF^QOH!^LLV*_9.X#SC=4WV-]`/UEFQ7[)W`><;JF^QOH!
M^LLV*_9.X#SC=4WV-]`/UEFQ7[)W`><;JF^QOH!^LLV*_9.X#SC=4WV-]`/U
MEFQ7[)W`><;JF^QOH!^LLV*_9.X$GZ4>K]?8JX*]BZTI^JYL7(%29KCU*7A-
M+^BJR*@;FHU"\N$QG6O6M;NVR!0[G+B#6PMB5IB4R<@\*\T:@Q.E#4'4)]07
M>'X0-EO0Q-<!H]^9B:_%_P!0G]/K9;`E_@,!@,!@,!@,!@,"(6PVXD-UBLFJ
M8G9T,LY1!K4BMFN::S*YJVW+B2166UXOKT"*'R^,U%7$Y=F$F:LTT6*FUT4C
M)2B-93TPN.Z&D\B#;,.ORKYU4B^\F1VD"&LVIKD[TYO,QK^PZ[=FYIAW"\<B
M7K898$5C$W2IT)3:<8#D;<'ODH/`R.Z`$`0@AI274ZKJY;"C,&54A>]6I)O9
M#55D2EUA)*K&S*I7+]<(MM36"1^00>TIG(8SYV*A>G%:S=W2#[T/8U")Y\$N
M*EO1*PLOP&`P&!%G9?:>/:N*JA<9Q"K!D$!LB;/$'DDOKB`V1:3E6BI/"9%*
MX^_/T%JZ"S>3KHJ^ND>X9C5I18.$"YP2#,").)0<F#8U*7M7.P<5<)G6*B8*
M6!LD"J,*S)K5]HU*Z\.Z)N:G50!/'+:AL(D:UOX1/2?D"TA(8B,,Y,*`<(TD
MX!8;@P&`P&!H:V;[::KG]!UB"(2J:S+8.>NL/CJ&-F1M&DC+'%8LYS*<V%+'
M&4/\?3@C,28VT/`TK?X0>EJI606E0G`[X-3A^-(;`-=T/EW0\<*F%=SG7^U#
M*MGL4F(HPK/,-7Q&+V+"IA'GB'2*4,+M$YY7LV:W-)SRI*<$8SC4:]*E6)S2
M0AO_``&`P&!IV^KMBFO-9.=H3!OD3V@2R*O82R1J((D#A*YE8%N6+%*CJR"1
MI.[NC$QA?IW9DY:&=(:XKV]L3GK@FK%:5*`T\L(M:9[DU/>"HFMXE2M@4"\.
MS/<-J,44F".O.6N2`B6Q4TJN]EC0X5I-YLU%R"+75SR8]%J>4I:D4@2J4!JX
MHQ08G"P?`8#`B!-?7ZUI^$#>'TS]/;`E_@5M=2$I?*HQ1M:M%]!IXA_N%0_V
MBP1C9=3J[<$^I%CJ:TVZ0*JSL%AG5=3(L-46,_Q6;OJ=N=V_PC'XTM;S3^`+
M.2S0BYT38[(U$-N>U5LJ76+'YNVT'##[,>MW"]\E,SMZHZ_=(_>KC7UO$7G?
MQK/K\NFKJ%TB+*[NK;)DBAU=1N#0UEFHT987@*$B57W#OI,G4][*"U:;O@DL
M[O=43VW<5)'=`B[DH*[;GM1A[`@]GGL<X'RC9F<P`BC&IM,+$Y$O(BQH4H@"
M>$Z@I6G=1`$5R'ER(5)RS0'_`/Y0F`"+@7'/''/`?R%C90B+&%G:PC)=#WPD
M86])P(IZ4E*"%+P6+@GL@=%!"LT`U''8-&`T?'(N>!<]D/Z,9F<Y&J;CFIM-
M;UQQZA<A,0I1HUBA4?RJ4GJDHBN2%!RA3SR8,0P\B&9SVW////Y<#TL!@,!@
M,!@,!@,!@,!@,#7]L3HRKJLLNS"HR^30VNJ_F4Z+AT9)"HDDL,B,<<I`",QX
M@7'(3WQ^$W\)4@.>.P)0:#C_`'X%0>H_5#LF[KNB-9S%%K5+F:QMA7NF(ZMU
MXG4DE*YDC:KIST;U`HI:_?KQWREGE6M0I^ZP!YD!:9A+%(UD>$2D+[^4)R@N
M\P&`P&`P&`P&`P&`P&!$#J$^H+O#\(&RWH8FN`T>_,Q-?B_ZA/Z?6RV!+_`8
M#`8#`8#`8#`8%8W4K?JTAL:K.9VS6NXLPA[0JER$^5ZN=0%@T)C4,6NWBIWH
MCM=]DO4*T*:Y^JE'>(O`!?)LG&V=X./8X;N_.>_P];2%NLBL]*)<ZV9&;8EJ
M,#Y?]B5E!+DO@O:6\7JDWN0R66UE![#N`=H7A%9E*%D:4@;TA;9*'YJ3M@D:
M?OM2:!0:8%8W3`IBJ'JUJ-V!B4HTA6L%@LK39T4IVOMT]G]@I/5+P1KTXUS'
MR*LKFTK#75XEFU>5P`,44K^8^E5L,83N+>V%MB09J3D.ES`8#`8%-_5D76I9
ME:IZJUIG;U*YP6*[X--*)HK9"+4=L`]V/(-4;!F%*";W,=H59(G5+`GI4URQ
MYB)3PD5/$;,"XB2.2-+RB5A)/I_1S8-FB5PO-WL5G0>/3BUD4QIRM+JL)ILR
MTX)%W6K*X#81#^^,DVLIMC[#)KU(E3PP1LI_<2XZR+TR0LML)"4RM@3]P&`P
M&!1OU5+/3AFU5:]3$*IRYL&5-4XJ5Z:NE'U`-S05,LCU;W$1)GY'<6G^P]/O
MK5:SR!M4)F_B&*2I9&V56>)S;36AT\,HPD7TK4O#+3-GQ@J'N3.F:+F7JRYP
MOT@V>T2,MI0]P"OUSC,G"`[F7?>>RMH29&X\&M3C-9(N;Q.0D!:),F-3MP%R
ML+/<!@,!@0*ZF\B;8SI1;*IUA<%GJ=Z?J5@R9GL^1RR%5PTO%D7S6->L$_G=
M@P-2CFM8Q&JWV3II.X2MJ-`X15*T#=B.>Z(PX%*E#V([=.'99#`^(CJS;2"8
MMM0$RN80;:_9BZ+8BD?V@V^;ZZ!"X49>SM9#?&G*06W:QTS2QI()IYL,EI>U
M8U/"UF`,P.J#`8#`B!-?7ZUI^$#>'TS]/;`E_@43=2'2+9#8:U]@G*N-?==K
MV@MZ:M:B4ZSN=U6F&'N563'7W8_9.XIT>UQE92MH)W-IL5CM&-IQGIUC>9RH
M90=W+-"01R$)N:>UE?[#<&VMRWG65<TZ*^)%3CE'(#7-J*K81E'5W69,!>Y(
M^/IM;5@0!Z>B&U`1QP%":9RC0D%C.$$HL(0G[@,!@,!@,!@,!@,!@,!@,!@,
M!@:WN13/T50VHLJAN,=[225O.%-:M)*]E:S72?D1AT-AS<4YR1O=XZW&+9$!
M,4$]>D5(B>1=N>485P('(<N3.T;$5P9$[&U+OW>^47RYPNRI#N<8Y](?6BFT
MO,IC]+2J305K<3FKIK538EA+)9LPACD:.BC/*'MX6,;TK>RWI`C:#5Z@.JV$
M.$F=H7$'2:LJ>-S%RB[`X2V.I%0%Z5@DRQI2*'YE3+BS#2UB=J=##2`&A$+@
MP)?`N.>>SV<#*,!@,!@,!@,!@,!@,"('4)]07>'X0-EO0Q-<!H]^9B:_%_U"
M?T^MEL"7^`P&`P&`P&`P&`P*=>I'(H]6U]ZQ6VV$Q>U+AC-=WY'8=K9+=;-H
M-F2'Z(2=[I=1,[GC;?J93&P=B5#(*_<&)I93)(LB:]K6H9,:V".3'*"Q##[]
M<HS8U;Z0(7.B(K:DPDLMV`L&T7NI(10)&GJ=G:Y_9<CD4SJ^#4COZTUX\0"I
MT)BX0>5*PE"XOAQRAV;^"`+^""@AIT_%;HY[=P="2I3.!D5<+4:98C0'=%%6
MKC;K&JZ[C(&Q^3Z@B,V)9W!@4V)'@+26?@LQ()];^'/@+<M'W0.D;`8#`8'.
M;U3-+U+]LK6VS\OJ+2R]:_42LII5M-I])>_M[+J96Q+24MBJ6(OI^JD/G\PG
MU:%S`T+ZAYE1#,B9'-5VI"XT9"-$H">?2B5U$.B+0:*?K^@*P0Q>_P"3QZ:0
MO7?1"[.G?'&F=D5Y5S@X%S&A[\9(_.G&P!,+BW=\O_"8*-6W\(D8.>34!W'`
M6?X#`8#`J\ZI2T$7K2J[)L!Y+4ZQU[8;DY;*5<#9"&ZH+[2C#M")(RPM`GMN
MQ+2I&`NJ./SE6D5*8B_3".,LC`+@2I6/A$!$K#W.F'W^ZTY8$Z87GL4'8EJ'
M2?62NE&P4;VD<ZGJDN`P-D<HLX73#;#MN'N);O9;2_/*1C:)3)&J.(G(I&C<
M.4X2T:(+)\!@,!@1,WDEMJ0K6&PGNG(WXSS`]TK.,N*<-9O5TG,%9S:UX/"[
MLL%'3D=X$^VRX5=3+^_R5-&4@#CWX]I`A`4=R?W(853=+9!:+7L=.JNGB)M%
M%*]AMGNCI!X3I)#M5ZNK*XHWL"]5_"YTX.+3!V]-.YC>M'DIY'$5;6X%<H8Z
MJ=>_`*>_48TP=!F`P&!$":^OUK3\(&\/IGZ>V!+_``&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&!K6YF>6R&G[78(!,4M=3M\K6=,\*L%=QR)%!9:YQ=T11N8K`\?
ME$EC#R>2M,X_W@(YP.7S1%JIN0]0'7<NO]C-;[FED3L.6VT(ALZM!^ZKY$X8
MHT+?*&LFL(+4$PM^4S:1W&#8HERFY,Y!'49:*O92^-IQZ,TTQOY#K-P&`P&`
MP&`P&`P&`P&!$#J$^H+O#\(&RWH8FN`T>_,Q-?B_ZA/Z?6RV!+_`8#`8#`8#
M`8#`8%:6PNG8G>[2=MWWJ0[4ZUK(C&9-!(P1%B]!F&L8)"[#4P51)XAW]<FF
M4_?).TO\DK]L<2>)4]/JA`XA&)O,2@-$5R$J6J`!C>O4GA=I[#69;S.NA<WX
MD]\6$.G8I/.8E(&QT/5N_"^BJIIZLFHN,,*P7>"Q%'DXP$IRS3QJ#>!FC#G0
MT=C$1;-NM?X/(;YB+[#FJ5:_7;3,@@^G=STDNDDJ1]/><ZY5!4\W?IW(%\8H
MAZLV@*[=I\JC7<3UC\24C``;:2L2(E@=6>`P&`P*:NH'N+/8U)WJIZ9*VYBB
MJK9EKG$;!MG6E9I4C'S:FWLN#4^N-/.S7N)5]TIE\9E$^D;)P^OC*PE&Q_EW
M;C>#EA`74A&&Z.FNW'M[5M2FGSE;KWLTS;*I8SM6]7%+ZDF[HNLQ'KGK](X%
MXH/]#U#0-4+(%_9XEL+-0B;H8P*PG''@<B.7`"D8@LMP&`P&!2=U!WF\D>P%
M.V9"I4TM3)K+-D3[%651TR.H=N.O<I':573B,OAACMK,8IBSNA3,7*@9#RSH
M^%,47]Q1KE9?+GWFM#?73)87I1'MI;CECDH6S38'9]=8DG2%:;;.Z+L+6K:J
M0I*O4A3+3.V#6UV7(5#DBAH%[I+P<JT3XZJU!(3^#$)B9,%F^`P&`P*V.J0\
M;`EZV.D6H:LYQ+/#;I$I+9<XB5_5IK>@AE5UG:59SFTH;)K3FME5S*(,UWA4
MC7(XP.11T:E;'$ZD];SR48!/W0-0]+J=Z]6@Y6;+=>*XE+*P(FUL8WN<*.HC
M"-YHDM<N'$\XN-$)H/MGLBBA+\GX3F'#-.3MIAY0!%\&#[7D'`7"X#`8$0)K
MZ_6M/P@;P^F?I[8$O\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@1.WAB,JG.KERQ
M9AMFIJ4CCQ7LZ06W/KGJJ;6[#VNEUL(DB*RN0L,`OG720LKL2PJ1*"7<$@&!
M"609SRD.$,`R@KJT6V,VF9YMKA26P=E,Y%93*'J812+K+^F=8NKLEV)60*J'
M.6-P8W8B3?\`O2&UU,.8+$ELF.CL@KR,KW)H:7'A`@2\)3N4H7C8#`8#`8#`
M8#`8#`8#`B!U"?4%WA^$#9;T,37`:/?F8FOQ?]0G]/K9;`E_@,!@,!@,!@,!
M@,"GCJ9$,4-MS6.[I+$J;MAMB,7N^'IJQVHB=UI]9&EREJZI5G%MOE_UIKGL
MQ`M=[,C#<PJ&IL72^/\`<WME>79.W*DG!#AR<&X--8;7-6Z,3%85):<NRIY(
MHV!M@V):PJD,WUW885-7J4RISHZ@DZ(XY&\0-A;U)S>20`"0E<XGJC"D3>0>
M6@3!2OI%)RO[0&I"-!KU`8%6*O:F-R`B7/O4*N/;"9O4KMOIE<O^NDD7Q62Z
MT5FGEJ6`Z[P_FNHTL-FKZT1I[;7X9R)R7<HI)@=9^`P&`P*[[]Z:E-;"V++;
M*D%H;(09SG4@HN7REBJNW#X9$W69:V2AAFU*RXYD"R.''$@@LNBS<XI3N#.`
M\J498A!%QQSQR$@-;M8H;K*WVD1&)?:$_>[FM`%O6--;?F0YS,I#,B*OK*G$
M)Q[R-`VA+;VVO:@84)!`2N`@"DY%V>1#YP)(8#`8#`I)ZJ]20F473I3)Q!GA
M-NR*?S.OZ]D#SU%-MM'-?(KRUU+:3VN"[GZZOBHTVW)@TOK@A:C65N:)`^(R
MC4B]X.:4'#4H"7_3\I'S-UY9![HUP<F93^T#)'*Y%#=MMDMU%4L$V06$Q=D7
MRZZ-J3U5H<R!K9V4M`4T<&FMJ!L3)!$"X$<:``3WP&`P&!!#J71QED^F=F)'
MNP8W6`6:641-V"5R^!2FV(V9.ZXV$JNP:WB3M4L(6M\PMM/8M@1ELCW$3;#.
M_I.-T"V$@-&JX+&%>FK#CM=<F\W%R2V<T!7-I1JCXE7LYIB::,;*:\V)+M<E
MMK)Y&]SB'O$VV"?6N=+"71K\&-2KN[RE@RE8(M>W$&O'(%87]8#`8$0)KZ_6
MM/P@;P^F?I[8$O\``8#`8#`8#`8#`8#`8#`8#`8#`8#`8&H=@G&%L]"W<[V0
MV.SW7;74-E.,]9F!K(?'UWA:&&/2F4MC*RJ0&)GAV7L91Y29*8$0%!PPEBXY
MX%S@<\]/ZS3`VP-"VZ^I[LI&X9;1<E(TODM:=2V:[&3:KGD&MD[G_*NP6N8Z
MXP-JY\*4%'7IH',F5ZD13<M=N&0!YR9Y"O6ATW)$_>B5,E[NH4][)R4_?*LS
MNRI1W$L)?=U)W:A[JH-[7MAB['';"YYY[&!]&`P&`P&`P&`P&`P&!$#J$^H+
MO#\(&RWH8FN`T>_,Q-?B_P"H3^GULM@2_P`!@,!@,!@,!@,!@4\]1*IYMNB*
M#PG6YRMN4O5/V!84.M)+!=J(YKUK\R2WF-U;)D\$VPC#U5UW/UN-;@PR)&L:
MT33#7D3<48K$-0C&J)[L&ZZO'(]`]&&Y);\;H=HG,/1R5,WQG3W7NU6:F3Y<
M_KGEPA[>FKBMX[/YP'PDL,)#(7XAJ2$*U@SUW>B()H2`!59IW.&60;):%6-%
M#K#LZ]+,3S2&WC%;BZ7$?UT8=5:\=*7M>V9^VT5?C1J13<TK!C27@WIFP+,_
MSN?`EOALSDL8S3#',(=-V`P&`P&`P&`P&`P*%>KA?EPQ@Y]@3OIA2$CH6'0,
MRRH[M;LQ0-A[J5<78X6.2DG0ULH&F8BN4UD\-P"2DHYA.93$V$(G(LHKA8`1
MW``EWTF(55D9TZATLJJV*_N!'=2AHN>9/U51'76"5RP3^65S`&]_A$/BNLT#
M@<(:6>+D,*8D('(+K(N3.1<KW%2+DO@L++\!@,!@0*ZB:\)6O<B;Y)7S3*ZY
M4'0ES72I3;DIJ-YKNVV2\:8.U_E3-(XC4]JN42#%K&4ER8R8G)RVV&'QI.N<
M`^#A*UK>&M=(J*V2B5IS6T]L&>42RQ#Z_1U_#;9G^RE:W,_M,+%(RW]TKN-P
M>F]/=1*ZA3.YN2-&M<G7AM7O3X<W(@+E)P4:?DL+/\!@,"($U]?K6GX0-X?3
M/T]L"7^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P--WRJL]JK60R2I7IC;)3$6M_
ME7+8_11?*T\Q2LD4D"I+#DP6QT0+V%8\/W"(7#@4G<S"BB1E@1'"-XY`%(?3
M';:B17G%9M"#:AA\XM&$N[A-81%^C-=.F<[(-<V,R5/,4>+ZD+RY0:.A9Y,#
ME6X(B1&HGQQ3BY)$:<<`_D.B#`8#`8#`8#`8#`8#`8$0.H3Z@N\/P@;+>AB:
MX#1[\S$U^+_J$_I];+8$O\!@,!@,!@,!@,!@5<1?IP`76SM99U@79L1%>;RV
M(56C$&'7[:V_JGC2"'BIZGH"F#*(A#7R'QPB<&OL#<!J3DY:S@U"))VRD0N.
M2B0G_4]9-E00AM@C/*+(F*!L4.*DI^MBQI?:LW5"<EQZ\TMRFLY=7J1N*=,8
M?R6G+.4#`G("$LO@(`\<<!LC`8#`8#`8#`8#`8#`8&*Q>"PB$&24V%PZ*Q`V
M:297-9B9%X\T,!DLF*]N:VA=+9*-J1I!/LF6M+&B2FKU7)JHQ.C(+$/D!180
MAE6`P&`P(1=1ER3M>G5K'.-3UK=$?6.54L<QB%QU6=>55LL`DERU['K"MN?T
MXF-3+;.BM!0AS<)VL9$YZ54XE1SDDA0G-$`XL*I.B=+J0>[`EY-`U-HT>TKZ
MYM-/:%SZ9:T532O,6E=8[53VLZYKZPYE3_*F)RH-SU8VI9>SLHA$+F9.UG+#
M.5:5V0FE!T<8#`8$0)KZ_6M/P@;P^F?I[8$O\!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@:SND,O'3EL@KZ7,<`GPJSG@81/).%(.-0F7BBSKQ&I=(0+RCT(F.-O
M7)"Q7P<`97*<D?;AY#V>,"AG1>+;>Q?9.$JYG'-DZDKV6;)O4K42'8O<B)WK
M!+JIR3],BI&1XJ*KDH-A[==;1L1QW,J1YLU@<DC0C*CL":GSE.H:B'=8R##H
MRP&`P&`P&`P&`P&`P&!$#J$^H+O#\(&RWH8FN`T>_,Q-?B_ZA/Z?6RV!+_`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`K&ZM;;(0ZD.4OC5T753
M;I%+.HA*WJJ@L&&U4A?GJ=7[54"CI=KV/+:RM$4"J)B?9"G7R5\3(#@LS"4N
M6*4CBF),0'ACNMS1(JQWOF5063<=_P!UR@>KC=85=R*>WO`K!B#="W&<11JL
M%#*:PKR@:#20&<#G`$1<<<U_C-X>8$JTU(H:S`.3?R%K>`P&!$":^OUK3\(&
M\/IGZ>V!+_`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$;-P:CC=X:S777DEIV+W\
M6YUW*E\?I^9*CFZ/3V:LK(N=85'ESLE5MZMC\(R=*E*`O)4$'(A#X.+,`,'`
MN`I&T;K76^#WUH8DULH.#/5C1J"R^,;5N#SHM:=%SW74X5%3E6FM3B?6.TE#
MJZ='S(MLK8Z(+E[@_/K3*UZTLXXEO<CAATF8#`8#`8#`8#`8#`8#`B!U"?4%
MWA^$#9;T,37`:/?F8FOQ?]0G]/K9;`E_@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@1$WND5DQC5BR5]4Q)/-)*X.%:Q1Z;%-6NMX@:*NG-K0>%
M7=/"J58@&O%O+*PIA_?Y(GC"8H\Y^/:0(0DG<G]R&%3G2+B\ZK#9"W:Q,CL;
MA\7;:_LGFP833VBT$TUK"-V?$]BW:&P253-RB4"8T]KR.[J<1I)3#CDCAVC>
MQ*'0:LI3RL1&)0Z'L!@,"($U]?K6GX0-X?3/T]L"7^`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P-([)R,Z*T!<KNAM*$TF^AK69((G;%C/;3'83`)J[,"]KADHD;
MN^'$-:5M:90K2'#X-%V!\![7C@7//''(<]NF5;2PWJ#50PEVE85JR2FIDJNR
MPV&P.JP][=,]+U+-]$UE*+XNZ:_RW:>Q9F1>KCM6ZN$CCTK(@[;&0UK.5R+E
M<2M*1MB<.H#`8#`8#`8#`8#`8#`8$0.H3Z@N\/P@;+>AB:X#1[\S$U^+_J$_
MI];+8$O\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"F+JHRZRF&
M?4TV-*C=ULK<S6G=>8-+MI56VUT]=2MPX@YZM(]2V^S3=4(+.'7B*J&B4S]6
M0RS$GF"/IZ`075.L"E+)P,3Z8;W(P7"4P1Q%OCQ`7/36IY#>KCN76V\,51+-
MP&^4*44S=H:][FPZ-D\2*1LKPH&\I(48&/G@1I3.$Y?!!7.!>3@,!@>.?'F!
M2_MDK4L;.HE+*SOD>9I*>V(C7]I8).MCSE)6-L>3"!.*!GD+C$6E0N3%&`)5
MG-B09H1B3$\@#V,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@02WQIZVK9C^NKE45
M?U[;+G36SL0N635C9TW,@$4FL7C]<6M&2T)K_P"(UC)0N3-+I@TNR0![2>7P
MH;@FA$6:64/@(":9:;[:U7*M,(Q--<-<J2K+6.Y=R[1=9+4]X&RI>Y1S9@B]
M%[)6[%`D="URD0M+,\V.P!6#Y<^]CO%T@X*?@12<!(7T8#`8#`8#`8#`8#`8
M#`B!U"?4%WA^$#9;T,37`:/?F8FOQ?\`4)_3ZV6P)?X#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8$0.H3Z@N\/P@;+>AB:X%>]:_P!L#M;9_LX_
MVB/-)_:GW+\#]V_L.=[^,O\`:VNOSE^!O'3_`-7>*_G.\,>"/"?\N\%][]V_
MC.VP-C_<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]
MX#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]
MX#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]
MX#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]
MX#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]
MX#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]
MX#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]
MX#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]
MX#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]
MX#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]
MX#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`?<R]
MX#\/;`?<R]X#\/;`?<R]X#\/;`?<R]X#\/;`T1M+_;F_LQ[&>>G^TQYG?,1;
FWG9\7OI]^'_-IYOI#X]^`^]_X_PQXK=]=[=I_#[MVO8_+V,#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>v365643_chrt-scatter2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v365643_chrt-scatter2.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!`0(I`P$1``(1`0,1`?_$`+$``0`"`P`#`0$!````
M```````'"`4&"0,$"@$""P$!``("`P$```````````````$"!@@$!0<#$``!
M!`("`0$'``0,`P0'"0$%`P0&!P((``$)%!$2$Q46%Q@A(B0*(R66YC=H>)BX
MV!E9QDAY,3(F6$$T5B>7M]=1-;4V=K9WB#DZ$0$``@(!`P,$`00"`@,`````
M`0(#!`41$@8A$P<Q(A0(05$R%0EA(W$6@6(7_]H`#`,!``(1`Q$`/P#[^.`X
M#@.`X#@.`X#@8LX:$QH*8D9Y^W%`P`L@:,DW>?PVHX2*:+/B+]SG[._<;LV:
M&:F??L[]F./?`XCT9Y79FAK+4LGLJ@+IO:^9)I$!\B-F"J?%4U#XM6^N=J2B
MPBU=(R@Y9UL5R#&S)O`XDX;-1B7:[LRZ$.<T^^\4WBK8.CTZW"K2`4;1FPI6
M/V$[K^_)UJY`XUTR`#&IZ+O-N)]`JVK,W8`L^>"8QP")DUDC,#F6"KEXPPSS
M^$W<*8])Y!5RZ_)76T6FQ*+Q)G<SU"II]L#]:DX37%>2\-<(C4K7<Y<5_P`!
MKHC)[0BS]LM$9,2"Q-X9Q99))3COL%UVGCZ\@-#;)_Y1*(AYZKX9&X-<UNV#
M<E8UA8=>02K8_"RILN9NY$F6IZJ7CV03^-1T-8T\A,/ETIQ]2]3`AXI!SA8N
M3'M$6>;X)6JO=J!32G=C;:LN&SC7E34&23^+;+PJT.XF1-U@]KJKXI=Y8ID9
MKB33B(2B-E*<G861L'@P@Y^*Q(X)JX(NTUVZ04@`>3FUS>UD7B\BU8V/K"I'
M/CDV.W(;5.;@,!GM[6T]A=NZNQJI$JV$5%8MA=X30S'+--CWD-?N&!5F7=,^
MGF"*/:+C,-7V$\Q4NA527&YJO4ZS,]C*(O/0R"V34$MDNM<V8A:PW2OP=6D9
MG2<LKW:IC`WY"4L@9^+BF2,BR)A9RN+=%QV,6[<F.@MS+O(_%J^OB%4_8.O=
M^P.)V!=,6URBMU2U.HA$3-W)-!V+F-C04!4MC.[Y+7K\W@N!ZF`R,/(]V;:K
M=8.%!R*Q),+#;*[$E=?Q,25CM%VQ>\BFA@B+8A:Y4KZ.`8TT$BEBKZ1V19MN
M3BN:SK^/J9XHL&7;XKZTF5>MVK-LOEDKDB%$J*\HY79K;_4VL*=HZ;.M:-D]
M-MB=A7]I2-&KV4BA,\I.Y*MJEX"+8L+\?.5(S#I#("4</="(_(,B,A-@'@1Z
M\`(FR3(/6\B&QNY>N(J\[LA\[I:IZPJ&(PAMK35<QA"=GS[?S88XP.&GE$AL
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M>RGF>O'-RO=NHM+6C,*#CGB:V+WW`M3D>UT3#2V<Q9<?'(^\N+"4[$0^R1M2
MT,:Z=YRIA#E$I&9<(9]!,C37M#)4+]SCRS0RKP^#J8:]W<2?UU0M<WWM8G&2
M>O\`FKK7'+!`$)(B),@W5]*E;2F0J.!'IQX#K_*8O6P--%3')=T]'-7H62JK
M=^-W;LY;^N%94W<<@%4(\B`VTMA5DJS&T4.*6/1]97[78V+D'-D_<2;O)3#+
M29IY=#XYGB-<ME<GW;=LL/</0NWP'`<!P'`<!P'`<!P'`<!P'`<!P'`XGZ^^
M4.93($T:94M:6Q]E73)MZ;DHN)4RQJ.*AHMJ5KGM*M055DK0G%GV;7<6`FK*
M!*-C`IQDX>8DL<7B?Q,%444U@NF1WWI\=H2`\BOTQ:3JC9#25?[`-8^E&PC2
MSVE>6&/CQ@>[(1\M*1L>0=!0TC3>O^\2ZC3IH@JJW7<X?"[5".]@]]H7#[%5
MH>%)VMG/AMXT%4I"806O8+.XZ_GDRCDQV)E]#ADY;8T0S6L+O6>HR9$RX3:N
ML(P-DPI_A@]<Y=L\`P9+RSZRL:VU[LIE'[ADS?9+6ZN=FH1#XG$H]()X)C=U
MOX/&:(KR4@&,SS11MV\;&G:47C`8<X)IO2XLNHJY0&"7Y!`)ZH?<`9;)"]8M
M8]26/K+8>NC>+';.@]PDJQ*YCX'.X\8D\-L(;,:CL&RX`4C90?&BJ#CI,IZI
M@^$NTEDND\4%EPH2*\IDZGVP.G*837>^JRUWOZAML-A!;F;P6%RB:7O6E55U
M7,VK0[6,8K6=SJ=1B5%6LFS=8Q4V/%R!\W*L,,6V3CU3=H&K[)^9>3UQ1>SI
M.!ZG6M%MF:+J:MKN#U+;137V4,EZLLFQ'5>MYE-,JNV>S91Q]$S8ERQ.QER;
M929D]7;9M6K]K\=9(+:7CY*X_KQ(AJ%IZR[&Q2O69*EH_8]L&_L:,C%?RF\W
MT2$`8Z*#KW5E,+O6@9R;#V<O>UX/E8L0NMW@U=$<T'>#8+5[&7N]H*)1\\'I
MVTKP/RN7-X<%B%7-XBUR'.%0$ADCN5S^:V)+(-758UR&&QI;!V<-EFC;L@X9
M#FW3DF08,G(<YH1Y63EU;':,UW36OD\=U1L@\W(A]R2&3+4ZL>JFSM4)0UK^
M611B6!;$*!C#."2]@]6-D@K&5"C8H@-5`.WBO3Y-N&R>8#?2T--]9;<5U?"Q
MN6;/@Z,LR]FO4K;+$(745/56-S>RZW)\Q;*)9N_F)/X$<BHSO/K,Q)"":F6&
M8T:75;A6+R5^3FV-4[MOV%Q^W:RJ-U1FM577C2%62ZFSUK9[@3:=R:Q8X^A,
MSL0#+0@W7N$IR:*B(Z@0?]C56JY5R:6=+C6*J&(2W$_*/8$"LS=1E?-"VD:I
M;7W=VMZ!>73`6=7]0:DHC;E,:CJQ`/+4"UA`K!M$T,N6[B"IMS'`9-04!>-'
M"F&6/PTL@Z,;`;<5=K/**ZCUIM)4/&V3%;UE(R;L6(9>&!/Q^K1S<$MC\C?/
M#S`LUD1NN0QDH(2;,G3==O'R';A9KVFC\<*(R[RVTY,*6K2=5NTO2!OK%C^L
M]DD'!.I8!))%58:X=[:LTX1JBU8<:MD"S`6'*I^:D81WTS>D4P;2.G""2CIX
M/8CR05BKSRT[:3N9:\(O=2I\Q>6#O;Y)-72%)QUK2&4WF<7U:ZM!E6G74JSV
M/FM>PZ10)[$$FL^,.Y"P#/2PHEF!3?#UQ7;T.KL`W@K><ZE6EMPK$+$C,?HY
MGL6A;M9&6,86LV&S/5203N)717WPQ<J?0<W(`TGKHDT9.6AM040Z^"K@[Q24
M]_$.=>S7E^.QC5>U9_#Z$O#7:TB.JF&VVL:]]1>LCS2X*K%S6IHU,W8J,5K9
MMB/QLXAR5O`LR$7,)L3"+<ZR6Q2SS]2DU"X0[R+H8O+MATNU*VEB-V4[#:3L
MMA0"8FH9O9EEUML/84LJZL)9%7=>V[**Y!M6\R@AE*492`^'9P]@,=$RCE$4
M@J^P#2PGE<KF01XD*$T7<I38MALR,U';:O`C%(26<&[A+4MAL:BL%L6.VX4H
MQW7HRB,7$G*&LI,G\H9,7+=XW1(IXLE`QH_RX5M(!7RB-Z\;!]WIG?\`<.NF
M&O$R=T%7TW0E6O\`&(5*KBF9*92.\4J@8U9$6=A!FR1CJ1**%GQ1FD/;.<';
M=50+VZS[%0+:NFHU=E<M9$*!'B4QC92,S%B/&S*$3FMYK(:WL>`R]@(*G@R$
MF@T^B9(4\R8/R`Y=9IVLS=.FJB+A0)ZX#@.`X#@.`X#@.`X#@.`X$);+5$1V
M`UVO6B!,V=5J0NBH;%JEO8+`.E("$*^X43+1-:3C0JY`2@1)!4"V3ANGFX2P
M[6PQ][+V>WKL*>RCQLQ<K7.Z]=Q>T#D+;[?ZX5=J:Q,L8XQ>D:@H^JZ?DE3!
M8\`QS*M$CA3+JPI043>?L'I71GKI-+VM^E%0L)MKJ\TV9U?E^N$?F*E/JDTZ
MZ>P*>"8R.EBM:2JHY]#K*K:3#(J6>,11E2*2N"CG"+9PKBAGVACUG[V/MQ["
M,X/X^:F@DOIDDQ(D"T%I#4^X=6XU!CS-$DY,=;`3*L9A=-M2N5YN<'9VQ[,=
MU8SR,/56WJ7KM\_<J+]YO%\<PJI5GB1/4%3^K8ZG-FT\]HM9K`=SU38NXZ8^
MY$:N+MWK^0U:;QFRZ;BEK50\^GXG1"84''?E,K&O0^`!#+IPOBZ(I.PN+7^C
M<#"ZV[!Z^V?)SUNN]O5KD+[3V,0:#XR9M*2WK$L:^FCP:$&8NQ$-`A:Y9#HU
M'1R/JOE8$,Q167>N$UG;@*,37Q(W3="QIQ?F\*,R6:Z1371ZOOH77!I7*(^'
MRNTJ!M%:>6DB^N>=_=*52AQ03(1,![7*.1V1!7RS9J/$=9+Y.0UGOPP3'$=L
MA\HV%H2O">Q4;TA<JQZFM'Q]4TW65IZ#[/$MD*?D$#K".[#9/U:SE*Y9P/E4
M?+G2<@(NELG;.3#FV"`Q$,M(O#;)2MP/;:%[`4R--(;HQS>$%+">FPJ17B3G
MH^QF4\)U3:-[N[R:RN;4$'9^I$Q`&)0C!.-#T1C=<H69#LF;L+E[N:,N]MIG
MKY/Q<RJD47H-U9F+2&;`:^--GZ6DC:TAD5%D9,O5KVR:M0'6]!T(IUU%)+D_
M=X!TBA-%5@\1?*I]!!^HGB]E>I$_U<E878T+-@FN%:[BT6]#%Z)0`&+`IO:6
MZ85L$$:]%XS:C"-0NSJYLJOAO3PRS`K`3@7)PS;1\,JHB[;AO5FZ+7K)-OY;
MMW7NRE4`)*_B<7@U9C+;U5>7B5HR*"0F#64AJIDJVPL"81).R)*X=E#KD>)9
MORGQ&S5XX=-Q[+%(,/>OA^U)NZ<UM9JT19PZ>1K9<#LS99R/+S))"WI,S&2=
M"3C20=*=LQD94EYF0IOEG[1-1RCDSQ2ZZSPSR[X&V,_'&%:5_'H%U:Q3-&/^
M2N9>1S`EW$VF*CHU+]FYWLFI5.37Y]WBD+8OIQF)Q+=9Y*J)-^G';7'+/M+$
M,MNCH>[VLM&B;8%S>JA96E8[:D30ANP&NHO:.JW#:UGE=O7-C1.OC=B5V+AE
M_0;[>8MH[*ELR[=D/+DFCD8\0=Y8=!5.OO#"QB=$2&B9!L:^D@PEX[MG_'$(
MD8NIAL5)L*SV$GI*5B)\6'IS@R'*3Z#!WB;)U@S1%"3#I/)TBT%I9XLD@_NQ
M?#PXL.8O+#(V;K0]GMHU'3-8[#3*=:%5_<$@=&*=C*T*;V9JRXM>U)<UUVED
MCB.:#-PTDB-H`DLAS-?!CVO@X4<AT4U]U9!:^6=M-80"1K$VFR]BU7/,8OV$
M9B6<`;U7K12^MHV/#G+)UFD6:OA5-(DNU/3L\4%'N3?!+O!+%3,+5<!P'`<!
MP'`<!P'`<!P'`<!P'`<##R%B4)@#@T&8^GC1`.38AS_H4RGR,H[9+H#S'RU5
M9LD1^6.U,%O@9*)XK>Y[G>6/7?MZ#F-2WB_!416<I@L)N4]@>=^.JE_'S`)P
M[B;/-_7P^IQ-SJ%[FZ&)G\$)#,K,GMO]'B[7-5JCTJ%:()*]8^^IV%GK!U$@
MDZT9E^B/3U037,GU8,:J-"_0Y%ZZ!Q0A5*]4CC;89TY9I*D`@[--T@GBNC[%
MT<?=4P[ZZSZ")ZL\?D=K@EJ.<(V4<G,CUIE%[7!,I,?CPM$_?>RVPL,-PR>7
MQ+7K%TFE'S'RZ>2E!F,:I+M&`LTB-:Y(,AS9+@5HKKP\B:=UUC=9UK?I!O=U
M?7_5E\5O>4SK1G*``-G0/9".4-1YZI1$UB"L@HNNZL)N@O0AM)!;M<F1('D'
MC,L]S6Q"[=%:D-X$QO\`/77-6]\6[M80:+W[-$XGG74.+QP-"$*YBM95]7:$
MHESN!UA$XE@XP:,G!PR46?$W[UV1<N7>6>(<^B?A^M2:1NMJVLG>4\0JZ@=2
MM@M-]?T:ZI%I6=L1JO+RJV.U*TG-D6IC:TI:S^WH-&8@,P2)"044$O\`X"G:
M@M-9=1?L-+>^$0X7$W@PSOK7ZMD[RU*QU;)QC7#18!0]7Q#.*V(-LRL+%B<%
M$7U('RA)E(L7_P!5,BQ<IW($7#=,:YCJ;7O!P&R;%>&N7["RV]9H5V&I(9++
M\-4O8QZPC.EHZ?6]"+-I6*U2,$1&J[3E5^N)#!=2CDQJ9N>=5XWZR.-W!<JF
MTEK?-\JOP+Q[N:5/]P0U#Y9S&KF<@HRQ75AXQ:[Z&_(G7"QW9:OI1`"*%A4&
MZM"MU33X#A*,RL8>_4F*H`LW36[Q>=>_AD%9]<_%7,-=)EK[+@^R<9DF5";%
M;G6XV8.]=649;RJN]WW8J6V972S&&VP#C,5ET9LILZ>@#PD8V!L@:R(O.-JY
MM^R"P35OEXM=9=\H+=C":QMO$[CN"EUZ72O49E(G<AC(5HC)^XDY6C;&5QT#
M+&\.)3`DZ:,WWM2^(\6Z[RZZ5R]H1O:'C"/O76Q$9UYOR/TE2NWM+PNB=A*\
ME]*/;ODZ$,A==2"H&[VB;$*W%#$ZYD!.M#WH5^Y.&GPO%VWZ>IL<%EG7QPV8
MEXOX@M1.W-"A[1-!X[M-LK4>PR)!2.)E7M=)5%#M3(:(@[?U<AQ6E:)!CJFU
MS5).%FR^.9A3VI9]M^LE@F[?;26*[YTW'Z@E4Q,0)N`LR.3I.0@QK8J]=@OE
M$EKVU((NT=.V2/R>WZ.L*4PXBK[_`'D@//K*=8*=X])Y!6=[XEH2L/VV8M+?
MDC?+:3:_7C95LHYBXYXE5@*AMLQFZZE/1UO@8:=%8_-=@CL\.+OU<D%FCJ=N
M\^D5NV^/2P;13WC:?5A=4*M,C>#>3`JQW#WFVOK^)-*OSCQ1NGO2E."<SKZ6
MRM6Q3[61_1,RL0F[&%F@D3VL.Z;,UV>2R2CY<,U,]0C-2Z">0&E*\)%K1EM_
M(^1>WXR,1#MQ1-Q,]NI#<MJCZ[&-<23U)]D%/V+@(:NLU$NWO26*N::/>?>&
M(5.$^*6VMA=>X:!VXV29G)L#TL%ZN5"G%:":5\[I6,3HS1L\M8E8K!:UYB/M
M2Y#9"AXV&<%A>,-"MV0Y;IN&2S=+99!9'<;QDL-KK-LVU\+98Q<S/*IU'KAO
M"9G5S:U*?*=ZF;%7#L(,8W'7RDVA>=PU;9;NW51!Z+9$`W2C9@FLF_Z4R]U,
M*33+QQV)J"T.[`0&8?7%CY;=T]LS7^.M>D`?"-:ZS(=JY+-0K0^)K+";[`2"
MW-8)=3CH>#QA\7?LIZ'<.EBZQLVOUFY9AK%!>*^U+Y@CC8&^G=8-MCU=Q]O;
MR@;;;#3N.6G6!^IMB@E40(N/L?4_NWHR:@3R094.!D4;;H3M&31MF@U:%G3Y
MPJ426#N9JOK\+U@HV&TV-+"9`K'\CI,W(`-=0"I`AF22J0$Y.>>!*UK`''X3
M#`*1$MF@/8-$%%&[!%'%RY>NNEGBX6%X#@.`X#@.`X#@.`X#@5WVRV,CFH^N
M=M;(2V.226QVI8OE)2@"*),\RSU+)^R%I**.B+EH+"@V#@A@X*E':N#,2+2<
M/5^^D4,^!0B->1$I:;C4UQF%<0-"T]XP^O2,@H.VJ3V1H*Z0AG4*][[:.@ES
MX1)5<U7;52$X)DOE#&,2AE)!3='I=00LOZ\(RIOR]77?;'6%Q7/CYEWK-U*"
MG^P^M#&5;&5<`^<PJH'E;-K+4M%RU#&L:XQ71MD"M%\FF)]8W@12Z?(A>\'/
M38)UISRP51>%27=<L.KB<)1>E]!-?]_'#8P[#LRTAAM_PK8.9BZ]0;I*.6XV
M61=/7M\T>.,E5F2JSY+)'/-/#++(**)^3;;DIMO%HC`(PSF5,VKY(M9*,9A3
MCBOP1&LZ9MOQ`P#<,G`6+](,S,'CA*R"YJ49F'2[U9NB%6$IY8(OV*:`7%8^
M6N*-MJ0&LLTJT+%2M@2;8N'5RP9[`U/+;N^;ZXPBQ;*+G+<UX!.E);3\!L."
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MP>JIM+ZR:UL);R^/[>RS4(7)KGN>'T)1;Z5PS6ZE-E'I*07/)!1X;%"TJ`W8
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MHR*W;K,6UTH<=KCY!;:VA?RZ6Q628,<=15J*-*V15,F;,19"<52`A<]P=H/4
MV8]8XI)?@9M6K@$\3R#$C/.]4:$!NJ82VN8G@7KK42R=TX5":HV>I.]SDKK*
MJ'$5:S:!V$M7K]PQIZ[PF4^"*9A5LC`MRW=.5&)9Y\M?XMPG%/?6THU:VP:-
MD47;46DM7:=4/?3/65:=:^$@H]C:6Q>R]6@)05LQNV$8129$PE;-7DTZ(RHG
M$8P''X*,OB.$7[I^&8U_\O.JUAQ>Y3E\6SK5K;A1MM1"G)/-BVV=-3+7N52Z
MP*WZM2(#JROY=_"8[+33N*MB'K!*S(>69.1#W')OFBC\?(,.^\J+QI);;D..
MLTF5U>H/;&+ZD6WL?U:<$[Z&R:;EJM`1VQX=6+=%R=F56BC-PA,3SWUK%ZP;
M+YKL6I3%NYQ0"(--_))?A..5#CLA4)J10:Z-\=OM/8=LHVE5<"WSR7PW9;:@
M/3@SNE8H`%*85D!KNGVL07D*CQ(XJ>8=K.ACELHJ95#;@/FCJ@;:$J@ETP$/
M58T)2>R-^IX!+WJJVK9AD$U:#-)38S386E(4\R/45+"40<9D1#%1\:P7Z;K-
MG2S)ZGDWZ#RFO+XXIYT5QVQU3F6OP['2Z?;O1<HA;E83]M(H7%+'I*K@E2/%
M\',2'1F\3LKO<*U=-';GN+CEW2'6!UXEFNLU"P6E/D6A>W-B6?3#D;6D=M>L
MH7!+.<,*AV)K;9ROSM>6$3E``<\86)7&+!$?,(O(H@Y9GPKY@VS8^J8.&R[Y
MJ\37Z#H_P'`<!P'`<!P'`<!P'`<!P'`Y/2#RGQF&;?PK5V;5F!C+:R+Z>:YP
MM^O?]4O;S?S%./2,\)L$IJ^Q=*SH)0THRC"S<=(U'^;]3M=LX6%(,W"3C(*L
MRWRLW7)Y]H#:D+IF25_IYL1.-K9B'E^<IK27$]AZ-I?1_::YH:E)0"X-8_2!
M2>2NN04IC.`PB_</!#11(LX'Y]K"W`;X%\O5T20>%="/'U,$W4TTT:;_`$%8
M&MBJM&*.]:62#3N593!5`01PB5P)N38KH''$.BK$FD1]]^6#YMW*20>9#RQ(
M]6$JA6=;W%?:U[W;IW4%'UN1*5#7H&&NMFM%YCMT"/\`<AS!L)&RAS:/P1=>
M5*&'DA*,%UULQ#==)%$:L&24\J*?<MBSJ;5U<]?22J4_(@!ON@JW[K>WALAE
M^F%85M9Q,=&I'E%6DWGK@Q$YLQ=1#H&K&E7S\DHT*M,LDDTTPAZV?+Y=\IU"
M,7KK=1M?&S#2Z=$`8>9P+8^I+YJ`O7FSFS44JJ0QM::QYL/;![E&)+8QTV`<
M,^OIUQ*F!5!X0;M'7283H1\TE)BK_7JI^(KU"!A]G8_IO)Y=ELM3?W>$WL=F
MHFIW3EGK/V0ZGY.GHK<YI*+EY%FZ;/VBZ#DEB)5"M\R7`QS_`,R(X96JMIGM
M>L:_B4TV5LO4K7H_;NQ%.5G&+BMNG+#OF'V>=-2(R[<-:EIZ(!:"*/U3A;!4
MF[>Y?+&0ETXS89D0V:N/+>'O9G7<*U[IH/;VQLRM2^:Q/5H!O^NW-51!'6D%
M6LIM2P$]A(TPEH*6P=>/7=!E0.0T.H2?KRUDB]9B\D2';(+`>+6_;4V=TTC=
MRW0J8[L`[>>YT9>L)"'AX$_&X[6&Z.P-60&%G!T"3PBG1B"P"%BPSE=KFY[=
MK,,EU7+M951RJ%=?)':^T%+XV?9$8VN&Z^`P=6B1FEE&0*O:RMVS]T=N'#6:
M%GM5S6"SRNYA/Y%$7Z[2."QX>O'D>-X(.R91\8:M6^':(:GL#O;L<OL/I;7-
M0(`81`&NUM&43NU)/EXV7-BULVM5DUG135VM3)86['J95H+!I%)B>99)NV*Y
M`,.:*^H4,IL0Q>M?DDOQJ:D#2_:A-2VH9!Y5=L=$X9L"VE5<!"H9X/VLN>L]
M?@(^G8V`8.Y!6L7#1<1%B,D>D6\AR)8J.5F)!%-4DL%[-GMOIS2MZZ[ZV5+K
MV2OBU]D8+L)/8UVM9,=JV"PT-KJM36$D=3Z3F!4C+,V)W.Y639CF+$EG'K\4
MTU&^#=55VV"N\9\I96YAT''ZP:L3:YK1<5#+[GNFK"UDP6O"U*AX#<D_UYD4
M!6.9XRL-.;9*W73\S!`![+)`*4SBKU=8NQ1[;Y+!J(?S.598ML5M`Z0K;[C1
M^>UOK);+=0Y;=?5K<DK@&TZ(I]%Y/0M#2950]>X>L1I;'*<*LB0[((\;N6#;
M`@0;J-N@L)XY-F+ZV8`[3D+W@0N#O:EW+O\`I*%(BS@(QCG#Z[E68@<%?9A$
M\,%RD7PQQ;+O\_9T2SR^+ACCUU[.!4#Q[^2N^9M2VE!#;2G))BVVO>696]?;
M%M9)6ZSZP[EKX-;UC-0$AIB!A`;>!BY_7%0'%8L[:+.\R"PKI%\S'.';;%<,
M]"/-U42Q>W@]Q5Z)K\E5^I4YW)SC-;WY46PL\&P*NY1!X5(*KMF*5\2;X5/L
M2ZEME!!PV.9/"XPD\7<I(E^\V:O7`]/9;R$[V5>ZI"-?@P6JR53/:G4J!%21
M.V(%85;S"L[ZF4DCI2$`;":"!(T7<(MU&<V9QEB@L@"Z>L7K5X2:.L5L0W"!
M^9^C)WL#$*L8,:]ZKFR-B9=JS7\Z8;(4\=M@E:$3-3")-C\EUG&$5+#BE13B
M;PAT)`&\W+DB[4=CW;D6S'/4GG0>A1GDPF.R$YTME65+6_1=3[)F+X3K8<K)
MJ9FZUTL*IJ.P9'(G4SCK"/R":0L0#.0_!6-]"C`TD9772S?(X->LVJ@5@V"\
MU<E,:[;M1NM8_%Z.V>K3QZ7;N743V)7=1&RYVMVU:/HE$GP&_(0!:GX_55QQ
MF5V*'[^GGJ4E"OL<'V.!!;)DLGV'TC<!P'`<!P'`<!P'`<!P(EO.K7ET57*J
MV&V?9U,%3^(9P'M"G)"A&;$AQF.R`3)PY,&1>CRXIVUS)!DD2(U^S>##`Q5P
MP>H+-'*R68<_*O\`%'7L)L..7/*;4D4JML;M;$MM9"8BM?5;44'DLR@FO-T:
MVQH!W7$"C#04P&J0Z[B9`H24<.SY8PBAFL_]&B@R1"6J"\=U8Z]_@O\`3,WG
MAK\"]9+4U<KGY[E'^_K&(6Q]AOG,AFOR\,S]Z2#?Q_&^E[8^D:_MKGWTL_X+
MX853&^%V*PJKOLU4.UU[U5`IAI)5^AUZI"`52GY%;E1TP-M057QUH?D\&*=U
MM/$AMT2%B3>!T,4'@]WCTW09/D4G^(2PW\4]?@9)%IK"[DLB.RV([5ZY;6"B
M+L7##S#*0:^:4B-"^H:[%.0C;!:-SND6;M9XKBK@]9G7OJFRF**.#7L([A_A
MV!08W1ZL?V?L]"&ZX7!:MF5-!LZ^IM-#Y3=\$N>N++CUDRL?#6$RM"2.8E>!
M9F*D9%]T_888XJKX/7:B[I4)@/>*;7N9TIJKK_.S<XEU:ZL:>6/I2,%OG(1J
MZL*K[0I"!4/(3$M?,0Z*K"8-XQ`&[MFZ%^BP:D5LU<,/U$L<`QK7Q@C9/`[,
M@]Y[*V[;&4UKV(5W$)`'C52U`_K)2O9R#L^%VZ)%5S!1L7E&P0JQX@!-920P
MP>,L'8-NFT&,VJS]N\#$R;Q;J3YT4M2Q-I[3ENVW=B4'84-V0SA-5BL*]PUG
M4LONJ8%'*D81G&#JUW_[Z)>X-LG7:SPL2DCMUB[;=I,$V0>B+\69^-"K(?1O
M=2]5[$N.\K$O6W3$\B%/3RJ;3+VI3U&T])XE8.O;N%BZSD<1C8^A!#^)>\DF
M4C+A5P@F]79N7;=R$X+^.JHO].>1>-4?*IT/J&24C,:0=S)+*+)SMN)G6!A0
M^='-F$:'082^]>=<*LV+(0V#CTNTVS5HBU231Q"%9[XIV-SB9X^OK:"V[AM<
MR#HF*US:<BAM/#^ZWC.N5XA]B8&/?5T&@S.N;+4FEHQT>ZG>)P>LQE#9D@V3
M:CDD$.D@Q;3Q,I82:?V01VJM,C;TKM.AM@HC8Z,`IX*O55[4)"974X4["HD%
MB#&&=5O(*4ECB&OHPZ8K9*!%W6>1#,@ZS?8AM1SQ91B=F8%(K=V!MVY#+6*[
MH5[>'=A)1DD'O"M-Z`-<`K;KI$&R',&51Q&.,JACK6,M(WZ9(</9KIN,7CEZ
MX>9!@7/B>&RVD[IHJV]HK?L2*6EK1(=40*[&(T_7#B&UW)FC-D7F9=C`H,'#
M69=A!L+9I*2$TW4:MT6^>+$>R[>$,G@2QM-XVJTVFG-IV3(+`G$4EUC5?JA7
MK+L4QB)V,QLAIQLK/MIZIDCR(2L`8!SEF5L.>*-9`$-)NQ!0,VP0Z206R[<]
M!G-;=#1]%V+?-CS6V3%_D-B%*L-S038-<U>&`A)G5D6(0(04@X6%QL&&C<;2
M@>;`4T%]-EE&R3#M95XZ<NG"V84[J+QMV[+;)V[SO6UK`AFN-H^1-39H9K<)
M9TX7BMNQZN_LC,:ND3R;#QARPX?#Y'/JW;]2&,JNVJY-L#30R39M7CW%^%MA
M/CBJH54U'T_U-K"<1^B]Q;0W.!$/6"&1DU-[6M*_[6-Q,L]'"VF;6*L"^PQ1
MLT49>F))MF37OMSVKTHHH%1X_P"&*-P6(U1%N[OFMO5]KQ1UXZ\5Q1$EA=,5
M[$)Q2%S4^O54G@-D3"!5V,D9FPI@*%A42<Z=]/'.>([M;H=TN[?*N0K52/CQ
MV!VGM@NXW,0VC!TK&O'I*M,!#:_WVIK.R1$VE]PT#:`J35J1UN*3H1,9)5)'
M7ID]?3>0I,V4C*YC%!X?!!L_^*'9W6?5L_19V;S.=7A*;KFDS&QV.I+.877E
M4P:+1B+YDG#1O'JVJP"`C?U,>(%E7)DT\]4]>Y)MT4>VK-NDVQ"WO`<!P'`<
M!P'`<!P'`<!P'`<#C\EXDA0F:Q\[%MF;)`0V#;FG=X(+7W5>T\^Q3M:<6/-;
M$GC&Q+"RA[>S[4`YYV=)!D?Z)E^EP8\FGBMF1S8,<T`]=GX@XZB1I,"\VCNU
MY1.L6.P3+72A4P-4,(Y7P'8>DK>H<K'B\J:PC&7S,;5L'N%XSAGJ'*&8MDV2
M0>=D>^\EN!88'X[JQ`_1OIIO/%OHKQ^.O'<P^/E'_P!KK%W]*>_-WGPPV'_C
MS'Z21]G>'NC_`.$S_9_^[[`C&N/$[35:3.H9J*L>SG[^G;.UHM(&T(9Q7MF4
M+ZP:33W1N)#RWIH\@MV-D%?6`Y+D?@Y)*]F44NT<TFWOH9!DBWBQJHK8DULM
MM<5\1"236:;ASKLS7<N'0651`[N55=551+R<!F8,,E(HH<K\=4K`C&B"*V3E
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MU'X62TUU<!:9Z]QC7V.SV=6BQCLNN*;.[`LM2/*SF4R&[+HL*\9:2D*D4!1B
M.YNNY58[U/#MJP:I_!PP]N'O>]WV$$VAH9+IGM-)MLH%MG9]0V`>KN*5:-:"
MZLUTL9K"89&52K]T'@96X*HG<AA[.7G33A^;2'NFZ11SBAVXQ4Z:MND@UVZ?
M$)H3?,MK*R9YK3K\XMB%75%[SGEJ,]=:';SN^Y0"%'VA@=<I[JO.WDJ`S8P=
MZ*E6^66/2Q%FW4Z[Q^%CUT&[-?'=6+2#@H)A-YYD.`^0.5^1%L\RRC_K5K.E
MNP\SV.>PA?V!ND/H-M*9LX8I=8X=$/EZ2?O..UO>4R"-=Q-7-C;HWIT9N*D[
M%D5+1BD*.WCC<YMD",JV7(#9#<1K4'J!PB05Y8?3LC*0LP&5U(7>*XMOAV-?
MA6RCETEAFFV>AZH[Q;"JW%P%36[9Z[]?Y\$I^24;:-IA!=6S"87=$)G9LMNJ
M1S"5I2R#.X\"NAK;]CRN1!Y"*9-6HPA*RG68YT@J@BW#59[X?*UET;A=-";P
MM(!JI$A-!AV.NI@'7%C#H6WUS`Q".0Y:A+"G\4.3;7Y]+QT%&Y2ER!6]22>X
MN"+-0:5>.WZP7@ULUF:ZV%MAU`D^/2R,WQL#/-B&D</B0;96OY/:*S<M/`@P
MV(;,W1X"_DV"KMGT]3[<,D%.F_:BWN?$R"C-8>(")PZ%UG3=@[.7G<E`48'N
M)"D*LD0^LHJY@DGO&O[&JZ535W/8/#`4IDIR(06WI0/B&2V:/8%,VMFID]61
M9*M0U<5X6H0]0CP2S]C+'L2%!M2+@TA<0L=7E,U:(RHNT,ZG*C28'.M(5'G$
M:NB)3"EP)KJ4I]K=NGK-/'!FU1PQ2Z"8)9XVYI9(](Y:^ZUYV+<0"T-:;*KV
M?E8U6PB&P535R;')O#Q[*D8W'Q%>/BDW(2LGW*S62214MEFSP35:LAK-DF&Q
M51XW`-.V>(-Q"[YZ.HV*6[/;RANOPR)UF!:BYM8IZ5R\O'3-MA(HQM64U"$F
MLV(%1$9<D,46ROIFSAP['LV[/`/5$^+.EF%4:MTXZG=H/HKJQ"]AH'&W2)0,
M(/2H)LC6DUJV9*'2XH,V7&E!`*<NEACD;TTS0=I)9Y>_UCWUV%9R_A%C\KB/
M4(F6V%IEHYGIA>.A*@D#5M#P(6WH&Y$*L6]4*&0V!"6+*U`YZGPS]X=5P<HE
M<DNT/1-6_NI]!W/X#@.`X#@.`X#@.`X#@.`X$5WE9:U-4W:-L-HPXFKFN8'*
M)DUB+:01J)*21S'Q#HDW#92R9D@\2BS<@LWQ36)$W2#!@EEDNOGBFGEWP.0M
M?^:@#.0UY``M=4A:5UUG/-1*XKL+J]MX`V"U]N"6[LS6:0"H@C78_&I8!](E
M(D<KDXO-DEHL]P!CV72K)0LLK@WX$<@_)/MY7>S-_518FOHF:69+]T=4]1:A
MH\7>PMK4E8F;+T:L'8Z1SX9>CBE!<OEE4OUZN<OGSAY#V\A;)NUND!6;AK@/
M<A8.C?*+:]A3BE1%IZE`:J@5N;<WWH,O-8_L:G9QH%M5KN.OU_,4!T+^R\'P
M/T,96URD#(3*G!04?6>XI>IC35JI@ZR"MU%>72X))KHWE-5ZR2"]15&>.W7#
M>N[+&OK9N'0:P"M?6]'KE,.8VR^W6M6<6G=\="J/*.VR*8:'14HITKBL]"^Z
MV3=!(,T\MH"JB&P$N%@RQT`]VAUSJ*,2/9JXHU26KM,#+@\?E0;5#9-/[:B%
M%SR04+6+]F>Z'*Y&6DX=O9\8Z31=LACM%`:&,+>4'9)I?-7RE6DH:RUP<>,+
M>?<.PX@'O*"SE\6EVL-BU:!&R&O[#B$%-BY9#2WS5%F`<(D&29@'->B[]BQ>
MAOE2X;5;'ETM&F:?KBV[-UNUTII"S*SD-X1B/;!>0FOZG*22MA\=CLFC<+@2
M"%,S$I8.S<I%D2*G4.&LLP++%@ETK)^U7B:280K)?)S>,GM+8DQE'I-%-5&5
M3>$^UJ3)P2=5Z#N@0YWXVW^WG:,E8R2G)^$R$V&$<J,I4.R>/LQ0B,JH"'J#
MT_@2$!=T;Y*)`0F<>EN5`#T=,9=MV3T=C&Q^%QI+V$0O`?;9_71N?7H/[;)"
MT*3-['QU:&,3B4V<&EGBJ+W('@-4]7T&H:Q^42QKV/Z;%)OJF/J:FM[3%O0N
MBIHUOQO8%BLIY3T#LRSB#>RZO0J:*@8Q!YC":>/N0A8=*S9#)5)LB_%C\G/M
M2"Y>S>U0/7LE'A;OY>DDUK^V]B+9D)=N0<B*WUAUR%@C5S3I9$>HVR?R1TYE
M(8(#89.$<E')18C[CEL)>-E`Q\.WUUPD3*;NI?)RE$NJ_;U\1D`?8@*O31?Y
M);0HP7K`N/:S!1FF0^N&\;)I-!^&?SE%X.<-73-NYP^%V$`;%^2%U7,/MV;T
ME3SRS`FN.L$EV^O1.U'-@Z]2$55P<I8HV)1"&0F952_FQ:T+=RI6991]$J/"
MB\T`[9UDZS:%6"RH3'M?MK+J2*E(74E<Q.S)Y$Z#M'9VP<9W8A"M8;"JFJ_T
MC9LB_-AH-89AS,+2D"KE@!0Q'8,46PDL_=.<>V#=@2"M.?E78H#X/=9*K1,=
MU!DMG3.FC%K2"?O$+'%2ZLM=;+OVW)4QK4?!R(5[7M1$J>D4/+YK'VI94R()
M.DFF+%BWS)AMS3R$6K&05_EK:U8<"#=0ZCUANB+KR!6[$S4Q1K.S#-L!LH;:
M)&R!]3U_![`@+:H2!,YFR-&!F3?%XW&JD5V"/9,)\J_9V8RBR=5*VGL#%PN1
M[(Z63K9TI'V1-\7=5W,:G/:N@;"@:YA=H/;'1:3_`&E'H,G/I&B^60EQFHG[
M%L,$@NGP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#CC=WD*DE$;2V]4D/K&
MP+PF1>Y-'J"A4%/6G!8-6(&2;)UU?4L92H&_0JE[+(R#8=U;DI*LW[V2N%TO
MAK"VJ6:&3%Z%7[=\B^RTXO/3NLW,"%Z\#ZZ\D=L4-O.E"-@\9)''XC7O2N0;
MG>BAD_)T"$DLUI\S5ID5*B6"@&*F";D*K&%4FR3Y0DD&>JW]X5UHE3=S*9ZX
MH$5`3.N5T[.0MG1^X58[)7K'H=2,(0LP[!MD*+BL>C3RB;=D4#R<.A@ED9ES
M#UK!T.>$&CY--!4-NVSWR\DU5P^K>F^D\,J24S/:#0V+#I$CLB-LFOY)7^PN
MS4:JJ5TS*9`7U[C[V!W0[0(-!1G!@*-#`3`_\V%FB:S#)JH$E0/R!V$<L*::
M_4)5Y;8#84OLKO"Q'QJ^;SCM5P&#4]JG8M=0:;R=:Q*[UZF!L%#<)7;4>#1`
M%G%Y":<JOL_7E\D6KAZF&-">6*S+@)!8UK)J$/G\M2U<F&R5C#[<V)8TV&KT
MM5=ZV=KG;5'YFXO4=UN)'8\=M.IC#`8Y09)`2G;511P_'(])*+!?$5N/79G2
M>!;QL@<JS@-G455UWP>$]M664^/Y73&8P:K"MF;%%XJ+SGLP.3(8#:H^I]+V
M4>88Y+=)>U3H(_K#?BM3DNC%1V'B:"6,\L*;4,;G(F"RYCKT1V-JFK9'<%L5
M9!K(/IX]E<8="(/(W?1-VDU8.,8Z^1R51?I9,<0]ZPM]JJ;,P(BA<V^P-A6!
M8D0J2K48\I(QM,2VP)7V3)OA^6P["(2:MG#>NX#&CDJDS4(L=/#0(-SG@-6<
MJ-6[@,&`WC?8:L3B\YE6;-.Q(3?D[U5'UI#IEF6`V5?<>V3>:IP8'#9L=C<?
M<,(_9=L9,$>W3X9UF`2=K^HQ<8LE%50A5'R)7(0FESZ_AZ*JI]LI0LFM+*PV
MRMXR9G1(^KZPHC6F\EIXC8>5+K3/(E(7&UD<BC06K&DO:5&'GG3C-J*R27#V
M*S\FINX,Z*G\)HYBEK_;=O5%K^^E4@L5PTLQK:]J4RTM@SA%8`/@Q`"=B-.%
MGZ48/N7AT:]<%FAE1!K@W$(9F`VYEO[-7U9W]:1JBGE7BJ.WCIC4[$#-)9&)
M5(I3%)Q86M\#G=B**UD<D\2"%(^[O$C@Q&MRI;VN@':+O-!191-L'3O@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X$#;/:\0K:^A[&U\L(A(A$3L@2R'OC42=#&DE
M!OA!H9)0!P-F<$GP"[X+(0K5UBW(L'XYU\'X+ILNW442S"C+KQ1Q>1RRW+$L
M3:?9.?65<L7UJ;&Y\^2HJ/&H59>GMJRJVM;K=J<;$:7!Q6#'*V,S-^R[#]CG
ML<.CUL\3+$BLX>K.PV"`^+6NHW:S*^)]L!L9=-RX[/P';4U+YT2J,6P,636^
MMEHZK1F/(Q6"5#$@D?K-G6%KO>_E8_!N[[),FCCM[W^UX.PE`'X]*7`?:_T<
MGM!7[3;WWOY"XYZDU%,_6W1L+^1OUI&#?PH4CZFKQGY.G_E;)#TQ9'T@_P".
M2<_"<>J"-Z4\4FO%$5#:]+Q&9701BUPZ44MH?)G\DD4'>'V-0T5&+UBD1D8)
MT,KH..;601';!&<R+QPU=#%EFS+M$>WQ37P<A_37QAP>(*R4[3.Q&R--SZ16
M#6%B9S&.'*Q.M>W-7:E0+3-E$#T"EU6FZ\G$!D]65T.?DV)L8_<)R;'L@.<C
M^L$$$0T<)X>Z-C0*&1Z.VO<H9F,HG>/7VRG`]*HFCBX(;Y`IBWM.\21<<TJM
MO%*_/#[A'LY%'\(B,!"A633`=Z)47DHSR"0K'\9D#FTCCYZ,WQ?E2]=:GQC2
M:RD("O4:[^V=>8:[D)(#&BT@FM3RXS`I!D^EI3IX9B*H!^Y;O\NL<TEVPYRQ
M"-Q/B`JEH-8@2U\7P9C^5*:(TU*!G6%0CE)=UXXMA6.P>L,U>OV]69N1,@%/
M4WL?.(#_`$PXR$)+9Y((D4FK]`)88>-N`L+1'23&Y;H7HP+L86V]!:E+9UCC
M2@C9,U*#-@/9XV+H5NC<"D?1M0^[FC:-JR;,*WF"_9#I'O#!!LB&V5KX]*7J
MR-Z0Q:/R>T'@_0>86#-J>6,FHHX>20K9%3W#3IQO92C*%#T#`]I&;L*KM,!:
M891-^W:9J**I)K(+A'.[&FUB[#R.=J04L!&!KOU]A>LMF%GY<@&DT6K7O9B`
M2:T5X0X08&&:A:34/*9MTE@J@G@J<$AT%E.D%U%6X2UCH%0IU$T5MOZPO.US
MDH&S'+86>%A$6OJ,R`!&W,-B[ZKK`HZ/U"I22D8BC]VP:=PIO'LLTR+]5QVN
MX(D%G(8F1>/NLY=-<I9)K0O(\*D<%IR`7+`"\EA1.(;$!Z!E$KF%5.+B>OJ]
M<3UVZ"FID]Z)(@3@%A*66?3,\V*,_?0S#S67H3";?D?<DL"Y+S-*R:IUJ'NX
M4@^J4*&V.I?ZV/S8?6ULM0=0C7`V/C%):7%_$ARL3?D`Q5TU(N'GQ.L\0T\G
MXO\`7F2"+3A<U/VI-ZFLA3:]X%IH\>B;2OJ?-;NX6"GLM):KSC$(CTU0DD]P
MMJ5)MGA\R?5CS62DF@?M@R=K-\@WI]H;74FJ+8>K;)LJXK6-;55ZSJ6\KFFI
M*NV]KS"KQD?,Q497R64*K6'UK'HBP`RDVG@R&QMHCFYD!1ZKTH_?N72@2G%J
M>-K;)6!L1.'8U9UA`0])TS'ARCASU$JX1,=3.P)&5<KIHX82ZV)SB/Q>MT/B
MM4`T3"]]9].LWN/06.X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!1";^/2E
MY]L(ZV4,2>T&TZ=W!K?=:@H::BB,3QE6KT(MF!0`?@Q=0IX8ZCY</<A-0PEV
M_P"W+AR@UR;+M,,%4UPQN?C<H)S<3FZ29>QC)I_M;9FWI.+E2D1=0DI/[8TH
M;:&RN(D!?4)3)N*URIIMZU%EZWHAU(,\UE'RK+OIAT&GP[QC00779.B;,V#V
M5O?6I&AIIK+!M>;%F45%5]#*;G,=:0UX%*/:TA,"F5M2:-0IG@&CYZ9DSQ8*
MRZR606^9K."*P:W)_%LTGL3(LK'W'VML>R1YK6HQ5MP3![2RAZI5-3;B&7E4
MBX6"QVGHY44L//Y\(0<R<M((^3)2'!/%'-5%NFD@F&U$?&;!A$C<652][7I1
M5V]W)LE;K&WXGC3TH.-&NV<@B<GNNJ749L6II;!3M5E#L$!D!S5^-<$QI(*R
M<=/U.TUL%PW2E/'/0]!F6YR"FK,4?8:QN=72.4@D0,OE((^8M">7-+[-D#ON
M+-R)&X)W9-E&"A<CVOB.<.'>66#!+OV]]A[4BTU&QC3+7+4FIR#HQ']6S6AF
M,$=V0_;N3$BB6DMT41/QJ4G(1X8!#N)E(8O3?PTW:8]NP1-+I.NFJ::>*>(1
MGK=X]!\?A4=6VCE!:\#CH]L59YBCI9E!Y=KG7UF[@2&SY%L'U#Q&5;1R4SP;
M(&%T2>/X]R]\<;(!39%JQ;,6KU1OT$E&/'W5ORJ#":[LJ^*>2J.U`UPT=E#I
MV)F#2BY8.K:SZ=*CJICMZ1.X(A'H'**LN$\#<1I4<Z`CF3E/L0T&K((JX!DB
MNB-=/*=;4<'L:WHG#0$FJZR*^=@B%=NY375U5G;3^\W-YBI%*ZUDKV;V59]J
MONC,M[F?U0&,.L,^^AZ'3M_T["/2OC%I8D\6)HV7>X8O,HG9,&V'-AI1!VQS
M:J+6[)QLLL,9<YI>N71,&H:?L,FS5U`580]""%_E@I9B.;L6K4)&K?0VH:QL
MY.?AI%81.,`;2L*[JPH\N[A*=-TU;EJA2L?GL]KL2`@H*9Y%BXN4'DFR!PZ;
M'ADY$13%MV2:J>"(8UWIJ/:MZRK($8>.*9%[3V%NE;SB5/T24TL"W"=YG-E:
MYB33$2(##&D/B5\21J?0<Y^Q<>PA8<5BD[Q=.7C4+U\!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`X8^6CR;6_H];NLE00,YK)0<7O4'99PYMINM&+GE&O$=/PA6.-0%.M6U+&8
MJ^'V!+\#JQ'UQDR.&,QS'/W<7*JGNIAY:=\K1'#&C9%M986J561\YH]L/ME<
M(JGR$OOR/$X_1%D,XLXN.E-B:^E!VK"50D(QGT[^G7;![+U7S])HEEVJU735
M#<&OGI\>2<:GDDEA^_JRRK.,U+,YG&;0U9OZ$3<=%+UGK:O*DD(Z'F($F=E`
MF=F2#5=@L)1?8+,'2:W7?_>QQ`9\O=.SP/2Y6G).2JXT3\A-8Z47/56T&L.P
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MH[9^\W[:K=.>L<EL,TG&*(:K`O-S1-Q[3:/4!2M6VY/X1NM5=TV`PMY2!V>`
MRJF1TQ.'];GZYFT)<5B]2;'`$RCQ5I*5W1D<E$\$F#EUBJT,#EU@K5Y//,7;
MVE^_D;U$C%BZ#49!"VGT/V/RM+=AQ>S5N;ETBNFTZQ=0",*TVJ^ZR62#05`B
MGBY98_J].>\E^_X)/H(=OWSQ;"T78MR1/&JZ[LV/ZX>+6);CSV8UA1FTLL@]
ML7?;0O%Y63NJ+"1Z:"(KJHR[-B5RL@.,W"N26!='US-P%?XI!="I/.)KR`K>
MBA^UQ2:"+GD-7TE-=E976&J>R0+7S60KL(HFG4#>\CLN%2EW0H^QUG:&`?"1
ME%E%D%$WRJB+%P@OD$[EO,CI\WLFTZKC[>^)<=K92\(Z-EX#76Z2=.6C;&O$
M4.RNU*/JBVA,(*1>>6Q&THV\9]B1W;EP[()>E9=.G"B"2H9K5+RFTY>_C6CO
MDQN2/FM7JGR@I2;V$,F[68&D8@V$$<ABWTN97@,2,6L)+/,T4!#\,%R3-.U\
M6[+!97V8]AJK/S8Z)HU/;ELSDQ>%/(T3(*@`VO6EQ:WW57]W1-*_SF`"F)'E
M4):&_6QR)V,^R[[&OQK5ZBIAAE[_`+F7LQ["UNH6[M);KA++)5*VLZ,GZ:L)
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MR@44]6#ND&F:!DMV/$8K-WI8?TL%M`?E]TM/;#!];VQFX&,B-6@/H%O9!R@+
M@!4.SV9(@49*EK`8N8M$6D(#;`-Q"W7;B.N7*2[=YUDQ4SQ?X]M>@@.%>:C7
MC8>7ZEEM=;`<!*.O&S)O$2$YO35[8Z*"K?81&J[$G!L9KQ9!%O#(2V,5T^@#
MC.3$R3<N(:)I]L.OAOU,?<"%MGOW@RBHYJ?M;:NKT:GQ"]*)HF+;'5M`]GJ$
MNNF(G==*'KNA%+N+?K]>3#(82FE:MSTP2;8O6CELIV\61Q]S+'%;K`+F>6CR
M1,O&%6NK5T2=M%<:ML_=&L*%NZ1R<?)2JT&I^3UQ<4]F,SB8R*N4B)"9"<*T
M0P9(9(O$EOCYX>G44R3]T(+@'D@V%EFOVKVUMA+:VT'5>[6\.NM1:RP@S%+,
MNF>G=<KUDST3#6LZE546+E"XCL=;0=))TPRQ2=12$J9=(E\WZ_:R+8*@P?SI
M7K+`<.(R.(T'6H^34/YA+4/3HI&+5F$?@#CQU2TE':\/$8C&YFC*93%R8UE\
MPDXU@M@4?XI9HC%6JF>'L"\1#SG:55B+CP6WI?8QV71VL=59]?E@U-K'?I.B
MJG";40D#):_L^<2Y2/'QM5UC)G1M'%HD;*K%F^3E-KEBX<I..\`EVS?,;I!4
MM\FM?);(;<SD<=N.M]<SL^CM`W!*:.$;#6KD`5B%'$[K`1!_70^S%Q4E:OW`
M]9_AZ5I\7M3/I1!9/`.I?`<!P'`<!P'`<!P/E^MOS3;1Q_>F]=<8HIH15V%'
MWW$:LBVJFU\LL>E]J=J:Y(]1#M_<]%WC,)9"]8AP^9]2!]W%`[M`D^>Y"LTE
MLL57#7%8+\#?+53]=MKXRN:996I(HWY";=TIIJK-5=;=@)A<1@Y6]=PRQ"-?
M$*[3^MY%:$^@\:+O2I^3QUNRBRC#-NFW03<X98KAB7WGO\>64.A4QAQO8"UD
M[%A]N3Z&QFJ-6[XF\V*0ZB)VXKVV9$_BPZ#XDHH'A)IDX6?.36(Y!%DWS6RS
MZZ]WK(*V;R><D;KY5.R-WZ]R"K[XC$6T4UTVEH.#H4S?BT@6<;)3XE$8-9UO
M3QD5&1%I2[EKVWR5#XM01]@];J-WKUNH[;XIA-M?>7*-UVC=_P"6,V`G)76>
M6A->AZ3H34G:B+[!/M@ML]9`MQKU4E4=AOY;,I;,IP:[)DH_&V+)H8B0-KF.
MD.:I-HY7["3IGYN-(H95\'M#MKLI*TIB/M8R6K^$:L7C)+8J8#1)!(5=$@O*
MO&T.3.5"#K,@OC@2<FL6J7>'62S?M=!-17$/2L'SK>.ZNS;D<\G%M2F/AHKK
MC8LVLR`Z\W5,*DK&J-KHX+E-(6Q9]E"84I%8)!9:).L>TU2#A%[\=UBC@VS5
MP6P2"7]'/(N(W6NG>6FV-*V-5[G2[8%Y2&<FE86;H@[+:M0[![U)&SZ15W#1
M,:/9OEE_>CR;PL\3%=LB?:W;0DTRR#CWK+YQM@]A-N3E$$+9\9->(1W<NT:"
M[H,_UM"ZVZF%;5/:9:-E"T($`>CM=O[`EL'!.G`5)5;!HJ1ZQQ51P3[]S@1]
M6O[PELS:'XT*,Z4B\/9;3^2*X]?HN6DVK6VRH6N]4Z0]7E)GDE,8&AHZ9WN\
M2;_%?E!JC0!$$D".9<3CB&)]H!U[K;S?>/6R6-BG>K"LBNH=`J8F>QP>>W'1
M-PU7"[EH&OB;4-+K;H(Y,8<-PMZ+BBI)FABB)P5*.E'B73=HK^O[@0)>?G[U
M_K.GQ5EP:@-HYC*4MD]>*#G5+6'0=ZTI:T(";$N7B\0L_P"E2]12HM(Q9V/"
MW3F-,&K?K.4/TTAS==%TY0Z4#HKM=OS0^G8ZJL;+8V]+9[>;HXUIZD:4IBQ;
MCO2P_I$,QD<Z=@:N@P$I(TQL`CY%%V;=.\&S<=@KA@IG\95)+,*PSKS>Z"Q"
M(5),H])[DN9I>5-S6^JS"T1KM=%JRDS6E9RE6&V::,Q^.0U5_!E*U/LWB)]$
M_P!"\Q&0]SBY^&HG[G8>KY'O)KAK3XS!?D(U@>5;8D;G+K7`I74FM1M,V5;.
MJ^OZ<0H&VFLD8@UP$U&-1,8EOKU6^6*3QMFEDFLA\3#-+@4\T9\Z*%IX;L&]
MDI9J]85.:@5[35AO]DM&4[QF%?%B5P'9#%!5-X5_8\=^YDBL[(X':^E5"(/1
MJ^1))LKV@XP[]\+DM?-MI0[K][*<!VS&%DL;H2U\5U44U;NKK<!2VUX8ZLI*
M*MM=L8IG.W'_`+LV:L@S>8I=L$1N/\(M@XRQ0["-/]=S6-SL?2E7#(?9&="V
MSJ!<NW)W9\W!+;C@"J`-('R@:<1^?PHA4W:X1G%.HP73D!9X59I`B;9HP5;J
M+$V.2H;N/\[/CX[KBQ;.F$DO"J!%:#Z@DY6/6YK3>,`GTBK2_9?C!:<N&OH&
M9A*<GL&JY[)_>;-"HAL[Q3RQZ^.FC\5'XH8>/^8*IA<PVN,V6_F#.#5&STP9
M5WKX)U(V5![H#YQM:"L%S&(+-J_-H$U9_,+.(Q#I>."@006Z!L$%_G&662J2
MB8>*%^7V&WUMAX^:>UV#9$ZRVH+>0.#7BG:T%GU;7=1]M:30ZL#3VLRT&DO8
M-Q%I4U.3M5N<:DF3K+!/%'X&>&7>6780;O3YM3^G^^<NT2%5S`YS:-BT903C
M32+E#+V)O;.V7OBS)S7[0!9$W+FF<,B%1Q%I'&Q%\Z[Q;D%??[:MLEW3ALEP
M/-Y`O*9LAH1#;[;GSNJUBWQ0OCJJ;;`]3X6JK\"L2$]G.UR%"GI..L%_8KF.
MKTJV8N%!X\-G\&6J%661)PJDR<8,4@WF(^5&Q9+M%-Z,D3^CZT$1/RIJ:'1=
M(O7]NS*36S#L-<V-QX-09:,2Q"/P.T%RCM7+HN7;J1[$>TR1[:>I534Z":J`
M\WOC_P!D#T<&0>96M'([-ZEM6ZJ[M"UZ#M^I:DLR#T2C@[NUQ7%B3V(@X_-7
MU2#U.G!],>HMBP3ZRQRS[5PS3Q"2-1_+!J+NK:[*DZ=<74)L@Q1KO9J+@;>U
M\N"F$YKKUA,(U"`ER0DI9$1CXN60&9%Y<QR#/6*RV+Y#-3+KK'-NXP2#+//*
MKI$+M(/3!NUG@"R3FU\QTK'QLY"IB,7RON$16+S0H%<.7(7%DTB[^/S@,J./
M*J8""&9-!-!QFIWECB'-38/]X%K.IZVO79BH60O9"G()JG2FP-<4P.K"]JKM
MLVA:=^RFF,;!G-REXU-:]BU/F,8ZHJ+[RB^#Q-5)-1PX[0(L_8&^!_/!5L.V
M]VQI/8>O[4KFF:DDFC`FN+/9ZX7YTI!6&X=%5[839?<@F_`K!M>BB-C6,QCK
M`><;A26#KM5LLU47:NLD@^@+@.`X#@.`X'/K='4C8?8*10*9:[[FEM:2D9CL
MLADUKV;4S'MF-<K>BTK5&.\<YY1TFF$`:+S*-/1G60LRW+(JHHKK(*I+I9^[
MT'*)U^[UUA6E(2<0SG,XO5^WTLW5HB05G&(Y7M/+VG/-KK,:7<5D=7*KD5:Q
MHGZ:EH5LQBH#H>M'QW6"&;I;+K%PHL%0=;_%#M]NG:&P,UVYFVQ5=Q4A4NA=
M>0VP=BJAHB$VH?D.J=^+WF_B0.IZ3GI>.MH"&8AQXA61/R7;LT4(/"#=/)#W
M&J`=?IKX<HU,]CS^Q"M\'&#P[Y*M9O(WG%DX"P<-6QK6Z@Y)13*J<2N4J255
M%RQI(\B2I;M#%5HHETCBU5ZR^)T$6C_`K6*\+UWKJ7WU+I%#:0DWDY*G60^%
MCH\4L`!Y-:\M&MYO'TBN,D*=1%U6P:T7"C!]@B_[?+-L.U$4.LN_8&/(^&W:
MN7ZN2#6&RO*E8TJBP:N:*I^CQ`#7P#7-9Q*MJ-F$=D#<9=,`A]LLY!?AZP8Y
M&&T>D+W"2Q9N\$]J88-$OBJ>\'BUB\"T2UMN&J+>'7V)<YUEN#.-P\8)`M?(
MO4D!6DUA:W-=?#T$C,<CTW),(=#6G;?LNQ[QP>O,.\NT'2KM;)1[F$D:[^&%
MKK7;&H]N0C9D\Z-:PS+=0L6&%*L!K"[.A6Z5I(6C*(=EUW*LW<,)1%\WQ:-B
MR2C_`+<H]>]VV1R]OM"5=F_'-?MG[Q-MZM:-Y7VJ%AJZI1K4R0`^];Z\O4:=
MAD=MZ<W#B5Q7GTE'MQ;YX<EZ2/>"+3O/!-CUWTMWTMEAB&D6CXBS%W.MJ)-;
M&U!B4V-MKX[(AH38DT:4]&XZDB\C9::F2-UL(R&E3<.B0//)HIWV`1].T;=(
M]=8.<NLO9B%?K7_=]*UL/8EK>(ZSJ9Z&S&`ZS02^8_<^AFLVT\PER.M$$%5>
M.*TQ8&P(^:CM?W5B5\`8##R:8"0IJXLTET?A.DTETPL;KWXKK;UYL@X$B^^-
MB)Z1NK4V&N$)J.%J2&1\_P!2;8QS*R\BCD[V$4.FI#/:WB,HFS\J%%?(ASGI
MW@U]<]>IH98+!DHEXC(VAXGW'BDLV]9-/X(/C+&+PBW0T'`P:81%M#9\&M"I
MR.0'YI)PITM`IU'&+Q51?/#`KBCVGG@CCE[>@@66>$2:WDSN>:[7;ME+NV2N
M0YJ*T<W#'M>(?4<4B%5Z@6^A<\6KN-U,`G1I/(A.Y9FZ5.&79QSEVJJGVT:M
MD4?3J!TMUMTX&ZZW_N[?#*>/I4[W2MF`VJ3C;H`W$MX`X@E5QVKT@K`FD5?J
MR%$DA'^GF2ZB+3)+-7M/K#+K'W^PY7:T^">QZ9BNE=*VCY!I==>K>B5VQ;8>
MEZ-8ZV595Q#*T8&<EDIAC^06V,.R:>D`(R2S-\Y<C_B]8/T\\4%,^DL>NN@@
MMM^['PR3&$G]U;;$K-4PA.X=<E)TPH8/%]@+%C>V((ZP:FKHO<M9TXD5I3ZG
MS11%V$<NFB`'%N@LV2#-?7/%E@N/,_$AL=>6LUET1L]Y)9M;\D/&M9B=0RD#
MKQ!JTKFF,-89Z'L"/.T:<8S:0_6\JGQ0.GA(R;N0-O4IHM\6J#1-)1-<-3K;
MP1PZNMV2.V.%I4C)`,FV1=;?3&,2G036697L_OHOT*D!]:'[;6$QF]BU=6+Z
MU1N<J9AP`]F9"OU\\!YMMCEGGF&V0'PD@8#KKXY*`%[-SIGWX\'VP#^-6)'H
M8/CTLG#R^(-:D*S),\DY0_P@)J$]V?D^8.D<R7>;E@G[<</?[[Q"CP[]V&$+
MP*UHS+-OP[R66[IAUIE+Y_"M5@T)-2H2TORE[X9718SM[=,OE%F762(4ZD/,
ME"IA1%^D]]YL@/3;X-\P[G;OZ017=[#4UI,).F"$:N;EU+M]\D=1(=,!=BNJ
MJC-BQQ"O#+,H09-1HLWC8.2RCWW'>2.33''I#/W^^\0H8#\(X.%CXK5L"V4D
MD>U<JGR145Y&Z#H%[7+`VG1YZK9<1GDVHB%S;*9L%L:?L&6E%G3!MF-Z5C?:
MBGN>M46755".FO@`B#:$-H7ULU),TFU#^4:CNB'=7C.E,VODU+%2IV1=M_K;
MO'IQ4613O!HV]_W3'6'M44:>WV=!L$L\#T3E-%;RT@ILE(F37=G6GQZZXE)%
MA6@U9Q7K+0.'XQ$1*V`[*9IIR)U9B?7QW+119I@+R_5P5<]?K<#GWMAX^-O)
M?O'(:NH*#;,QG7:V/*+K1OM8`\J`UO):ID"\.SK@G<=[X7;C(FU[@"3D57W3
M/"N<P_J7<BQ1=HO%&7?6&8?7_P`!P'`<!P'`<!P'`X2[G^'BY=S2%S5Q-=_#
MCW3V][`;3^2T-:&M==W=9M6JN<8WW)(UK+L7,)8T(T=%RBT:P[8ML(X6["=.
M%^VF6*JN:O85JVC\7TZUC58[!ZS&=EIU=BGDQV"W7B]C4'75+V/86O87:#7Z
M/458<)>T]>TZ'"[^A)./0MLS=NT2S`XBY>I//3J)MUO>#UO%_P"&>T8+3M1V
MML;-Y57=S.-<=^*.D%6'A$.E$D$@MT]A3=LAY?.91#CS:*_<8!'>V:A,4+;]
MCNG[M9'!9+I'W>PD`]^[R0TY0-D4/GM')FS2Q/'EJ]H`M),:K%*.!0?6>U?N
M@QLU(9W.<$G9*7+_`+&J+[6329X?PF+E7O\`4X$Y;!^&+*VMC+[VVKK:,Y3]
M^V/LWJ5M54<B4J8)8$7J&>ZK:YFM;$@<CAY28A$;7A]BQ*1O'+U#MT!=LG&2
M72#GO'#/M4(IV(\&]L;4CZXQV!\@\BO$N,K:^X#;"=TZY12?U^=+7C)T)$VL
MFBJCPL@!7]"3VJF;?$5&';UI-.AHW'#I/'%QABXZ#\P\`$5[UAW"UJ6V=D&;
M3;C4_P`<>JS^7)56.2<0<5X[H(A`X],&87.=K)GB%GLV^*[QIFY:IC5?;TFH
MOCWU[`Z7:L:4.-7+_P!V+=#VZ0E\-W)N09?#FLRL+%#G-<6%]'@X;)EA\Y9%
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M*C9O8&DY/"-G/)/,K<MG.\M:+QJN?B==(+7]6U`:UAD64FC;0+1#*;G,3CJ?
M%ELG$G>NI+UD^71;>G3:((YMU@LGN5H=8NPME:V;(41LUEK+M=K*%LV'Q:U'
M],1R[H)*H)<X>.#;'C,RJ0W*H9VZR<O8FQ?"7;,ZS5%N<%.LNG22N2?`J_2/
MA!KRBB59%8]?,R.OX3I[MGK'*R4BAH#(K8LRW%M'*X+.NPBJ')B!H-TUF+MU
MTQ`M6G;9%CFDAZK^!]]0)*L_Q/-I[XM:3\:878$Q#LZ-#ZWLHS?&%<B3Y1R6
MUOET2F(`TYKQ])FXC^.B,22Z5;9D54DL5._TJ]=>[V%?K"\)]N78%VJEMX^1
M6QISL]L?2U/Z\!KTC%&PJG(_7U.5'<:=V_0Y2K*FET45L,;84ES<CY`LO(1[
MUV`=J#TET4<LO>"*:^_=["U*3K&^J!W`B]+[*QR^^[[K"60O4"%L*0K\A*]>
MWNN]P0K#7EG:C$:<BD_C+W)VU6S.-S(YYWFLZ?%'2R[I4+&67X7GUVO:I,7=
MN;:EMR03J!L[IML)*IG`8<L?OF`[/E7$E.F@BXAZ)8T\8@LE[:]@4V;<J@U&
M#6K/+K//%9RN%>:^_=W(W&J7F%422^:5Q)%I%K.O%IQ1OCQUDUH/#HCKE;$/
MMC(=89ZM,ON1<$RL\I!Q^!DH5DJ0E-PCZML&27RS[R"PVV/AC>;'6UMA<<5V
MG,5B;VFLS1"PCT/(U@XF]9.AFD,5LZ+HU?:47$6I7)*W*OMO&R?6%!>9(-BV
M>"FF7O.<<<L.PP>F_@SB&H-T:[W`%O=,[AKW=^^UU!X+'*1BU7PUZKO=`Z=A
MIN%@@46E"X*!Q.K%ZG[6"M!K+IKZ)ZFRQ10P:8JK!,NUGAMH'<N]-GKBNXZZ
M,L]C]1J^U;9`F48&-I)3Y2M;"D-FQ>YJ[L!9\Y(,9D+E91DZ1;>C3;=J"TNG
M';A!11#L*[7]X,Y/M)%["0O?=F236RK-\=%7>/>76GC2@H>4.CJJVC6V1&74
M9$=V4\;OIQ(4^D1!5K@N@V<.<52.&:7Q>F:83/\`Z.4:_(_\A_OP<]9_J5_Z
MCGTM]`L/2_.OL)]BOM3\U^JOB_*_2?QE\V^!\7XG\#Z7V?PG`AZ/^"B!0?7_
M`$DIXI:TFN"/Z-:P^1#7SZ2PC(*"O=B`.^D*4B\E'.S[V0'AM9/@3+K)LU7R
M1+-U<W'Q%ND\<.\<@K-X?-0]U8GOH!O_`&!$;(#ZFH3QB"=#H7EM%"=?*WEP
M<TTNZ`S<'7$#&4%+)<RM2)UW#J]RP(6$35;*R=\02[103P1RPP"V>WG@AK?:
MK8#:[8A"_P"9U;,-DJSK$#&4@,/&ETJ/N6MYWKI+N]@H6NYD0[MU-)((U9B`
M1TE\-GGT/;.L.G.6#QPGF'CN7P*U%:D&O"LP]URBOX/;7CTUF\?H(4'A`5^X
M@<;U=G6,[AL_P=+FFJ$A>&GK9NW(#>T&762."F2;O!13K-,-DMOPOYWA"_(*
M&L3:$H_FGD.*>/:365-150B!#6+RW1(33S5V8`Q5&<*M5V=QEJIR=JL^W*&`
M'$EVBEF\Z0QS4#N5P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<!P'`Y&>>@B0$^'GR`$13YX,(,Z$++-'X]RLS>M5>
MC@+KI5NZ;9IKH*===]]>]CEUW^G@<`Y-L+2'C(N"77'XGE`MXPV%>):W+SVV
MIN&7U.;RI$-:P6QJ:C]%63-4.[`EC.,39D4/'\B[)H2'$EH@Q?YIIH]8?'R"
MT\J\K>]%0BMN:0`[(Z#;F6S"=<M7+ZI3:&%-XS2]'QV9;$W<\JLKKG-<CMZF
M:V+64O&A*QROOF4DC:1O!9#(DIA@NFCB$4UYY-[4O2V]&P%UPZNYW?U.[W;1
MU,?,V=1"5;V54:@#261VA&G@L?75Y6M4G4T*=J+M'18&>)CR`%=+#-@/==Y9
M9ABX)YKO))7E'U#LC;RM`7JQVH\8.W>X]<T_7%(2:MNZ7L?5_J+_`"?,[+G=
MPS$I9T+D`LVX)R-#%L&7:I(9)L,\.DO><!T?\5_D+V(V+W)M[6*T]F=4-MX1
M`-/Z,V#&6[K'`%(4@TG5NR4OT>KR3^EMNT@CAY"1F*#?#X.3)=9MDW7<-T'"
MBJ705G?>77<!78)Y*Q]HZO,JZ4\K+CQ?,?'XXKUR^VK:17.>9UZVV;7FN-QL
MR;R;(+=XR;*.=1Q*,J1;KOKYEBIWZ[H);\"$-F(GQP[=6O/Y='9K8=W;2[S3
M*9S`-#"L2D!^41>P)O7I,W*R)&=S3.0OB#N)]K#\D^F/0L5DV']].LVO;UP'
M#WQVZC[)NM&(!N3"*0):S51&?&'OL0V%O)QMI)+-*[Z/9S0,SC]2(=T6W,/&
M55.JTF37.08NWF".?7;7I-/KM3/#OH+A:]>3K<_1W56M8#:UP:^3B(9>`G6#
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MVK7%*V#*XI8[&9-%U7\82[F>`5!9XVP)F.D4'.>8<2A?DF\ANP$XTPC4TV:C
ME*DZ=\T1K4.SI8/@`^!,KLACO7AC9L61NZ#T]MM.JE]&#67-#'\;:RLZ+>/W
M@ISDN@\#N$"(7I\_)ZJ4K9K:"N-H;:![761K[+8OIS0<9V=(:E4Q0=KK2MZN
MEY#KSMD784`9(B:[Z12%#Q9CYOB:S8+LQ8Y=PJ[6;!4S;/;78)SY(_&#E9!'
M;'.N:0VBH>BXB:KN@KY1I'<;&4Z\%I5>^RX&;1B&.ZZNP3/+"R",H@$$%BJP
MJ/Q\P740P0(9YH!ZWC4V_P!S-:A&I0YQ9E93W6K;+<GRG5`SJ@M5QW&S('(:
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ML+M_XP[8#WF4.`#&M'D/'6MJU&*V)U(ML%=^LDW1'.*_R@DDV66J%*[)L,=`
MPL><YESH2,G6I-RV(.V93M$6'O;L;^[&4[NU<6X@2DIEKM;-6^`B\9Y'J(V'
M<126=")''_(E3\9%FY8)J>PY!$B2)H,XR7;=M#'J<6R^."F2>7OI]!#/DYVM
MWWFFF_E+U'OB[J8E+RNX7XP+@3G=8T+(ZR2)5;NA?(*#S[7Y4&M=TI<*`P13
ML;WB:</'#LR$P*#W;?#YF@N,"PT0\GF_M7;E?C)"HE026ONJ^UM*^/M_1KIK
MK)21BQ:^&UU7R1:V:G?7+OY'=AG=I25D8S*U[`([6TK#EPV#<:F:?%$G>?0:
MKCY,]V]C?'SL/>J6]NFD2DFP'CLWLV&K_6VIX1/(]M;J.O0H$^\1:Q6>Q.UW
M[XX<:Q5@L/>R,\E$7T=E3MJ0%MR/3!5@X"%ZO\DU^4`E)9(-*ZUS2];(U<\)
M]5R7?":0^3_*XCCM><GT3*6]M"5=W.;ZF,;U^']]M5W"A1AF\DRBSM_E@FY4
M9(A<`MY7M]QRJ.L\(N+52X+4$>6[5KQ[M=Y(U2Y<K0]D5[LQK-8%UEC3.IHQ
M>:S-.WZ-E`=H-.,&$KQ'9=X8->\DE5%7/0=A/%!M#>.S%-[##=BS,-EUL:L[
MP[3Z:G[%@L.7KP#:*&ODX2CXNP^H$M(I8G#WTA'OD^UV")%TBCFG^JIE[>^^
M!U%X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@:W+X;$+"C)F%SZ*QN<0Z1,\A\@B<O!C)+&3H_//!3-B9`FFKT
M639Y*)XY=I+I9X=]X]=^S]'7`T.N=>J"IX+(HW4E'T_5L=F'L^K0%<UI"X0%
ME'L:+,.OJ(7&0HQB;]C%RHC^TIJ_P2F6'_=R[Z[#58?J!J77E=S2H(!J[KK!
MZFLA9PXL2KX?2=:QFNYZX=IX).UYI"0L991J4K.DDL<5,GS9?+/''KKOOOKK
MK@>]"]5-7:W`1**UWK=0<"B\!,&I#!8W"Z>KR+`(4?D@G,#(CD2#@XZQ'1PP
M?!*9,GKEFFBLZ:9=HJY9)]^[P/5E>KM,'(%E"(K"HS4;H36LUJRMIS5$/A$4
MF]+1F>#^V1M.H2?TT]8PO%1;!%SDU1:Y#G*[=/U+9?#KO#L*A:&^+Z#:1V-9
MUS+6B<N&V;+@<%J=20N:TIZFHS&*RKXO)9(,`@*\I&%PJ)]')'+)<^+'S#A%
M9X5(J=*]_!_7QS"['XU:Y_>?\COL#2?Y#?*_D?WY^U<%^\_R7T?R[Y/]T?D/
MUQ\K^7_P'I_7?"^#^I[ON_HX&]Q:O8!!H\XB,)@\/A\4=O#9!U&(M&0L?CSD
MA)7SHG(WS@*)9-!JSP^2?+N'JN27>;M=;-17O++/+OL/")K2N0$"3JH%`(2%
MJ]("\BR5;B8J"&P).,$4'#4A'$X>S8(Q[`"^;.U4UF?3?INK@KGCEAWUEWUV
M&E&-:M<Y")Z`'Z!I,X"ZJQ*B^@IBJX*3$]4D@Y'O4:=Z'/0*[/JK$7@EHKC'
MO<^48JMDLNF_O)X=]!6.]O''1MBT@1IBC0\'U$;D)!71Q^_I2BJ'4B\O'UAF
M2QB\`M6K)979FO[/J]JV,N,<0I!GU@V4[P5:JH9X?K!K^N_BLU-IC74GKM9=
M>0?:T)+[KL79&QRNQ5553,Q\PO.TS^<BEDX9U[W#4:ZAB:*_2348Q$C6R`YB
MV22P[RRZS4S"[LTIFG[(K5S3%B516L]IYZ)%@'E432"Q>4UJ[!`\V:@4*Y@I
MP6^BZXD/F.;Y-6V;7M%OV@GVGCC[F/L#1V.I>JPR/(Q$;K/KZ/BC>11J7H1A
MC3-<M(\A+(6(QC\.E"(5"-IC4Y%$P.&+(8]Q2Z<L&G72*&>"?7N\#V[0U9UC
MN\^SE=T:YT1;TI'AV\>826T*AKZ?GV(!H]($FH-F9E<>+$6P=L1+.G";;!3%
M'!9RKGUCUDIGWV&]NJLK%ZV@+)[7,#=LZI>#B-7-'40C[AM6Q`.)5`B7T!05
M'YI0YX+!+J,FRH[IMF@TSR1P[Q3[[QX&!9T'10YO&V@^E:E8M8:>D\IB#9G7
M$.;-XI)YM@12F<CC:*(;!,$>ER9=WB4>->DG#_%TMTOFITIG[P:O-M2]5K*K
M>,4W8VL^OL_J&$NFSZ&55-J9KF55O$7K/%Q@T>1B#'8V_C`!TUP=J])J-&J6
M>'2N?6/?7O=^T)",5/5DBKO[0R"M*_.5-\G&1[[7F(;'2==_(`N33,,#^BGH
MU>-?)Q.8]#MLV]-\%#M!/O#''W,?8&Q2B+1B<1TU#YI'`,OB4E&N@TCB\H$#
MY!'3XA\ED@^%&@A9N[&%1KQ#/O!5!=)1)3#OOK+'OK@0.EIAIXWIQ;75#4_6
ME'7UP6R/N**2HJKDZ<7.Y*8+9&EJQPBV,)5+9+)XY]N<F/:W>6/7?O>WKK@;
MD,UUU]",JO&AJ*IL2.H]1\M2S`96,)8,J@5)]I]DE:O:M0B2$`4(=HX=KY"<
M6G:O>/7O>WV=<#+3&DZ:L0B4+V!4E8SDL<A+FM3128P**R8B8KEZ9:2-Y`"C
MTT*>N2$)=R$>@_5%*Y9L%'J":^27:N&.70>F>H.BI5W)LI/2U2R/*:C8>&F6
M1ZN8<8[EHBO":1J`"I-V0#..SPV#&4,'8=!U\5(8YPQ5;8IY]=9<#'OM;-=2
MEP#]AB=!TJ1OX2QZ&"KQ?59!G=P#1N+/H=B/'V8X!*31FQQ']=(=))O<4^D>
MO<]GN_HX&/B.JVL%?R:QYK`]<*%A,RN-J^8V[+8C3]>QN36HR**9JDV=CG@T
M=9%9PU(JJ99+IDU76"V67?>?7???`_1NJVL`:-2:%A]<*%%0Z:15K!9C$QM0
M5ZQC4LA#%R2>,H=)@36/)"ST59O#+Q5(>Z25:)J.ULL4^LE<^\@]J):R:VP"
M'PFO()KY2$*@%:3!"PJX@T2J>!QR'P"?-<7^+6<0F,AP#,+%9@VQ*NNDR;!!
M![ATY5]BG7Q,_:$BQ6"PB"X'TH1#HK#4Y9*CDZE*<5CPB/826;R=QB[DLQ/X
M"&;/$S*I"ZPZ5?$''Q';M3KK)53/OKV\#:N`X#@<7YAY([&JMYL8?LM@-!-X
M:6V*B>NU)R?5S86KG]Q2>H[">5W"UFFVTKF)6G9.-EZS5L;<(A8KFXZC1+M^
MRR>="B::8;-^9VTGY-_@'Z+7S\G_`)9]V/NI]+V5]E?L%]%_,/F7VW^O/K'[
MA_='_P`,^C^J?2?+/X]]_P!_^)>!'M4^4:U;A@[W8()7M:QZD:=NW5C6#8J%
MDG,M,V9W<>P+'7M2?G:QF;9</&\8#1[O9F/9()/@+M[,&K0ADFH(63;HKAT4
MEN[.KT#N5AK],+7'QZW"DHAT*'14C'IDDF]E=@(!W$,!-I'C'<XHJ0D.!]GB
MWPZ??I57Q2[[Z4ZRQZ"U'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P*0'?'OKK+RTR=SQ&R)]')6/N1@,KR76E-2<#K?O8-L6:7&1JX2
MF5:OX:8ES8\]2:NDG>:T:;.UVP#(4U761S#TO]/6EOA?-OK*_/NG]:?7'W[^
M]4P^]GK_`*`^UGR/ZQ]1Z;Z+^WW[#\E]'\M]5_&OP?G7\8\#SA?';K1&3,#=
MQ<7/HW%H%E2;Y.KA5H3C"L)A)M;FX-"B)Q8<6=F7?4SFU;9Q82N@1=KY+%'8
M<:X*^O6&L,VP87R)_P!'6N7]O_0C_%-6G`O_`,!P'`<!P.+OFT\QL*\.M!0"
MRB%6O+KLVX9H_A=8UPE)TX4*7Z`B<#$KE<ED^0:1.&0.-MW;-+X+9DX<NW;]
M!/KX2?:KA(,/X/O,[%/,A2MIS9*H7E'6?2$P!QBQ(+C*?KF/*CI>/)$H9*(W
M*LP$8<KMS.`(BBNS798+,EV??\(LFHGGV';K@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.!0#R)_T=:Y?V_]"/\`%-6G`O\`\!P'`<!P.>7DF\8>
MK?E3H\71>T(R7)"HS*D)K!IU6YP?&;'@<EP'O!#I]&S)<')@JC4J)?J(/&1`
M<_8..NDE<D.UV[=5(,3XS/%7JGXH*?D]0:OLIP_1G4H3E\_L"T9`,D]BS<NS
M9_+0V!LF!CT2CS87'AV6:+%F/%LFR7:RRN6&:ZZZJ@=(^`X#@.`X#@.`X#@.
M`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!6_7*\"MV_?CYJ#'@_M%LA:%'
MCOE[ARX^;BH#\C]&<>^HZZ^`0(?-LOB)I_P>/N=>[_V]\"R'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P,:N9#M234,Y*C6YA\-*&60E=\U1)
M/`X-P):&RK5BHKBZ<#0[H\Q3=+X8=I-U'J&*F6/:R?60:K]TZQ^E?KO[CP/Z
M(]9\N^LOJ^/_`$K\P];\M]#]0_,?E'K/F/[/\+XWO_'_`%/9[WZ.!FG$OB;2
M0!XFZE$=;2F0L7I,!&G!L:C(#@T;CAF1(!PRCG$B38L,%,>UE4$\TTNLNN\N
M^O;P*1>1/^CK7+^W_H1_BFK3@7_X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.!'+FWJM:68VIES8,12MAU!9%9R=>9'1_P!6X5[$
MBT2`R*9N@N*_;QC'19B="&^;I;%-+)5\GUAWE^M[H0>(WQT[/PV33\'L/6I>
M)Q%U#&9@D-,]O%E5K)=.V599@!2"&9B6M;1>#W"477$MWJ,D4;JXC<W7:>?6
M(>^ZW?U$985DJOL15GP+A'LBU>.T)0R=,C8DE(T86.+.GS7)9I'1;^<.,`*+
M@GFR15/Y?+,<NWW[/P/=ZW-U2^HK)BJNP%6LS50!9U(K(1(RH<,914'5CYL+
MM,F],D%&P9=K5I9Z@SDW;=PM]//%TFY#TRRF&&0214EV53>\=(2JHYP%G`4.
M>=Q8ZL*S72>QV3L6(THZCDE#$$&9F.'DA)ID\]&^;MW';-ZW<=8=HKI9YA5'
M03_G5_Z@&QW_``;P.@'`<!P'`^:3]X"\^4A\/[JD:QJ.DX[;=SW.%/3?LC8A
M,N/KN'PB/DT0>/:K"-NF)^22(Z7S5Q32P=L4&:#;M3/-;)7!/$.@7AJ\G(GR
MS:6!]H&]=+53*Q,^E-2V7!\"V9\(,G<18Q\TNZBIY9F.=DXZ9C4L&/4_CMTU
MFB[A5IEDMZ?U*P=6>`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@?,_MEJCY#
M+&VIM2PBM45S,T[0T:\BE.LSE;W1.S0I"D'MN:12&G=;6T:F-#P6&Q:U;>BD
M%/-<TG<CR1,$I-)R79AD/`"A:P;M]HN_S!_*+\1[$_`KYI\C_'S\87GU1]^O
MQ_\`H;\G?QN^FOKCY'],?^[#UGR;X_O?MOP?DG\:<"*:(U.OJ`P$14UD4#+G
MFR<OOWQOVIKQ;J5>B)&#UFUHH47K%U+Z9D=V#,2$;A9;79G75CLUP:Q/'*7?
M5^;0;T4:%'^:8=$O(FPV2^J-<G_U92'XX?G?H1C]*?;Z>?>WYK^15:)_&^X'
MW-^A/E_U)_"_"^F?B>A_@OB?%_AN!UNX#@.`X#@.`X#@.`X#@.`X#@.`X#@.
M`X#@.`X#@.`X#@.`X#@.`X#@.!S6V;T[/W-LVQGT,&A8,,FOCN\@NKEA7$&P
M#C9F-GU_R[2'[,.G?;3)K*)%B`C]1RERU<==JI#.V>*7OHY.DNE`J,YUEV[E
M%XZR;9%*(3AC_36-TE#U]<X_:]=/G.Q&4?J[:FJK)*Q4M@8&P!I&ZY[V"8'*
MZ3E#\&](.V+W%^W`YY(9JA'>&B.WPN#;O0["!,R;[R<U994))EV%IQ?!GI`<
MM+9#=2T%')94DL.(28/"H1MVB8;*0U`NNO8HDHIBDDS)HD40]ZR]"-M+'K>K
MZ(8Q,:`0U+LW8.Z8O;1>S`707:YW)K<*SZL*P,,0_P`VFD<&VF$.*YV.X/#D
MFK`XV2]%B=04R=)!T'JJF+_EKW<&T"9F7:@S+9&?50]@(T2O45IS>NXW4]=P
M*(OI3(V#QG9=,K3:R7(8D-<H(]FTVT=;C%.G6#['X+(,!XQ0$CBT-VTCTNG9
MBSI*)WPV+:&)\?#Q<`9E+S'.(Y9%"`:%!8[%1SA3'+K'M-BR;(==8]=]8>WO
MOOL.F'`<!P'`^*K]\FLK4J"4[J,`M_65.Y[_`)Y)+15J&P\9E(*^^V<%A2$&
MSL=F4*1M+)U,6\F)2\/@U#K]](-U$E7GQ4L\.DG82U^[4^8?QKR_6JG]$8S'
M8#I?L:UETF`@J*^8SPV&NTV\:L3JMF`+6EHIT-)RZ=NG2K/$$7.KGNG(WILS
M359],<.@^OO@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X%`/(G_`$=:
MY?V_]"/\4U:<"_\`P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`Y_P"@G_.K_P!0#8[_`(-X'0#@.`X#@?*1MKO;^[P>
M:&[(7XX[XL@E84_!VD^CE)V>`'SN!1G[M/E6T:>Q>LKG9-T1!;&;N4L1Z&+Q
M!>.'W+=MDU4<+]#%L@Y&:B_N?^VM$>12G[5F6PU+/-6:&OF'W$#F<9?3#JYY
MN#K.7C9K$(]W`G$3:1^*2:0/`[9H3<?/7+47AFLX;9/LDTD%0_T*N`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@4`\B?]'6N7]O_0C_`!35IP+_`/`<
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M#G_H)_SJ_P#4`V._X-X'0#@51,D-X\3!7&/1'5%<!B2?8@UC-B6\U,+!^G2O
M0U4JV8U>\9-R2C+W.UTT554L%>\NL,\L>NLNPQOS+?O_`-C=/_\`XEW1_P#2
M;@>B3_.\R-("",(U!7'E6+L:^1PM*[VV:S-\W4:NDL7#6JT7+?)1!7+KK-//
M!3#OOVXY==]==\#XN==_W.W:&B-KZGO?+9G7N302F;@@UO1Z&9*V8.D4A4@,
MP%S`/$3IW"!+LA[-5<6FW=$6R"BSA+K/M-NVS4Q[1#[(,+:VW4FJU;)N]"U+
M%;L^B*\!PO2S,IJ@/R;)/.GRT6QK7LXFS[9KX*]*Y(=8?#SQR]ON]]=\#=/F
M6_?_`+&Z?_\`Q+NC_P"DW`?,M^__`&-T_P#_`(EW1_\`2;@9Z+O]U%)&$PFL
M5U=:1+(DTQD;F+S^V"$C0#]JX^N5",2U:#!CHE@A[>TDUW"*66?LZRSQZ_3P
M+1<!P'`<!P'`<!P'`<!P'`<!P'`<"G%D;ZZVU--S]>34E<:,HC+ANU+I1O5?
M:B>A,%G3%J11Z82Z!4O)HB:3[:O$^\LV3YQAAG[R>7?2F&>.(67@$[CEFPV/
M3Z(J&%HU*1^!0.H?B\HA1G-FHHHGCV0BLU#1Z5`W'OI=^U!\R;+]=>SOO#V=
M]=]ARXV%\FTSU>LPO"K8H6)L^C<7OB4U%#15Y,WEQ2F/5"N3"P&;RX`E`UJZ
MBD+V&ES=HP#X-I.3.1Y`FQ<E1V.61AL`#._GAL%]^/PQ^PU)_E[\/ZZ^4_D#
M-OL=]A_HGY]]ROKW\??K?YY]?_\`A'Y%]-?%^)_&_J/2_LO`TRM_*C(K8C.%
MR16BXRSH*`VMK+K[L07.6^^3M&N[OV+9TDL8`P^&#ZO>1:>16CG6PT3Q+DU#
MXS(VV=D%AR/Q!B+8J$K>1.SJV]#KE6?W"@_W(_/?0AW]O_JP#];^D_)BM"?J
MOI3U_P`^]/\`+?VCW_3^[\#^$]ON?IX'3?@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@0_==SA:,BH^6G85<$[:$9`UCJ8BE*BGUSRI
MLY=CBI/`D0B]=`SYMA'T4A&:2K]5'%JDY601RSZ472QR")M?-TJJV4ED@A<%
MB=ZQPS&0JATGE:]#VA4PWTR))F*5:,RD[C@5D]+8.WN/M:)YY+])XYY^[[N&
M7?06YX$"[06;8-,Z_P!M6M5\"`V9-*\@LDF(N&R:9+0(&5PCHAV7>]D),WCL
MJ<LT6S1GFI[B;)51?W?AX]X=Y=9]!0*R-][Q90^1RVLH75;O+7_Q^4_Y!=A`
M<OQEG;J<QFW&ESNPE1T^0&&6+2$R!=IKA,5?GIG$\V;K_+&RC#+!RN\;!%$]
M\KECU[6$<V?<0&MY/0%^6WLSKMK+$&"LP`V<I:M'A[_(5K(;0ESU4K'\('>:
MFMA_-P@S`,W\.:O!_:JA9?-P@W#HCKI<]I2:SKWH&\4*]=6A2+6IY9W*JJ%R
M4!"I9`+H"R5Q&'.,;EIZ5F(](@<H@$A&.T>RCY)TV9M'^/;?MYDR:A'F@G_.
MK_U`-CO^#>!T`X#@.!`^Q>T&O&HU<KVWLU<E?TA7*)1B#PE5A2%D!8/SI+I;
M-@"#I.,_6G#CI!JLM@S9)+N>VZ"JON?"24SQ"`"_E*\=0+7T%M45W,H!MK[)
MY(K#8]9N-@"'(8O,F^*:KZ'L6;11<VM+!;97%P\&]-?6LFO?QUTDT?U^!_FF
M:[^+?RM[!^36'[$T.SE%F`9+M>M;0+R'P"9,9=1A0"RL]8N6M9K;PXQBS=N&
MXI);)W&5\T)(BOBH(=C4'N"S-,/]:K@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@<*_+W8E>16X].8K;-B:HQ"!RR%;3E%P.Y^W<SU+I>22.*D=;$P9)@9A+9^[
ME%E1QE(W^`SI\AV.9#2!/'O/%V[9]9AU$U"=Q-_K13CR"D*?*Q!Q#VR@`C0-
MH$KIIIVP[=N^L%:]M0PW:DYO'^\^LNL'JR>&>2G6>/L_5X$"3_QO5-;:I49;
M=I7Y9M=?4EU3:!55+I;#G,;IR<7Q%K)ADQEU8S(=7HV[&)0)'+@DK6,HE986
M'Q9N3Z1%-FJ+(<FS!_IWQCY_]T/R.V3_`"3^I/G'Y3^IH'[O?3OT']NOMC].
M_8#[!_;3Y'^T_+OHGXOSG^-?C_,?VG@>K&/&714(7B8J%S*XHS580U0TQF%'
MLY%#B%<W'96M3:&(5-:5J%#\",6L2G0U>M(PX*K"I,(9R->/,NRS9[ATO@N&
MN^1.L:V]#KE9GV]@_P!R/SWT(:?<#Z3`_6_I/R8K09Z7ZK]!\^]/\M_9_<]1
M[OP/X/V>Y^C@=-^`X#@.`X'-SRJ>3.G_`!0:IO=H+?C$HG2+^<1^KJ_@$049
MLR\WL63C)">&!,S)+WAT>%MH]$BA!X^6P6[2;,L\4D5U\TD%`J1X5_.W37F0
M$6N(`5%**!N6F6\<,RZMSDJ8V""(Q.5*OV(V1Q">,0,16+IL2PQ5L0;NPXY5
MMDLVR3^/BMG\$.[7`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P(#VK;
M$GFKNR+0,Q,$S#J@[A;"AL>*E@)\@27KR1),6(,X`'ECH8P[=98IMG;)JY=M
MULL5$4E%,<<.PY:^)]C!VLD?Y1I+5A$IW2X3!^E2OAMV'\;%B)I^OC/:J<UL
M>V+4F4/F#?!QUUTYC@T4.5Q?=8ND_AH-LD>P[C<#5YO$`UA0N7P&1X.%8].(
MN?B!Y-HODU=*!I*)=A2F#9UCUEDV<9L7N?6"G77?>&7L[_\`1P*I6)H+0%F!
MXI'CW5C#0(&G0VO$G#Q2RI5%!MO4,"ZZ]'4EP-`CUHC-(CGDHYZS]O2#WTY(
MBTQ<8LB9!LZ#'FO';K1)C,\=R@7/I)%I[E=CY2KBMH3C.L(?)MD6YQ"]YQ7D
M6:&6G4,FUDYRDLNN1:+XK"W9@DX%>@6)/\W(;>#U86K2!6B+I.WY]%[@M4U&
M#AZ_K16ZOB;*.(LA'@0UBY&35VV"+A64(!YBVK)#!JV;JO%R'>"A!=RX<!`O
MC%#2R/0W;0).II]Q)<-WPV+;'YO].#8C]2/\<XCEF2^F@ZJXP/\`$PRQQ^"C
MGEAU[OM]OZ>!TPX#@.!\T'[S)XE]G/*=KQ0C/54K%7]@4#84MDKZL)?),8@R
ML`).`8@,J["2!_UW'6\JBKD*GD@B2S9MEF3UYWBZ35P30<A\LL@_=#/)ZGIK
M`SPZ4UR9OYI;4V,'=5,K'%(QZ/0B3QR#"A\N#6$\<-H$I9*Y.(J)FF6*^31<
M3B.R1?Y+ME6V0?83^[I>,J]_%MHD=I[8^2A7]IVA=4DN@Q"XH<^H8M6;4Q$8
M/#F$6;F,4$F961+MX7T\*.6>6;'XKC!!')7IOVY<!WPX#@.`X#@.`X#@.!Z)
M(F-#,'94P08B1;!'-R^)$G:#%@R;I]>W-=V\=*)-VZ.'7_;EGEUCU_\`;RF3
M)3%2<F6T5QQ'69F>D1'_`#,^D.3IZ>WR&U32T,63/NY;16F/'6U[WM/TK6E8
MFUIG^(B)E^CB(\NQ:%!+]D4&/VZ;IB1'.D'K%ZU6QZS1<M';;-5NY;JX=]=X
MYX998Y=?IZ[Y-+TRTC)CF+8[1UB8GK$Q_6)CTE&WJ;6ALY-+>Q9,.YBM-;X\
ME9I>EH])K:MHBU;1/I,3$3#W>6<<X#@.`X#@.`X'*J_(!N5E<<LE.OU1'HTS
M6?#\FMC1'?U[&DY:/P',?FBKS5JX=9KRUU"&G2O2K7-TFS3)N<44U?F3?/+'
M)$+QZTV0[MVB:SL,DX?+F9%'<,I`D6`BXP;%R86\=A9-'I$#!2281YE)HR?'
M.1Q+Y83>BU7[591FKVUS2]@3EP'`<"@'D3_HZUR_M_Z$?XIJTX%_^`X#@.`X
M%!O)-XYJ"\HVL1G5[87N3#8ZK)@L^ALRA3U@QF%>V)&VI8>%EL?4+CBX=PM\
MG/D!SMNZ:JIN1I%RECVDKFFND%6_$/X1-9?#Z!M#.H)7/K4LRY,@+6=V=8N0
M=N^[CT56*N(_%8P``LFHV.A471A9PZ[[S<NGSGW,E5NTT&Z2(=G>`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@5<VWK.;VI6P>/U_5M%VK(F,T'FDF-
M[S>=UN+B:+<#)&&4U@$ZK2"3V;Q>S!BY)-JQ=CTASA)D]>=X/4LO8FL%<=2U
MMA:LNYW1&PY)TW[DU2R2S*EC\?V(D.SL(["0F9PN,V!F2G-S457VR025`7UA
M@<6V!Z4RH86:$E\FO;95@NGT'3'@.`X#@.!S_P!!/^=7_J`;'?\`!O`Z`<!P
M'`<#@/Y/OWC#1OQ97G'=<K8C5S6Q:ST"&ELS!TT"B)%O6T:D&2F8123D9C,H
M@T6D1E@EV\;#&G:RG3/)-9?-OBNW^,'8[7/8.JMK:,J[8VD))C+*IN"(C9G"
MCGI5V#AP,(8YX*-"0YUC@[%FA#]%9F^:*]=*M7C=5'/KWL.^!-7`<!P'`<!P
M'`<!P.3_`)@]8-@-J-:0<.U_4[+EH[8`Z52BO.CC&.Y3P$U%E&B""#\H['B7
MCN/E'2+U-D[7107]SM3#O)R@W3S\[^2^`YGR#@J:O#?=DIFB]\?=%?<K$3'U
MF8B9K,Q:*VF(GZQ]T5B=W_T*^9?B[X5^7]GG_E&/8T=OB\FMK[WLWS_A9K9,
M=K3-,=;Y:5SXZVQ6S8J6O3K%+1&')EM7^_#[K#?VJ^LIJ&;`9=AS,AL(I*XS
M7_9UE(LH*`>"1#-5LN\%NR`AB[.E6:[U1FS<+(H_$Z4S[Q<K.,,)^->!YCQ_
M@;:O,_;EOFF]<?=%O;K,5CIUB9K$VF)M-:S,1UZS]TVB*_OI\R?%_P`U?,.O
MY!\71[_'ZO%8];8W?9O@_,STRY;1:*9*TRWKAQ7IAKERTK>W;-*Q.''BM;J[
MST-I$<!P'`<!P'`<#@I:TXH&2;*F@-M;,W'6QF5;ERG7LU%HCY$+PH<%"8'&
M-29+=XJ<]5['+6!,(ZG()##6X7+MBF);*+%L7":GJN^NE@[/TU':KB%50"*4
M@G&TJDC<7%@J_P`(B53/1[J-"F^+)AV/.IO2>1OWL4.^U7BKEPX=+]YJK*J*
MYYY]A)G`<!P*`>1/^CK7+^W_`*$?XIJTX%_^`X#@.`X%"/)1Y#Z5\7^J\HVI
MO)A*)``%'`<-BT-AC-NYDLXGDG[>9`HR.7?K-!`I/-H-=NW3QXLFBW9M%<L>
ME5OA-U0JWX?O-CKOYAXM;KVIH-/*GGM(E(VA.*[L!8*0=Y1^:)&,HI*P!T"X
M58%A;]S'G[9PGDF@Y9N&_72F'::R"JH=F^`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@<VO)+**6C@/5-GL;,%H'1<LVE7CMCRI*TK+IS`:R0U8VBE,
M8Q<3FK)E!S[)%[/HR(;](N':C)RHKCADCDKVCFF$2^*J?:.3F))GJ&D5?EMC
MY;788O=`]C:%FVS806/A3;QL-".3USSVRK#"PL27/]J(#.RG;))X^S5Z3^(K
MEEV'7_@.`X'AZ<-^W&33I='MUBCBXR;=*X>HQ;YYYI8+Y(^]\3I'-1/+'K+V
M>[WECWU[?;UWP/&R?,B+?!X/>-7[13)7!-TR<).FZF:"RC=?'!=#/-++)%=+
M+#/KKOVXYX]]=_IZ[ZX%"=!/^=7_`*@&QW_!O`Z`<!P'`<#Y</,)^[$U?Y4]
MHF6UX':.1:V3XO$8Y$;0%95(SN"/SC"'-L14:/"$E+)K1]$#R$=P38.LLEB3
M1PDT;9X-T%<5\W(=]M-=5:YT@U=I/5"IG!I[`:0A+.'A2LC<-W4@/..G+LJ=
MDAQ5FW9L>BTED1)V_<8-T46R2KG+!%--+'##H+,\!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<#C5-#6JLJN??8!LE:VKM%3F-DH=':\SLV!:M!YW7D&;TE$Y?\`
MDGB:NZ-2'.U&LSD\P?M,B!3%]%A[:))"<&S8DQ-J.`OSIA)R$TU4H66$XW&X
MJ[D%;@"G8Z'0]:O(D^;.D,LV,IC%?NE%WT%C\W8_#-,PSE19T+;O\&RZBBR6
M>>0<([H@F-JS?;(WKI"K"J^S(ZUW3"DGZ,-MYSM=N@YDA<P.L&+9V0A"@$5C
MM(QR(AR+6G!"<E(DW2S.-N&&0--HG@0#)_;&G_R7^J?QAF'^DE]0?"^Q7X:7
M)]O_`,IOL;Z+[M?BM]J/J#[<?(/X@^:?2OR[[B_K^[\U_:^!H=(4];HH!$!U
MS4Y;Y#>)6\/'8;TXM.14[9TFD5.:;183J_A9E>RR_.P1:/5N\A(X!:R-JAR)
M]J\,]'$VSSHDZ-#4G0=,_(G;$\^J-<JI_&2\/H3\[]"'OY+_`#_6W[)>I_(J
MM"WRGY#^0?Y'_,/7_P`6>]]O_2^N_7^-Z/\`:^!UNX#@<U#GC.CYPT7-9[L>
M2L7F8*$"F0P'NO9HL*.R(.U7>3$0,0_@!PMIVM\-NAA^HBECCAU^CK@8O_2Z
MCO\`YYO)_P#WYK2X#_2ZCO\`YYO)_P#WYK2X%;-L/`?KYN13AFF;IVR\A<SC
M[EXWD$>QG6U4DLD/&9J+:/VH&6)1&<"C$<)O!:9)=/O!9'K+-NX5PP42SSZ5
MP"$]#_W:76/0J/2M.LML=YQ\]GSAIU.)U6EY.*+ZD`<,JZSC(!Q'JY&-$%QX
M'M^X53S>.7J^3EVOGCG@GE@BF%__`/2ZCO\`YYO)_P#WYK2X#_2ZCO\`YYO)
M_P#WYK2X#_2ZCO\`YYO)_P#WYK2X%[Z9JYM2]:QNM&DZM"RF\:^<?#FMS3DK
M95E&OG!\H?S^I)J:_C,U\NS*]M&?Q?\`U9@@@AC^HECP)0X#@.`X#@.`X#@.
M`X#@.`X#@.`X#@.`X#@4PW6G4@KR-TA(<3=F12IDM@XIEL7,:G!$3TGBU0C8
M38L@'O":0*.RF3C*_,W,%B`B4OQK3I9C&R3Y59RR98NGK<(]U[O4-=NUME2&
M@;6F5SZXG:I&E9N7=M"+^EJ_NP$:`12(QVA)L\!,F9A]+X6R-NYT%8D'[($0
M&"77PFCPT][<AT1X#@.!PXVPUHLQ[=GD:.4[#;8-N[O\=%2!LGJTCL20#)])
MQ-O;'*V!3-6FY=(G$8A4HD%8/4V+4(#=!VH]P;;/.\&N3GU602_K(9KRAC.Y
M=[0:BK>IK4(H^U[0@M6PK3:_0$Z-V6*C/<-M.P(3J3"JA5O10*1:&H>%<N6<
M/31S^EWQ'O'M@W6(9AO'C%G`6RH;MI.XZRF`X))]\-BR8UC/Z]GU43)LV4SB
M*>*<AKFTHS#K"B)#K)/OWFA86R=8X]]9=I]8Y8]]ATPX#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X&IR2!0:9.0KR7PN)RMY&R"1:.NI)'`YQR`*H
M=]]HDPJY1FZ5%D$>^_U5D.TU,?\`T=\#;.`X#@.!0#R)_P!'6N7]O_0C_%-6
MG`O_`,!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`
M<!P'`<!P.?\`H)_SJ_\`4`V._P"#>!T`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.!0#R)_T=:Y?V_\`0C_%-6G`O_P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`Y_Z"?\`.K_U
M`-CO^#>!T`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!SZLGR
M"1BJ;$VH@TQIRTA+/5_7V'7QU(WF4120NG">2NPH3&(A4X]*1.%EGQB50/H:
MW=FE`Z&;\@GAEBFAAFXX&D_Z@%A_=3\6OQN%_F1ZSYU]H_OBP^V_V?\`H;ZS
M^\/WB^W/S3Y'\T_\*^A^E?6_5?\`!>[\J_CC@:[!/*=&[.%C+*A5-GG%`@9]
MKE2]Z6&;FH$3,::O+9=I5*T=K]2N&C`PRE[&L7=Y1-":EDC[)(7\V[6'HED&
MKI5()>\B?]'6N7]O_0C_`!35IP+_`/`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<"'[\N>.Z]U%-+?E`TP<'1)F/Q91J.?*_J
M282>0FAL5A4(C71PF%"]R2;3$XP$C^GCQHU[>/$_BK))^]GB&ET3L*XMM>W8
MM+:X.55:E&2@5&[!KQ\=CLS4R;26$`;`B,JB9R*NW"$@B\G"'NVS=15!DZQ*
MCGS7)OUZ?%14/'J[LT#VEBUA2L#!+`KM&O;DGM-/P%FAT8[+E2T`4&HOR[N/
MX.7;@*S)J$>LVR#G+%WTA[N2R:6>7:6`0OH)_P`ZO_4`V._X-X'0#@.`X#@.
M`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X%.+FTN@5YS"\Y1,)))&J%Z:
MR1/6@HQ")B6[V),H7-K.GL>L:)E"3$HBWG`2163ZICDY:N6K9T+;*]I*?KX=
MA#7^GL>^X7Y$_DU-/RX^:>F^_7VSJKTWVP^A?H;[,_;KY!\F^@_C_P#B;_UK
MUWU?^U_'^7_Q5P,-"_%O7M<-`<&A5N6"-HUY,M>;6N&IWP&N265WW-K0TK5&
M&69+9KU$F9H:2GCJFHHO-FK)/!L?[`-T4.A[9<@B]#5O(G0X'ZHURO;Z^N_Y
M[^=^A`[Z"^]ED_9+X?Y%5H!]3]E?J'[<?,/@?M'J/E_Q?7?M/O?&_7X'6[@.
M`X#@.!\<V]W[W)6^F._\^U*'ZE2"TJKI&>)UQ<-LMK,;1J8Y2(=E@VG65?5^
M[A[X46;PM^IF@AB0,L>C*[53'K-DEFFY[#ZRV5TU(]7@K'JR(2S,6:!$R:`1
MTI)PPJ32T&<;>K%D`,<(/6QHFB[1Z[]WX*&?ZV&6/_;CEUT$G<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"%]AJ4";$4Y-:@/%RD<0E+<2[
M$RD&FQ7-0^81.0"9G`YH(;%6SP4[*0V;QX>4;HND5FJRK3'!;#-/++'L(RI'
M7:?5;+IO9,IMT+/K&N.?,)9=!MK5V,0#FXY%*N8UO75?5V"PG4@=0`#$G0I,
MRJN_?2-Z0?O2./:B*+EO@R#U`.KTJA,(O6-UI?<LK2475L!,KW3L.-PFOC9N
M&JS1\!<DHFP"6,%G<1,,\FH3)MD[<L/C=X.,LD\$E,<<N!!_C%`2.+0W;2/2
MZ=F+.DHG?#8MH8GQ\/%P!F4O,<XCED4(!H4%CL5'.%,<NL>TV+)LAUUCUWUA
M[>^^^PZ8<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`H!
MY$_Z.M<O[?\`H1_BFK3@7_X#@.`X#@<%=H?W;CQ>;=[>NMS;;KZQ.I[(C@F3
MV5`(G/OIVHK;D8OILFJ9G4:3".3Z3PXV9))D^@I8.D1RQS67PS<KN%U0^1GR
MZ>"SS!7AY@K?M&F*KE%APFWK;B\LI#82/3$+'895<*32#,X4+-&<#+0]6OV,
M9"TV'>*;3%S\(7@Y'IN.UD/B!_I60T:="Q"*AY0<^IY,)C8,;(I+Z7!C]0G6
M`QJU+G/1)=]IL_FQ!)1Q\+']5/XGN]?HZX&R<!P'`<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`Y_Z"?\ZO\`U`-CO^#>!T`X#@.`X#@.`X#@
M.`X#@.!$-LW]2=#MPCNY[3@]8-9(L^;`%YK(1X!(PN,P;*D$1^;]9+IRHS3>
M)9*=8^WO'I3'V_\`;USK>1YCBN(K2W*;&+7K>9BO?:*]W3IUZ=?KTZQU_P#+
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M].G7W._MZ]O\=.WKU].O3[FPMO\`5GYI'RC7QFOD&*?CB=&=F>4_#GW8O&7V
M_P`+\7\B:SGF)B_N_D1C]OK?M[H]F?YDO[P;6#&C83-XW2[\O<,BD<@`R>JG
MLY;LA<,:1U`&[ZDBLK1C3IZ8$2=$]@F,ZZ&-LLW#1[@IWCTUQ[<1G^9="G$X
MMO!JS;D[WM6^&<D1%(KVSW=_;,VBW=TK]D>L7B?[?NGB/]67F6S\D<CXYR_D
M.+!X#J:F#-K\E33M?)MVSSFK^/&M.Q6F++KSAFVQ/Y&2(QY->U(M[TQB_JQ?
MW@ZK05:53)J_I4C+[`F;4D]G\!+3QL#9UC\I+K"^QJLD9Q<RM(GI[%KDY8J=
M,&>&+%5)97'%7O)KC.[\S<?AT=?/IZMLNYEB9R8YR16,72>G3NBENZ;=.M?M
MK]LQ,^OVJ^)_ZLO-.2\OYOA_*?(L.AXOQ]\=-+=Q:5LUN0]W%&3W(U[[&*,%
M,/=&/-$YLLSFK?'29I$9I\EO_O!E4Q-A5;JJ::)V0YEL6'2BP&)B;-HGG`'J
M[T@.?0?%5I')+\UD314?VOZC+!!MZ15#/K#/M;+%%R7S+QVO37MQVK;/;)CB
M^2+7BGMSUF)Q^E;=;1TZ]?2.DQ/\^E?`_P#5IYOSFSS6#S?R##Q&'1W<FOI7
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M7QX#+(N68'XS*`PN11TZ*<IO!9H$;8H$A!8:[1RR1=,"(]RFLBICWWCFGGUE
MUW[.^9+@S8=G#38U[1?!DK%JVB>L6K:.L3$_S$Q,3$_T>#<MQ7)<#RNSP?,X
M,NKS&EL9,&?#DK-,F'-AO./+BR5GUK?'>MJ6K/K%HF)^C,\^KKS@.`X#@.`X
M#@.!0#R)_P!'6N7]O_0C_%-6G`O_`,!P'`<!P*';X>3#2SQJ0R)3;<.Y6-9-
M+`+/0L"`M`$FF4SF3P3@R6.K`8C#A!LXN)CK<DWS(/U$DF+3MR@DHMTLY;I*
MA..K^TM";FTG#=B-:;&#VE44[;NE0$H$(D&.?3D>Z58%0YH(:9C3\<D`=^AF
MB[8/VS9VW4Q_73ZZ[Q[["P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`Y_Z"?\ZO\`U`-CO^#>!T`X#@.`X#@.`X#@.`X#@.`X$(["
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M=O\`;_\`7KZO;9_=W]C9^2X^4_\`-U_]@C1_"]G\?#^'^+W^[[,ZW9V3_P!O
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M$18)(!@)\S3?(`P[))FBLGDB[R9IIH*+9I))8X.1^/?$^4V<6SLZL1?%2M(B
MEK4K:E(B*5M%9CKVUB*Q,=)Z1$3,Q$1%?!_W7_8_X^X/?X#@N?M?6Y#:V-FV
M39PX=G-BV-J]LNSFP9,U+32V;+>V6U+1?%&6ULE:5O>]K=!V+%F,9,QHYJW8
MCQ[5NQ8LFB6"#5FS:)8(-6K9!/K%-%NW03QPPPQZZQQQZZZZ_1S,Z4KCK%*1
M$4B.D1'TB(^D0U8V=G8W-C)M[=[9-K+>U[WM,VM:]IFUK6F?6;6F9F9GUF9Z
MR]KEGQ.`X#@.`X#@.`X'&>P;]O<==5P6`,N25"V-0^1G3G3*.:N-@E6J0B:U
M)?@O5!"P)D?<OX2]M1Y-FPS8<].FA$>=:-V8F&-F>#7%#HVH_#<?(K:TR?N*
MPK"$ZP;46@^KG:?42YCDLKBJ,)#!'<-K2Y()9<Q^22)20L>B1@7'A2Z?;7I'
M#+)XGVCUW[?T\"9_S[_J5>0#^[C_`#RX#\^_ZE7D`_NX_P`\N`_/O^I5Y`/[
MN/\`/+@/S[_J5>0#^[C_`#RX#\^_ZE7D`_NX_P`\N!\U/[PQI'/_`#!"*"F5
M(T;NA65Q4,G-8^W"VIKE)L:SE\1G:H$B\S6)Q4W)S,8D@4K&TNTUD!3O!^W<
MY8+=X=MT.^!;KP'G8-H7XX*TJN"TMO%L,A.95,KAD5K0[69ZQ@AZ3RMRR!/6
M<$:E)8B8^F0(^)M6."SS'!P\<MUG.23?I;%LB'9S\^_ZE7D`_NX_SRX#\^_Z
ME7D`_NX_SRX#\^_ZE7D`_NX_SRX#\^_ZE7D`_NX_SRX#\^_ZE7D`_NX_SRX#
M\^_ZE7D`_NX_SRX#\^_ZE7D`_NX_SRX$0VSY*+>BC<(I4WC*WMMMP]6?8&VY
M*OAM;8@T4,&V3%9)<B_D.);M]FHKCWAATEVC\+KOOO+W^O9UO([/):]:3QVM
M79M,SW1.6,7;].GUK;KU]?Z=.C._!^#\$YO+L4\XY[-P6+'6DX;8^/R;_O3,
MV[XF,>?![79$5F)F;=W=TCIV^M9Y[YB-J8+#))+91XE-HZW"A!+IRXG-C'!+
M>#1QPICZ88^DZH@$N1Q$Y%%T4U.DNL,LO?ZZ^(EUWVICBO-^3^0<)Q6;E-CB
MZ>UBK$STV8MTF9BL3-8QQ,Q$S$VZ3'V]9ZPV)^)?U_\`A3Y7^1>+^/N&^0-F
M>1Y'/:M:WX/+K]U<6*^?)2N;+O6QTR7QXKTP]U;1;+-*]MIF*S7BO//5L,;I
MZ;S8EI`_GBL)453DML5R7,B:8@'9?%%"(XS]B80DAYFH_)9]I^ZV(J>H_5]O
MI>LNL^8;QGRES6YP.YRM^/Q7G3[.ZU<EJ4_[)[:?9,7M;MGUOTOZ5Z3Z=6TG
MG_\`KR^*_&?F+QCXYU/-=_5IY/&S.OK[&GBV-F?P<7O[77:Q9-;#AC+CGMU9
MR:L]V6+4CW9K,$#\]6PQ>F9O/"FD#^9]0U7-F=N"`%S(RDH,^+XLVD4;3QD4
M0D)]FN]*N\<.L$27?3GXB>'OMN\^L^W'_*7-;/C^US&3C\5_Q;5K:]<EJTB<
MD]*?9,6M,1/]W2\>DQ].J?-O]>7Q5P/S3X[\8Z?FV_K3Y!@SYL.ML:>+/LWI
MIUG)LQ7:QY-?#2U\<3[$7U;?=6\],D5F&J`OWB^QP\!CZ\]T\=R"53"1RN#Q
MNQ(&;,B:?^M`E?2&S$0IE@4'2<\P>,8=%R!%VA@26]YDTR4^*W]_'V?7B_D_
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M1FR8=;#MZ6+:S7R:T4OGF,^'+J8L=;UR4I@B^"9G-:*=UYM$1L6NGG`VCML"
M?Z&>.Z?[%R"/$T?G)'6A^Z9`HX,+X.,@#61#9?C)'#0D]['NOAJX$,L7/2&?
M?2*76'?O=CX?Y_S_`)/CS5Q\=AR9L,U[K5RSBITOU[8Z7KDF;?;/7[O_`(A@
M_P"S_P"E_P`,?`&[Q>?<\WY+1XOE<>6N+%L<=7D-B<FO[?O9._5RZ=:X?^['
M%8G#UK,S$Y++7PWRD[1F)0%&3+Q![OPR+O'N*)J4M6T?E#@(R[PS[R>I1]JU
M&N"N>.?777PL%TN^_>]OO?HYGFKO\_EV*X]KCZ8M>9^Z\;-;S6/Z]L8XZ_\`
MCK#3OG_#OAC0X;8W.`\UVN0YG'CZXM:W!Y]:N:_6.E)SVW,E<<3'6>Z:6CT^
MBT?Y]_U*O(!_=Q_GESOWC!^??]2KR`?W<?YY<"]$>,?4(`&?^5F`?SP.,,?)
M9"R^6GQ'S)D@]^5G!WQ5OEY@?\;X3E#W\_A+898^]W[/;P,QP'`<!P'`<!P'
M`XG;E7K;T3M?;`Y'KEF5=GM6:RU(F&O='@RL-8QZ_P`_;EBS<432E(8W&"9N
M9-;KE81.M&3=-?OH2Z8J.1OP"B_2^`;1O?<LT'6/;X89L?)M<XG2.A5I[+UU
M(X>9@K,?/;FA\SD<=D:DJ2E<=.IRT#1/<9"($`'2G0]VI-OAD$,U\&&:(0Y1
M&Q>Q4\EVNUG2BT)E%;FOG>';+5VT]12KV(EH-3M5U)`]F2$%)L89U'!<H$R*
M+L*CA4X=&7+W!T5;3%0:Y6S;D`V+,+EZ8VU<K?6V]97;!2=;/6+5^U.WT!0P
MA,9A4>F$R!5ML'-H;%(_$8J_D$6APO$7'AJ#=LW<E4NL4$/:JY55[RSS"G.B
MNY%BCAFUI7#0#=LZUE>]&SQEHI&@^MSQ,9\ME[6&/P9G(MLF"4;R028BCE)Z
MBA@Y:)*]>ZBY<8>Q7(+T?G#8O^W)O_\`R;U9_P`UW`?G#8O^W)O_`/R;U9_S
M7<!^<-B_[<F__P#)O5G_`#7<!^<-B_[<F_\`_)O5G_-=P'YPV+_MR;__`,F]
M6?\`-=P'YPV+_MR;_P#\F]6?\UW`?G#8O^W)O_\`R;U9_P`UW`?G#8O^W)O_
M`/R;U9_S7<!^<-B_[<F__P#)O5G_`#7<!^<-B_[<F_\`_)O5G_-=P'YPV+_M
MR;__`,F]6?\`-=P'YPV+_MR;_P#\F]6?\UW`?G#8O^W)O_\`R;U9_P`UW`?G
M#8O^W)O_`/R;U9_S7<!^<-B_[<F__P#)O5G_`#7<!^<-B_[<F_\`_)O5G_-=
MP-'C7DJ?3"4V+"HWH'ON4E%3'`<;L,0E$]9TEHR;DD0`ST(P=+.=I$&KI0A$
M9,P>XY-E%L,<''6.66*G66&(;Q^<-B_[<F__`/)O5G_-=P'YPV+_`+<F_P#_
M`";U9_S7<!^<-B_[<F__`/)O5G_-=P'YPV+_`+<F_P#_`";U9_S7<!^<-B_[
M<F__`/)O5G_-=P+KPF1NY?$8Y*7T3E$$>'P[$JZADV1"MY=&%GB&*R@61HQP
MW)0*1AAEE\-?%H0>-^L^N_<5SZ]F78;1P'`<!P'`<"+7]'4H5M(1>).GZM(W
M6`$Y`05P/Z_B;RT@@+)$BWR"B+`<"5)8-$Y-S#O#MLB[P1[P=+8^[[%,^L@E
M+@.`X#@52J[=K6^XY1'XC!)A*EB<R=2EA`R$JIZZ:YB%D$(1B45E@ZL)_8U>
MQ2"682!-`;YTNW`DB*V+)DX<]8]MT%5,`ENVKOIRA8ZSEMV6C`:HC)$LF!&F
M[!E06*#B1M5B_*XB!K@R\:8$"6(@2[>9HH^^HFR:+N,NND4%<\`SA.RJ\#5X
M[MPI.8BQJMC$<I^ZL=>1"<(,C!L!/S[N8=RGU?83*,Y!.^G>+[I;MMFV[Z4Q
MS[P[Z[X%5-4:]A>@^BU9P>R+>B+R!T57Q%]([C)?!A\/7`.C1>38GU?F)1^D
M.8]MC6&&'63E7M7+W?<]N6>./`G*IMC:@NPG(X_`9(4[ED19B"DE@LUA$]JN
MPPP*1*DD(W*'E>6G&(9-\(?)UPSS`88Z8=BR6;-?%LNKVBKUB&[O[(A`NR8G
M4+\^W;6/.8/85D12+Y-WV3HQ"*J/5E&+`/HNTVN8U%O&SUR1ENJFJNFNKD53
M[2P4P36R2#>.`X#@.`X%5+1W7URIF:RB`V'+98)-0.)QZ>6*3%TY=4O@E8PF
M5*2+`%+K3M"&UY(*TK&-NTXB46S>GRXYNW;#UUULTT4LE.@GV=$X&-@LM,68
M0B+"LV,7-$9V4G3L,U@K.%MQCAQ(GTM>GU$P#>+H!L%5'JKS+IIBVZSR5[ZP
M]O?*9,>/-CMBS5K?%:)B:S$3$Q/I,3$^DQ,?6)^KE:.]N\7NXN2XW-EU^1U\
ME<F++BO;'DQY*3%J7QWI,6I>MHBU;5F+5F(F)B80U0/6H\YJDT/UE8T`?I8J
M6.@).%IL5`E:]=GE6+1M)@4F!1-KB#^=+#'+?%\T>H=.,FRJ7Q<.T\\/;Q-?
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M;3200".UI6-;ZN7-;UJR"J8Y6H$;%K$;VQJY>&NA`+T)"X"0(Q;M:W4B+M==
MF[Q>(,<F^6'7:O2F$Z_'<?J:TZ6K@PXM.W7KCI2M:3W?7K6(BL]?Y]/7^5.:
M\Y\V\DY['Y5Y%S'*[_E&+V^S<V=O/GVJ>U/7%V[&7);+7VY]<?2\=D^M>CPP
M>_-%H*</ZZ5_'PM?"%K0>TS(Q@#6BQ()0#^X#>+$*YKA_:"%5!]?R<XDBKUJ
M-3'=FE79)RLBS3P56432[:W&\=I:]M33U\&+5MUZTI2M:3UCI/6M8B)ZQZ3U
MCUCZK<]YWYQY5S6+R7RCF>5Y+R/!%(Q;6UM[&QLXXQVF^.,>?+DOEI&.\S:G
M;:.RTS:O2?5.=`A=;)!1\1E.N<+K!A0MWP<!9$82@<`#PV'3N$65&&)P(?=1
M9`$$P6;R>+E4,\TWK/!?)%7X:V'7?MPZC6XSC=+!;5T]?!AU;]>ZE,=:UGK'
M2>M:Q$3UCTGK'K">?\]\Z\KYC#Y%Y1S7+<EY!K]GM;6UN;&QL8O;MW4]O-FR
M7R4[+?=3MM';;UCI*0*\JFKJC$.0%45M`:Q`O7V9-X$KR'1Z%B'9)1%)NH0<
MC8V.&LUWV:"&&':N>':G>&&/7M]G777+:7'Z'&XYP\=@PZ^&9ZS7'2M(F?ZS
M%8B.O_+Y>5>;>9^=;U.4\WY?D^9Y/'CC'3-O;6?;RUQQ,VBE<FQDR7K2+6F8
MK$Q7K,STZS+?N<QC!P'`<!P'`<!P'`<!P'`T60U?6DME$3G$KKN"R>:P)9PX
M@TOD,2`&I1"W#S'K%VO$Y`2'N2T<6=8X]=*9,UD<L^NOUN^^!AS%'4I(4`+8
M_3]6G&T5F1RQ8PW,5_$R:$<L&3GR,KDLZ`I/1*R8>92&4%W9)\3;])O7;]TL
MX55S64SSR#,-*OK1A/RML,:[@K*TSP5K&SEE-(D`;3\S'6.2.3$"5F2(_"1$
M0K/)NGVDU6<YH)]X8^[CU[O7L#8@L>`1M%ZVCH,.!;DC!>0D6X48R%HD#\@(
M+ECQQZDQ00P=&#91TJY>.5.LEG+A3)13++/+OOL*,>.S^CK8W^W_`+[_`.*:
MR^!?_@:C/I]"ZMA<GL:QI.%A4$A05](Y;+9&^1&`HZ"&(Y."!8L0<98(,V+-
M##O)13+OKK'KK@:;4^P%)WKB?^S]HPNPUXHH-3E#"-&VCXK'.S2;Q4*H=#]9
MX%!+<U@-<]LU5T4TW?IEOA99_"4]T-FD-H5I$I1$X/*[$@L8FL]6<-X-$)#+
M0`6431PSQZR=H1./DB#8M(UFN.77:F+-%;+#KO\`6ZZX&S%#@4'BQS-F!8?`
MH48@QF90@T'XD3117X`P.QR=K(].RA%?]1!NG[RJV?Z,,>^^!I]G6Y5U+1M.
M7VW8,/K>,KE&8)F9F<@&Q]D1/$L%\QL?%9D7"&1:0$\6JOI6+;I5VY^'ETFG
MEWUWP,E`+$@-K109.ZQFL5L*%F<GR8J5PL\+DL>?K"R#H24;MBP=R[8J.A19
MBNT=)=9_$;.D%$5,<5,,L>@]H+-HC(SLQC`&1AR\BKTH+"3D*/?(.243+FXZ
M*EH@:>:IY9*CGA*,'6;]'!3K')1JY34Z_5RZ[X&T<!P'`<"N(7;[5Z0V0M3X
M:^*Q>V:C+CT`^B\94-2-+SR+9D<)'"6*#A5+`C+@O8=YVY&M\E'B6+-?+M/W
M45>\0F*<3V#5E%RDWLF9Q.O86#326-R^<2(/$XN'2<.$FB"I0^>>,!(]-9TO
M@EADLKAUDIGCCU[>^^NN!GAA,:;&CS(8@Q+AR[%H3$EACMN_&DQK]NF[8D![
MYHHJU>L7K57!1)5//)-1/+K+'OOKOKO@>$&<"R8*(DD;+BY!'9`+'G`!\&0:
M%@IL*6:)/Q9<048*N&)(628N$UF[A%3-)9+/'/#+O'OKOL(,J:CG5:7'M/::
M\B;EV^QEB5W.&09(:HS6BJ4&HVMZ@5'.GN;QQ@64(N8'F^Q4P30Z3P<])=XY
M=X=YY!J$-WSTPL$6X-PW9RF3XIM%1\Z]:SG`?%%U"2A,&%8S$9ZAPCF7BJQ>
M4"VW9!KTLT36)L\,U,<G2'2@6VX#@.`X#@.`X#@.`X#@.`X#@.`X'!(!X_=B
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MA>N\)7M'`PVM>QWDNO"U!!PDX+/(C8=Z3`Y;4GKAJ]<=^_W'ZI?3#N+B4\<<
M,$1(=LGCCCUC[.!:/@.`X#@<M)YI+.+OVMW#-3JQ+<KK7"]M>-<*?+1RN"U+
M-1-X#`/>QP^UXA*"!ZOYK<<+;L(_83)GT]`DXJX61+*Y-72BZ/Q6P<T)3I9Y
M!IA/Y:[;5,8BD:.)["K36*-K/A6-5V=F(V.JB]=?8@[(']D;4ELVA\D@-5$X
M2U>DXK#T(@WE/0]G'F`!1TB/#LWJW`[%=V+MM=5GU><IT9L-8%?.8Y3DV,UO
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MQ!"<]CZL`RX]'H*T(!>FK>9`86<CJ"(ER\)BFC4*Y"N&QH*^M?M9Y]#-I,;*
M<E7%`^3!AK+7#;9*OJZF\,D<SL$-+J)LZ,8LMB6C"4(P>$30;#!<=`%I/,HB
M[3S%`A1025S>9ATHU_UIWBC6X44L&RR,_=Q,=:<PDIF:(RZ--H`2HLG1A>+0
M2GB@W&\SLV.N(E*B8SI0%W`18;&0AU)'@8S<9]HOP[E\!P'`<!P'`<!P'`<!
MP'`<!P'`@#7:B_L%';'`?5/U9]P-@+\O3U?R3Y%\I^^%IR6R_I;X'S<SZ_Z8
M^HO1>N]]'UOP?C>G0]_X6(3_`,"E7D=KR;VSHAM?6E:A24BGTWI*;QR(@PZ+
M=R4)'B0Q1`>V8-W66+9=UDMEUWA@IW[F7?7L[_1P*9[5ZP7Q$"`6THG86P5X
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M@FKSL3>-@BZAK`?.EU4F;IM@Z^"%(XWK??-C;*=S8Q&[_H'7?8?9^_[>F-<5
MQ<,II>2,XNPU%H*F8!+K;*4/,X\<C4DM&U*L)2=J+;F5G#7!TUS(8MB;HPSX
M%%(S'_(Q5<+BUPR5S:$(V'VK'ZO:JV"T,&>V":UP;*>-'62O#VQCB&M334-(
MIQJYMM4&2[Y='#`B-`92;TBV#?-QBN'U/1X*C&P`..MGI@DW`AQ@5N1D)<A(
M#Y!$6R08I/3AXLNZ*&S#K!#I1R\<JJ.'*V62BF66>7??89C@.`X'#<1IO?Y"
MH-GI&6/6L2)Q'<'<O:77G5X'E4-<H6)90:X;/L;7!]U;\CAQZ0!!,NEC@48:
M+N'B+-%SDW[>=*#L'+)P%:ZCKG<^/W)`9Q;T!V6NK7.DK=I2[Q4*EP&=R>7*
MOI'KKN)2L]E<5"7_`++7]:,E-5?94IA+UZ$4+"\<T\E3X*/-LT4?7AUEU+UT
MP_#+"D=@JU9I1N=SS8N8.:2E:()\T@U46_LM:EPU+2AUG&BIF,9?:>L)>#CB
MS9@[<CT\A/:2.>:../M#R:'U[<-6>,K22J7`<7!;SK?235ZOS<>L8<0?#HE8
M4.I&!QV2@98,`E!Q!90(8&N6RZ;9VGETLGW[,^^NOTAMNDC':9A4.:6UA2*D
MICW*IUD'Z#"Y2Q/MP^5CSC-AU)',EDTCQ>M5068_L1TW^#Z<;TFFIUGEUUWT
M''-AXWKT->*'5L#8\LN.77]3VC.NM20&B&X"M8@M24G-Q_7T5:H[!W'(PVD<
MGE\!#0)08T6)E'+5O@@Y650<NLD5T`D"\ZNWB&2>WJ;K=CM8ZI=AL99;RC;%
M:75>TYDK2.O=.M+S$'BQ0X.VBI"[Y;$Y1L?,[<P'FY!8&,0B+X#DU)L7+7,2
MFV"$E[,VMS/:_IVK-=C4]E2>R/BVBO3"&6^1C=6PN'R"FJ.,[%5;LW2L'LT&
M#2L*2VP,L*0%VKF-*DBL.*AUV.:@-D3S9!>WQEPK>2.2M\^VMF5J&7>=#P<?
M;8J=Q&3CHHXV8^:XO)84KV32K;J^@A5NT0R(=.\X#$X57KMH]'^A026:J#F(
M=DN`X#@.`X#@.`X#@.`X#@.`X#@.`X#@1?</_P"1^_\`]85G_P#,N(\"4.`X
M#@.`X#@.`X#@.`X#@0_;'_WC3O\`_,`3_P#:LRX$P<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`YP[,?\`^A'C(_\`[H?_`"2`\#H]P'`<!P'`<!P'
B`<!P'`X0VI__`-!^L/\`8AL#_P#%K$X'=[@.`X#@.!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>v365643_img-lifecycle.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v365643_img-lifecycle.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`AP(K`P$1``(1`0,1`?_$`,8``0`"`@(#`0``````
M```````'"`8)!`4!`@,*`0$!``(#`0$``````````````00%`@,&!P@0```&
M`@(!`P($`0@&"`(+``$"`P0%!@`'$0@2(1,),11!(A464?!A<9$R(Q<8@:$D
MEI<9L=%"T]355U@E5L'Q<G,U5976UTA9$0`"`0,"!`,%`P8,!`<``````0(1
M`P0A!3%!$@9181-QD2(4!X'1,J&QP4)2(_#QDC-3DY05%E87".'2-%1B<H+3
M)%48_]H`#`,!``(1`Q$`/P#]_&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8!$,?NVCR6\[)UY;.'P[$JVLJOMF4;&8."QQ:G;;'9*O%K(R)B`W
M5=#*5AP!DP$1`O`_QP2I+V"C`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`:OK?+M=0_*_09ZPK(LZ]VFZD+ZDJSMPH
MDBD?9&C]E3%Y6BO=.8`^XE:IL4/MTAX,L=N<"<B`AE)S-H'/KQ_5]?\`JX#(
M4\X`P!@#`&`,`8`P!@#`&`,`8!\552IB0HG3*8XB!2G,`&-QQR)"\^1Q`!^@
M`/J(?3%56CXBL5QXGN0PF`1$./7T#TY`/YQ`3%]?YAQKS![X`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`5M[/=7]?]IZ$VI]S7F(&:KLRVMFNM@U9X$=<
MM;W>-(<(BV5=^9-9$CYBH?DR*Z:S9<O)%4S%],I&5091'R\:]0-7V%IZ3]@(
MF+'VXV\WN)VGJK85A:$]$QL<-3!F:.A+G`/SJLR-VXCZ@E@:G()M[Y6ZP;W[
M%TYZT[,;&#\K+5O962JDFE_]Z?9=*;1QQ'\`*KQ_/D!ZK=@OD_F_[JO?'IK2
MFG3#R4>;%[<TR3:./K^1JA0JS,.B#Z?VE?$/YL`X2W='MGI$QI?MYTKDH36_
M@4[K:76>\)[UBZH4H>3EQ=Z<:*KETB(=F7\RC]!NZ1`/H41P7\QL0UULBC;:
MJ$)?M<6B&N-/L3--]#S\$[3>L'B"@?0%$Q$47"1P$BJ1P*HD<HE,`"`@`&<8
M`P!@#`&`,`8`P#P(\<>@CR/`_3T#U]1Y$/0,CK30&GOY'6&V7E_I*E=0D%:Z
MOK"^Q-04A)2TLY$NPDIZK7*8$L=65T%W<BWIM&4%@H/OG*079"H'!4YD_,;[
M=R+=RS*"=%U</_3_``]YJG;Q+_<&-C;M.4-NNPN0C*.G3<?2XS;7*--5S399
M+H!N)]L[5:T'(RH6%U0F=98!8C*R*SV00DV#SP;3*DBS;'-.1Z\6J5R)3*>I
MR\^(_78;/F2R[,NKC%I>\X[7/HN7\%WHY#Q[CCUI4356OT-^QHOGFX-N,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`'\O]?/^K`&`,`^9TDU$U$E$R*)J
ME,15,Y2F(J0Y1*<BA#`)3E.4>!`>0$,`U<]8(6'TCWU[<:&JC1&L:^MM-UCO
M:J5-$A6T0C8)XDC`W1:KLB^*#-B+F,24<(H@!"K*"80`392(VE9"C`&`,`8`
MP!@#`/`@`_7^7IQ_T#@>9AEYH=0V'!+5VYPC:<B'/H=JN=R@H!A#P\F[QDX:
M/6BOB(A[B:I#``_7CG.F[9M7E2XJG3D8]G*M2M7XJ4)1:?C1\:-:I^:::Y,J
M#IFI1G5?;DII"'9+,M6[83>W/5#M<[AXG6Y^&!-.TZV6DWJCEXLF9HN$C%)J
MJG$J0+D`1,(\8>/9AA7'&*I";J:[!P[&UOY3&CTV9ZINKI32C<FVW3FVV^/&
MI>],?(!'D1Y,/'(```'IZ!Q]0_G_`!_HXS9&WJGP_C\SWP!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P#!;]LBDZO@EK+?[/$5.!15(@:4FGB3-O[RG(D2()_
M(RI_$!'Q`/("E$WT`1#JN7K=E5N.B.%R[;M1ZKDDD9%%3<7.1S28A9)I*Q3]
MJB]9/V"R+MH\:+D`Z:[5P@84U"'`P"`@)@XSG"<;J_=T*I1=OUH24K;\#N,Y
M'(8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`5;[$]
MH*WUW_;19B&DK*\L!WZYXV&D*\Q=L8B.%!->24"?DXI%QYNG22"222AE553<
M%*(YKL_<[.WM0G%SG):)&#E9<K-RU8MQZ\BY.BCS:\B8M:[(KFUZ1`7^INE%
MH*PLDW;3WDRD=H'`YD';)^@`F^U?Q[Q%1!=(?5-1,WKQP.96/D0R+*OP_FVC
M)QK]O)MJ_#^;?\7YR0L[SM&`!^G\O^H<`]!'\/Q#CD/QY_``'\H"(\8(4K[&
M]):MO_856W)%;>WEHG<-)JLA3JY?=*7&,KZRD'(/QE!C+-!S<!/0UFBB20@H
M=NLF7W2AX"<`XXH:(51AOEEU,`1D5:^J/:VMLO$&,S>(^X:(VC(MDC$3]J:5
MK"5JH*K]0AN?=09MR>1!\@Y,&!J2)U^[:[6L.X'/7/M'I%CH_<3JLNKM2'%5
MN0;`UUL2K,7*+:35KME-$PCM*8A%5R@Z:+MRF*'YP$2B&*"K+^Y"C`&`,`8`
MP!@'@0`?J'/X?]'_`%8!6CM%44[32*[XN7T8X@+_`%RT(2\*50+!&?HP/G#E
M:"41`ZA)%ZU$[7@"*>XFX,02#Y>FJW=RAC>K!M34EJN-.9J-[DUAIQ;4NM:K
MCYT.QHMSG*\^C:=;Y`DL1\BS4@K&<B:3B0:2"H(1;HQ4`^U=L')@(D*B8BH@
MY6335`"K(&/SQ<B480LW76;5:^*?!C"R+MGIQ<F77)I-2\4]%P]G'S184OT]
M1YX$0]0X^F;*E.)MSVP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!JT[&04U=>
MX-09/K(YCJ)1]=1$B87U7C[?7H*Y7&3O+*(DAB'ITB$DI./K3I`'')A2(CQ^
M4##Y>9S?F+N\=$Y..%"S5Z:-^)Y#<HY=[?E9?J+;U8BZ]'5%2;N5UKX)&:_'
MM#VBI5[<U#LTI*.S5C9R2T#'OX\D8T@JU;:;6[7!QL6S()T42_I\J59TFFHH
M0CHZA0X```,W9HWK<)*\ZINJ]G$RNV;.1C8N1BWY.73?^&O*+2:_.;%LW)Z4
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`4V[7=<$
MMZ04>_AF,<XNE="2:Q"CY8K(JK*30,D[:_?F:.Q0\%P36`!3,4XI^(\`("&N
MW'!63TS@DKT>#,.Y;N6LVUN^'26=COX.KA]WY#%^B,--TB@7C5U[>)!LJCWE
MLUN4$FNV,A')+TFGL*U,0J22;?WJ[<X2&))%=`GXKRBS],1]]%P0G5M./+%Q
MOD[NLXMF'LL+]O'GCY*4;JN-M>W7W/D7QS;&X/`^@#P'(\?3^/\`7@CX%?NS
M&UUM.:HG+6V<MV$@L(Q$7*R("G"PSYVT>."RLV[`IDV+!DW9J&!0_!#K^VGR
M`J!F%FW7:L3EU=-%Q\#`W2_=Q\.4[#2NNB3>B572K]G'VE).A.U=P[&V?=3V
M>3LMMH2])_6V]YL8'BTK`Z?6M9&C2,+55VZ`P+:7KR$DJ)4/-NLU1:K%,8BB
M9SZG9\S,R;K5QN=A<W3[/><5;6#O,MIADO+C##MW)7%1QZYOA5):TK[C:T<>
M"_3GU#TX$W/KZ!P`#^/]6>C1LF:UA^4_K>K8K+%1U0['6&#K<],5I+9-7Z][
M#M&L;++P+TS*::52XP,9(,I<8]XW,FH8"IE!0H@'/&4A'NL;E/=P>\E`WE5M
M8[:H&E-!ZHNU?;6;;&NYW6KV]7F\R$<G]M6XVQ(MI20@XV(;"<Z_M%3%7D`Y
MP#;:`<?R^O\`3D*><`8`P!@#`&`,`Z"R0K&P1:L9(`;V%#H."G(J*2B#EDX2
M>-'"9@^ID'*!#<#R4W'!@$HB`]-ZU&[#IGJO#E[CIOV;=^T[=S1?I15":+9B
M)O:5[!&=_IJ`6>AKM(IHHUF:LS<IIK0L*@8@)IH1[Y),[5H8_P#<^#8#`84!
M-FBO>M<:Q?P9$75-:?!X)K7BGH><;S*SQKD5\Y:EUVG^W#]FO@FJ]/LTT+>0
M[M5_%Q[Y=JJQ6>,FKI1DN``NT.X035.V7*`B!%D#'$I@#T`0ST,:]*KQH>G@
MW*"E)4FTJKP?A]AV6<CD,`8`P!@#`&`,`8`P!@#`&`,`8`P!@$/[0V*>J,58
MN#`CJU/R)(,4Q\UTHP[]8K1D]=-TOSN5U')^&K,IB*/%>">2:7NK)=-V;CPX
MF#GY?H6_3LZY,E1+P9I>[^5Z<TYK+9>P]@7G8DS:5*@PG8I2(N]NIS.:9GN+
M)%QKVQ25&L%?D)MO6EIUVY;BNL"*(OS-F*2+8#ICYO/Q5;4HWKLW.[5JK>B;
MKT\>"KHEHD>#W#!R+5U6LV_==Z["M.ITXMN+UU2JTO#@M"T.E:1:(EE+;$TW
M;+F%>AE8>0GFMAD92PN+]+#`Q;:3E9MT]D%I>[-8B(;E39IG<'<-F:A6[8IE
M&+=NIDV+%Z73DX-R3M+3I;='1:Z?P9LL#$RW)YFW7INRFJIR;4FN+:TKR6J;
MIP=50V/4"]LKY$(OTB&8/TBHEDXDZJ2RC)RHD1P0$UT1\';-=!4BJ2Y0`BR1
MRCP41,4-[;NQDO,]?C9$<J'7`D+.PR1@#`&`,`8`P!@#`&`,`8`P#T,<B1#*
M*'*4A`,8QSF*4I"AR(B8P^)2E*'XC@&"3^TM<59LX=V&]52(0:IKJKG>ST:D
M"16P`*_F'OB<OM\^H>//\V6A*D>_YK.MO_K=K?\`WHC?^^R%/JAVEZY.5DFZ
M&ZM<JK+J$223+9XT3***&`I"%#W@]3&'C`)7B[E4IOV_T>S0,F*H<ID82[!V
MH</+Q`2D0<*'X$?YLM"5,DR%&`,`8`P!@#`&`,`8`P#QP'KZ!Z_7T#U_I_KP
M./$J!NB/M-0VCK39NMF31>SR[:7H-[82"K=E&W6F-D'TS66TL^33,^4FJE9G
M:RL&IX*`W3EY%$`2(\54+K,_(>%)7+,>J<M-?O-+N5[(Q+V.\:*G.;:;?->;
M_-^@L)2KPPN;0RC8JC-\V*D$A'.`."[54X#]!$"@LV.)!\5`_@(&X,`E#+QL
MJ&3'J@9^-E0R8]4>/-&<J<^!_'Z^(\<")1_T"`&$/ZLR#,23='P*>;L`-WV^
M'ZY1;@KNI.$$;9O-XW>.$7:-)07,6$J#%TP6:NFK^VS;8!5415*JBT:'*8#$
M7$`P,B-O-KBNC7ZRIR\'R-9F0AGOY%I/':^-^7A]K+"Z\U?0-5PB=?U]5(:J
MQ)3$54;Q3-)%5XX(@5N#R1>>`O9-[]L0J?NKJ*'\"@'/``&9&/CVL6WZ5J,8
MQ\$J?F,K&Q,;#@X8L(QBTDVEJTN%7S,^/]./H(^@#_#D!]?H(>@?Q#C.\R&:
M:=%ZF^0_HQKJ-TUK[6.@.U&IJT_L;VIJ,-BRVHMI)$L5EEK&])9AN,++U*3>
MG>3)Q!9NZ2+XI@`EY-R%.-*$R-/D%M6LYJ$B>X/6#8?62%L,FSA(K9)I^K[-
MU2WF'RZ;5E'3UPI;E<:\9XY5`I%G35-MR/`J%'!:T-E$<_9RC)M(Q[MN_8/$
M$7+-ZT72<MG39PD19%=!='E%5)0B@"4Q1$HAP/.0IS<`8`P!@#`&`,`ZR8E(
MJ$CG<M-R+"(BH]`SE]*2CE!E'LFR?`G7=O71TVS9$O/J8YB@'.%QJ1TYFO*S
M?(%1;18W%3ZW:SMO8Z]Q8K$0?5R&,QJD0JL=PS^X<VB232!!HH9(0%7A%%4@
M_D5-Z\3H@Y=5%U>--?><6HN2DTG)<'S7L\#K7$+\DNW"HK.)_5G7")<%Y4CX
MXBUQL+8Q2"8ISN$?)#R4.``)07$"^OUSD74\+=$]RW%`O^*/=';\VM[31%5"
MMD;UYH)6XJ+B!#,G#9R03N%C#SY>7AP4>>,%H<,?C1;C_P#VC[$?[XRG_P!,
MMD%#V2^-QXR53=1/;'L,P?H&Y0=*61R_*F'/J46KN34;*@/X>11XRBAR5>MW
M>REJ(N:#V\;W!NS.`H0NQZT0Z:R28&*DBL[9$5_((<>?)1$1_'(*'V>]ENX&
MCU15W[UT0NM(8)J_J6PM+203+@A4R@89!:MK>T\;M"!_:*9%+Q#U\\#4M'HK
MM1I+L2S54UM<6SZ69D*>2J\FBM$6:,,(%]PJ\2^*DNNF@H(E,JC[J0#_`-K+
M[`BQ>0HP!@#`&`,`8`P#U'G\.?H(?AP'\_`\<C@C*A[O[M:.T?)&JLC,2-SV
M(98C-#7=$CU[#9SO%4_--%PDU*+1D?\`,'D4R@J@`^B8Y00<3:7R$;@06/0]
M,T;1E>>>:L78=D3@RMB.R5]OV17KS%-TLV=>V<3\'22X'T'@0'%!4P^.Z)]D
M;#)&F]E=P;*V?NI%[+N$Z/"(L_MW\BU2;*K-UGS@1$4$VY$DQ$`]M'S*0"@8
M0S@[?4^9C1Q+,;KOSJY-U]A7CMW\8;0^B+U+H;:WQMFP1$6Q5AZLX>O+*K)O
M5IB*;K$1AA<OA6(4@"KX`D;Q]H1#Z!F#G8RGC-M5FJTTK[CQ'U.VV6Y=G9DL
M"W=N;K&,?3].4HSKUQ5$XZJJK7V$^4[XO8:%K4,TC>QF_:^B6.:.CQ3&RR+%
M%JX7;IJ.2`U+(I`B8JQA`0\0$!^H9EV;<;=J*@E&-%P5.1ZW:-OM8&!:Q;74
MI^G&J;K1T5?R\3ND>B'8&AF0<:@[C79@LR;.T6R5PAT9-);[Y\K(.D')T5CJ
M';G64_)Y>0DY$0SL44N!GQLQA^"B7D9&-S^1?4#),;+K37G86(:ARZD:3-EK
MUJ^T3.0IA3B)'[!%X]42Y$/$5/S?@/TSD=FI+&GN]^E-HSYZ+-*S>I]F(N3,
M5J)LR/4KLDJ_3X*HVCW3GQ:N5!4Y!,AQ255^I"&#UP*EU`'D.?Y?Z!_$,A3S
M@#`&`,`8`P!@#`,2N][J&MZW(6^]6&-K%;BTP.]EI5P5NV2\C`5,A1'DZJRI
MQX(0@&,8?H&",U_F[B;IWNZ5C.H>E'LU7%%G#!3<FRCGK5/;&`P(C(P[!P4K
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MN;J=-K+Z/[+M]O5IB3WFE*VFV1.,JD7S,NV0L;47)`46.`E(8Y@\1^I@Q0=+
M7,RZG]\V]=M##7/:C6\YU[NC\PIL)B1,:6UY-K`8"`6.L[0JJ"0*";@HF,<H
M#_:,7!:T-A#-XTD&K=\Q<H/&;M%-PU=-E2+-W""Q`426063$R:J2A#`(&*(@
M(9"G)P!@#`&`,`8`P!@#`(UV1436V):%;`!GT*_"9CR^0)&%R1JZ:<HJ@4QD
M7((.S`FIQ_=G`!_GS"S+'KQ5-*,PL_&N9./\#:E%U7W5Y$/52Q^=RA;"BW=-
MB33UW5;9%B@J4T'90;>^B"C4"F.S:27VPJE4'Q3$W'KQZC@69J.7Z\=+<]*<
M*?8:O#N2>4K]NBMS^&ZOV9^SS)(V'/RIWT?38!VHSDYM`57#U/T%BT$_CY.#
MG\?LT5D$G!O>Y`W]P)2`)Q#,W+ONV_0A^*2X^!G9UV?JQQ+=5<N:5\%_%5D?
M:*J$?5)K8\PS9!%,)9Q&N'3AT95(9(K%NY($P]4=F4.@H<I3CX`?V2(F*<O]
ML1S&VZWT.<V_A_*8^T6'CW+L9.MO3BZOVO[B9*=M#6^P'<@SHE]IMR=1"2*D
MLWJ]GAIY>-2<+.6S91XC%/79FJ:SEDN0HJ>/)TS!]0'C:1G:E+X6G(VMG(Q[
M[E&U)2E'P9(&=AW#@`^@?Q_UCR/]8X!C%SI]8V!59ZDW."C[-5+1%O(6?@I5
MJB\CY*,?H'0=-G#=8IBG`Z9Q\1#\Y#<&*(&`!`1FJ*H2\M\:6YXW5-VG9Z3Z
M.[JE(Z*T?;9QX:2;]<MGNW#_`)T_-OEU#R)J)<"N"J0KE7W`:+H"W$2E$N4<
M#<$7D0_JX_'\`Y]?Q]?QR%/;`&`,`8`P#%[K<(&@56>N5G?MXR!KL8ZE))ZY
M5*BBDW:I"H8!.<0#S4X\2A]1,(`&`S5O5J#LKY"I"+V'M\)*A=9FBR$C2M7L
MW8ED+[[2B@H3-B<I<`BV`/0`*(G'G\@E_M93CQ-HU*I=7U[6HNH4R#85VN0S
M=-I&Q,<@"#9LBD0J8>GJ910X$Y,<PB<X^IA$?48RHRK!1@#`&`,`8!2KL)TH
MH6Y)%&_U5XYU?NF(41>P&QZV*C9T$@R$5603+9N=,CYL"P!R;CW2AZAZ\!E)
M0Z3JUV+O<]<;'UOW_#(5W>>N(I@[7DT7#8T5LF&<$,LC8X,$2))F52CU&YG0
M)![7NF/X\>)BD!/D7PR%&`.0'Z>N`,`J'V0[>T+K/LCKS2MB>$7";\L%OJK2
MXNWJ#.*K,U`,H!S&)2QEA+X-)M:9]D%@$`14*7R]#<AAY&7"QD6;$Z)76U5\
MJ4^\\+W9W_M/9N[[5MF[/HM[K>N6XS>D82MJ#3D^"3<TJ^);)HLFND55)1-5
M-5,BR:B2A5$E$U`Y(=,Y#&(8A@^@E'@?K^.9:DI<-5XGNJPE\5MIP:33XU3Y
MKR9R!$/H(?P'UXX$0'D`Y'TY],H-9VZ-O;/[#[0G>K?71\O6(^N"V2W-N1(?
M,E=9.B@+BMP/F02N))RFH!#G*8#AR(%X\3&"G'\Q9OK]U1U'UUCS?LJ"(M9W
MJ`$G;E)"9U89E81`ZYUG9S&%!%94/+VD_$G]."T+,!D*,`Q.W6J/IM:GK5)@
M(1M?CG\H\$AB$,*,>DNLN4GF<A?=,5+@.1]1'.N]-68]3U,K!Q9;AE6L2RTK
MEVYTZ\M::F%ZPW5KG;K5VXH]D9RZK'V#2;!$W#Y@#E,%F_W38W]Z1)T@;S2/
M]#E#R#TSC:OQN/1_%X<S*W+:-PVQ_P#S(25JK2=/A?L?`F#.XU8'Z?Q_F_C@
M$$[SZYZI["P)8+9%8:RIFI3FB9E(5&LS"K\"!5H]^W,1=/Q$W(IB(IG_`!`<
MJH2A2O6]VV#THV+6M#[GF'=OT9>9)&$TQM=V9,B]<E%Q(5O2K04``J"/D(@D
MJ8W!!$OCR0P^`&TK^7\O].0IX,8I0Y,8"@'U$P@`!_I'TP//D`$!^@@/]`@.
M2J7$'G%5X@HO\A/:&2Z?Z&:[LCX5M8&T5L6AP<]%KJF14<5RP3`,9G[-0@&$
M'Q6HB*7("43AP/US`W+.^1Q7?6K36A\X^J?>]_Z>]KKN6S;5R%O,L0FJT_=S
MFE.GFEJ6!T'O/7/8K65=VIJ^PM+#6+$S173405(9S'N@3*#F+DVX#[C*19*\
MD53.`&`0YXX',K'O+(QX7E3XE4]3VWW-L_=VU6]\V.]&[AWHIZ/6+:UC)<4U
MX,F?.XWQTT_-1-;AI>P3KQ"/A86,=RDH]<G*5NUCV*!W#M903#P!2HICR'U-
MZ`'KE(:J]8:YG._=M9]@MSD5;Z&@Y1\GJ+4X^8(3:;)06R5LG%R@DHX(X.4Q
MRE]2GY\0X*!O(.)MACV#.+8M(V.:HL6#%NDU9LVR9$F[5L@0$T4$4DP`B::9
M"@``'H`!D*<E10B1#J*&*0A"B8YC"``4I0Y$1$?0``,!Z*KX%<JA%V2=-KG:
M3I53[]>0NJDHQ?D,B[9T'8ZAY!A`B@H'!9*!>0-=(H/H!B-%^.1-F#:BZ_-Z
M]3;T\M/N1HL:U>ORQMQ>DJSK_P"2]RU_9<;7\EECC#^4W`_0!_T>F9RXF]?`
MIEMCM$YT_LL*[/ZON\M2P0I2B]_AX\5(MBXM,G.0"J`ME3%7?,85[^F?<O$@
M!NW-)E(<0.`>YB9.:L:ZH2B^E\6EP_A0]9M':LMZP(W[&1#YM7+U+<GJ^FTI
M)>3EJEXZ'-[#VZH7SJW?K56I4]@KSR%26CGM>3E7RKTQWC(42-TJ\=K/*@!E
M0`Y6AR./`#`!@]<QMRN6K^W7+L-6HZ:>:.SM7#R,#NS&Q<N*M7/5IU-Q73H]
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MAE71J8_7`3E5:++*`FB8YR_4I@``$P%[S5<#:6'KZ_Z./X"'U_UY#D>#<>@C
MQZ<CR/X>@_3^?C&O(43XD0OM_:0C7KN.D=K:_8OV#E9F]9N[7!H.6KINH9)P
M@NBJ\*HDLDJ42F*8`$I@$!#G.MWK*T<X>]&AN=T=O69RMW,W&A.+::=R"::T
M::KHT]&CB_YB]!_^L.MO]\(#_P`=D]>Q^W#^4OO./^+>V_\`[#%_K8?>01V>
M[0ZTKW7G=-@H.Y*,C<8/6UME*LXC+1`NGR-@90KMS&&9-0=*?=N@=)%$J?B;
MS'\O'KF%N&;:LX5ZY"<.M1X=2/-]X]Y;5C=J[AE;5G8SW.WAW966KL*^HHMP
MIKQKY%=_C*^1NO\`<.B1]+NA3P'8"I59G)VN#=D(V)<(E$[9H&P*X`HM@7C9
M%TN4ZR1"B+14QB"(AXF'HVC=<;<;:CHLF,55/G[/'S/)_1CZNX?U$VJUMF<^
MCNNQ9CZZ>GJ./PNY!<&F^2K30VS)B(D*(_7CU]!#U`1#Z"(B7^C\/IFX3JJG
MW`]\H-<7<WLIM_3%FKM8U]$-5"V"&4F(YZ6`=V)S*/(R5;!)PJRQ7C%C7D"Q
MPF.*JA7)U"&'P`IBAFBW;<,K"N1=M+H9K+]R_=W&UMEG)Q\57->N\FX_DX$S
M=6.RD3V(AK`H+-@SGZF>`+)_IJ[MS&O&D]%JK-738[]E'/4%VDLPD(YRBJD`
MHNF*A0$Q1`PY^#G?.VW)*GB=N)D.4YX=]QEE8[HW%_"Z\X^3+-MH6*9/WTJW
M:-TI"5!L:0=I$`%GA&)#)M??4+ZG%$AQ`O\`3F2H+\1EJ,4^HANY46WR,_(2
M$(_;F):CQE=6>G(F@>J4]%$7<J1!(3>Y(/)21`_B/IX>X3GT)ZZ[+Q\B<WZ3
M7I7**7E'F:S+Q<BY/]V_W=RD7Y1Y_:S,Y77[5UKJRT2.7-'H3]<G((7@I^^J
M16:CEX]1ZLD"B!ESE%?R$@*)^0>@&*''&7#&]+'=FWQIH92Q%#%EC6ZI.+55
MQX<31W)T'L3U\W&VN[UA;[E<2PX,[SL&`@I12%@JU!3L66&O2KF,AOTY>K#4
M9!S%?HBSI^X37<.GJQ?<;*.">3NXNY8N=&_:2<T_SZ/\C9YS/N*UB8\8XD7W
M/;N4=^W6D<9NBZ_&3>E/.IOV@Y*.FH^/F(QZVD6$@S1=LWS-=-PT<MW!"G(J
M@LD<Q%$U`]0X$0#Z>F>UA\4%-_BH>OKUJ,WJZ'=_S9R`P"+=TZCI^]]8734E
M^C4Y6HWN!?P$PU.4!,5-V0/MWB!A#^Z=1[DA%TCAZD53*(>H`(4C*E?'QL>V
MNJ3?>N&S'"TCLWJ7;BZBF+$N<3&NE419$?Z^M_B81,FO)551`C@H"<I5DA_,
M81'#"\.9L'R%&`,`8`P#69\I$B^)IW5E726.2&OF]Z76+,W*(E!_#_IU@F09
MJ&`Y.$E)")0$P#Z"4!`<$9LBB(J-@XN/AH=DWCHJ+9MV,<P:I%0;-&;9,J2#
M=%(H`5---,H``<8*=C@#`&`,`8`P!@#`-87?`H4[<747:%<(5C=$MDR525DD
M2BFH^KTA#JNEX^0,D`'=LB.40X3-R']Z(Y2<S9[D*:[_`)3MU[)Z^=,K_M#4
ML[^V[Q$6/74=&R_VZ+K[9O/7F#AY$!17_NS`HQ>'*/X@`^GKFIWJ]?L8$KF/
M+IO=44G[9)'R?ZU]R;QVI]/LG>-AO*QN<;^/",W'JHKE^$):>:DT4\JW7SY=
MK+7X*RM>[6N6[:PPT7--T5:$\4600DV2#U-%02."IB<A%^#"`>HAF&L;?)M2
M=V*^'@?.L'M'Z_Y6);SH]S8BC=MQDD[,FDI*OOU,A_RQ_+]_[XM;?\/GO_B<
MY_*;W_2P,S_!O^X'_,V#_9Y?>1!L/XNNY'9RXZK)W$[+4S:&M*'-S+QQ"0%;
MD:].E9V&.18RWZ1)$<&(@_.#)N=,QRF*4Z(<AP(@.-D;+G9SC',N1<(O2GG2
MII<_Z)=_]Z[IA2^HV\8^?LN)*X^BW;=N2]114G777X8M>%"4NGF]]G=3]X1?
MQX=FGKBR_=G=J=;=O"^([5MM-2*HM'UNQE56,[0E(UL4$BF.4O)R&*`F+X".
M1@Y-W#RH[5?\&XLW?TY[EWOL+N7_`$A[TG\S=:<L#*K64[#X0G7@X:17NU5#
M;WL^;?5C6&PK%$&,,G`TNRR\</!1-]['0SQTU``$?'D5DBAGH.JLGY'Z1:<(
MJ+XHJ1\;E8CH[K+`70#_`'MEV=/6FX6V85$5'<E*'L,G')@NL</=$J"#(!`H
MC^0YS?QRU.*+]`'']8CD*><`8!Q';%H_;+-'S9N\:N"G(LV<)$505(?T$JJ9
MRF(<!#Z\@.4YPG*U+KM:2169OU:UY%;;CMK5Q!S7WS547$G",!61@I-TDQ19
MMGWVJ"K?VY%,K)$RBI_=]P$O'C@YLPXX5JUD_.1_&U0W]_N?<LW:%LF9)SQ[
M4NJ+?GR\RTF99YT8`P"FGR`TN"N74G<?ZT@!E:I67%W@G9/$KF/GJQQ(,7+5
M4?5)18A3MS"'J*2Q@_'!'P)=ZU3TM9^OFE;!/.U'\U+:PI3N4?K"85W[T\`Q
M*X?+B81,*SU0HJGY]?(XY6$8-WBEY"`Z;]I9V(DG$/+PW7W<,I$2K1PHU=QT
MJPU]874<\:N41*JBY;NTB&3,40,!P#CUXS`W/K_N^]Z;E&?INCCQ^RAXOZDY
M5W!^G>_9MB<K=^UL^9*,HOI:DK%SI:?)UX>=#3STW^/:>[%=;-2[HL?<CL_#
M3>P*VK-2$9#7588]HJ27D6`)MQ<+&5$@I,RB/(\\CFCPMMGF8MO(G?N]3C3\
MI^?^P?I/G]X]E;;W#N/<>]6\K(L.3C"ZU&/QR5%7EH6>_P"44?\`][G;3_?0
M/^]S*_N1_P!/=/7?Z`/_`#-OW]<8O:_A<J5W8(P5Y[8=D;I`%?,I->"M%A:2
M\4X6CG!5VYE63L5$3"10/0W')?PSC+MZW=_G+]U_:=-__;GMF=&-G>=\WC-V
MY34I6;MRL)-<*D%[!:NOB@[2:O<Z4ED;;H[L_8XZOVGKG'>3FX1L^U!G%*7N
MC131-<I4#'<@JZ\O:!7VS)ASQY)\/3EL>4HVY2N8TU5QXR3X5IQIP/+[M:?T
M)[QP;W:[A=[8WF_&U>PE+JO0E^'U[4%63BDDFZ:M4X\/T1-#>2!1`.`X*`<\
M\\`0H<F`0]#<AZA^`YZ54:ZDJ5UH?K6E$E^K14\:4YE/OD&,])TXWL9@90BP
M5=A[ID@.)RL1LT&61.`)\F`",3*"8?H!0'GTP0F3KJ6"3T+IHE;!J2&#65+,
MR*S`I4``:^P,Y$I0^A_NS']S\?<YY]<%)EY#^(?R_P#JP"N^XU+#&.BA"++K
MM[_'_L%=L=P"32/DG;HJC241,8?[EU^DN'Q`\>`,8">0_E#,>\Z-+FUH:O<W
M>C'TX/X;RZ&^2]OY41+MF0AML7UCU>GI#LAIE^V<1-BIFU=9J.ZU!;("(ITA
M(3,$PO\`#M;`VCTHIN^6^]8RZ,<+IRV(+51<P<9UW)J])XLDTJ<?$YREZM]8
M4NI)133Y/3Q+&5VWZYK3Z#U"&U8&9O$'"1D8G!6.\P<CLN73C(Y)()29C#.T
M)B0D)!!+WW#C[8ONG$Q^``<R?5M5Z>J/7X55?<9GJVU+HZH]?A55/0\Y#VK[
MZ@7ROM&#Y_\`<MAAIH$G<+:(Y'VE"/8=THD5N_\`(H\BW$"N4#IG,)/`I5#<
M&^M>G-:2T^QEQ\^YC9"E;;MY475/A5^3Y^PR2NT:I52J-*7"0$?'U:/0^U8P
MB:0NV"+8A_,B1479G'D0IP`2E'R`!`..,YP@K4?3A^$RKV5D95QY-^3=W]KF
M5DV/V:2U-,6"(O&L[.%2:+-HV`E8V/36:615<'9'#5HW.H+;[-N1N43*+';`
M(J`DD14_B!]7E;A\K/\`>PD['.B;_AR/;[#V;_B"Q&_MV9;AEIZQG**==*TU
M3T3;X/AR+)ZZML=>*C7+;$QLE$1D[&I/&$=,,TX^39-Q\DDVSQBBJN1HLD!.
M#)B;R)QP8"F`2AL[%Z-^TKD*J#\>)Y'=<*[MNYWL')E&=^,J-Q=4WY/F40^4
M@&0:*IJ@`F%B+MVE$JQB%.9_^J'6=`8K$$@,L*IFOGR`>G'USL->S8U">^,-
M$"Z$XNAC&'W`J<^X*XM416$_/_;%3GG^?#"X',7XX)R/`>?(B/''`$-SSS_-
ME155237&OZ&?FAZ3]*.GW9*Q=P[CO^MQ$Q:HWMYNF'CW$C9PB%"1*=PF%DRI
M(?<HB=,53F]>!X$.,\;M>#A9:O/*47*-^=*Z:-GXV^G'TU[#[NS>XL[NRW">
M7#?\N,*W.AJ/J2=*55==:E\/^5!\9'_R)5_]_`_\?FT_N;:/"/O1]0_T)^C'
M_;VOZ_\`XGJ/Q0?&/SQ^QZT41`0$I+Z4/(H^@AP+X?+GGC"VC9J]-(]7M1UR
M^@_T8G))6+2:U_ZCP^TK1\C&D=#=7=1:(VUUOFGFN.PNLYZ&HO7-E03_`+@F
M-H-9-^Y?.J!,Q3947%@KWVOW2OW)A,FU'E'\PKD3'"W?%QMOM6LG$2CDVY4B
MN;ZFZZ<7Q/(_5WMSM'LGM_:^X.S+GRG=V%?C;P%9?J2R5.=9V9QBW*Y;=9/J
MUZ:]/.ANUT/8=B6O36M+)MNM(T_9<U3X9_=JTW6(NC%6!=J0SY$AB%*5+W5/
M[P4?S>P)Q3$QA)Y#Z3'=R5B,KO\`.-:GZ0[;R]VSMAQ,S?;*Q]XN6(RO6TZJ
M$VM4G^6G*M.1+.=QNS"[?2:S>HT\59H9M+-15]Q(5B"1=HN00]MTS<%\5FRZ
M9@Y`Y#`//\0],Z;MBQD+INI-'1>Q[&1'HNQJBOZO4;7U?1CI/5+J;U7=HA15
MPUM==?N'"LXZ44?.C$O<>].JRM\8L_D%EU4'`%$3''P,7GC.E8D;*IBT@S&L
M[7AXW_2QZ'^?VG75G:FZHRQNZ9=*C5Y.;KZ+$CV5KSIU'H6I!X4ZA92MQ4FH
M0&I&R1.'2!UCF*H/*8"7TS77<_<;-WT':AT)\:\5Y+Q\C`GN&YVLMXWHVW!/
MC75K_P`/+[*E@JS?(VQR+F,,48^89"'G&.1_O#(<$$7#<3IH*F`@G\3E,0IR
M&Y]!)XF-LK.7:O:23C/P>C_+0V>/F6;\G;X75^J^/N="0^?^O,LS#YK)E524
M2.4AR*$,0Y%"@<AR&#@Q3D,`E,4Q1X$!]!P%3];5%'Y6L7S1VPT&.J'D<WUC
M=P>2;FIV5)=6$K-H(J43L:@Y;'(K"L;"*H&4;B0S=)8/),`$X@&HS+M[#DK>
M.O@DZUY>S[319<\K!R(QQJ+'EX\*^'E7D65IM^_7)!6'FHY:#G$FJ:WV[A0/
M8<G`J0.VZ!E/;4^Z:FX,9/@Q!2.!DU%.%/;R,;-A=GZ5Q.-ZE==*TIP]YG8V
M;"[/T;BZ;U.#\J5I[_NYDGYG\3/*Y]L]]QW63KWLK=+]B,JM4H=%."A2G,F,
M[;)Z09U^I08*%`QDAE[')MF_GP/C[G/X941D6]*>M<QIFKV#9.SY-Q8NQ6]W
M+"Z[MGEW)U6;>;.@<T;4X%N'"3.$J+%P5DD4`$3BD)OQP$B[P?0,A1@#`&`,
M`KAVKT0R[$:=G*$H[-%S:*[2Q5*:22*LM$6>$.9Q&N"%,8G";D!.W5X$!%%8
MQ0^N",A[J1VM_P`26Q=1[:8NZ/O^D,6T9:(&Q$2CE;.NS*9NO.0)#*F!VBK[
M8&4`HB(F,(@'`Y2)E\,AR&`,`8`P#P`@(<A],`\_3U'TP#'[1:JY2X*2LUKF
MHZOP,0V4=R,K*.DFC-J@F7R,=154Q0Y$/H`<B8?0`P#6/J=68[N]BHO>\K`2
MD)U[TFFH&FV\PP,V4OMIDB*LYFS*BJ/@HR9NV9P(4@&`"%3YX,H<`OF0VK_R
M_E^&0I2OY!.LUL[=]7KEHRDV&O5>QV.:I4HRF;062/#-B5BUQ5@<$<%BFCUX
M91="/,1,`3,43B'EP'(YK=UP[F?A2QK4E&XY1:;X:-/]!\Z^JO9NX=^=F7^V
M]KOVL?-N7;,XSN)N"]*["XZJ*D]5&BTXE((3K9\R=>AXF"B^X?7-*.AHUG%,
M4CT"5.8C-@@1JU(916E+'.9-!(H<B/(Y@+'[A245=LZ)+AX?8?.,;L__`'"X
MV-;Q<?N'9X6;<5%5L3DZ)45:VCM?\!?FB_\`>/UP_P"'TA_^Q,OH=P_TMCW'
M?_A7_<5_F7:/[*__`&BIW8O??RC=&[YH!QMS:^O>P$9MFV6*NQ&N]7TDK.8G
MI2'CHX6D0LL^KD0NF23D9UL`&0,=0J::G`>7B`X>5E;W@.$;KA<E<;4>A:JE
M*_G/"=U]U?6OZ9[WM/\`?^?B;Q9W"Y>A#'QK'1.4H1A1?@BW5W(\.2?`V'=+
MNFED@+#)=K>U`M+=VSV4F22E!-XKP>J8-T431M'J38Z7#-S%M#`BZ5`ZAA,3
MP`P@`F/ML#"G"?SV4^K):T7[-3ZO]./IYF8>1<[V[YE\SWWFR]1M_@QK;KT6
M;2?X7&+I*CY>-6]E[J.:OV#V-?-R+L9%NNT=-SEY35;.4C(+(J@`CY`=(X@/
M/U`<V^G%<3[2ZOCQ-7&C;FKTOVY/]9]F$6C-2W6S/+#HZ^/2>U$)&FA%9Y59
M.0,;[=LN@L0I4RB)1\_S<?GYP<5X&U9-0BI"*)G(HFH4#IG(8#$.0P<E.4P"
M(&`P#SR'H.0Y'TP!@#`&`,`8!X$Q0*)A$`*4!$3"(<``?41'Z``<8!J[[6WZ
M1[-W)ETPTTZ6>H2LG$2.^KM&^VXB:A2(YZD_=P_WQ3>W^L.EVJ0@B4W*AP*D
M/('-E.+U-DE3K453*O7:?!("VA*K!Q-=B$##Y&2C89@A',B'/Z>9RMVQ>1_$
M?7\<AR,+WCJV-W?I_9FGIA^[BHK9]%ME#DI1@1)5]&L;9`2,"Z>M$UO[E1P@
M@_,)0/P41SKNVX7;;M7*]$DTZ>:-/W#L]KN'8,W8+\Y6[&;BW+,I1I51N1Z6
MU72J7#S-653^(26H\''5>G=[NVU5K<.V^VBH&!MZ\5$1K<5#JBW9,64HBW;I
M"HH)O$I0#D<T4=@=N'IV<F]&W6M$SX?A?0/(V[&MX&!W1OUC#LPZ8PMW>B"5
M:T2C))>PR7_E87S_`/T1[F_\0)/_`,YQ_<5W_N\CW_\`$R_]$-T_S;W'_:)?
M\Q1SY`^J.]^HNB$]MZW[M=M=A6T+W2JO&U::O\^HVE#V.839?;IH,915PNN<
M1`"E#QYY]1X],Q\O;LW!Q9WL:_<G-4_%J?-_JEV#W1V+VS_?^R]R[_E[G'(M
M0A:G?FU)SE3@I.NOM]AL!Z/=,[U%3QNUW;"73OG9*Z1$8A%,WY`?Q^H:N5$#
M)5ZNF<G<)HRKE$X"]62`OY^2E$?41V.V8EY*.7F.N0X^X^K_`$S^G^[8UV/>
MW?\`-9G>61:BE&3<K>-;II&TFOAEK65/UF]=6;6D2^)``>>0$>?(1$1'_P"T
M(`)OZ<W!]NHEHJM>9U5BA(NS04Q7)R/;RL).QKV(EXUVD5=J_C9)LJS>M5TA
M$/-)5!40$/J(>@>OKE1&:KM7;$G>A]N0Z\;J%1UH>5E7BFHMOK&7^SA6\@X,
MY:5*U*G`Z386P>104\B@!PYX$IN2B&U)G,QTK#IS4*Z;2\<Y9B[8NXU9)XW>
MH>T*J1FRJ)SIK`L4?02B//.<+C<(UBJL.347)<4M%XE3H?8-EV2W+2[76K'&
MJ7%DJ_AYDE6F(L:3*-W"\JQC;$=RF9L(QBB#9('*9P*LH51,Q"@(&/KK>7*Z
M_1G;DIZZTT3\*GGK6;D94ODLFU<76G6?2Z1=:I-_I,W36[`2>RJ](5FP:6DM
M%))?;3XF_<+W8:DDT;.6<H>'>L2*UL!+,IB02',!B$`Q1_-Z9W+YYW5).V['
MVU-NOG97E*$K3QZ+Q;X:Z\#JM4V![<]Q;\3M.K8FN*ZZN<%7Z#=S1(%D;K7)
M.G14PXDB2*S8JJ@,9-TX:B*2@D`"<#G)6HJ]ZCA1-:2IQ+8C;N9#E<@E+2CI
MJ]/$EVSKUN>F$J!8HY;RG(5:2AG:@^TFY69N"_J",3(H*%=L9B&_V5R`D,0_
MB<JB8_W1Q#MN4=/!G*\[-R?RMV-6UH_N?BN)SZY%V:&=*,I&90G80A/*-=O#
M"2P(*^7YF#WV4",7K=-,0\%O(JGIP8IAY./*U":6LJHY6[=VU2$I5@^#?$R]
MTS;.D_%PV27*`E,!%44U@`P&`X#XG(H'(&#GT#T'.;BIKIEP,J-R=O\``Y+S
M7$P2\;`U_IZJNK+=9Z&J%>CP<+F7?+H,RJ*&%1THBT1/PH[<KJF,($(`B8QO
MIA4C\,51'&4NI]3;<O%\37YJZ/MW=7==>W_;H9U7M`:N>NSZBJTLFL#BZS1/
M-)*ZR+!8I$B-2*?WB/)1'\A"A_VASEP."U-I0<@``/'/`<\!P'/X\!Z\!D.1
M\EB>91X_M`10`X`.?S%XX`?3C+RIXBM'7DM:>)K!G_A_Z0VJRV>W2U$M@3=O
ML4U:)U9GL*WQR+N9GY%Q*R3DK1I*)MTO==NSCP4H`&:2]L&WW;CN34G)ODVC
MXID_[?OIKEY=[.O8V0LG(O3NS:R+JK.Y)RDZ*5%JWIR.K_Y,G13_`.1[M_Q0
MN_\`YOG5_AS;/V9_RG]YU?\`YX^F7]!E?VF[_P`Q!?9?XD^GM!T%N*Y4>D7<
M+C6M<VR:J_CL.ZR!@GX^&=KQ(E9*2JJ;HXO"D`I/$>1_CG"_L&'"PWC>I"ZN
M%)5/-]X?07L+;>UMPW#:L?*>YV<.X[*]>[*MSI?2J=5'5I*CXG$^+GX_+72J
MSK3L;V:>R]DVK&4%M7]3T2P)E59Z;I[CS>)<L72:@'NLH5T<5U_15N"QR`/)
MC\-FVN[9CZ^?*4[E712XK5^/Y/!''Z)?2K.VS$PN[N^/WF^V<56\7'>L,:T]
M6VI5I?DVVVN"=-=*;TTO,4R^?(&]>0$.!#U'@!_`1`/Q_'/15KY'Z6U_6I4^
MF`,`8!@EJHL=:C-G*XBSD61A^VD$DRG6*0#`;VC?G24,@8P`8``Y3%,`"`A^
M.+DXD,BE=)+@_!F'E8=O*5)Z-<&N*(Q4UO:G,W&A-JQ\JP8NA4C+;$.'$9<H
MM0#BJDJZ*J@LT>M.4R)J)G45`2E]0',.WA7K=V,KC]1I\>:,"&!D*[%9#4[<
M9)QE'2:IPZ_%>\L(0HD*0IC";Q#@QC<<B/'`&'@``!'\>``.<VRX>9NE5'TY
M#GC\0X'^OGC_`*,%,6M]786Z'4B'Q?0RR2R2I`**B"A!$HB'D`\I+(B9-0OI
MY)G,'(#G5?M1O6W"?#E[3HR+,<BWT2^SV^)`,K5KNWF(R'=,3+ND797--V'&
MD6>)1SIM]XM^BVMF4A%T8Q=LB0H*@90#`<$Q-Y)@8^G>-D0DK<XN33JIKRY,
MTWRE^%Z$+B<I*55<6M$N4O?Q^YEGF97!&R!78I?=>T3[CV1.*(K^)?>]GW/S
M@D*G/B`^H!FZMIJ-'Q/0:FM?Y>@0_P`A^T'"KMLW4BK9IBP-&ZYP`\L\K>Y*
M)/-H-F0?S+2$RK'`W13*`F,=0.`SL1&;)8UX,A','XHJ-Q?,FKP6ZH"55`7*
M":PHJE$`$%$O/Q,'\0R%.;@#`&`,`8!X$.0'TY_T<_ZA^OK@%5^P_4W7O8%)
MG,/C/ZCL:"+Y578U86^PL,*X`P'#S.02DD&AC!^9-7GT^G&70A5\NR^\_61(
MS;9U#8]D]<1:B:*-QH1%&U]:Q)!%%-Q+0J2:ZT@X(FA[AQ*DJ?DX\FX`.`U)
M3HOR1=7[8Z2B;!9Y76-A.014A=A0<C"J)K$*)U4ONR(+MB@F4H_F5%(!X_CZ
M8!;*M[>U3<$DEZKLJB6$BQ4S$"'MD$_4Y62*LF0Z+=\HLDL*1P,)#E*<`'U`
M,A:F7?K\%_\`G43_`/J3/_OLM&2J..YM589HF</+'`M6Y!`IUW,O'H(D,;^R
M!E57!2%$?PY'%&4@6[]Q^L.OD5%+#NNB&43`X`U@YE*SNCJE,9/[<$:V65,F
MN*I1+XG\1`?KQD)5%7Y+Y"I'9#\E6ZK:1O.V)QX8R2-HG8MW7*+'^("!G;R0
M4()#H!Z<`=9N(CZ<#E!\H/J!N;?DPPMO='8!):(CG1'<3IBBJC'4U$"^"J'Z
MZN@5(\DLDJ`>8>H&`O`F$!P*&R>#@XJMQ3&#@F#6+AXMLBRC8YBB1NU9M$"`
M1-%%),`*`!QZC]1_'UR%.VP!@#`&`15=M-4/8%ZUEL2TPR,M9-1*V=W1EG(`
M=&)D+6VBF<C(II&`2_>D;Q"94E/JF!C<?7.FY8A=N0G+C!NGVFFW#8-KW3<<
M/<\ZU&YE8,IRLMJO3*XHJ37G2*)13*)?+GGU,(\B/UY_F_#@`SMYOP-TWU.J
MT/IE(17N#35`WE3WM(V)!I3,*[$JJ9BG%O(1[M(1,@_C'J?"[-XW/P)3%$.1
M^N5$:J4&0HW<KJ.JNTU4HGV2TPS(=PSJMJD"M]B0#,O)SL8V0.HD20]E,!\>
M3B)N``$S#@:F>TOY*^OLD=G#[)-:]-6HZBC5_%WZM2K1FSD$3$(JT"10;JG.
M'N*!XG.BD7@>1$`]<"I<RL[=U7=&Z3JI['H]B16_L#$6B%>G`WCY"FHB@].L
MBJ4/[1#E*<OX@&0M20RF`Q0,40,4P`8I@'D!`0Y`0$/00$,`\X!A%AV7KFI-
MUG=IOM-KC9N'*R\Y9H:*3)R(E`!,]>H@)S&*(`4/S"/H`<XH2JXE-[S\DO6J
MN+OX>HS%@VO94$@(TAM>UV3ERO7ZJ@)H,4WID42'.H<0_.B5<H`/IY#Z914C
M%VV[M]M11BY2+1ZLZ9DDS+/E4':<ALR;9>0*-T"^!P_2TGZ)N#\@D8@_VB#@
M:EW-$Z`U]U\JHU>AQJJ8.W"CZ<G9)87L]/R:OC[K^4D%`%98QQ+^4G/@F'H`
M8"1..0HP!@#`,9L]3K]N0CFMBAV<RWBY5C.L$GR)%TFLM&*"JQ?)D/R`.&R@
M^1!_`<X3@KBZ9?A,;)PL3.A&WF6XW(0FII-5I*/!F0HE\2`'`E^G!1X'Q``X
M`.0_@`9SHHI17!&0JO5Z5Y>!]<%&`8?=Z'4=D5]_5+Q7HNRUZ1()'4;*M4W2
M)N2B7W4O,/-!P0!_*<H@8/P'*2E37>XZ?[[T`XDYKJ-N%1.O"J#IOIG8Y33%
M;%/S4.K'Q<NJ)UH\@)F\$N2#QR'J''.!0C#:7:#=T>E$P/8;0NT-8,6CY)R^
MN6K$TKG5)0@'43,E)MB$>H?:"H05"%5=-UBB`>GX9T7;7KKH58>9@Y>-<R4H
MPDX:\N9UD-WDT+7J>RI-<V2,:U>6.X2%I9HUI_3;3Q8I.3EFK.LDX>0S)VK,
MO#_J)E5FX)I*E.10@@),Q9V,BWB]%N3<JOAIQ\#$5C*V_'Z++=Z3DVZ47'PK
M1<7[C+K=O;1,=6M'5^,W+5I63BH4M,LLA'W)^@C%.WD,W6<67WO>*NN8)9`Y
MBJ&%0Y04XXXSJ^6R?3L1;?5"-):F/DX69"SCNRW*_&*C*CX:<=>-'4L+>^T/
M5>0J"`-NP-#0G*<1M-5B9-(.)-XUEX5OY(KK-62!GL@C(`0R+MNF`F=(*&)Q
MR;TV,[?5!+FC;Y&/ZMF*4OWUMJ2?BU]_,PMU\H'61LQ13C)*RW.P_:HG-%4R
MLR4BBXD!;HG7:LW3Y%@LJD5T<R95!1*81+SX_3GE!-*CT,B,I3MJ4])TX&-A
MV@[B;R;*L]%=:'VO(>1,5LC?]OKF8?8$4,'^WMJ\[2CW3D`1Y,`>PLF/\<YG
M+B9E3^B2UGMC;8W:?8TGO:U-3E=QM==)FC-?P#ODAQ^Q@$E#%<`D)>"^8^/\
MV"4-A3!BSC6C=@P:-F+)HBFW:-&B1$&[9ND4"IHHI)E*0B9`#@````,AR.7@
M#`&`,`XKIJ@\240<HIN$%2"11%4I3IG#Z^)BF`2F`1_B&543J<+D(W(.W<2E
M!\F?9(@)IE(`>(%Y``]`X#D>```]```P^)STY*B/ID`P!@#`*O\`9+9'8>CM
M:S%]==$-=P6BRNUVSN7L5OCZE1Z0W1*4Q9"S+"=2=>IN!,()ILD5#"(<")>>
M<J(533[T[LT%)-&7>GKU_AK4)1^T8,-WZ9?RNR=51B[Q8B)"W1N#/]T5!FF=
M0!.\614;%`!_-SADU1L!V#N#5VK:(\V3L6^5FG49I%A+J6.=EFD>Q59&;E=H
MBS,NH4[]PZ2.7V442G56,<I2%$Q@`1:FMJ@['[\=SHE?96GIZC=3]$33QPEK
MMY=J$K>MNW"M(BNB6UNXF1>L(BK-YU4"+-$CI'7(AP)@`PX&IR;'\?>YZG'G
MV[K#MKN:W=IX-5.683FQK&4NM+HBV4*X<T2>H,6W1@8ROS!""W*Y02^Z;`('
M`PB`\JBAW##Y+SZX8-X;M3U=['Z<OJ)00=EJVMI?;%`F'*1#>\XKMUI9'S`4
M7)TSG0;.02=>R'(EY`W!A'WD?D?F-@1BD3UFZD]H=BWF3341@%[_`*ME]/:^
M:.%$U"IRDW;+L+%(T8R4$%%$VZ9UE2AXD_,(8]I*^!ZZW^/^P;%E*9MSO#M2
MU[PV=#O4+:RULC)!$:,H%B%ZE*-HZ`J<41HG86\$J@@5%Q(BL<5$1.4"@/&*
ME5>9M((`@'''''T]?P_C_-_1D*>V`,`8`P!@#`&`>!`!XY`!^OU_#D!#T]/Q
MYP",[WIC4VSD/MM@ZZIUO2`O@7]>@8]^H0OUX2761%9(>?Q*8,$H5:M/QJ=/
MK,!SH:S<51V<"`#VFVNS0/M@FI[GY(PDDY@3'4#\ACG:&4\.``P<!Q:BAA(_
M%+U1,(F%'9Q1$>1`NPY'Q`1^H!RV^F*L41S8WXK^I#%V5=Y"7V=;%`0-&RNQ
M;$1DL(_0RPPZT2]$Z?\`V1!<.,5%$3I5.DG5&EJMG$#HVBE=-`(#=Y+1ZMB>
M$$GJ4XN[`XDW)S@/J)A,(B/J(Y*BB+-,XYC'-R-8]HV9MTBE(DW:H(MT4TR@
M`%3(1),I2D#CZ<9:BAS<A1@#`&`,`8`P!@#`&`>./Z?ZQ_Z`$,`P:YZQUYL6
M.-$WJDU>V1Y@5_V6>A&$DD4RW`*G3^X1.=)0_C_:*8#<_CS@%0[3\:'3ZS"J
MLCK9Y57BAR&^[I]OM4("8$*8H%3C1E7<(0/S<C_LO)A`.<$H1H7XI-+$*4B6
MZ.SJ*1``J:1-@TT2))E#@B91/K8YQ*0H<!R(CP'J(XT\$*'G_E3::_\`6SL_
M_P`0*5__`!GET\$3I1G]9^,;J#7S%6?T2:N+DBA%".+?<[,_+^1(J?@K'L)&
M+AURB("8?-L(^0XJ6A;RAZBUAJ^."*UY0JK3V(>/DA`PC"/%42<>)EU4$2+.
M50X_MJ&,?G\<"A(N0HP!@#`&`,`8`P!@#`&`,`]#IIJE$JB9%"CQR4Y2G*/'
M/')3`(#QS@$8V[2>HK\@*%VUI1K44P.__P`;K,4^,4SX.'ATE7#959$[GT\S
M%-R/&"4(K'I)U+'@1Z_:QY```/&M-"\`7^S]`^H`'URU%$<IKTPZILG+=XVT
M#K!-PU6370.-6CU`(JD<#IF%-5,Z9P`P!Z&`0'\0R"B)LKNOZ+4D`;5>FUBO
M-R@)2H0T'&QR12B;RX`C1LD4`$WK_3@IEP`````'`!]`#T`/YN`_#`/.`,`8
M`P!@#`&`,`8`P!@#`&`8C>Z+4]F4^R4&]04?9:?;X=_7[)`RB0KL):(DFZC9
MXR=)E.03)+)*B'H("'/("`^N5.A"CM(^+/IO2K%"656D6R_N*L=-2H1.VMG[
M!VA5Z@9$W+8:U5+E896O1HM2`4B0@W,*9"%`O''.04-A:""+9%)NW231003(
MDBBD0B:229"@4A$TR`4A"%*'`````!@I]<`^:B2:H`"I"J`4?("G`#%YX$.?
M$?0?0<`]B@!0`I2E*4/0`+Z``!].```#Z8!Y`.!'U]!_#U$>?7GU$1]/YL`\
MX`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P"B^V=[=@:ONO:>LJQ4-3MZU!]2[OO74MB?V2TS=FM^Q*5
M.UR-<5O8%=_;M:A:-2S.9<&H'CY.=?/D5C.?=CCH`W7`S7L)V`D*KT5WAVGU
M,"9I2N=3-E]@-:!881:22-(0^GIK8M-"<KC1^T</TQ<-VWW+))TF=4/)(JI1
M$#@!0V(^1S9NJ0VW7=K4Z>VC:*E/:_?4F(F=62W5K94SK^XT6\3\A81U?99[
M8UFOD2C9M93$5%/ZW'K'7?)+HR#5@S8*2[@"3MI?([;DM/[0VOH+KW*7BNTZ
MOP?[>MM[NU2J4')7F3U_KK;4A`3%:92TC;F\'"T&_BD>1:D<"K8HY=E[)&AD
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MO/RLLM42<[2=K]>;+2=LP4T\`*`KM/6,FVGJ;":TUULVQ6.LW1K)DKC^:;-]
MIPT$RAUSM%7]A<&+[Z42F>7*!./:7Y"M9=8HG4$B_K-@N#W<E$O.V*W`H/(N
MI3+G7.M&>O7=P/&-;6JQ&2V(JKM2#;1-=4^T4?NG*A5G+0B"B@`1PS^2\CJ>
M"$'KK>TOWO=-XZ^T`[&Z400VY9-#=NJ3T\LZ\LT._2=ZTK\E<]CQ4XT7?E<O
M`KZ,B=9HF]:MF3\"2T>\S@EEC(B7T1=(6'A;AI/5^YI]>X:_?CK':O8+8;+5
MFNJM%1D1-R!]B0Y;?,1AY269JMD&<7,-'"*;I<DBTCP(^;?)`ZMDSH*H:IZZ
MV[8-W["]?M"=@ZS"K7ZDU",@(#>M#W[L%I%66>G3@4CJNQN@'C-11FW=BYD)
M5F4$TFP.G3<"#(KYB8=*(LEGL>H#$B+#;HN4T3!M+O`0UHM>D!ZH]7>R<Y8[
M2O8UFU;8[**'9F&C8^";N_9=OI-NV4<H-V;^6`"7+_\`)^PI$5<+<EU]ODGK
MNK[$"DM;R_L]:JT._C8K5M>VM:[58W4X1&'U'%LX^Y1,1'.+J]KT2XG5ED9&
M0B&R:#QT!M0162<))+H*IKH+ID6161.51)9)0H'3524()B*)J$,`E,`B`@/(
M8!],`U2[.[A[^US=^RJQ%M-W;7W7[6&W-S7.%HE$V`]E=0US3LI4+37Z!LS=
M3N^.==V+;_834"4Y(LZVQ@H>4IOW+%T\3DF)4W,@!;CN?M:Y:2ZV;$V5KXZ*
M=P@UJ0PA55JN[NPHJ6K8E2J+M=K4&$A%/+-)(,)Y4[1BFX2,Y<E3(`^O`@:Y
MA^4BV:*I.YG.]J+9-ASVI+A<YY-FGKIYUZVO+=>J?IW4&Q9.]AHBTV&[7*RS
M#BW7>P0T4_C$&U152@`+,2L*Z,7[H"QFS>]>RHMH$GJSKTI/59;LW3.OT5?+
MEL&L0L3,_IO=/7?37=;O]K1CI];XF0BKO;W2=;4,BX:/46:CYZ+0I6S*0`P>
M&^6"DW67E8#6.G[1?I60OD!2]9E8W*HL&-M;S6XHO2BD_<'JZJW^%B:$Y--9
MMLQD$W$C(UE<5VZ)Y)L_B68!E\G3:&UUL'9<UJ:V6K7.G+_-:IVILF,?U.N!
M";1E;"JVUQ38NANIR4GIR+DV-BJ[5_-(*^RT<V!NH""J2$H,:!U,S\C6ZB;2
MHFNXWJI-,;<^T[9-[VK6,GLK6[A^IJ>3K:,_KFU([%CYI>LQ$\#VJ6F&DX%-
M"16+--68D<?I#HLP`&52?RLZRB;'+H+:PO#^CDU?.["JUM@I:K3KZP2<%J.,
MW(:F3$7&R*]9H<Y*P+]1BV0EYYO)(R+911\R91HIR)P,9O/RU5G4L[9:+MK1
M5IINSJ!:KE&7VC-;]2+&X1JM#USU_P!D2MBH<G'+)M]@3UDB.Q$4->@4B,WT
M@1D[!T:/=%2:*@3MN/M]>M+]A]D5!WJMY=])Z\TIUAV;=+A`S-:AY?7"&X=Q
M]BM;6R=>QLW-)2]\39QVNHJ1:Q,4S!P#*,EA*NL_5BXU\!`$?\JK*KUR_P!V
MV'IR[.]1Z=NTU3MI;EA7U/0&.?N5+H_K#:N:L1L$G:["5DSK:#.35]UOXG?-
M%VI77F]1C@.);ODTV=I^X;,8[HZR3U:9U5CJR33A&5YH[Z(J-?LE0O-QL]EN
M.Y4))36\*U<IPS")8+SRM;KC>P%<MWDV@Q,TDW0%F.R/<&VZ!W?J:C,]8,;[
MK[9VI;C8(Z9B;6S86N3VPMV`ZI]?-4TZ,:R)4(!C59ZV]G(X).4<.#^PW7!R
MF7Q9*HNP+&Z,V^.XZO.R,A4Y"B6ZDWBSZUO].?R<;/%@;C4W"!'Q(NQ1!ACK
M#7Y6.>M9"/>%(W749/$RNFS-V5PT0`FC`&`,`BG=<U?X'7,P]U:^H,=?E7U=
M80#O93.P3%902?6.*;6%PG6*K(0UBN]F9U51\O"5]K(19IZ82;,#R$>DX.^;
M@5`ZC]MMA[DGM>5C9L3"Q\_>*+VA>.&,91[7K64@K)U)[*P>EK%)6&C72QVJ
MPTPVTZAMBI336NNGS]S75D7B!Y"2360<`!#?=OM]V%TCM_;4'JHKYW7].]7M
M5;W2@(SK9=]UQMHL%NO/8^)GHK9%UIEO@GNJ*:$)IAB"4@DS?.D$UG[M-N\,
MT!HH!G4K\G5-C=JW'5C755DLCMJG)L]7SU2MU/L=?V-9X_L;I'JLUKTC9HQV
MM2*:XG-L]@ZZ9$A9B5D(V(!ZK-,XE^U"-6`P^Y_)A:M5[#O=8VUHR+HL>QJ^
MAX[7D?([3KBLE.[:V7>NW-9MT=:+5&HRE5K^NX:!ZI2\PP?E*I**,6H@JQ_4
M7R,4T`]K3\I==9U-SLQ#6EVJ&I*=5M#;"V'=[`G7)>89,=L6*SM)77\;1XB>
M4>OIJNPE#F%G<PV=KQ9N&AHT9,CDQD0,\DN_FRF>S(?0K;J%<7>_I>HN=FCK
MU3<&IV4-':M5BY.2K]G?7]64/`?JTU(UR5@CQB153M)YF3W%AAERS10(CU=\
MI[VR4Q;9L_IV2=:KV%:ML,.OE^-<==T,+L%:(RL='JEEKUPM;9S4'4Q4)4B`
MR#EP+QU-LG+-O%'.K&C(`99(?*4T#3;K:=9ZY[!M,G4:#V/VAM:G?N2OU!Q2
M:'UCL<95;M/Q3^_-JN_MQ9F0FF[V,:ECF3Y2'2<++(H._L6#\"<NNW?C7/9#
M=]_TS3ZY,(&J2>T7$/:OU.(DV<NUTSL^/U%=QL44Q5%]17DE:I5!U76[H5U)
MF&]UR;[19!9H0#$ZOWWLU]CM:&HW66Z2\[OBKP6TM#Q<GL?6<(QNNE9ZKS=R
M0N]FE#2[YS0K`VA8IJFI!K,WAQ?3L<DFZ.D27<1`$4O?E?BE("9V)6.M.U;3
MJ-%JV)5+8RL5%3M-UGWOQ_PWR.-8&+UPE+/9MJLII-V\BO-183GM3=!HDDJT
M<F?-P.ZOGRQZ;IML&"CZ?.6Z"_<EY3:VF$L%?*E9M>ZWL-?UU;;K0(9RH21O
MDPGME2R0K&"8>;F01ILBX36!=Q$L9$#J2_)'LX;-/2P]7)I34K#6.U+773P]
MM3MVU;7/Z\[+5GKDV=A3JC#S01-)?OY=Q,.!1_4YEO#)`O\`9F=$/'B!91AW
M*;633&C=D437"UTN7838MAU-KZ@0^PZ(YASW:EP^VK+<RS&R(Z0DX.)A86MZ
M/L3@05;A-(ND$8Y_&1\F+IFT`J+N#Y9ZY#P^^JSKV@3$=LC7NA]KVF!7L\A5
M9X*[N*C]2)+M8WKUZJ%4L4@8:'$P*!8EW.LY59FZL:!V#?R;K-)%<#8MULV7
M8ML:[L=IM!(U.3BM^]KM:-BQ395HU&NZ7[2;CT[3SJI+.71SR2M2HC$SQ4#`
M1=X*JA2)E,"90)]P!@#`-,VHOE6KN^IS>EDU=:]&VG5&K=C=6_V8VJ-Q8W#8
M-OT?N[9*^H;9L.XL8>Q+FI;YK).DK-"QWV)GJ<05FSDDD)&05;QX&P;LGLB]
MTIGJ&GZRD*G7KQO/<D7J2%NM[@I.T5&CHEH>PMH3\[)5V)L%4=34H_K.LGL1
M"-S231`]ADV'O"HCYH*@5'V[\@9>H;&(I&\);7^]=JJRFWGIQTJ_CZ.NM0--
MP^I9^PM9ZGVVSV)*#[`&CMWULC.IIRHMIPL@C(IN8MHX!NV`X.L.ZVT[S"=W
M)E9&HG0T'J':M_UJHA`R;,73^H]M?DETM7QL;=U*?<.VJM'ZHU4ZZ(%:JB^4
M?*<D!<B2`&<Z_P"_;Y[/U;6VUM(VC7>TIO7\-LQ2&-:*=8H\]%L.I-E[)KM@
M4DJO)S$6PF)24TW9(5Y#@X<'C7C(BQ'#QBY:NUP(\L?RD%A*M9+RTZW7R2IU
M>N&KJ>I9#V^LLXA->_\`5/7';.8GK))$;/8W7=/J]9VC%5PLU8EHN(<6=PFD
MY=,&*A7^`<6N?)M.-)&#:[%TBBP@[=V*VWJZ#O\`6]@P`ZWA]=4G8E,H-,L]
MHV'-BUU\QO5S6MZKII#KS+)O+LX1\>*=.W7VT>N!?7L/NB0T=3*_8H6A2&RK
M!;=F:WU97:K'S\/6/?G=EVN/J<;(R4[.<LH^#AEY`'3XY4UW(-$E/MT'"_MH
M*`:ZI'Y;*!8'3DU,A5H6KPFSJPF]O$J=I:XZ5TY&[=9ZTV3.R<-6W(R^O;4L
MV<IRD#'R!5G$A$.DUP(#QM)QS`#CF^8RB+ZVEK[$Z2M4O(0K)K<'E4CKY2)B
M2<:W?5M]9DI&%)65[#+638485D,=+P$>P<LX*3.B:0E6\6]C91\!)MA^2**7
MMVQ:'#Z_LE.<U9O2I:I6>WJ0*+Z]0\GM#2U"L,A`:^F):N3%BK9E-ND2;S<`
MYGHQBLP=)2ZD6^_3V$B!\J#\E4M?F&K&;7K%=8>_=A:3IO877FG2FQM>&9[`
MJVVZIM*]?>V2UQ[Q[':[6K-*TU-2ZB+M)PJ[:+1Z")?U-RO',P,MN'R#N*]U
M]Z^[TA>O5XL;K>U7NEQ<Z]4NE`A9G6\'KK5=OVU<ALTVO+/*_+R$?#TQS'H(
MQ*KTCJ470*"A6AEGB(&%7;Y/V5%UQ;[K,:`MR5BHEZDZ[8M>!?:,_LYZNPT9
MJ/L.E8ZY&UQS89^W2RU"WC7VCAG'1R\9%SJCA!]*MF)6DD]`Y<Q\FK2"9VVW
MR/7J_(:G@'VZ(Z'OQ;;2G3VS*]?H@+MLZ10I4>]>ST9"L-;,9:09'7_VU[)0
MCEC]JFFLP>O`)^_SI4+]@?XA_IJ7Z7_C7_AE^F_NF`_7/\/O\R_^5W_,%^G^
M[S_A'^\?_BWZCY?:_MW_`&WW^/R8!-6U]*U?:L'=&;DRU>L]TU;;=.+7Z'`Q
M+5"46\BW_<C*!="L1)D^5.V37;+B4_V[Q))7Q.!!3,!U^]#Z(I?73:;;?"M9
MKO6^(U+:8':2=A6<,JNTU.K6'<%9(AZ+$Y9`6+JMKJ,R(M1%VL*A4D`,L8A1
M`KZTZQ_'VZ&98FKFH[')UE2N6"VR4_L1Q<+>UB9J-D8^LQE[M%AM\O:WVN['
M%61TFW@Y9TK7Y))ZH'VJH*CR!V4=UMZ!OWKBNQM+T;)RTGIV(HKB+1L$9)S;
MS4[S7<'4(:1%(9QQ**+2>JZ!&1Z5E#_XL[@X)HE]\=LQ0!(#T@*!T&G=RL8R
ML,-/6#<=[JL=OF"9PLT6<>RM6J.WJ5;QV?5DF<D\A&2,CNRE0<K+2$>"*M@G
M(A!T_,\6:B=,#KJE7/C]V+'1/8>)C].E;TR23V*\M4[*,Z\I5YBX[.M&YH.=
MV1%R\HR1:O@V[<Y:SU\+`@;]+G)-=_%E;N%A4$#H-2=>.C72+6.L7#E[K&)E
M--ZMB;LTVM9)9@C;IN#U#J2U4FQ;28(!)NW!84E3V59'KQM%)FBD7=ID')$?
MN7ZJJH'=QG6_H)*J,;E3H34,/.'H,=MZLVJ$G(-9Y`5%WKM?7D/NR,@;"ZEZ
MR#5?63\L(M./XMRTDX)-*,?BZCTRM0`@+KYTVZ.4JI7#7]VL6O\`:TE==V0Q
M6T]/MX374;9;.KHC5,%!TW4J4)-H*6BMRNIUHM"3:LG\DUE%';N.,FG%-F<0
MP`N#<:SU([%:T"U[(KM%E]9:MLVV-<'E[FC^S8.M&UM?YS36UZ?(/72\$B.N
M9&U:\6CI*+<G/7YYJR;BN@Y;@AP!TFXZ5TIIM$NDKM&M:Y/`:YUCN_>,U#)&
M_4[/$T"R;&ANR&W-B5FO13Q2S`L^V]KN-LR$G&I`Z:V*+:K,547*27`'.U;H
M7I[=/V=L?7&HZ6F.G+!;-1U-ZVKSN$0AYKKQM*^Z[=,G4(I]JPL;C7>S8:>6
M@I&0;O%63QRXD(]9-1XHNJ!ENLNG76/3-A86O5^FJC3+%%-8QA%RL2D_!S&1
MD%%VZ!K\1'?<OG";&%KE?O4I&QK)(I&L=&N0:-DTFR*"28'3N>C?4QW7RU97
M1M.)`D+54R1[4LJR*5"F:XKVGX-H5=E)-W16(ZIJ<77'R`']F6A8]NS?%<H)
M$(`&17/J/UMV#$+05NU!4Y.*<622M:[1)%[%%6EYNNQM1GTU589Y'KG@['5H
M9I'244)ABY%DV31<MU2$*4`+$(HI-TDD$$DT$$$R(HHHD*FDBDF4")I))D`I
M$TTR%`"E````#@,`^F`4]LW1W0\Q&;180,1/5`^ZUK:AM`8R[7Q[$6:`VG=0
MM^[(5&IR=K<5.`6VNF^E&KQ]'LFSQF,JNX:G36X$0)*[+R6@XW3%L'LY+UN$
MTM(.*S#6E]:Y9[!0Y'DO:X1A52'EXUTRD8YX:VKL?MET%DE$%P(IYD`@G*!7
M>5ZI_'7(0]NB;)3M+SC*DN)N&V@]M=[-8)ED79<?7JY,57<5FL%K?6"6A[:P
MJL,U"'LCIPR6"(CRIH>3)I[0&6!HOHD66O[D*_I,)Y-O$6/83G]TQOZS`)T>
MU4C;K>T2CC]>^_J#AK>HRO6J2DB&:*OIDC*4?*K.C)+B`I&M^C3[=-L@*%!Z
MGD-T(Q>O^Q$Y$P3W[^2C(.[7BR6BF[#KK1%XM$0L/<-B5=]-//T<$4)&6!.1
MD$U%W3==8#&[]UBZ.6VKW.9"/T_6'0L[MJ-SL1C.P@MZC>+L%HA%@D".9D*V
MYV9"3&RY`L;^HD/*L%I55NV,B5R<AP.MZ^:]Z05&[R&B-3TB%0V/K>!NM>L*
MQJ[/-WAXZ-@M6TVYLAGI`5&ZT26#G*ZQ:,$5Q9,6)"-F":+=N)"`<>S=9OC_
M`'=>OKZ'+I&C/V$;?M8N[PQG*'-,M7V"=TM9M8W%C^UKZM:=6MYH^L7KI:=A
M9J'=Q\V1DFZFV3[[8IR`1=1NI_1G2\52]2;4D:'N'8NY-J2=TBRN6Z9']CD]
MFTNKUY^DWJD1/3<R&F[E4-&PJ$TE-/9:(LDE&).955X\5((`6@O5)Z;W[=1+
MMM*!UVIN2A62AZNB9>_OB0;^7EH!*+W'KRNP4?,23&-O;.#G=E(2T<F5N]3;
MV$A5D@!\P1.@!S:MK3J,O'*5V.I5!B$+[MJW2*=2L:)(M[>-FZ7N$Y!6&8CJ
MW.NB.K*:#FH-RN!T45FZS,Q%Q*9!4IA`@9YUV^+N#F('62]4T8TL.V+A::_$
M0K.TN59VW6755&<(W2D.Y2/L"LDI%T_6JY(V2K[MP2-2A",XY9J+5)FW(!->
M_P`G4BQZF0WSM&NU?;&NZC5Y2I5R>IT>OL$SB`V/;:-!O*]2V]*6>'F%)B]U
M.O'0(S\U&DO$,G2!D7+-)5("/->=LNF6E*UK;6L2E8-%M[?V#A>ND'0[]K38
ME'L[;>6W*U=-MUG]Z)6Z&)+JJ;@1K\DZ;VM\X<LIV?<BV4?JRBBR10)DM/<O
MKS2H;7$_:+NI#QFV.R<SU*HR[B!GC#*;Q@=EW34,A6W)$8]4T3%AL*@R$<G*
MN_9C%5C-@*N(O&H*@6CP!@&#['UM1=NTV6U]LBM1]MI\VI%.)"&D??(F+Z`F
M8^QUZ69.VBS9_%3E<L<0TD8U^U51>1\@T1<MU4UTDU"@1KK_`*UZUUA=*]:*
M3%(U^*I.M;#KBBU*.2.C&5U/85Z:;#V]9W3TZZLC9[5M:RUR`=2S^3.Y>JNX
M@SD5C+OGIU0(SW?JGIWL'8\_*;]@J[^Y(76M*86B6NMIL%0H]EUR_E-PRU<J
M5J1-8H2B;!B8M6OVUXYBI1!^FT9.7"BR8-W)O(".@U?\:,]<=QR*D=H1>U5&
M4(UVZ]?65LS:U&4[$/H#:C=,[A],MH.LJ;2MD?'6E`8T4"O+2V2EDQ_5T0<D
M`R2ZZ9Z'4.?J>IKG1==TF0N6KY%2LJ/%WM2:GJ&F]K5IT@LC=4I.,"*ND-MO
MM`1W&/0>)3[F3L\@LW6.HX>"8"38W3_41M^X*#%5?3I/V#&ZV<6ZEM7<$?\`
M:,1KA&4D=:+VNN$?&_1XV%;R#Q=J9\B1)<BJISBH`F'`*A/>L_QG6Z_0L#&2
M.FTVFE-;R6ZK72V-I04B7>N=V1Q*%5;].W52>^X+0V%;U6_A&C5&0-$MZ^X/
M'JH)1CQ%%P!9.]ZMZ72456M:V6F:WFV<S;"VZJTV!,FZD8Z?V7+,(TFQX&,K
MKXDK7&XS$PT6;SS,&Z<2Y.W<-ED%2(*%`JUV"Z3](MLZXK$3';/U3J72T?9M
MHPMX3B'^N9.)N#_8PT=CM"/:;"L4BK.5#83YQ06IWBC>06:+RZYY:2C'L\UB
M92,`MCJ9#IU&[@W)8=9M]=U[<<1*7%CLX0=I1,\Q))/*_?-B3\7!R;TB,35[
M=8I)C*6"5BVS=C.320.7ZKAXA[A`,-<=>?CP"CM9/]KZ!C*)?;$G/5ZTQ5KA
MX&.DY:LPMLCDF5!N<38&"T;"P%5E)]B$3"/$(UK$/9-K]N5HX>)*`3U7-6==
M65H7B*E5];M+70;A`[(=5NN&BT'U*MB^CR]?JQ/KU>,<$+7/>T*U"N,$S-D6
MQH=,")$X+Y`!0Z@6_P")78YM3Z/U^WTD_A=-ZRMUWH,#&LUH&GT#3T0ZUM9;
M,%G>JGBXIOKVQR5P@9!Q$3IU(^6>M??<-E%XXYD`+6V34'2V:B*JWLD3I]2(
MDZ7?'-*4<6B.8HRE)F;/";INL_6WJ,XV/(Q\3;Z^PM*<JV.H>#?-DY!JNU4#
MW<`Z.IU[HKMW1.M*'5E=1VK3-BI_^/VLH@MC*C)NZO8UI:=E=QQCM_*-+^U>
M3SNVR9YR>553?NEY602D5C*.GA%`,7OFL?CYB*Q:MGRU#U)/5\(-;24VVH;9
MO8FCM.0UJCJ9U3HND4MVX8KWA'2+H*^91DR_7V].(+$JA8U/V@`M1HU]KJ=U
M13+MJ>&<05!VK'N=V0C)]"RE;E%UMY2;[;\W,S=?FTF\Q!V"Q6"[.I"0:.DD
MEV[UTJ0Z9#%$@`2Q@#`&`0?L+0=(V$_+(.V_Z0YE+YIF\7A[%IBE*7;_```M
MQ-B:N@I"0%8!:1<-?6#)VN"9#?=LDUV2@>VZ.8H';;LA-+V6@OZ]OK]DCKZ1
M=-'3@M\EF$'%)2M9,>XQDJPF'SV.4B9ZL*5TTLT>M5T7D>=@+M)1,R'N%`@V
MQ==.C:E0J6N+-2=+MJNSC[YL"N0S^8C8US/0%B,VG]OV22D1EVTU>JG>#*HO
M;FI(KOXZ?Y35F`<_D-@$D5[5O6MDO?X2LP6NR.MJLYZD["B8N39JN;8UFIO8
MNY[!7)-DC(*+'4=RW8.Q6!9`A2*%3LRB_`(JI"`%8J)ICXT[_H_WZU3],AI^
M#?0NQIE&7EQ@SU`7=1DJ/`!=%)>;:SM7K+C7#YU!-86340B#UM<\<1J,><4!
M`SW9VJNA4/K=P39,?J.%H"4.KO1)P:U&B'"U<UUINM:O?7ZOOX.<;6)]7XK1
MU:C(-ZI'J*-7<(1-LN55-82J`>S?0_0:V*PUJ8U;2KDH1(=A(K],GFD5&#2K
M(RICI6\+UUA,L8L^J9_]BPK]RW<-1KCJ08D>JHF=B=8P&?5EYUP>P$725K1!
MSL16MV1ZU->W6RM5$K!MJ<_2M]5L=>S#QVU:W!1B6_MU8Q*,%PB@"1FJ9?\`
M93D*!%MAJWQ^ZNE+I?W\3IUO--MK:R;7E6*D6<Z\IFP]D[SAJS5',E7V,D^2
MURQL&\[&F^FC)MH]@ZE@<2,D"BR*RY0/FUZG?'6^;TJMLM>Z)>IWMC*2&OXM
MO8V3IQ>:4>&9M)2I59-.P*.K=I5M`M6I1JC;[FHMVR#?Q8$*DEX@=U$Z'Z$0
MB]XMD9"Z71"H1\5!;`E5+NU>1M(2@YNMNTAL(/+*XBZ;,/K)K",5E'BI6KZ7
M?PJ9WZKA5`1`#@[?ZL]?-GU"!T71IO7NN+C6=>ZNCJ/',8ZL6^7B=0:FFC+T
M.+0JDG)-K.VI,,_<'*SE(9]#R;9R)?9DBE%5)8"5M=]2M+:_TCIS0RE9;VVH
MZ2UN;6=4<V-NR(_5AI&BNM>6ETY;036&A&3BW5R2>).T&+1HQ1([.FU0;HE3
M3(!]+?T]ZR7T7`V_35/G?O91>6DONT'A0F#O:%1=82D7.`W>(A.U><H6L:Y&
MR,,\]^)D48-B9RV54:HG(![2?5O5S37)J)KJN5VANXIC>OV-/.($EU3I]@V'
M69&IV6R&@[,^<,[,ZDX>572=(R!U47A5#%5`P&-R!`7_`"NNHOM^S^TK![/^
M0#_EH>U^Y''M_P"5K[K[[]$\/M_']X???WWZQQ]Q[OY^/+UP#8?@%;.Y5,K>
MQ^I'9S7EONE+UO6[YH3;5,E-B;%<,&E$H25HHLY!I72V.I1[&L&T'5G+XCY=
M11P@!"("(*$$`,`&FFT=4Z3.[.V1?]C=K.D3.M2<+V*B;E66UH@(6NL=?6/N
M7UHVW=0GJFG(Q%#CC:QM&NXV@69Z[8+/)^7G$9"9?(OW@1@@1=O_`%70]M=K
M=Q:++M#1&G:TR;]I]E2N^;;_`(6,;^PKUZZW:F4GJ?(SX[16->M-U6!D8H9B
M$5:QBZ.OD6C>33AV+"%?6`"^?1SKW5M7;U:W)IV!Z][1ODW2]\MKM4*):86=
MMD&>6V!J-)5S7%(<(I&3AX:Q4=XG9%DH"NH$L$L=15L=\X=N'(%.ZYU9HKVL
MZUC:UVR^.]%UK5G/4>(:ZTDJE"*;NA[MMB?EYF>V%=$IFR6"L[8I6RZXLA`R
M\$W7D@F4+0D1RQ/8GJ,8!F-5ZKZFJ6OJ_KFS]L^B$[6;)U\K=:=WZW&@[)?X
M"F5S4/8:DZMG]'2]BV>(0NN+;4W\I8E5'#M[]D6*MB"#N30E%7T.!@^R^DVO
M9UQNI]>.[/52$K]SZ[;2/:8>=O%1_0M?R%M^,\="VEJN=PO`O%]'U/6#]._%
MDY-T#-&FD;@M"E!)&=(!(/:#JE2=A[/WM*5+M?TYID1?9XUJKM3L5DK]9G]9
M/XK0/2RI0+5S+U26C[+)5F>=:\K;MQ$?=L86/9V*#E#LY=55HT.!=2U:9KL=
MHFJ$)N?0+[]D=[>QNZ(4=FR3%WHV^7?9?8GLRZ::2O1RRZ)S6[7EGVV=!)-`
M7#N-O]3;'^T5.U.WP#7)L/I%K.UK6M^T[U]2HFIW_KR\7AT(>9I5.IE(7=_&
M;+Z$CQU'5HRSR3JL=?3:I9OMBM1_<;YA'4Y620*P=-U!G40-ZO66FQ]$UQ9(
M2-N-;O3=]V#[;7)2;JKU%_&,9#8O:S<^P9:G.EVZ[@A+)KN4LZU?F41,!VTO
M&.4CE(<AB%`L'@#`&`,`8`P"J_=.FP%^ZX7FL6*XZWH;9Q*:^E(VR;<>LH[7
MA+)6MD5*S5>%LK]\N@FR9VNP0[>*!5/W7"9WH"BBX4`J"@&HI#JEKG]^VFW[
M([7]+9.K.]BZK>W)B6R5F'BY*1HGR:]?-PU<92E!+--;U&:O%_J4E23Q;9E]
MP6^OVI5I"7?OU4VH%>I'3M8W)OS;NMXS;NA-*M]+?Y@5$MG3KS5E9V%LR<LG
MR;:$VS3H?:DDVV!>D=B5<]^H#VKI2R;94]?L,PR/*,4[#)O:C'@;/>B77VF:
MPM-L3J>_]*[0EK=UQ@:S;E-36.'>WNGNDNSO;[8L79X%S'/)1-:FOIC=DW7D
M7AV<4S)*T;AHQ02\XZ,`I38.JNNK#I;5;:*[@="(!/4[>G5&%6H:E!K6L-LT
MN/ZTW6ILKCLI_/3>QV;K8DUKP)^R,2@SDD6M/)+1A7;ELNO-M0+V],>N=5T_
MNF1EX/L-K7;3IOKFQ5<(2O6$LM<U&AX?K5'FL<RW=6BTS'BDG0VR[M1R[>*@
M,ZS%1PJ94%%0*.Z%ZI:@IFW=1;'VWVOZ-;#JS&:ZO.WE9B[)3VU>N<]1M1_(
M'1=)S-%HSF7+K:I%VG/[UD+%6X"#CFS&)4HKQ.,5DU&ZKQ`#)]!]8M5T;8_6
M1C4>T/1J\0\5NW36VX%VREJ_(;EE)&O]+UM14G3NB7<5;3M%*38M41+>YQ7M
MIJF_27$F#=BHT7)((@9UV(ZT=>+'O+O7-[&[)]3Z[L#>>E]X4VF0FQK-1VU^
MT=*VWKETEU\K<9!"=EDIN";U.3UW6[`]6:%;J(M[#!*B8IUFIS@08PZL0VV-
MAUO8LSVBU_J%6R=B]LL'&K[7<*;&7V$2J7RX]LMJ:ULNN&:;U]-H[0V5;[\T
MK1&9'L*ZAK+#L2.DI)ZR6@P`R1OULTA+:LI-9?\`9CXW/M:CI^Y:U3EZD6,K
MT%<M+*]+-D:U?[,N3Z`V_'6>3>/X.;&SR;=A-1I8^I(+$0L`F;IRN`6MI&B'
M49TAVWK9IOC0,I*/MY0=GB[*C9XA]KFBV6%V!JF<C]97W:<3#0EFOEFEK-72
MIJS$VS-91/.-F2OW?VK=1<#IMP]>Z5L/9+2Z]W=W];ZQ8Y2P5-G>=71=[5J$
M1':'C^LGR!:TUU`5^Q6J7KEQ6ODU:=X[`MJ-C!M$"DSK+M%@G[D"L_.!7>=Z
M%05CU'&TGL1\A=/:/Z_#]VZMJ_9E,L>N:0XL>ZMU=U[UL/9%^NL-:TYV*>7/
M5EJ::_AGC.%<M'$-;D)IF11H1ZDB8#?U7BSQ("#):5(M:SEAXPMC6@R.4X56
M>*R0"74ATWO+PD6>0!06X*_WH)"4#?FYP#N,`8`P#6!V(TWI>:[D:XV[N+<7
M7^&A(&8ZO<ZDVO,U1&8G9^I4;Y-JSKG[&(M+Y-HXF+9;>P!I.M?W!EEG%`EC
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M+)IQ3IW[\(T`ZN$Z7:&D-57/7B'<SKBRM-WJ76E60V)0[E4&UNI]%9;(WE88
M<U1D"V-1S'U65L-Z?,J/[(L84SN%4*Q9M$T@9-@,8M^M:HPVWUWV)';)^,Z:
M?R-Z:54M%8+5MCUHAV%)Z@[U0K=N0@U+<XE2[9V!0+XL],+1N[]NDPL?'`=9
MDU4F<`Y3;J+ULKFB(+7NONYO2Q[>*-L"2L\UM6WO-0SSJ[T1G\<"^CUZML-I
M(3%@;*IS=+?PMQ?_`'PR;%A72-I$$'2:#83@5M[0:8AM/:CN=6-LSJ]M9YO2
M&[DZ\AY&SV6N7'6FGY#9T5U(0E)EY>=C;8C9_7^QM?[/C40=68[$\"W:KQTD
M_/#2"4)6ID#:GU=ZSU[7'>':FPFW9S6.SI!^^[:3L3KZ*L%?>;:C$]S[XI6P
MM@5ZQ0\.LA)1U5TC/&B:XK]\M-F6,>'\BPAVY&CP#[=QM.:HO]W1GZINSJIK
M>R):OH]8"M;#?4!HK.M/\T>B+97EBNW:,F[JZ<Y9Z_'0$'/,V#F1BK-*1JL;
MQ(`U$`('ZZ=;=<:ANU6;S/9?HWLR+F;8I*/4[,X8V[8,'!Q/:ON#L>I5[3<C
M9=C2C]I^O6_8LM67:KQ=XX8RM2FP]V47=KMHH"**9U$ULTU!5=4I]OND#N'=
M4/5DJWVG!6"!/L9*:U[T&C](5J"UY,!:S-6.H]CZIHZNP9%<JJROZ%*V)NDW
M<LWPS"`%JM&:VU#_`)UM>V#6U_U<KHJ@:5U/$56OTZ9I+6D7?N:IIC8<-5K=
MJ,(*=<#8;$WZ-/YW]48-FJ*1:T,<^;BX20>*-@-RF`,`8`P!@%1.UE-U/9YW
MJC-[FN.HZQ4-==FT;DTA-PO:TUB-B6]]U_[`:^IE.JJ%J71C)&^,;)>V]@CT
M2E5=%+!*JH%!5(IR`:DZYTNTQ$WCKY+S'<_K98-5M-5];7+JJ.[K2T47VO-8
MM=H/Z&AJ!PTDFLD[T_M:HHSR+/[65C8UJS0L1O;FV#YXQ:@6`^/7J=":)W$V
MGGW;C4^_;)$ZON=*LT'59J(?6V>WQ8IW7=CNNR;0BE/RC@)>'ZOUS4$$V;E0
M0<LHWR<J"+.68II@5KJO6"B+Z_KD77.UGQZ)+:[AV]'BAUN_IT4PW!%6OL_#
M6E_.;:M2LK:7M?VA"[8IYH2KS46R>R+.V.)Y5JLT?S2C>-`["D=4-3TREO=>
MVKMST,L->NE#M[64O%K4A[/L.G5=.*[80FN5--R]GVDJM!4M[79^7E)`7CQ\
MI'N(*X-DW4DE)K/88#&-E])M>SKC=3Z\=V>JD)7[GUVVD>TP\[>*C^A:_D+;
M\9XZ%M+5<[A>!>+Z/J>L'Z=^+)R;H&:--(W!:%*"2,Z0";-Y]9=0SVT.TLY$
M]G>G%<ANQ$'8Z-(P5^F*PI.=>-=RO7/IM0I/8FHTVUFCFD#L2OHU2"FC-U$V
M;%TWGJB\.]:@T;IR($(U31.E;\_N,KMK>'1'7<)0^\O:ZUNX$9F@M;KL"(4^
M;/5>V;'"[Y=/K6YC%%D;#KVNU1"/6(X%U;K9"IOB1SYN@P=`2(7JE27VT:K)
MTGM?TZ/!1'8FG[7J<)#V2`AK.R%/Y3]_;UK^KT#4R79N;FUM%AL,[0XI&57>
MQ\)<868:1<49\Z?+-P*HZ`TG"[<9[(C83<W7_326E=>?&K2*Q,K2>JZK.[DE
M=/RW>BL4QUV%",NFV8J0G-DAM)C(P%D8(3]?D+E!*+0+N;_3G'VX%Z.I/5BB
M:QW[U]M5'[2]8+M%0\5"&5BJ58HRQV39$BIU/?UR!J]"I]AM%]BJBFPHSUO:
<8FRTYU`R"E"9)PRL<XAU57I@-ZV`,`8`P#__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
